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The publications included in this thesis cover four broad areas of fertility regulation.
Postpartum Contraception. This section includes a number of studies investigating
mechanisms underlying lactational amenorrhoea together with three studies investigating the
relationship between infant feeding practices and the duration of amenorrhoea. A study on
the effect of progestin-only oral contraception on bone mineral density during lactation and
two studies on the timing and quality of advice about post-partum contraception complete
this section.
Modern methods of contraception. A number of general reviews of modern methods of
contraception are included in this section together with an overview of new developments
and possible future methods. Original work includes studies on continuation rates of
Norplant; acceptability of future methods (male and female): ovulation during the use of
hormone replacement therapy; morphological and functional changes in the endometrium of
women using low dose progestogen only methods and the use of antiprogestogens for
various approaches to female contraception.
Abortion. The papers in this section concentrate mainly on service delivery issues including
the establishment of a centralised referral system: audit of quality of care; counselling:
acceptability and patient satisfaction.
Emergency Contraception. Original work on the efficacy and mode of action of emergency
contraception; knowledge among teenagers; prevelance of chlamydia infection among
women using emergency contraception (EC) and the need for de-regulation of EC are
included in this section. The thesis ends with three studies on advanced administration of EC
and its effect on use, risk taking behaviour and abortion rates.
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The 66 publications I am submitting for the degree of DSc span 17 years of research
which followed the work included in my MD thesis. The publications cover four
main areas of research on fertility regulation - the contraceptive effects of
breastfeeding, modern methods of contraception, abortion and emergency
contraception. I have summarised the work in the introduction below referencing
each publication in the text as it contributes to the theme. The publications are not
therefore in temporal order.
II
Fertility Regulation - From Laboratory Bench To Service Delivery
Introduction
th
Throughout history, mankind has tried to limit family size. Until the 19 century this
was achieved by natural methods of fertility regulation including abstinence or
infrequent intercourse; the avoidance of intercourse during the fertile period of the
cycle; coitus interruptus and by breastfeeding. Male condoms were used primarily for
the prevention of infection during that time.
Postpartum Contraception
Breastfeeding is associated with a reduction in fertility. The demographic
importance of the contraceptive effects of breastfeeding has been recognised for over
half a century, but our understanding of the mechanisms underlying the effect of
lactation on fertility stems from a body of work undertaken largely in the 1980s and
1990s, much of it in Edinburgh. A longitudinal study of the changes in the pituitary-
ovarian axis accompanying the return of fertility in a cohort of women after
childbirth was the subject of my MD thesis (1983). In women who do not breastfeed,
follicle stimulating hormone (FSH) and prolactin (PRL) concentrations return to
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normal within four weeks of childbirth. However, for normal ovarian follicular
development, LH (luteinising hormone) as well as FSH, is required,3,4 and in bottle-
feeding women it is the return of a normal pulsatile pattern of LH secretion which
determines the timing of the resumption of fertile cycles - usually within eight to ten
weeks postpartum. The resumption of regular ovulatory cycles is substantially
delayed if women breastfeed their babies, with the duration of infertility determined
largely by the frequency of breastfeeding and the timing of the introduction of food
other than breast milk.5 Full breastfeeding is, at least initially, associated with
complete suppression of ovarian activity and therefore with amenorrhoea. The
suppression of ovarian activity is the result of a disruption of the normal pulsatile
pattern of LH secretion.6 It is assumed that the suckling stimulus directly inhibits the
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release of hypothalamic GnRH 7 but, despite detailed investigation, the exact
o
pathway through which suckling acts remains unclear. Suckling is also associated
with an acute increase in prolactin secretion9 which is essential for the maintenance
of lactation. Although it has been tempting to assume that prolactin per se is
instrumental in maintaining lactational infertility, a precise link has been hard to
identify. 10 Research using women with pathological hyperprolactinaemia as a model
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supports the arguments against a direct role for prolactin inhibiting follicular
development and ovulation. Nevertheless a simple disturbance in the pulsatile pattern
of GnRH secretion may not by itself be enough to explain lactational infertility, since
restoration of a normal pattern of LH pulses using physiological amounts of
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exogenous GnRH delivered by a pulsatile infusion pump stimulates follicular
development but does not restore normal ovulation. This is in contrast to the effects
of such therapy in women with either pathological hyperprolactinaemia or
hypogonadotrophic hypogonadism, in whom normal ovulatory cycles are restored.13
Our understanding of the exact mechanism by which breastfeeding delays the
resumption of fertility post partum is still incomplete.
Although the major role that breastfeeding has played (and still plays) worldwide in
limiting population growth is well recognised, differences between infant feeding
practices and their effect on the duration of lactational amenorrhoea had been the
subject of limited scientific investigation. In 1989 the World Health Organization
(WHO) Task Force on Methods for the Natural Regulation of Fertility embarked
upon a large multinational study designed to explore the differences between
populations in infant feeding practices, the duration of amenorrhoea and the risk of
pregnancy. This large longitudinal study was undertaken in seven countries, five of
them in the developing world, and involved detailed and prolonged follow-up of
4118 breastfeeding mothers and their babies. The study generated an enormous
amount of data and the cohort of infants continues to provide evidence on the
relationships between intra-uterine and early infant growth and future adult disease.
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The findings from the WHO study 14,15,16 have confirmed that the duration of
postpartum amenorrhoea is strongly linked to the breastfeeding stimulus but also that
cross-cultural effects are also important. They also confirm that the lactational
amenorrhoea method (LAM) is a viable approach to postpartum contraception with
cumulative pregnancy rates during amenorrhoea ranging from 0.9% (95% confidence
interval, CI - 0%-2%) to 1.2% (95% CI = 0%-2.4%).
Although breastfeeding still plays a major role in fertility regulation in many
developing countries, it seldom features as a 'contraceptive choice' in developed
countries. Since lactational amenorrhoea depends on frequent breastfeeding, in most
parts of the world where women return to work outside the home soon after
childbirth and are separated from their infants for intervals of eight hours or longer,
LAM is not a very practical method of contraception for many women. In the UK
many breastfeeding mothers rely on progestogen-only (which unlike combined
hormonal contraceptives do not interfere with milk production), or barrier methods of
contraception. Progestogen -only methods may offer an extra health benefit for
lactating women since they appear to confer a degree of protection against the loss of
bone mineral density which inevitably accompanies the hypo-oestrogenic state
associated with lactational amenorrhoea.17
The WHO study further demonstrated that breastfeeding promotion and contraceptive
advice to women after childbirth should be culture specific. Although women during
pregnancy and the puerperium represent a captive audience for education and advice
about postpartum contraception, countries, and programmes, vary widely in their
interest in making use of the opportunity. In Scotland, despite a number of health
professionals taking the opportunity to discuss contraception with women after
childbirth, the advice given is often ill-timed, of poor quality and, in relation to
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breastfeeding, actually incorrect. Although in the UK a considerable amount of pre¬
natal education takes place during the antenatal period, contraception is seldom
discussed and the topic is left for perfunctory consideration after the baby is born. In
a multi-country randomised controlled trial19 we tested the hypothesis that expert,
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individualized contraceptive advice given during the antenatal period would have an
impact on contraceptive uptake, patterns of use and pregnancy rates during the first
year after childbirth. Despite recruiting over 1600 women in centres in China
(Shanghai), South Africa (Cape Town) and in Scotland (Edinburgh) we were unable
to demonstrate any significant effect of the intervention. Pregnancy rates were
determined by the inherent effectiveness of the contraceptive method chosen rather
than by the quality or timing of advice.
Modern methods of contraception
During the 19th century barrier methods of contraception for use by women and the
intrauterine device were developed and continue today to provide contraception for
millions of women worldwide.20 In the United Kingdom hormonal contraception,
including combined and progestogen only methods, is currently the most popular
method of fertility regulation.21'22 The combined oral contraceptive pill was
introduced in 1960 and much of contraceptive research, at least by the
pharmaceutical industry, has been and still is dominated by minor changes in the
steroid hormone recipe for 'the pill.' The 1990s saw the introduction and
increasing uptake of long acting progestogen-only methods of contraception
including implants 24'25 and the hormone-releasing intrauterine system LNG-IUS.26
The latter method is particularly attractive to older women 27 since it is highly
effective, lasts for five years and is associated with a reduction in menstrual bleeding
at a time of life when menstrual dysfunction is becoming common. It can be
combined with exogenous oestrogen for women in the perimenopause who still
require contraception but begin to experience vasomotor systems and wish to take
hormone replacement therapy (HRT). Unlike conventional oral HRT which is not
reliably contraceptive28, the LNG-IUS provides highly effective contraception while
simultaneously protecting the endometrium from the potentially neoplastic effects of
unopposed oestrogen. Contraceptive implants are as effective as female sterilisation
29'30 but have the advantage of being reversible.
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While a broad range of contraceptive options is presently available, none are perfect
and rates of discontinuation can be high, even for methods which have to be removed
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by a health professional should the user wish to stop using it. One of the
commonest reasons for discontinuation of all hormonal methods of contraception is
so-called unscheduled bleeding.32 Irregular and unacceptable endometrial bleeding is
particularly common with low dose progestogen only methods of contraception.
Although our understanding of the morphological and functional changes in the
endometrium of women using these methods is improving, 33,34,35 we are still a long
way from finding a strategy - other than changing to a different contraceptive
method, or adding oestrogen - to solving the problem. One solution may be the
addition of an anti-progestogen which might improve bleeding patterns, either
through a direct effect on the endometrium or by inducing ovulation. 36 In a double-
blind, randomised placebo-controlled trial involving 100 implant users in China
once/month administration of mifepristone has been shown to improve bleeding
38
patterns.
Antiprogesterones indeed represent the most exciting advance to date in the
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development of new methods of contraception. Although currently licensed in the
developed world only for the induction of abortion, the anti-progesterone
mifepristone has been shown to be effective as a contraceptive when given daily,
once weekly, once per month 39 and post coitally.40
New methods of contraception, if they are to be widely used, must be acceptable to
the men, women or couples for whom they are intended. The theoretical
acceptability to women of a pill which need be taken only once a month (and then
only if intercourse has occurred) seems obvious and has indeed been demonstrated in
a number of developed and developing countries.41'42 Less predictable, and indeed
commonly regarded as being somewhat unacceptable, particularly in developing
countries, is the concept of a method of contraception which is associated with
amenorrhoea. Although a large multinational study undertaken by the World Health
Organization in the 1980s strongly suggested that women preferred to have regular
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menstrual bleeding, more recent work suggests that amenorrhoea is becoming
acceptable - even desirable - even in the developing world. 43 Yet more controversial
is the potential acceptability of hormonal contraception for men. Despite decades of
research into a 'male pill', many opinion makers have suggested that most men would
be reluctant to use a 'pill' and that in any case women would not trust them to take it
reliably. Multicentre studies of men 44 and women 45 undertaken in China, Hong
Kong, South Africa and Scotland demonstrated that there would be a market for
hormonal contraception for men and that women, while they may not trust men in
general, would trust their own partner to use it. Women felt strongly that men
should take more responsibility for the regulation of fertility than they currently do.
Whoever does take responsibility for contraception, incorrect or inconsistent use as
well as method failures will contribute to the burden of unintended pregnancy. Poor
compliance probably accounts for the majority of contraceptive failures but is
extremely difficult to measure. 46 When failure occurs women must have access to
abortion.
Abortion
Abortion is an intrinsic part of fertility regulation, indeed it is almost impossible for a
country to achieve a low fertility rate without recourse to abortion. The UK is no
exception, with a total fertility rate in 2000 of 1.7, around 1 in 5 pregnancies end in
abortion. Therapeutic termination of pregnancy is a core service provided by the
National Health Service 47 The availability and accessibility of abortion services
48varies widely in the UK but in general are well organised in Scotland. The
establishment of a centralised referral system49 which we described in 1991 reduces
the time women have to wait to have their abortion and is now recommended as
standard practice. Scotland's abortion services were audited nationally in 1993 50
using criteria for good quality care agreed nationally by the consultant body.51 Two
thousand and four patient episodes of abortion care were reviewed in two rounds of
audit, the second taking place after recommendations for change - arising from the
results of the first round - had been disseminated. Increased availability of medical
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abortion was one of the major improvements demonstrated in the management of
induced abortion. In 1994 57% of women seeking abortion in Edinburgh who were
eligible to do so chose a medical procedure in preference to surgical abortion 52 and
this trend has continued
In Scotland the majority ofwomen are satisfied with the care they receive while,
undergoing induced abortion.53 They receive adequate emotional support and
counselling 54 and appreciate the opportunity to choose between medical and surgical
abortion.55 One of the few failings of the organisation of abortion services in
Edinburgh (and elsewhere in Scotland) is the provision of appropriate contraception
post-abortion. We are presently undertaking a cluster randomised trial to determine
the effect of offering individualised expert contraceptive advice, provision and
follow-up to a cohort ofwomen undergoing induced abortion to determine the effect
on contraceptive method chosen and continuation rates.
Emergency Contraception
Many unintended pregnancies could be prevented by the use of emergency
contraception even if unprotected intercourse does occur. Emergency contraception
(EC) is estimated to prevent between 60 and 85% of pregnancies.56'57 It has been
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licensed in the United Kingdom since 1984. Although we are still not entirely sure
how it works 59'60, it is extremely safe.61 It must be used within 72 hours of
intercourse and is probably more effective the sooner it is used. For this reason it
was argued for much of the 1990s that it should be made available without the need
to see a doctor.62 EC was eventually taken off prescription in the UK in 2001
improving accessibility. This should improve its use particularly among teenagers
who are well informed about it63 but who have a tendency to lead somewhat risky
sexual lifestyles.64 Even availability 'over the counter' may not increase the use of
EC sufficiently to make an impact on abortion rates since at £24.99 per course (in
2003), it is extremely expensive and women still need to be motivated to go and buy
it. A potentially better solution is to provide women at risk of unprotected
intercourse or contraceptive failure with a supply of EC to keep at home so that it can
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be used every time it is needed. A pilot study65 undertaken in Edinburgh
demonstrated the safety of this approach and suggested that it may reduce unwanted
pregnancies. A much larger community based study involving over 17,000 women
living in Lothian has now been completed and the results are in press. The initiative
made no significant impact on abortion rates 66 despite quite promising patterns of
use by the women who had a supply to keep at home.67 The most likely explanation
for the failure of advanced provision of EC to influence abortion rates lies in the
observation that many women simply do not recognise that poor use of contraception
puts them at risk ofpregnancy and so, even despite having a supply of EC, they do
not use it. If abortion rates in the UK are to be reduced by interventions aimed at
increasing contraceptive use perhaps a major effort needs to be made to encourage
the use of methods which are less dependent on compliance.
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Contraception - past and future
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Modern contraceptive methods have a surprisingly short history and are dominated by the oral contraceptive
pill, which came on to the market in 1960. New developments since the advent of the pill have been largely lim¬
ited to tinkering with the contents and routes of administration of hormonal contraception. The knowledge that
would allow a more exciting approach to new contraceptives does exist but the will to proceed is hampered by
financial, political and moral factors, and perhaps ironically by the AIDS epidemic.
hroughout history, mankind has tried to
limit family size. Until the last century,
this was largely achieved by behavioural
modifications, including abstinence,
infrequent coitus, the avoidance of inter¬
course during the fertile period of the
cycle and coitus interruptus (the with¬
drawal method). In population terms,
breast-feeding, which inhibits normal
ovarian activity, has been one of the most
important means of limiting fertility,
whereas for individual couples, coitus
interruptus - first mentioned in the hook
of Genesis - has had a major role to play.
One artificial method of contraception,
the condom, has n surprisingly long histo¬
ry. Penile sheaths were described in Egypt
in 1350 BC. Originally made from animal
intestines, and later from linen or silk,
they were used mainly for protection
from venereal disease. Not surprisingly,
given the place of women in society,
female barrier methods arrived much
later on the contraceptive scene. The first
'womb veil' is attributed to an American
working in the early J 800s and the first
cervical cap was produced in Germany
around 1830. It took more than 150 years
before the female condom' came on to the
market in 1993.
The intrauterine device
Until the second half of the 20th century,
the only other artificial method of contra¬
ception was the intrauterine device



































Figure I Intrauterine devices through the 20th century. Dates represent roughly the time of first
availability in the UK or USA.
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Germany from loops of silk-worm gut,
later from silver-copper alloys and even¬
tually from plastic (Fig. 1). The modern
IUD appeared in 1969 when copper was
added to the plastic frame, improving
contraceptive efficacy and allowing the
size of the device to be reduced2. Most
recently, the plastic frame was removed in
the belief that side-effects will be reduced
through use of an even smaller device
(Fig. 1 )3. lUDs fell into disrepute in the
mid-70s when a rather fearsomely shaped
device with a multifilament tail - the
Dalkon Shield - was shown to be associat¬
ed with pelvic infection and infertility4.
Nevertheless the IUD is one of the most
commonly used methods of contracep¬
tion in the world, thanks mainly to wide¬
spread use in China. Despite being highly
effective, extremely safe, long-acting
(lUDs are licensed for 5-10 years of use)
and very cheap, the copper IUD is not
popular in the USA, nor in much of
Western Europe.
Advent of the oral
contraceptive pill
The advent of the oral contraceptive pill,
developed by Pincus and Rock and col¬
leagues5 and first marketed in 1960, her¬
alded a revolution in contraception and
arguably laid the foundations for women's
liberation. Perhaps the most widely
researched drug in the history of thera¬
peutics, the pill has been repeatedly shown
to be safe and effective". It has been, and
remains, a favourite subject of media
hype, and despite its safety record, the
majority of women still perceive the pill as
potentially dangerous7. It is of course sta¬
tistically much safer than pregnancy.
Developments in oral
contraception
Much of the very recent history of contra¬
ception centres round hormonal methods.
In the first two decades after the pill was
marketed, research efforts were concen¬
trated on improving safety and reducing
side effects. This was achieved by lowering
the dose of oestrogen (ethinylestradiol)
and experimenting with different types of
progestogen. The dose of estrogen has
s4
"The cdvent of the oral
contraceptive pill...
heralded a revolution in
contraception and arguably
laid the foundalions for
wornen! s liberation."
been reduced from 150 pg to 20 pg, and a
pill containing 15 ug is currently in clini¬
cal trials8. Nervous of compromising effi¬
cacy with such a low dose, investigators
have tried reducing the duration of the
pill-free interval from the traditional
seven days to four or five days and substi¬
tuting the placebo tablet or pill-free day
with a small dose of estrogen alone9.
Biphasic and triphasic regimens (in which
the dose of hormones changes two or
three times throughout the 21 days of
treatment) were introduced in an attempt
to improve bleeding patterns and safety by
mimicking the normal physiological cycle.
These regimens have never proven better
than monophasic pills and are indeed
more complicated and more expensive.
Most of the efforts with new progesto¬
gens have centred around producing less
androgenic compounds. Ironically, this
may have resulted in a slightly increased
susceptibility to venous thrombosis and
a marginal reduction in safety, resulting
in the pill scare of 1995 (ref. 10).
Drospirenone, the most recent progesto¬
gen to reach the market, has anti-miner-
alocorticoid properties that are reported
to reduce fluid retention". Heralded by
the media as the pill which "makes you
lose weight", rumour has it that supplies
were sold out after only one month of
this pill coming on to the market in
Germany.
New routes of administration
Although the pharmaceutical industry
still seems pre-occupied with the dose
and type of steroids, research into hor¬
monal contraception in the last twenty
years has concentrated on the develop¬
ment of new delivery systems. Avoiding
the oral route has the theoretical benefit
of bypassing the first pass of metabolism
through the liver and providing constant
release rates ofsteroids. It has the very real
benefits of reducing or eliminating the
need for compliance and increasing choice.
Injectable progestogens (depot medroxy¬
progesterone acetate and norethindrone
enanthate) were approved in some coun¬
tries in the early 1980s. Combined injecta-
bles (containing both estrogen and
progestogen and administered monthly12)
are now widely used in Central and South
America and have recently been approved
in the USA. Progestogen-only contracep¬
tive implants became widely available in
the 1990s. Initially marketed as six sili¬
con-rubber-coated rods that were
implanted subdermally in the upper arm
(Norplant), the number of rods was
reduced to two (Norplant 2, ladelle) and
finally to one (Implanon)13. Implanon
lasts for three years and to date no
method failures have been reported. The
addition of a progestogen to the
intrauterine device has produced an IUD
that is licensed for 5 years, but which, in
contrast to the copper IUD, is associated
with a significant reduction in menstrual
bleeding (Fig. 1, LNG-IUS)14. The con¬
cept of a five-year contraceptive that dis¬
penses with menstrual periods is
extremely attractive to many women in
Europe. In the UK for example, the lev-
onorgestrel-releasing device presently
accounts for 11% of the hormonal con¬
traceptive market. At the end of this long
list of new delivery systems comes the
contraceptive vaginal ring13 (worn in the
vagina for 21 days and removed for 7
days) and a contraceptive trans-dermal
patch16. Both contain ethinylestradiol in
combination with a progestogen and both
will become available in the USA during
2002. Lagging behind (estrogen replace¬
ment therapy for menopausal women is
already available in both forms) is the
development of a trans-dermal gel and
trans-nasal spray delivering contraceptive
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Figure 2 Percentage of married/cohabiting women of reproductive age using contraception and average family size28.
hormones. If and when these become
available, all the different routes of
administration of hormonal contracep¬
tion will finally have been exhausted and
perhaps technology will move on to
something that is radically different.
Health benefits of
contraception
The idea that contraception can be used
not only to prevent pregnancy but also to
confer health benefits, and particularly to
reduce the frequency of menstrual bleed¬
ing, has received considerable interest in
the last couple of years. However, this
hypothesis is not new. It was demonstrated
in the early 1970s in Scotland17 that
women could, and would like to, run
packets of oral contraceptive pills togeth¬
er, allowing a three-monthly, rather than a
monthly, withdrawal bleed. The idea has
recently been rediscovered in the USA,
where in 2002, a three-monthly combined
oral contraceptive pill (Seasonale, Barr
Laboratories, NJ) is in clinical trials.
The potential for additional health ben¬
efits may restore the enthusiasm of phar¬
maceutical companies for contraceptive
research. The use of selective oestrogen
receptor modulators (SERMS), for exam¬
ple, to develop a contraceptive pill that




seems to have almost ground to a halt
with regard to steroid hormone methods
for women, some exciting work has been
undertaken on some different technolo¬
gies. The feasibility of hormonal contra¬
ception for men has been recognised for
more than fifty years'". It is, after all, based
on the same concept as the pill. A variety of
regimens have been tested, most of them
(and probably the first to reach the mar¬
ket) comprising a progestogen to suppress
spermatogenesis, combined with testos¬
terone replacement to maintain sexual
function19. The long delay in the develop¬
ment of a hormonal method for men is
due partly to the lack of an appropriate
long-acting form of testosterone replace¬
ment, but also to the commonly held
belief that 'men would never use it' and
women would never trust them to take
it2". Although contraception is still very
much seen as the responsibility of the
woman, particularly in developing coun¬
tries, recent surveys of men and women in
Scotland, China, Hong Kong and South
Africa suggest that a male pill would have
a significant place in contraceptive
choice21-22. Lured by the potentially huge
market of testosterone replacement thera¬
py for ageing men, the pharmaceutical
industry has at last made some, albeit not
absolutely wholehearted, commitment to
the development of hormonal contracep¬
tion for men.
Immunocontraception also seems to
have been in the pipeline for a dispropor¬
tionate length of time. Vaccination
against the egg (specifically the zona pel-
lucida), sperm and embryo (specifically (3
human chorionic gonadotropin) are all
technically possible2-'. However, progress
has been hampered by a variety of factors,
including uncertainty about the long-
term effects of immunizing against
human tissues, and fears, perhaps ironi¬
cally from women's groups, that contra¬
ceptive vaccines too easily lend themselves
to coercive family planning policies.
Perhaps the greatest promise for a radi¬
cally new method lies with the use of
antiprogesterone. Orally active and effec¬
tive as a daily24 or once-a-month pill25,26,
the antiprogesterone mifepristone is now
marketed in China as an emergency con¬
traceptive27. Elsewhere in the world, its
development has been seriously inhibited
by the anti-abortion lobby, because the
Nature Cell Biology & Nature Medicine - www.nature.com/fertility S5
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principal use of mifepristone is as an
abortion pill. The saga of mifepristone
illustrates the difficulties that almost
every advance in contraception has
encountered. It may seem obvious, but
contraception cannot be separated from
sex, and everyone is interested in sex. Thus,
in contrast to, say, anti-hvpertensive drugs,
everyone tends to have a view on contra-
ception. Contraception is also inextricably
bound up with social, cultural, moral and
religious factors that often influence, if not
the availability of methods, certainly their
accessibility. The increasing tendency
towards litigation, which even if unsuc¬
cessful, is extraordinarily expensive and
time-consuming, has also served as a
damper on the development and availabil¬
ity of new methods. All these influences
make the pharmaceutical industry nerv¬
ous when it comes to taking on new leads.
Impediments to
contraceptive development
In recent years, research progress has
depended largely on not-for-profit organ¬
izations, such as the World Health
Organisation and the Population
Council. However, two significant factors
have had a major effect on even their
enthusiasm to develop new methods. The
first is the HIV/AIDS epidemic. Although
it led to the renaissance of the condom
and a renewed interest in the develop¬
ment of better barrier methods, albeit
with limited scope for much improve¬
ment, it has undoubtedly reduced the
interest in developing other new methods
of contraception. This is partly because
funds and research efforts have been side¬
tracked into developing microbicides, but
also because of the commonly-held view
that it is bordering on the 'unethical' to
work on new methods of contraception
that do not simultaneously prevent HIV
transmission.
The second major impediment to con¬
traceptive development has been the
widespread view that the population
problem has been solved, with the result
that donors no longer regard contracep¬
tive research as a priority. It is indeed true
that in the thirty years between 1965 and
s6
1995 the total fertility rate (TFR) in the
world fell from 4.9 to 2.8 children per
woman and that in 1997, 51 countries -
accounting for over 44% of the global
population - had fertility rates below the
replacement level (2.1)28. However, the
TFR in most countries of the African con¬
tinent is over 5.5, and in these same coun¬
tries less than 20% of married women are
using wmliatepliuii (Fig. 2)'K. Despite
higher contraceptive prevalence, abortion
rates continue to rise in most countries
worldwide, including the developed
world, and unwanted and mis-timed
pregnancy accounts for tens of thousands
of maternal deaths each year.
As more and more women start having
sex at an earlier age, delay childbearing
for longer and have smaller families,
many of them are destined to use contra¬
ception for more than thirty years. Most
women will do almost anything to avoid
an unwanted pregnancy and presently
tolerate the inconvenience, side effects
and albeit small risks of currently avail¬
able methods. Many live in countries and
have lifestyles that do not put them at
risk of HIV, and in any case many would
be prepared to use a method of contra¬
ception while at the same time using
something else which prevents infection.
Modern scientific methods can now
identify genes whose products are solely
involved in reproduction and which are
therefore prime targets for the inhibition
of conception'9. We have the wherewith-
all to produce much better methods of
contraception. It seems extraordinarily
complacent to expect people to settle for
second-best. □
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FIG.3.Changesiurinarytotaiestrogensdpregna dioir latiohsucklingfre¬ quencyanddurationpl smalev lsofprolactinibreas feedingw ma .Notthv t fourfeedsachd ywitsucklingdur tionf50min/day,ollicularev lopme tint rm oestrogenibelowthelow rimitfno mal(10ug'24hr),here sprolactir mainabov theupperlimitofnormal(500mil/lite ).Firsenstruationotpr c dedbyvulati n,a foursubsequentcycleshavinadequateorpusut umunction.(Fror f.12 )
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FIG.6.Diagrammaticrepresent tionofthcontrolgonadotropinsecr ti na dinteractio withprolactinduringlactationalamenorrhoeadresump i noffollic l rgrowtndovulatio
inbreastfeedingwom n.Sucklingc us sdecreaseihypothalamiccap citytreleaG RH, withsubsequentreduc dpulsatiles cr tionofLH(1)inthfa fhighp olac nlev ls.Pul atile secretionofLHccurs30%thtimeinlactationalam no rhoeadiniti t sfolliculardevel¬ opmentwithanincreaseoestroges cretio(2).Ho v r,be ausfthincr asen¬ sitivitytohenegativefeedb ckffectsofisestrogen,pr bablyb causefthr duced hypothalamiccap citytreleaseGnRH,u s tilLHsecr tioniswi chedoff(2)andfurth r secretioninhibited(3).Thisprocesscont nueu ltsu kli gstimula dpr la tinlev ls decrease(5,6),atwhichtimehypothalamiccap cityreturntn rm lwithlneg tive/ positivefeedbackactionofes rogen,llowi gmaint in dpuls tileLHs creandsustained folliculargrowth,ovulationandlute lfunction(7).Fr mr f50.) ofGnRHandLHsecretion,incethpatt rnfsecre ionioft nsimilat thatinhyperprolactinaemicatients(25,32).Howev r,tae ologyfitu ta y tumoursremainunknown(33),sherelev nceofth sobs rvationsremains questionable. Similarly,ithasbeensugge tedthatprol c ini hacdirec lonthypo¬ thalamusoincre seturnoverofdop mine,eprolactin-inhibitingfa t r(34). Suchashort-loopfeedbacksystem,byw icprolactincontrolsito nsecretio , appearstoo erateinprimatessw llr d n s(34).Si canincreas dopaminewillalsosuppressthsecret nfLHinwo ,possibleth raisedlevelsofprolactininducedbys klingmightsuppressGnRHandLH secretionbyanincr asedopamin .Howev r,rece tstudi sthr t(35,36) haveshownthatlactationiassociatedwithsignifi nreduc ionb alhypo¬ thalamicdop mineturnov r,c st ngonsiderabled ubttthe ryfdopamine- mediatedsuppressionofGnRHsecretion. Thus,itmaybet aterais dlev lofprol ctinm relrefle tst engthof thesucklingstimulus,altho ghhowthisirelayedth o ghhypothalamic-
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FIG.9.Excretionofurinaryt talestrogenandpreg anediolim n ualcy l s( )du i g lactation(n=54),b)af erlactation30),dinon-pregna tc trols(=27).Noth althoughtheurinarypregnanediolissig ificantlyreduc ddur glact t n,indicatina equa corpusluteum( nction,o st ogenevelsw rn tsignifica tlydilfer nt.(Fr mr .7.) Innon-breastfeedingwomenithasbeensugge t dthatinadequ tcorpuslut functionresultsromar ductioitheFSH-LHra oundimofmen es, i.e.,10to5daysbef reovulation(46)Plasmalev lsfFSHrelwatth upperlimitofnormal(3-6).Howev ,basalplasmalevelsfLHa p aredtb marginallylowerth nnormalduri ginadequatelute lp as s(6),l ghth pulsatilesecretionofLHa pearedtbn rma(19). Morerec ntlywhavm asur dthec angesinuri arysteroidandgonadot o- phinsinearlymor ingurines ecimenscollect dda lyur glactationalamenor- rhoea,throughascri sofinadequatelut lphasesduringbre stfeeding,untilt returnofnormalmenstru lcycles(A.GlasiendAS.McN i ly,unpublish observations).Inall8casesinvolvi g19inadequ elut alph ,thincrease oestrogensinthfollicularphasew ss milarregardlessfsubsequ ntlutfunction (Fig.10),sug estingthatfolliculardevelopmenwasn r al.Icontr t,therwas aprogressiveinc ea ethamountofpregnan diolexcretdu i gthlut al phaseinconsecutivmenstrua!cycle ,showingagradualimprovem ntc rpus luteumfunctionwithsuccessivecy le .Thiwaa sociatedithprogr ssiv declineinsuckling,unt lcompletweaningo rreda dnor allut af nction wasachieved.Th sprogres iveimprovementwaalsoassociat dithprog essiv increasetheamountofLHrel s dduringthemidcyclpreovulatorys g (Fig.10). Thus,itwouldappeart atsuck ingcannsomeydisr tt enor algene ¬ ationofthepreovulatorysurgeandresultinfailutdisch rgnormalam nts ofLHaroundthetimffinalmaturationfthepreovulatoryfolliclandy bethecauseofsubsequentinadequatc rpulu umfu tion.Ifthw rt case,thenitouldbenvisagedtdura ioofmenstrualcyclwithinade¬ quatecorpusluteumfunctionisdependentonthd ratiofc nc mitantsu kli g activity,perhapsinarticularigh -timefeeds.Whaveprevio slyshownth prolactinresponsetsucklingigreaterntheaft nothanmor i g(15).
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FIG.10Changesiurinaryoestrogen(EC),pregn nediol(P:C),aLH(L ;C)arlymor ¬
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Editor
A.S.McNeilly MethodsofAsses ingRe umptiofOvariaActivity Clearly,theonlys tisfactorymethodfs essingr umpti nofov riaact vityi measureoftheincr asnoe trogensec etion.Thincr asei prog steroner gnanediol, beingproductsofthec rpulute m,cc rsaftervulation,bywhicht meonceptioand thuspregnancycouldhaveocc rred.Itispossibleth tme surefelectro ytch g s usingadipstickforalivaorbreastm lm ghteused,th reindicationsofs nificant changesinelectrolytesthmid-follicularphaseftmenstrualc cle(1).
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Moredirectly,asimpleme hodf rthm asu mentofoestrogenneedsbd velop d.
Intermsofchemicalendpoints,adipstickethodc ulbdev lopedw ichulmeasure anincreasei oestrogensiblo d,urine,rsaliva.Thtt rworeth lypracticalbodyflui srsuchatest.Asimplerandequallyappropriatemethodt em asurement ofcervicalmu uso tputaintheBillingsmethod(2).Thei cr asem cusroduction
isdependentonincreasingamountsofo strogen,andth yincrea emucus breastfeedingwome ,hodurinl c atio aln rrhoeaoftenhasv ryl wo str gen levels,wouldbp tentiallyaexcellentmarkerf rthr ump ionofvariactiv t . ComparativeAspectsoftheRol fPr lactininthSuppre sionofOv riaA t vity Thisisanmmenselycomplexsubj ctwhi hasb nrevi wedcently(3).Studi si ratsmaybevermisleading,inparticulart rmsofffectsprolactinndc rpuslu um function,sincenfu ctionwilloccurithabs cefh ghlev lsfprolactin,whi ha womanwouldbeindicativefp thologicalhyperprolactinaemiadmenorrhoea.Sim l rly,increasesinprolactinindu enincreaseindop minet r ov rihhypothalamusft rat,mouse,andhams er.Ithratt isiassociatedw hdecre seigonado rophin secretion,wh reasinmiceandhamstersgo ad trophinse r tioi nhanced.Fi lly,d ry cows,whicharemilk dtw edaily,returntoo strousbetw en30and9d postpartum. Iftheyaresuckledbyourcalves,oestrousnsetidelay dpt300orm ed .Ib th cases,howeverplasmalevelofprolactinretha e.T us,itrydiffi ulttor tionalize thevariableeff ctsofprolactintsingleme hanismf rthsuppres ionfov ianvity. 1.HartmanPE,rosserCG.Acuteh ngesintcompositionfilkd ingthvulatoryen trual cycleinla tatingwom .JPhys ol(Lond)1982;324:21-30. 2.BillingsL,BillingsJJrownBBur erHG.Symptomsa dnormalchangesacco panying ovulation.Lancet1972;1:282-4. 3.McNeillyAS.Prolactinandovar anfunctio .I :Mu lerEE,odRMs.euroend crine perspectives,vol.3.Amsterdam:El vierSci ncePublic tions,1984;279—316. CRobyn:Isthefrequ ncyasimporta tthedurationfsucklingim in a ingthe lactationalhyperprolactinaemia?C uldi ald tco ributeta swerh squ stion? A.SMcNeilly:Theprincipalsuppressorofgonadotr phinsecretion,ap e tlythr ugh suppressionoftheab lityfhypothalamustgeneratea dmaint inpulsa les cre on ofGnRH,istheucklingfreq ency.Itappearsthatwhesu klingrequ ncyiigh,10to 20timesp rday,th nurationofeachsu klingepi oden tverycritical.How v r,he sucklingfrequenciesdeclinetol veln rmalithWesternworld,i. .fivt ixtim s perday,th nurationoesbecomefimporta ce.Isclearfr udatth tcline insucklingduratioaloneienoughtrigg rresumptionfvariaact vityi heabs nce ofachangeinsucklingfreq ency. Idonotbelieveanimalstudi sw lh punravelthrel tiveimpo nceffr quencyand durationnybettertham res udi sidifferenthumanculturalsituatio s. C.Robyn:Auditory,olfactory,a dv sualexteroceptivestimulic ntributetincr ased serumlevelsofprolactininanimals.Iotaw refd tathei fl enc sth s
J. steroid Biochem. Vol. 32, No. IB, pp. 167-170. 1989
Printed in Great Britain. All rights reserved
0022-4731/89 53.00 +0.00
Copyright £> 1989 Pergamon Press pic
FSH AND THE CONTROL OF
FOLLICULAR GROWTH
Anna F. Glasif.r. D. T. Baird and S. G. Hillier
Department of Obstetrics and Gynaecology, University of Edinburgh. 37 Chalmers Street, Edinburgh
EH3 9EW, Scotland
Summary During 70 days or so from the time of recruitment until just before the beginning of
the cycle during which a follicle is destined to ovulate, folliculogenesis is a continuous process
dependent on gonadotrophins but independent of the fluctuations in their concentrations occurring
during this time. For follicle growth to continue beyond the 2-4 cell antral stage FSH concentrations
must rise above a certain threshold level at the correct time. Once threshold levels are exceeded a
single follicle becomes dominant suppressing FSH concentrations to subthreshold values. The
period during which FSH concentrations are above threshold can be imagined as a gate through
which a follicle must pass if it is to ovulate.
INTRODUCTION
In the human female 99% of oocytes formed during
fetal life undergo atresia or degeneration [1] and
normally only one preovulatory follicle develops to
the point of ovulation. In this paper we shall consider
the role of gonadotrophins and in particular of FSH
in folliculogenesis and in the process of follicle selec¬
tion and dominance.
RECRUITMENT
The ovarian follicle destined to ovulate is drawn
from a pool of non-growing primordial follicles, each
consisting of an oocyte, a few granulosa cells and a
basement lamina. Within the ovary at any one time
90-95% of all follicles are primordial and only a few
are recruited into the growing pool. The cohort of
growing follicles undergoes a process of development
and differentiation which takes about 85 days and
spans three ovarian cycles [2]. During this process
normally only one follicle will eventually ovulate, the
rest undergo atresia at various stages of development.
MECHANISMS OF RECRUITMENT
Mechanisms involved in the process of recruitment
are poorly understood, but appear to be independent
of pituitary control and probably depend on ovarian
paracrine mechanisms [3], The number of primordial
follicles recruited into the growing pool is not con¬
stant but varies with age. being greatest in early life
[4] and decreasing progressively with advancing
years. In addition the fraction of primordial follicles
recruited is probably a function of the actual size of
Proceedings of the XIII Meeting of the International Study
Group for Steroid Hormones (Rome, Italy, 30
November 2 December 1987).
the total pool available which appears to be affected
by testosterone [5] and may be influenced by other
factors such as nutrition, activity of the thymus gland
and opioid peptides.
INTERMEDIATE FOLLICULAR DEVELOPMENT
Over the next few weeks the recruited follicles
undergo development and differentiation. The num¬
ber of granulosa cells increases; the oocyte becomes
fully grown and a zona pellucida develops; thcca cells
align outside the basement lamina and the follicle
acquires an independent blood supply [6]. Only a
fraction of the total number of follicles that started
the growth sequence reach the stage of becoming
potential ovulatory follicles, i.e. follicles capable of
undergoing maturation to the point of ovulation. At
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Fig. 1. Intercycle FSH rise #—# stimulating follicle































Fig. 2. From Zeleznik A. J. and Kubik C. J. (1986)
Endocrinology 119 2025-2032. Plasma gonadotropin and
oeslradiol concentrations in a cynomolgus monkey infused
with hFSH and liLH at a frequency of 1 pulse/'h. The first
arrow indicates the initiation of liFSH and hLH infusion.
The subsequent double arrows indicate a doubling of the
amount of FSH given per pulse. After the initial rise in
serum oestradiol concentration, the amount of FSH was
reduced by 12.5%/day.
only about 20 or so precursor follicles [1] 2-4 mm in
diameter capable of further development, a process
which depends on the appropriate gonadotropin
stimulation.
As the previous corpus lutuem regresses, FSH
secretion increases [7] (Fig. 1). This rise in FSH is
thought to propel suitably responsive precursor fol¬
licles into the final phase of their growth cycle.
Follicles which reach this stage of development at any
other time will not receive adequate LH stimulation
and will become atretic [8], It may be that by
increasing the amount of FSH available or pro¬
longing the duration of the late luteal phase rise more
follicles would be available for development in the
follicular phase of the next cycle. For follicular
development to occur at all, gonadotropin concen¬
tration must be above a certain threshold require¬
ment. Treating women with hypogonadotrophic hy¬
pogonadism, Brown 1978 [9] showed that ovaries
remained unresponsive to subthreshold levels of go¬
nadotropins even if the same dose was continued
indefinitely. The threshold varies between individuals
by as much—in the case of exogenous gonadotropin
therapy—as a factor of 10. A stepwise increase in the
dose of gonadotrophins will identify the threshold
requirement and when this is attained follicular devel¬
opment begins. In a given individual the difference
between a subthreshold dose and a dose sufficient to
stimulate follicular development may be as little as
20%. While early follicular phase rises in FSH con¬
centrations are only small, the increase is nevertheless
enough to initiate follicular development beyond
4 mm. If this early follicular phase rise is inhibited by
oestradiol injection or by the injection of follicular









Fig. 3. Plasma oestradiol and urinary pregnanediol concentrations in a woman with hypogonadotrophic
hypogonadism treated with LH 4.7 U/pulse and a dose of FSH increased by 30% after 5 days. Following
the initial oestradiol response FSH was reduced ▼ by 10%/day—follicular development continued to
ovulation.
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DAYS PRIOR TO hCG
Fig. 4. Growth of the three largest follicles in a woman with
hypogonadotrophic hypogonadism. Treated in the first cy¬
cle with FSH concentrations maintained above threshold
levels all three follicles continued to grow. In the second
cycle the amount of FSH per pulse was reduced by 10%/day
from the time of the initial rise in oestradiol •—• Only
the largest follicle • continued to increase in diameter, the
second O and third ▲ largest appeared to undergo atresia.
There is good evidence from the work of Goodman
[11] in the rhesus monkey, and Nilsson in the human
[12], that follicular development at this stage is
subject to critical phases. Destruction of either the
dominant follicle or the corpus luteum results in a
delay of about 14 days before a second follicle reaches
the same stage of development. This suggests that at
the time of ablation the follicle destined to ovulate
has already been irrevocably selected and no other
follicle is capable of substituting for it. The dominant
follicle inhibits growth of both new follicles and less
mature follicles and the next follicle to ovulate is the
product of a new cohort of follicles which develop
subsequently.
SELECTION
Developing follicles acquire FSH receptors during
the early stages of differentiation. Binding of FSH
stimulates the induction of aromatase systems en¬
abling the aromatisation of androgens, produced by
theca cells under the influence of LH, to oestrogens.
In response to stimulation by FSH and oestradiol the
precursor follicles eventually also acquire LH recep¬
tors. The follicle which most rapidly acquires aro¬
matase activity and LH receptors probably becomes
the dominant follicle [8],
In natural cycles normally only one follicle is
destined to ovulate. Once a follicle has acquired
dominance its presence appears to inhibit the growth
of less mature follicles.
Zeleznik and Kubik [13] 1986 recently reported the
results of a study in macaque monkeys demonstrating
that after stimulation by elevated FSH concen¬
trations, follicles can continue to mature in the
presence of FSH concentrations which are unable to
support the growth of less mature follicles^ Animals
were treated with a GnRH antagonist to block
endogenous gonadotrophin secretion. Follicular de¬
velopment was then initiated with a constant dose of
LH and a dose of FSH which was increased every 3-4
days until the initiation of oestrogen secretion, i.e.
until the threshold level for follicular growth was
reached. A progressive reduction in FSH dose over
the subsequent 5 days to concentrations below the
threshold dose was accompanied by continued pre¬
ovulatory follicular growth (Fig. 2).
In Edinburgh, we are carrying out a similar study
in women with hypogonadotrophic hypogonadism.
Follicular development is initiated with a constant
dose of LH given subcutaneously in a pulsatile
manner. The dose of FSH, also given in a pulsatile
manner, is increased every 5 days by 30% until the
threshold level—determined by increasing oestradio!
secretion and ultrasound evidence of follicular
growth—is reached. FSH administration is then ei¬
ther continued at the threshold dose or decreased by
10% each day (Fig. 3). In the women who have so far
completed treatment, reducing the dose of FSH
below threshold levels results in a reduction in fol¬
licular diameter in the majority of developing follicles
(Fig. 4).
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IRQ BOTH LH & FSH ARE REQUIRED FOR THE DEVELOPMENT OF THE NORMAL
FOLLICLE
A.F.GIasier, E.J.Wickings, M.W. Rodger, S.G.Hillierand D.T.Baird; Department of Obstetrics &
Gynaecology, University of Edinburgh, Centre for Reproductive Biology, 37 Chalmers Street,
Edinburgh EH3 9EW
The current hypothesis for selection and growth of the preovulatory follicle involves activation
with FSH; increasing oestrogen secretion dependent on the conversion of thecal androgen
stimulated by LH; and subsequent suppression of pituitary FSH by rising levels of oestrogen.
This implies that the dominant follicle must become increasingly sensitive to FSH. We have
tested these hypotheses relating to follicle growth in two women with hypogonadotrophic
hypogonadism. In experiment 1 follicular growth was induced by either Metrodin (FSH) or
Pergonal (FSH and LH) the dose being increased by 30% every 5 days. ''In the second
experiment when the threshold was reached (plasma E2 concentration >300 pmol/l) the dose of
FSH was reduced by 10% each day. 5000 units of hCG were injected when the E2
concentration reached >1000 pmol/l (day 0). In experiment 1 on day 0 the number of large
antral follicles was much greater in the cycles treated with FSH alone than with LH and FSH(9 &
12 vs 3 & 2) and the plasma E2 / follicle was abnormally low (268 & 92 vs 547 & 553 pmol/l). In
experiment 2 when the dose of FSH was reduced there were fewer large antral follicles than
when it was maintained above the threshold level (2 & 2 vs 5 & 5). We conclude that (1) both
FSH and LH are required for normal secretion of E2 by the preovulatory follicle confirming the
two cell hypothesis (2) once selected the preovulatory follicle can continue growing in the





































































































































































































































































































































































































































































































































































Figure6.2Chang sinarytotalestrogensa dpregnanedioli relationtohesucklingfrequencya ddurationdevelsf prolactininbreast-feedinawoma .(FromH wiea dMcNeilly.1982.) developmentisalsouppressed,asureith ro t ogenv ls
















































































































































































































































































































































































































































withraisedlevelsofprolactin(s eMcNe lly,1984)w ichh slto thesuggestiont atprol ctip rsemaybinv lvednthsuppres¬ sionofovarianactivity.H wever,hilstprol ctinmaybin l ed, thisinvolvementappearstobminimala drelatedthf ct thelev lofhyperproiactinaemiaisdir ctlycorre atedwithsu k ing activity(McNeilly,Gl sierndHowie,1985). Ovarianctivitycabestimulatedduringla io ala enorrhoea bytreatmentwithexogenousgonadotr phins(AndreassendTys . 1976;Nakanoera/.,5)inspiteofr isedlevelsprolactin.Thus, lactationalinfertilitysm stpr bablyduetreduct oni gonado- trophinsecretion. Gonadotrophins Duringthemenstrualcycle,follicleg owthistimulatedin ti llybyFSH.Continuedf lliclegrowthrequiresbothFSHanLwhichis releasedinapulsatilemannerfromthpituitaryosti ulateoe tra- diolsecretion(F gure6.4).Thincreases radiolch s criticalleveasthpreovu atoryfoll lematur sandtriggerth mid-cyclesurgeofLHwhi hcaus sovulationndtformatif
OJthecorpusluteum(Fig re6.4).Thmaintenanceffollic lard v l¬ opmentisdependentnthulsatilesecr tionofLHwhichcursas aresultofthepul atiler leasefgonadotrophin-releasinghorm n (GnRH)fromthehyp thalamus.Itmenstrualcycle,o stradiol appearstoincreasethfrequencyfp lsatileGnRHrel aswh eas inthelutealph serogesteroneandoestra iolfr mtcorpus luteumsuppresshfreq ncyresultinginareductiontheulsatile secretionofLH.Thisdecrea eappearstobr latedtinc sen hypothalamicpioidact vitywhichaffe tst eGnRHneurones (Crowleyetal.,1985;Lincoln.,1 5). Duringlactat onplasmalevelsofFSHincreasewithinhrewe ks postpartumandremainwiththeno malrangeftmenstrual cyclesthroughouthpostpartumperiod(s eMcN illy,1979).In contrasttFSH,LHlevelnlyin r a etohelow rimiformal bytwentydayspostpartumandremainsup ressedithm jorityf womenthroughoutlactationalmenorrhoea(Delv ytl.,1978; Rollandetal.,1975;McNeilly,How eouston.1980;G i r. McNeillyandHowie,1983).TheslevelsfLHarssociated withlowamplitudepu sesofLHtfrequ ncysimilartorl ha thatofelutealph se(Maddenl.,1978;Tysoa19 Glasier,McN illyndHowie1984).Th sreductioniLHsecr ti
AlanS.McNeilly,P.W.HowiendAn aGlasier109 OPIOIOS.GONADOTROPHINSANDTHEMENS RUALCYCLE LHSURGE



















































































































































































































































































































































































































































































































































































































































NUTRITION,LACTATIONNDREPRODUCTIIEDEER ADLIBITUMFOOD MAXIMUMILKPRODUCTION 2SUCKLINGEPISODESPERDAY NOREJECTIONS 800SEC.UCKLING/DAY NORMALONSETFESTRUSIAU UMN RESTRICTEDFOOD 30%MAXIMUMILKPRODUCTION 4SUCKLINGEPISODESERDAY 5REJECTIONSP RDAY V300SEC.UCKLING/DAY!c~_ *~~OESTRUSNSETD LAYED 7-20DAYSINAUTUMN F̂romLoud n.Mllno&McNeilly(1983)Naturo30245-147
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III women, breastfeeding results in a variable period of
ovarian inactivity which is apparently related to suppression
of the normal pulsatile release of luteinizing homone (IJI).
However, pulse profiles had only been studied during the
daytime. Since resumption of pulsatile LH secretion during
puberty is initiated at night, the present study determined
the pattern of pulsatile LH secretion in relation to that of
follicle stimulating hormone (FSH) and prolactin, and suckling
and ovarian activity at 4 and 8 weeks postpartum in 20 fully
breastfeeding women with lactational amenorrhoea. Blood
samples were withdrawn at 10 min intervals for 24 h from
0900 It to 0900 h at either 4 weeks (n = 9) or 8 weeks (n = 11)
postpartum, while the mothers and babies continued their
normal pattern of suckling activity. At 4 weeks postpartum,
no LH pulses occurred over 24 h in six of the nine women
while one (;i = 1) or two (it = 2) LH pulses occurred in three
of the nine women. In contrast, LH pulses were present in
nine of the 11 women at 8 weeks postpartum. The pulse
frequency varied considerably from two to eight pulses over
the 24 h and there was no influence of the time of day or
sleep on the time of the pulse release. Lactational amcnor-
rhoea was maintained for at least 10 weeks afterwards and
there was no relationship between the time of resumption of
ovarian activity and the presence or absence of pulsatile L1I
secretion at 4 or 8 weeks postpartum. Plasma concentrations
of FSH increased from 4 to 8 weeks postpartum and were
higher in women with than in women without LH pulses. In
two women, clear pulses of FSH with a half-life of —72 min
were observed coincident with LH pulses. There was no
difference in the suckling pattern or plasma concentrations
of prolactin in women in whom pulsatile LH was or was not
observed suggesting that prolactin perse was not involved in
the suppression of pulsatile LH release. Assuming that each
pulse of LH represented a pulse of gonadotrophin releasing
hormone (GnRIl) released from the hypothalamus, the
present study suggests that during the period of total ovarian
inactivity, suckling disrupts, but does not totally inhibit, the
normal pattern of pulsatile GnRH release and hence release
of LH and FSH from the pituitary. Thus, suckling maintains
ovarian activity during lactational amenorrhoea by causing
an abnormal pattern of gonadotrophin release that is
insufficient to drive follicle development.
Key words: pulsatile LH/lactational amenorrhoea/FSH/prolactin
Introduction
Although breastfeeding plays an important role in the regulation
of fertility, the mechanisms controlling the suppression of ovarian
activity during lactation remain unclear (see McNeilly, 1988a,
1992). Previous studies (Glasier el al., 1984a) have suggested
that lactational infertility may be due to the inhibition of the
pulsatile secretion of luteinizing hormone (LH). In those studies,
the secretory pattern of LH was studied for only 7 h between
0900 h and 1700 h. However, the maintenance of night-time
breastfeeding is associated with a prolonged duration of lactational
infertility (Howie and McNeilly, 1982; McNeily et a!., 1985).
In non-lactating women there is a significant diurnal variation
in prolactin secretion with a nocturnal rise in prolactin concen¬
trations which, if maintained during breastfeeding, may be of
importance in suppressing ovarian activity. The prolactin response
to suckling is greater during the evening and night than during
the daytime (Glasier et al., 1984b; Diaz el al., 1989, 1991).
There may also be similarities between the resumption of
ovarian activity during breastfeeding and those patterns observed
at the onset of puberty where pulsatile LH secretion occurs
initially only at night during sleep (Plant, 1988; Wu etal., 1991).
It is thus plausible that disturbances in the secretory pattern of
gonadotrophins and prolactin may be responsible for the
maintenance of infertility during lactation, but that these
abnormalities are not apparent if the pattern of hormone release
is studied only during daylight and waking hours.
The aim of the present study was to establish the 24 h secretory
pattern of gonadotrophins and prolactin in relation to suckling
pattern during the early part of the puerpcrium, at 4 and 8 weeks
postpartum, when women were exclusively breastfeeding and
amenorrhoeic.
Materials and methods
Subjels and sampling methods
The study was approved by the Lothian Health Board Ethics
Committee. Full details of the longitudinal study were explained
to all the potential recruits while they were still in the postnatal
ward of the Simpson Memorial Maternity Pavilion (SMMP),
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Royal Infirmary, Edinburgh, and they were given a detailed
information sheet about the study. The women were then
contacted by telephone after discharge from hospital to allow them
time to discuss participation in the study with husbands and
friends. If they decided to volunteer for the study, they were
visited in their own homes when a written informed consent was
obtained with the understanding that they could withdraw from
the study at any time.
The mothers chose their intended feeding practices following
the advice of their midwives and health visitors. Health care for
the mothers and infants was provided by their own general
practitioners and apart from the interest obtained from taking part
in the study no benefits would accrue to the women taking part.
There were no financial reimbursements for taking part in the
study.
Twenty-four hour secretory patterns of gonadotroph^ were
investigated in 20 breastfeeding women at either 4 (n = 9; Group
1) or 8 (« = 11; Group 2) weeks postpartum. All the women
were amcnorrhoeic at the time of investigation. The infant feeding
pattern was recorded daily in a diary, the total number of suckling -
episodes over 24 h was recorded daily. Night-time suckling
episodes were defined as those which occurred between 2200 h
and 0600 h and were recorded separately from daytime feeding
episodes. The average duration of the suckling episodes was
recorded in minutes. Any supplementary food other than breast
milk given to the baby was recorded. Supplementary feeds were
defined as formula or cow's milk feed from a bottle or cup, or
any feed of solid food. Forty-eight hours prior to admission to
the Research Unit for serial blood sampling, a more detailed
infant feeding chart was completed. In addition to the suckling
frequency and duration, the exact timing of each suckling episode
throughout the 48 h prior to admission was recorded.
The women were admitted with their infants to the Research
Unit of the SMMP. While in the Unit, no restrictions were made
on physical activity or food intake beyond that placed by a hospital
environment, and women slept at night according to their usual
pattern. Breastfeeding took place on demand. The activity of the
mothers was recorded by observation, including meal times, times
and duration of breastfeeding and sleep pattern. Lights were
switched off between 2300 h and 0700 h. On admission to the
unit, a 20 G Venflon intravenous cannula was inserted into a
forearm vein at - 0900 h and a 2.5 ml sample of venous blood
was collected every 10 min throughout 24 h; the plasma was
separated and stored at -20°C and later assayed for LH, follicle
stimulating hormone (FSH) and prolactin. At night during sleep,
the blood samples were collected through a long intravenous
catheter which passed through a hole in the wall to the adjoining
laboratory, allowing blood samples to be collected without
disturbing the women's sleep.
Ovarian activity was monitored by the measurement of urinary
oestrone glucuronide and pregnanediol glucuronide in weekly
urine samples from 2 weeks postpartum for the duration of the
sampling period until the first ovulatory cycle.
Hormone assays
Plasma concentrations of LH and FSH were measured by radio¬
immunoassay as described previously (Djahanbakhch el al., 1981;
Hunter and Bennie, 1979) while plasma prolactin was measured
952
in a two-site immunoradiometric assay (NETR1A, St. Bar¬
tholomew's Hospital, London; Wu et al., 1990). The intra- and
inter-assay coefficients of variation were <8% and <11%
respectively for LH, FSH and prolactin. Concentrations of
oestrone glucuronide and pregnanediol glucuronide in urine were
measured as described previously and corrected for the amount
of creatinine in each sample (Fraser et al., 1989). All urine
samples were assayed in one group with an intra-assay variation
of <10%.
Statistical analysis
The data are presented as the mean ± SEM except where
otherwise stated. Comparisons between mean hormonal
concentrations and the various parameters of pulsatile LH
secretion were performed using Student's unpaired /-test on log-
transformed data. Significant hormone pulses were identified
using the 'MUNRO' pulse analysis program (Zaristow Software,
Haddington, Scotland EH 14 4PD) which is based on the Pulsar
algorithm (Merriam and Wachter, 1982). To identify an LH peak,
the algorithm was adjusted to require a threshold of two standard
deviations (SD) above the baseline with a minimum pulse interval
of 30 min. A 30 min smoothing window was used to generate
the moving average in the baseline calculation. The nadir window
was 30 min and the rise threshold (in SD units) to which the
peak must rise above the nadir was 0.5. The mean pulse
frequency, pulse amplitude, pulse area and nadir levels of LH
release were compared between the different groups of women.
Results
Comparison of suckling pattern and ovarian activity at
4 and 8 weeks postpartum
The mean number of suckling episodes and suckling duration
during the week prior to the day when the pulse bleed was
undertaken are shown for both groups of women in Table I. All
the women were fully breastfeeding at the time of the investiga¬
tion. There was no statistically significant difference in the timing
of the eventual introduction of supplementary food nor in the
total duration of lactational amenorrhoea between the two groups
of women.
While there was no difference in the total amount of time that
the baby spent at the breast during 24 h (suckling duration), the
women who were studied at 8 weeks postpartum were giving
significantly (P < 0.05) fewer breastfeeds (suckling frequency)
than those studied at 4 weeks postpartum (6.47 ± 0.40 versus
8.30 ± 0.66 episodes/24 h). This reduction in suckling episodes
was accounted for by a decline in night-time feeds which occurred
significantly (P < 0.01) less often by the eighth postpartum week
(1.42 ± 0.20 episodes/24 h compared with 2.49 ± 0.32
episodes/24 h at 4 weeks). The mean urinary oestrone-3-
glucuronide excretion at 4 weeks postpartum (24.45 ± 5.33 pg/g
creatinine) was not significantly different from that at 8 weeks
postpartum (20.01 ± 2.57 yeg/g creatinine; Table I).
Comparison of mean LH, FSH and prolactin
concentrations at 4 and 8 weeks
The mean ± SEM plasma concentrations of LH, FSH and
prolactin for the 20 individual women were calculated from the
29
J
Pattern of 24 h pulsatile LI1 in lactational amcnorrhoca
Table I. Comparison of suckling pattern and ovarian activity (mean ± SE) al 4 and 8 weeks postpartum in fully breastfeeding women and the subsequent
lime of introduction of supplements and duration of amenorrhoca
Time postpartum
4 weeks 8 weeks
(// = 9) (/i = U)
Urinary ocstronc glucuronidc (/*g/g creatinine) 24.45 ± 5.33 20.01 ± 2.57
Urinary prcgnanediol glucuronidc (ftg/g creatinine) 0.53 ± 0.08 0.51 ± 0.07
No. of sucklingepisodes (24 h) 8.30 ± 0.66 6.47 ± 0.40*
Suckling duration in min (24 h) 137.46 ± 12.89 143.70 ± 15.81
No. of suckling episodes (day) 5.92 ± 0.39 5.05 ± 0.29
Suckling duration in min (day) 97.84 ± 10.31 112.14 ± 12.54
No. of suckling episodes (night) 2.49 ±- — —L42- ± 0.20**
Suckling duration in min (night) 39.62 ± 4.09 31.57 ± 5.40
Time of introduction of supplements (weeks postpartum) 16.29 ± 1.70 15.18 ± 1.03
Duration of amcnorrhoca (weeks postpartum) 33.71 ± 5.44 33.36 ± 4.48
*P < 0.05, **P < 0.01.
Table II. Mean (±SE) plasma concentrations of prolactin, follicle stimulating hormone (FSH) and luteinizing hormone (LH) and the characteristics of
pulsatile LH secretion over a 24 h period at 4 weeks postpartum in fully breastfeeding women. The urinary concentration of oestronc glucuronidc in an early
morning urine specimen on the day of sampling is also given




LH (U/l) LH pulse parameters
No. of pulses Inter-pulse







1 1905 ± 156 2.30 ± 0.30 14.67 1.16 ± 0.02 None - - -
2 1237 ± 109 0.93 ± 0.02 20.62 2.71 ± 0.02 None - - -
3 1214 ± 84 1.12 ± 0.03 18.86 2.11 =t 0.02 None. - - -
4 2631 ± 254 2.23 ± 0.05 13.58 3.98 ± 0.05
.
None - - -
5 1454 ± 67 2.01 ± 0.04 21.52 3.28 ± 0.03 None - - -
6 2259 ± 39 2.16 ± 0.04 24.45 1.82 ± 0.03 None - - -
7 3686 ± 38 2.10 ± 0.05 19.74 2.55 ± 0.07 2 440 2.48 ± 0.44 184 ± 32
8 2584 ± 156 2.63 ± 0.09 60.44 2.54 ± 0.08 2 210 1.84 ± 0.45 162 ± 59
9 4927 ± 68 4.34 ±0.11 26.14 2.84 ± 0.05 1 - 1.63 409
Table III. Mean (± SE) plasma concentrations of prolactin, follicle stimulating hormone (FSH) and luteinizing hormone (LH) and the characteristics of
pulsatile LH secretion over a 24 h period at 8 weeks postpartum in fully breastfeeding women. The urinary concentration of ocstronc glucuronide in an early
morning urine specimen on the day of sampling is also given















10 1268 ± 35 2.75 ± 0.09 20.00 1.66 ± 0.03 None _ - -
11 3515 ± 165 0.93 ± 0.04 13.97 1.48 ± 0,03 None - - -
12 2019 ± 133 4.32 ±0.11 10.86 3.49 ± 0:20 2 340 ± 94 10.87 ± 1.38 673 ± 222
13 1514 ± 103 6.64 ± 0.11 15.56 2.61 ± 0.06 5 257 ± 26 1.25 ± 0.16 88 ± 9
14 3380 ± 165 4.39 ± 0.07 9.91 2.94 ± 0.07 2 160 LI 7 ± 0.19 173 ± 109
15 5416 ± 224 3.38 ± 0.06 19.90 4.81 ± 0.25 4 270 ± 5 7.22 ± 3.94 477 ± 296
16 1307 ± 59 4.96 ±0.11 22.01 6.12 ± 0.21 2 550 4.38 ± 1.58 324 ± 198
17 938 ± 49 2.69 ± 0.06 30.26 3.77 ± 0.15 7 147 ± 36 3.38 ± 0.71 204 ± 44
18 1213 ± 106 5.12 ± 0.06 18.46 6.05 ± 0.14 8 186 ± 41 3.74 ± 0.35 223 ± 24
19 3389 ± 113 4.04 ± 0.12 35.17 4.22 ± 0.17 4 180 ± 48 5.36 ± 1.48 339 ± 134
20 812 ± 68 5.04 ± 0.16 23.61 1.63 ± 0.04 3 470 ± 147 1.26 ± 0.09 128 ± 55
144 samples obtained during the 24 h of serial blood sampling.
Results for Group 1 studied at 4 weeks postpartum are shown
in Table II and for Group 2 studied at 8 weeks postpartum in
Table III.
The mean concentrations of LH, FSH and prolactin for both
groups of women are shown in Table IV. The overall mean
concentration of LH at 4 weeks postpartum was not statistically
significantly different from the mean LH concentration at 8 weeks
postpartum. Similarly the mean prolactin concentrations were not
signiftcandy different when the two time periods were compared.
In contrast, the overall mean FSH concentration at 8 weeks
postpartum (4.02 ± 0.46 U/l) was significantly (P < 0.05)
953
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higher than the mean FSH concentration at 4 weeks postpartum
(2.20 ± 0.32 U/l).
Individual 24 h secretory patterns of LH
The various parameters of the individual pulsatile LH secretion
in the two groups of women are shown in Tables II and III. At
4 weeks postpartum, the 24 h LH secretory pattern showed a
complete absence of statistically identifiable pulses of secretion
in six of the nine women studied (Table II). In the other three
women, there was a return of pulsatile LH secretion although
there were no more than two statistically significant LH pulses
over the 24 h as detected by the 'Munro' computerized algorithms
(Table II).
Figure 1 shows the 24 h secretory pattern in two women at
4 weeks postpartum. In Subject 1, the LH secretory pattern was
fully suppressed and non-pulsatile. In contrast, the LH secretory
pattern of Subject 7 showed a return of LH pulsatility which was
characterized by a slow frequency (2 pulses/24 h) and small
amplitude (2.48 ± 1.00 U/l). In contrast, at 8 weeks postpartum,
nine of the eleven women studied showed a return of pulsatile -
LH secretion (Table III). Only two women had a fully suppressed
LH secretory pattern. All the women were amenorrhoeic and
the ovarian activity was completely suppressed as shown by the
low level of urinary excretion of both oestrone (Table III) and
pregnanediol. Figure 2 shows the LH secretory profiles in two
women at 8 weeks postpartum. Subject 10 had a fully suppressed
LH secretory pattern. In Subject 17, seven statistically significant
LH pulses were detected over 24 h with a mean LH pulse
amplitude of 3.38 ± LOO U/l.
Comparison of the pulsatile secretion of LH at 4 and S
weeks postpartum
The mean concentration of LH and the various parameters of
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Fig. I. Changes in the plasma concentrations of luteinizing
hormone (LH) over a 24 h period ai 4 weeks postpartum in two
fully breastfeeding women. The asterisks indicate a significant pulse
of LH.
in Table IV. Although there was no statistically significant
difference in mean LH concentration at 4 and 8 weeks post¬
partum, the 24 h secretory patterns were significantly different
as characterized by the gradual return of pulsatile LH secretion.
The LH pulse frequency was significantly IP < 0.05) increased
at 8 weeks postpartum (3.36 ± 0.78/24 h) compared with the
frequency at 4 weeks postpartum (0.56 ± 0.29/24 h). However,
the LH pulse amplitude, pulse area or nadir between pulses was
not significantly different at 4 and 8 weeks postpartum (Table IV).
Comparison of women with pulsatile and non-pulsatile LH
secretory patterns and pulsatile secretion of FSH
Ignoring the time postpartum, the 20 women were divided into
two groups according to the presence or absence of pulsatile LH
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Clock lime
Fig. 2. Changes in the plasma concentrations of luteinizing
hormone (LH) over a 24 h period at 8 weeks postpartum in two
fully breastfeeding women. The asterisks indicate a significant pulse
of LH.
Table IV. Comparison of main concentrations (mean ± SB) of follicle
stimulating hormone (FSH), prolactin and luteinizing hormone (LH) and the
characteristics of the pulsatile secretion of LH at 4 and 8 weeks postpartum
in fully breastfeeding women
Time postpartum
4 weeks 8 weeks
(/i = 9) (n = 11)
Mean FSH (U/l) 2.20 ± 0.32 4.02 ± 0.46*
Mean prolactin (mU/l) 2433 ± 409 2252 ± 442
Mean LH (U/l) 2.55 ± 0.27 3.53 ± 0.50
LH pulses absent 6 2
LH pulses present 3 9
LH pulse frequency (per 24 h) 0.56 ± 0.29 3.36 ± 0.78*
LH pulse amplitude (U/l) 1.98 ± 1.26 3.93 ± 0.82
LH pulse area (U/I) 252 ± 79 292 ± 62
LH pulse nadir (U/l) 2.01 ± 0.49 2.78 ± 0.52
*P < 0.05 compared to 4 weeks postpartum.
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plasma concentrations of FSH or prolactin, the suckling and
ovarian activity and the subsequent duration of amenorrhoca in
women who resumed compared to women who had not resumed
pulsatile LH secretion. Eight women had a non-pulsatile LH
secretory pattern while 12 women had a pulsatile profile. Table
V shows the mean suckling frequency and duration in the two
groups of women. There was no statistically significant difference
in the suckling pattern in the two groups or in the time of
Table V. Comparison of the. pattern of suckling and ovarian status (mean
± SE) assessed by the urinary concentrations of ocstrone glucuronide and
prcgnanetliol glucuronic in fully breastfeeding women at 4 and 8 weeks in
whom pulsatile secretion of luteinizing hormone (LH) either had not (« =
8) or had relumed (a = 12). The subsequent time of introduction of
supplements and duration of amenorrhoca for these women is also shown
No LH pulses LH pulses
(n = 8) (n = ■ 12)
No. of suckling episodes (per 24 h) 7.4 ± 0.6 7.2 ± 0.6
Suckling duration in min (per 24 h) 139 ± 15 142 ± 14
No. of suckling episodes (day) 5.4 ± 0.4 5.5 ± 0.3
Suckling duration in min (day) 99 ± 12 110 ± 12
No. of suckling episodes (night) 2.2 ± 0.2 1.7 ± 0.03
Suckling duration in min (night) 40 ± 4 32 ± 5
Oestronc glucuronide Otg/g creatinine) 18.7 1.4 24.4 ± 3.9
Pregnancdiol glucuronide (mg/g creatinine) 0.49 ± 0.07 0.53 ± 0.07
Introduction of supplement (weeks) 15.4 ± 1.2 15.7 ± 1.13
Duration of amenorrhoea (weeks) 38.2 ± 5.3 30.5 ± 4.7
introduction of supplementary food or in the total duration of
postpartum amcnorrhoea. In spite of the return of pulsatile LH
secretion, there was no statistically significant difference in the
mean urinary oestrone and pregnanediol excretions in the two
groups of women, indicating no return of ovarian activity.
The mean LH concentration was significantly (P < 0.01)
higher in the women with than in those without a pulsatile pattern
of secretion (3.63 ± 0.41 U/l versus 2.27 ± 0.34 U/l). Although
the mean prolactin concentration was higher in the pulsing group
when compared with the non-pulsing group (2599 ± 451 U/l
versus 1936 ± 292 U/l), the difference did not reach statistical
significance.
The mean FSH concentration was significantly higher
(P < 0.001) in the pulsatile group (4.14 ± 0.37 U/l) compared
with the non-pulsatile group (1.81 ± 0.25 U/l). In addition,
pulses of FSH were identified during two periods of sampling,
one at 4 weeks and one at 8 weeks postpartum in women in whom
pulsatile LH secretion had returned (Figure 3). No pulses of FSH
could be identified in the other 10 women in whom pulsatile LH
secretion had resumed (e.g. Figure 3d). The start of each pulse
of FSH coincided exactly with the start of an LH pulse (Figure
3). The limited numbers of pulses in two women did not allow
a proper statistical evaluation of pulse parameters, but overall
the first decay component of each pulse suggested a mean half-
life of -72 ±5.8 min (n = 5 pulses) with a second component
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Fig. 3. Changes in the plasma concentrations of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in fully breastfeeding
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Discussion
In women who are breastfeeding and not using contraception,
lactational infertility can be divided into three main phases before
the onset of the next pregnancy: (i) the initial recovery from
pregnancy, (ii) the period of lactational amenorrhoea and (iii) a
period when menstruation returns associated with inadequate or
adequate corpus luteum function (McNeilly, 1988a, 1992). In
bottle-feeding women, the resumption of menstruation occurs at
around 8 weeks postpartum (Gray et al., 1987; Howie and
McNeilly, 1982; Howie etal., 1982b). Therefore there appears
to be a finite period after pregnancy during which the hypo-
thalamo-pituitary-ovarian axis takes time to recover from the
effects of pregnancy, even in the absence of breastfeeding.
Thereafter, the suppression of ovarian activity during lactational
amenorrhoea is maintained only if the infant is being breastfed.
The aim of our study was to establish the 24 h secretory pattern
of gonadotrophins and prolactin in relation to suckling activity
and time postpartum during lactational amenorrhoca. At 4 weeks -
postpartum, we would expect ovarian activity to be suppressed
due to time for recovery from the effects of pregnancy, regardless
of the infant feeding method; at 8 weeks an increase in
gonadolrophin secretion, particularly pulsatile LH secretion, may
occur since suckling activity may decline even though
amenorrhoea is maintained (Howie and McNeilly, 1982;
McNeilly el al., 1985).
Although all the twenty women taking part in the study were
fully breastfeeding at the time of the pulse study, there was,
nevertheless, a significant difference in infant feeding patterns
over the 4 week interval. By the eighth postpartum week there
had been a decline in the average number of suckling episodes
over 24 h as a result of a reduction in the number of night feeds,
the frequency of feeding episodes during the day remaining
unchanged. Moreover, despite a fall in suckling frequency, the
total duration of breastfeeding over 24 h, i.e. the total duration
of the suckling stimulus, was maintained. These findings support
those of Howie et al. (1981, 1982a) who described an early
reduction in night-time feeds and observed that when the number
of suckling episodes was reduced (in this case with the intro¬
duction of supplementary feeds) the suckling duration tended to
be maintained for at least some weeks. It would seem that while
the mothers are quick to impose a more sociable and convenient
pattern of feeding on the baby, the child itself manages to take
in the desired amount of milk by spending longer over each feed,
confirming our previous reports in women in Edinburgh (Howie
et al.. 1982a,b; Glasier et al., 1983; McNeilly et al., 1985).
Despite a change in the character of the suckling stimulus
between 4 and 8 weeks postpartum, there was no significant
change in overall plasma concentrations of prolactin, confirming
our previous observations (Howie el al., 1982a; Glasier et til.,
1984b). Moreover, the alteration in suckling patterns appeared
to have no'effect on ovarian activity, as reflected both by
continuing amenorrhoea and by the lack of ovarian activity
indicated by the extremely low concentrations of urinary oestrone
and pregnanediol glucuronide.
Although we were unable to demonstrate any differences in
mean basal concentrations of LH between the women bled at 4
and 8 weeks postpartum, there were clear differences in the
pulsatile pattern of secretion of LH. Pulses of LH only occurred
in three of the nine women at 4 weeks postpartum and only one
or two pulses occurred in the 24 h, although the amount of LH
released in each pulse appeared to be similar to that at 8 weeks.
However, by 8 weeks after delivery, nine of the 11 women
showed the occasional statistically significant pulse of LH
secretion during the 24 h period although the frequency varied
considerably between two and eight pulses in the 24 h. These
results are at variance with a recent report in which low-amplitude
pulses of LH at a normal follicular phase frequency of around
one pulse per hour appeared to occur in all fully breastfeeding
women at 3 weeks and 3 months postpartum (Nunley et al.,
1991). The reason for this discrepancy is not known since in both
studies ovarian activity was fully suppressed. It may be that the
difference is due to the different assay methods employed in the
two studies. In previous studies using the same radioimmunoassay
as in the present study, an absent or reduced LH pulse frequency
was also observed in women in the early postpartum period
(Glasier et al., lP84a). It is of interest that LH pulses were
released at apparently random intervals throughout the 24 h.
There was no enhanced release of LH as seen during puberty
(Plant, 1988; Wu et al., 1991) suggesting that the inhibition of
GnRH output by suckling and the subsequent gradual release from
this inhibition may not be equivalent in mechanism to that
occurring during puberty.
It is clear from our results in the present study that, even though
pulsatile secretion of LH may resume, the frequency of LH pulses
would not be expected to represent an adequate signal to cause
resumption of ovarian activity (Crowley et al., 1985; Lincoln
et al., 1985). We have been able to induce follicle growth and
ovulation during lactational amcnorrhoca by treatment of
breastfeeding women at 6 weeks postpartum with a constant
90 mill frequency of pulsatile GnRH (Glasier et al., 1986). Thus,
it appears that the ovarian inactivity which causes lactational
amenorrhoea is due to a suckling-induced disruption of the release
of GnRH from the hypothalamus at the normal frequency
occurring during the follicular phase of the menstrual cycle
(Backstrom et al., 1982; Crowley et al., 1985). In the present
study, the presence or absence of LH/GnRH pulses at 8 weeks
did not predict the time of resumption of ovarian activity.
The mechanism by which the suckling stimulus disrupts the
pattern of GnRH output from the hypothalamus remains unknown
(McNeilly, 1988a, 19§2). While the high plasma concentrations
of prolactin associated with lactation have been correlated with
the duration of lactational amenorrhoea (Duchen and McNeilly,
1980; Robyn and Meuris, 1982; Gross and Eastman, 1985;
McNeilly el al., 1985; Diaz etal., 1989, 1991; Fink eta!., 1992),
there is no clear evidence that prolactin is the causal agent in
suppression of GnRH (McNeilly, 1987). Indeed, in the present
study, plasma concentrations of prolactin were the same or even
higher in women in whom LH pulses had resumed than in those
in whom no pulses were occurring. This, together with the
observation that pulses of LH occurred at random throughout
the day, including during sleep when prolactin concentrations
are at their highest, suggests that prolactin perse is not implicated
in the suckling-induced suppression of hypothalamic GnRH output
■
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at least in the early postpartum period in fully breastfeeding
women.
In addition to the difference in LH pulsatility, we were able
to demonstrate a significant increase in basal FSH concentration
by 8 weeks postpartum. This supports previous studies (Rolland
el ill., 1975; Delvoye el <tl., 1980; Glasier el al., 1983; Kremer
elal., 1991; Nunleyera/., 1991) which were unable to define
a role for disturbances of FSH secretion in the maintenance of
lactational amenorrhoea. It was also clear that plasma concentra¬
tions of FSH were significantly higher in women in whom
pulsatile secretion of LH had resumed, confirming many previous
observations that GnRH is important in the maintenance of FSH
secretion (see McNeilly, 1988b). Of considerable interest was
the observation in two women ofclear pulses of FSH apparently
released in response to GnRH since LH was released coincidently
with each pulse of FSH. The first phase half-life of 60 to 90 min
calculated from the pulses of FSH was within the range previously
reported for the clearance of endogenous FSH after hypo-
physectomy (Yen ft al., 1970) but somewhat shorter than for
exogenous FSH prepared from urine (Diczfalusy and Harlin, _
1988). It has been suggested that the absence of ovarian steroids
in juveniles, men and postmenopausal women results in the
release from the pituitary of acidic forms of FSH with a long
half-life (Wide and Wide, 1984). It is interesting in the present
study that the FSH released had a relatively short half-life since
these women had low levels of ovarian steroids at a concentra¬
tion which was equivalent to that in postmenopausal women
(Fraser el al., 1989). Low-amplitude pulses of FSH have only
been observed infrequendy during the menstrual cycle (Backstrom
el al., 1982), the long half-life and slow clearance making it
difficult to observe pulses. It is interesting that we observed FSH
pulses in the present study when Uiere was little negative feedback
on the pituitary due to the low concentrations of ovarian steroids
and that, as the frequency of LH/GnRH pulses increased, so the
amplitude of the FSH pulses was decreased while the mean
plasma concentrations of FSH increased. These results suggest
that the pattern of GnRH input may alter the release of FSH
independently of the normal negative feedback control of FSH
secretion (sec McNeilly, 1988b).
In conclusion, it would appear that by 2 months after delivery,
while ovarian activity remains suppressed in fully breastfeeding
women, pulsatile secretion of LH has resumed at a low and
varying frequency in the majority of women. Assuming that each
pulse of LH represents a pulse release of GnRH from the
hypothalamus, our results suggest that the suckling stimulus does
not totally inhibit GnRH output, but disrupts the normal pattern
of release. While the resumption of GnRH is also associated with
an increase in FSH concentrations to within the range normally
occurring in the follicular phase, the presence of a grossly
disturbed pattern of LH secretion results in ovarian activity
remaining suppressed. Whether the resumption of even this small
amount of pulsatility is a result of the passage of time or of a
change in the suckling stimulus remains to be determined. There
may be some aspect of the suckling stimulus, such as suckling
intensity, which also changes with time and which we were unable
to measure. However, the observation that prolactin concentra¬
tions, reflecting the suckling stimulus, remained unchanged
suggests that time postpartum may be associated with the return
of pulsatile secretion of GnRH.
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INTRODUCTION
Although there may be dispute over the best way of implementing the contracep¬
tive effects of breastfeeding into family planning strategies it is an irrefutable fact that
breast feeding profoundly inhibits reproductive function.1-2 The problem with provid¬
ing exact guidelines for the use ofbreastfeeding as an absolutely reliable contraceptive
on an subject to subject basis is due to the very nature of the driving force of the
suppression of fertility, the baby itself. The degree ofsuppression ofovarian activity is
related to die strength of the suckling sdmulus, which is an uncontrollable variable
related to the nature of the sucking acrivity of the baby and the sensitivity of the
mother to this sucking activity. Ifdie baby sucks well and the mother activates the milk
ejection reflex quickly then the baby receives the required amount of milk quickly.
However, this quick suckling activity which provides the required nutrition for the
infant may not be sufficient to maintain complete suppression of the pituitary-gonadal
axis widi a consequent early return of fertility. Attempts to overcome these problems
of variation in suckling activity by maintaining or increasing suckling activity arc
unlikely to succeed since the baby appears to adjust die suckling activity to maintain a
reasonably constant nutrient intake. Thus, increasing suckling frequency in an attempt
to prolong die period of infertility in breastfeeding women in Santiago, Chile failed
because die infants suckled for a shorter rime at each feed maintaining a similar overall
suckling stimulus throughout die 24h period.3
A further confounding issue is the impact ofgiving supplementary nutrition to the
infant. In some societies die nutrient value of this supplement is low, it is introduced
gradually and, where suckling frequencies are normally high die impact on overall
suckling patterns may not have a major effect on the suppression of fertility.4-s In other
societies where high caloric supplements are introduced diis may have a dramatic effect
on suckling patterns as we found in Edinburgh where babies reduced the duradon of
each breastfeed without reducing die number of feeds per day.4 The consequence of
this decline in overall suckling activity was an earlier return of fertility. This enormous
variation in the patterns of suckling and effects of introduction of supplements has
deflected attention from the fact that suckling has a powerful inhibitory effect on
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ovarian activity which occurs in all women. The major purpose of this short review is
to summarize our knowledge on the mechanisms by which the suckling stimulus
inhibits ovarian activity. As a preliminary it is important to review recent studies on
the other two major components ofsuckling, the release of prolactin, which is essential
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SUCKLING AND OXYTOCIN RELEASE
Remarkably little attention has been paid to the importance of oxytocin in
lactation. In women only 20-30% of the normal volume ofmilk at any feed is released
in the absence ofoxytocin release.
While oxytocin is released in response to nipple stimulation6-6 a major release of
oxytocin occurs before the onset ofsuckling (FIG. I).6 Spontaneous, regular release of
oxytocin may also occur throughout lactation in the absence of suckling.9 Oxytocin
release is very sensitive to inhibition particularly by stress,10 and any inhibition of
oxytocin release would lead to major problems in cither initiating or maintaining
lactation and may be a cause of lactation failure in women. Treatment with nasal
oxytocin has resulted in a dramatic improvement in milk production, indirectly, by
37
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allowing release c>( stored milk and toiuinnanon of normal prolactm-mdueed milk
production." The failure 10 empty the breast adequately may lead to reduction in the
capacity of the breast to produce milk due to the presence of local paracrine (actors
within the breast which modulate milk production.12
In the vast majority ofeases, particularly where breastfeeding is the accepted norm, .
a lack of oxytocin release is not likely to be a major problem. However, it may be that
in tentative mothers trying to establish breastfeeding with little support, the potential
stress involved may prevent adequate oxytocin release, reduce milk production,
amplify the stress level with further inhibition of oxytocin release and so the down¬
ward spiral of failure of lactation proceeds. Intervention with oxytocin, or correct
counselling and support while establishing breastfeeding should overcome these
problems.
PROLACTIN RELEASE
The plasma concentration of prolactin increases progressively throughout preg¬
nancy associated with an increase in pituitary size.12-14 At term, concentrations of
prolactin arc between 10 and 100 times higher than during the normal menstrual cycle
and remain elevated for up to 3 weeks postpartum even in the absence of suckling."
Prolactin is the essential hormone for milk production in women; absence of prolactin,
either due to treatment with bromocriptine15 or in hypopitruitary patients16 leads to
failure of milk production. Thus, at term prolactin concentrations arc sufficiently high
in almost all women to initiate lactation although there is no correlation between the
prolactin response to suckling or basal plasma concentrations of prolactin and the time-
to onset of milk production or the amount of milk produced.17 Prolactin is released in
response to the suckling stimulus of the baby and there is no evidence of release before
the onset of nipple stimulation.6 While prolactin may be released during removal of
milk by breast pumps, the amount released is very variable and may be the cause of the
variable success of maintaining lactation with these pumps. A prolactin response
equivalent to that induced by a suckling baby was only induced with an electrical
pulsatile pump.8 There is no close correlation between plasma concentrations of
prolactin, either basal or amounts released during a suckling episode, and the amount
of milk produced throughout lactation.7-" This suggests that adequate amounts of
prolactin arc available at all times throughout lactation. Nevertheless treatment of
women with dopaminergic antagonists which increase plasma concentrations of
prolactin do lead to an increase in milk production.18-19 However, since these drugs
have been used in women in whom milk yields were low, and since these drugs
potentially can act as tranquillizers it may be pertinent to question whether they may
act by reducing stress and increasing oxytocin release in these women, thus working
indirectly to increase milk production. It does appear that in most lactations the
suckling infant induces sufficient prolactin release to maintain lactation.
An increase in prolactin occurs within minutes of die onset ofsuckling and release
may continue for 20 to 40 minutes, apparently regardless of the duration of the
suckling stimulus.20 There is no change in the half-life or form of the prolactin released
during lactation.21 From at least 4 weeks postpartum die sleep-associated increase in
prolactin which occurs in non-lactating women resumes21-22 and the prolactin re¬
sponse to the suckling is greater at night than during the day.20-22-23 This increase in
prolactin release is apparently not due to any change in the suckling acrivity of the
baby,20 suggesting that this may relate to a decrease in hypothalamic dopaminergic
tone during sleep which causes die sleep-induced increase in prolactin. Prolactin
38
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release during lactation remains under dopaminergic but not opioid inhibition.
Treatment of breastfeeding women with the dopaminergic antagonist-metodopra-
mide caused a 20- to 30-fold increase in prolactin release, some 8 times the maximum
elicited bv suckling indicating a profound dopaminergic inhibition of release.24 In
contrast, treatment with the opiate antagonist naloxone was without effect24 confirm¬
ing previous studies in women,25"27 although in monkeys prolactin release is depen¬
dent on opioids.28 Progesterone29 but not the synthetic progestagen norethistcrone24
enhanced the prolactin response to suckling.
Although there is no doubt that prolactin is required for milk production, the
potential role for prolactin in causing the infertility associated with suckling remains
very unclear. Studies in animals do not support any major direct role for prolactin in
lactational infertility. An increased release of prolactin in response to suckling over a
24h period was observed in women with prolonged lactational amenorrhea,23-30
although we could not confirm this observation.22 The apparently close correlation
between the duration of hypcrprolactinemia and duration of lactational amenor¬
rhea31-32 suggested a role for prolactin. However, it is more likely that since the plasma
concentration of prolactin depends on the frequency and duration of suckling, the
hypcrprolactinacmia reflects suckling activity and that the true relationship is between
high suckling activity and prolonged lactational amenorrhea.2-33"35
OVARIAN ACTIVITY POSTPARTUM
In non-breastfeeding women ovarian follicle development monitored by measure¬
ment of estrogen and progesterone and suppressed throughout pregnancy, resumes
within two to three weeks postpartum and first ovulation can occur as early as 6 weeks
postpartum.4-36 During lactational amenorrhea ovarian activity is apparently sup¬
pressed in the majority ofwomen since ovarian steroid secretion is minimal.2-4-5-33-34-37
In some women transient increases in ovarian estrogen secretion occurs indicating the
development of follicles, but ovulation rarely if ever occurs.4-5-38-4 2 The pattern of
ovarian follicle development during lactational amenorrhea has been clarified in a
recent study43 using serial ultrasound visualization of follicles during lactation (FIG.
2). Between 8 and 20 small follicles up to 8 mm in diameter equivalent to follicles
present in the early- to mid-follicular phase of the normal menstrual cycle were present
in most lactating women.43 The appearance of these follicles was episodic, they
persisted for a variable time and produced little or no steroid. In some women large
follicles developed and produced estrogen but did not ovulate becoming luteinized
unruptured or atretic follicle or developing into follicle cysts.43 These observations
profoundly alter our views on die mechanism controlling lactational infertility indicat¬
ing that, as in some other species,33-34 follicle growth is not completely inhibited. The
cause of this follicle growth and variable pattern ofsteroid secretion will be discussed
later in connection with the changes in the pattern ofsecretion of the gonadotropins
luteinizing hormone (LH) and follicle stimulating hormone (FSH).
As lactation progresses the possibility of ovuladon occurring before first menses
increases to 10 to 15% of women depending on the pattern of suckling. If suckling
continues then a high proportion, up to 90%, of first ovulatory cycles arc associated
with short or inadequate luteal phases.4-5-38"42 The proportions of normal, short or
inadequate corpora lutea and the number ofeach that may occur before resumption of
cycles with normal luteal function varies with each women and in each study. This
relates to the variation in tire suckling pattern of the individual baby and mother and
the consequent effect on the secretion ofgonadotropins.
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FIGURE 2. Changes in die number and size of follicles within the ovary, visualized by
ultrasound in relation to changes in die pattern of ovarian total estrogen and pregnanediol
glucuronide secretion in a breastfeeding women. Note that follicles up to 20mm in diameter were
present in die ovary around day 120 postpartum but were stcroidogenically relatively inactive
secreting only small amounts of estrogen, compared to similar sized follicles at day 270 which
were secreting normal amounts of estrogen and subscquendy ovulated to form a normal corpus
luteum. Around day 190 a follicle developed which did not ovulate, the luteinized unruptured
follicle, LUF. Between days 210 and 240 a large follicle developed which did not ovulate, the
persistent unruptured follicle. Menses (■) occurred after the decline in estrogen and progester¬
one secretion. (Redrawn from rcf. 42.)
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G O N ADOTROPHIN S
Follicle growth, ovulation and the formation of a viable corpus lutcum able to
support a pregnancy depends on the initial stimulation of follicle growth but not
steroidogenesis by FSH followed by induction of steroid secretion by the pulsatile
secretion of LH. The developing follicle secretes increasing amounts ofestradiol which
induces the preovulatory surge of LH when the follicle is mature at about 20mm in
diameter, ovulation takes place and normal corpus luteum function, particularly the
secretion of progesterone, is maintained by continued pulsatile secretion of LH. The
pulsatile secretion of LH is caused by the pulsatile release of gonadotropin releasing
hormone (GnRH) from the hypothalamus.
During pregnancy pulsatile release of GnRH is inhibited so that at term pituitary
content of LH is reduced to around 1% ofnormal.44 Plasma concentrations of FSH in
breastfeeding women increase to within normal early follicular phase levels by 4 to 8
weeks postpartum.22-26-31-45-46 It is this increase in FSH which is probably responsible
for the induction and continued production of the waves of follicle development
observed by ultrasound during lactational amenorrhea. However, in the absence of
adequate pulsatile LH stimulation these follicles will remain cither stcroidogcnicallv
inactive, or will produce only small amounts ofestrogen.
Plasma concentrations of LH increase from undetectable levels around day 7
postpartum26 to low normal by 3 to 4 weeks postpartum.2-4-22-47 Recent studies
monitoring the pulsatile patterns of LH secretion over 24h periods during the
resumption of ovarian activity have now determined that pulsatile release of LH can
occur by 4 weeks postpartum in breastfeeding women but that the frequency remains
slow and variable (FlG. 3).22 In another study very low amplitude LH pulses were
released at a normal frequency47 but the overall results indicate that LH pulses and, by
implication pulsatile release of GnRH from the hypothalamus, is not completely
inhibited throughout lactation. Thus when FSH stimulates follicle growth to occur
pulsatile LH release may be occurring and this would allow the production ofestradiol
from a proportion of follicles. However, the amount of estradiol produced will vary
considerably since the frequency of LH pulses is very variable.
As lactation progresses and suckling declines, the frequency of pulsatile LH
secretion increases to near the frequency occurring in die normal follicular phase and
sustained estradiol secretion will occur.2'45 Although a normal increase in plasma
estradiol may occur during breastfeeding this may not trigger the release of preovula¬
tory surge of LH as would occur in the normal menstrual cycle. Is has been shown
previously that in breastfeeding women the ability of estradiol to induce a preovula¬
tory LH surge, positive feedback, is severely impaired.48 Thus, although a follicle may
grow to be of preovulatory size, and produce a normal estradiol signal, no LH surge-
would be induced and the follicle would become a luteinized unruptured follicle,
atretic, or cystic, as observed by ultrasound.43
Only when suckling has reduced to the point where there is no longer an inhibition
of both the normal pattern of pulsatile LH secretion and generation of a preovulatory
LH surge will normal luteal function resume. This is apparently confirmed by our
earlier observation that replacement of a normal pattern of GnRH release using a
pulsatile infusion pump in fully breastfeeding amcnorrheic women at 6 weeks postpar¬
tum resulted in development of normal estrogenic follicles observed by ultrasound,
but inadequate luteal function occurred in the majority of these women related to a
poor preovulatory LH surge.49
The link between the suckling stimulus activating nerve terminals in rite nipple and
the disruption of the pattern of release of GnRH from GnRH neurons in the
hypothalamus remains unknown. Although high dopaminergic tone within the
41
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hypothalamus associated with feedback effects of high plasma concentration of
prolactin have been suggested as a possible mechanism, this docs not appear to be the
ease. Treatment of breastfeeding women with the dopamine antagonist mctoclopra-
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FIGURE 3. Progressive return of the pulsatile pattern of LH secretion over 24h periods at
different stages in the return of normal ovarian activity in a breastfeeding women. No follicles
were present at 4 weeks and at the introduction ofsupplements at 16 weeks only limited estradiol •
secretion was evident indicating die presence of a follicle. Follicle growth had resumed after first
menses, but was associated with an inadequate corpus lutcum, while normal menstrual cycles
resumed after weaning when the pulsatile pattern of LH release was normal. ► indicates an LH
pulse.
release of LH.24 Thus an involvement of prolactin in suppressing GnRH output
through altered hypothalamic dopaminergic activity docs not appear to be tenable.
Opiates are known to suppress GnRH release and are associated with the decrease
in GnRH pulse frequency caused by progesterone during the luteal phase of the
42
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menstrual cycle.:>0-sl There is conflicting evidence for a role of opiates in suckling-
induced inhibition of GnRH release in other species-" and no evidence for a role in the
lactating monkey.28 Similarly, there is no evidence in breastfeeding women to support
a role for opiates in suckling-induced suppression of GnRH release.24-26
SUMMARY
Breastfeeding delays the resumption of normal ovarian cycles by disrupting the
pattern of pulsatile release of GnRH from the hypothalamus and hence LH from the
pituitary. The plasma concentrations of FSH during lactation arc sufficient to induce
follicle growth, but the inadequate pulsatile LH signal results in a reduced estradiol
production by these follicles. When follicle growth and estradiol secretion docs
increase to normal, the suckling stimulus prevents the generation of a normal
preovulatory LH surge and follicles cither fail to rupcurc, or become atretic or cystic.
Onlv when the suckling stimulus declines sufficiently to allow generation of a normal
preovulatory LH surge to occur will ovulation take place with the formation of a
corpus lutcum of variable normality. Tlius suckling delays the resumption of normal
ovarian cyclicity by disrupting bur nor totally inhibiting, the normal pattern of release
ofGnRH by the hypothalamus.
The mechanism of suckling-induced disruption of GnRH release remains un¬
known. It docs not appear to involve prolactin, dopamine or opiates although a
combination of these factors might be involved. Prolactin is the major hormone
responsible for milk production and is present in sufficient quantities in almost all
women to allow the establishment of normal lactation. Oxytocin is essential for milk
let down and is susceptible to inhibition of release by stress. The successful initiation of
lactation which would lead to the potential of utilizing breastfeeding as contraceptive
may require more attention to be paid to the establishment of non-stress release of
oxytocin.
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The role of dopamine and opiates in the suckling-induced'
suppression of gonadotrophin secretion and prolactin release
was investigated during lactational antcnorrhoea in fully
breastfeeding women at 12 weeks post-partum. A total of 26
women, 20 using non-steroidal methods of contraception and
six using the progestogen-only pill, Noriday (POP), breast¬
fed their babies on demand at a frequency of 3.6 ± 0.2
suckling episodes during the 8 h study period while blood
samples were collected at 10-tniti intervals. Five hours after
the start of sampling six women were given the dopamine
antagonist mctoclopramide (10 nig, i.m.) while four women
received saline. In a second experiment, six women using non¬
steroidal contraception and three women on the POP received
an i.v, infusion of the opiate antagonist naloxone (1.6 mg/h)
for 2 h, while four women using non-steroidal contraception
and three women on the POP were infused with saline. Two
hours after the i.m. injection or start of infusion all women
were given an i.v. injection of 10 pg gonadotrophin releas¬
ing hormone (GnRH) and samples were collected for a further
1 h. All samples were assayed for luteinizing hormone (LH),
follicle stimulating hormone (FSH) and prolactin. Plasma
concentrations of oestradiol were < 60 pmol/1 in all women
and they remained amenorrhoeic for at least 10 weeks after
the study. Pulsatile release of LH was only observed over the
S h pre-treatment period in 10 of the 20 non-steroid taking
women (1-3 pulses/5 h), and in one of the six women
(1 pulse/5 h) on IT)!'. Treatment with mctoclopramide caused
a substantial (29-fold) increase in prolactin over baseline, 7.4
times the maximum released in response to suckling. There
was no effect of metoclopramide on the pattern of release of
LH or FSH or the response to GnRH. Infusion of naloxone
in women using either non-steroidal contraceptives or
progestogen-only pill did not affect prolactin release. Nalox¬
one infusion did not affect LH or FSH in women using non¬
steroidal contraceptives, but caused a small but significant
(P < 0.05) increase in both LH and FSH in women taking
the progestogen-oniy pili. There was a significantly greater
release of LH and FSH after GnRH in all women after nalox¬
one infusion. These results in breastfeeding women daring
532
lactational amenorrhoea confirmed that suckling suppresses
the pulsatile release of LH but not through a dopaminergic
pathway, showed that prolactin remains under dopaminergic
control during human lactation, but suckling does not appear
to affect prolactin secretion via an opiate pathway and
indicated only a minor, if any, role for opiates in the suckling-
induced suppression of GnRH/gonadotrophin secretion but
a potential, previously unreported, effect of opiates in
reducing pituitary responsiveness to GnRH.
Key words: dopamine/lactational amenorrhoea/opiates/prolactia'
pulsatile LH/FSH
Introduction
The suppression of ovarian activity in breastfeeding women is
associated with an alteration in the pulsatile pattern of secretion
of luteinizing hormone (LH) (Glasier elal., 1984; Tay et al.,
1992). Since there is clear evidence that pulsatile LH release
occurs in response to the pulsatile secretion of gonadotrophin
releasing hormone (GnRH) from the hypothalamus (Clarke and
Cummins, 1982) it is assumed that the suckling stimulus inhibits
the release of hypothalamic GnRH. It is not known how this effect
may be mediated.
In all species studied, lactation is associated with increased
prolactin (McNeilly, 1988). Because of the close association
between raised prolactin levels and the suppression of ovarian
activity post-partum in the human (McNeilly, 1988; Glasier and
McNeilly, 1990) together with the knowledge that disturbances
of LH secretion are associated with pathological hyper-
prolactinaemic amenorrhoea, it has been suggested that prolactin
may play a role in suppressing gonadotrophin secretion. High
levels of prolactin increase dopamine turnover in the
hypothalamus and in some species (see e.g. Adier, 1986;
McNeilly, 1988) there is evidence that increased release of
dopamine into the hypothalamo-pituitary-portai system results
in decreased release of LH. Thus it has been suggested that
increased dopamine tone may inhibit the GnRH pulse generator,
thereby inhibiting the normal pulsatile pattern of LH secretion.
Changes in endogenous opioid peptides and alterations in
dopamine turnover are both known to modify the secretory
activity of the hypothalamic neuroendocrine neurones. Opioids
may play a role in the control of the human ovarian cycle (Quigley
and Yen, 1980; Ferin el al., 1984) and abnormalities of opioid
tone may be involved in disturbances of the menstrua] cycle
(Quigley and Yen, 1980: Grossman ei al., 1982). Moreover,
there is some evidence in species other than the human that
'/) Oxford University Press
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suckling-induced release of opioids may be the principal mediator
of the suppression of LH release during lactation. Both the con¬
centration and secretion rate of /3-endorphin in hypothalamo—
pituitary-portal blood increased in response to suckling episodes
in ewes (Gordon et al., 1987) while treatment of both suckling
rats (Sirinathsinghi and Martini, 1984) and sows (Mattioli et al.,
1986) with the opioid antagonist naloxone resulted in a signifi¬
cant increase in LH concentrations. In the human, treatment of
non-breastfeeding women with naloxone between 13 and 25 days
after delivery resulted in increased concentrations of both LH
and FSH (lshizuka et al.. 1984) and it has been suggested that
the hypogonadotrophisin of the puerperium is due in part to
increased opioid inhibition of GnRH secretion.
In order to determine whether a suckling-induced increase in
either opioid or dopamine tone may be involved in the suppression
of pulsatile LH release in the human we have investigated the
effects of the dopamine antagonist metoclopramide and of the
opioid antagonist naloxone on the secretion of LH, FSH and pro¬
lactin during lactational amenorrhoea in breastfeeding women. -
Materials and methods
Subjects and treatments
Twenty-six women who intended to breastfeed their infants
without supplementing for at least 3 months were recruited from
the postnatal wards of the Simpson Memorial Maternity Pavilion
(SMMP) in Edinburgh. The women were in good health and had
a history of regular menstrual cycles prior to conceiving. Six
of the women who were specifically recruited to investigate the
influence of progestogen began taking the progestogen-only pill
(Noriday, norethisterone 0.35 mg/day) at 6 weeks post-partum
while 20 used no form of steroidal contraception but relied on
non-steroidal methods. All 26 women were studied at 12 weeks
post-partum while fully breastfeeding and amenorrhoeic. Written
informed consent was obtained and the study was approved, by
the local ethical committee.
On the day of treatment with either the dopamine antagonist
metoclopramide, or opiate antagonist naloxone, the women were
admitted to the research ward of the SMMP at 0830 h. An
intravenous cannula was inserted into a forearm vein and kept
patent with heparinized saline. Front 0900 h 5 ml ofvenous blood
was collected every 10 min for 5 h in order to establish the
baseline pattern of secretion of gonadotrophins. After 5 h (at
1400 It) the following treatment groups were established. Group
A received a single i.v. injection of metoclopramide 10 nig: (i)
non-steroidal contraception, n = 6. Group B received a single
i.v. injection of normal saline: (i) non-steroidal contraception,
n = 4. Group C received an i.v. infusion of normal saline for
2 h: (i) non-steroidal contraception, n = 4; (ii) POP, n = 3.
Group D received an i.v. infusion of naloxone 1.6 mg/h for 2 h:
(i) non-steroidal contraception, n = 6; (ii) POP, n = 3.
The administered dose of metoelopramide has been used in
breastfeeding women and shown to cause maximum release of
prolactin (Guzman et al., 1979), while the infusion rate of
naloxone has been shown to induce an increase in LH and FSH
in non-breastfeeding women (Ishizuka era/., 1984), and
neutralize the effect of morphine (Grossman era/., 1982).
Women were allocated at random to groups A, B, Ci and Di,
and the six women on the POP were allocated randomly to either
naloxone or saline treatments. Since there was no significant effect
of either a single i.v. injection or an i.v. infusion, the control
group effectively consisted of eight women comprising the four
women of group B and the four women of group Ci, although
for analysis their results were not combined.
Blood sampling was continued every 10 min for 2 h until
1600 h when all 26 women were given an i.v. injection of 10 /rg
GnRH (Goiiadurclin, Ayerst, Andover, UK). Blood samples were
collected every 10 min for another hour after GnRH administra¬
tion until 1700 h when die cannula was removed and the women
allowed home. Plasma was separated and stored at -20°C until
later assayed for LH, FSH and prolactin in batches. Serum
oestradiol was measured in the first sample collected from each
woman.
Throughout the day women were allowed to breastfeed their
babies on demand at a mean frequency of 3.6 ± 0.2 and
1.4 ± 0.2 feeds in the total 8 h and the 2 h treatment period,
respectively. Regular meals were provided and no restriction on
movement was imposed.
Hormone assays
Plasma concentrations of LH and FSH were measured by radio¬
immunoassay as described previously (Glasier et al., 1984; Tay
et al., 1992) while plasma prolactin was measured in a two-site
immunoradiometric assay (NETR1A, St Bartholomew's Hospital,
London; Wu ct al., 1990). The intra- and inter-assav coefficients
of variation were <8% and <11% respectively for LH, FSH
and prolactin. Plasma oestradiol concentrations were measured
by specific radioimmunoassay following diethyl ether extraction
of serum as described previously (Glasier et al., 1988). The intra-
and inter-assay coefficients of variation were 4 and 15.8%,
respectively.
Statistical analysis
The data are presented as the mean ± SEM except where
otherwise stated. Comparisons between mean hormonal concen¬
trations and LH pulse frequency were performed using analysis
of variance (ANOVA) on log-transformed data. Significant
hormone pulses were identified using the Munro pulse analysis
programme (Zaristow Software, Haddington, Scotland EH 14
4PD) as described previously (Tay etal., 1992).
Results
All women were amenorrhoeic at the time of the studies and
remained amenorrhoeic for at least 10 weeks afterwards. The
plasma concentration of oestradiol at the time of sampling was
<60 pmol/1 in all women indicating an absence of ovarian
activity.
Effect of metoclopramide
Mean basal concentrations of LH, FSH and prolactin, mean
concentrations following the i.v. bolus injection of either 10 mg
metoclopramide or normal saline and following 10 /tg GnRH i.v.
for women in groups A and B are shown in Table I. The changes
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in mean plasma concentrations of LH and FSH throughout the
total sampling period for all women and the prolactin response
for two individual women, one treated with metoclopramide and
one control subject, are shown in Figure 1. One subject had
surprisingly high concentrations of both LH and FSH (mean basal
levels 12.0 ± 0.7 mU/1 and 37.0 ±0.6 mU/l respectively)
throughout the sampling period and a response to exogenous
GnRH stimulation at least three times higher than that of the other
women in the study. The plasma oestradiol of that subject at the
time of sampling was <60 pmol/1 and she remained
amenorrhoeic for a further 13 weeks, subsequently resuming
regular menstrual cycles. This subject's results were included
in the analysis.
In the 5 h prior to the injection of metoclopramide, five women
had no statistically significant pulses of LH secretion while in
the other five women a single pulse of LH was identified. There
Table I. Changes in the mean (± SF.M) plasma concentrations of LH. FSH and prolactin in breastfeeding women with lactational amenorrhoea, 12 weeks
post-partum during the 5 h before (basal), the 2 li after i.v. injection of 10 mg mctoclopramkle (n — 6) or saline (it = 4) and during the 1 h after i.v.
injection of 10 ng GnRH




3.42 ± 0.50 3.36 ± 0.84
metocloprainide 2.71 ± 0.42 2.90 ± 0.75
GnRH 24.08 ± 4.03 29.32 ± 11.50
FSH (U/l) Basal
Saline or
3.75 ± 0.40 4.08 ± 0.84
metoclopramidc 3.24 ± 0.32 3.64 ± 0.65
GnRH 10.76 ± 2.05 10.77 ± 1.68
Prolactin (mIU/1) Basal 1345 ± 140 1489 ± 1318
Saline or
metoclopramide 2140 ± 370 8760 ± 1157**
GnRH 2475 ± 450 5516 ± 753
< 0.05 compared with saline control (ANOVA).











Fig. 1. Plasma concentrations (mean ± SEM) of (a) luteinizing hormone (LH) and (b) follicle stimulating hormone (FSH) in breastfeeding women
with lactational amenorrhoea, 12 weeks post-partum during the 5 h before, 2 h after the i.v. injection of metoclopramide (•; n = 6) or saline
(O; n - 4), and after the i.v. injection of a 10 bolus of GnRH. The profiles of prolactin in two individual women treated with saline (c)








were no differences in basal plasma concentrations of LH. FSH
or prolactin between women treated with metoclopramide or with
saline prior to the injection of metoclopramide (Table I). Suckling
occurred 2.1 ±0.2 (SEM) times during the 5h before
treatment and induced a significant (P < 0.001) 9.6 ± 4.6-fold
(SEM; n = 19 suckling episodes) increase in prolactin after
every suckling episode with plasma prolactin concentrations
increasing from an immediate pre-suckling concentration of
694 ± 160 mU/1 to a maximum of 2542 ± 435 mU/l.
Administration of mctoclopramide caused an immediate, highly
significant (P < 0.001). increase in plasma prolactin to
maximum concentrations of 14 954 ± 1936 mU/1 (Table 1), a
response 29.1 ± 8.3-fold higher than basal prolactin and
7.4 ± 2. i-fold higher than maximum plasma concentrations of
prolactin after suckling. There was no correlation between the
basal concentration of prolactin, the response to suckling or the
response to metoclopramide. Despite the massive increase in
prolactin concentrations immediately following metoclopramide
there was no change in the concentration or pattern of secretion
of either LH or FSH. There were no significant differences
between treated women and controls in either the LH or FSH
response to exogenous GnRH (Table I. Figure 1).
Effect of naloxone
Ten breastfeeding women using non-steroidal methods of
contraception were infused i.v. with either naloxone 1.6 mg/h
(n = 6) or normal saline (;t = 4). Mean basal concentrations
of LH. FSH and prolactin togedrer with concentrations in
response to the infusion of naloxone and exogenous GnRH
administration are shown in Table II. Mean concentrations of
gonadotrophins during the study for both groups of women are
shown in Figure 2. Six women, three in each group had no
statistically significant pulses of LH secretion in the 5 h prior
to the onset of infusion while four women (three naloxone-treated
and one control) did show a pulsatile pattern of secretion although
pulse frequency was low (1.8 ± 0.34 pulses per 5 h). Because
of the possible influence of the basal levels of LH and FSH on
the subsequent response to both naloxone and GnRH, the results
from the naloxone group were analysed together (Table II) and
as those with and those without LH pulses (Figure 2a,c).
Pulsatile LH in lactational ainenorrhoca
The intusion of naloxone did not significantly affect either the
concentration or the pattern of secretion of either LH or FSH
in the naloxone-treated women compared with the controls
(Table II; Figure 2) regardless of the basal levels of LH or FSH.
Although there was an increase in both LH and FSH during tire
naloxone infusion in those women with LH pulses, LH and FSH
levels during naloxone infusion were not significantly different
from the overall mean level of ESH and LH before infusion
(Figure 2a,c). There was no increase in either LH or FSH during
naloxone infusion in the women without IH ptdses (Figure.2a,c).
Suckling occurred on demand throughout the infusion of naloxone
or saline at a frequency of 1.7 ± 0.3 and 1.5 ± 0.2 episodes
respectively. We did not attempt to fix the time of suckling to
the time of infusion. Although this made the prolactin data more
difficult to interpret there was no change in prolactin during the
infusion of naloxone (Tabic 11; Figure 2). The concentrations
of both LH and FSH following GnRH were significandy (LH:
P < 0.01; FSH: P < 0.05) higher in women who had been
infused with naloxone compared with controls regardless of the
basal level of LH and FSH either before or during the naloxone
infusion (Table II; Figure 2a,c).
Of the six women using POP contraception a pulsatile pattern
of LH secretion was identified in only one with only a single
pulse in the 5 h sampling period. Mean concentrations of
gonadotrophins and prolactin during the sampling period are
shown in Table III. Mean basal concentrations of prolactin and
FSH were not different from those in women using non-steroidal
methods of contraception. Mean basal concentrations of LH
tended to be lower in women using the POP compared with
women not exposed to exogenous progestogens (3.3 ± 0.4
versus 7.7 ± 1.7 U/l) although this difference was not statistic¬
ally significant. Naloxone infusion resulted in a significant
(P < 0.05) increase in both LH and FSH concentrations
compared to saline infusion and within the group when compared
with baseline levels but did not significantly affect prolactin levels
(Table EI). Concentrations of both LH and FSH increased
significantly over baseline levels IP < 0.05) in response to
GnRH stimulation and the plasma concentration of LH but not
FSH after GnRH was significantly (P < 0.05) higher in the
group treated with naloxone (Table III). The magnitude of the
Table II. Changes in the mean (±SEM) plasma concentrations of LH, FSH and prolactin during 5 h before (basal), the 2 h during i.v. infusion of naloxone
(1.6 mg/h; n - 6) or saline (« = 4) and during the I h after i.v. injection of 10 /ig of GnRH



































*P < 0.05. **P < 0.01 compared with saline control.
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Fig. 2. Plasma concentrations (mean ± SEM) of luteinizing hormone (LH) (a,b) and follicle stimulating hormone (FSH) (c,d) during the 5 h
before, 2 h after i.v. infusion of naloxone (O.G: 1.6 mg/h) or saline (•), and after i.v. injection of a 10 /tg bolus of GnRH in breastfeeding
women with lactational amenorrhoea, 12 weeks post-partum, using either non-steroidal contraception (a,c: n = 6, naloxone; n — 4, saline), or
the progestogen-only-pill norethisterone (POP; b,d: n= 3. naloxone; n = 3„ saline). In the non-POP group 3 women (O) had, and 3 women
(□) did not have, a pulsatile pattern of LH release in the 5 h period before naloxone infusion.
Table III. Changes in die mean (±SEM) plasma concentrations of LH, FSH and prolactin in breastfeeding women with lactational anicnorrhoea, 12 weeks
post-partum, taking the progestogen only contraceptive, during the 5 h before (basal), the 2 h after i.v. infusion of naloxone (1.6 mg/h, n — 3) or saline
(/i = 3) and during die 1 h after i.v. injection of 10 /zg GnRH
Hormone Treatment Hormone concentration
Saline Naloxone
LH (U/l) Basal 3.10 ± 0.52 3.74 ± 0.78
Saline or
naloxone 2.50 ± 0.44 6.85 ± 0.95*
GnRH 17.47 ± 2.26 30.42 ± 3.34*
FSH (U/l) Basal 3.99 ± 0.65 3.99 ± 1.03
Saline or
naloxone 3.05 ± 0.18 5.12 ± 1.33*
GnRH 8.10 ± 1.24 10.08 ± 1.35
Prolactin (inlU/l) Basal 610 ± 120 1450 ± 170
Saline or
naloxone 1010 ± 260 2020 ± 250
GnRH 930 ± 390 2180 ± 300
*P < 0.05 compared with saline control.
increase in LH, but not FSH, following GnRH stimulation was
lower in women using POP than women using non-steroidal
methods of contraception treated with saline, but this difference
was not significant. In women using non-steroidal methods of
contraception the prolactin response to suckling before infusion
of naloxone or metoclopramide was not significantly different
from that in women taking the POP (non-steroidal method:
1289 ± 183 U/l; POP: 1096 ± 219 U/l).
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Discussion
In this study we have sought to determine the role of dopamine
and opiates in the suckling-induced inhibition of LH and FSH
secretion known to underlie the suppression of ovarian activity
during lactational amenorrhoea (McNeilly, 1988). As in our
previous studies (Glasier ct al., 1984; Tay ct al., 1992) using
the same radioimmunoassay reagents, we confirmed that LH
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pulse frequency was low at 12 weeks post-partum, when ovarian
activity assessed by the low levels of plasma oestradiol was
suppressed (data not shown). In contrast, a previous report
suggested that a normal frequency of LH pulsatile release had
resumed in most breastfeeding women by 3 months of lactation,
although the amplitude of these pulses may be reduced (Nunley
et al., 1991). We can offer no explanation for this difference
in pattern of LH release in the two studies except the difference
in assay reagents used. We also showed in the present study that
pulsatile release was fuither suppressed in women taking a POP
contraceptive, but that in all women, a bolus injection of GnRH
caused a substantial release of both LH and FSH, confirming
that the assay method used in the present study would detect LH
pulses if present.
The short-loop feedback effect of prolactin causes an increase
in dopaminergic activity in the hypothalamus of the rat
(Selmanoff, 1985). This finding together with the suppressive
effects of dopamine on LH release in certain situations in women
(Ferran el al., 1981), and the resumption of normal LH secretion
and ovarian activity in hyperprolactinaeinic patients when treated
with dopaminergic drugs to suppress prolactin (Thorner ct al.,
1974) have suggested that the high plasma concentrations of
prolactin associated with lactational amenorrhoea were causal in
suppressing GnRH release, via raised hypothalamic dopaminergic
activity. However, this theory has been questioned (McNeilly,
1987) but has not been tested in breastfeeding women before.
Indeed, there is little evidence to support the theory of prolactin-
induced increased hypothalamic dopaminergic activity, since,
even in lactating rats, hypothalamic dopaminergic activity is
reduced, and the ability of prolactin to increase hypothalamic
dopamine is suppressed (Demarest et al.. 1983; Selmanoff and
Wise, 1981).
Our present study shows that blockade of dopamine receptors
by the dopamine antagonist metoclopramide in breastfeeding
women did not affect the pattern of LH or FSH secretion, or
the pituitary response Ur GnRH. However, metoclopramide did
result in a very large increase in plasma concentrations, of
prolactin, to levels several-fold higher than after any natural
suckling episode. This implies that prolactin secretion during
human lactation remains under dopaminergic inhibition and that
suckling could increase prolactin release simply by reducing
dopamine release from the hypothalamus since the time course
of release was similar after suckling and metoclopramide. This
does not exclude the possibility that suckling may release other
faclor(s) that would positively drive the release of prolactin as
suggested by studies in the monkey (Frawley et al., 1983).
Nevertheless, the present results showing no effect of inhibition
of dopamine and absence of effect of a very large increase in
plasma concentrations of prolactin supports our contention that
the suckling-induced inhibition of GnRH release is not directly
related to prolactin (McNeilly, 1987, 1988; Tay eial., 1992),
a conclusion also reached in recent studies in the rat (Maeda
et al., 1991).
Studies.in animals have suggested that suckling may suppress
GnRH by increasing hypothalamic opiate tone (McNeilly, 1988;
Rasmussen, 1991). Treatment of lactating rats (Sirinathsinghji
and Martini, 1984), sows (Mattioli et al., 1986) but not cows
(Canfield and Butler, 1991) with opiate antagonists increases LH
secretion while suckling causes an increase in fl-endorphin
concentration in the hypophyseal portal blood in lactating ewes
(Gordon ct al., 1987). Infusion of naloxone at the same rate used
in the present study (Lodico el al., 1983) in non-breastfeeding
women, resulted in an increase in LH and FSH which occurred
from day 15 post-partum onwards, this increase in response
coinciding with both an increase in response to GnRH and with
an increase in ovarian steroids. Treatment with naltrexone in non-
breastfeeding women on day 7 post-partum did not affect LH
(Kremer et a!., 1991).
In the present study administration of an opioid antagonist had
no statistically significant effect on gonadotrophin concentrations
in breastfeeding women who were not taking steroids and were
hypo-oestrogenic (oestradiol < 60 pmol/1) studied at 12 weeks
post-partum regardless of their pattern of gonadotrophin secretion
before naloxone infusion. This suggests that opiates arc either
not involved in, or make only a minor contribution to, the
suckling-induced suppression of GnRH release in these women,
a conclusion in agreement with recent results in the lactating
monkey (Gordon et al., 1992). In contrast, a significant although
small increase in both LH and FSH occurred after naloxone
treatment in the breastfeeding women who were taking the POP.
In the normal menstrual cycle (Quigley and Yen. 1980)
administration of naloxone increases LH concentrations in the
late follicular and luteal phase but has no effect on the early
follicular phase when circulating steroids are low. Our results
suggest that opiates are either not, or only minimally involved
in, the suckling-induced suppression of GnRH and hence LH and
FSH release, but that a more significant inhibitory effect of opiate
can be induced by steroids during lactation. Breastfeeding women
are more sensitive to the negative feedback effects of oestradiol
(Baird et al., 1979; Glass et al., 1981) and we have previously
suggested that the disruption of the pulsatile pattern of LH and,
by implication GnRH, is related to this suckling-induced, en¬
hanced steroid inhibition of GnRH release (McNeilly, 1988). The
present results suggest that the effect of steroids in lactation may
involve increased opiate activity.
A surprising result was the enhanced release of both LH and
FSH in response to GnRH after naloxone infusion, which
occurred regardless of the basal levels of LH and FSH, and by
implication GnRH input, before naloxone treatment. To our
knowledge this has not been reported before in any circumstances.
This increase in release presumably related to an increase in the
sensitivity of the gonadotrophs in the pituitary to GnRH, induced
by blockade of opiate receptors. This is a very surprising result
since there is no evidence of opiate receptors on the pituitary
gonadotrophs (Horton et al.. 1990) all effects of opiates
apparently acting via the hypothalamus (Horton et al. 1990;
Rasmussen, 1991). At present we have no explanation for this
finding. It does indicate/a potential role for opiates, possibly
/3-endorphin of pituitary'origin, having a direct effect on the
pituitary gonadotrophs to reduce responsiveness to GnRH during
lactation.
There was no effect of: naloxone on the release of prolactin
in the present study. This confirms previous studies in which
naloxone failed to affect basal and breast-pump induced prolactin
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release in the first 2-3 days post-partum (Lodico et al., 1983).
and the response to stickling between 55 and 129 days post-partum
(Cholst et al.. 1984). Thus, although opiates will increase
prolactin release in non-lactating women (e.g. Tolis et al.. 1975)
and are involved in maintaining prolactin secretion during
lactation in the monkey (Gordon et al., 1992), there is no
evidence to support a role for opiates in mediating the prolactin
response to suckling in breastfeeding women. In addition we
found no evidence that the progestogen norethisterone enhanced
the release of prolactin in response to suckling. This contrasts
to a recent report in which suckling induced a significantly greater
release of prolactin in women using a vaginal ring releasing
progesterone (Diaz et al., 1991).
In summary, the present study in breastfeeding women during
lactational amenorrhoeu confirmed that suckling suppresses the
pulsatile release of LH but not through a dopaminergic pathway ;
showed that prolactin remains under dopaminergic control during
human lactation, but suckling does not appear to affect prolactin
secretion via an opiate pathway; and indicated only a minor, if
any. role for opiates in the suckling-induced suppression of
GnRH/gonadotrophin secretion but a potential, previously
unreported, effect of opiates in reducing pituitary responsiveness
to GnRH.
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Figure1.Developmentandregressionftheduc ala dalveo arystemithbr ast:(A)prepubertal,(B)inacyclingn lligr vida,(C);primigravidat8weeksst tion,(D)3weekspostpartum48hafterl stsucklingepisode,(E)5yearsafterl std liv y.M ifiedf omDabelow1957. ofoestrogenandprogesterone,suggestingthatapitui aryh rmones chsprolactinmayalsobeinvolved. Changesi pregnancy
Inthenon-pregnantstateithadultwomanc n ectivetissunddiposetissuepredominateandglandulartiss ei c nty.Ipr gnancythehumbreastundergoesmark dchanges.Itfi ttrim erb thduc alandsecretorylementsundergohyperplasiawhichre ultsi r pidincre ei thenumberofalveoli.Inl t rpregnancy,dev lopmentischaracterizedy- alveolarc llhyp rtrophyandthe e:ismarkedd c easeihrelativeamountofadiposeandfibr ust ss e.Within48hfdeliveryal eolibecomedistend dwithilkf llowingi t nsesecr toryactivity.W thweaningandcessationofbr stfeedingregressionftheglandccursrapidly,remainingilkisresorbeda dtherest adyecr seglandulartiss endincre singpredomina cefcon ectiveti sue.M nyf
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thealv olipersist,however,untilthnextpr gnancyothatet suedo snotresemblethepr pub rtalb easthistologically. Endocrinecontrolfbreastevelopment Theendocrinecontrolfmammogenesisasb widelyinvestigatedi someani alspeciesincludingthr tinwh chcomplexint ra tionbetweenovarianandadrenalst roids,growthho monendpr actins requiredtoenablethproductionfmilk.Inthehumanf iramountf preparationoccurswith utp egnancydint en -pregnantst tea ulbreasttissuei ufficientlydifferent atedtob gincretingmilkafterly14daysexposurethighconcentrationsfo strogens(Tys tl,1976).Milk productiondoesind edccurins mew natmi -cvclefollowingfollicularphaseoestrogenstimulationndwheihnormalcycle prolactinlevelsarenormallyslightelevated.Milkproductionaypersist untilme struation. Sensitivityofthebreasttoovarianste oidsp rs ststhroughoutherepro¬ ductiveyears.Invitroculturesofbrea ttissuepondoestrogenwi hductalevelopmentandtor g steronewi ha v larprolifer tion(McNeilly,1977).Changesi m toticact vityithebreastlobulescanseennrelationtofluctuationsi steroidh rmoneshr ughouth menstrualcyclewithanincreasec llproliferationits condh lft ecycle(Goingetal;1988).Flu tuationsr atedhmenstrualcycleh v alsobeendescribedinsecretorypr ductsf mtheb a tin ludingIgA,secretorycomponenta d(3-lactalbumin.How ver,oclearrelationshipbetweenc llprolif rationands cretoryactivith sy tb nd scr beddtheincreasenmitotici dexthsecondalfheycleid m nstrable womenonthco bi edralcontr ceptive.Premenstrualmastalgiai thoughttobed eyp raemiaandtissueo dema,h w ver,rathth nomarkedcellproliferation,andind edthisisr f ectedbysignificantincreaseinb stvolumeithsecondhalfothycle(Milligantal,1975), LACTATION Initiationofmilksecretion Whilemilkisecr tedintotha v olifromthesec ndtrim sterfpr gnancy




























































































































































































































































































































































































































































































































































































































adirectelationshipbetw enthamou tofprolactinsec tedinr sponst adiscreteucklingepisodeanthmounofmilprodu d,nu berf workershavsh wnthatincre singp olactinoncentr tionsiw menby theadministrationofdopa inantagonists,suchassulpirideme - clopramide,willresultinasignificantincrea emilky d(Yliko kaleta , 1982). Mechanismsunderlyingtrelea eofp o ctinduri gs cklap or understooda dmuchofthwo kh sbeencarri do tinthr tw ichmay differconsiderablyfromthhumaniniarea(seMcNeilly.1988). However,evid ncfr mani alstu iessuggeststhacklingatnippl mayresultinchangesdopa intur over,allowingpro acttbe releasedintothcircu ation.Tchangeidopaminturnov rm ybe secondarytosuckling-inducedincreasesopioidss cha(3-endorph (Gordonetal,1987)whichmayalsinflu ncereleasofgonadotrophin- releasinghormone(GnRH).Therasbe nreportfincre sesplas a p-endorphinconcentrationsduringsu kliinwome(Franceschinietl, 1989)butadirectrelationshiph sy ttoconfirmed. Whilenecessaryformilkprodu tioni ruminant ,growthhorm ned es notappeartbeessentialforlactogenesisinthhum .Wowith isolatedgrowthhorm nedeficiencycabreastfe dsuc ssfully(Rim int al,1968)andcutecha gesingrowthhorm nconcentrationswi hsu kli g havenotbeenidentified.Similarly,ch ngesiinsulina dcorticos ero d concentrationshavebeedescrib dinr lationtosu kli gmsp c s
...butnoti .thehumanalthoughlac ti nisassociat dwi haltera ionin generalmetabolism(lllingworthetal,1986).Fi al y,bothfreandou levelsofthyroxinearereduc dndthy ihormone-bindingglobulinlev ls increasedduringlactatioiwomeal houghtherapp arbspecific rolefortheshorm nesinilkproduction. Duringlactation,milkisontinuouslysecretedintthlveoli.Oxyto in causescontractionfthemyoepithelialcell ,expe l ngmilkfrothalve l andalveolarductstowardthnipple.Tmechanismu derlyingthis—th milkejectionr flex—seemstobco monallmammal .Affe ntimpuls s fromtheareola,stimulatedbyt bysuckling,pro otreleaseofxytocin fromthep steriorpituitary(seWakerlevt,1988).Inwom noxytocini releasedevenbeforthons tfsuckli ga dthsp ntaneousejec iono milkoftenccursinthabsenceftsu kli gstimul s,parti ularlyin responsetoassociatedstimuliu hathso ndofb bycrying.Iinow clearthatoxytocinisecr tednpuls sduringthsu klie isod(McNei ly etal,1983)buttheamountofxy cime suredduringsucklidon appeartoberelatedhamountofmilkeject d.Secreti nmaybinhibit d byothphysicalandpsychologi alstress.Inthlighofthisundersta ding, nasaladministrationofxytocin,ac ihgbfacilit tintheledowrefl x,h s beenusedwithvariabledegre sofs cc sinthr atm ntfw mhoar havingdifficultyestablishingbreastfeedinginthefirstfewdaypostp rtum.A rathermorexcitingp ospectaybthepos ibil tyofenhan ingth establishmentoflactat o ,andthereforefsuccessfulbre fe ding,y administeringantiprogesteronesuchaRU-486immediatelyafter deliverytoacceleratehini i t onofm ks creti n(Wolea ,1989).
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388A.OLASIERNDSMcNEILLY LHsecretiondu i glactation(Figure5).Intharlypostpa tumw eks duringf llbreastfeedingtheri compl tesuppr ssionfpulsatilLH secretion.Through utthperi dfamenorrhoea,veiftp sis sl r intothepuerpe'rium( po24w ks),sup r ssionfLHp lsat l tvmayb seen(Glasiertl,1984).Aucklingctivitydecr asestherigr dual returnofpulsatility,robablyccurringfi tanighsid eswi htheon et Supplementaryfood Week Figure4.Mean24hsucklingfreq encyanddur tionmeap olacticonc ntratioi samplest kenev ry2we kfrom7b e stfe dingo nshowinrelationti fi st introducingsuppleme taryfo d.Thpercentagefwomehoshow devid ncef llic l r developmentandfovulationrshowitb ttomfigu .FromH wiec l(1981)wi h permission.
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havesignificantnegativeef ectomilky ld(Ko ts wang,1982). Gestagen-onlypreparationsdonotinfluencemilkoutputdw dely prescribedeith rasoralrparent rald potpreparationsu gbreastfeeding.Mechanicalm thodsofontraceptionpresentrt u ar problemsduringbreastfeeding. Theuseofalong-actingagonistnalogueGnRHcontra eptivef r breastfeedingmoth rsh srec ntlybeeninv igated.Thth ore ica advantageofthisprepar tiontiinthef ctto lysma la ou tp s s intothebreastmilkand,presumablybec useofi ivationthestomach, iswithoutbiologicalactivitynthenfan(Dew rt,1987).Fras (1989)haveshowntanalogue,givsn alspray,tbeffectivi suppressingovarianactivitydthpostp rtume iod.Teffectsf GnRHanalogueislow-releasedepotform,hichldbmu r practicalmeansofadministrationrenowbei ginv stigated. Perhapsmorecriticalt nmea sofcontr c ptionhoseist m postpartumwhenishouldbintroduce .Iq itecl art tb eastfe ding aloneffordssompr tectionagain tpr gnancya dyithn rmmo t countriestadviseheearlyusfnartificialmethodco tra ption,i. . notimmediatelypostpartum,thenby6w eksafterdeliv y.Ti abundantevidencetosuggesth ,ide elopingcountries,m tp oplely usepre cribedcontraceptivesf rmax mumf6onth(Laukaran,1981). Iftheintroductionfacontraceptivepreparationisdelayedn illy necessary,interbirthrvalsm ybsignificantlyprolongedthuim rovi g thehealthofb tmoth r.andinfa tndi flu ncingpopul tiongrowth.T




9yearsreducedtheiskby63%wh ncomparedithom nhobrea tf foratotalfn y3yearsless.Twoca eo troltudi sfr mN h America(Byerstal,1985;McTi rn nandThom s,1986)efr SouthAfricahaveconfirmedthesfindings.Ti id ncefbrea tcancer
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Twenty-four hour patterns of prolactin secretion during
lactation and the relationship to suckling and the
resumption of fertility in breast-feeding women
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lit breast-feeding women prolactin released in response to
suckling is essential for the maintenance of lactation. This
physiological hyperprolactinaemia is also associated with
lactational infertility. However, it is not clear whether there
is any direct relationship between changes in prolactin per
se and the duration of infertility. To address this question,
our study determined the pattern of prolactin secretion in
relation to suckling and the return of ovarian activity in
(he same cohort of breast-feeding women. Blood samples
were withdrawn at 10 min intervals for 24 It from 09:00
to 09:00 h at either 4 (n = 9) or 8 weeks (n = II)
post-partum wiicn the women had completely suppressed
ovarian activity, at the time of the introduction of supple¬
ments to the baby (/t = 17), a time associated with reduction
of suckling activity, at first menses while still breast-feeding
In = 13) and in the follicular phase (n — 9) of the first
menstrual cycle after weaning. During sampling, mothers
and babies continued their normal pattern of suckling
activity. The pattern of prolactin release was very variable
at each stage of lactation, depending on the pattern of
suckling. Frequent suckling was associated with elevated
prolactin concentrations during the 24 h period throughout
lactation. When suckling was less frequent, prolactin con¬
centrations fell to baseline values between breast-feeds, but
prolactin was released in response to all suckling episodes.
An increase in prolactin concentrations at night, independ¬
ent of suckling, was only evident once breast-feeding had
ceased. The prolactin response to suckling declined signi¬
ficantly only after the return of menses at 33.6 ± 3.5
weeks post-partum. There was no relationship between the
duration of amenorrhoea and the plasma concentrations of
prolactin over 24 ii, or day or night separately, throughout
lactation. However, there was a strong correlation (r =
0.843; P < 0.01) between the timing of the introduction of
dietary, supplements to the bahv and the duration of
amenorrhoca. These results suggest that there may be no
precise link between the release ofprolactin during lactation
and the duration of lactational infertility in breast-feed¬
ing women.
950
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Introduction
Prolactin is essential for die iniliation of lactation (McNeilly,
1977; Glasier and McNeilly, 1990). The administration of
dopamine agonists, such as bromocriptine which decrease
prolactin secretion, results in the inhibition of milk production
(Cooke el al.. 1976; Martin et al., 1981). However, in women
the relationship between prolactin secretion and the mainten¬
ance of lactation is not clear. In breast-feeding women, basal
prolactin concentralions fall as suckling activity declines with
time post-partum (Howie et al.. 1981; Andersen and Schioler,
1982), although individual suckling episodes are associated
wiih an acute rise in prolactin concentrations even after
prolonged lactation (Madden et at., 1978; Gross et aL, 1979;
McNeilly et al., 1983). While daily milk output and the yield
during an individual suckling episode were correlated with
basal prolactin concentrations in one study (Hcnnart et al..
1981), there was no relationship found between the acute rise
in prolactin concentrations and the amount of milk produced
during a single suckling episode (Howie et al., 1979; Glasier
et al., 1984; Unvas-Moberg et al., 1990). Nevertheless, the
administration of dopamine agonists, such as metoclopramide
(Kauppila et al., 1981) or sulpiride (Aono el al., 1982;
Ylikorkala et at., 1982) which increase prolactin concentra¬
tions, have been shown to improve milk output io women.
Whether or not prolactin has an instrumental role in the
mechanisms underlying lactational amenorrhoea has not been
resolved (McNeilly, 1994). However, one investigator (Diaz
et al., 1988. 1991) hits suggested that women who show a
more marked prolactin rise in response to individual suckling
episodes experience a longer duration of amenorrhoca. To test
this hypothesis further, we investigated the pattern of prolactin
secretion in breast-feeding women for 24 h at different times
during Ihc post-partum period and related the changes in
prolactin response to the duration of lactational infertility.
Materials and methods
Subjects and sampling methods
A total of 20 women who intended to breast-feed their infants were
recruited front the postnatal wards of the Simpson Memorial Maternity
Pavilion (SMMP), Royal Infirmary, Edinburgh. UK. They were aged
between 18 and 35 years, and io good general health with no history
of infertility. They had delivered a healthy infant weighing >2.5 kg.
None were using sleroidal contraception while breast-feeding. The
infant feeding pattern was recorded daily. Night-time suckling episodes
© European Society for Human Reproduction and Embryology
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Patterns of prolactin secretion during lactation
a) 4 weeks
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Clock Time Clock Time
Figure 1. Changes in the plasma concentrations of prolactin over a 24 h period for four individual women at (a) 4 or (b) 8 weeks post¬
partum. The asterisks indicate a suckling episode.
Table I. Comparison of the concentrations (mean r SE) of prolactin over each 24 h sampling period and during daytime (07:00-22:00 h) and night-time
(22:00 07:00 In at different stages of lactation in breast-feeding women
Stage of lactation No. of
subjects
Mean plasma prolactin concentration (mlU/t)
Overall 24 h Day Night
4 weeks 9 2434 ± 409 2325 = 436 2543 433
8 weeks II 2253 T 443 2138 ~ 525 2530 ± 397
Introduction of dietary supplements to the baby 14 1404 i 223 1301 r 222 I580 * 260
l ust menses 13 463 ± 102 386 i 95 6I8 :► 121*
After weaning 9 166 ± 14 113 ± 1-1 256 - 20"
aP < 0.05 compared with daytime.
hP < 0.001 compared with daytime.
were defined as those which occurred between 22:00 and 07:00 li.
Any supplementary food given to the baby other than breast milk
was recorded.
At four key stages of the study, the women were admitted with
their infants to the Clinical Research Unit of the SMMP for serial
blood sampling throughout 24 h. The first admission was at either 4
(w - 9) or 8 weeks (n -II) post-partum when the mothers were
fully breast-feeding and ovarian activity was fully suppressed. The
second serial blood sampling was within I week of the introduction
of supplementary food to the baby (n — 14), mothers having been
encouraged to supplement their babies' diets by health visitors and/
or friends and relatives. The third study period was within a few
days following the onset of the first menstrual period while the
mothers were still partially breast-feeding (« ~ 13). Finally, the
women were studied in the early follicular phase of a normal menstrual
cycle after the complete cessation of breast feeding (/t - 9).
During blood sampling, no restrictions were made on physical
activity or food intake beyond that placed by a hospital environment,
and the women slept at night according to their usual pattern. Breast¬
feeding took place on demand, and the time of onset of suckling and
the duration of each feed were noted in detail. In addition, the
activities of the women, including meal times and sleep patterns,
were recorded. On admission to the unit at 08:30 h a 20 gauge
Vcnflon cannula was inserted into a forearm vein and the cannula
kept patent with heparinized saline. From 09:00 h. 2.5 ml venous
blood samples were collected every 10 min throughout 24 h. At night
during sleep, blood samples were collected through a long i.v. catheter
which passed through a hole in the wall to the adjoining laboratory.
allowing blood samples to be collected without disturbing the women's
sleep. Lights were switched off between 23:00 and 07:00 h. The
plasma was separated and stored at -20°C until assayed for prolactin
in batches.
The study was approved by the Lothian Health Board Ethics of
Medical Research Committee and informed consent was obtained
from all the women.
Hormone assays
Plasma prolactin concentrations were measured in a two-site iimnuno-
radiometric assay (Netria. St Bartholomew's Hospital. London, UK;
Wu el al., 1990). The intra- and intenussay coefficients of variation
were <8 and <11% respectively.
The data are presented as mean ± SEM except where otherwise
stated. Comparisons between mean hormonal concentrations were
performed by an analysts of variance on log-transformed data. The
prolactin response to suckling was determined by the difference
between the increments in plasma concentrations of prolactin at 10.
20 and 30 niin following the onset of suckling and a comparison
between the maximum prolactin concentration in response to suckling.
Results
Mean plasma concentrations of prolactin in relation to time
post-partum are shown in Table I. During full breast-feeding in
951
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Figure 2. Changes in the plasma concentrations of prolactin over a 24 h period in two individual women measured at (a) 4 weeks post¬
partum, (b) within 1 week of the introduction of dietary supplements to the baby, (c) in the follicular phase of the cycle following first
menses and (d) in the follicular phase of die cycle after weaning. The asterisks indicate a suckling episode.
the early post-partum weeks, the mean prolactin concentrations
were significantly (P < O.(X)l) higher thiui after weaning and
when compared with concentrations measured at the time of
the introduction of dietary supplements to the baby (/' <
0.05). However there were no differences between women
sampled at 4 weeks compared with 8 weeks post-partum.
Dietary supplements were introduced at a mean of 14.9 ± 0.9
weeks post-parlum (range 9-24 weeks) for reasons unrelated
to milk production. Ai this time mean concentrations of
prolactin were sliil significantly (P < 0.001) higher than after
the babies had been weaned. The introduction of supplement
coincided with a sustained decline in suckling duration 3.6 ±
1.0 weeks later (range 0-22) and suckling frequency at 6.9 ±
1.7 weeks (range 1-22). The decline in suckling duration
preceded the decline in frequency in every individual. The
return of menses occurred al a mean of 33.6 ± 3.5 weeks
post-partum (range 16-65). and mean prolactin concentrations
remained significantly elevated (over baseline; P < 0.05) at
this time. Only after the resumption of menses was there a
significant {P < 0.005) rise in prolactin concentration at night¬
time (compared with daytime), when 10 of the 13 women
studied at this time breast-fed their babies between 22:00 and
07:00 h. The night-time rise in prolactin concentration was
more marked (P < 0.001) once breast-feeding had ceased.
Representative patterns of prolactin secretion among indi¬
vidual fully breast-feeding women are shown in Figure 1.
When suckling episodes occurred very frequently (subject 5
at 4 weeks; subject 16 at 8 weeks), prolactin concentrations
remained above baseline throughout the 24 h period and a
discrete response to every suckling episode was difficult to
define. This was in contrast to less frequent suckling (subject
2 at 4 weeks; subject 11 at 8 weeks) when the prolactin
concentrations fell to baseline values between breast-feeds,
while each feed was accompanied by a marked and clearly
defined rise in prolactin concentration.
Frequent suckling was associated with a sustained rise in
basal prolactin concentrations throughout lactation, even at the
time of resumption of menses. Figure 2 shows the 24 h pattern
of prolactin secretion at four time-periods for two subjects.
Subject 4 maintained a high suckling frequency and was still
breast-feeding her baby 13 times during the 24 h when she
was sampled following first menses. In contrast, subject I
breasi-fed much less frequently and reduced to four feeds per
day by the time menses resumed. In each stibjeel a decline in
24 h prolactin concentrations occurred with time postpartum.
Suckling was always accompanied by a rise in prolactin
concentration, but the magnitude of this rise also decreased
with time.
The mean prolactin response over the first 30 ntin after Ihc
stait of suckling at each post-partum period is shown in
Figure 3. There was no significant difference in the prolactin
response in terms of either the amount of hormone released
or the maximum prolactin concentration achieved during
suckling episodes at 4 and 8 weeks post-partum. At the time
of introducing dietary supplements to the baby, prolactin
responses to suckling were reduced, although this was not
significant, but the response was significantly (P <0.05)
reduced after the return of menses.
952
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A First menses
0 10 20 30 Maximum
Time after start of suckling (min) response
Figure 3. Changes in the incremental prolactin response and the
maximum incremental response to suckling al various times post¬
partum.
0 10 20 30 40 50 60
Duration of amonorrhoea (weeks)
Figure 4. The relationship between the duration of amenorrhoea
and the time when supplementary feeds were introduced to the
baby.
Tabic II. Relationship in individual subjects (;i 14) between the duration of amcnorrhoea, time of introduction of supplements to the baby and suckling
frequency and the mean (±SBM) plasma concentrations of prolactin over 24 h. during daytime (07:00-22:00 h) and night-time (22:00-07:00 h), and (he mean
increment in prolactin in response to suckling throughout the 24 h period of sampling at the lime of the introduction of supplements
Subject Duration of Time of Suckling
no. ainenorrhoca introduction of frequency
(weeks) supplements (day/night)
(weeks)
Plasma concentrations of prolactin (mIU/1)
Over 24 h Daytime Mean prolactin increment in
response to suckling
15 65 24 7/0 905 28 907 ± 41 901 ± 43 331 ± 74
II 48 20 7/0 1064 ± 45 854 + 54 1525 ± 45 675 254
10 44 18 5/1 1093 ± 51 732 ± 42 1616 .T 72 715 ± 135
6 38 18 8/1 1227 ± 49 1279 ± 78 1073 31 688 ± 144
3 37 12 6/3 919 52 715 ± 44 1324 112 1103 £ 275
2 36 12 5/2 660 ± 45 728 -L 70 627 ± 49 1564 411
14 35 14 9/2 1855 ± 95 2260 ± 142 1358 90 1482 ± 366
5 31 15 6/0 1505 ± 50 1430 ± 66 1783 ± 75 962 T 306
16 31 16 5/2 1155 ± 88 532 ± 21 2247 ± 163 760 + 282
13 29 16 3/0 397 ± 21 257 ± 24 605 ± 20 606 ± 77
4a 24J 17 11/2 1867 i 77 2027 ± 113 1744 ± 105 892 204
12 21 9 9/1 4386 ± 188 390 ± 242 5233 ± 324 4556 571
18 16 9 5/1 962 ± 72 927 ± 105 825 ± 40 2500 ± 628
1 16 9 5/2 "'2278 ± 224 2486 ± 224 1941 i 136 4336 ± 1086
uWeaned abruptly.
The relationships between the liming of the introduction of
supplements, suckling frequency, the duration of amenorrhoea
and patterns of prolactin secretion are shown in Table II for
the 14 women who were sampled within 1 week of starting
to give their baby dietary supplements. The timing of the
introduction of supplements and suckling frequency varied
considerably. The duration of amenorrhoeu was strongly correl¬
ated (r = 0.843; P < 0.01) with the timing of the introduction
of supplements (Figure 4). No clear relationship for the
duration of lactational amenorrhoea could be found with
suckling frequency at the time when supplements were started,
mean plasma concentrations of prolactin, either for the 24 h
period or for day and night separately, or the mean prolactin
increment in response to suckling.
Discussion
While it is accepted that prolactin concentrations in breast¬
feeding women fall with time posl-partum despite sustained
lactation (e.g. Howie et al.. 1981; Andersen and Schioler,
1982; Howie and McNeilly, 1982), our study has demonstrated
that the immediate response of prolactin to suckling also
decreased with lime, regardless of the suckling frequency or
time of suckling during a 24 h period. These results extend
those of Nunley et qL (1991), who investigated the pulsatile
release of prolactin during lactation. They concluded that both
the amount of prolactin secreted and the rate of release of
prolactin at each release episode decreased with time, while
the frequency of release episodes remained the same. However,
the suckling pattern of the individuals studied was not recorded,
and so it is not possible to distinguish between spontaneous
prolactin release and suckling-induced release in their study.
Here, we have been unable to identify the clear spontaneous
pulsatile secretion of prolactin unrelated to suckling.
We were unable to identify a nocturnal rise in prolactin
concentration in the early post-partum weeks. A nocturnal rise
in prolactin concentration in non-lactating women has been
recognized for many years (Sassin et al.. 1973) and can be
953
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demonstrated in women who do not breast-feed their babies
as early as 10 days after childbirth (Liu and Park, 1988).
Previous studies have suggested thai suckling episodes which
occur in the morning are associated with a less marked
prolactin response than those occurring in the afternoon,
particularly after 13 weeks post-partum (Glasier ct al., 1984;
Diaz et al., 1988). These results were interpreted as indicating
an altered sensitivity of the hypothalamus to the effects of
suckling on the release of prolactin (Glasier el al., 1984).
Certainly there does not appear to be any lack of releasable
prolactin in the pituitary at least alter 12 weeks post-partum
(Tay el al., 1993). In our study there were indications in some
women of an increased release of prolactin in response to
suckling during the afternoon and evening (Figure 1, subjects
2 and 11; Figure 2, subject 4) but this was not a significant
finding. However, an analysis of the changes in mean prolactin
concentrations over the 24 h periods of observation indicated
a significantly higher level al night-time (between 22:00 and
07:00 h) than during the daytime (between 07:00 and 22:00 h),
but only after first menses while breast-feeding, and then after"
weaning (Table 1). It is possible that the nocturnal rise in
prolactin concentration is less noticeable during the early post¬
partum weeks when daytime suckling frequencies are high,
inter-suckling intervals short and basal prolactin concentrations
elevated. It was noticeable that when suckling frequencies
were high, lack of suckling during the night was associated
with a decline in plasma prolactin concentration, until suckling
occurred, when values increased (Figure 1, subject 11 and
Figure 2).
In our study the periods of sampling were chosen to coincide
with episodes which we have shown to be associated with
aspects of the return of fertility in breast-feeding mothers.
Thus, the introduction of dietary supplements to the baby in
the particular study cohort in Edinburgh. UK is associated
with a reduction in suckling frequency; the resumption of
ovarian activity (Howie el nl., 1981) and the menstrual cycle
after first menses while breast-feeding continues is associated
with inadequate luteal phases (McNeilly el al, 1982). It was
hoped that sampling al these times might identify any alteration
in the prolactin responses to suckling which might be related
to the duration of amenorrhoea in the former case or luteal
function in the latter.
In previous studies in Chile, it has been shown that an
increased prolactin response to suckling was associated with
a longer duration of amenorrhoea (Diaz et al., 1988, 1991).
In contrast, we were unable to identify any relationship between
the magnitude of the prolactin response to suckling episodes
and the duration of amenorrhoea. In our study, no restriction
was placed on the way the mothers breast-fed their babies,
and during the periods of sampling the mothers continued to
suckle their babies normally. In contrast, in the Diaz et al.
studies, all subjects were exclusively breast-feeding and
amenorrhoeic when they were admitted to the study at 3-4
months post-partum, and the women were specifically asked
to breast-feed exclusively (even water was not permitted) and
to delay introducing dietary supplements to their babies for 6
months (Diaz et al., 1988. 1991). It may be that this artificial
restriction on the natural pattern of suckling resulted in the
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higher release of prolactin observed in the women with
prolonged amenorrhoca (Diaz et al., 1988, 1991). In our study
we did not interfere with the natural pattern of suckling
established by individual mothers and babies. Perhaps babies
which were naturally frequent feeders would elicit a greater
suckling stimulus and hence a greater release of prolactin
if their suckling times were strictly regimented, as in the
Chilean study.
While it is possible that any relationship between the
prolactin response to suckling and the duration of amcnorrhoca
was missed in our study, the fact that we sampled women
during normal breast-feeding suggests that the relationship
between prolactin response and the duration of amenorrhoca
is not strong. In contrast, in our study there was a strong
correlation between the time of the introduction of dietary
supplements to the baby and the duration of amenorrhoea
(Figure 4). This confirms previous results in our study popula¬
tion (Howie et al., 1981; Howie and McNeilly, 1982) and of
others (Gray et al., 1990). However, the effect of dietary-
supplements on the resumption of fertility varies within differ¬
ent societies and the type of supplement given (Lewis el al.,
1991; Kennedy and Visness, 1992).
The results of our study do not identify a specific pattern
of prolactin release or an amount of prolactin released thai is
predictive of the duration of infertility in breast-feeding women.
The pattern of suckling had a major impact on the changes in
the plasma concentration of prolactin al all stages of lactation
investigated. Thus, at present it is not possible to confirm that
the increase in prolactin associated with breast-feeding is
causally related to the suppression of fertility post-partum.
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Abnormal twenty-four hour pattern of pulsatile
luteinizing hormone secretion and the response to
naloxone in women with hyperprolactinaemic amenorrhoea
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Summary
OBJECTIVE Hyperprolactinaemic amenorrhoea is assoc¬
iated with disturbances of pulsatile gonadotrophin secre¬
tion. The underlying mechanism remains unclear and the
aim of this study was to investigate the 24-hour secretory
pattern of gonadotrophins in women with hyperprolac¬
tinaemic amenorrhoea. The eflect of opioid blockade
using naloxone Infusion on LH secretory pattern was also
studied.
DESIGN The secretory patterns of LH, FSH, PRL and their
responses to naloxone infusion were studied by serial
blood samples collected at 10-minute Intervals for 24
hours. On the following day, naloxone was infused at a
dose of 1-6 mg per hour for 4 hours.
PATIENTS Eight women with hyperprolactinaemic amen¬
orrhoea, two women hyperprolactinaemic but with normal
ovarian cycles, and nine control subjects in the early
follicular phase of menstrual cycle.
MEASUREMENTS Concentrations of LH, FSH and PRL
were measured in plasma samples obtained at 10-minute
intervals for 24 hours. In one woman, concentrations of
urinary oestrone glucuronlde were measured daily during
treatment with pulsatile GnRH.
RESULTS The number of LH pulses per 24 hours was
significantly fewer in women with hyperprolactinaemic
amenorrhoea than in those with hyperprolactinaemia with
normal cycles or control subjects (mean ± SEM 4 5± 2-4 vs
13-5±2-5 vs 17-3±0 8, P<0 001). The magnitude of each
episode of secretion was significantly higher in the
hyperprolactinaemic amenorrhoeic women (P< 0 05) so
the overall mean concentrations of LH throughout the 24-
Corrcspondencc: Professor David T. Baird, Department of
Obstetrics and Gynaecology, Centre for Reproductive Biology,
University of Edinburgh. 37 Chalmers Street, Edinburgh EH3
9F.VV. Scotland.
hour period was similar in the three groups (5 2±1 1,
4 8±08 and 5-2±0 4 U/l respectively). In women with
hyperprolactinaemic amenorrhoea there was no signifi¬
cant change In the pattern of LH secretion during sleep in
contrast to the control women in whom there was a
slowing in the LH pulse frequency during the night. There
was no significant change in the mean concentrations of
LH, FSH and PRL during the naloxone infusion. There were
also no significant changes in the LH pulse frequency In
response to naloxone Infusion when compared with an
equivalent period of time in the previous 24 hours. In one
hyperprolactinaemic amenorrhoeic woman, follicular de¬
velopment, ovulation and pregnancy were induced when
gonadotrophin releasing hormone (GnRH) was infused in
a pulsatile manner at a dose of 5 /ig every 90 minutes.
CONCLUSIONS The suppression of normal ovarian cycles
in women with hyperprolaclinaemic amenorrhoea is due
to a significant reduction in frequency of LH (GnRH)
secretion which is not due to an increase in hypothalamic
opioid activity. As normal ovarian cycles can occur or be
induced by exogenous GnRH in hyperprolactinaemia, it is
unlikely that a high level of prolactin by Itself inhibits
follicular development and ovulation.
Pathological hyperprolactinaemic amenorrhoca is assoc¬
iated with disturbances ofpulsatile gonadotrophin secretion.
Most authors have described a reduced LH pulse frequency
which increases following treatment with bromocriptine
(Moult et al., I982; Sauder et at., 1984). However, Klibanski
el til. (1984) reported a reduction in pulse frequency when
hyperprolactinaemic patients were treated with bromocript¬
ine. Although Moult et at, (1982) described a fairly consistent
pattern of high amplitude, low frequency pulses the consen¬
sus of opinion suggests that the pattern of pulses shows
marked variability between individual women. Whatever the
characteristics of the disturbance of pulsatile LH secretion, it
is clear that ovarian function can be restored by the
exogenous administration of pulsatile GnRH (Leyendecker
el al., 1980; Poison et at., 1986).
The mechanism underlying the disturbance of LH se¬
cretion in hyperprolactinaemic women remains unclear.
There is evidence that high concentrations of prolactin
increased dopamine turnover in the hypothalamus in the rat
(Adler, 1986) and it has been suggested that increased
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Table 1 Details of subjects with
Time off hyperprolactinaemia
Age bmi bromocriptine prt e2
Subjects (years) Parity (kg/nr) (months) (mU/1) (pmol/l)
1
2
38 0 + 0 19 6 nt 2500 105
26 0 + 0 7T-5 5 662CT 00
3 44 2+1 31 14 1967 56
4 27 1+0 25 11 4030 100
5 29 0 + 0 22 7 7440 92
6 22 0+0 29 nt 2270 <46
7* 41 1 +0 36 nt 5720 56
8* 23 0 + 0 20-1 9 6850 110
9+ 37 2 + 0 21 3 2200 182
lot 41 2 + 0 25 nt 1620 153
* Microadenoma on CT scan.
1" Regular ntenscs.
NT. Never treated with bromocriptine.
dopamine lone may afTecl the pulse generator. In the human,
Quigley el til. (I980) suggested that the attenuated pulsatile
pattern of LH release characteristic of hyperprolactinaemic
patients may be due in part to an increased inhibitory effect
of endogenous opioids on ClnRH secretion.
In order to determine whether an increase in opioid tone
may be involved in the suppression of pulsatile LH release in
women with hyperprolactinaemia, we have investigated the
effects of the opioid antagonist, naloxone, on the secretion of
LH and FSH.
Materials and methods 1
Subjects and sampling methods
Ten women with hyperprolactinaemia (serum prolactin
> 1500 mlJ/l) were recruited from the Reproductive Endo¬
crine Clinic or the Royal Infirmary of Edinburgh. Eight of
the women were amenorrlioeic and two had regular men¬
strual cycles (Table I). No woman was on any medication
and all had normal thyroid function tests. In those who had
previously been taking bromocriptine, the treatment was
stopped for at least 3 months prior to the study. All the
women had normal skull X-rays but subjects 7 and 8 had
evidence ofmicroadenoma on CT scan. The two women who
had regular ovulatory cycles (subjects 9 and 10) were studied
in the early follicular phase of the menstrual cycle.
The stgdy was approved by the Lothian Health Hoard
Ethics of Medical Research Committee and informed con¬
sent was obtained from all women. The subjects were
admitted to (he Clinical Research Unit of the Simpson
Memorial Maternity Pavilion for Ihe study. There were no
restrictions on physical activity or food intake beyond that
Table 2 Details of control subjects
Age BMr PRL e2
Subjects (years) Parity (kg/in2) (mU/l) (pmol/l)
11 30 1 +0 23 84 645
12 31 1 +0 22 80 159
13 32 1+0 22-5 <36 179
14 30 1+0 24 127 134
15 26 1+0 21 63 159
16 32 1+0 22 289 222
17 26 1+0 23 154 210
18 31 1 + 1 24 92 245
19 25 J+0 20 324 248
placed by a hospital environment. Lights were switched off
between 2300 and 0700 h, when they went to sleep.
On admission to the Unit on Day 1 at 0800 it, a 20G
Vcnflon cannula was inserted into a forearm vein and the
cannula was kept patent with heparinized saline. From 0900
h, 2-5 ml sample of venous blood was collected every 10
minutes throughout 24 hours. At night during sleep, blood
samples were collected through a long intravenous catheter
which passed through a hole in the wall to the adjoining
laboratory, allowing blood samples to be collected without
disturbing the subjects' sleep.
At 0900 h on Day 2, an intravenous infusion of naloxone
was commenced using an infusion pump which delivered a
constant dose of I -6 mg/hour for the next 4 hours. During the
infusion, blood samples were again collected every 10
minutes for 4 hours. The plasma was separated and stored at
— 20JC and later assayed in batches for LH, FSH and
prolactin.
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Fig. 1 Twenty-four-hour pattern of LH secretion in two women with hyperprolactinaemic amenorrhoea. a. Subject 4 (Ei 109 pmol/l;
P4 1-5 nmol/l; PRL 2931 mli/1); b. subject 2 (E2 132 pmol/l; P4 < I ninol/1; PRL 7384 mU/1).
♦Statistically significant pulse of secretion.
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Fig. 2 Twenty-four-hour pattern of LH secretion during the early follicular phase in two control subjects, a, Subject 11 (E2 645 pmol/l;
P4 < 1 nmol/l; PRL 84 raU/1); b, subject 12 (E2 159 pmol/l; P4 1-7 nmol/l; PRL 80 mU/l).
♦Statistically significant pulse of secretion.
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Fig. 3 Twenty-four-hour pattern of LI i secretion during the early follicular phase in two women with hyperprolactinacinia and regular
menstrual cycles, a. Subject 9 (E> 665 pntol/l; Pr 3-6 nmol/l; PRL 1554 ntU/l): b, subject 10 (E- 257 pmol/l: P4 < I nmol/l; PRI.. 1678 mU/l).
♦Statistically signifiCitnl pulse of secretion.
Control subjects
i
Nine women (25-32 years) were studied in the early follicular
phase of a normal ovulatory cycle (Table 2). Venous blood
samples (2-5 ml) were collected every 10 minutes throughout
the 24 hours as described above.
Induction of ovulation by pulsatile GnRH pump
In subject 4, treatment with the dopamine agonists bromo¬
criptine and iisuride had failed to induce ovulation. She was
then treated with gonadotrophin releasing hormone
(GnRH) delivered in a pulsatile manner using a Mill Hill
portable infusion pump (Sutherland er a/., 1984). Initially
this was set to deliver at a dose of IS /tg GnRH subcutan-
eously every 90 minutes but this was later changed to 15 /rg
subcutaneously every 120 minutes and then 5 pg intraven¬
ously every 90 minutes. Ovarian activity was monitored by
the daily measurement of the excretion of ocstronc glucuro¬
nic and pregnanediol glucuronic in urine and the measure¬
ment twice-weekly of the concentration of oestradiol in
plasma and follicular diameter and endometrial thickness by
ultrasound.
Hormone assays
Plasma concentrations of LH and FSH were measured by
radioimmunoassay as described previously (Djahanbakhch
et at., 1981; Hunter & Bonnie, 1979) while plasma prolactin
was measured in a two-site immunoradiometric assay
(NETRIA, St Bartholomew's Hospital, London) (Wit et til..
1990). The intra and inter-assay coefficients ofvariation were
<8 and <11% respectively for LH, FSH and prolactin.
Concentrations of oeslrone glucuronidc and pregnanediol
glucuronide in urine were measured as described previously
and corrected for the amount of creatinine in each sample
(Fraser et al., 1989). Plasma oestradiol and progesterone
concentrations were measured by specific radioimmuno¬
assay following diethyl ether extraction of plasma as de¬
scribed previously (Glasier el al., 1989).
Statistical analysis
The data are presented as mean±SEM except where other¬
wise slated. Comparisons between mean hormonal concen¬
trations and the various parameters of pulsatile LH secrc-
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Table 3 Mean values of basal LH and
parameters of LH pulses among the three
groups of subjects
Hyperprolactinaemia, Hyperprolacliriacmia,
amcnorrhoea regular menses Control
Mean LH (U/l) 5*2± LI 4-8±0-8 5-2±0-4
LH pulse frequency (per 24 h) 4-5±2-4** 13-5±2-5 17-3 ±0-8
LH pulse amplitude (U/l) 4-9 ±50 2 ±0-4 22+0-2
LH pulse interval (min) 498 + 482* 105 ±15 83+4
LH pulse area (U/l) 339 ±367* 84 ±2 62+6
k P < 0 05 Significance of difference from control.
11 ^<0 001 Significance of difference from conlrol.
Fig. 4 The excretion of •, oestrone-3-
glucuronide and O, prcgnanediol
glucuronic in urine during the induction
of ovulation with GnRH in subject 4. The
route of administration was changed front
subcutaneous to intravenous on day 26.
5000 11J hCG was injected on day 37 after
the emergence of a single follicle 16 mm
diameter.
KM |1 1r i i1
40
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lions were performed using Student's /-test. Statistically
significant hormone pulses were identified using the
MUNRO pulse analysis program (Zarislow Software,
Haddington, Scotland, EH 14 4PD) as described previously
(Tay cl a!., 1992). The mean pulse frequency, pulse ampli¬
tude, and pulse area of LH released were compared between
the different groups of women.
Results
individual 24-hour secretory pattern ot LH
The pattern of LH secretion was highly variable with pulse
frequency ranging from 1-8 per 24 hours in individual
hyperprolactinacmic women (Fig. I). In subject 4, the
secretory pattern was almost fully suppressed with only Ihree
statistically significant LH pulses detected by the MUNRO
computerized algorithms over 24 hours. However, in subject
2, eight statistically significant pulses were detected over 24
hours with a mean pulse amplitude of 3-82 + 0-52 U/l. In
contrast, LH pulses occurred much more frequently in the
control women (range 14-21 per 24 hours) (Fig. 2). In subject
11,21 LH pulses were delected over 24 hours and 17 pulses
were detected in subject 12. In the two women with
hyperprolactinaemia who had regular menses in spile of
being hypcrprolactinaemic (subjects 9 and 10), there were 16
and 11 pulses per 24 hours as shown in Fig. 3.
For each subject a single tnean concentration of LH was
calculated from the 145 samples collected over the 24-hour
period. This value was then used to calculate an overall mean
for each group of women. Although the overall mean
concentration of LH in women with hyperprolaclinacmia
amcnorrhoea was similar to controls and to women with
hyperprolactinacmia and regular menses, the pattern of LH
secretion was very different (Table 3). The women with
hyperprolaclinacmia had many fewer pulses/24 hours than
women with regular cycles (P < 0-001). However, the magni¬
tude of each episode of secretion (as measured by lite area
under each LH pulse) was significantly higher in the
hyperprolactinaemic women and, hence, the overall mean
values were similar.
Induction of ovulation by pulsatile GnRH pump
In subject 4, ovulation was induced by the administration of
exogenous GnRH in a pulsatile manner. In the first cycle,
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Fig. 5 Change in mean concentration of LH, FSH and PRL in
response to the infusion of naloxone among the women with
hyperprolactinaemic amcnorrhoea. O, Overall mean value,
a, Basal; b, naloxone.
GnRH was administered subcutaneously (15 pg/90 min),
and although ovulation occurred, the luteal phase was
inadequate. Following menstruation, the patient was main¬
tained on GnRH subcutaneously with the pulse frequency
reduced to every 120 minutes (Fig. 4). As the ovarian
response was inadequate, the regime was changed to 5 /*g
GnRH intravenously every 90 minutes. A single dominant
follicle (16 mm diameter) emerged within 10 days and
ovulation was induced by the injection of 5000 IU of hCG.
The patient became pregnant and eventually bore a healthy
baby.
Effects of naloxone
Despite a rise in the mean concentration of LH in one
subject, there was no significant difference between the basal
Fig. 6 A comparison of the patterns of LH secretion during
H, sleep and □, waking hours for a, women with
hyperprolactinacmin and b, control subjects, i. Mean LH; ii, LH
frequency; iii, LH amplitude.
concentration of LH, FSH and PRL between 0900 and 1300
h on Day I and a corresponding time period 24 hours later
during the infusion of naloxone (Fig. 5). Moreover, the
frequency of LH pulses was similar during the same two time
periods (113 ±0-48 vs 1-38 + 0-32, Mann-Whitney P = NS).
Effects of light and sleep on LH secretory pattern
The mean LH, frequency and amplitude of LH pulses during
sleep, were compared with those during daylight hours in
both hyperprolactinaemic amcnorrhoeic and control women
(Fig. 6). In neither group was there any difference in mean
concentration of LH. However, in control women during
sleep, there were fewer pulses (P < 0 001) and their amplitude
was greater (P < 0 05). There was no such difference in
hyperprolactinacmic women with amenorrhoea.
Discussion
The most obvious feature of the women with hyperprolac¬
tinaemic amenorrhoea was a significant reduction in the
number ofLH pulses during the 24-hour period as compared
with the control women or those with hyperprolaclinaemia
but with normal cycles. These findings confirm that LII
pulses occurring at intervals of not less than every 2 hours are
necessary for normal cyclical ovarian function. The fact that
normal follicular development and ovulation occur if this
optimum frequency is present despite abnormally high levels
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of prolactin (subjects 9 and 10) suggests that high levels of
prolactin are unlikely to play a direct role in suppressing
ovarian activity.
It could be proposed that hyperprolactinaemic women
with normal ovarian activity secrete a form of prolactin
which although recognized by the radioimmunoassay is
biologically inactive (Whittaker et at., 1981: Fraser et at.,
1989). However, it is unlikely that all patients with hypcrpro-
lactinaemic amenorrhoea have biologically inactive prolac¬
tin because galactorrhoea is a common feature of this
condition. The observation that follicular development,
ovulation and fertility could be restored by injecting GnRH
at a frequency which simulated that observed in normal
women (Fig. 4) strongly supports the view that the under¬
lying cause of the amenorrhoea is the disturbance in the
pattern of secretion of GnRH which results in the abnormal
secretion of gonadotropins (Leyendecker et at., 1980;
Poison et at., 1986). A similar conclusion concerning the
cause of suppression of ovarian activity during lactation was
deduced from the fact that ovulation can be induced by
treating lactating women with GnRH in a pulsatile manner
(Glasier et at., 1986).
It has been suggested that the reduction in LH pulse
frequency in women with hyperprolactinaemia is due to
suppression of the activity of the GnRH neurones in
association with increased secretion of endogenous opiates
(Quiglcy el at., 1980). Support for this hypothesis comes
from the report that infusion of opioid antagonist (naloxone)
in some hyperprolactinaemic women resulted in an increase
in the concentration of LH and the frequency of LH pulses
(Grossman et at., 1982; Seki et at., 1986). In our study,
although one subject apparently showed an increase in LH
pulse frequency during the infusion of naloxone, overall
there was no significant rise in the secretion of LH when
compared with an appropriate control period. Throughout
the 24-hour period there are considerable spontaneous
fluctuations in the timing of LH pulses (Figs 1 and 2). It is
possible, therefore, that the apparent increase observed by
Grossman et at. (1982) was due to spontaneous fluctuations
and unrelated to the infusion of naloxone. However, Cook et
al. (1991), demonstrated an increase in LH pulse frequency
during naloxone infusion for 8 hours compared to an
equivalent period during the previous day. One possible
explanation for the lack of response in our study may be that
the shorter duration of infusion (4 hours) was insufficient to
allow adequate opioid blockade to occur. Both women who
had normal ovarian cycles in spite of being hyperprolactin¬
aemic, showed an apparent increase in 1.H concentration
during infusion of naloxone (Fig. 3). In normal women, the
concentration of I.H increases following naloxone only
during the late follicular and late luteal phase when the
concentrations of oestradiol and progesterone are relatively
high (Quigley & Yen, 1980). In lactaling women, there is no
increase in LH secretion after naloxone except in women
who arc treated with 30 /<g levonorgestrcl per day as a
gestogen-only contraceptive (Tay el at., 1993). In the mon¬
key, the concentration of/(-endorphin in the hypothalamic-
hypophyseal portal blood is increased during (he luteal phase
of the cycle or after treatment of ovariectomized monkeys
with oeslradiol and progesterone (Ferin, 1983). These find¬
ings suggest, therefore, that a certain minimum level of
steroid is necessary before endogenous opioid regulation
of gonadotropin secretion can be revealed by infusion of
opioid antagonist. Experiments involving the infusion of
naloxone in hyperprolactinacmic amcnorrhoeic women
treated with a gestogen would be of interest.
In control women (but not those with hyperprolactin¬
aemic amenorrhoca), the frequency of LH pulses slowed
significantly during the dark/sleep period as has been
observed by others in women in the early follicular phase of
the cycle (Kapcn et at., 1976; Crowley et at., 1985). We are
unable to distinguish precisely between dark and sleep,
although all the women apparently slept uninterruptedly
soon after the lights were switched ofl'at 2300 h. The cause of
this diurnal variation in pulse frequency is not known,
although it is associated with a nocturnal rise in the secretion
of prolactin and melatonin (Brzezinski et at., 1988; Berga &
Yen, 1990). There is no such diurnal variation in either
prolactin concentration or LH pulse frequency in hyperpro¬
lactinaemic women with amcnorrhoea, as shown in our
study and by others (Klibanski el at., 1984). In rhesus
monkeys the onset of darkness is associated with a striking
reduction in the activity of hypothalamic GnRH neurones as
reflected by recording of multi-unit activity by hypothalamic
electrodes (O'Byrne et at., 1991).
Further experiments exploring the relations between diur¬
nal rhythms of prolactin, LH, melatonin and hypothalamic
electrical activity, may help explain the pathogenesis of
hypothalamic hyperprolactinaemic amenorrhoca.
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SUMMARY
Four fully breast-feeding women at 6 weeks post partum were injected with
LHRH (01 /rg/kg) every 94 min by pulsatile infusion pump. While follicular
development occurred in all women, and evidence of luteinization was apparent
in three out of four, normal ovulation and luteal function did not occur. This
suggests that a simple disturbance in the pulsatile pattern of LHRH secretion
may not, in itself, be enough to explain the suppression of ovarian activity
during lactation.
The mechanism by which breast-feeding delays the resumption of ovarian activity post
partum remains unclear. Disturbances in the pattern of LH secretion may be, however,
instrumental in maintaining lactational amenorrhoea (McNeilly, 1979; Glasier et al.,
1983). Recently we have demonstrated that during complete suppression of ovarian
activity there is a reduction in the frequency and amplitude LH pulses in 76% of breast¬
feeding women studied (Glasier et al., 1984).
Longitudinal studies have demonstrated that the resumption of ovarian activity is
associated with a decrease in suckling activity and an associated decrease in prolactin
concentrations (McNeilly et al., 1980; Howie et al., 1981). The elevated concentrations of
prolactin in peripheral blood may be instrumental in maintaining amenorrhoea post
partum, acting either at the level of the hypothalamus or directly at the ovary, or may
simply be an index of the level of hypothalamic activity during suckling. In order to
establish whether the restoration of a normal pulsatile pattern of LHRH secretion, in Lhe
presence of hyperprolactinaemia, would result in normal ovulation we have studied four
breast-feeding mothers treated with LHRH administered by pulsatile infusion pump.
SUBJECTS AND METHODS
Four women aged 22-33 years, three primigravid, were recruited from the post-natal
Correspondence: Dr A. Glasier.
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wards of the Simpson Memorial Maternity Pavilion. None was using any hormonal form
of contraception. From 4 weeks post partum, and for the duration of the study, ovarian
activity was monitored by the estimation of oestrogen: creatinine and pregnanediol: crea¬
tinine ratios, in daily early morning specimens of urine (EMU) which were stored at
— 20°C and assayed in batches. Once the study was completed EMUs were also assayed
for LH, the samples from each individual subject being assayed in a single batch. All
mothers kept a record of the frequency and duration of suckling episodes, and of any
supplementary feeds, either bottled milk or solids, given. Night feeds, occurring between
midnight and 0600 h, were recorded separately. Records of any menstrual bleeding were
kept. At between 6 and 7 weeks post partum the women were fitted with a Mill Hill
portable infusion pump (Sutherland et al., 1984; set to deliver 0-1 ^g/kg LHRH in saline
solution in a bolus of 40 /d every 94 min. The pumps were worn on a belt around the waist
and the LHRH solution delivered subcutaneously into the anterior abdominal wall. For
the first or last week of treatment all four women received only normal saline solution, 40
fi\ every 94 min, as a placebo.
Once each week follicular diameter was measured by ultrasound and 5 ml samples of
blood were collected every 15 min for 4 h. After each sample the cannula was flushed
through with a heparinized saline solution (5000 units heparin in 100 ml saline) and the
first 1 ml of the next sample was discarded. No restraint on activity was made during this 4
h period, and breast-feeding took place on demand. Blood samples were centrifuged at
4500 r/min for 20 min and stored at — 20°C until assayed for LH, FSH and prolactin.
The study had the approval of the Reproductive Medicine Ethical sub-committee of the
South Lothian District Health Authority.
Assay methods
Urinary excretion of total oestrogen was measured fluorimetrically (Brown et al., 1968)
and pregnanediol was determined by gas-liquid chromatography (Chamberlain &
Contractor, 1968). Creatinine was measured by auto analyser and the steroid:creatinine
and LH:creatinine ratio determined (Metcalf & Livesey, 1979). Both urinary LH and
serum PRL were measured in duplicate by RIA (McNeilly & Hagen, 1974). Interassay
coefficient of variation (between 80 and 20% B/B0) was 6-5% and interassay coefficient of
variation 9-3% for LH.
All samples for prolactin were measured in the same assay with an intra-assay
coefficient of variation of 5-8%. Serum LH and FSH were measured by RIA (Hunter &
Bennie, 1978). The intra-assay coefficients of variation were 10% and 9% and the
interassay coefficients of variation (16% and 15%) for LH and FSH respectively.
Oestradiol and progesterone were measured by RIA (Scaramuzzi et al., 1975; Biickstrom
et al., 1982). Sensitivities were 5 pg/ml for oestradiol and 140 pg/ml for progesterone.
Interassay and intra-assay coefficients ofvariation were 13% and 9% and 15% and 8% for
oestradiol and progesterone respectively.
Statistical analysis
Student's r-test for paired observations were used throughout.
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RESULTS
Pattern ofovarian activity
Daily oestrogen:creatinine, pregnanediol:creatinine and LH:creatinine ratios, together
with suckling frequencies are shown for one woman (Mrs A) in Fig. 1. Within 48 h of
starting LHRH, urinary oestrogen excretion had increased more than fivefold compared
with the mean of the preceding 14 d and remained elevated for 8 d. A surge ofurinary LH
occurred 4 d after the start of LHRH treatment. Ultrasound scans at 1 and 7 d after
starting treatment also showed evidence ofsome follicular development. There was a rise
in urinary pregnanediol excretion but the maximum prcgnanediol: creatinine ratio
reached on the 14th day after starting treatment was only 0-93 and serum progesterone
never rose above I nmol/1, suggesting that ovulation did not occur. Menstrual bleeding
occurred 10 d after starting LHRH. After 14 d LHRH treatment was stopped and the
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Fig. 1. Subject A (Mrs A, para 2+0; weight 55 kg, 6 weeks post partum). Daily urinary
oestrogen creatinine (• •) and pregnanediolcreatinine ratios (O O) together with
suckling frequency (□) before, during and after LHRH administration. Follicular diameter is
shown at the bottom of the figure. Follicular development was apparent in response to LHRH
administration but pregnanediol creatinine ratios did not reach a level of one. Solid feeds were
introduced in the thirteenth post partum week.
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Fig. 2. Subject B (Mrs B, para 2+0; weight 60 kg, 7 weeks post partum). LHRH administration
resulted in a rise in urinary oestrogen:creatinine (• •) ratio and ultrasound evidence of
follicular development. Follicular diameter is shown at the bottom of the figure. A rise in
pregnanediol:creatinine ratio (O O) suggested that lutcinization had occurred. Suckling
frequency (□) fell and solid feeds (■) were started from 10 weeks post parlum resulting in a
normal ovulatory cycle at around 17 weeks.
during this time and for a further 4 weeks of the study, during which time breast-feeding
continued unsupplemented.
Mrs B (Fig. 2) showed a sustained rise in oestrogen excretion accompanied by
ultrasound evidence of follicular development until 14 d after starting LHRH infusion,
when a fall in oestrogen and pregnanediol concentration preceded the onset of
menstruation on day 15. An LH surge occurred on days 8 and 11, followed by a rise in
urinary pregnanediol concentration on day 11. Maximum pregnanediol (creatinine ratio
of L54 occurred on day 14 with serum progesterone of M2 nmol/1. The follicular phase
lasted 10 d and luteal phase (from the first rise in pregnanediol to menstruation) lasted
only 4 d. Supplementary feeding started as soon as LHRH treatment was stopped at 10
weeks post partum, and oestrogen: creatinine' ratio remained elevated for a further 3
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Fig. 3. A more prolonged rise in urinary oestrogen:creatinine ratio (•——•) is seen in the case of
Subject C (Mrs C, para 1 +0; weight 72 kg, 6 weeks post partum) with a more marked rise in
pregnandiol:creatinine ratio (O O) in response to LHRH. Full breast feeding (□) continued
unsupplemented throughout the study.
weeks. An apparently normal spontaneous ovulatory cycle occurred at 17 weeks post
partum.
A similar sustained rise in oestrogen excretion with ultrasound evidence of follicular
development was seen in a third woman (Mrs C)(Fig. 3). Before the start of treatment an 8
mm diameter follicle was present which persisted and reached a diameter of 60 mm 17 d
after starting treatment. This increase in follicle diameter was accompanied by a sustained
increase in oestrogen (creatinine and was associated with three peaks of urinary LH. The
final increase in LH on day 14 of treatment was followed by a rise in pregnanediol (creati¬
nine ratio (maximum 2-71) on day 15.Serum progesterone on day 14was7-61 nmol/land
menstruation occurred on day 22, giving a follicular phase of 15 and a luteal phase of 5 d.
After stopping treatment with LHRH, ovarian activity suppressed again and Mrs C was
still partially breast-feeding at 42 weeks post partum. The dominant follicle, which
reached 20 mm diameter 10 d after starting treatment, persisted and reached a diameter of
60 mm 7 days later.
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Fig. 4. With Subject D (Mrs Dt para i -f-Q, 54 kg). LIIRH resulted in a marked rise in urinary
oestrogen:creatinine (• •) ratios, large numbers of small follicles were seen on ultrasound
scan and a marked rise in urinary pregnanediol:creatinine (O O) ratio 14 d after starting
LHRH was followed by menstruation (■). A second rise in pregnanediol:creatinine ratio
suggested luteinization of a second follicle. Suckling frequency (□) and frequency of solid feeds
(■) are shown in the lower part of the figure.
A rise in urinary prcgnanediol:creatinine ratio (maximum 2-33) occurred on the 14th
day after starting LHRH in the fourth woman (M rs D) (Fig. 4), four days later menstrual
bleeding occurred coincidental with a fall in pregnanediol excretion. A second rise in
pregnanediol:creatinine suggesting luteinization of a second follicle, occurred two days
later and was sustained (maximum 2-61) for a further 9 d despite continued vaginal
bleeding. A marked increase in urinary LH concentration occurred immediately LHRH
treatment began and two further 'surges' occurred, perhaps coincidental with luteiniza¬
tion of a second and even third follicle. LHRH treatment was given for a total of 34 d,
after which Mrs D received subcutaneous saline for 7 d. Ovarian activity remained
suppressed for a further 8 weeks of study, during which Mrs D continued unsupple-
mented breast-feeding.
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Table I. Mean serum prolactin, oeslradiol, progesterone, LH and FSII together with the frequency and





treatmentI 2 3 4
Number 4 4 3 3 1 2
Prolactin (mU/1) 1611+359 1195 + 82 2046 ±789 1174 ±401 1071+290 631 ±32
Oestradiol (pg/ml) 52 ±9 135 + 28 112 ± 32 79 ±36 65 43 ±5
Progesterone (nmol/1) 0-4 ±01 0-3 ± I-5 3-4 +1-5 1-4 + 0-9 0-99 0-3 ±0-03
LH (U/l) 2-7 + 0-5 5-3 ±1-2 6-9±2-3 4-l±t-4 3-8 + 0-2 2-6± 1 -0
FSH (U/l) 7-2 + 0-6 4-9+1-2 7-3 + 2-0 4-4±0-8 5-6 + 0-3 6-0±0-6
LH pulse amp (U/l) 1-7 ±0-9 5-7 ±2-7 2-7 + 0-8 2-0±0-8 1-5 ±0-3 3-2±0-3
LH pulse freq./4 h 1 ±0-4 l-5±0-3 1-8 + 0-2 l-7±0-3 3-0 I-5 ±0-4
FSH pulse amp (U/l) 2-3 ±0-2 1-7 + 0-3 1-4 + 0-6 1-5 1-6 1-3
FSH pulse frcq./4 h 0-8 + 0-2 1-8 + 0-2 0-5 + 0-3 0-3 + 0-3 2-0 1-3
FSH: LH 3-0:1 ±1-0 1-3:1+0 6", 1-2:1+0-2" 1-3:0-2" 1-5:1 3-6:1 ± 1-6
Significance of difference from suppressed (paired /-tests): aF<005; "P <0-01.
Patterns ofgonadotrophs secretion
The mean concentrations, together with the frequency and mean amplitude of pulses of
secretion of both LH and FSH during serial blood sampling episodes are shown in Table
1. The FSH: LH ratios and mean concentrations of prolactin are also shown and results
are subdivided according to weeks of treatment. In all cases, mean concentrations of LH
were higher during LHRH administration than when ovarian activity was suppressed by
unsupplemented breast-feeding, although this did not reach statistical significance. There
was also a tendency for FSH concentrations to fall as oestrogen levels increased, in
response to LHRH. The increase in LH and decrease in FSH concentrations was reflected
by a marked fall in the FSH: LH ratio during LHRH administration (P< 0 01; after 1 and
2 weeks of treatment; and P< 0-05 after the third week). The patterns of gonadotrophin
secretion during serial sampling episodes in two women are shown in Fig. 5. On most
occasions a pulse of exogenous LHRH was followed by a pulse of LH resulting in an
increased LH pulse freq uency, clearly seen in the case ofMrs D (upper figure) in whom the
FSH:LH ratio tended towards unity during LHRH administration. During unsupple¬
mented breast-feeding, and despite the suppression of ovarian activity, one woman (Mrs
A—lower figure) had higher concentrations of LH and a more markedly pulsatile pattern
of LH secretion than that characterizing the other three women. In this case LHRH
administration did not result in a normalization of the FSH:LH ratio.
Patterns ofprolactin secretion and suckling behaviour
Mean serum prolactin concentrations were higher than the normal range for non-
lactating women throughout the study. An acute increase in prolactin secretion occurred
in response to suckling in all women. There was no significant difference between mean
prolactin concentration before or at the end of LHRH administration and there appeared
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Time (h)
Fig. 5. Patterns of LH (• •) (U/l) and FSII (O O) (U/'l) during serial blood sampling
episodes in the women: (a) Mrs C; (b) Mrs A.
to be no direct relationship between either the degree of hyperprolactinaemia or the
frequency and duration of suckling and whether or not ovulation occurred or the
adequacy of the resultant luteal phase.
DISCUSSION
The pulsatile administration of LHRH resulted in follicular development in all four
women, with evidence of luteinization occurring in three out of the four, despite full
breast-feeding and hyperprolactinaemia. In the three women who continued full breast¬
feeding, ovarian activity resuppressed and amenorrhoea persisted for at least 36 weeks
post partum. The duration of the follicular phase and length and adequacy of the luteal
phase was extremely variable between the four women.
The dose, frequency and site of administration of LHRH was identical to that used
successfully to induce ovulation in women with hypothalamic and hyperprolactinaemic
amenorrhoea (Glasier et al., in preparation). Each pulse of exogenous LHRH resulted in
a pulse of endogenous LH secretion, such that LH pulse amplitude and frequency, in at
least two out of the four women (Mrs A and Mrs C), during the follicular phase was
compatible with that characterizing the normal follicular phase (Backstrom el al., 1982).
In all four women an increase in urinary LH excretion was identified just before an
increase in urinary pregnanediol concentration, and in two women an increase in LH
concentration and in LH pulse amplitude occurred at this time. Thus, despite maintaining
a constant frequency and amplitude of LHRH pulses, a mid-cycle surge of LH occurred
indicating that the positive feedback effect of oestrogen is present. Furthermore, a fall in
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FSH secretion, presumably in response to the secretion ofoestrogen and inhibition by the
developing follicle suggests that negative feedback mechanisms were also intact.
In the three women who appeared to ovulate in response to LHRH, the most striking
feature was a fall in the FSH:LH ratio towards unity. Wildt el al. (1981) showed that
changes in the frequency of LHRH stimulation to hypophysectomized rhesus monkeys
altered not only the absolute levels of FSH and LH in the circulation, but also the ratio of
one to another. It has been suggested that alterations in the ratio of FSH:LH may be
involved in the pathophysiology of some amenorrhoeic states (Leyendecker, 1979; Yen,
1980). Furthermore, the onset of ovarian activity at puberty (Burr et al., 1970) and the
resumption of menstrual cycles after post partum amenorrhoea in rhesus monkeys (Plant
et al., 1980) has been shown to be associated with a change in the FSH: LH ratio towards
unity. Our observations may therefore explain why one woman (Mrs A), in whom an
abnormal FSH:LH ratio persisted despite LHRH administration, failed to ovulate, and
may also provide indirect evidence that a change in the FSH: LH ratio, as a result of an
abnormal pattern of endogenous LHRH secretion, may be instrumental in maintaining
lactational infertility.
Whether prolactin itself is merely a marker ofsuckling or whether it is directly involved
in the mechanisms underlying amenorrhoea associated with breast-feeding remains
unresolved. If suckling acted simply by altering the pattern of LHRH secretion in breast¬
feeding women, one might expect the administration ofa physiological regimen of LHRH
to result in normal ovulation, yet all the woman had an abnormal luteal phase. Naturally
occurring first cycles in both bottle- and breast-feeding women post partum are often
anovulatory or characterized by a deficient luteal phase (McNeilly et al., 1982c;
Poindexteret al., 1983). The delay in the resumption of normal ovulatory cycles in bottle-
feeding women depends mainly, if not exclusively, on the time taken for recovery of the
hypothalmo-pituitary axis from the suppressive effects of pregnancy. The breast-feeding
women were treated at 6 weeks post partum when these effects might still be expected to be
in force. Had LHRH administration continued beyond first menstruation, subsequent
cycles may have been characterized by normal ovulation. Ishizuka et al. (1984) has
suggested that post partum hypogonadotropism may be accounted for by the extension
from pregnancy of increased hypothalamic opioid inhibition of LHRH secretion. If this
were the case, the restoration of a normal pulsatile pattern of LHRH should result in
normal ovulation, unless coexistent high circulating levels of prolactin were acting
directly at the ovary to influence ovarian function (McNeilly et al., 1982a, b).
In conclusion, sustained ovarian activity can be induced in fully breast-feeding women
by the restoration of a pulsatile pattern of LHRH which induces normal ovulatory cycles
in hypogonadotrophic and hyperprolactinaemic women, principally by restoring a
normal FSILLH ratio. However, normal ovulation does not occur in breast-feeding
women in spite of continued LHRH administration. Whether prolactin is involved in
suppressing ovarian responsiveness directly, or whether as yet inadequately defined
deficiencies in LH secretion, in particular around the preovulatory surge, are responsible
for the failure of normal luteal function, remains to be investigated.
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SUMMARY
Sixteen women with primary and secondary amenorrhoea were treated with
pulsatile GnRH administered subcutaneously. Ovulation was successfully
induced in 6/8 women with hypogonadotrophic hypogonadism; and in 2/2
women with idiopathic hyperprolactinaemia; but in only 3/6 women with
amenorrhoea associated with an elevated LH:FSH ratio. Using serial blood
sampling, we were unable to demonstrate the establishment of a physiological
pattern of gonadotrophin secretion in the presence of an apparently normal
menstrual cycle. Nor did we observe a consistent relationship between injection
of GnRH and the resultant gonadotrophin response. A reduction or total
cessation of both pituitary and gonadal sensitivity to GnRH was observed in
four women. Possible reasons for these findings are discussed.
Since the late 1970s, GnRH given in a pulsatile manner has been used to treat a variety of
amenorrhoeic states. Most studies report excellent results in women with hypogonado¬
trophic amenorrhoea (Mason et ah, 1984; Santoro et al., 1986) and in hyperprolactinae-
mic amenorrhoea (Abdulwahid et al., 1985; Poison et al., 1986). Results of induction of
ovulation with GnRH in women with polycystic ovary syndrome (PCO) are variable and
often disappointing (Adams et al., 1985; Burger et al., 1985). In our hands some women
prove difficult to treat, GnRH failing to induce ovulation or even in some cases follicular
development. We report our findings in a group of 16 patients with amenorrhoea in whom
we have carried out intensive monitoring, both of pattern? of secretion in response to
GnRH and of ovarian activity.
PATIENTS AND METHODS
Patients
Sixteen women presenting with primary (2) or secondary (14) amenorrhoea, 14 of whom
wished to conceive, were admitted to the study. Eight women, including two with primary
Correspondence: Dr A. Glasier, Department of Obstetrics and Gynaecology, Centre for Reproductive
Biology, University of Edinburgh, 37 Chalmers Street, Edinburgh EH3 9EW.
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amenorrhoea, had hypogonadotrophic amenorrhoea with basal LH concentrations less
than 1 -5 U/l (group A); six had gonadotropins within the normal range and an elevated
LH:FSH ratio (group B); and in two diagnosis of idiopathic hyperprolactinaemia had
been made (group C). The means and ranges of age, body mass index and basal
gonadotropin concentrations, together with basal PRL concentration, are shown in
Table 1.
Treatment
GnRH (HRF Ayerst, South Way, Andover. Hants 0-5 mg ampoule) was administered by
automatic portable pulsatile infusion pump (Sutherland et al., 1984) with a pulse interval
of 90 min. The dose varied from 0-1 gg/kg/pulse to 0-4 jug/kg/pulse, and route of
administration was s.c. in all but one patient who received GnRH intravenously. Each
pulse was contained in a volume of 40 /tl. The site for injection used was the s.c. tissue of
the lower abdominal wall and was changed approximately every 4 d. All patients were
started on a dose ofeither 0-1 or 0-2 gg/kg/GnRH and maintained on this dose for at least
21 d, if no response or an inadequate resporTse was observed the dose was increased in 0-1
gg/kg increments, each incremental dose being maintained for at least 21 d.
Monitoring
The response to treatment was assessed by frequent (daily or three times weekly)
estimations of total oestrogen and pregnanediol to creatinine ratios in early morning
urine specimens (EMU). Blood samples were taken once each week for the measurement
of LH, ESH and, where relevant, PRE.
Follicular development was monitored using pelvic ultrasound scans once each week
and more often in the late follicular phase of the cycle.
Serial sampling techniques
•i
In 13 of the women a serial sampling episode was carried out once each week to determine
the pattern of secretion of LH and FSH in response to the pulsatile infusion ofGnRH. An
indwelling cannula was inserted into a forearm vein at 0845 h and 5 ml of venous blood
taken every 15 min for 4 h. After each sample, the cannula was flushed through with
heparinized saline (5000 IU of heparin per 100 ml normal saline) to prevent clotting, and
the first 1 ml of the following sample was discarded to avoid dilution. Plasma was
separated by centrifugation and stored at — 20°C until assayed for gonadotrophins.
Hormone assays
Urinary excretion of total oestrogen was measured fluorimetrically (Brown et al., 1968),
and pregnanediol was determined by gas-liquid chromatography (Chamberlain &
Contractor, 1968). Creatinine was measured by autoanalyser and the steroid: creatine
ratio determined (Metcalf & Livesey, 1979). FSH and LH were measured by the specific
double-antibody RIA methods of Hunter & Bennie (1979). The intra-assay coefficients of
variation were 10% and 9% and the interassay coefficients ofvariation 16% and 15% for
LH and FSH, respectively. The sensitivity of the systems were 0-3 U/i for both FSH and
LH. Results were expressed in U/l of the appropriate standards obtained from the
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Table I. Mean values and ranges for age, body mass index, basal gonadotrophins and prolactin
lor women in group A (hypogonadotrophic amenorrhoea), group B (increased LH: FSH ratio)
and group C (idiopathic hyperprolaclinaemia—shown as individual patients)
Subjects Age (years) BMI LH (U/l + SEM) FSH (U/l + SEM) PRL (mU/l)
Group A 29-3 20-5 1 -2 ± 0-2 3-1+0-6 I75±39
(« = 8) Range 24-35 Range 18 5-24-8 Range 0-7 1-5 Range 2-0-5-1 82 354
Group B 27-8 23-3 15-2 ±2-9 4-7 ±0-9 259 + 50
(n- 6) Range 26-33 Range 20-1-27-1 Range 9-9-21-4 Range 3-7 -6-3 99-456
Group C 20 23-4 6-0 7-7 2281
30 22-0 6-4 7-8 1516
National Institute of Biological Standards and Control, Holly Hill, London (LH: MRC
68/40 77 IU/ampoule; FSH: MRC 69/104 10 IU/ampoule).
PRL was measured by the double-antibody RIA described by McNeilly & Hagen
(1974) using MRC standard 75/504 (10 IU/ampoule). Results are expressed in mU/'l. The
sensitivity of the assay was 18-5 mU/l and the inter- and intra-assay coefficients of
variation were 17% and 10%, respectively.
• To reduce variation, plasma samples obtained from each woman on all occasions were
assayed as a single batch in each RIA.
RESULTS
The response to treatment of the patients in groups A and B is summarize in Table 2. On
the basis of steroid concentrations in early morning urine specimens and ultrasound
evidence of follicular development, we have divided the results of treatment into five
categories, (a) Patients with no rise in oestrogen excretion above the mean baseline value
observed during the 21 d before starting treatment, and in whom no follicles of greater
than 8 mm in diameter were demonstrated by ultrasound, were said to have shown no
response to GnRH. (b) When urinary oestrogen excretion increased to a level of more
than 100% of baseline and greater than 10 /rg/mg creatinine/24 h on three consecutive
days, and there was ultrasound evidence of follicles >8 mm in diameter, follicular
development (FD) was said to have occurred and (c) if menstruation followed, but the
criterion below for ovulation was not met, the response was described as an anovulatory
cycle (AC), (d) Ovulation was said to have occurred when a rise in oestrogen excretion was
followed by an increase in pregnanediol:creatinine ratios > 1 -0 mg/g creatinine/24 h. but
was deemed inadequate if the luteal phase lasted less than 10 d, or if pregnanediol.'creati¬
nine ratio was <2 mg/g creatinine/24 h. In a number of women an initial increase in
oestrogen excretion was followed by a return to levels equal to or less than the mean
baseline value, if this pattern persisted for more than 10 d it was termed desensitization.
In group A, six out of eight women ovulated on a dose ofeither 0-1 or 0-2 pg/'kg GnRH
administered s.c. One women (patient F) failed to respond at all to s.c. GnRH, but
ovulated in response to both 0' 1 and 0-2 pg/kg doses given intravenously. Two women in
group A desensitized, one following ovulation (patient A), and a second following a
short-lived episode of follicular development (patient C).
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In group B ovulation was induced in three women with a dose of 0-1 /ig/kg GnRH; one
woman failed to respond, and in two patients desensitization occurred. One patient in
group B (patient K, Fig. 1) ovulated immediately GnRH treatment was started having
previously been amenorrhoeic for 3 years. Following menstruation and despite
continuing treatment with the same dose ofGnRH for 6 weeks, ovarian activity appeared
to be completely suppressed. On cessation of treatment the patient ovulated spon¬
taneously, conceived and proceeded to a full term delivery of a healthy infant.
Both women with idiopathic hyperprolactinaemia ovulated in response of 0-1 pg/kg
GnRII administered s.c. The results of one woman are shown in Fig. 2.
Serial sampling results
The results of six serial sampling episodes for one woman with hypogonadotrophic
amenorrhoea (patient A) are shown in Table 3 and in Fig. 3. The patient weighed 48 kg
(ponderal index=18-5). Serial sampling was carried out on two occasions before
treatment was started, mean serum LH concentration during these two episodes was
1 -5±0-1 SEM U/l and mean basal FSH 2-5 + 01 SEM U/l giving an LH:FSH ratio of
0-58. Using the definition of a pulse as described elsewhere (Glasier et al., 1984), only one
pulse ofLH secretion could be identified during one of these sampling periods and none in
other. The patient was treated for 42 d with s.c. GnRH at a dose of 01 /zg/kg/90 min.
During the first 28 d, urinary oestrogen:creatinine ratios rose to a maximum of 23 pg
Table 2. Response to treatment by dose of the patients in group A and group B
Patient 01 (pg/'kg) 0-2 (ng/kgj 0-3 (pg/kg) 0-4 (pg/kg)
A FD Ovulated+ descn Desen
B FD Ovulated —
C Desen Desen
D Ovulated x 3 — —
Pregnant
F. Anovulation — —
Ovulation + preg — — __
F No response No response No response No response
Ovulated IV Ovulated IV
G — Ovulated* Ovulated —
H — Ovulated — —
Group B
1 Ovulated*
.1 No response No response
K Ovulated+desen
L FD + desen
M Ovulated
Pregnant
N — No response No response No response
FD, Follicular development: desen, desensitized; preg, pregnancy; dev,
development.
* Inadequate or short luteal phase.
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01 uq GnRH 90 min
| ^
Time (d )
Fig. I. Daily oestrogen:creatinine (C) ratios (• •) and pregnanediol:creatinine ratios
(O -O) for one woman in group B (patient K.). GnRH was administered from day 19, ovulation
occurred followed by menstruation (0) 12 d'after the first rise in P:C ratio. Ovarian activity
remained suppressed for 6 weeks until GnRH treatment was terminated when spontaneous
ovulation resulting in a pregnancy occurred.
oestrogen/g creatinine and ultrasound scans showed the presence of multiple small
follicles. Thereafter oestrogen (creatinine ratios fell to a level consistently below 5 /rg
oestrogen/g creatinine despite continued treatment with GnRH and the continued
presence of multiple small follicles. Seven days after the start of treatment, levels of LH
and FSH had both increased to a mean of 21 and 4-4 U/l, respectively, although the ratio
of LH to FSH, however, remained unchanged at 0-5:1. After 21 d of treatment, serial
sampling showed a further increase in mean LH concentrations to 4-1 U/l and a
normalization of the LH to FSH ratio to 1-2:1. Pulse frequency had fallen, with, at 35 d,
no pulses of LH secretion identifiable in response to GnRH. After 42 d the dose of GnRH
was doubled to 0-2 /rg/kg/90 min and,this resulted in an apparently normal ovulatory
cycle with a luteal phase lasting 13 d followed by menstruation. In the mid-follicular
phase, despite GnRH stimulation apparently adequate to induce ovulation, gonado¬
trophs levels were still low (LH 11 U/l, FSH 1-3 U/l, ratio 0-8:1), and no statistically
significant pulses of LH could be identified. Following menstruation, despite continuing
GnRH treatment, oestrogen creatinine ratios fell to below 10 pg oestrogen/g creatinine
and remained suppressed for a further 70 d despite an increase in the dose ofGnRH to 0-3
pgjkg. During this period ofdesensitization mean basal levels of LH varied from 0-4 to 4-1
U/l and FSH from 1-7 to 4 0 U/l. Changes in neither basal gonadotrophin levels,
LH: FSH ratio (varying from 0-2:1 to 1-2:1), nor pulse frequency appeared to have any
effect on ovarian activity. Ultrasound scans continued to demonstrate the presence of
multiple small follicles (4-13 mm diameter). After 28 d of treatment with 0-3 /ig/kg/90
min, GnRH treatment was discontinued and the patient subsequently conceived on
hMG.
The pattern of LH secretion in response to GnRH administration in one women with
hyperprolactinaemic amenorrhoea is shown in Fig. 2. Two serial sampling periods were
carried out before treatment was started, one preceding, and one following a week of
treatment with 0-9% saline solution, 40 /d/90 min s.c. given via the same infusion pump.
On each occasion LH: FSH ratio was less than one and only one pulse of statistically
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Fig. 2. Daily oesirogcn:creatinine (•—'-») and pregnanediol:creatinine (O O) ratios
during GnRH administration to one woman with idiopathic hyperprolactinaemia (basal PRF.
2281 mU/l): 0-1 /ig/kg/90 min GnRH resulted in ovulation and menstruation. The pattern of LH
(O O) and FSH (• •) secretion before (A + B) and at various time points during the
course of treatment (CD + E) are shown below. A final serial sampling episode (F) was carried out
2 months after cessation of treatment when the patients was once again amenorrhoeie (| denotes a
pulse of saline at B or GnRH at C, D, E).
significant LH secretion could be identified. The LH:FSH ratio was reversed during the
mid-follicular phase of the cycle, although on this occasion no significant pulse of LH
secretion was identified and no temporal relationship between exogenous GnRH pulses
and endogenous LH could be determined. Both LH and FSH concentrations were
suppressed during the early and late luteal phases. Thus, despite successful induction ofan
apparently normal ovulatory cycle we were unable to demonstrate that this had been
achieved by the restoration of a normal physiological pattern of LH secretion. A further
serial sampling episode was carried out 62 d after cessation of GnRH administration
when LLI: FSH ratio was seen to have fallen to 0-4:1. Two statistically significant pulses
of LH secretion could be identified, but basal LH concentration was low (1-3 U/l + 0-1
SEM).
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Fig. 3. Daily oestrogen:creatinine (• •) and pregnanediol:creatinine (O O) ratios
during GnRH administration to one woman in group A, hypogonadotrophic hypogonadism
(patient A): 01 /rg/kg GnRH administered lrom day 9 resulted in follicular development only
followed from day 38 by desensitization. Increasing the dose of GnRH to 0-2 gg/kg resulted in
ovulation and menstruation followed by desensitization despite increasing the dose by another
increment. The pulsatile pattern of secretion of LH (• •) at various time points during the
course of treatment (A -F) are shown below. J, denotes a pulse of exogenous GnRH from the
pump.
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The pattern of ovarian activity demonstrated in the patient from group B in whom
desensitization followed ovulation is shown in Fig. 1. During the period of densitization
mean basal LH during serial sampling episodes varied from 4-3 U/l + 0-7 SEM to
13-6 U/l ± 3-0 SEM. No consistent pulsatile pattern of secretion of LH could be identified.
Immediately following disconnection of the pump from the site of administration of
GnRH (anterior abdominal wall) a 5-pg dose of GnRH was given s.c. into the upper arm,
this resulted in a 300% increase in LH concentration within 20 min of administration.
DISCUSSION
Ovulation was successfully induced with s.c. administered pulsatile GnRH in 6/8 women
with hypogonadotrophic anienorrhoea; in 3/6 women with an elevated LH:FSH ratio;
and in 2/2 women with idiopathic hyperprolactinaemia. Although theoretically, success¬
ful ovulation induction with pulsatile GnRH, at least in women with hypogonadotrophic
hypogonadism, should result from the establishment of a pattern of LH secretion
consistent with that seen in a normal cjcle, we were unable to demonstrate this.
Moreover, we were unable to demonstrate a constant relationship between either the
pattern of LH secretion or the LH: FSH ratio with the prevailing pattern of ovarian
activity.
Desensitization was observed in 5/14 women and to our knowledge this phenomenon
has not previously been reported in association with the pulsatile administration of
GnRH. Results from the episodes of serial sampling carried out during periods of
desensitization suggest that while at times pituitary secretion of LH became refractory to
GnRH stimulation, at other times both the pattern of LH secretion and the LH:FSH
ratio appeared to be sufficient to induce at least follicular development, suggesting
refractoriness at an ovarian level. Desensitization may have arisen as a result of an
inadequate dose or pulse frequency ofGnRH or as a result of the route ofadministration.
While we used a dose of GnRH smaller than that administered in many treatment
programmes (Mason et a/., 1984; Abdulwahid el a!., 1985), ovulation was successfully
induced in a proportion of women sufficient to suggest that desensitization was not the
result of inadequate amounts of GnRH. Furthermore, desensitization is more likely to
occur with excessive GnRH (Knobil, 1980; Wildt el al., 1981) than with too little. While it
has been suggested that GnRH pulse frequency is important for the induction of normal
ovarian activity (Knobil, 1980) most treatment regimes use at least a 90-min pulse
interval. Moreover, there is some evidence to suggest that, at least in women with
hypogonadotrophic hypogonadism, the pituitary-ovarian axis may respond adequately
to pulse frequencies which fall within a tolerable range rather than to one critical
frequency (Wildt et al., 1981: Crowley et al., 1985; Santoro et at., 1986). Desensitization
therefore seems most likely to have resulted from the route of administration.
Pharmacokinetic differences in s.c. and i.v. routes of GnRH administration have been
described (Reid et al., 1981; Handelsman et al., 1984; Menon et al., 1984). Administered
s.c., GnRH absorption is prolonged and delayed, and peak values significantly reduced.
Chronic administration of any substance s.c. may lead to problems at the injection site.
Menon et al. (1984), using a heparinized preparation of GnRH given s.c., reported the
frequent development of haematomas at the site of injection. Skarin et al. (1982) reported
pituitary unresponsiveness in a hypogonadal male patient treated with heparinized
GnRH, treatment was successful when heparin was removed from the preparation. While
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we did not use heparin to administer GnRH by the route and while the site of injection was
changed frequently (and seldom did we observe signs of infection at the site), a local
subclinical inflammatory response may interfere with GnRH absorption. The dampening
of both plasma GnRH and LH profiles known to occur may in effect convert a pulsatile
pattern of administration into a continuous infusion pattern of GnRH. Both pituitary
and gonadal desensitization have been observed in monkeys (Knobil, 1980) rats (de
Koning el al., 1979) and in humans (Rabin & McNeil, 1980) with GnRH given as a
continuous infusion.
Desensitization was not demonstrated In either of the women with idiopathic
hyperprolactinemia but treatment was discontinued after one ovulatory cycle since both
patients had previously responded satisfactorily to oral bromocriptine therapy.
In conclusion, we have found a variable response to s.c. pulsatile GnRH therapy in
women with anovulation of different origins and suggest that, perhaps because of the
route of administration, both pituitary and gonadal desensitization may occur.
Nonetheless, because of the potential hazards of out-patient i.v. therapy, including
venous thromboembolism and sepsis, we believe that GnRH should be given initially to
all patients by the s.c. route. 4
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Objective: To delect differences between populations in both infant feeding practices and the duration of lactational
amenorrhea, if they exist.
Design: Prospective, nonexperimcntal, longitudinal follow-up study.
Setting: Five developing and two developed countries.
Paticnt(s): Four thousand one hundred eighteen breast-feeding mothers and their infants.
Intcrvcntion(s): Breast-feeding women collected ongoing information about infant feeding and family planning practices,
plus the return of menses. Fortnightly follow-up occurred in the women's homes.
Main Outcome Measure(s): Breast-feeding frequency by day (and by night); 24-hour breast-feeding duration, percent of
all infant feedings that were milk/inilk-based (and solid/scmisolid foods): time until the end of full breast-feeding; lime until
regular supplementation; and time until the end of lactational amenorrhea.
Result(s): Differences between the centers in the duration of amenorrhea were substantial, ranging from a median of 4
months in New Delhi (India) to 9 months in Chengdu (China). Women in developed countries (but also women in Chengdu)
were more likely to delay supplementation (for up to 5 months), whereas women in Santiago (Chile). Guatemala City
(Guatemala), and Sagamu (Nigeria) started supplements much earlier, sometimes as early as 1 week after birth.
Conclusion^): Both breast-feeding behavior and the duration of lactational amenorrhea vary markedly across settings,
indicating that breast-feeding promotion and family planning advice should be site- and culture-specific. (Fcrtil Stern'35
1998;70:448 - 60. €1998 by American Society for Reproductive Medicine.)
Key Words: Breast-feeding, lactation, amenorrhea, infant feeding, fertility, postpartum, international
Breast-feeding suppresses the resumption of
ovarian activity after childbirth and thus is
associated with a period of infertility (1,2).
The duration of infertility varies between indi¬
vidual women, between societies, and appears
to depend largely on infant feeding practices.
Several studies have suggested that full un-
supplemented breast-feeding protects against
pregnancy (3-5), and some investigators even
have argued that the contraceptive effect of
breast-feeding can be relied on as long as the
total daily duration of suckling exceeds a cer¬
tain threshold (6). However, in at least two
countries, Chile (7) and Mexico (8), full un-
supplemented breast-feeding does not always
appear to be associated with inhibition of ovu¬
lation, and some fully breast-feeding mothers
do conceive. The apparent differences ob¬
served between populations may be an artifact
related to differences in study design and in
definitions of the key variables.
The return of menses during breast-feeding
may be the most important readily observable
correlate of reluming fertility. The first menses
is a definitive sign of the need for contraception
for women who do not want to become preg¬
nant (9-11). Although the return of menses is
an imperfect reflection of the recovery of post¬
partum fertility, it virtually always is a sign of
some kind of ovarian activity.
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We report the findings of a large, prospective, longitudi¬
nal, multinational study designed to detect differences be¬
tween populations in breast-feeding practices and the dura¬
tion of lactational amenorrhea. We describe the infant
feeding practices observed in seven different cultures and the
duration of amenorrhea in these settings. A companion arti¬
cle explores the relation between feeding practices (and
other variables) and the duration of amenorrhea (12), and
future reports will address pregnancy, postpartum bleeding




Seven centers were chosen to participate in the study.
Five centers were in developing countries. These centers
were located in Chengdu (China), Guatemala City (Guate¬
mala), New Delhi (India), Sagamu (Nigeria), and Santiago ~
(Chile). Two centers were in developed countries. These
centers were located in Uppsala (Sweden) and in two sites in
Australia (Melbourne and Sydney, each of which contributed
half the required number of subjects.)
In Chengdu, women in rural townships were recruited by
a government research institute. In Guatemala City, women
were recruited through a government maternity hospital. In
the Melbourne/Sydney center, women were recruited by a
private periurban hospital outside of Sydney and by the
medical research institute of an academic hospital in peri-
urban Melbourne. In New Delhi, women were recruited by a
government research institute involved in maternal and child
health in south Delhi. In Sagamu, women were recruited
through a government teaching hospital. In Santiago, women
who had their infants at a large urban university hospital
were recruited. Finally, in Uppsala, women were recruited in
the university hospital after delivery.
Based on existing data and allowing for a discontinuation
rate of 10%, it was calculated that 528 mother-infant pairs
would need to be recruited in each center to detect a be¬
tween-center difference of 1 month in the median duration of
lactational amenorrhea. Each center initially was asked to
recruit 550 women, and the target was changed according to
the discontinuation rate.
Women had to be aged between 20 and 37 years and to
have had no more than tiiree previous live births. To mini¬
mize the number of dropouts from the study, women were
required to have breast-fed one infant for at least 4 months.
Women also had to be literate, intent on breast-feeding their
baby for at least 6 months, and of "normal nutritional status"
(i.e., neither obviously malnourished nor obese). Their in¬
fants had to be singletons, vaginally delivered at term (2:37
weeks), and above the 10th percentile in birth weight (or
2:2.5 kg if norms for the population were unavailable). Both
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mother and infant were required to be healthy when they
were entered into the study.
Mothers who intended to use hormonal contraception or
to have interval sterilization that would involve separation
from the infant for more than 8 hours and those who had a
history of spontaneous irregular menstrual cycles (<21 or
>35 days) were not recruited, and neither were mothers who
were suckling more than one child or infants who were being
breast-fed by more than one mother. If this situation arose
during the study, the mother-infant pair was withdrawn.
This study was approved by the World Health Organiza¬
tion Secretariat Committee on Research Involving Human
Subjects. Local ethical committee approval also was ob¬
tained in all centers, and all mothers participating in the
study gave informed consent.
Methods
Mothers were admitted to the study within 7 days of
delivery. At admission, personal histories and the socioeco¬
nomic status of both the mother and her partner as well as
medical and obstetric histories of the mother were recorded.
Details of the pregnancy, delivery, and postpartum period,
and of the mother's diet and use of nutritional supplements
and measures taken to prepare for breast-feeding also were
documented.
The mother's height, weight, and upper arm circumfer¬
ence and the infant's weight, length, and head circumference
were recorded in all centers at admission to the study and
then at monthly intervals. The skinfold thickness of the
mother and the chest circumference of the infant also were
measured monthly in all but one of the centers. Standard
scales, tape measures, and calipers were provided to all
centers. The mother's body mass index (BMI) was calcu¬
lated as her weight (in kilograms) at 6-8 weeks postpartum
per her height (in meters) squared.
Mothers were instructed to fill in a card on which they
recorded the daily number of breast-feeding episodes and
manual breast expressions, the number and type of any
supplementary feeds, and vaginal bleeding and spotting (sep¬
arately). Any episodes of illness of either the mother or the
infant, together with any medications used, also were re¬
corded. For 24 hours every 2 weeks, a detailed record day
chart was completed in which the timing and duration of
each breast-feeding episode were recorded. The type and
amount of supplementary food and when (in relation to a
breast-feed) and how (via cup, spoon, or bottle) it was given
also were noted.
Only suckling episodes that lasted at least 2 minutes and
were separated by 30 minutes or more were recorded as
breast-feeds. Episodes that occurred within the same 30-
minute period were recorded as a single breast-feed. The
same time limits were applied to the definition of an episode
of manual expression. Breast-feeds that started after 10 pm
but before 6 am were defined as night feeds.
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Any substance the infant received that was not maternal
milk sucked from the breast was defined as a supplement.
Supplements were divided into four categories: water or
noncaloric fluids; caloric fluid feeds; milk or milk-based
feeds, including expressed breast milk; and semisolid or
solid feeds. If more than one type of supplement was given,
the episode was classified according to a hierarchy in which
solids were regarded as more important than milk-based
supplements, which were more important than caloric fluids,
which were more important than water and noncaloric fluids.
A supplement was considered as a "taste" if less than the
equivalent of 2 teaspoons (10 mL) was given.
For the purposes of the present analysis, three breast¬
feeding categories were defined: full breast-feeding when the
infant received only breast milk, vitamins, medicine, and/or
other noncaloric fluids, or tastes of the other categories of
supplements; partial breast-feeding when the infant received
caloric supplements in amounts greater than tastes; and
weaned when the infant no longer was being breast-fed.
The commencement of regular supplementation was de¬
fined as the point at which at least seven supplementary feeds
were given for the first time in each of two successive 2 week
periods, with the starting time taken as the midpoint of the
earlier 2-week period. In the variable TRS (time to regular
supplements) (A), all food and fluids are regarded as sup¬
plements so the infant is receiving only breast milk. In
TRS(B), water and noncaloric fluids are not regarded as
supplements, and in TRS(C), only milk or milk-based feeds
and solids or semisolids are regarded as supplements so that, for
example, fruit juice or sweet tea is not counted as a supplement.
Follow-up visits were made every 2 weeks in the moth¬
er's home. At each follow-up visit, the breast-feeding card
and the detailed record day chart were checked and the data
were transferred to a standard follow-up form. The first
detailed record day chart was completed during the third
week of the infant's life, with a follow-up visit arranged for
the next day. At each follow-up visit, mothers were asked
whether the detailed record day was a typical day, and,
whenever possible, they were asked to avoid days that often
might be atypical (e.g., weekends) and to ensure a 14-day
interval between recordings of detailed infant feeding patterns.
Whenever possible, follow-up visits were made by the
same person and arrangements were made to visit at exactly
2-week intervals. Visiting workers were asked to avoid as
much as possible giving mothers advice that might interfere
with spontaneous infant feeding behavior unless it was ob¬
vious that the mother, the infant, or both were failing to
thrive. At each follow-up visit, the mother was asked
whether she believed that she was pregnant. If so, arrange¬
ments were made to confirm the pregnancy by clinical ex¬
amination, pregnancy test, and/or ultrasound scan.
Mothers were withdrawn from the study when pregnancy
was confirmed or when they had experienced two normal
menstrual periods. Subjects were free to withdraw from the
study at any time for any other reason. An additional form
was completed when the infant was weaned. Completed
forms were checked by the principal investigator and sent
regularly to the Special Programme of Research, Develop¬
ment and Research Training in Human Reproduction at the
World Health Organization in Geneva, Switzerland.
Infant feeding patterns were analyzed for all subjects who
continued to breast-feed and remained amenorrheic. When a
subject weaned her infant or when menses resumed (con¬
firmed as a first menses by the occurrence of a second
menstrual bleed or pregnancy), she was excluded from fur¬
ther analysis. The discussion that follows relates to data
analyzed in this way with values taken from the detailed
record day charts.
Women who weaned their infants before a first menses
were included in a separate analysis of breast-feeding fre¬
quency until they left the study. In this case, breast-feeding
frequency and duration per 24 hours were set to zero (rather
than the subject being excluded). When weaned infants were
included, the breast-feeding trends and the relative positions
of the centers were unchanged, but the absolute values of the
infant feeding variables tended to be slightly lower.
Menses was defined as 2 consecutive days of vaginal
bleeding with at least 1 day requiring sanitary protection.
Any bleeding that occurred within 14 days of the end of
lochia was ignored, as was bleeding associated with a gyne¬
cologic procedure such as the insertion of an intrauterine
device (13). To use menses as an indication of fertility, it was
decided to ignore bleeding episodes that were unlikely to be
followed by ovulation. Thus, for a bleeding episode to be
defined as a first menses, it had to be followed by a second
episode (of at least 2 days' duration with at least 1 day
requiring sanitary protection) that occurred >21 days but
<70 days later. (In all centers, only 0.8% of first bleeding
episodes were followed by a second episode within 21 days;
however, 20.7% were followed by a second episode after an
interval of >70 days.)
A bleeding episode that was not followed by a second
episode within 21-70 days was ignored and the next episode
then was defined as the first menses. Only one bleeding
episode could be ignored in this way. Thus, a first menses
can be described as "confirmed" by a second episode within
the time limits or "unconfirmed" if the subject left the study
for some reason before having a second bleeding episode.
Conception can occur only if ovulation occurs, and thus a
pregnancy conceived during amenorrhea was treated as if it
were a confirmed first menses, with the date of menstruation
(and thus the end of amenorrhea) imputed as the date of
conception plus 15 days. If a woman conceived after a
vaginal bleeding episode and if the date of conception plus
15 days (i.e., when menstruation would have occurred if the
woman had not conceived) fell >21 days but <70 days after
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the first bleeding episode, then the pregnancy served to
designate the first bleeding episode as a confirmed first
menses. If the date of conception plus 15 days fell <21 days
or >70 days after the first vaginal bleeding episode, then the
dale of conception plus 15 days was taken as the date of the
confirmed first menses and the first vaginal bleeding episode
was disregarded.
Application of these rules to the data of the 3,337 subjects
who reported two menstrual periods each, the 85 subjects
who became pregnant, and the 150 subjects who left the
study after the first reported menses yielded 3,264 episodes
of confirmed and 307 unconfirmed first menses.
When a vaginal bleeding episode occurred, women were
asked whether the blood loss was greater than, less than, or
equal to that experienced during a normal menstrual period.
The first episode that she believed was equal to or greater
than a normal menstruation was defined as the first menses
according to the woman's perception.
Thus, for the purpose of the study, the end of amenorrhea
could be defined in three ways: [1] by the onset of a vaginal
bleeding episode >14 days after the end of lochia that was
not associated with a gynecologic procedure, lasted at least 2
days, and required sanitary protection for at least 1 day (the
first reported bleeding); [2] by a menstrual bleed confirmed
as the first menses by the onset of a second episode meeting
lite criteria described earlier ("the HRP rule," an algorithm
created by the Human Reproduction Programme of the
World Health Organization for this study); and [3] by the
woman's perception of a first menses.
Statistical Analyses
Data collected at the time of recruitment to the study,
such as maternal parity and infant birth weight (admission
characteristics), were summarized as means for quantita¬
tive variables and as percentages for categorical ones.
Differences between centers were tested with the use of
analysis of variance and the associated F tests and x2
tests.
Time until the end of full and partial breast-feeding status
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was calculated with the use of survival analysis, and for each
breast-feeding status, the 50th percentile of the distribution
was taken as the summary index. Observed times for those
who had their first menses or withdrew from the study before
the end of each breast-feeding status were censored. The
distribution of time to the start of regular supplementation
also was calculated with the use of survival analysis. Sur¬
vival times of subjects who withdrew from the study for any
reason as well as those who had their first menses before they
had started providing their infants with regular supplemen¬
tation were censored.
The distribution of the duration of lactational amenorrhea
was calculated with the use of a survival analysis, with the
50th percentile of the distribution taken as the summary
index. Observed survival times of subjects who withdrew
from the study before the end of amenorrhea were censored.
Center estimates were compared with the use of either the
log rank test or Wilcoxon's test. Survival analysis was done
with the use of PROC LIFETEST of the software package
Statistical Analysis Systems (SAS), version 6.8 (SAS Insti¬
tute, Cary, NC).
RESULTS
Of the 4,118 women recruited for the study, 3,422
reached one of the two end points of tire study: 3,337 had
two normal menstrual periods and 85 became pregnant. A
total of 696 women withdrew for various reasons; 150 of
these withdrawals took place after the occurrence of the first
menses. Table 1 shows the number of women admitted to the
study at each center and the number who completed and
withdrew from the study.
There were three main reasons for withdrawal: the subject
wanted to withdraw (213 women, ranging from 13 in Upp¬
sala to 70 in Melbourne/Sydney); the subject was lost to
follow-up (208 women, ranging from 3 in Uppsala to 51 in
Santiago); and the subject began using a hormonal method of
contraception (107 women, ranging from none in New Delhi
451
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Sydney New Delhi Sagamu Santiago Uppsala
Mean no. of previous live births 1.0 1.7 1.6 1.5 1.9 1.5 1.4
Mean no. of infants previously
breast-fed 1.0 1.7 1.5 1.4 1.9 1.5 1.4
Median duration (mo) of breast¬
feeding (last child) 16 13 12 18 10 12 —8—
Median duration (mo) of full breast¬
feeding (last child) 7 1 5 5 1 4 5
Median duration (mo) of amenorrhea
(last child) 8 4 8 2 6 3 7
Mean (±SE) time (h) from deliver)'
to first breast-feed 39.7 ± 0.9 7.5 ± 0.2 1.4 ± 0.3 6.8 ± 0.3 10.5 ± 0.3 8.0 ± 0.2 o 'o 1+ o
Percentage of infants breast-fed
within 1 hour 0 1 58 0 0 0 76
Percentage of infants given food/fluid
before first brcast-fccd 97 19 3 35 84 99 1
Mean (±SE) birth weight (kg) 3.3 ± 0.02 3.2 ± 0.02 3.6 ± 0.02 3.0 ± 0.02 3.2 ± 0.02 3.4 ± 0.02 3.8 ± 0.02
Mean (±SE) length at birth (cm) 49.1 ± 0.09 49.9 ± 0.07 51.6 ± 0.09 49.7 ± 0.09 50.2 ± 0.11 50.8 ± 0.07 51.8 ± 0.08
Mean (±SE) mother's BMI (kg/in2)
at 6 weeks postpartum 21.5 ± 0.08 24.8 ±0.12 24.8 ±0.14 21.4 ± 0.13 24.5 ±0.12 24.8 ± 0.06 24.0 ±0.12
Noic: The numbers from which Ihe means and percentages were calculated for each characteristic are approximately the same for each center as the total
number of admissions in Table 1. except for the mean duration of amenorrhea after the last child, for which numbers for the seven centers, respectively, arc
533. 618. 517, 497, 652, 451, and 564.
to 32 in Melbourne/Sydney). Most women were still breast¬
feeding at llie time that menses returned.
The mean age of the mothers varied from 26.2 years in
New Delhi to 30.9 years in Melbourne/Sydney. In each
center, except the Australian center, the study sample con¬
sisted of one predominant ethnic group. Almost all the
subjects were married and came from urban areas, with the
exception of New Delhi and Chengdu, where 20% and 9.9%,
respectively came from rural areas. The mothers had com¬
pleted the least number of years of education in Chengdu
(mean, 5.3 years) and the most in Melbourne/Sydney (mean,
14.3 years).
The protocol dictated that every subject had breast-fed at
least one child of her own. The mean number of live births
varied from 1.0 in Chengdu to 1.9 in Sagamu. Previous
breast-feeding experience is shown in Table 2. Whereas the
reported median toutl duration of breast-feeding of tiie last
child was shortest in Uppsala (8 months), the median dura¬
tion of full breast-feeding was shortest in Guatemala City
and Sagamu (I month) and associated amenorrhea was
shortest in New Delhi (2 months), where women had breast¬
fed their last child for the longest period (>18 months). In all
centers except New Delhi and Santiago, the median duration
of amenorrhea extended beyond the median duration of full
breast-feeding of the last child.
More than 90% of the infants were delivered in a hospital
or health center, except in Chengdu, where 73% of the
infants were delivered at home. The interval between deliv¬
ery and the first breast-feeding episode varied significantly
between centers (P < .001) (Table 2). in Melbourne/Sydney
and Uppsala, the infant usually was put to the breast within
2 hours of delivery before any oilier food or fluids were
given. In contrast, almost all the infants in Chengdu and
Santiago were given some food or fluid before the first
breast-feed, which did not occur for a mean of almost 40
hours after delivery in Chengdu.
Infant weights and anthropometric measurements varied
significantly (P < .001) between centers (Table 2), with the
smallest infants born in New Delhi (mean admission
weight, 3.0 kg) and the largest in Uppsala (mean admis¬
sion weight, 3.8 kg). Statistically significant differences in
BMI were observed among the mothers (P < .001) (Table
2).
Less than 3% of the women in each center were vegetar¬
ian, except in New Delhi, where 77% were vegetarian. Only
in Santiago did a substantial proportion (21%) of women
smoke during pregnancy, only 7% smoked in Uppsala and
fewer elsewhere. Alcohol consumption during pregnancy
was highest in Melbourne/Sydney (64%) and Uppsala (59%)
and lowest in Guatemala City (6%) and New Delhi, where
no mother drank alcohol during pregnancy.
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Infant Feeding Patterns During Lactational
Amenorrhea
Differences in infant feeding patterns between centers can
be seen when daytime (6 am to 10 t'm) and nighttime (10 pm
to 6 am) feeds are considered separately (Fig. 1). Breast¬
feeding at night occurred least often in the two developed
country centers (Melbourne/Sydney and Uppsala) and was
most common in Chengdu and New Delhi. In Chengdu, infants
were breast-fed three times at night for the first year of their
lives.
In all centers except Chengdu, the mean number of breast¬
feeding episodes and the mean total duration of breast¬
feeding each day fell with time after birth (Fig. 2). This fall
FERTILITY & STERILITY® 453
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was most noticeable in Uppsala. In Chengdu, whereas the
number of breast-feeding episodes fell with time after birth,
the mean total duration of breast-feeding per 24 hours in¬
creased gradually over the first 6 months and thereafter re¬
mained fairly constant throughout. Nevertheless, for the first
4-6 months of life, infants in Chengdu spent the least amount
of time breast-feeding. Infants in Uppsala spent twice as long
breast-feeding each day compared with infants in Chengdu,
and infants in Santiago spent nearly three times as long
breast-feeding each day compared with infants in Chengdu.
In all centers, as the frequency of breast-feeding declined
with time after birth, the longest interval during which the
mother was not exposed to the suckling stimulus increased.
Mothers in Chengdu and New Delhi consistently experi¬
enced the shortest interval between breast-feeds. In both
centers, the infant was almost 1 year old before the longest
interval between breast-feeds lasted more than 6 hours. In
contrast, the average infant in Guatemala City, Melbourne/
Sydney, and Uppsala was going more than 6 hours without
breast-feeding by 6 weeks of age.
There were marked differences between centers in pat¬
terns of supplementation. In Chengdu, Melbourne/Sydney,
and Uppsala, breast milk accounted for >90% of the infant's
intake for the first 18 weeks after birth. In Uppsala, however,
once supplementation was started, it progressed rapidly. In
contrast, in Chengdu, 70% of the infant's feeds still included
breast milk at 1 year after birth.
Mothers in New Delhi and Sagamu were much more
likely to give their infants water or noncaloric fluids in the
early weeks—and indeed throughout the study—than were
mothers in the other centers, where water and noncaloric
fluids were introduced only gradually. Mothers in Guatemala
City and Santiago were more likely to give their infants
caloric fluids than in the other centers and, at approxi¬
mately 22 weeks postpartum, 5:5% of the infant's feeds
consisted of caloric fluids compared with <2.5% in all
other centers.
Caloric fluids did not account for >10% of the number of
feeds (and in most cases, £5%) in any center, even when the
infant was more than I year old. Up to approximately 20
weeks of age, milk or milk-based feeds (Fig. 3A) were most
likely to account for a substantial number of feeding epi¬
sodes in Sagamu, whereas at 14 weeks of age, >20% of the
infant's feeds were of this nature. In this center, milk or
milk-based feeds declined in frequency after about 16 weeks,
when solid or semisolid feeds (Fig. 3B) were introduced.
In all other centers except New Delhi and Santiago, milk
or milk-based feeds accounted for <10% of the infant's
feeds, and in Chengdu and Melbourne/Sydney, this type of
supplement seldom was important. In New Delhi and San¬
tiago, supplementation with milk or milk-based feeds in¬
creased gradually with time throughout the study, accounting
for approximately 12% of feeds at 1 year of age. In all
centers, the percentage of total feeds that consisted of solid
or semisolid foods rose markedly from 16 weeks after birth,
but the rate of introduction was slowest in Chengdu.
All centers showed a decline in the prevalence of full
breast-feeding over time, but the pattern varied among the
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Mean percentage of all feeds in 24 hours that are milk or milk-based feeds and solid or semisolid feeds among all women who





















centers (Fig. 4). In all centers except Chengdu, full breast¬
feeding had virtually ended by 30 weeks. In contrast, in
Chengdu,, 55% of mothers were still breast-feeding fully at
approximately 6 months postpartum. The median and mean
times until the end of each of the breast-feeding categories
for the women who experienced amenorrhea is shown in
Table 3. Women in Melbourne/Sydney and Uppsala fully
breast-fed for a median of approximately 3.5 months. In
Guatemala City, Sagamu and Santiago, less than one-half of
the mothers ever fully breast-fed.
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Start of Regular Supplementation
The time to the start of regular supplementation is shown
in Table 4. In Melbourne/Sydney and Uppsala, there is little
difference among the three categories of supplements, which
suggests that when supplementation starts, it does so with
caloric food. Regular supplementation with water and non-
caloric fluids starts in Chengdu at a median of 153 days
(21-22 weeks) and caloric supplements of any description
are delayed until approximately 34 weeks after birth. In
contrast, women in Sagamu start giving regular caloric feeds
(milk or milk-based or solid or semisolid) from a median of
4 weeks after birth.
Return of Menses
The concordance among the three definitions of the end of
amenorrhea in each center is shown in Table 5. The concor¬
dance was highest in Chengdu, where in 92% of cases the
woman's perception of a first menses matched that defined
as a first menses by the HRP rule, which in 94% of cases also
was the first reported bleed. In 96% of cases in Chengdu, the
first reported bleed was the same as or heavier than a normal
menstrual period. In Uppsala, in 90% of cases the first
reported bleeding episode subsequently was confirmed to be
the first menses (and thus the end of amenorrhea); however,
in only 68% of cases was the first bleeding episode believed
TABLE 3 1£& 1 1 1 M
Time (median and mean no. of days) from delivery to the end of full and partial breast-feeding, by center.
Amount of breast-feeding
Full Partial
Center Median Mean (95% CI) Median Mean (95% CI)
Chengdu 192 150(141-159) 557 279 (266-291)
Guatemala City 7 25 (22-27) 581 182(172-192)
Melbourne/Sydney 107 99(94-103) 490 234 (223-245)
New Delhi 78 68 (64-72) 495 142(132-151)
Sagamu , 7 21 (18-23) 396 213(203-224)
Santiago 7 34(31-38) 493 163(154-171)
Uppsala 111 98(93-103) 295 208(199-217)
Note: Ci = confidence interval.
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Time (median and mean no. of days) until the start of regular supplementation, by center.
Time to regular supplementation (TRS)
Center
TRS(A)* TRS(B)f TRS(C)$
Median Mean (95% CI) Median Mean (95% CI) Median Mean (95% CI)
Chengdu 153 132(124-140) 237 177 (168-186) 265 200(191-209)
Guatemala City 24 54(49-58) 26 57 (52-61) 122 100 (95-105)
Melbourne/Sydney 161 142(137-146) 162 145(141-150) 164 147(142-151)
New Delhi 51 53 (50-56) 94 86(82-91) 95 89(84-93)
Sagamu 12 12(12-12) 14 32 (29-35) 26 40 (37-43)
Santiago 27 55 (51-59) 67 72 (67-76) 148 114(109-119)
Uppsala 152 139(134-144) 152 141 (137-146) 153 142(137-147)
Note: Regular supplementation occurred when at least seven supplementary feeds were given for the first time in each of two successive 2-week periods. CI =
confidence interval.
* TRS(A): Time to regular supplementation where a supplement is water, a noncaloric fluid, a milk or milk-based supplement, or a solid or semisolid food,
t TRS(B): Same as TSR(A) except that water and noncaloric fluids arc not considered to be supplements.
+ TRS(C): Same as TRS(B) except that caloric fluids also arc not considered to be supplements.
by the women to be the same as or heavier than a normal
period. Combining all centers, 89% of the first bleeding
episodes were confirmed by a second and 80% of these first
bleeding episodes matched the woman's perception of a first
menses.
Duration of Lactational Amenorrhea
The median duration of lactational amenorrhea in each
center, calculated with the use of each of the definitions of a
first menses, is shown in Table 6. In this table, estimates
from all confirmed and all first menses are shown. In all
centers, the median duration of amenorrhea was shortest
when defined by the onset of the first vaginal bleeding
episode, which preceded the woman's perception by as little
as 5 days in Chengdu and as much as 44 days in Santiago. In
all centers except Melbourne/Sydney and Uppsala, lacta¬
tional amenorrhea was longest when defined by a confirmed
first menses according to the HRP rule; in the two developed
country centers, it was longest when defined by the woman's
perception. The difference between the duration defined by a
confirmed first menses and that defined by the woman's
perception varied from 1 day in Melbourne/Sydney to 23
days in Sagamu.
There were statistically highly significant differences
between centers in the median duration of lactational amen¬
orrhea. Chengdu's value is significantly higher than all
the others. Melbourne/Sydney's value also is significantly
TABLE 5
Concordance among the three rules for the definition of the end of amenorrhea: number (percentage) of women whose
values on both variables were the same, by center.
Woman's perception same as Woman's perception same as HRP rule same as first
Center
HRP rule* lirst reported blcedt reported bleed
No. (%) No. (%) No. (%)
Chengdu 497 (91.9) 521 (96.3) 508 (93.9)
Guatemala City 516(75.0) 526 (76.5) 594 (86.3)
Melbourne/Sydney 484 (77.6) 462 (74.0) 576 (92.3)
New Delhi 443 (80.6) 477 (86.7) 475 (86.4)
Sagamu 463 (89.0) 489 (94.0) 476 (91.5)
Santiago 496 (71.9) 485 (70.3) 573 (83.0)
Uppsala 360(71.3) 341 (67.5) 456 (90.3)
All centers 3,259 (79.1) 3,301 (80.2) 3,658 (88.8)
* HRP rule defines the end of amenorrhea as a menstrual bleed (at least 14 days alter the end of lochia, not associated with a gynecologic procedure, lasting
at least 2 days, and requiring sanitary protection for at least 1 day) confirmed as the first menses by the onset of a second episode,
t First reported bleed is a menstrual bleed at least 14 days after the end of lochia, not associated with a gynecologic procedure, lasting at least 2 days, and
requiring sanitary protection for at least 1 day.
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Duration of lactational amenorrhea: time (median no. of days) from delivery to the end of amenorrhea, by amenorrhea
definition and by center.
End of amenorrhea defined by
HRP rule*
Center
Confirmed first menses* All first menscst Woman's perception First reported bleeding episode:}:
Median (95% CI) Median (95% CI) Median (9.5% CI) Median (95% CI)
Chengdu 282 (266-304) 277 (261-300) 273 (252-290) 268 (250-282)
Guatemala City 209 (196-228) 189(175-205) 191(174-208) 152(137-167)
Mclboume/S ydncy 272 (258-285) 268 (250-276) 273(258-289) 248 (235-268)
New Delhi 122(111-134) 118(108-130) 103(96-117) 93 (86-99)
Sagamu 234(215-255) 222(205-237) 211(188-227) 205(180-223)
Santiago 171 (156-183) 159(145-175) 159 (147-175) 115(105-127)
Uppsala 230 (221-241) 224 (217-235) 239(227-251) 214(204-223)
Note: CI — confidence interval.
* HRP rule defines the end of amenorrhea as a menstrual bleed (at least 14 days after the end of lochia, not associated with a gynecologic procedure, lasting
at least 2 days, and requiring sanitary protection for at least 1 day) confirmed as the first menses by the onset of a second episode,
t Same as HRP confirmed first menses nile except that cases are included even if they dropped out of the study after the first menses but before the occurrence
of (he second, confirming, menses.
4 First reported bleed is a menstrual bleed at least 14 days after the end of lochia, not associated with a gynecologic procedure, lasting at least 2 days, and
requiring sanitary protection for at least 1 day.
higher than that of all the other centers except Sagamu,
whereas Guatemala City, Sagamu, and Uppsala show no
statistically significant differences among themselves. San¬
tiago and New Delhi are significantly different from each
other and from every other center. Whichever definition of a
first menses is used, the rank order of centers, in terms of the
duration of amenorrhea, is basically unchanged.
DISCUSSION
In this study, menses was chosen as a proxy for the
recovery of ovulation and thus for the return of fertility
because it is a discrete event that is easily recognized and
recalled. Moreover, the collection of biochemical data on
ovarian function would have been impractical in a study of
this size.
In calculating the duration of amenorrhea as a surrogate
for the duration of infertility associated with breast-feeding,
we chose to ignore bleeding episodes that, by virtue of either
a short (<21 days) or long (>70 days) interval before the
occurrence of a second bleeding episode or pregnancy,
seemed unlikely to have been either preceded or followed by
ovulation.
In Iheir detailed study of the return of fertility among 40
breast-feeding women in Manila, Eslami et al. (14) demon¬
strated that, for women who menstruated before 6 months
postpartum, menses was a poor indicator of full fertility
because only 25% of women who menstruated (defined as
bleeding for &2 consecutive days) experienced ovulation
within the next 30 days. Women who menstruated before 6
months experienced a mean interval of 8.4 weeks between
the first menses and the first ovulation.
In the present study, when menses was defined using the
HRP rule and only bleeding episodes confirmed to be a first
menses were considered, between 21% (in Melbourne/Syd¬
ney) and 62% (in New Delhi) of women had their first
menses before 6 months. If only 25% of these bleeds are
likely to be associated with ovulation, then our estimation of
the duration of infertility is shorter than it may have been in
reality.
Other studies also have described a tendency for menses
occurring in the first 6 months of lactation to be associated
with anovulation. Campbell and Gray (15) compared wom¬
en's descriptions of their bleeding episodes with their hor¬
monal profiles in a study of the return of fertility in Balti¬
more. Ovulation occurred in only 35% of cycles in which
bleeding was described as "light" or "spotting," whereas
menses reported as "regular" or "heavy" (which would cor¬
respond to our definition of a woman's perception) were
preceded by ovulation in 84% of cases.
It is clear that there are substantial differences between
centers in the duration of lactational amenorrhea, with
breast-feeding women experiencing a median of about 9
months of amenorrhea in Chengdu compared with about 3-4
months in New Delhi. There also are profound differences
between centers in patterns of infant feeding: women in the
developed country centers and in Chengdu were much more
likely to delay the introduction of regular supplementary
feeds until at least 3 months after birth (Table 3), whereas
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women in Guatemala City, Sagamu, and Santiago started
supplements when the infant was approximately 1 week old
(Table 4). The factors influencing the duration of amenor¬
rhea and any substantive differences among the centers are
the subject of another article (12).
Some information about the infant feeding characteristics
may seem contradictory when the centers are viewed relative
to each other, but there are corresponding explanations,
again in relative terms. For example, both a high breast-feed¬
ing frequency (Fig. 1) and the highest proportion fully
breast-feeding (Fig. 4) are reported in Chengdu, yet this
center reports the shortest duration of feeding in 24 hours
(Fig. 2). This is because the average duration of suckling is
short in Chengdu, the shortest of all seven centers. Similarly,
Santiago reports the highest rate of milk or milk-based
supplementation before 27 weeks of age (Fig. 3) and a low
rate of fully breast-feeding (Fig. 4), yet the most minutes of
breast-feeding in 24 hours in the first 27 weeks (Fig. 2).
Mothers in Santiago reported long average suckling dura-,
tions, the longest of all seven centers.
The subjects who were recruited to the study were chosen
because they were highly likely to breast-feed successfully
and therefore may not be representative of their communi¬
ties, especially in terms of the duration of amenorrhea and
the duration of the various types of breast-feeding (e.g., full,
partial). In connection with this multicenter study, surveys of
infant feeding patterns typical of the local area were under¬
taken in the developing country centers using the simplified
methodology for community-based assessment of the dura¬
tion of breast-feeding and amenorrhea (16). The durations of
lactational amenorrhea in the simplified methodology sur¬
veys and in the current study (a woman's perception of a first
menses) agreed within 1.8 months.
Although any differences may reflect selection bias due to
our admission criteria, they also could be due to measure¬
ment effect: the surveys relied on recall, whereas our study
measured the durations of breast-feeding and amenorrhea
prospectively.
Although the infant feeding patterns of the subjects may
not be representative of their country or region of residence,
there was a difference of I month or less in each of five
centers (not in Guatemala City and Santiago) between the
mean of the women's perceived end of amenorrhea reported
in the study and that recalled to be associated with the
previous pregnancy (Table 2). This suggests that participa¬
tion in the study did not of itself significantly influence infant
feeding patterns.
This study detected profound differences in breast-feed¬
ing and supplementation practices across seven cultures, and
profound variations in the duration of amenorrhea regardless
of how the return of menses was defined. A companion
article examines the relation between the length of lacta-
FERTILITY & STERILITY®
tional amenorrhea and feeding and other variables, control¬
ling for center effects.
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Objective: To determine the relation between infant feeding practices (and other factors) and the duration of postpartum
amenorrhea, and to establish whether there are real differences in the duration of postpartum amenorrhea for similar
breast-feeding practices in different populations.
Design: Prospective, noncxpcrimental, longitudinal follow-up study.
Setting: Five developing and two developed countries.
Potient(s): Four thousand one hundred eighteen breast-feeding mothers and their infants.
Intcrvention(s): Breast-feeding women collected ongoing information about infant feeding and family planning practices,
plus the return of menses. Fortnightly follow-up occurred in the women's homes.
Main Outcome Measure(s): A multivariate analysis explored the association between the risk of menses return and 16
infant feeding variables and 11 other characteristics.
Rcsult(s): Ten factors (in addition to center effects) were significantly related to the duration of amenorrhea. Seven of these
were infant feeding characteristics and the remaining three were high parity, low body mass index, and a higher frequency
of infant illness.
Conclusion(s): The breast-feeding stimulus is strongly linked to the duration of postpartum amenorrhea. Cross-cultural
effects also are extremely important and may have caused the variations in feeding, the variation in amenorrhea, or both.
(Fertil Steril®1 1998:70:461-71. ©1998 by American Society for Reproductive Medicine.)
Key Words: Breast-feeding, lactation, amenorrhea, infant feeding, fertility, postpartum, international
Although the precise mechanisms underly¬
ing the inhibition of normal ovarian activity by
breast-feeding are incompletely understood,
there is general consensus that the duration of
postpartum amenorrhea is strongly influenced
by the pattern of infant feeding (1). Most in¬
vestigators agree that the duration of breast¬
feeding is an important determinant of the
length of amenorrhea, but there is less consen¬
sus about the role played by more precise mea¬
sures of suckling activity.
The frequency of breast-feeds and their du¬
ration (2, 3), the maintenance of breast-feeding
during the night (4, 5), and the introduction of
food other than breast milk (2, 6) all have been
shown in a number of studies to be critical
factors in determining lite duration of amenor¬
rhea. Other investigators, however, have failed
to confirm the importance of some of these
variables (6-8).
Variables other than the many facets of in¬
fant feeding patterns that have been shown—or
are thought—to influence the duration of lac¬
tation also may affect, perhaps independently,
the duration of amenorrhea. These include the
place of delivery (hospital or home) and the
mother's employment (9); maternal age, parity,
and education level (10); the use of pacifiers
(11); the interval between delivery and the first
breast-feed (12), and maternal nutritional status
(13). Although it is difficult to imagine pre¬
cisely how, it may be possible that subtle phys-
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iologic differences between populations—and between indi¬
vidual women—themselves may account for some of the
differences in the duration of amenorrhea reported from var¬
ious countries by some investigators.
In a large multicenter study of different populations, we
investigated the known and unknown factors that may influ¬
ence the duration of amenorrhea in breast-feeding women.
The purpose of this article is to determine the relation
between infant feeding practices (and other factors) and the
duration of postpartum amenorrhea, and to establish whether
there are real differences in the duration of postpartum
amenorrhea for similar breast-feeding practices in different
populations.
MATERIALS AND METHODS
A total of 4,118 breast-feeding mothers from seven cen¬
ters (Chengdu, China; Guatemala City, Guatemala; Mel¬
bourne/Sydney, Australia; New Delhi, India; Sagamu, Nige¬
ria; Santiago, Chile; and Uppsala, Sweden) kept a record of
infant feeding from the first week postpartum until the sec¬
ond postpartum menses (n = 3,337), until pregnancy (n =
85), or until withdrawal from the study (n = 696), whichever
came first. Mothers were aged 20-37 years, had previous
breast-feeding experience, and were neither obviously mal¬
nourished nor obese. Their infants were all singleton, term,
vaginal deliveries above the 10th percentile in birth weight
(or s.2.5 kg if norms for the population were unavailable).
Mothers kept a detailed record of infant feeding patterns,
including the frequency, duration, and liming of breast¬
feeding episodes and the interval between them, and the
frequency, type, and timing of supplementary feeds. They
were visited at home every 2 weeks, at which time diary
cards were cheeked and additional data on sexual activity,
contraception, episodes of maternal and infant illness, and
maternal diet were collected. The details of recruitment,
admission characteristics of the subjects, and record-keeping
are described in an accompanying article (14). This study
was approved by the World Health Organization Secretariat
Committee on Research Involving Human Subjects. Local
ethical committee approval also was obtained in all centers
and all mothers participating in the study gave informed
consent.
Menses was defined as 2 consecutive days of vaginal
bleeding with at least 1 day requiring sanitary protection.
Bleeding that occurred within 14 days of the end of lochia or
in association with a gynecologic procedure, such as intra¬
uterine device insertion, was ignored. For a bleeding episode
to be regarded as a confirmed first menses, it had to be
followed by a second episode—meeting the same defini¬
tions—>21 but <70 days later, or by conception within
6-55 days (thus implying a second menses within the 21- to
70-day time limit). The end of amenorrhea thus was taken as
the date of onset of the first menses. If conception occurred
during amenorrhea, the end of amenorrhea was taken as
occurring 15 days after the estimated day of conception. For
a more detailed description of the basis for these definitions,
see the accompanying article (14).
Application of these definitions to the data of the 4,118
subjects yielded 3,264 cases of confirmed first menses, 307
cases of unconfirmed first menses, and 547 remaining cases
without a first menses.
The duration of amenorrhea was determined for each
center by survival analysis in which the relevant event is the
occurrence of a confirmed first menses and the dependent
variable is thus the time from delivery to this occurrence. All
other events, such as withdrawal from the study after an
unconfirmed first menses or withdrawal from the study for
any other reason, were censored (14). All seven centers first
were compared in a group and then in pairs with the use of
the log rank test or the Wilcoxon test, and the Bonferroni
criterion was used to control the error rate in the multiple
comparisons (15).
A total of 82 variables were evaluated regarding any
possible relation with the duration of lactational amenorrhea.
Of these, 31 were related to infant feeding and the remaining
51 covered admission characteristics of the mother and in¬
fant such as anthropometric measurements, including mater¬
nal body mass index (BMI, kg/m2) at 6-8 weeks postpar¬
tum, maternal nutrition during pregnancy and follow-up, and
maternal and infant illness. A number of variables were
time-dependent and some, such as the time elapsed before
50% of feeds were supplements, were constructed specifi¬
cally for the analysis. Each variable was analyzed initially by
a univariate analysis using Cox's nonparametric hazards
regression model (16).
Variables whose univariate test had a P value of £.2 and
those that, in the light of existing research in the area, were
believed to be of biologic importance then were included in
a multivariate regression analysis. Variables associated with
previous pregnancies (e.g., the duration of breast-feeding of
the previous child) were excluded. In this way, a total of 27
variables were selected for a final multivariate analysis also
with the use of Cox's nonparametric hazards regression
model (16). As used in the analysis, the hazard h; (t) of the
return of menses at time t postpartum for the ith of N women
in the study is postulated as follows:
hi (t) = h„(t) exp(/3, x,,(t) + p2 x2i(t) + ... + /3p xpi(t))
where Xjjft) is the value at time t of the jth explanatory
variable and the /Is are regression coefficients.
Corresponding risk ratios are obtained by exponentiating
the regression coefficients. Adjustment for any statistically
significant differences between the centers was made by
including a factor at seven levels for centers, with Chengdu
as the reference. To examine differences between various
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Note: CI — confidence interval.
pairs of centers, the analysis was repeated using each of the
other centers as the reference, and the Bonferroni criterion
was used to control the maximum experiment-wise error rate
for these multiple comparisons (15). Modeling was done with
the use of PROC PHREG of the software package Statistical
Analysis Systems (SAS), version 6.8 (SAS Institute, Cary, NC).
Data on 4,091 of the 4,118 subjects were entered into the
multivariate hazards model analysis. The remaining 27 sub¬
jects were excluded for missing at least 1 of the 27 variables.
None of these 27 subjects had a confirmed first menses. Of
the 4,091 subjects, 827 (20%) were censored, 520 for having
no menses and the remaining 307 for having an unconfirmed
first menses.
RESULTS
The duration of amenorrhea varied from a median of 122
days in New Delhi to 282 days in Chengdu (Table 1).
Unadjusted differences between the centers are highly sig¬
nificant (P < .0001). Chengdu's value is significantly higher
than all the others. Melbourne/Sydney's value also is signif¬
icantly higher than all the other centers except Sagamu,
whereas Guatemala City, Sagamu, and Uppsala show no
statistically significant differences among themselves. San¬
tiago and New Delhi are significantly different from each
other and from every other case.
Table 2 shows the estimated risk ratios and their 95%
confidence intervals for the 27 variables included in the
multivariate analysis. A risk ratio of >1.0 indicates a "risk"
factor for the return of menses (i.e., an association with a
shorter duration of amenorrhea). A risk ratio of <1.0 indicates
a protective effect of the variable on the return of menses
(i.e., an association with a longer duration of amenorrhea).
The risk of the return of menses was found to be signif¬
icantly reduced by a higher number of live births, lower
maternal BMI, higher proportion of visits at which the infant
was reported to have been unwell, shorter interval between
delivery and the first breast-feed, longer time to regular
supplementation with any food or drink, longer total duration
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of breast-feeding in 24 hours, higher percentage of breast¬
feeds to total feeds, higher frequency of supplementation
with water and noncaloric feeds, longer breast-feeding status
as opposed to weaning, and longer duration between delivery
and the time that supplements started to provide at least 50%
of all feeds.
After adjustment for the 27 variables included in the
multivariate analysis, estimates of the risk of the return of
menses, and by inference the associated duration of amen¬
orrhea, for the seven centers fall into three clusters.
Chengdu, Melbourne/Sydney, and Sagamu, with the longest
durations, show no statistically significant differences among
themselves, whereas Melbourne/Sydney, Uppsala, and Gua¬
temala City, which have the next-longest durations, show no
statistically significant differences from each other; thus,
Melbourne/Sydney straddles both groups. Santiago and New
Delhi, with the shortest durations of lactational amenorrhea,
are significantly different from each other and from the other
two groups.
Thus, compared with the results of the unadjusted anal¬
ysis, the main consequence of the adjustment is the elimi¬
nation of the observed differences in the duration of lacta¬
tional amenorrhea between Chengdu, Melbourne/Sydney,
and Sagamu, as well as those between Melbourne/Sydney,
Uppsala, and Guatemala City.
DISCUSSION
There were statistically highly significant differences in
the duration of amenorrhea among the centers (Table 1).
These differences were reflected in the multivariate analysis
as highly significant center differences (Table 2). In addition
to the center differences, a total of 10 variables were signif¬
icantly related to the duration of amenorrhea; 7 of these were
related to the pattern of infant feeding and 3 were not.
Infant Feeding Variables
Many of the breast-feeding variables are interrelated, and
some provide only a slightly different way of defining the
breast-feeding stimulus. It is not surprising, then, that only
some of the infant feeding variables are significant in a
multivariate analysis. For example, if most of the women
breast-feed at night, then the "duration of nighttime breast¬
feeding" will be simply a subset of the variable "total dura¬
tion of breast-feeding." Once the "total duration of breast¬
feeding" variable predicted a certain amount of amenorrhea
duration, then the "nighttime duration of breast-feeding"
variable was unable to predict any more.
Breast-feeding status (breast-feeding versus weaned) was
found to be a highly significant variable, with the duration of
amenorrhea strongly related to whether women were fully
breast-feeding (i.e., breast-feeding in which the infant could
receive water and other noncaloric fluids as supplements) or
whether the infant had been weaned. Because the duration of
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Hazards model of the return of menses: risk ratios R and their 95% confidence intervals RL and Rg for variables in the
multivariate analysis.
Variable R Ri. R.j
Non-infant feeding variables
Years of education of mother 0.997 0.985 1.009
Number of live births 0.894t 0.845 0.946
Infant's weight at admission 0.924 0.845 1.011
Sex of infant (M/F) 1.062 0.989 1.140
Maternal BMI at 6-8 weeks postpartum 1.0491" 1.036 1.063
Has the infant doubled its admission weight? (N/Y)* 1.006 0.907 1.116
Use of pacifier at around 1 month postpartum (N/Y) 1.018 0.922 1.124
Frequency of red meat consumption* 1.005 0.988 1.021
Percentage of visits when the infant had been unwell* 0.997| 0.995 0.998
Was the mother working outside the home? (N/Y)* 1.062 0.959 1.175
Infant feeding variables
Time interval between delivery and first breast-feed 1.005$ 1.002 1.009
lias regular supplementation with any food/drink started? (N/Y)* 1.2675 1.056 1.520
Has regular supplementation with caloric fluid or food started? (N/Y)* 0.858 0.678 1.086
Has regular supplementation with milk-based feeds or solids/scmisolids started? (N/Y)* 1.173 0.984 1.399
Frequency of nighttime breast-feeding episodes* 0.997 0.932 1.065
Total frequency of breast-feeding in 24 hours* 0.991 0.957 1.026
Total duration of breast-feeding in 24 hours* 0.997§ 0.995 0.999
Total duration of nighttime breast-feeding* 1.003 0.998 1.007
Average duration of suckling episode* 1.005 0.992 1.017
Percentage of feeds constituted by breast milk* 0.99 It 0.988 0.995
Frequency of watcr/noncaloric supplements* 0.913t 0.881 0.947
Frequency of caloric fluid supplements* 0.986 0.945 1.028
Frequency of milk/milk-based supplements* 1.010 0.985 1.036
Frequency of solid/semisolid supplements* 0.997 0.967 1.027
Breast-feeding status
Mainly breast-fed* ref. ref. ref.
Partial breast-feeding* 1.058 0.899 1.244
Weaned* 2.1861 1.695 2.821
Arc supplements providing 50% of feeds? (N/Y)* 1.2035 1.042 1.389
Centers
Chengdu ref. ref. ref.
Guatemala City 1.552f 1.257 1.915
Melbourne/Sydney l.305§ 1.026 1.662
New Delhi 3.113T 2.509 3.863
Sagamu 1.001 0.803 1.247
Santiago 2.233t 1.818 2.742
Uppsala t.580t 1.234 2.023




§ P < .05.
lactational amenorrhea is related to die duration of breast¬
feeding, this observation is hardly surprising.
The total duration of breast-feeding per 24 hours also was
a significant determinant of the duration of lactational am¬
enorrhea. Few studies have measured the duration of suck¬
ling episodes. Howie et al. (2) demonstrated that the average
duration of suckling each day was related more strongly to
the resumption of fertility (for which first menses is the
proxy in the current study) than the frequency of suckling
episodes. Further, two studies that had a design similar to the
464 WHO Task Force WHO Multinational Breast-feeding
study of Howie et al., one performed in Mexico (7) and the
other in Egypt (8), were unable to show any relation between
breast-feeding frequency and the return of ovulation.
Andersen and Schipler (3), who studied a Danish popu¬
lation, and Stem et al. (17), who compared American women
with IKung hunter-gatherers, also described a positive rela¬
tion between suckling duration and the length of amenor¬
rhea or anovulation, as did Gray et al. (18). In the study by
Gray et al., the relation was independent of suckling frequency
(18).
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Although it is thought that the suppression of fertility is
related in some way to the disruption of the pulsatile release
of GnRH from the hypothalamus (1), the mechanism by
which the infant's suckling on the nipple might cause this
disruption remains unclear. Whatever the mechanism, it
seems logical to argue that the longer each day that the infant
spends suckling, the more sustained will be the stimulus
inhibiting ovarian activity and therefore the longer the du¬
ration of amenorrhea. It is possible that the amount of time
that the infant spends suckling is a more direct or sensitive
reflection of the stimulus that inhibits ovarian activity than
the simpler measure of suckling frequency.
Some investigators (19) have found that the interval be¬
tween suckling episodes also may influence the duration of
amenorrhea. In this study, the longest interval between
breast-feeds did appear to be a significant determinant of the
duration of lactational amenorrhea in the univariate analysis
(P < .0001); however, it was excluded from the multivariate
analysis because a substantial proportion of values (16%)
were found to be missing for this variable.
The other infant feeding variables that appear to have a
significant influence on the duration of amenorrhea are re¬
lated to supplementation. The later a woman started to give
regular supplements (of any description), the longer she
remained amenorrheic. The risk of a first menses increased
substantially once 50% of the total number of feeds the
infant received consisted of supplements (regardless of their
nature) and the percentage of breast milk feeds declined.
Most investigators agree that the duration of amenorrhea
is related to the pattern of supplementation (2,18-21). Un¬
fortunately, many neglect to define supplements, and it often
is not clear whether water or caloric fluids (e.g., fruit juice)
are regarded as such or not. Moreover, most make no dis¬
tinction between tastes, occasional supplements, and regular
supplementation.
Not all investigators agree, however, that supplementa¬
tion has such a clear relation with the inhibition of fertility.
Lewis et al. (6) found both the introduction of supplements
and the amount given to the infant to be poor predictors of
ovulation. In that study, water did not appear to have been
classified as a supplement. In the study by Jackson et al. in
Thailand (22), no correlation was found between the early
introduction of supplements or the quantity consumed within
the first 3 months postpartum and the duration of breast¬
feeding. However, in this study, water was not considered to
be a supplement and it is not certain that variables associated
with the duration of breast-feeding also are associated with
the duration of lactational infertility.
In developed countries, supplements often replace a
breast-feed, and this pattern was seen clearly among women
in Uppsala, as described in the accompanying article (14). In
developing countries, supplements are given more often in
addition to breast milk, and in Guatemala City, Sagamu, and
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Santiago, the median time to first supplementation with
caloric fluids or foods was only 7 days (14).
The influence of supplementation on suckling activity
may depend on how it interacts with a breast-feed—even
whether it is given before or after a suckling episode—as well
as its caloric value. Supplements given after a breast-feed may
have a negligible effect. Indeed, this is the basis of advice,
albeit unproved, to breast-feeding women to suckle the in¬
fant first and give the supplement second. When supplemen¬
tation significantly alters the percentage of time an infant
spends suckling, it seems logical to argue that it reduces the
stimulus to the inhibition of ovarian activity. An infant receiv¬
ing nutritive supplements needs less breast milk to provide its
daily caloric requirement. A less hungry infant may suck less
often, for a shorter period, or perhaps less strongly.
Mothers who gave their infants water and noncaloric
fluids to drink were more likely to experience a longer
duration of amenorrhea. There were substantial differences
between centers in the prevalence of supplementation with
these fluids. In Uppsala, for example, water or noncaloric
fluid accounted for <1% of the average infant's feeds for
most of the first 6 months of age, whereas in Sagamu, water
and unsweetened tea were given from the first week of life
and accounted for at least 12% of the infant's feeds before 6
months of age (Fig. 1). Nevertheless, even after correcting
for these center differences, supplementation with water or
noncaloric fluids remained associated with longer durations
of amenorrhea.
It seems unlikely that supplements that have no caloric
value would somehow increase the amount of breast milk
required by the infant. An analysis of the prevalence of
supplementation with water showed that mothers who gave
their infants more water or noncaloric fluids tended to breast¬
feed their infants more often. This trend was the same for
nighttime (Fig. 2A) as well as for 24-hour breast-feeding
episodes (Fig. 2B).
Further, mothers with a higher frequency of water and
noncaloric fluid supplementation also tended to have the
shortest interval between breast-feeds (Fig. 3). In view of the
strong association between the longest interval between
breast-feeds and the duration of lactational amenorrhea in
the univariate analysis, exclusion of the former variable from
the multivariate analysis because of sample loss problems
might have increased the relevance Of the prevalence of
supplementation with water and noncaloric fluids as a cor¬
relate of the duration of lactational amenorrhea.
Mothers who gave supplements more frequently with
water or noncaloric fluids also tended to give more milk or
milk-based supplements (Fig. 4), although there was no
obvious difference in the pattern of supplementation with
solids or semisolids. During the first 6 months of life, some
infants appeared to receive little supplementation with fluids
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The interval between delivery and the first breast-feed
was a significant determinant of the duration of amenorrhea
in that the early onset of suckling was associated with a
longer duration of amenorrhea. Paradoxically, the center with
the longest mean interval until the first breast-feed (40 hours
after delivery) was Chengdu, which also was the center with
the longest duration of amenorrhea. Nevertheless, in the
multivariate analysis, the inverse relation was maintained
after correcting for the effect of the individual centers.
A number of studies have reported a long duration of
breast-feeding associated with the early onset of suckling; it
is interesting that all were performed in developed countries.
In a study in Dundee, Scotland, Salariya et al. (23) described
a median duration of 182 days of breast-feeding among
women who put their infant to the breast within 10 minutes
of delivery compared with 77 days among women who
delayed suckling for 4-6 hours. Similar results were ob¬
tained in the United States, Canada, and Norway (12). In
contrast, a controlled, albeit small, study in Thailand was
unable to show any deleterious effect on the duration of
breast-feeding when the mother was separated from the
infant in the immediate postpaitum period for the purpose of
sterilization (22).
It is possible that the effect may be more obvious in
developed countries, where instrumental and operative de¬
liveries and the use of narcotic analgesics are more common.
However, one study in England (24) showed no effect of
mode of delivery on the duration of breast-feeding. In the
United Kingdom, women who are committed to breast¬
feeding arc more likely to ensure that they suckle the infant
as soon as possible after delivery. Many now incorporate
this request into their "birth plan." In our study, only women
who intended to breast-feed for at least 6 months were
recruited; even so, it is possible that women who were more
committed to breast-feeding tended to breast-feed sooner
after delivery.
It is interesting to note that, in all centers except the two
in developed countries, the median interval between delivery
and the first breast-feed was >6.5 hours, and many infants
(ranging from 19% in Guatemala City to 99% in Santiago)
were given food or fluid before the first breast-feeding epi¬
sode (14). This may change in the future as the result of
"baby-friendly hospital" initiatives.
One result worthy of comment is the failure to find a
significant association between the frequency of breast-feeds
and the duration of amenorrhea. Some investigators (4,5)
have reported such an association. In our univariate analyses,
the frequency of breast-feeding during the daytime, the
nighttime, and over 24 hours each showed a highly signifi¬
cant relation with the duration of amenorrhea. However, in
the presence of other variables in the multivariate analysis,
they lost their importance. The validity of this finding is
exemplified by the New Delhi center, which recorded the
highest breast-feeding frequencies but the shortest duration
of amenorrhea among the seven centers.
Non-Infant Feeding Variables
Women who have had more previous live births may tend
to experience longer durations of lactational amenorrhea.
The influence of parity on the duration of breast-feeding has
been recognized before, although, as with other variables,
different investigators disagree about its effect. A review of
World Fertility Survey data (25) from eight developing
countries reported no consistent trends. In Bangladesh and
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Mean number of breast-feeds, by time and by the frequency of water or noncaloric supplements, all centers combined. (A),
Nighttime breast-feeds. (B), Total breast-feeds in 24 hours.
Time puslpanum (u)
-no water or lion-cnloric fluid (0)
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"high frequency (>3)
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Time postpartum tw)
Indonesia, women of higher parity breast-fed their infants for
shorter periods, whereas the opposite situation prevailed in
Guyana, Panama, and Sri Lanka, where breast-feeding du¬
ration was longer among women with the most children.
Kurz et al. (26) described a positive effect up to parity
three, but thereafter the relation disappeared among women
in Guatemala City. Taylor et al. (12) found no correlation
between parity and the duration of breast-feeding among
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American women. Higher parity may be associated with
earlier supplementation, as in northern Thailand (22), where
early supplementation was significantly associated with
large household size. Family size may reflect socioeconomic
status, which is known to have a negative effect on the
duration of breast-feeding in developing countries (10).
The effect of parity on the duration of amenorrhea may be
related to previous breast-feeding experience. In our study,
467
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Time postpartum (w)
all participants had between one and three children and must
have breastfed at least one of them. The experience and
confidence gained from breast-feeding one child may in¬
crease the duration of breast-feeding of subsequent children.
At each follow-up visit, mothers were asked whether the
infant had been ill and the nature of the illness and its
duration were recorded. The percentage of visits at which the
infant was reported to have been unwell correlated with the
—•—no water or non-caloric fluid (0)
-•—moderate frequency (1-3)
—1 ~ high frequency (>3)
Time postpartum (w)
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Mean total duration of breast-feeding in 24 hours, by time and by infant illness, all centers combined.
Time postpartum (w)
duration of amenorrhea, with more periods of illness leading
to longer amenorrhea. To our knowledge, this relation has
not been described before. In their study of women in north-
em Thailand, Jackson et al. (22) reported that infants with
lower birth weights tended to receive supplemental feeds
earlier. In the present study, low-birth-weight infants were
not recruited and all infants had to be healthy at the time of
entry into the study.
The number of infant deaths in each center was low: in
all, only 14 infants died during the study, 5 of them in
Chengdu and 3 in Sagamu, and even these deaths give
substantially lower rates than the norms for China (41/1,000)
and Nigeria (81/1,000) (27). Figure 5 suggests that when
infants are unwell, the total duration of breast-feeds during
24 hours may be longer, up to the 22nd week postpartum.
Perhaps mothers respond to an infant who is unwell by
increasing the number of breast-feeds. Infants who were sick
may have cried more often and been comforted by suckling.
Mothers with a lower BMI at the third follow-up visit
(approximately 7 weeks after delivery) tended to have a
longer duration of amenorrhea. The relation between mater¬
nal nutrition and the duration of amenorrhea has received
substantial attention during the last 40 years (13). Because
low body weight is known to be associated with pathologic
amenorrhea (28), it seems reasonable to predict a relation
between poor nutritional status and prolonged postpartum
amenorrhea. Although some demographers have found lit¬
tle—or even no—-effect (19,20,29), others have suggested
that better maternal nutrition is associated with shorter am¬
enorrhea (30). Even in those studies that indicate an effect of
maternal nutritional status, the effect is small, with a differ-
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ence of at most 6 weeks between malnourished and well-
nourished mothers.
In the present study, obviously malnourished and obese
women were excluded, and we have to assume that most
mothers were well-nourished. A study of well-nourished
breast-feeding women in Mexico (7) did report that women
with a lower BMI were more likely to have prolonged
amenorrhea, although overweight women were not excluded
from participating in that study, and the range of BMI was
from 17.0-33.8. Those investigators suggested that a higher
percentage of body fat may be associated with an earlier
return of menses. A strong, negative effect of BMI also was
found by Popkin et al. (13).
A number of factors that have been shown in previous
studies to affect the duration of lactational amenorrhea,
including the sex of the infant, employment of the mother
outside the home, and the use of pacifiers, were not found in
the present multicenler study to have a significant effect. In
the univariate analysis, both the duration of breast-feeding of
the previous child and the duration of lactational amenorrhea
in the past were found to be highly significantly related to the
duration of amenorrhea experienced during breast-feeding of
the index child (P < .001). In a second multivariate model
that included the duration of amenorrhea with the previous
child, the variable remained significant (P < .001) and the
present results changed only slightly: the total number of
previous live births lost its importance and the infant's
weight at admission became significant.
Of profound importance is the effect of the center in
which the study was undertaken. After the statistical adjust-
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ment for 26 other factors in our analysis, there are still
substantial differences in the duration of lactational amen¬
orrhea between some centers and others, indicating that there
may be other factors that influence the duration of amenor¬
rhea that either were not recognized and measured or were
measured inadequately in this study.
These other factors, we believe, show up in the significant
center effects. The duration of amenorrhea in women in New
Delhi, for example, was one-half that of women in Chengdu.
In New Delhi. 77% of women were vegetarian, but in other
centers almost everyone was nonvegetarian, so vegetarian¬
ism was not included as a variable in the multivariate anal¬
ysis. The other dietary habits included were not found to be
significantly related to the duration of amenorrhea. Although
diet is known to affect patterns of menstruation (31), the
effect of diet in our study was less pronounced than the total
effect of the differences between centers.
In conclusion, 10 variables were identified that were
associated with the duration of lactational amenorrhea. Some
related to the way in which a woman feeds her infant,
whereas others were a feature of the characteristics of the
mother or infant. Some of the variables, such as breast¬
feeding status and parity, might have been anticipated on the
basis of the results of previous studies and from our under¬
standing of the physiology of lactational infertility. Others,
such as the effect of water and noncaloric fluid supplemen¬
tation, are more difficult to explain and may be mere asso¬
ciations, and not causal.
This is the largest known study of the effect of infant
feeding patterns on the duration of amenorrhea. Some infant
feeding variables undoubtedly are associated with, and prob¬
ably influence, the duration of amenorrhea. In addition to
these variables, however, there remain others that in this
study appear as "center effects," which are associated with
amenorrhea and probably with the duration of postpartum
infertility.
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Objective: To determine the risk: of pregnancy during lactational amenorrhea relative to infant feeding status.
Design: Prospective longitudinal study.
Setting: Five developing and two developed countries.
Palient(s): Four thousand one hundred eighteen breast-feeding mother-infant pairs.
Intervention(s): Infant feeding practices, menstrual status, and pregnancy were measured.
Main Outcome Measure(s): Life-table rates of pregnancy.
Result(s): In die first 6 months after childbirth, cumulative pregnancy rates during amenorrhea, depending on
how the end of amenorrhea was defined, ranged from 0.9% (95% confidence interval (Clj = 0%-2%) to 1.2%
(95% CI = 0%-2.4%) during full breast-feeding, and from 0.7% (95% CI = 0.1%-1.3%) to 0.8% (95% CI =
0.2%-1.4%) up to the end of partial breast-feeding. At 12 months, the rales ranged from 6.6% (95% CI —
1.9%-11.2%) to 7.4% (95% CI = 2.5%-12.3%) during full breast-feeding, and from 3.7% (95% CI =
1.9%-5.5%) to 5.2% (95% CI — 3.1%~7.4%) up to die end of partial breast-feeding.
Condusion(s): These results support the Bellagio Consensus on the use of lactational amenorrhea for family
planning, and confirm that the lactational amenorrhea method is a viable approach to postpartum
contraception. (Fcrtil Steril* 1999;72:431-40. ©1999 by American Society for Reproductive Medicine.)
Key Words: Breast-feeding, lactation, infant feeding, amenorrhea, fertility, pregnancy, postpartum contra¬
ception, lactational amenorrhea method, LAM, international
Breast-feeding is associated with the sup¬
pression of ovarian activity and thus with a
variable period of amenorrhea and infertility
(i). The risk of the resumption of fertility, and
therefore of conception, during lactation is re¬
lated to infant feeding patterns. Women who
breast-feed their infants frequently and who
delay the introduction of supplementary feed¬
ings tend to remain amenorrheic for a longer
period (2, 3). A consensus meeting held in Bel¬
lagio, Italy in 1988 (4,5) postulated that full or
nearly full breast-feeding during lactational
amenorrhea confers 98% protection against
pregnancy in the first 6 months after childbirth.
This degree of protection has been shown to be
valid in several clinical studies (6-8). Al¬
though these clinical trials involved up to 485
women who were prospectively using the lac¬
tational amenorrhea method (LAM) (9) to
avoid pregnancy, each study involved a homo¬
geneous group of breast-feeding women, and
one study (6) involved extraordinary support
for breast-feeding. One multinational study
concurred with these results but involved small
numbers of women at each center (10).
A large prospective study was conducted to
determine the relation between infant feeding
practices and the duration of amenorrhea (11).
This study also measured the occurrence of
pregnancy among women in five developing
and two developed countries. The purpose of
this analysis was to determine the rate of preg¬
nancy during lactational amenorrhea according
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to infant feeding status among women in this multinational
study to support or refute advice to breast-feeding women
about the efficacy of lactational amenorrhea as a period of
significant protection from pregnancy. This analysis has the
following advantages: il includes a far larger number of
women than has been studied similarly in the past, and no
attempt was made to alter the indigenous infant feeding
behaviors of the women who participated.
MATERIALS AND METHODS
Subjects and Procedures
Seven study centers participated in this research. They
were located in Chengdu, China; Guatemala City, Guate¬
mala; Melbourne/Sydney, Australia; New Delhi, India; Sag-
umu, Nigeria; Santiago, Chile; and Uppsala, Sweden. A total
of 4,118 women were recruited into the study. The first
participants were admitted in April 1989 and the last com¬
pleted the study in December 1993. All were aged between
20 and 37 years at the time of entry into the study, had
breast-feeding experience, and were literate. None was plan¬
ning to use a hormonal method of contraception after child¬
birth, and all intended to hreast-fecd for at least 6 months.
Women with a history of irregular menstrual cycles (<21 or
>35 days) or of infertility were not recruited. The infants
were all singletons who were delivered vaginally at term
(£37 weeks) and were above the 10th percentile in birth
weight (or £2.5 kg if norms for the population were un¬
available).
Mothers were admitted to the study within 7 days of
childbirth. Each woman kept a daily record of the number of
breast-feeding episodes and the number and type of any
other foods or fluids (supplementary feedings) given to the
infant. Days during which vaginal bleeding or spotting oc¬
curred also were recorded. For 24 hours every 2 weeks, a
detailed record chart was completed in which the timing and
duration of breast-feeding episodes were recorded, together
with the details of supplementary feedings. Every 2 weeks,
mothers were visited at home, where the feeding diaries were
checked. At this visit, they were asked whether they had had
intercourse since the previous visit and what method of
contraception they were using (if any).
The return of fertility was the end point of the study.
Because the detection of ovulation or measurement of hor¬
mone concentrations would have been impractical in a study
of this size, the reappearance of regular cyclicity or the
occurrence of pregnancy were regarded as proxies for the
return of fertility. Thus, participation in the study continued
until the woman experienced what she considered to be two
normal menstrual periods or until conception occurred,
whichever earne first. At each follow-up visit, mothers were
asked whether they thought they were pregnant. If the an¬
swer was "yes," arrangements were made to confirm the
pregnancy, with a pregnancy test and/or an ultrasound ex¬
amination.
Mothers who started using any hormonal method of con¬
traception were discontinued from the study from the date of
the introduction of such a method. The study protocol per¬
mitted the use of nonhormonal methods, but in the preg¬
nancy analysis, the experience of users of such methods was
restricted to the period before their introduction.
This study was approved by the World Health Organiza¬
tion Secretariat Committee on Research Involving Human
Subjects. Local ethics committee approval also was obtained




Bleeding per vaginam that lasted at least 2 days and
required the use of sanitary protection for at least 1 day was
defined as a menstrual bleeding episode. Bleeding episodes
that occurred within 2 weeks of the end of lochia or that were
associated with a gynecologic procedure, such as the inser¬
tion of an intrauterine device, were ignored.
Confirmed First Menses—Human Reproduction
Programme Rule
A bleeding episode was confirmed as a first menses only
if a second bleeding episode (meeting the same requirements
listed earlier) occurred within the next 21-70 days. If a
second episode occurred outside these time limits, the first
episode was ignored and the second episode was defined as
the first menses. Only one bleeding episode could be dis¬
counted. In this way, the first menses was "confirmed" by the
"HRP rule" (named for the Human Reproduction Pro¬
gramme of the World Health Organization that created this
algorithm for the study). A bleeding episode also could be
confirmed as the first menses if conception occurred within
the next 6-55 days, on the grounds that had conception not
occurred, there would have been a second bleeding episode
within 21-70 days. The main operational definition of the
end of lactational amenorrhea in this study was the date of
the confirmed first menses by the HRP rule.
During breast-feeding, a bleeding episode can occur as a
consequence of ovarian follicular development followed by
the withdrawal of estrogen (i.e., in the absence of ovulation).
Bleeding also can follow ovulation with inadequate lutein-
ization. Early "menstrual cycles" in breast-feeding women
can be extremely irregular, indicating that ovarian activity is
present but fecundity has not been restored. The HRP rule
was created to more closely approximate the true return of
fertility and not just the return of menses. By "confirming"
that the first menses is part of a cyclic pattern, the HRP rule
allows isolated bleeding episodes reflective of ovarian activ¬
ity, but not true fertility, to be ignored.
All First Menses—HRP Rule
If the subject had one bleeding episode but discontinued
participation in the study before the episode could be con-
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TABLE 1
firmed as a first menses by the HRP rule, this first "uncon¬
firmed" menses was added to the confirmed first menses
described earlier to comprise all first menses. Thus, this
second operational definition of the end of lactational amen¬
orrhea included all the cases of confirmed first menses but
avoided the loss of cases in which a bleeding episode prob¬
ably marked the return of fertility but the women were not
observed long enough to confirm this. Undoubtedly, in some
cases, this definition abbreviated the period of amenorrhea
that would have been seen if the women had been followed
up for a longer period.
All First Bleeding Episodes
Because all bleeding episodes during the study were
recorded, the end of amenorrhea also was defined as the date
of the onset of the first bleeding episode, regardless of
whether it qualified as a menses by the HRP rule. Thus, a
third operational definition of the end of amenorrhea was
studied, namely the first-ever bleeding episode. Although'
this definition included episodes of bleeding that clearly
were not indicative of the return of fertility, this definition
was included to compare the findings of this analysis with
the results of other research. Other studies have defined the
end of amenorrhea as the first bleeding episode without
attempting to interpret the meaning of the bleeding in terms
of Ihe degree of fertility that it represents.
The WomanPerception of the First Menses
Finally, concerning each bleeding episode, the women
were asked whether they perceived the bleeding to be more,
less, or the same in amount as a normal menses. Thus, a
fourth definition of the end of amenorrhea was explored,
namely the first lime that a woman perceived that the bleed¬
ing episode was a "normal" menses (i.e., that the amount of
bleeding was the same or more than her former menses).
This definition was called the woman's perception of the first
menses.
Breast-feeding Status
Breast-feeding status at the estimated time of conception
in the women who became pregnant was defined in terms of
three categories: full breast-feeding, in which the infant
received only breast milk directly from the mother's breast
and no other liquid or solids, or in which the infant received
water and other noncaloric fluids or tastes of caloric supple¬
ments, vitamins, or medicine in addition to breast-feeding;
partial breast-feeding, in which caloric supplements were
given in amounts greater than tastes; and weaned, in which
the infant was no longer being breastfed.
A more detailed description of the subjects, methods, and
definitions used in this study was given in an earlier publi¬
cation (ll).
FERTILITY & STERILITY®
Number of pregnancies during the study by breast-feeding
status at the estimated time of conception, by
contraceptive use at the estimated time of conception, and
by study center.




Study center No Yes No Yes No Yes Total
Chengdu 13 2 7 2 2 3 29
Guatemala City _ — 9 7 0 I 17
Melbourne/Sydney — 5 4 3 2 14
New Delhi 1 0 4 2 2 0 9
Sagamu — — -- 3 2 5
Santiago — — 2 0 1 0 3
Uppsala' ~~ __ 5 1 1 1 8
vMI centers 14 2 32 16 12 9 85
Note: Numbers represent the numtier of pregnancies.
WHO Tusk Force. Pregnancy during breast-feeding. Fcrfil Stent 1999.
Statistical Analyses
The median time until the start of intercourse and the use
of contraceptives was calculated using survival analysis (12).
'
Survival analysis also was used to calculate cumulative
pregnancy rates and their SEs during amenorrhea and up to
the end of full and partial breast-feeding, with adjustment for
the occurrence of sexual intercourse (i.e., including only
those periods when intercourse was reported). The observed
times for a subject were censored when she reached the end
of amenorrhea; when she reached the end of each breast¬
feeding category; when she started using a method of con¬
traception (coitus interruptus was included as a method),
assuming that women were continuously protected by their
method; and when she withdrew from the study. The rates
were compared by y2 test.
RESULTS
In all, 3,422 women completed the study with a recog¬
nized fertility outcome: 3,337 were regarded as having had
two menstrual bleeding episodes and 85 became pregnant.
The remaining 696 women had only one (i.e., unconfirmed)
menstrual bleeding episode before leaving the study (n =
150) or left the study before they had even one bleeding
episode (r| = 546).
Table I shows the distribution of the 85 pregnancies that
occurred during the study according to study center, breast¬
feeding status at the estimated time of conception, and use of
a family planning method at the estimated time of concep¬
tion. One third of all pregnancies reported in the study
433
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Number of pregnancies during (versus after) amenorrhea among breast-feeding women who were not using contraception
according to four definitions of the end of amenorrhea, by study center.
End of amenorrhea* according to the indicated definition
HRP rule
First reported
Confirmed first menses All first menses Woman's perception of first bleeding episode
during amenorrhea during amenorrhea menses during amenorrhea during amenorrhea
Study ccmcr (after amenorrhea) (after amenorrhea) (after amenorrhea) (after amenorrhea) Total!
Chengdu 18 15 16 15 20
(2) (5) (4) (5)
Guatemala City 4 3 4 3 9
(5) (6) (5) (6)
Melbourne/Sydney 2 2 5 2 5
(3) (3) (0) (3)
New Delhi 2 1 2 1 5
(3) (4) (3) (4)
Sagainu 0 0 0 0 0
(0) (0) (0) (0)
Santiago L 0 1 0 2
(1) (2) (1) (2)
Uppsala 4 4 4 4 5
(1) (1) (1) (1)
All centers 31 25 32 25 46
(15) (21) (14) (21)
Note: HRP = human reproduction programme.
* See text for definitions.
t Total number of breast-feeding women who were not using contraception at the estimated time of conception.
WHO Task Force. Pregnancy during breast-feeding. Fenil Stcril 1999.
occurred in one center (Chengdu). Twenty-one women
conceived after the infant had been totally weaned, leav¬
ing 64 women who became pregnant during breast-feed¬
ing. The cases of pregnancy after weaning are not con¬
sidered further, as the focus of this analysis is pregnancy
during lactation.
V
Among the 64 pregnancies that occurred during lactation,
one fourth (11 = 16) occurred during full breast-feeding and
three fourths (11 = 48) occurred when the infant was receiv¬
ing caloric food supplements of varying amounts (i.e., during
partial breast-feeding). Nearly all the pregnancies that oc¬
curred during full breast-feeding (15 of the 16) were in one
center (Chengdu).
Among the 64 women who conceived while breast-feed¬
ing, 18 reported using a family planning method during the
estimated time of conception, leaving 46 pregnancies that
occurred among breast-feeding women who were not using
contraception. Contraceptive failure was associated with the
use of withdrawal, natural methods of family planning, bar¬
rier methods, intrauterine devices, and vasectomy. About
half the .contraceptive failures occurred after the women
clearly were already cycling (i.e., menstruating by the con¬
firmed first menses—HRP rule).
Conceptions During Lactational Amenorrhea
Table 2 shows the distribution of the 46 pregnancies that
occurred among breast-feeding women who were not using
contraception according to whether the pregnancy occurred
during amenorrhea as per each of the four definitions of the
end of amenorrhea. When the confirmed first menses—HRP
rule was used to define the end of amenorrhea, 31 pregnan¬
cies (67%) among breast-feeding women who were not
using contraception occurred during amenorrhea. However,
when all first menses—HRP rule or first reported bleeding
episode was used to define the end of amenorrhea, only 25
pregnancies (54%) occurred during amenorrhea. This is to be
expected, because when bleeding episodes that are not con¬
firmed to be cyclic mark the end of amenorrhea, the period
of amenorrhea is shortened.
When the end of amenorrhea was defined as the woman's
perception of the first menses, the number of pregnancies
that occurred during amenorrhea was almost the same as
when the confirmed first menses rule was used. However,
this is just a coincidence because the women who became
pregnant during amenorrhea are somewhat different under
the two definitions. Women frequently reported vaginal
bleeding episodes that they did not describe as normal
menses.
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Six-month cumulative pregnancy rates during lactational amenorrhea up to the end of full breast-feeding.
End of amenorrhea according to the indicated definition
HRP rule
Confirmed first All first Woman's First reported
Study center menses only menses perception bleeding episode
Chengdu 1.8(0-3.5) 1.4 (0-2.9) 1.4(0-2.9) 1.4 (0-3.0)
Woman "months 1,390 1 188 1,374 1,364
Guatemala City 0 0 0 0
Woman-months 93 93 88 86
Melbourne/Sydney 0 0 0 0
Woman-months 742 742 753 707
New Delhi 0 0 0 0
Woman-months 356 353 327 307
Sagamu 0 0 0 0
Woman-months 13 13 13 13
Santiago 0 0 0 0
Woman-months 78 78 79 70
Uppsala 0 0 0 0
Woman-months 297 296 305 284
All centers 1.2 (0--2.4) 0.9 (0-2.0) 0.9 (0-2.0) 1.0(0-2.1)
Woman-months 2,969 2.963 2,939 2,831
Note: Values arc percentages, with 95% confidence intervals in parentheses. Cumulative pregnancy rates were censored at the initiation of contraception and
adjusted for exposure to coitus during each fortnight. MRP - Human Reproduction Programme.
WHO Task Force. Pregnancy during breast-feeding. Fertil Sterit 1999.
Rates of Pregnancy During Lactational
Amenorrhea
Cumulative pregnancy rates at 6 months after childbirth
during lactational amenorrhea up to the end of full and
partial breast-feeding are shown in Tables 3 and 4, respec¬
tively. The corresponding rates at 12 months after childbirth
are shown in Tables 5 and 6. The breast-feeding categories
arc used cumulatively so that, for example, for all centers
combined, in the 6-month life table using the confirmed first
menses definition, the 5,639 woman-months of exposure up
to the end of partial breast-feeding (Table 4) includes the 2,969
months of exposure during full breast-feeding in Tabic 3.
All Centers Combined
For all centers combined, women who were still breast¬
feeding and remained amenorrheic (according to the HRP-
confirmed first menses definition) at the end of 6 months had
a cumulative pregnancy rate of 0.8% (95% confidence inter¬
val [CI] = 0.2%-1.4%), whereas at the end of 12 months,
they had a cumulative pregnancy rate of 4.4% (95% CI =
2.5%—6.3%).
The cumulative pregnancy rates calculated from delivery
until the end of full breast-feeding and from delivery until
the end of partial breast-feeding were not significantly dif¬
ferent (P<.05) at either time limit (6 or 12 months). How¬
ever, for each breast-feeding status, the pregnancy rate at 12
FERTILITY & STERILITY®
months postpartum was substantially higher than that at 6
months postpartum.
There were no statistically significant differences in preg¬
nancy rates among the various definitions of the end of
amenorrhea at either 6 or 12 months. Although the various
definitions of the end of amenorrhea yielded different num¬
bers of women who became pregnant before the return of
menses (Table 2), these different numerators did not result in
significantly different rates of pregnancy.
Center Differences
Among the individual centers, as seen in Tables 3 and 5,
there were no pregnancies during amenorrhea and full
breast-feeding in any center except Chengdu. Thus, the preg¬
nancy rates during full breast-feeding are entirely a reflection
of one center.
The 6-month pregnancy rate during partial breast-feeding
and lactational amenorrhea was notably high in Uppsala at
3.2% (95% CI — 0%-7.8%j). No pregnancies were reported
in the other developed country (Melbourne/Sydney) under
these conditions.
In Santiago, no pregnancies were reported during amen¬
orrhea except when amenorrhea was defined according to the
woman's perception. Using the woman's perception of the




Six-month cumulative pregnancy rates during lactational amenorrhea up to the end of partial breast-feeding.
End of amenorrhea according to the indicated definition
HRP rule
Confirmed first All first Woman's First reported
Study center menses only menses perception bleeding episode
Chengdu I.I (0-2.2) 0.9(0-1.8) 0.9 (0-1.9) 0.9(0-1.9)
Woman-mondis 1.937 1,934 1,910 1.900
Guatemala City 0.7(0-2.1) 0.7 (0-2.2) 0.7 (0-2.2) 0.8 10-2.5)
Woman-months 812 799 801 723
Melbourne/Sydney 0 0 0 0
Woman-months 1,109 1.109 1,131 1,053
New Delhi 0 0 0 0
Woman-months 731 721 665 610
Sagaimi 0 0 0 0
Woman-months 281 281 277 272
Santiago 0 0 4.3 (0-12.4) 0
Woman-months 258 254 263 229
Uppsala 3.2 (0-7.8) 3.2"((>-7.8) 3.1 (0-7.4) 3.5 (0-8.4)
Woman-months 511 511 521 481
All centers 0.8 (0.2-1.4) 0.7 (0.1-1.3) 0.8(0.2-1.4) 0.8 (0.1-1.4)
Woman-months 5,639 5.609 5,568 5,268
Note: Values are percentages, with 95% confidence intervals in parentheses. Cumulative pregnancy rates were censored at the initiation of contraception and
adjusicd for exposure to coitus during each fortnight. HRP = Human Reproduction Programme.
WHO Tusk Force. Pregnancy during breast-feeding. Fertil Sleril 1999.
TABLE 5
Twelve-month cumulative pregnancy rates during lactational amenorrhea up to the end of full breast-feeding.
End of ainenorrliea according to the inchoated definition
HRP rule
Confinned first All first Woman's First reported
Study center menses only menses perception bleeding episode
Cltcugdii 7.8 (2.7-12.9) 7.4 (2.4-12.5) 8.4(3.0-13.7) 7.7 (2.5-13)
Woman-months 1.706 1.704 1,682 1,669
Guatemala City 0 0 0 0
Woman-months 95 95 90 88
Melbourne/Sydney 0 0 0 0
Woman-months 762 761 772 725
New Delhi 0 0 0 0
Woman-months 362 358 331 309
Sagamu 0 0 0 0
Woman months 13 13 13 13
Santiago 0 0 0 0
Woman-months 79 79 80 73
Uppsala 0 0 0 0
Woman-months 298 298 307 285
All centers 6.8(2.1-11.5) 6.6(1.9-11.2) 7.4 (2.5-12.3) 6.9(2.0-11.8)
Woman-months 3,315 3,308 3,275 3,162 .
Note: Valdes are percentages, with 95% confidence intervals in parentheses. Cumulative pregnancy rates arc censored at the initiation of contraception and
adjusted for exposure to coitus during each fortnight. HRP = Human Reproduction Programme.
WHO Task Force. Pregnancy during breast-feeding. FertU Steril 1999.
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TABLE 6
Twelve-month cumulative pregnancy rates during lactational amenorrhea up to the end of partial breast-feeding.
End of amenorrhea according lo the indicated definition
HRP rule
Confirmed lirst All lirst Woman's First reported
Study center menses only menses perception bleeding episode
Chengdu 5.8 (2.7-8.8) 5.1 (2.2-8) 5.6 (2.5-8.7) 5.3 (2.3-8.3)
Woman-months 2,934 2,930 2.S67 2,844
Guatemala City 4.2(0-9.1) 2.3 (0-5.8) 6(0-12) 2.8 (0-6.8)
Woman-months 1,159 1,132 LI28 998
Melbourne/Sydney 2.6 (0-7.6) 2.6 (0-7.7) 5.3 (0-11.4) 2.8 (0-8.3)
Woman-months 1,517 1,517 1,556 1,427
New Delhi 5.5(0-13.4) 3.8 (0-11) 6.5 (0-15.8) 4.8(0-13.9)
Woman-months 960 950 854 788
Sagamu 0 0 0 0
Woman-months 506 504 486 480
Santiago 0 0 4.3 (0 -12.4) 0
Woman-months 323 313 326 271
Uppsala 5.4 (O-JI.6) 53(0-11.6) 5.2 (O-l 1) 5.9(0-12.6)
Woman-months 634 633 652 599
All centers 4.4 (2.5-6.3) 3.7(1.9-5.5) 5.2 (3.1-7.4) 4.1 (2.1-6.1)
Woman-months 8,033 7.979 7,869 7.407
Note: Values arc percentages, with 95% confidence intervals in parentheses. Cumulative pregnancy rates are censored at the initiation of contraception and
adjusted for exposure to coitus during each fortnight. HRP - Human Reproduction Programme.
WHO Tusk Force. Pregnancy during breast-feeding. Fertil Stcril 199*).
and amenorrhea was 4.3% at both 6 and 12 months (93%
CI = 0%-I2.4%).
Resumption of Sexual Relations
In all centers except Sagamu, women started having in¬
tercourse on average when the infant was about 6—8 weeks
old (Table 7). In Sagatnu, where a period of postpartum
abstinence is traditional, the median time for the resumption
of intercourse was >17 weeks postpartum. Women were not
asked how often they had intercourse but simply whether it
had occurred sioce the previous follow-up visit. Women in
Chengdu reported intercourse significantly more often
(PC.001) than women in any other center: intercourse was
reported during >82% of the follow-up interviews.
Use of Contraception
Women who intended to use a hormonal method of con¬
traception after childbirth were not recruited to the study and
those who started to use hormonal contraception during the
course of the study (it = 107) were discontinued. For those
women who initiated the use of nonhormonal contraception
during amenorrhea, the median time to the start of contra¬
ceptive use is shown in Table 8. In Uppsala and Melbourne/
Sydney, >70% of these women started using a barrier
method of. contraception, as did >50% of the women in
Guatemala City. New Delhi, and Sagamu. More than 90% of
these women in Santiago and 48% in Chengdu used an
intrauterine device. Female sterilization was common in
New Delhi (26.4%) and Guatemala City (11%), whereas in
Chengdu, the partners of 50% of the women who initiated
the use of contraception during the study underwent vasec¬
tomy. Withdrawal was used commonly in Sagamu (29.4%),
Guatemala City (11.7%), and Uppsala (9.9%).
TABLE 7
Median time to the start of intercourse and percentage of
2-week intervals during which intercourse occurred since
admission to the study and since the start of intercourse,
by center.






No. of confidence admission resumption
Study center days interval to study of coitus
Chengdu 42 40.9-43.1 82.1 99.2
Guatemala City 40 38-41.5 58.4 80.6
Melbourne/Sydney 52 51.5-53 69.3 81.7
New Delhi 52 51-52 62.4 92.4
Sagamu 122 108-137 47.5 81.0
Santiago 51 50.5-52 62.1 86.2
Uppsala 53 51-54 61.2 79.5
WHO Task Force. Pregnancy during breast-feeding. Fertil Stcril 1999.
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TABLE 8
Percentage of women who were not using contraception
before their first menses and the median time to the






who were not using No. of
Study center contraception days 95% CI
Chengdu 68.4 126 110-165
Guatemala City 58.1 52 51-53
MelbourncySyduey 46.3 51 48-56
New Delhi 61.7 44 39-52
Sagnmu 59.4 81 79-93
Santiago 17.2 39 39-40
Uppsala 31.3 56 55-68
A'ale: The first menses was defined as life confirmed firsl menses—Human
Reproduclion Programme rule. CI " confidence interval.
WHO Task Force. Pregnancy during breast-feeding. Fertil Steril 1999.
DISCUSSION
Pregnancy rates (luring lactational amenorrhea of 5%-
10% (without regard for lime postpartum) have been re¬
ported consistently in demographic studies (13, 14). Esti¬
mates of the risk of pregnancy during amenorrhea calculated
from ovulation rates have varied from 0.9% (15) to 1.7%
(16) at 6 months, figures that are in close agreement with the
findings of this study. In this study, the cumulative preg¬
nancy rates ranged from 3.7% (95% CI = 1.9%-—5.5%) to
7.4% (95% CI = 2.5%-l2.3%) among amenorrheic women
at 12 months, findings that are in agreement with the esti¬
mate of 7% made by Short ct al. (16) in a study of Australian
women, but lower than the estimate of 17.2% made by Diaz
et al. (15) in a study of women from Santiago, Chile.
The overall rales of pregnancy observed herein during
lactational amenorrhea until the end of full breast-feeding
did not differ significantly from those until the end of partial
breast-feeding, at either 6 or 12 months. The pregnancy rate
had been expected to increase from the full to the partial
category of breast-feeding because previous research linked
breast-feeding frequency and the delay of supplementation
to the duration of lactational infertility. The dose-response
was not seen when the centers were combined because of the
pregnancies that occurred during lactational amenorrhea in
the full breast-feeding category (all of which occurred in
Chengdu).
Mothers in Chengdu were more sexually active and
avoided supplementing for a longer period than generally
recommended; this period was longer than that in all the
other centers. However, actual breast-feeding behavior in
Chengdu during full breast-feeding appeared to be reduced
compared with the other centers (11). The mean total dura¬
tion of suckling was lowest in Chengdu during the first 6
postpartum months, and at no time during amenorrhea did
infants in Chengdu spend more than a mean total duration of
80 minutes per day at the breast (11).
Some investigators (17, 18) have suggested that there
may be a threshold for suckling duration per day that is
required for nipple stimulation to maintain suppression of
the hypothalamic-pituitary axis, and that when suckling du¬
ration falls below this threshold, the risk of ovulation and
therefore of pregnancy increases. Finally, it is important to
remember that the breast-feeding status reported here (i.e.,
full or partial breast-feeding) is actually an index of the
degree to which the infants were given supplements and not
some amount of breast-feeding (see definition). Thus, this
analysis more accurately supports conclusions about how
much supplementation can be tolerated than about how
much breast-feeding stimulation is required.
The comparatively high 6-month pregnancy rate seen in
Uppsala during amenorrhea and partial breast-feeding was
characterized by a wide confidence interval because of the
comparatively small number of woman-months of exposure.
In Melbourne, the closest comparison group, no pregnancies
occurred under the same conditions and the exposure time
was nearly double that in Uppsala.
The pregnancies seen in Santiago only when the woman's
perception of the first menses was used to define the end of
amenorrhea suggests that this somewhat subjective measure
of the return of menses may not be appropriate for use with
the LAM. All the other definitions applied in Santiago re¬
sulted in pregnancy rates during amenorrhea of zero. As in
Uppsala, the confidence interval of the pregnancy rate was
wide, owing at least in part to the small number of woman-
months of exposure.
Small numbers of woman-months of exposure to preg¬
nancy were seen in Sagamu and in Santiago. These were clue
to censoring for lack of sexual activity and for contraceptive
use, respectively.
Care was taken in this study to define the end of amen¬
orrhea carefully and to consider whether any one definition
of the first menses would be associated with a higher or
lower rate of pregnancy during amenorrhea; however, no
difference in the rate of pregnancy during lactational amen¬
orrhea was found when the various definitions were com¬
pared. Thus, although a careful interpretation of the meaning
of a bleeding episode (i.e., the HRP-confirmed first menses)
resulted in a longer duration of amenorrhea and a corre¬
spondingly higher number of pregnancies, the corresponding
pregnancy rate was not significantly higher than when a
simpler definition of menses (i.e., the first reported bleeding
episode) was used. By the latter, simpler definition, the
duration of amenorrhea is shorter, and more months of
unnecessary contraceptive use would result if women started
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131
to use contraception at the end of amenorrhea. However, the
simpler definition may have more programmatic and per¬
sonal acceptability, and women may find double protection
to be acceptable in the face of early unexplained bleeding
episodes. In this discussion, however, the illustrations of the
pregnancy rates generally use the HRP-confirmed first men¬
ses to define the end of amenorrhea because this definition
resulted in the greatest period of exposure to pregnancy
during amenorrhea, presenting a "worst-case" scenario.
The Bellagio Consensus (4, 5) led to the development of
the LAM of family planning (9), which advises that a woman
has a cumulative risk of pregnancy of <2% if she is amen¬
orrhea: and fully or nearly fully breast-feeding as long as the
infant is still <6 months old. If any of these three conditions
is not met, she is advised to use a method of family planning
that does not interfere with breast-feeding. For all centers
combined, the highest 6-month cumulative pregnancy rate
among women who were fully breast-feeding, amenorrheic,
and not using contraception in this inulticenter study was
1.2% (95% CI = 0%-2.4%). Thus, this study confirms the
Bellagio Consensus (19).
It is important to note that the women in this study were
not using the LAM. Indeed, the method had not been created
until after this study was begun. Women who are proactively
trying to avoid pregnancy through good breast-feeding prac¬
tices and the recognition of the return of menses may behave
differently than women who are simply breast-feeding their
infants. Therefore, the efficacy of the LAM is only simulated
in this study.
However, it can be argued that the efficacy of the LAM
would be better in actual use than in simulated analyses of
observed breast-feeding behaviors because users of the LAM
learn the breast-feeding behaviors that maximize milk pro¬
duction (and, simultaneously, the duration of lactational am¬
enorrhea) when they learn the LAM algorithm (9). The fact
that contemporary breast-feeding practices were studied
herein (i.e., there was no attempt to change existing breast¬
feeding behaviors) suggests that the rates produced may
underestimate the pregnancy protection during actual use of
the LAM.
The extent to which women in this study represent likely
LAM users is not clear. All mothers previously had breastfed
an infant for at least 4 months and intended to breast-feed the
study infant for at least 6 months. To date, the studies of
LAM efficacy suffer from the drawback of including only
women with breast-feeding experience. It is reasonable to
characterize typical LAM users as women who intend to
breast-feed for at least 6 months, but the effect of previous
breast-feeding experience on current LAM performance is
unknown.
Short.et al. (16) recommended extending the Beilagio or
LAM guidelines for populations with a long duration of
breast-feeding, suggesting that, provided women remained
FERTILITY & STERILITY®
amenorrheic and continued to breast-feed, the method could
give good protection for up to 12 months after childbirth
irrespective of when supplements are introduced. In this
study, the highest 12-month pregnancy rate among tire am¬
enorrheic women who were not using contraception was
7.4% (95% CI = 2.5%—12.3%). The range of the CI suggests
that although attempts to extend the LAM beyond 6 months
in the presence of some degree of supplementation (provided
that amenorrhea persists) may be possible, they should be
made with caution because more pregnancies can be ex¬
pected than would be seen with LAM use for only 6 months,
as determined in the original Bellagio Consensus (4,5).
The period of lactational amenorrhea is characterized by
a profound degree of protection from pregnancy. Although
the suckling stimulus drives die neuroendocrinologic mech¬
anism of lactational infertility, the degree of supplementation
to breast-feeding in this study did not yield a dose-response
in the pregnancy rate, probably because of the prolonged
duration of full breast-feeding in one center that accounted
for alt the pregnancies that occurred during full breast¬
feeding in amcnorrheic women.
Regardless of the degree of supplementation, the preg¬
nancy rale increased with time from the 6th to the 12th
month postpartum. Overall, the rate of pregnancy during
amenorrhea was unaffected by variations in the definition of
the return of menses. This large, multicenter study found that
the cumulative 6-month rale of pregnancy during lactational
amenorrhea was between 0.8% (95% CI = 0.1%-] .4%) and
1.2% (95% CI = 0%—2.4%). This is equivalent to the pro¬
tection provided by many nonpermanent contraceptive meth¬
ods as they are actually used and upholds the 1988 Bcllagio
Consensus.
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Summary
BACKGROUND AND OBJECTIVES A worldwide trend
towards increasing life expectancy has meant that osteo¬
porosis is emerging as an important public health pro¬
blem. The loss of bone mineral density and its restoration
in association with a premenopausal but physiological
hypo-oestrogenic state may serve as an important model
(or research into the pathogenesis and prevention of
osteoporosis. With this in mind we have undertaken a
longitudinal study of changes in bone mineral density
over one year in women after childbirth.
DESIGN Observational study of 31 women in the first year
following childbirth; 11 Intending to breast-feed and use
barrier methods of contraception, 9 intending to breast¬
feed and to use the progestogen-only pill and 10 intending
to artificially feed and to use barrier methods.
PATIENTS Recruitment was from the antenatal clinics of
Ihe Simpson Memorial Maternity Pavilion. Only non-
smokers who had regular menstrual cycles prior to
conception were included .
MEASUREMENTS Bone mineral density was measured
at the lumbar spine within 3 weeks of childbirth and
repeated at 6 and 12 months post partum. Plasma oes-
tradiol, prolactin and osteocalcin concentrations were
measured at each visit.
RESULTS Breast-feeding women using barrier methods
lost a meanitSE of 4-9 ±1-5% of bone mineral density in
the first 6'months following delivery. This was however
reversible since by one year the bone mineral density
Correspondence: Dr Lucy E. Caird, Department of Obstetrics and
Gynaecology, Centre for Reproductive Biology, 37, Chalmers
Street, Edinburgh EH3 9EV, UK. Fax: 031 229 2408.
was no different from that measured immediately post
partum. Breast-feeding women using the progestogen-
only pill lost a significantly smaller percentage of bone
mineral density in 6 months and by one year bone mineral
density was 2-95 ±0-75% higher than post partum. Artifi¬
cially feeding women had a steady increase In bone
mineral density in the first year and bone mineral density
was on average 4-3 ±1-2% higher.
CONCLUSION Breast-feeding results in a reversible
reduction In spinal bone mineral density. The small
amounts of gestagen in the progesterone-only pill
would appear to protect against this loss. The mechan¬
ism of this loss in bone mineral density and the potentially
bone protective effects of gestagens require further
study.
Premenopausal hypo-oestrogenic states (premature meno¬
pause, hyperprolactinaemic amenorrhoea (Schlechte et al.,
1992) and hypogonadotrophic hypogonadism (Biller et at.,
1989)) are associated with a loss of bone mineral density.
Lactation is associated with hypo-oestrogenism which may
be prolonged in women who breast-feed their babies for a
year or more, the norm in many developing countries. The
evidence for a relation between bone mineral density (BMD)
and lactation in humans is available from cross-sectional
and longitudinal studies. Goldsmith and Johnston (1975) in
a cross-sectional study in which the BMD of the radius was
measured reported that bone mineral density was lower in
women who had lactated in the past although this effect was
less apparent in post-menopausal women, suggesting that
the bone loss was reversible. In their study however, women
were regarded as having lactated even if they had done so for
a total of only two weeks. Wardlaw and "Pike (1986) in a
similar cross-sectional study measuring BMD at the radius
suggested that BMD was reduced in women with longer
periods of lactation. In a prospective study, Hayslip and
colleagues (1989) described bone mineral loss from the
spine, but not from the forearm, during the first 6 months
post partum in lactating women but not in women who did
not breast-feed. Bone mineral density was not measured
after weaning and no account was taken of ovarian activity.
Kent and co-workers (1990) also described bone loss in
lactating women and reported the restoration of normal
bone mineral density after weaning; however, in their study
BMD was measured in the forearm and no mention was
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made of ovarian activity. More recently, Sowers et al. (1993)
demonstrated a reversible reduction in BMD at spine as
measured by dual-energy X-ray absorptiometry with
lactation exceeding 5 months duration.
Menopause related bone loss is a direct consequence of
oestrogen deficiency and can be prevented by the adminis¬
tration of exogenous oestrogens (Lindsay et al., 1976). It has
been suggested that progesterone may also be involved in
bone metabolism. Oestrogen receptors are present in
osteoblasts whereas it is thought that progesterone receptors
are 'induced' only in the presence ofoestrogen (Eriksen et al.,
1988). Mandel et al. (1982) found that bone resorption (as
assessed indirectly by a reduction in the urinary excretion of
calcium and hydroxyproline) was inhibited by medroxypro¬
gesterone acetate. In contrast, Gallagher et al. (1991) found '
that medroxyprogesterone acetate failed to prevent post¬
menopausal bone loss as assessed by direct measurement of
spinal and radial bone density.
We were interested to observe changes in bone mass
which may occur during lactation and, in addition, to
observe the effect of progesterone as commonly used in the
minipill for contraception during this time. With this in
mind we undertook a longitudinal study of changes in bone
mineral density over one year in women after childbirth.
Subjects
Thirty-one women were recruited from the post-natal wards
of the Simpson Memorial Maternity Pavilion in Edinburgh.
All had regular menstrual cycles prior to conception and
had no significant past medical history. None of the women
were smokers. Twenty-one were intending to breast-feed
their infants for at least 6 months. Of these, 12 planned to
use barrier methods of contraception (group A) while 9
intended to use the progestogen-only pill (POP) (group B).
Of these, 3 used Noriday (0-35 mg norethisterone) and 6
used Microval (0-3 mg levonorgesterol). Ten women
intending to artificially feed and to use a barrier method
were also recruited (group C).
A simple dietary history, including alcohol intake, was
recorded. Vegetarians and women regularly using vitamin
or calcium supplements were excluded from the study. All
the women were judged to have a daily calcium intake of
about 800 mg. Exercise patterns before pregnancy were
noted on admission to the study and women with a history
of regular strenuous exercise, e.g. marathon running, were
excluded. Height and weight and, in the case of the breast¬
feeding mothers, suckling frequency, were recorded at every
visit and blood was taken for the measurement of calcium,
phosphate, albumin, alkaline phosphatase, osteocalcin
(except group B, the assay was no longer available),
prolactin and oestradiol. All participants kept a note of
the date of their first menstrual period post partum.
Bone mineral density (BMD) was measured by dual-
energy X-ray absorptiometry (DEXA) using a Hologic
QDR 1000 densitometer (Hologic Inc., Wallham, USA).
Half-way through the study this was exchanged for a whole
body version of the same system (QDR 1000W). The second
system was cross-calibrated by the manufacturer to give the
same BMD as the first for an anthropometric spine
phantom. There was no significant change in phantom
BMD during the entire period of the study. The mean
difference in phantom BMD between the two systems was
only 0 01 % and the coefficient of variation during the entire
study period 0-31 %. In addition, measurements performed
on a group of subjects on both systems gave a mean
coefficient of variation of 0-65% which was not significantly
different from repeat measurements performed using the
same instrument. Therefore for the purpose of the present
study the two instruments were essentially identical. Bone
mineral density of the lumbar spine was measured on three
occasions in all women—within 4 weeks of delivery, and at 6
and 12 months post partum. The lumbar spine was chosen
for its higher trabecular bone content and its excellent
reproducibility (0 8%), in contrast to the femoral neck
(1-46%). In addition, it was felt appropriate to keep the total
visit time to a minimum since we were dealing with
volunteers.
Calcium, phosphate, albumin and alkaline phosphate
concentrations were measured at the time each sample was
taken using a SMAC 2 analyser (Technicon) in the
Department of Clinical Chemistry at the Royal Infirmary
of Edinburgh. Oestradiol, prolactin and osteocalcin were
measured in batches, samples having been separated and
stored at -20°C. Oestradiol was measured by radio¬
immunoassay using the Clinical Incslar kit (lncstar Ltd).
Interassay variation was 8% while intra-assay variation was
6%. Prolactin was measured by an in-house poly-mono-
clonal radiometric assay which used polyclonal antiserum
from the Scottish Antibody Production Unit, Carluke and
l25I-labelled monoclonal antibody from Netria, St Barthol¬
omew's Hospital, London. The standard used was 83/573
(NIBSC) and inter and intra-assay variations were 8 and 5%
respectively. Osteocalcin was measured in plasma using an
in-house radioimmunoassay using antiserum raised in
rabbits against bovine osteocalcin. I25l-labelled osteocalcin
and the standards were prepared against bovine osteocalcin.
The antisera cross-reacted with human osteocalcin. Inter
and intra-assay variations were 12-1 and 4-5% respectively.
Full approval for the study was obtained from the
Lothian Health Board Paediatrics/Reproductive Medicine
Ethics of Medical Research Sub-Committee.
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The data were normally distributed so mean, standard
error and range are quoted. Analysis of variance with
repeated measures was used to compare data between the
groups of women and the changes over time.
Results
Not all of the breast-feeding women completed the study;
one left the area after the first post partum BMD
measurement and two women conceived during the study,
neither of whom was scanned at 12 months. These results
are not included in the analysis. The total number of bretist-
fecding women who completed the study was 18,9 in each of
the two groups A and B. All the artificial feeders finished the
study (Group C). The characteristics of all three groups of
mothers are shown in Table 1. For the purposes of the
discussion the term breast-feeders will be used throughout
for those women not using steroidal contraception (A), POP
users for those using the progestogen-only pill (B) and
artificial feeders (C) for the others.
All the women lost weight during the year of study and
there was no difference in the rates of loss between groups.
The mean fall from immediately post partum to six months
was 4%, and from six to twelve months a further 2-6%.
Bone mineral density
The mean bone mineral densities of the spine in the
immediate puerperium and at 6 and 12 months post
partum for the three groups are shown in Table 2. The
change in spinal BMD with time post partum is shown in Fig.
1 for each group. In all the breast-feeding women there was a
fall in bone mineral density and this was significant as a group
(P < 0 001 Anova) between the immediate puerperium and 6
months post partum. In contrast, a fall in BMD occurred in
only two bottle-feeding women over the same time period .
From 6 to 12 months post partum, BMD rose significantly
(P < 0.001) in the breast-feeding women. Theabsolute BMD
at 12 months post partum was not significantly different from
that measured within the first 4 weeks after delivery. There
Table 1 Subject characteristics. Values are
mean ±SE; range shown in parentheses. The
groups are comparable with ANOVA except
that the breast-feeders are significantly taller
than the POP users
Breast-feeders (A) POP users (B) Artificial feeders (C)
Subject characteristics (»=9) (n-9) ("—10)
Age (years) 33-4 ±1-25 33-1 ± 1-2 31-7 ± 1-2
(28 -40) (28-39) (28-41)
Parity 1-3 ±0-21 1-1 ±0-1 1-3 ±0 21
(0-2) (1-2) (0-2)
Menarche (years) 12-5 ±0-37 13-3±0-55 13-2 ±0-35
(11-16) (11-16) (11-15)
Height (cm) *169±2 162-3 ±1-2 166 ±2
(155-179) (157-169) (156-176)
Weight post partum (kg) 690 ± 2-2 64-5 ±4-0 72-7 ±3-5
(53 4- 82 5) (53-4-91-4) (156-176)
Body mass index 22 7 ±012 24-5 ±0-16 24 8 ±0 13
(kg/m2) (16*8—27* I) (21-1-34-7) (18-8-32-3)
*/><0-05.
Table 2 HMD (g/cnr) at lumbar spine.
Values are meaniSE; range shown in
parentheses. There is no difference between
the groups at the first visit
BMD at spine (g/cm2)
Breast-feeders POP users Artificial feeders
Time (A) (B) (C)
Post partum 1-028 ±003 0-991 ±004 0-998 ±0-025
(0 893-1 197) (0-83-1-182) (0 899-1-156)
6 months 0-976 ±0-028" 0-977 ± 0-039* 1-02 ±0-025
(0-884—1-112) (0-803-1 141) (0-859-1 122)
12 months 1-024 ±0-025 1-02 ±004** 1-041 ±0-027**
(0-914- 1 133) (0-851-1-19) (0-868-1-158)
*P<0-05, **7><0-0I vj post-partum visit.
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Fig. 1 Changes in HMD for each individual subject in a, group A
(breast-feeders); b, group B (POP users); c, group C (artificial
feeders).
appeared to be an overall increase in bone mineral density
during the 12 months after childbirth in the bottle-feeding
women,. HMD was on average 4-3 ±1-2% greater at 12
months post partum than within a month of delivery; this
increase was statistically significant (P < 0-01). Seven of the
nine POP users lost bone mass from delivery to 6 months
(-1 4±0'53%). This fall in HMD was overall significantly
Fig. 2 Percentage changes in HMD± SBM for each group. ■,
Group A (breast-feeders); •, group B (POP users); O, group C,
(artificial feeders).
less than that seen in the breast-feeders (P < 0-01). From 6
to 12 months a significant increase did occur in POP users
(P < 0 005). Overall BMD was significantly greater at 12
months (2-95 ±0-75%) than at delivery (P < 0 01). Figure 2
shows the percentage change in each of the groups. It would
therefore appear that some protection was afforded to bone
mass by the use of the progestogen-only pill in breast¬
feeding women and that these POP users are better offat one
year than the other breast-feeders.
The significant increase in BMD which occurred between
6 and 12 months post partum in the breast-feeding women
appeared to be inversely related to the duration of
amcnorrhoea (r=-0-6) although this did not achieve
significance. Menses returned at a median of 36 (range
23-41) weeks post partum. Thus all except one woman (who
had only just menstruated) were still amenorrhocic at 6
months post partum while all had resumed menses by the
time BMD was measured again at 12 months. No
correlation was noted in the POP users in whom menses
returned at a median of 41 weeks. Menses returned at a
median of 6-3 weeks (range 4-10) among the women who
did not breast-feed.
Biochemical parameters
Mean plasma oestradiol concentrations arc shown in Table
3. At the first post-partum visit there was no difference
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Table 3 Plasma oestradiol. osteocalcin and alkaline phosphatase concentrations at each visit. Values are mean ± SE, range shown in
parentheses
Breast-feeders (A) POP users (B) Artificial feeders (C)
Time of Oestradiol Osteocalcin Alk phos Oestradiol Osteocalcin Alk phos Oestradiol Osteocalcin Alk phos
sampling (pmol/l) (pg/1) (IU/1) (pmol/l) O^g/l) (iu/1) (pmol/l) (/rg/1) (iu/1)
Post part am 55±3" 5-15 JL 2-10* 1061± 9-8 60-3 ±6" na 114± 13-8 164 ±33 10-54 ±0-98 108 ± 11.58
(50-81) (1-5-17-2) (47-160) (50-86) (53-202) (50-353) (5-9-13-8) (62-181)
6 months 132 ± 38 12 2± 1*" 76-4 ±8-6 145 ±38 na 83-5 d= 13 227 ± 81 5-8 ±1.13 48-1 ±4-05
(60-357) (8 4-15 8) (45-118)* (50-423) (33-160)' (50-856) (1-7-11-5) (28-70)
12 months 199 ± 50 7-47 ± 1-2" 73-8 ±7-4 258±77-6 na 72-3 ±13-9 167 ±43 3-67 ±0-591 53-9 ±5-6
(50-443) (2 6- 13-3) (42-108)' (50-724) (26-135)' (50-451) (2-0-8-5) (36-95)
Oestradiol: "denotes /><0-0l v.r artilicial feeders at post-partum visit and breasl-leeders/POP users (A and B) at 6 months.
Osteocalcin: * denotes P < 0 05, ** denotes P < 0 01 and *" denotes P< 0-001 v.v artilicial feeders.
Alkaline phosphatase: 'denotes P<0 05 vs artificial feeders.
between groups A and B and these levels were significantly
lower than in group C. All the women in groups A and B
had oestradiol concentrations in the post-menopausal
range. At the 6-month visit mean oeslradiol concentration
had increased in groups A and B and was not different from
the artilicial feeders (C). Serum prolactin concentrations
were significantly higher in the early post-partum period
among the breast-feeding mothers (A and B), 2319 ±572
and 2278 ±607 U/l respectively, than among the women
who did not breast-feed (C) 291 ±96 U/l. There was no
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Fig. 3 Plasma osteocalcin concentration ± SE in groups O, A
(brcast-fccders) and •, C (artificial feeders). P-values are shown
for between group comparisons. *P<0 05; **/*<0-01;
"*P<0 001.
Plasma osteocalcin concentrations increased in women in
groups A and C between the third trimester of pregnancy
and the early puerperium (Fig. 3). Concentrations were
significantly higher (P<005) among the bottle-feeding
women than among breast-feeding women in the early
post-partum weeks (Table 3, Fig. 3). By 6 months post
partum osteocalcin was falling among the bottle-feeding
women and the fall continued, so that by one year after
delivery osteocalcin concentrations were no different from
those measured during pregnancy. Among breast-feeding
women however plasma osteocalcin concentrations contin¬
ued to rise after delivery until by 6 months they were
significantly higher (Z3 < 0-001) than the values measured in
the bottle-feeding women. Although osteocalcin concentra¬
tions fell between 6 and 12 months in breast-feeding women
they remained elevated at one year after delivery when
compared with concentrations measured in bottle-feeding
women one year after childbirth (jP<005).
Alkaline phosphatase concentrations (Table 3) were
elevated in the early post-partum period in all groups. In
all groups of women alkaline phosphatase concentrations
fell with time post partum but were still significantly
elevated at 6 (/,<0-01) and 12 months (P < 0 05) in groups
A and B when compared with artificially feeding women. No
significant changes in either plasma phosphate or calcium
qpneentrations were noted in either group of women.
Discussion
It is clear from this study that lactation is associated with a
significant, but reversible loss (4-3%) of bone mineral
density during the first 6 months after childbirth. This loss
would appear to be reduced by the use of the progestogen-
138 )
744 L. E. Caird et at. Clinical Endocrinology (1994) 41
only contraceptive pill. Although BMD at the end of the
study does not appear to differ between the three groups, the
women studied lactated for relatively short periods
compared to some other groups, for example in the Third
World. In such women the situation may be quite different
and therefore ultimately more clinically relevant. By 12
months post partum BMD is no different from that
measured within 4 weeks of delivery in breast-feeding
women. Interestingly, women who did not breast-feed or
who used the progestogen-only pill (POP) appeared to have
an increased bone mineral density at one year compared
with that measured immediately post parlum. Previous
investigations of bone mineral content during pregnancy
have shown contradictory results. Lamke el at. (1977)
suggested that a fall in radial BMD occurred during
pregnancy and this concurred with the finding by Drink-
water and Chesnut (1991) that both radial and femoral neck
BMD fell. More recently, Sowers el at. (1993) recorded no
change in femoral neck BMD in 32 women from pre¬
conception to post partum. In a second, as yet unreported,
study we have measured BMD in the forearm of nine
pregnant women early in the second trimester (14 weeks)
and found no difference when the measurement was
repeated within one month of delivery. Perhaps the fetal
calcium load required (30 g for the skeleton) is not
compensated by the increased gastrointestinal absorption
and the decreased loss through the kidney. The use of the
POP does not appear to affect circulating oestrogen so it is
unlikely that . this is the mechanism for the relative
protection offered. It may simply be the presence of
progestogen, albeit at small amounts, that offers this
'protection'. Norethisteronc is itself relatively androgenic
and may be bone protective. It is thought in addition that
some gestagens may be metabolized to an oestrogen-like
metabolite and this may explain our findings. Interestingly,
Cundy and colleagues (1991) described significant loss of
bone mass in women exposed for a mean of 10 years to the
long-acting depot medroxyprogesterone acetate contracep¬
tive, Dcpoprovera (DMPA). These women had low
circulating concentrations of oestrogens. The number of
subjects was small (n = 30) but a later study (Cundy et at.,
1994) suggested that there was some recovery of BMD when
DMPA was discontinued. Of course the effects of progesto¬
gens themselves may differ depending on whether they are
given in oestrogen deficiency states or whether they induce
oestrogen deficiency, as with the use of Depoprovera.
Our results suggest that the rate of recovery of bone
mineral density during the second 6 months post partum in
breast-feeding women may depend on the duration of
amenorrhoea and thus on the duration of hypo-oestrogen-
ism. The increase in BMD seen is similar to that seen when
post-menopausal women are given oestrogen (Stevenson el
at., 1990). It would be interesting to repeat the study with a
much larger number of women with a wide range of infant
feeding patterns since the women in our study all tended to
breast-feed and remain amenorrhoeic for a similar duration.
A clearer relation might emerge in a group of women who
had long periods of lactational amenorrhoea. In the United
Kingdom most women introduce supplementary feeding
when the infant is about 5 months of age. Suckling activity
declines quite dramatically once supplements arc started
(Howie et at., 1982) and the loss of BMD over the first 6
months may also be a function of the metabolic require¬
ments for the production of milk. Elevated concentrations
of plasma alkaline phosphatase and osteocalcin in breast as
compared with bottle-feeding women also suggest increased
bone turnover. The elevation of plasma osteocalcin may
reflect the recovery of BMD to 'normal' by an increase in
osteoblastic activity. In bottle-feeding women this was seen
early in the pucrperiunr, whilst in breast-feeders this was
seen at 6 months, after which BMD increases. This was
before the return of menstruation and after the introduction
of solids in all except one woman suggesting that it may be
the demands of milk production rather than hypo-
oestrogenism that is the cause of bone loss.
As significant loss of bone mineral density appears to be a
feature of lactation and would seem to be reversible we
suggest that breast-feeding women may serve as an excellent
model for the study of the relation between hormonal and
nutritional factors in osteoporosis. This clear loss of bone
mineral density should be taken into consideration by
scientists working on new methods of contraception for
lactating women because some methods, e.g. the analogues
of GnRH (Eraser et at.. 1989), are themselves associated
with bone loss.
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Who Gives Advice About
Postpartum Contraception?
Anna F. Glasier, Janet Logan,* and T.J. McGlew*
Women were interviewed to determine what advice they
received about postpartum contraception and what they
thought, of it. Only 4% of women discussed postpartum
contraception antenatally. Up to 84% discussed the issue
with a midwife on the postnatal ward but discussion was
often felt to be brief, limited and frequently held as the
mother was leaving the hospital Obstetricians appeared to
have little interest in the subject, and only 50% of mothers
left the hospital with supplies of a contraceptive. Almost
all women discussed contraception with their general ptac- "
titioncr at the postnatal check but a significant number
fell that the choice of method was limited to condoms or
pills. The postnatal check is traditionally held at six
weeks—two to three weeks after the recommended time
for starling contraceptive precautions. Women with short
inter-pregnancy intervals were younger, less likely to be
married and more likely to default from postnatal follow-
up. Pregnant women should be offered the opportunity dur¬
ing the antenatal period to discuss postpartum contracep¬
tion with someone who has a special interest in the
subject. The postnatal ward is not an appropriate setting
for discussion about future contraception. Contraceition
1996;53:217-220
key words: contraception, postpartum, advice, interpreg-
nancy interval
Introduction
Almost all women in the United Kingdom re¬ceive high quality antenatal care from generalpractitioners (CPs], obstetricians and mid-
wives but the postpartum period is relatively ne¬
glected. The UK Government's House of Commons
Health Committee in its recent report on Maternity
Services' concluded that postnatal carc "is poorly
evaluated and researched, delivered in often inappro¬
priate and fragmented ways and has dissipated mana-
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gerial focus which militates against efficient use of
resources."
Included in postnatal care is the issue of postpar¬
tum contraception. Frequent contact with a variety of
health care professionals during pregnancy and the
puerperium provides numerous opportunities for dis¬
cussion of future contraception. It is our impression,
however, that the subject receives scant attention and
is often less than adequately covered during the pu-
erperium. For this reason we undertook a study to
determine who gives women advice about contracep¬
tion after childbirth, what women think of that ad¬
vice and whether short inter-pregnancy intervals are
related to lack of good advice about contraception.
Materials and Methods
One-hundrcd-seventy-four women were recruited
from a large Scottish teaching hospital delivering
around 5500 women and undertaking some 2000 in¬
duced abortions each year. One-hundred women were
selected randomly from the labour ward delivery lists,-
50 Igroup A) were interviewed at home at eight weeks
and 50 (group B| at one year after delivery. Mothers
whose babies were in the Special Care Baby Unit were
excluded. Forty women attending for antenatal care
who had conceived within one year of childbirth
(Group C) were interviewed at home before 28 weeks
of pregnancy (women whose previous pregnancy had
ended in a spontaneous miscarriage were excluded).
Thirty-four women pregnant within one year of child¬
birth and seeking abortion (Group D) were inter¬
viewed after the request for abortion had been ac¬
cepted but before the procedure .was undertaken.
There was no randomisation in Groups C and D, all
women conceiving within one year of childbirth were
invited to participate. Women who lived outside the
City of Edinburgh or whose command of English was
poor were excluded from recruitment to all groups.
Women were told at the time of recruitment that they
were taking part in a study about fertility after child¬
birth or abortion. The hospital staff were given the
same information.
Semi-structured interviews covered socio-econom¬
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feeding plans, and advice received about contracep¬
tion. The nature of the advice and whether or not it
was seen by the woman to be appropriate or useful
was determined.
Results were analysed using chi-square on SPSS.
Results
Over 90% of women could recall clearly the nature of
the advice given after childbirth and who gave it.
Only one woman (in group B) was unable to recall
whether she received any advice. There were no sig¬
nificant differences between the groups in the sub¬
jects' ability to recall the advice nor in the number of
professionals giving advice suggesting that data col¬
lected from women one year after childbirth was rea¬
sonably accurate.
Women who had conceived within one year of a
previous pregnancy and who planned to have the
child (Group C] were younger (Table 1), less likely to
be married or cohabiting and had fewer children than
women who were not pregnant within one year of
childbirth (Group B). None of these differences, how¬
ever, reached a level of statistical significance.
Women who had conceived again within one year but
who opted for abortion (Group D) were the youngest
group, had the most children but were the least likely
to be married or cohabiting (p<0.05).
Advice Given Antenaially
Only seven women (4%| remembered discussing con¬
traception with a professional before the baby was
born. Another five remembered contraception being
mentioned in antenatal classes but in every case'the
advice was simply that breastfeeding could not be re¬
lied upon to prevent pregnancy.
Advice Given Post.nat.ally
Between 56% and 84% of women remembered a dis¬
cussion with a midwife on the postnatal ward. Al-











(years) 28.6 30.9 27.5 24.2
Age range
(years) 19-41 18—42 17-40 17-37
Married/
cohabiting 48 47 39 17
Single, living
alone 2 3 1 17
First child 22 24 9 12*
Second child 21 20 9 15
>Two children 7 6 3 7
'Two women put their babies up for adoption.
most 50% of the women in each group had something
negative to say about this discussion. The most com¬
mon comment was that the discussion was ap¬
proached as a necessary routine and sometimes un¬
dertaken with apparent reluctance. Discussion often
took place as the mother and baby were being dis¬
charged from the ward and was part of the check list
of topics to be covered at discharge, one woman said
that a list was actually checked off. A total of 39
women (23 of them in group B) described the discus¬
sion as "unhelpful."
Although midwives were the most likely profes¬
sionals to raise the issue of infant feeding in relation
to contraception—in group A 38% did so compared
with only 4% of GPs—their repertoire of advice to
women choosing to breastfeed appeared limited to
progestogen-only pills (POP) or condoms. The contra¬
ceptive effects of breastfeeding were universally de¬
nied.
Doctors gave little advice on the postnatal wards.
Only 8% of women in group B and 6% in Group D
remembered talking to a doctor. Again, most of the
comments about the quality of advice were negative.
Around 50% of women in each group left the hos¬
pital with supplies of a method except women in
Group D, only 12 (35%) of whom were given supplies
(all condoms).
Most women in group D were unable to recall
whether or not contraception had been discussed
during a home visit; however, between 20% (group
C) and 58% (group A) of women could remember
the topic of contraception being discussed during a
home visit by the GP, midwife or health visitor. Al¬
most without exception, midwives and health visi¬
tors raised the issue only to advise discussion with
the GP.
Although the majority of women recalled discus¬
sion with the general practitioner—usually at the for¬
mal postnatal check six weeks after delivery—five in
group A, four in group B and six in group C were
adamant that they received no advice from the GP at
anytime despite being seen in the doctor's office.
Some women chose not to attend a post-natal con¬
sultation. One in Group A and ten in Group D (29%)
did not see their GP for a postnatal check. Two
woman were already pregnant when they did attend
(late) for consultation.
Twenty three-women in group C (almost 50%) and
eight in group B were in some way dissatisfied with
the discussion, seven of them claiming not to have
been able to understand what was said. The common¬
est criticism of the GPs related to the lack of discus¬
sion about methods other than oral contraception or
condoms. In both groups A and B, 46% of women
started oral contraception postnatally while 32%
Contraception
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(group A) and 42% (group B| said they would use con¬
doms.
Most women discussed contraception with at least
two people, the commonest combination being the
midwife on the postnatal ward and the GP. Almost
hall the women recalled discussions with at least
three professionals and one woman in group C dis¬
cussed her contraceptive plans with seven. In con¬
trast, one woman in the same group claimed that she
had never discussed contraception with anyone.
Only 2 of the 174 women were offered written in¬
formation about contraceptive methods although a
number commented that they would have liked
some.
There were differences between the four groups of
women in the source of advice. Women who had
short inter-birth intervals were the least likely to-
have discussed contraception with a doctor on the
postnatal ward and most likely to have missed out on,
or avoided, discussion during the postnatal check.
There was no statistically significant pattern of dif¬
ferences between women who had not conceived
within one year and those with short interbirth inter¬
vals who had decided to continue with the pregnancy,
but women who opted for abortion were significantly
less likely to have discussed contraception with a
hospital midwife or doctor or with their GP (p<0.05).
There were also significant differences in contra¬
ceptive behaviour at the time of conception (Table 2|.
Women in group C were less likely to have planned
their pregnancy and significantly more likely (p<0.05)
to have used no method of contraception than women
in group A of B. Women in group C were least likely
to have experienced failure of a method of contracep¬
tion. More than half the women with short inter-
pregnancy intervals who opted for abortion (group D)
had used no method of contraception at the time of
conception (p<0.01).
Discussion
Despite the subject being raised by at least two pro¬
fessionals, many women found that they received
Table 2. Circumstances surrounding conception,- women
after childbirth
Group A Group B Group C Group D







*60% of women in group D had planned the previous pregnancy,- in all cases
the index pregnancy was unplanned.
64 62 55 ON O
16 24 30 56
20 14 6 44
little advice about postpartum contraception and a
substantial minority complained that the advice they
were given was limited. Only two out of 174 women
volunteered a memory of a lengthy helpful discus¬
sion, one with a midwife and one with a GP.
The postnatal ward is an inappropriate setting for
contraceptive counselling. Mothers are discharged
home after only three or four days and during their
stay are anxious to establish infant feeding and to
learn to care for the new baby. Midwives are good at
these aspects of postnatal care but receive only lim¬
ited training in family planning. For example, there
appears to be a universal belief among midwives that
breastfeeding docs not prevent pregnancy despite nu¬
merous studies demonstrating that it does and a fairly
recent consensus statement2 reporting a 98% success
rate for the contraceptive effects of lactational arnen-
orrhoea. Contraception—indeed sex—is probably the
last thing on a new mother's mind and to approach it
as part of a routine check list at discharge is almost
certainly a waste of time. Obstetricians very rarely, if
ever, raise the topic of contraception in the antenatal
clinic and once delivered, unless they are unwell,
mothers are unlikely to see anyone except the most
junior member of the medical staff who usually has a
limited knowledge of contraception. Indeed, obstetri¬
cians have very little interest in postpartum contra¬
ception at all. In a recent review of the puerperium
circulated to all fellows and members of the Royal
College of Obstetricians and Gynaecologists3 as the
basis for a self-learning exercise, contraception was
not mentioned although breast problems and depres¬
sion (areas in which they might be thought to have
less interest and expertise) were.
The onus currently falls on the GP. However, dis¬
cussion is often delayed until the postnatal check
which classically takes place at six weeks, at least
two weeks after the recommended time for starting
contraception. Despite many opportunities for doing
so the GP rarely raises the topic of contraception dur¬
ing the pregnancy although it Iras been demonstrated
that this is a useful strategy.4
Fair and Horsefall,5 in a review of postnatal care in
77 training practices in South East Scotland (where
the current study was undertaken!, found that 100%
of GPs discussed contraception at the postnatal con¬
sultation. Our study confirms that GPs rarely fail to
discuss contraception at the postnatal check but sug¬
gests that a proportion of women find the discussion
limited or perfunctory. At least two surveys of pa¬
tients' experiences of postnatal care, one in Hertford¬
shire6 and one in Grampian,7 have suggested that
many women are dissatisfied with the quality of post¬
natal care. While neither survey highlights the issue
143
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of postpartum contraception, this would seem to be
an area that needs attention.
In the United Kingdom, at least 30% of deliveries
result from unplanned pregnancies8 and substantial
numbers of pregnancies end in induced abortion. Less
than 70% of women in each of the groups we studied
had actually planned to conceive. In addition, contra¬
ceptive failures accounted for a significant number of
pregnancies and it is widely recognised that it is more
often the user and not the method that fails. Many
women in this study were using condoms—one of the
less reliable methods of contraception—while very
few used the more effective long-acting methods such
as the IUD or depo-Provera.
We were unable to demonstrate in this study a sta¬
tistically significant relationship between short inter-
pregnancy intervals and poor contraceptive advice;
nevertheless, there are suggestions that women who
do conceive again after a short time are more likely to
default from their postnatal checks and arc likely to
be young and unmarried. These high risk patients
could be targeted by health care providers for more
intensive discussions about family planning in its
broadest sense. The antenatal and postnatal periods
could offer an opportuinity to discuss not only the
appropriateness of the chosen method of contracep¬
tion but also its correct use.
Maternity care with its frequent exposure to health
professionals offers a golden opportunity to discuss
contraception at length. The topic should be raised
antenatally when couples are not distracted by a new
baby and when they have time to consider all the
options. Moreover, it should be raised by someone
who knows what they are talking about.
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Abstract
In response lo [lie concept that a good postpartum program should begin prenatally, this sludy was designed to determine whether the
provision of expert contraceptive counseling during the antenatal period would have an impact on contraceptive uptake, patterns of
contraceptive usage, and pregnancy rates during the first year after childbirth. Over SIX) women attending antenatal clinics in each of three
centers (Edinburgh, Scotland; Shanghai, People's Republic of China; Cape Town, South Africa) were randomized to receive expert
contraceptive advice (participants, n = 771) or the standard advice routinely given in that setting (controls, n = 866). Follow-up was by
postal or interviewer-administered questionnaires at 16 and 52 weeks after childbirth. There were no significant differences in the prevalence
of contraceplive use at one year (over 79% in all centers) between participants and controls. In Edinburgh, participants were more likely
to undergo sterilization (p < 0.01) than controls, otherwise there were no differences among Edinburgh, Shanghai, or Cape Town in either
the methods of contraception chosen or in the methods used over lime. Contraceptive counseling delivered antenatally appeared to have no
impact on the pregnancy rate during the first year after childbirth. In Shanghai, over 11% of women in both groups underwent termination
of pregnancy in the year of follow-up. In conclusion, although women in all centers said they found the opportunity to discuss contraception
amenatally was useful, it had very little effect on contraceptive use or on subsequent pregnancy rates. ©2002 Elsevier Science Inc. All
rights reserved.
Keywords: Contraception; Postpartum; Anlcnalul counseling
I. Introduction
Family planning providers have traditionally regarded
the postpartum peritxl as an opportunity for introducing and
promoting contraception, in many developing countries
special programs for the delivery of postpartum family
planning services have been in existence since the 1960s
111. In the UK, family doctors are paid to undertake a
"postnatal check" for all postpartum women six weeks after
childbirth, and almost all discuss contraception at thai con¬
sultation |2], A similar situation exists in Cape Town where
women are seen during the first week postpartum and then
referred for a later check to the local family planning clinic,
in Shanghai, the emphasis is on antenatal care and there is
no postnatal check.
a The three centers in this study arc part of the Contraceptive Devel¬
opment Network, which is funded by the Medical Research Council and
the Department for International Development (G9523250).
* Corresponding author. Tel.: +44-131-332-7941; fax: +44-131-332-
2931.
E-mail address: a.ghisicr@ed.ac.uk (A.E. Glasicr).
Contraception—indeed sex—is probably the last thing
on a new mother's mind during the first few days after
delivery, yet leaving the discussion until laler in the post¬
partum period may mean missing the opportunity alto¬
gether. Most women, even in the least developed countries,
have some contact witii health providers during their preg¬
nancy, and yet the opportunity of giving advice about con¬
traception during the antenatal period is often neglected. In
a study of 174 women delivered at a large Scottish teaching
hospital [2], only 4% discussed contraception antenatally,
and advice given by a variety of health professionals after
childbirth was often fell by the women to be inappropriate
and insensitively timed.
in Cape Town, efforts are made in die antenatal clinics lo
raise awareness of postpartum contraception, usually in the
form of group sessions led by the family planning advisors
or clinic sisters. In Shanghai, all expectant mothers do
attend antenatal courses, but the details given abotil contra¬
ceplive options available to them postpartum is limited.
In response to the concept that a good postpartum pro¬
gram should begin prenatally, we designed a study to de¬
termine whether the provision of expert contraceptive coun-
0010-7824/02/$ - sec front matter © 2002 Elsevier Science Inc. All rights reserved.
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seling during the antenatal period would have an impact on
contraceptive uptake, patterns of use, and pregnancy rates
during die first year after childbirth. The study was under¬
taken by the Contraceptive Development Network in two
developing countries, the People's Republic of China
(Shanghai) and South Africa (Cape Town), and one devel¬
oped country, Scotland (Edinburgh).
2. Participants and methods
In Edinburgh and Shanghai, women were recruited from
a single large maternity hospital in each city. In Cape Town,
recruitment was from three maternity obstetric units (MOU)
outside the city in Guguletu, Mitchell's Plain, and Retreat,
run by midwives providing a community-based antenatal
and delivery service linked to secondary and tertiary hos¬
pitals. Recruitment started in the three centers between
February and August 1997. In Edinburgh and Cape Town
antenatal clinic sessions were randomized on a weekly basis
(and on a daily basis in Shanghai) so that a single session
contributed either all participants or all controls. Specialist
(e.g.. diabetic) antenatal clinics were excluded from the
study.
Women were recruited into the study when they were
between 24 and 36 weeks gestation. In Edinburgh, all
women with appointments for a clinic randomized to pro¬
vide controls received a letter informing them that, after
childbirth, they would be sent a questionnaire designed to
seek their views about certain aspects of their care. A study
number was allocated when the letter was sent, thus a
woman became a "control" simply by virtue of having an
appointment for the antenatal clinic regardless of whether
site attended or not. All women with appointments for a
clinic randomized to contribute participants were sent, a
letter advising them that at an antenatal clinic appointment
that took place between 24 and 36 weeks of pregnancy, they
would have the opportunity to discuss plans for postpartum
contraception with a specialist nurse. Women actively de¬
clining the offer were asked to return a "tear-off slip," and
37 women (14.5%) did so. In Shanghai and Cape Town
women were recruited in person when they attended the
antenatal clinic session, and a study number was allocated at
that time. Sixty-three women refused to participate in Cape
Town, and there were no refusals in Shanghai. Only demo¬
graphic details and contact information were collected from
control women, whereas participants received formal indi¬
vidual contraceptive counseling. In all centers, counseling
was undertaken by a trained family planning nurse. Ante¬
natal advice consultations for the participant group lasted up
to 20 min -and were tailored to the anticipated contraceptive
needs of each individual woman who was then given ap¬
propriate written information to take home.
hi all three cases, women allocated to the control group
received the standard local care with regard to contraceptive
advice. In Edinburgh contraception is not formally dis¬
cussed at all during the antenatal period. Women are asked
by a midwife about plans for contraception just before being
discharged home with the new baby and, if appropriate, a
limited supply of contraception (i.e., three condoms, one
packet of contraceptive pills) is provided. Contraception is
further discussed with the general practitioner at the routine
postnatal check at around six weeks postpartum. In Shang¬
hai postpartum contraception is discussed briefly during the
group antenatal classes. Postpartum contraception may be
discussed before discharge from the postnatal wards, but
supplies of contraception are not usually given. Further
advice may or may not be given thereafter by health care
providers during the postpartum period. In Cape Town
postpartum contraception is discussed during antenatal
group sessions. Contraceptive advice is again given by the
midwives or family planning advisors following delivery,
and most women are offered Depo Provera before being
discharged from hospital unless the patient has decided to
have tubal ligation. During the postpartum period, nursing
sisters at the baby clinics will inquire about contraception
and advise when necessary.
All women were contacted at 16 weeks and 1 year after
childbirth. In Edinburgh both questionnaires were sent by
post, whereas in Shanghai a telephone interview was con¬
ducted at 16 weeks, and a questionnaire was sent by post at
52 weeks. Because many women in Cape Town were func¬
tionally illiterate and living in informal housing with unre¬
liable mail deliveries, contact was made by telephone or
personal visit, and the information was collected by inter¬
viewer-administered questionnaire. At 16 weeks, the ques¬
tionnaire included demographic data; reproductive history;
contraceptive use before the index pregnancy; plans for
future pregnancies and contraception; details about who
gave advice about postpartum contraception; and, for par¬
ticipants only, whether the expert family planning advice
received at the antenatal clinic was found to be helpful. At
one year after childbirth, women were asked for details of
contraceptive use: currently and during the past year (using
a monthly calendar), plans for future childbcaring, and de¬
tails of any pregnancies that had occurred since the index
child was born.
In all centers, up to three further attempts were made to
contact nonresponders (by letter, telephone, or attempted
visit) before follow-up was abandoned.
2.1 Statistical analysis
By estimating a 10% pregnancy rate at one year after
childbirth, it was calculated that a sample size of 600 par¬
ticipants and 600 controls would be required to detect a
significant difference at the 5% level if antenatal counseling
reduced the pregnancy rate to 5%. Anticipating a drop-out
rate of up to 25% at one year, it was decided to recruit a total
of 1500 women, 500 in each center, equally divided be¬
tween controls and participants.
The two groups were compared by t-tests for quantitative
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Characteristics of the two study groups as derived from the 16-week questionnaire; figures arc shown as mean ± SD or %
Edinburgh Shanghai Cape Town
Participants Controls Participants Controls Participants Controls
Questionnaire 171(67) 214(62) 254 (98) 263 (99) 192(75) 197 (78)
returned (%)
Age (years) 30 ± 6 31 ±5 28 ± 4 28 ± 4 25 ± 5 25 ± 6
Number of children 1.8 ± 1 1.7 i 1 I 1 1.9 ± 0.9 1.9 ± i.;
Marital status (%)
Married 75 74 100 100 51 49
Cohabiting 19 20 0 0 8 7
Single* 6 6 0 0 41 44
Partner's age (years) 35 ± 11 35 ± 11 31 ± 4 32 ± 4 28 ± 6 29 ± 7
Smoking, (%)
Never 57 56 99.6 100 58 50
Past 21 29 0.4 0 1 3
Now 22 14 0 0 41 47
Years education 14 i 3 14 ± 3 13 ± 2 13 ± 2 10 ± 2 10 ± 2
Index pregnancy
Planned, (%) 73 77 84 89 76 71
Unplanned, (%) 27 23
' 16 11 24 29
Last contraception, %
Oral 44 48 2 4 24 22
Injectable 1 4 0 0 39 43
1UD 2 1 0 0 1 2
Condom 42 37 35 31 1 1
None 5 5 43 50 35 33
Other 6 4 18 15 0 0
* A few women in Cape Town recorded "other" but because no details of partner were recorded they have been classified as single.
outcomes and chi-squaied tests for categorized outcomes,
using Yates' correction where appropriate.
3. Results
lu all centers, delivery details were checked before first
contact was made at 16 weeks after childbirth, and women
who had experienced severe pregnancy complications (in¬
cluding stillbirth or neonatal death) were discontinued from
die study. In addition, those who ultimately did not deliver
at the study site were discontinued from the study, with the
exception of Cape Town where participants continued to be
followed-up if they had been referred to a secondary or
tertiary hospital for delivery. A total of 506 women were
recruited in Cape Town and 537 in Shanghai. In Edinburgh,
many more women were allocated to the control group
(simply by having an appointment for antenatal care) than to
the participant group because the latter had to actually
attend the antenatal clinic before being allocated a study
number. In this center. 255 women (participants) received
expert family planning advice at an antenatal clinic visit,
whereas 349 women (controls) received a letter informing
them that they would receive a questionnaire at some time
after they had gone home from hospital.
Response rates for the 16-week follow-up, together with
demographic details of the respondents, are shown in Table
1. There were no significant differences within any of the
centers between participants and controls with respect to
loss to follow-up. However, there were large differences
between centers, with response rates varying from 62% in
Edinburgh to 99% in Shanghai. There were some minor
demographic differences between the three MOUs from
which women were recruited in Cape Town (e.g., differ¬
ences in the prevalence of smoking, past contraception,
unemployment), but because the number of women in each
MOU was relatively small, they were considered as a single
group. Overall, there were no significant differences within
any center between participants and controls in the demo¬
graphic characteristics studied, although obviously the char¬
acteristics of the cohort of women varied considerably be¬
tween centers.
Although the choice of main method of contraception at
16 weeks postpartum differed greatly between centers (Ta¬
ble 2), there were no significant differences between partic¬
ipants and controls, with one exception: in Edinburgh, sig¬
nificantly more women who had received antenatal family
planning advice had been or were planning to be sterilized
(20 women, 11.8%) compared with controls (6 women,
2.8%), p < 0.01.
When asked about contraceptive advice received, 90-
100% of participants in Edinburgh and Shanghai could
recall receiving advice during the antenatal period, com¬
pared with only 12% and 13% of controls, respectively
(Table 3). In Edinburgh and Shanghai, 67% and 90%, re¬
spectively, of the participants said they found the opporlu-
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Table 2
Mode of delivery and method of contraception being used at 16 weeks; figures are shown as numbei• (%>
Edinburgh Shanghai Cape Town
Participants Controls Participants Controls Participants Controls
Questionnaire returned 171(67) 214(62) 0©'o-.tV.r-t 263 (99) 192 (75) 197 (78)
Delivery
Normal 117 (68) 139(65) 116(46) 133(50) 170 (S9) 166(84)
PorccpsA'cntouxc 22(13) 37(18) 19(7) 17(7) M3)— 7(4)
Caesarean 32(19) 38(18) 119 (47) 113(43) 17(9) 24(12)
Current contraception
Oral 60 (35) 78(36) 3(1) 1 (0.4) 18(9) 16(8)
Condom 72 (42) 99 (46) 112 (44) 114(43) 0 0
Injectable 8(5) 4(2) 0 0 158(83) 155 (79)
IUD 5 (3) 5(2) 7(3) 8(3) 0 0
NRVWitlulrawa! 2(1) 3 (!) 9 (3.5) 7 (2.7) 0 0
Oilier 1 (1) 4(2) 4(1.5) 8(3) 0 0
Nothing/No plan 3(2) 3(1) 76 (30) 70(26) 2(1) 4(2)
Nothing/No info 10(6) 12(6) 0 0 5 (3) 9(5)
Nothing/planning 0 1(0) 0 0 0 0
pregnancy
Breast feeding 0 3(1) 39(15) 52(20) 0 0
Sterilisation 6(3) 1 (0) 0 0 8 (4) 13(7)
Combination 3 (2) 2(1) 4 (2) 2 (0.8) 0 0
Fertility treatment 0 1 (0) 0 0 0 0
Pregnant 0 0 0 0 2(1) 4(2)
nity to discuss contraception during pregnancy helpful. In
Edinburgh 23% of women, and in Shanghai just two indi¬
vidual women, did not lind the advice helpful, whereas the
remainder of the respondents were unsure. In Cape Town,
surprisingly, only 36% of the women in the intervention
group could remember receiving advice anlenatally, no dif¬
ferent than the figure for the control group. Only in Edin¬
burgh did the .majority of women receive additional contra¬
ceptive advice after childbirth, and most of them discussed
contraception on at least two more occasions: in hospital
and with their general practitioner. In Shanghai few women,
and in Cape Town hardly any, discussed contraception once
they had had their baby.
The response rale to the questionnaire administered at
one year postpartum once again varied between centers but
not between participants mid controls (Table 4). There were
no differences in patterns of contraceptive use between
participants and controls in tiny of the centers. In Shanghai,
21% and 23% of participants and controls, respectively,
used "other" methods, which for both groups included nat¬
ural methods (12%) and natural methods plus condoms
(6%). In Edinburgh, the significant difference in women
choosing sterilization noted at 16 weeks postpartum had
disappeared.
Table 5 shows that 8 participants (6%) and 19 controls
(10%) in Edinburgh were pregnant (3 and 9 pregnancies,
respectively, were planned) or had been pregnant and cither
spontaneously aborted (2 participants and 5 controls) or had
an abortion (2 participants and 1 control). In Shanghai, 29
participants (12%) and 27 controls (11%) had an unplanned
pregnancy during the first year after childbirth, and all had
the pregnancy terminated. One of these women had been
using an intrauterine device (IUD), the rest were using
condoms, natural methods, or no method. In Cape Town,
there were three pregnancies in the participant group (2%;
two were planned) and seven pregnancies in the control
Tabic .1







p 0.006; **« p < 0.001.
Cape Town
Participants Controls
Antenatal 143(90) 27(12)*** 254 (100) 35 (13)*** 69 (36) 56(28)
Postnatal (bosp) 106 (63) 149 (69) 17(7) 13(5) 5 (3) 18(9)*'
Postnatal (home) 105 (63) 154(71) 63 (25) 47(18) 4(2) 4(2)
6-week, check. 33(19) 43 (20) 28(12) 28(11) 1 (1) 8(4}
Nn advice recalled 1 (1) 8(4) 0 160 (61)*** 116(62) 121(64)
Table 4
Patterns of contraceptive use at one year after childbirth; figures arc shown in number (%)
Edinburgh Shanghai Cape Town
Participants Controls Participants Controls Participants Controls
Questionnaire returned 140 (55) 184 (53) 246 (95) 249 (94) 201 (79) 192 (76)
Using contraception 116(83) 146(79) 221 (90) 216(87) 175 (87) 162(84)
Oral 48 (37) 62(39) 5(2) 6 (2) 23(12) 24(13)
Condom 43 (33) 60(37) 127 (52) 100(40) 2(1) 0
injectable 4 (3) 2(1) 0 0 136(68) 124(65)
IUD 2(2) 6 (4) 38(15) 54 (22) 0 0
Other 6 (5) 9(6) 51(21) 55 (23) 0 0
Nothing 2(2) 10) 25(10) 33(13) 26(13) 30(16)
Planning pregnancy 13(10) 13(8) 0 0 2 1
Sterilization 13 00) 7(4) 0 0 13(7) 14(7)
group (4%; one planned). Two of the women in the control
group had a spontaneous abortion. There were no significant
differences in the number of pregnancies between the par¬
ticipant and the control groups in any of the centers (95% CI
for the difference in pregnancy rates between (he partici¬
pants and controls were: —10.6% to +1.7%, —4.7% to
+ 6.6%, and —6.0% to +1.2% in Edinburgh, Shanghai, and
Cape Town, respectively). Furthermore, there were no sig¬
nificant differences in pregnancy rates between participants
and controls when all centers were combined (x2 = 0.8).
Surprisingly, pregnancy rates at one year did not differ
significantly between women who did or did not intend to
have more children, either in Edinburgh or Cape Town (not
relevant in Shanghai), nor did the counseled participants
show a significantly greater tendency than controls to differ
in pregnancy rates according to childbearing intention. Con¬
traceptive practice at one year, however, did differ accord¬
ing to childbearing intention in Edinburgh and Cape Town,
primarily because all sterilized women belonged to the
group not intending to have further children, but again the
patterns were similar in the two treatment groups (figures
not shown).
There were no differences between participants and con¬
trols in the patterns of use over the year after childbirth
(Table 6). Neither die number of times contraceptive
method was changed during the first year postpartum, nor
the number of different methods of contraception recorded
on the 12-month contraceptive calendar differed between
the two groups. Ten percent of both participants and con¬
trols used at least three different methods during the year.
When continuation rates of contraception were examined,
there were no significant differences between participants
- and controls,-In Edinburgh, approximately 75% of both the
participant and control groups who were using the com¬
bined oral contraceptive pill at 16 weeks postpartum were
still using this method at 1 year (approximately 60% for
condom usage in both the participant and control groups). In
Cape Town, 76% of participants and 75% of controls con¬
tinued to use injectable methods at 1 year. In Shanghai, 22%
of participants and 21% of controls were using condoms at
16 weeks and continued to do so at 1 year postpartum (for
1UD usage, the figures were 1% and 2%, respectively).
4. Discussion
Although women in all centers said they found the op¬
portunity to discuss contraception antenatally was useful, it
did not make any difference to patterns of contraceptive use
postpartum. There was one small exception; in Edinburgh
more women in the group receiving antenatal advice were
sterilized subsequently by 16 weeks. In Edinburgh, the
family planning nurse routinely discussed sterilization with
women who stated that they planned no further pregnancies,
gave advice about the most appropriate tinting of steriliza¬
tion, and how to arrange it. Sterilization by 16 weeks was
facilitated if the decision was made during the antenatal
period.
Table 5
Pregnancies during Ihe year of follow-up; figures are. shown as number (%•)
Edinburgh Shanghai Cape Town
Participants Controls Participants Controls Participants Controls
Total 8(6) 19(10) 29(12) 27(11) 3(2) 7(4)
Miscarried 2 5 0 0 0 2
Termination of pregnancy (TOP) 2 1 29 27 0 0
Continuing 2 12 0 0 2 4
Not known 2 1 0 0 1 1
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Edinburgh Shanghai Cape Town Edinburgh Shanghai Cape Town
Par Con Par Con
2 0 7 9
4g At| 1 n
0 0 81 75
4 8 0 0
19 23 0 0
11 15 6 7
0 0 5 6
6 10 0 3
* Par - Participants; Con ~ Controls.
We recognized at the outset of the study that it may be
difficult to demonstrate an influence on contraceptive use in
Edinburgh where the prevalence is already high (89% of
both participants and controls were already using contra-
ceplion at 16 weeks, and 83% and 80%, respectively, at 1
year). We may have introduced bias into the study design in
the Edinburgh center because the participants were given
the opportunity to decline the additional contraceptive coun¬
seling and, hence, were a self-selected group (however, the
number of participants declining advice, 37, was small). It is
quite possible, however, thai women who were less likely to
use contraception (or use it reliably) were also less likely to
return their questionnaires, and it is not possible to deter¬
mine whether the intervention may have had an effect on
this subgroup. In a study of the quality of postpartum advice
in Edinburgh |2], women who were young, unmarried, and
defaulted from their 6-week postnatal check were more
likely to become pregnant again in the first year after child¬
birth. An analysis of 147 women in the Edinburgh center
who returned neither the 16-weck nor [lie 1-year question¬
naire showed them to be significantly younger (p < 0.001)
and significantly more likely to live in an area of socioeco¬
nomic deprivation (p < 0.001) than women who responded
to both questionnaires. However, there was no difference in
parity at the lime of recruitment.
In the People's Republic of China, the "one child policy"
has been enforced since 1977. As a part of that policy,
contraception promotion is perhaps more effective than in
any other country in the world. One-hundred percent of
women in the subject group remembered receiving contra¬
ceptive advice and yet, surprisingly, over 11% conceived
despite knowing that these pregnancies would have to be
terminated. Our results illustrate that after childbirth women
in Shanghai are using less reliable methods of contracep¬
tion; at 6 months postpartum, over 40% were using con¬
doms and 20% were using "other" methods, which included
natural family planning. This would suggest that either the
need to use a reliable method of contraception was not
stressed sufficiently by the healthcare providers or, alterna-
I.. >!,- t.. ,.li I
case, our results indicate that it would be beneficial for the
policymakers in Shanghai to re-examine their guidelines in
this area.
In Cape Town, a high percentage of women in both the
participant (83%) and control (79%) groups were using
injectable methods of contraception by 16 weeks (68% and
65% for participant and control groups, respectively, at 1
year), and this is reflected in a smaller number of pregnan¬
cies during the year of follow-up in comparison with Ihe
other two centers. Paradoxically, at least 62% of women in
both groups could not recall receiving contraceptive advice
at any time. This could be explained by a misinterpretation
of the word "advice," particularly in the Xhosa dialect in
Cape Town. Even though the questionnaires were translated
and then back-translated independently, the advice given
about postpartum contraception may have been considered
to be routine and not additional information or regarded as
"advice," possibly because of the background level of post¬
partum contraceptive education given antenatally.
In Edinburgh, oral contraceptive pills and condoms were
the main contraceptive methods used at three months with
no change at six months postpartum. The use of condoms is
perhaps surprisingly high, which may reflect a desire by the
client for another pregnancy in the near future. The high
continuation rates of injectable methods at both six months
and one year in Cape Town illustrate efficient and effective
provision of family planning services by MOUs.
Very few studies have examined the effects of antenatal
counseling on postpartum contraception. There is some ev¬
idence that women are more receptive to advice given
antenatally [3] and. indeed, that women may wish to discuss
contraception antenatally and also post hospital discharge
|4J. A study conducted in Egypt on the impact of antenatal
counseling on couples' knowledge and practice of contra¬
ception, followed-up immediately after delivery and three
months later, found that counseling sessions did improve
couples' knowledge and practice in the study group. Fur¬
thermore, involving husbands in family planning counseling
sessions led to joint decisions being made and encouraged
ntnmjo'e nco r<<\ntrir>onfu\n Tr* rt/snlritf o clitrlv lliftl
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investigated the contraceptive choices amongst Nigerian
women attending an antenatal clinic concluded that their
family planning program should be restructured and redi¬
rected to improve services at the community level [6]. A
medical bulletin from International Planned Parenthood
Pederalion (IPPF) suggests that postpartum contraception
should also be included in the training of traditional birth
attendants [7].
There have been many studies published concerning con¬
traceptive counseling during the postnatal period. In Nepal,
a trial of one-to-one counseling of mothers immediately
idler delivery and three months later had no effect on
knowledge of child care or infant health, but produced a
slight improvement in contraceptive uptake (from 14% to
20%) ill six months postpartum [8]. In the UK, it remains a
neglected area by obstetricians, as illustrated in a recent
review by the Royal College of Obstetricians and Gynae¬
cologists of the puerpcrium ant) postnatal care [9], where, it
is significant to note, that postnatal contraception was not
even mentioned in a review that included topics such as
postnatal depression and breast problems. Our study dem¬
onstrated that the majority of women in Scotland had con¬
traceptive advice at least once during the postnatal period,
usually from a midwife or health visitor.
The recently updated Cochrane report [10J regarding the
effectiveness of postpartum education on contraceptive use
concluded that this area has not been evaluated adequately.
The report slated that postpartum education may be effec¬
tive in increasing the short-term use of contraception; how¬
ever, there was limited data on the longer term effect on the
prevention of unplanned pregnancies and also a lack of
randomized controlled trials. The report called for research
to assess "the effectiveness of the minimalist education
provided in more developed countries and the variety of
programs provided in less developed regions." Indeed, the
very basis on which most postpartum education programs
are devised has been questioned [11]—that postpartum
women are motivated to use contraception and that they will
not return to a health center for family planning advice.
Postpartum contraceptive advice should perhaps be mod¬
eled on a study by Huezo and Malhotra [12], based on
family planning clinics in Guatemala, Trinidad, Tobago,
Hong Kong, Jordan, Nepal, and Kenya, where an attempt
was made to look at the various factors that may affect
clients' choice of a contraceptive method and to identify
factors which may affect either the duration of use of the
chosen method or the clinic services. It was found that a
high counseling score did not have a beneficial effect on use
continuation. The authors suggested that very often, because
too much time is spent on issues that are not essential or
relevant to the client, the person providing counseling has to
rush when providing instructions to clients on the proper
and consistent use of the chosen contraceptive method or in
responding to the questions raised by the client.
Studies such as the one described in this article involving
operations research are difficult to perform and monitor. As
the confidence limits demonstrate, in our study we could be
failing to detect a true effect on the pregnancy rate of up to
5-10% in each center even with our large sample sizes, so
we cannot conclude that the antenatal advice given was
totally ineffective. It is possible that although participants
received individualized counseling from a trained family
planning nurse antenatally, the content of the counseling
was not sufficiently different from the standard care to
enhance effective contraceptive use. Perhaps ifother centers
had been chosen, centers where the use of postpartum con¬
traception is less prevalent, contraceptive advice given dur¬
ing the antenatal period may have had a demonstrable ef¬
fect. On the other hand, it is possible that so many other
factors affect contraceptive use that dedicating resources to
any more elaborate (and expensive) programs than the ones
that already exist may be a waste of money and effort.
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In the UK over 90% of couples wishing to avoid preg¬
nancy use a method of contraception. A recent survey of
sexual attitudes and lifestyles (Johnson el nl. 1994) showed
the combined oral contraceptive (COC) pill is the most
commonly used method of contraception with condoms a
close second (Table 31.1).
No method of contraception is completely effective
and failure rates for most reversible methods are strongly
influenced by compliance. Pregnancy rates measured in
clinical trials are often lower tlian those experienced in
day-to-day use, since they are more likely to reflect per¬
fect or near perfect use. The comparative efficacy of
all methods currently available in the UK is shown in
Table 31.2. By convention failure rates are expressed as













Table 31.2 Failure rates ofcontraception
Method failure User failure Cumulative
Method (per 100 women-years) (per 100 women-years) pregnancy rate (%)
Combined pill
POP (25-29 years)


































1.0 at 3 years
2.7 at 5 years
3.2 at 8 years
0.4 at 5 years
1.8 at .1.0 years




Ihe number of pregnancies each year among 100 women
using the method (100 women-years). For long-acting
methods the cumulative pregnancy rate over a period of
time is often more helpful.
COC pill
The COC pill contains both oestrogen — usually ethinyl
oestradiol — and a progestogen. The dose of oestrogen
varies from 20 to 30 pg, most women now using the so-
called 'low dose pills' containing 30-35 pg. Low dose
pills are potentially safer since the cardiovascular risks
of the pill are mainly due to oestrogen. Although the
lowest dose pills currently available (20 pg ethinyl oestra¬
diol) have the same efficacy as 30 pg pills, cycle control is
less effective and breakthrough bleeding more common.
The progestogens used in currently available pills fall
broadly into three groups, first- and second-generation
progestins (e.g. norethindrone and levonorgestrel, respect¬
ively) and the third-generation series including gesto-
dene, desogestrcl and norgestimate. The pill is taken for
21 days followed by a 7-day break (the pill-free interval or
PF1) during which time withdrawal bleeding usually
occurs.
Combined pills are available as monopbasic prepara¬
tions, in which every pill in the packet contains the
same dose of steroids, and triphasic and triphasic pre¬
parations in which the dose of both steroids changes once
or twice during the cycle. Phasic pills were introduced in
order to reduce the total dose of progestogens and in the
belief that a regimen which mimicked the normal cycle
would produce better cycle control. There is no evidence
for better cycle control; failure rates may be higher if
woman get confused about how to cope with missed pills.
Every day (ED) preparations in which a placebo tablet is
taken during the PFI may improve compliance.
Mode of action
The principal mode of action of the combined pill is the
inhibition ofovulation. Oestrogen inhibits pituitary follicle-
stimulating hormone (FST1), suppressing the develop¬
ment of ovarian follicles, while progestogens inhibit the
development of the luteinizing hormone (LH) surge. In
some women, the 7-day PFI is long enough to allow early
follicular growth and 25% have ultrasound evidence of
follicles 10 mm in diameter on the last day of the PFI. If
the PFI is.extended beyond 7 days these follicles will con¬
tinue to develop and, despite restarting the pill, ovulation
may occur. For women who appear to have conceived
as a result of a genuine pill failure and who wish to con¬
tinue using the COC the PFI can be shortened to 4 days to
ensure suppression of follicular development.
Additional contraceptive effects include changes in cer¬
vical mucus characteristics interfering with sperm trans¬
port: a possible alteration in tubal motility; endometrial
atrophy; and impaired uterine receptivity.
Efficacy
bee Table 31.2.
Advantages of the combined pill
The COC confers a number of health benefits. Menstrual
periods are usually lighter, shorter and more regular
during pill use. They also tend to be less painful and
premenstrual symptoms less troublesome. For women
without contraindications to oestrogen the combined
pill is often the first choice of treatment for dysmenor-
rhoea, premenstrual syndrome, menorrhagia and an¬
ovulatory dysfunctional uterine bleeding. In countries
where iron deficiency anaemia is common, COC use
reduces the incidence through decreased menstrual blood
loss.
Other benefits include a decreased incidence of benign
breast lumps, functional ovarian cysts, endometriosis, acne
and possibly pelvic inflammatory disease. There is sub¬
stantial evidence that COC use protects against ovarian
and endometrial cancer. In a review of the published liter¬
ature the World Health Organization (WHO 1992) con¬
cluded that there is a 50% reduction in the risk of epithelial
ovarian cancer after5 years use of the COC. The protective
effect persists for at least 10 years afler pill use stops. The
mechanism for the protective effect is unclear but may be
related to the reduction in the total number of ovulations,
and therefore rupture of the ovarian capsule, experienced
in a lifetime.
In the same WHO meta-analysis COC use was sim¬
ilarly shown to reduce the risk of endometrial cancer
with an effect strongly related to the duration of use. The
risk is reduced by 20% after .1 year and by about 50%
after 4 years. The protective effect seems to be sus¬
tained for perhaps as long as 15 years after stopping
the pill.
Contraindications
The absolute contraindications to the COC are listed in
Table 31.3.
Relative contraindications include the presence of seri¬
ous, or multiple, risk factors for arterial disease — family
history; diabetes mellitus; smoking; increasing age; obes¬
ity; and migraine. Hyperprolactinaemia is also a con¬





Tabic 3X.3 Absolute contraindications to the COC pill
lschaemic hear! disease including cardiomyopathy
Most types ol valvular heart disease
Arterial thrombosis
yenous thrombosis or known predisposition to thrombosis
Past cerebral haemorrhage and current transient isehaemic attacks
Vascular malformations of the brain
|>u linonary hypertension
Hyperlipidaemia
Focal and crescendo migraine and migraine requiring ergotamine
treatment
Active liver disease, recurrent cholestatic jaundice and




History of serious condition known to be affected by steroids, e.g.
trophoblastic disease
Pregnancy
Undiagnosed genital tract bleeding
Oestrogen-dependent neoplasms, e.g. breast cancer
Risks and side-effects
MINOR SIDE-EFFHCTS
The recent publication of the 25 year follow-up of woman
using the COC. (Beral ct at. 1999) concluded that ten years
or more after COC use ceases mortality is similar among
pilot users and that of newer users
Contraceptive steroids are metabolized by the liver and
affect the metabolism of carbohydrates, lipids, plasma
proteins, amino acids, vitamins and clotting factors. The
combined pill has an effect on almost every system in the
body. Most side-effects are minor and include weight gain,
fluid retention, headache, nausea and vomiting, chloasma,
mood change, loss of libido, mastalgia, breast enlargement
and greasy skin. Many improve within 3-6 months of
starting the pill but side-effects often lead to discontinua¬
tion. It is worth trying a different dose of oestrogen or type
of progestogen if time alone does not solve the problem.
SERIOUS S1 D E - E F V liCT S
Serious side-effects involve mainly the cardiovascular
system and the pill affects both the venous and arterial
circulation. In both cases the increased risk appears to be
related to.an increased thrombotic tendency. Alterations
in clotting factors create a tendency to hypercoagulability
which is partly balanced by an increase in fibrinolysis. The
adverse effect on clotting is related to the dose of oestro¬
gen and lower dose pills are associated with a reduced
risk compared with pills containing 50 |ig of oestrogen.
Venous disease
Women who take the combined pill have an increased
risk of venous thromboembolism (VTE) compared with
non-users — the relative risk is 4.5 among European
women. The risk is unaffected by age, smoking or dura¬
tion of pill use but is higher in obese women (body mass
index > 25kg/m2) and possibly among women with a
history of pregnancy-induced hypertension (Pill). Four
studies published in 1995 and 1996 (McPherscin 1996)
demonstrated a differential risk of VTE depending on the
type of progestogen in tire pill. Combined pills containing
either gestodene or desogestrel were shown to have a
roughly twofold increased risk of VTE when compared
with first- or second-generation combined pills. The effect
may result from the balance between oestrogens and
the newer less androgenic progestins which antagonize
oestrogens less. (There may alternatively or additionally
be a direct effect of progestins on clotting mechanisms
although there is no good evidence for this.)
The publication of these studies led to widespread pub¬
licity and in the UK, Germany and Norway restrictions
were placed on the use of pills containing gestodene or
desogestrel. These restrictions were removed in the UK in
1999 but woman should be informed about the different
risks associated with pills containing third generation
progestins.
The risk of venous thrombosis returns to normal by
3 months after stopping the pill.
Arterial disease
Arterial disease among pill users is much less common
but more serious. It is related to age and the risk is
strongly influenced by smoking.
1 Women who do not smoke, have hypertension or dia¬
betes are at 110 increased risk of myocardial infarction if
they use the COC, regardless of age. The risk is increased
by hypertension (X3) and by smoking (xio) (WHO 1998).
The risk of myocardial infarction was thought theor¬
etically lo be reduced among users of third-generation
progestin-containing pills since these are associated with
more cardioprotective lipid profiles (increased concen-
tractions of high density lipoproteins in particular) and
may also have an increased tendency to fibrinolysis. These
effects too are probably related to the less androgenic and
effectively more oestrogenic nature of the pills. Although
preliminary epidemiological data have suggested a reduc¬
tion in the incidence of myocardial infarction among
users of third-compared with second-generation pills, the
difference is not statistically different.
2 In woman who do not smoke or have hypertension, the
risk of ischaemic stroke is increased by 1.5 fold among
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current users of the COC. The risk 0/ hemorrhagic stroke
is not increased. Smoking and hypertension significantly
increase the risks of both types of stroke. The incidence of
haemorrhagic stroke increases with age and current use of
the COC may magnify this effect.
In the RCGP study (Beral el at. 1999) the relative risk of
dying from cerebrovascular disease was 1.9 among cur"
rent and recent users (within ten years) compared with
newer users.
3 Most women have a small but non-significant rise in
both systolic and diastolic blood pressure when they start
the pill. Approximately 1-3% become clinically hypertens¬
ive and the incidence increases with age. I'll 1 does not
predispose to hypertension during pill use.
4 The COC is also contraindicated in migraine which is
or may be associated with transient cerebral ischaemia.'
This includes crescendo migraine and focal migraine
with asymmetric symptoms. Symmetrical blurring of
vision, generalized flashing lights or photophobia asso¬
ciated with unilateral headache are not features which
are regarded as absolute contraindications. It is import¬
ant therefore to take a detailed history before refusing
to prescribe the COC for someone with a history of
'migraine'.
Malignant disease
Breast cancer. Published data on the pill and breast cancer
are difficult to interpret because pill formulations and
patterns of reproduction (particularly age at first preg¬
nancy) have changed with time. WHO (1992) concluded
that while there appears to be no overall association
between oral contraceptive use and the risk of breast can¬
cer there is a weak association between pill use and breast
cancer diagnosed before the age of 36 years and possibly
up to the age of 45 years. I111996 the Collaborative Group
on Hormonal Factors in Breast Cancer (1996) reported a
meta-analysis of 54 studies involving over 53 000 women
with breast cancer and 100 000 control subjects. The meta¬
analysis is thought to include 90% of the published data.
The group concluded that use of the COC was associ¬
ated with a small increase in breast cancer and that the
increased risk persisted for loyears after stopping the pill.
The relative risk for current users was 1.24, for 1-4 years
after stopping 1.16 and for 5-9 years after stopping 1.07.
After 10 years the relative risk was the same as that of non-
users. Although the relative risk was higher for women
who started the pill at a young age (because breast cancer
is rare in this age group) there was little added effect
from the duration of use, dose or type of hormone. Ever-
users were significantly less likely (relative risk 0.88) to
have metastatic disease even if they had stopped the pill
more than xo years earlier. It has been suggested that
starting to use the pill may accelerate the appearance of
breast cancer in susceptible women. Alternatively, women
using the pill might have their tumours diagnosed earlier
although it is difficult to explain why a tendency to earlier
diagnosis would persist for years after stopping. A bio¬
logical effect of combined hormonal contraceptiorrTs"stiIl
a possibility.
Cervical cancer. Data on the risk of cervical cancer
among pill users is also difficult to interpret since barrier
methods confer some protection and cervical cancer is
often regarded as a sexually transmitted disease. More
than 3 years of pill use may be associated with a small
increase in the risk of squamous carcinoma of the cervix
but pill users are a captive population for cervical screen¬
ing. Recent evidence has suggested an increased risk of
adenocarcinoma among long-term users but this is a rare
tumour. In the RCGP study (Beral et al. 1999) the relative
risks of dying from cervical cancer was 2.5 among current
and recent (within 10 years) users.
Liver cancer. Benign hepatic adenoma is a rare con¬
sequence of COC use.
PRACTICAL PRESCRIBING
Women should be carefully instructed how to use the
pill and what to do when pills arc forgotten (Fig. 31.1).
Woman with a strong FIT of VTE may be scanned for
inherited thrombophilia. Many women choose or are
advised to have a break from using the pill for a few
months. While most cardiovascular risks decline when
the pill is stopped they recur as soon as it is started again
and unplanned pregnancies commonly occur during such
breaks. Most women who stop the pill regain normal
fertility within 3 months. Secondary, so-called postpill
amenorrhoea is almost always the result of abnormalities
present before the pill was started (such as polycystic
ovarian syndrome) but regular COC-induced withdrawal
bleeds mask these conditions. There is no evidence of any
adverse effect on the fetus as a result of previous pill use,
and there are no teratogenic effects reported.
Progestogen only contraception
Progestogen only contraception was introduced to avoid
the side-effects of oestrogen. Although much loss com¬
monly used than combined hormonal contraception it is
available in a wide variety of systems including oral, im¬
plants, long-acting injectables and more recently hormone-
releasing intrauterine devices (IUDs).
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Just take the delayed pill now,
and further pills as usual
Take the most recently delayed pill
now. Discard any earlier missed
pills. Use extra precautions (condom,
for instance) for the next 7 days
Fig. 31.1. Instructions for missed pills.
What to do if the patient has forgotten to
take pills at the right time.
When you have finished the
pack, leave the usual 7.day
break before starting the next
pack
7 or more pills
How many pills are left in the pack
after the most recently delayed pill?
Fewer than 7 pills
When you have finished the pack,
start the next pack next day, without
a break
MECHANISM OF ACTION
All methods have a number of mechanisms of action.
Given in high doses, e.g. injectables, progestogens inhibit
ovulation. In low doses ovulation may be inhibited, often
inconsistently, depending on the individual response. By
all routes of administration progestogens affect cervical
mucus reducing sperm penetrability and transport and all
have an effect on the endometrium which probably com¬
promises implantation.
SIDE-EFFECTS
All low dose progestogen only methods are associated
with a high incidence of irregular vaginal bleeding. This
is due in part to their effect on ovarian function. In the
normal cycle ovulation determines regularity. Inconsist¬
ent ovulation and fluctuating endogenous oestrogen pro¬
duction (rom irregular follicle growth leads lo irregular
bleeding. There is evidence to suggest that progestogen
only methods also alter the vasculature of the endomet¬
rium increasing the chance of bleeding.
ORAL. PROGESTOGEN-ONLY METHODS
A number of different progestogens are available although
as yet there are no preparations marketed containing the
third-generation progestogens. The progestogen-only or
mini-pill (POP) is available in daily doses of between 30
and 75 |rg and these lead to peak concentrations of around
2.5 nmol/1. It is important to understand that not only
do these pills not contain oestrogen but the dose of pro¬
gestogen is often considerably lower than that delivered
by the combined pill. A 28-day course of Microval, for
example, exposes the user to a total dose of 0.84 mg of
levonorgestrel compared to 3.15 mg during 21 days use of
Microgynon or 5.25 nig of Ovranette. Thus the mini-pill is
suitable for women with conditions on which the effect
of progestogens on lipids may be detrimental, e.g. mild
hypertension.
Around 50% of women using the POP continue to
ovulate normally and regularly, 10% will experience
complete suppression of ovulation while the rest will
have inconsistent ovulation often with a short luteal
phase or follicular development only. The last group will
experience irregular bleeding and up to 20% of users
discontinue the POP for this reason.
Efficacy
The POP has a higher failure rate than the combined pill
although the difference is less marked in women over the
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Table 31.4 Contraindications to progestogen-only contraception
Absolute
Known or suspected pregnancy—high dose androgenic
progestogens such as NET-EN may carry a very small risk of
masculinization of a female felus
Undiagnosed irregular vaginal bleeding
Any serious side-effect which is not clearly oestrogen-related
Current history ol serious cardiovascular disease
Injectable methods should not be used by women with a bleeding
tendency - including long-term anticoagulation -because of risk
of injection-site haematoma
Rein live
Severe obesity — the efficacy of low dose methods may be reduced
and injectable may exacerbate weight gain
Breast cancer
Molar pregnancy until urine is free of human chorionic
gonadotrophs
Severe hypertension
History of recurrent ovarian cysts — this does not apply to injectable
methods
Chronic liver conditions
age of 30 years (see Table 31.2). The reduced efficacy is due
in part to the fact that many women continue to ovulate
and in part because the POP has a shorter half-life in the
circulation so that missing even just one pill may interfere
with contraceptive efficacy.
Indications ami contraindications
The POP is commonly prescribed for women in whom
oestrogen is absolutely or relatively contraindicated,
e.g. women with cardiovascular risk factors, migraine,
diabetes or mild hypertension. It used to be taught that
because of the increasing endogenous risk of arterial dis¬
ease (myocardial infarction and cerebrovascular accident)
with age, women over the age of 35 years should stop
using the combined pill and switch to the POP. This is no
longer regarded as necessary except for women with risk
factors for arterial disease such as smoking, obesity or
family history. The other large group of POP users is lact-
ating women since oestrogen impairs milk production.
Contraindications which apply to all progestogen only
methods are shown in Table 31.4. In many countries regu¬
latory authorities stilt insist on a long list of contraindica¬
tions which really only apply to the combined pill.
Side-effects
As discussed the commonest cause for discontinuation
is irregular bleeding. The effect of the POP on ovarian
activity also results in a relatively high incidence of func¬
tional ovarian cysts or, more accurately and in many
cases, persistent follicles. It has been estimated that t in 5
women using the POP will have a 'cyst' demonstrable by
ultrasound. Usually these are asymptomatic but can cause
abdominal pain or dyspareunia. Most will disappear with
menstruation and so treatment should be conservative.
Other side-effects include headache, nausea, bloating,
breast tenderness and mood change. These often settle with
Jime but if nol, may be alleviated by changing to a dif¬
ferent progestogen. Oily skin and acne can be a problem
with the more androgenic progestogens — levonorgestrel
and norethisterone. Some studies suggested an increased
risk of ectopic pregnancy. This has not been confirmed
although it is probably true that the POP protects
much more effectively against intrauterine than ectopic
pregnancies.
Ijmg-tenn risks
Because progestogen only methods are much less pre¬
valent than the combined pill, data on long-term risks
are sparse. Depo Provera confers a high degree of pro¬
tection against endometrial carcinoma but although it
should theoretically also protect against ovarian cancer
there are as yet no data to support this. There are no
data on risks of cervical cancer although it is thought that
all hormonal contraception may play a very small pro¬
moting role. The recent meta-analysis on breast cancer
and hormonal contraception (Collaborative Group on
Hormonal Factors in Breast Cancer 1996) included a small
percentage of POP (0.8%) and injectable (1.5%) users. Use
of the POP within the last 5 years was associated witli
a very small but statistically significant increase in relative
risk of breast cancer (1.17%). The same increase among
injectable users was not, however, significant. For both
methods the relative risk had returned to normal 5 years
afterstopping.
INJECTABLE PROGESTOGEN ONLY METHODS
Long-acting injections of norethisterone-enanthate (NET-
EN) and medroxyprogesterone acetate (DMPA) have
been available for many years. Although equally effective
NET-EN is little used in the UK as the preparation has
to be wanned before it can be drawn-up and musl be
given every 8 weeks (at least initially) as compared with
12 weeks for DMPA (Depo Provera).
Depo Provera is given by intramuscular injection,
150 mg every 12 weeks. The high dose inhibits ovulation
and by the end of 1 year of use 80% of women have very
infrequent scanty vaginal bleeding or amenorrhoea. Heavy
prolonged bleeding may be a problem in around 2% of
women, it may be temporarily controlled by the adnunis-
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(ration of oestrogens (simply by adding the combined
pill), but will sometimes necessitate discontinuation.
Side-effects
It may take up to 1 year for normal fertility to return
following cessation of Depo I'rovera and women who
experience bleeding problems while using the method
will often continue to do so for months after stopping.
This delay in fertility makes Depo I'rovera an inappropri¬
ate method for women wishing short-term contraception.
Other side-effects include weight gain and a reduction in
bone mineral density (HMD). Data on the latter are few
and bone loss appears to be reversible. Amenorrhoea vvilh
prolonged use of Depo Provera is associated with hypo-
ocstrogenism. It has been suggested that BMD may be
protected by the addition of oestrogen (e.g. hormone
replacement therapy patch) but there are as yet no data to
support this and moreover many women who use DMI'A
have contraindications to oestrogen. It also adds consider¬
ably to the cost of the method. In the absence of data it may
be sensible to measure BMD in women aged 45 years and
over who have been using the method long term and to
stop treatment if density is reduced, allowing recovery
before the natural menopause.
PROGESTOGEN ONI.Y IMPLANTS
Norplant® is a long-acting hormonal method of contra¬
ception consisting of six flexible capsules releasing a low
dose of levonorgestrel (30-35 Hg/24 h after 18 months).
The capsules are inserted subdermally in the inner aspect
of the upper arm under local anaesthesia. Insertion and
removal are minor surgical procedures which require
specialized training.
Norplant® is highly effective (see Table 31.1). It lasts for
5 years and fertility returns rapidly after removal.
As with all low dose progestogen only methods
menstrual disturbance is the most frequently reported
side-effect, and occurs in nearly all users. Norplant® is ex¬
pensive even if used for 5 years but the additional cost is
justifiable as the lack of need for compliance guarantees
low failure rates. However, long-term use is essential for
cost effectiveness, and careful counselling, particularly
about menstrual irregularities, is vital to avoid premature
discontinuation.
Variable discontinuation rates have been reported
from different countries. In the UK continuation rates of
around 85% at 1 year and 72% after 2 years have been
reported. Menstrual change accounts for more than 50%
of discontinuations.
From the Autumn of 1999, Norplant® will ceased to be
manufactured in the UK. Its place will almost certainly
be taken by Implanon®, a single implant containing 68 mg
etonorgestrel and releasing about 67 g/day over three
years. A disposable inserted, facilitates insertion and, of
course removal of one rod is much easier than removing
six. Efficacy and side-effects are similar to Norplant® and
Implanon® will be available in late 1999.
IUD
lUDs have been used throughout the world for more
than three decades. The Lippes loop and Margulies spiral
made of biologically inert polyethylene — appeared
in the early 1960s. The addition of copper to the device
improved efficacy enabling the development of smaller
lUDs with fewer side-effects, particularly monorrhagia
land dysmenorrhoea. These early copper lUDs — the Cu 7
,a nd T Cu 200 — were superseded by a second generation
pi longer lasting, more effective devices including the
Multiload, Nova T and T Cu 380A which is now regarded
as the 'gold standard' against which other IUDs are evalu¬
ated. These devices contain either more copper wire than
their predecessors, copper sleeves and/or a copper wire
with a silver core.
Hormone-releasing lUDs were developed in the
-1970s but it was not until 1995 that a levonorgestrel-
'
releasing device (Mircna) became available in the UK.
Marketed as an intrauterine system (LNG-1US) to distin¬
guish it from non-medicated devices, the LNG-1US has a
sleeve of levonorgestrel 52 mg around its stem, releasing
20 gg of levonorgestrel per day and lasting for at least
5 years.
New developments aim to reduce side-effects and
expulsion. A smaller, lighter T-shaped copper IUD — the
CU-SAFE 300 which is designed for insertion without a
plunger — moves towards the fundus when the uterus
contracts. A frameless IUD, the Flexigard, Gynaefix or
Cufix consists of six small copper beads threaded onto a
surgical nylon thread the top of which is knotted and
embedded to a depth of 1 cm in the uterine fundus. A T-
shaped copper device with the tip of each arm expanded
into a soft ball is designed to block the ostia to the fallop¬
ian tubes.
Tailess or threadless lUDs may reduce the incidence of
infection. Many have been tried. Preliminary trials of the
Butterfly 1UD, designed to be removed with an IUD hook,
are promising.
EFFICACY
The currently available copper IUDs are similar in
terms of effectiveness (see Table 31.2), side-effects, expul¬






It had been believed that the 1UD worked by prevent¬
ing implantation. For many users this mode of action is
morally unacceptable and much effort has been invested
in attempting to demonstrate that the IUD works at
an earlier stage in the cycle. lUDs stimulate a marked
inflammatory reaction in the uterus. The concentration of
macrophages and leucocytes, prostaglandins and various
enzymes in both uterine and tubal fluid increase signi¬
ficantly. It is thought that these effects are toxic to both
sperm and egg and interfere with sperm transport. The
effects on the endometrium will almost certainly prevent




The effects of the IUD on the endometrium — particularly
the effect on local prostaglandins — tends to cause
increased menstrual bleeding and dysmenorrhoea. In
clinical trials up to 75% of women will discontinue
for these reasons. Bleeding can be both heavier and
more prolonged. In contrast the levonorgestrel-releasing
IUS decreases blood flow. Although the 20pg dose of
levonorgestrel is small it causes endometrial atrophy.
Andersson and Rybo (1990) demonstrated that after 1 year
of use median blood loss fell to xo ml among 19 women
with menorrhagia.
Perforatum
Perforation of the uterus may occur at the time of insertion
although it is often unnoticed. In large clinical trials it
occurs in 1.3 of every 1000 insertions. Routine follow-up
6 weeks after insertion allows most perforations to be
detected. Absent threads should be investigated by ultra¬
sound. At this stage the IUD can often be retrieved laparo-
scopically; left for months local adhesion formation often
necessitates laparotomy. There has been widespread
debate over the routine use of a tenaculum during IUD
insertion. On balance the consensus is that a tenaculum
should be used in order to reduce the risk of perforation.
Expulsioii
Reported expulsion rates vary from less than 1 to over 7
per too women in the first years of use. Expulsion is most
common in the first 3 months of use. Many clinicians
advise that IUD users should regularly check to feel the
1UD strings in order to detect expulsion. In reality this is
often not easy to do and results in more anxiety than it
prevents unrecognized expulsion.
Ectopic pregnancy
Women using an IUD face an 80% reduction in the risk of
jectopic pregnancy compared with women not using con¬
traception; with the LNG-1US the reduction is 90%. lUDs,
however, give less protection against ectopic pregnancy
than either hormonal contraception or barrier methods.
Some 3-20% of pregnancies which occur during IUD use
are ectopic. Since failure is uncommon, the overall risk of
ectopic pregnancy is less than 1.5 per 1000 women-years
of IUD use.
Pelvic infection
The risk of pelvic infection associated with IUD use has
been overestimated. A W1IO meta-analysis (Farley cl at.
1992) suggested that the risk had halved during the 1980s.
Infection is most likely to occur during the 20 days follow¬
ing insertion. Thereafter, the risk of developing infection
is not significantly higher than that among women using
no contraception (< 1.5 per xooo women-years).
The risk can be reduced by using aseptic techniques
during insertion and by restricting the method to women
who do not have multiple partners and whose partners
do not have multiple partners. Marital status and parity
are really irrelevant (in the late 20th Century) to the risk
of pelvic inflammatory disease. In some areas where the
prevalence of sexually transmitted diseases is high, bac¬
teriological and Chlamydia screening are recommended
prior to insertion. The risk of infection varies with the type
of 1UD. The Dalkon Shield (now unavailable) carried the
highest risk and is still the subject of litigation in the USA
despite the overwhelming evidence that IUD use is not
associated with infertility. The LNG-IUS is thought to
have a reduced risk of infection, presumably resulting
from the effect of levonorgestrel on cervical mucus reduc¬
ing the risk of ascending infection.
INSERTION AND REMOVAL
For women who are using effective contraception an
IUD can be inserted at any time in the cycle. Otherwise
insertion should be limited to the first 7 days of the cycle
when, in any case, natural cervical dilatation may reduce
discomfort. Postpartum insertion should be delayed until
8 weeks when the risk of expulsion is lower and, in
women who are lactating, the risk of perforation will have
returned to normal. An 1UD can be inserted immediately
after spontaneous or therapeutic abortion although expul¬
sion rates may be higher in second trimester abortions.
160
Contraception 381
lUDs specifically designed for immediate postpartum
insertion are now available.
Unless pregnancy is desired removal should only be
undertaken in the late luteal phase of the cycle or in the
first 7 days. In menopausal women the fUD should be left
in for 1 year after the last menstrual period. If the 1UD
threads are not visible or snap during removal it may be
possible to remove the device with a specially designed
hook or a pair of artery forceps.
Pelvic actinomycosis can rarely occur in association
with 1UD use. Actinomycosis-like organisms (ALOs) are
sometimes seen 011 smears but if the women is symptom-
free the 1UD can be left and the smear repeated 6-12
months later. If there are symptoms the IUD should be
removed avoiding contamination from the vagina and,
after cutting off the tails which will be contaminated, sent _
for culture.
Emergency contraception
Emergency contraception is defined as any drug or device
used after intercourse to prevent pregnancy. It has been
suggested that millions of unwanted pregnancies could
be prevented if emergency contraceptives were widely
used (Trussel etui. 1996).
COMBINED OESTROGEN AND 1' ItOC liSTOG EN S
The hormonal regimen most widely used for emergency
contraception is a combination of nx) pg ethinyloestradiol
and 0.5 mg levonorgestrel taken twice with the two doses
separated by 12 h (the CEP regimen). A licensed product
(PC4) is available in the UK; however, the same hormones
are available in some brands of COC and these are often
used because they are considerably cheaper. Whether
combined pills containing other progestogens are effect¬
ive when administered in the same manner is not known
but seems likely.
Mcchanfcm ofaction
The mode of action of CEP remains unclear but it
probably works by either inhibiting, or in some way
compromising, ovulation. It has also been suggested that
the CEP regimen may cause luteolysis or interfere with
implantation but there is no good evidence for this and
hormonal emergency contraception may be less effective
after ovulation.
Efficacy
Accurate estimates of efficacy are difficult to make (see
Table 31.2). Many women are unsure of the exact date of
their last menstrual period and most do not ovulate on
exactly the same day each cycle. The majority of women
who use emergency contraception are of unproven fertil¬
ity and many use it after an accident with a condom which
may not in fact have resulted in the leakage of seminal
fluid. The chance of conception following one act of inter¬
course has been calculated to be around 27% per cycle so
that even without emergency contraception over 70% of
women will not conceive.
Side-effects
Nausea (up to 50%) and vomiting (up to 20%) are the main
side-effects of the CEP regimen. Subsequent menses norm¬
ally occurs at the expected time but may be heavier than
usual, and some women experience mastalgia. Although
the method is only used within 72 h of intercourse no one
knows whether it is effective beyond this time limit.
Theoretically u5e of the CEP regimen once every month
exposes a woman to less risk from contraceptive steroids
than if she were to use the COC pill — although it exposes
her to a greater risk of pregnancy.
Eew data arc available on the safety of the CEP regimen,
but recently both the WHO and the International Medical
Advisory Panel of the International Planned Parenthood
Federation have advised that there are no absolute con¬
traindications to its use. There is no evidence that the CEP
regime is teratogenic should it fail to prevent pregnancy.
High dose oestrogens and progestogen alone are also
effective when given postcoitally.
I.E V ON O RGESTE RE L ALONE
Lcvonorgestercl 0.75 mg taken twice with two doses sep¬
arated by 12 hours may be more effective than the CEP
regimen and is certainly better tolerated (WHO 1999).
Iloth levonorgesteral and CEP may well be more effective
if they are taken as soon after intercourse as possible. This
method is likely to become available in the UK in 1999.
The IUD is a highly effective postcoital contraceptive with
failure rates of less than \%. In the UK it is used forup to
5 days after the estimated day of ovulation, which may
be more than 5 days after intercourse. It is particularly
appropriate for women who wish to continue the IUD as a
long-term method of contraception. Most women request¬
ing emergency contraception are, however, young and
nulliparous and it can sometimes be difficult to insert a
device.
Health economists in the UK have estimated that every
pregnancy prevented by the use of hormonal emergency
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contraception saves the National Health Service (ignoring
the cost to society of bringing up a child) at least £500.
Sterilization
Jn Britain almost 50% of couples aged 35-44 years are
using either male or female sterilization as thek method of
contraception. Vasectomy is safer, cheaper and performed
under local anaesthesia and the ability to check for
efficacy is a clear advantage when male is compared with
female sterilization. Male fertility, however, continues
well beyond that of women and these differences should
be discussed during counselling.
hemale sterilization
Female sterilization usually involves blocking both
fallopian tubes by laparotomy, mini-laparolomy, or more
commonly by laparoscopy. Bilateral salpingectomy or
hysterectomy may be preferable when there is coexistent
gynaecological pathology. Mini-laparotonry and laparo¬
scopic sterilization are probably equally safe and effect¬
ive; however, the latter is more common in the UK except
when sterilization is performed immediately postpartum
when the uterus is large, the fallopian tubes are enlarged,
the pelvis very vascular and the risks of laparoscopy
increased. Laparoscopic sterilization accounts for almost
10% of the gynaecological workload in Scotland.
A variety of techniques exist for occluding tire tube and
are shown in Table 31.5. The commonest method of tubal
occlusion during laparotomy and mini-laparotomy is the
I'omeroy technique where a loop of tube, is ligated and
excised.
Efficacy
Failures and complications of sterilization are a common
cause of litigation among gynaecologists. A prospective
study of ioooo women in the USA (Peterson cf at. 1996)
compared the cumulative pregnancy rate 10 years after
sterilization with a variety of different methods. Steriliza¬
tion using unipolar diathermy and postpartum partial
salpingectomy had the lowest failure rates while clips
were associated with the highest. The overall pregnancy
rate after 10 years was 18.5 per 1000 procedures. In this
survey 33% of the pregnancies which occurred (excluding
luteal phase pregnancies) were ectopic and the failure rate
was higher among women sterilized before the age of
28 years. When conception occurs following diathermy up
to 50% may be ectopic compared with only 5% following
occlusion with clips or rings; moreover tubal diathermy
has the potential for serious complications if adjoining
structures (mosl commonly bowel) are burnt. Rings are
Table 31.5 Female sterilization — met hods of tubal occlusion
Ligation Absorbable or non-absorbable sutures
The ends left tree or buried in the broad ligament or
uterine cornu
Electrocautery One or more areas cauterized
Bipolar diathermy allows only the tissue held
between the jaws of the forceps to be cauterized;
the temperature of the lube may reach 400 "C and
if it touches adjacent structures can cause local
burns
Cautery close to the cornua may increase the risk of
ectopic pregnancy
Falope ring A ring of silicone rubber is placed over a loop of
tube with a specially designed applicator
Destroys 2-3 cm of tube
Clips A variety of clips are available; the Hulka-Clemens
clip (stainless steel and a polycarbonate) and the
smaller Fits hie clip (titanium lined with silicone
rubber) are the most commonly used
Much smaller length of tube destroyed
Laser Carbon dioxide laser divides tube very cleanly but
may allow a high incidence of recanalization
The Nd-YAG laser is extremely expensive
Nd-YAG, oeodymium-yttrium, aluminium, garnet.
associated with a higher risk of haemorrhage from or
avulsion of the tube and because of ischaemia of the loop
caught in the ring cause much more postoperative pain.
Clips destroy less length of tube than rings but the higher
failure rate in the USA study may reflect the fact that clip
placement is technically more difficult than the applica¬
tion of rings or diathermy. Filshie clips are easier to apply
than the Hulka-Clemens variety and allow occlusion of
thicker tubes.
A number of chemical agents have been tested for their
ability to occlude the fallopian tube when instilled into
the tube either directly or transcervically via the uterus. A
252 mg quinaerine pellet is inserted into the uterine cav¬
ity through a modified IUD inserter passed through the
cervix. Two insertions, 1 month apart, are made during
the follicular phase of the cycle. Inflammation and fibrosis
causes occlusion of the intramural segment of the tube
and a failure rate of 2.6% after 1 year of follow-up is
reported. The method is cheap and can easily be per¬
formed by non-medical personnel. However, the safety
of quinacrine sterilization has not yet been determined
and morbidity appears to be higher than with surgical
procedures. Although widely used in some parts of Asia,




The timing of female sterilization
It is seldom possible to arrange sterilization for a particu¬
lar lime of the cycle and women should continue using
their current method of contraception until surgery. It is
not necessary to stop the combined pill before sterilization
as the risk of thromboembolic complications is negligible.
If an IUD is in situ it should be removed at the time of ster¬
ilization, unless the operation is being done at mid-cycle
and intercourse has taken place within the previous few
days in which case it can be removed after the next men¬
strual period. The da te of the last menstrual period should
be checked preopcratively. If there is any concern about
pregnancy, a test should be performed. A routine preg¬
nancy test on the day of sterilization significantly reduces
the rate of undetected luteal phase pregnancies. Curettage
at the time of sterilization is not usually performed, and if
it is intended as a means to terminate a luteal phase preg¬
nancy, it might be illegal unless the terms of the Abortion
Act are being met. It may also be ineffective since the blas¬
tocyst may be missed.
Immediate complications
1 The mortality from laparoscopic sterilization is less
than 8 per 100 000 operations. The commonest cause of
death is anaesthesia.
2 Vascular damage or damage to bowel or other internal
organs may occur during the procedure and is usually
recognized at the time of operation.
3 Gas embolism.
4 Thromboembolic disease is rare, but more likely imme¬
diately postpartum.
5 Wound infection.
It has been suggested that the operative complication
rate is higher when sterilization is done at the same tune
as therapulic abortion; however, the rate is less than that
of the two separate procedures added together. There is,
however, a two- to fourfold increase in the failure rate.
Long-term complications
1 Menstrual disorders — a number of studies have
demonstrated an increased incidence of gynaecological
consultation and of hysterectomy following sterilization
despite no demonstrable change in menstrual blood loss.
Changes in menstrual bleeding patterns are inevitable
with advancing age and after stopping the combined pill
and women who have been sterilized may be more likely
to seek or accept hysterectomy as they are no longer cap¬
able of child-bearing.
2 Abdominal pain and dyspareunia may occur after ster¬
ilization and are said to be more common after cautery.
Repeat laparoscopy usually fails to demonstrate any
pathology and the symptoms may sometimes be a mani¬
festation of regret.
3 Psychological and psyehosexual problems are rare and
when they do arise tend to do so in those who have had
problems before sterilization. Many studies report a better
mental state after sterilization.
4 Bowel obstruction front adhesions is a very rare
complication.
VASECTOMY
Division or occlusion of the vas deferens prevents the
passage of sperm. The vas can be ligated or occluded with
clips or by diathermy. Percutaneous injection of scleros¬
ing agents or occlusive substances suclt as silicone are
used in China. It has been claimed that the silicone plug
can be removed and the vasectomy successfully reversed.
No one method seems to be more effective than any other
but the non-scalpel vasectomy (NSV) which obviates the
need for a skin incision is associated with a reduced
incidence of haemorrhage and infection.
The success of the procedure is verified by the absence
%of sperm from two coasecutive samples of ejaculate col¬
lected at least 4 weeks apart. The time taken for azoosper¬
mia to develop depends on the frequency of intercourse;
it is estimated that some 20 ejaculations are required and
seminal fluid should be examined at 12 and 16 weeks post-
vasectomy. Contraception must be continued until con¬
firmation of two negative results has been achieved.
Immediate, complications
1 Scrotal bruising occurs in almost everyone, haematoma
(1-2%) and wound infection (up to 5%) are common
minor complications.
2 Up to 2% of men fail to achieve azoospermia, in which
case the vasectomy needs to be repeated.
3 Even despite two negative seminal fluid samples, fail¬
ure occurs in 1 in 1000 men up to io ybars after operation.
Lite complications
x The development of antisperm antibodies (thought to
be in response to leakage of sperm) occurs in most men
and appears to be harmless unless restoration of fertility is
desired.
2 Small inflammatory granulomas can form at the cut
ends of the vas — presumably also in response to leaked
sperm. Sperm granulomas may be painful and persistent
but can be effectively excised.
3 Concerns have previously been raised linking vasec¬
tomy with an increased risk of atherosclerosis, testicular
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Table 31.6 Points to cover when counselling for sterilization
The reason for the request—some women seek sterilization as a cure
for menstrual dysfunction, sexual problems or abdominal pain
Family size and the possibility of wanting more children
Previous and current contraception and any problems experienced.
Some women request sterilization because they are unable to find
any other acceptable method of contraception; this is not a good
reason for sterilization
The stability of the marriage and the possibility of its breakdown
The quality of the couple's sex life
The procedure
The failure rate
The risks and side-effects
Which partner should be sterilized
Reversibility
The practical arrangements, e.g. continued use of interim
contraception
cancer and other, mainly autoimmune, diseases. Several
large studies have failed to substantiate these concerns
(see Glasier 1995 for review). However, an increased risk
of prostate cancer has also been suggested. Only epidemi¬
ological evidence is available and there seems to be no
biological plausibility for such a link. Nevertheless, fur¬
ther research is required.
Counselling for sterilization
Most couples seeking sterilization have been think¬
ing about the operation for some considerable time.
The initial consultation should cover a number of points
(Table 31.6).
Reversal ofsterilization
Whilst as many as 10% of couples may regret being steril¬
ized, only 1% request reversal. Couples sterilized at a
young age, immediately postpartum or after theraputic
abortion are more likely to experience regret. A change of
partner is the commonest reason for requesting reversal.
More than 1 in 3 marriages end in divorce in the UK and
many couples now do not bother to get married. The
stability of the couple's relationship should be explored
during counselling.
Reversal of female sterilization involves laparotomy,
may fail •(microsurgical techniques are associated with
around 70% success) and carries a significant risk of
ectopic pregnancy (up to 3%). Ovulation should be con¬
firmed and a normal semen analysis obtained before
reversal is undertaken. Reversal of vasectomy is technic¬
ally feasible in many cases with patency rates of almost
90% being reported in some series. Pregnancy rates are
much less (up to 60%) perhaps as a result of the presence
of antisperm antibodies.
Barrier methods
Barrier methods work by preventing the passage of sperm
into the female genital tract.
MALE AND FEMALE CONDOMS
The male condom remains one of the most popular
methods of contraception. It is cheap, widely available
over the counter and with the exception of the occasional
allergic reaction is free from side-effects. Most condoms
are made of latex, the newly available plastic condom
Avanti is said to be less allergic and to confer better sensa¬
tion. It is more robust to storage in extreme temperature
but is very much more expensive. Use of the condom has
increased significantly during the last decade as a result
of concern over the spread of human immunodeficiency
virus.
In addition to protection against sexually transmitted
diseases, use of the condom — and diaphragm — is asso¬
ciated with a significant reduction in cervical disease
including cancer.
Most condoms are lubricated with spermicide. Spermi¬
cides are agents which are capable of destroying sperm
usually incorporated into an inert base which itself may
impair sperm mobility. The commonest is nonoxynol-9,
a non-ionic surfactant which alters sperm surface mem¬
brane permeability causing osmotic changes and death.
Spermicides are also available as creams, jellies,
foaming tablets, pessaries and aerosols (which are very
expensive). Used alone spermicides have a high failure
rate (see Table 31.1) but may be useful for women in the
perimenopause who have intercourse infrequently and
who are at a very low risk of pregnancy.
Laboratory tests indicate that nonoxynol-9 inactiv¬
ates many sexually transmissible pathogens including
Chlamydia, Neisseria gonorrhoeae and HIV. In vivo, however,
when used in high doses (as by sex workers) nonoxynol-9
may in fact facilitate the transmission of HIV.
The female condom is a polyurethane sheath, the open
end of which is attached to a flexible polyurethane ring. A
removable ring inside the condom acts as an introducer
and helps keep the device inside the vagina. It is available
in one size with a non-spermicidal lubricant. It is designed
for single use and is expensive. Failure rate are similar to
those of the male condom (seeTable 31.2). Its primary aim
is to prevent sexually transmitted diseases, but the female
condom has not become popular.
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DIAPHRAGM AND CERVICAL CAP
The diaphragm (and cap) are less popular than male con¬
doms. They must be fitted by a doctor or nurse and do not
confer the same degree of protection from HIV. Selecting
the correct size of diaphragm is similar to selecting the
right size of vaginal ring for the management of vaginal
prolapse. On vaginal examination with the middle finger
in the posterior fornix the point at which the symphysis
pubis abuts the ulnar border of the index finger is noted.
The distance between that point and the tip of the middle
finger is a guide to the appropriate size.
Natural family planning
Few couples in the UK use so-called natural methods
of family planning (NFP) although in some parts of the
world these methods are common. All involve the avoid¬
ance of intercourse during the fertile period of the cycle
(periodic abstinence). Methods differ in the way in which
they recognize the fertile period. The simplest is the
calendar or rhythm method in which the woman calcu¬
lates the fertile period according to the length of her
normal menstrual cycle. The first day of the fertile period
is calculated as being the length of the woman's short¬
est cycle minus 20 days, and the last day of the fertile
period is the longest cycle minus 11 days. If therefore
cycle length varies from 25 to 31 days the potential fertile
period and days when intercourse should be avoided
are days 5-20.
Other approaches use symptoms which reflect fluctuat¬
ing concentrations of circulating oestrogen and proges¬
terone. The mucus or Billings method relies 011 identifying
changes in the quantity and quality of cervical and vaginal
mucus. As circulating oestrogens increase with follicle
growth, the mucus becomes clear and stretchy allowing
the passage of sperm. With ovulation, and in the pres¬
ence of progesterone, mucus becomes opaque, sticky and
much less stretchy or disappears altogether. Intercourse
must stop when fertile-type mucus is identified and
can start again when infertile type mucus is recognized.
Progesterone secretion is also associated with a rise in
basal body temperature (BBT) of about 0.5 "C. The BBT
method is thus able to identify the end of the fertile period.
Other signs/symptoms such as ovulation pain, position of
cervix and degree of dilatation of the cervical os can be
used additionally to help define the fertile period.
A hand-held monitor with disposable urine dip sticks is
available in the UK to facilitate accurate detection of the
fertile phase of the cycle. Persona measures urinary con¬
centrations of oestrone-3-glucuronide and LIT and the
ratio between the two hormones is used to define the start
and the end of the fertile phase. A red light is displayed 011
days when intercourse should be avoided. Failure rates
are said to be around 6%. T he devise is expensive and not
available on the NHS.
Whatever method is used many couples find it diffi¬
cult always to abstain from intercourse during the fertile
period. Failure rates are high (see Table 31.1) and most of
the failures are due to conscious rule breaking. Perfect use
of the mucus method is associated with a failure rate of
only 3.4%. In a multicentre study of the mucus method,
couples who had completed their families had lower fail¬
ure rates than cou pies who were using N FP as a method of
birth spacing.
There is no evidence that pregnancies occurring among
NFP users which are conceived with ageing gametes (i.e.
towards the end of the fertile period) are associated with a
higher risk of congenital malformations.
LACTATIONAL AMKNORRHOEA METHOD
During the 1980s there was an increased interest in
the contraceptive effects of breast-feeding. Breast-feeding
delays the resumption of fertility after childbirth and
the length of the delay is related to the frequency and
duration of breast-feeding episodes and the timing of the
introduction of food other than breast milk. In countries
where prolonged breast-feeding occurs, ovulation and
therefore the risk of pregnancy may be postponed for
more than a year. In 1988 at a consensus conference held
in Bellagio, Italy, scientists pooled clinical and endocrine
data obtained from 13 prospective studies undertaken in
both developed and developing countries. They agreed
that a woman who is fully or nearly fully breast-feeding
and who remains amenorrhoeic has less than a 2% chance
of pregnancy during the first 6 months after childbirth.
The Bellagio guidelines were subsequently formalized
into a method of family planning known as the lacta¬
tional amenorrhoea method (LAM). LAM is actually an
algorithm (Fig. 31.2) which enables a woman to deter¬
mine whether or not her pattern of infant feeding com¬
bined with her pattern of menstruation, confers effective
contraception.
Since 1988 two studies have tested LAM prospectively
and demonstrated failure rates of 0.5-0.6%. In developed
countries where average durations of breast-feeding are
short and where few women practice full or nearly full
breast-feeding beyond 4 months postpartum, I..AM is
unlikely to be a practical method of contraception. In
developing countries, however, where women breast¬
feed for much longer, and where modern methods of
contraception may be expensive and difficult to obtain,
the potential for LAM is much greater.
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Ask the mother or advise her to ask herself
these three questions
1 Have your menses returned ? •- YES
I
NO
2 Are you supplementing reauldriy ? YES
I
NO
3 Is your baby more than six months old ? —YES
NO
There is only a 2% chance of
pregnancy at this time.
When the answer to any of these becomes YES
The mother's chance of pregnancy is increased. For continued
protection advise the mother to begin a complementary
family planning method and to continue to
breastfeed for the child's health.
Fig. 31.2 The algorithm for the use of the lactational amenorrhoea
method (LAM).
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HORMONAL CONTRACEPTION
David T. Baird and Anna F. Glasier
THE discovery that progesterone blocked ovula¬tion and the develo ment of the c mbined oral
contraceptive pill in the 1950s were landmarks in the
control of human fertility.By providing women with
a reliable method of regulating their fertility, the com¬
bined oral contraceptive has played an essential part
in allowing them to participate fully in society. In spite
of initial alarm that it would lead to sexual promis¬
cuity and moral degeneration, the use of hormonal
steroids rapidly became widespread and is the most
popular method of contraception in most Western
countries.3
Methods of Hormonal- Contraception
Hormonal contraceptive steroids are available
mainly as oral preparations, although preparations for
subcutaneous implantation and vaginal insertion have
also been developed4 (Table I). Combined oral con¬
traceptives are a mixture of a synthetic estrogen (e.g.,
ethinyl estradiol) and one of several C-19 steroids with
progestational activity (e.g., norethindrone). Most of
the oral contraceptives contain a fixed dose of estrogen
and progestogen and are taken daily for 21 days, fol¬
lowed by 7 days without treatment. They are highly
effective, with pregnancies occurring at rates of only
0.1 to 1.0 per 100 woman-years of use. They inhibit
ovulation and induce changes in cervical mucus and
the endometrium that make sperm transport and im¬
plantation of the embryo, respectively, unlikely. Tri¬
phasic preparations, which contain both estrogen and
progestogen, but in varying proportions, were intro¬
duced to reduce the total monthly dose of progestogen
and mimic more closely the hormonal changes of the
menstrual cycle. The dose of estrogen had to be in¬
creased, however, to inhibit ovulation reliably. These
preparations ofTcr little if any advantage over the
monophasic pills.
Administering a small dose of progestogen (noreth¬
indrone or levonorgestrel) every day provides an es¬
trogen-free method of contraception. Ovulation is in-
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hibited in only about half the women who take an oral
progestogen; the principal mode of action is their abil¬
ity to make cervical mucus hostile to the transport of
sperm. Contraceptives containing only progestogen
are less effective than combined oral contraceptives
(about 3.0 pregnancies per 100 woman-years), and
their use is often restricted lo women whose fertility is
already reduced, such as older or lactating women and
women in whom a combination oral contraceptive is
contraindicated. Progestogens given intramuscularly
inhibit ovulation more often than those given orally,
but progestogens cause menstrual disturbances as
often as oral preparations (see below).
Although the efficacy of hormonal contraception
was rapidly established, it took longer to determine its
safety and acceptability. In an attempt to reduce side
effects, the doses of estrogen have been reduced by 80
percent or more, and new progestogens and different
routes of administration have been explored. Al¬
though contraceptives given to large numbers of
healthy women must be as safe as possible, any poten¬
tial risk has to be weighed against the hazards associ¬
ated with pregnancy resulting from unprotected inter¬
course or the use of a less effective method.1 In this
review we shall discuss the risks and benefits of hor¬
monal contraception. In addition, we shall highlight
the most recent developments, including alternative
methods of delivery and the use of nonsteroidal com¬
pounds.
Developments in Combined Oral
Contraception
Since the mid-1960s, ethinyl estradiol has been the
estrogen in almost all combined oral contraceptives,
but the amount has progressively decreased; most
preparations now contain 35 /xg or less.5 In contrast,
in response to the desire to minimize the associated
androgenic side effects, the type of synthetic progesto¬
gen has been changed. The newest, so-called third-
generation, progestogens (desogestrel, gestodene, and
norgestimate) are extremely potent in their ability to
inhibit ovulation and transform estrogen-primed en¬
dometrium into secretory endometrium.6 They are
weak antiestrogens, have less androgenic activity than
their predecessors,' and are associated with fewer
changes in lipoprotein metabolism and perhaps carbo¬
hydrate metabolism.6
Risks of Combined Oral Contraceptive
Agents
A 1969 editorial in the Lancet concluded that the
wisdom of administering oral contraceptives to
healthy women for many years should be seriously
questioned.9 Twenty-four years later it is clear that
combined oral contraceptive agents are an extremely
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effective and safe method of contraception, but despite
extensive research the long-term risks are not entirely
clear.
Endometrial and Ovarian Cancar
Combined oral contraceptives have a protective ef¬
fect against both cancer of the ovary and cancer of the
endometrium. In a study of women who took oral
contraceptives containing high doses of estrogen and
progestogen for 2 years, the relative risk of endome¬
trial cancer was reduced to 0.4 and the protective ef¬
fect lasted for at least 15 years.10 Whether prepara¬
tions containing lower amounts of estrogen and
progestogen would provide equivalent protection is
less clear, but if the mechanism of action involves the
maintenance of regular withdrawal bleeding it is un¬
likely that the lower doses would be any less effective.
If lower doses enable women to continue to use one of
these agents well beyond the age of 35 years, the risk
of endometrial cancer may be further reduced.
In studies of ovarian cancer and the use of oral
contraceptives, there was a dose-dependent decrease
in the relative risk to 0.2 after 10 years of use (as
compared with the risk in women who had never used
oral contraceptives)." The effect was still apparent 15
years after discontinuation of the agent. The mecha¬
nism of protection against ovarian cancer is unclear.
Liver Cancar
There is a relatively close correlation between infec¬
tion with hepatitis B virus and cancer of the liver in
areas of the world where this infection is common.12 In
these areas the short-term use of combined oral con¬
traceptives is not associated with an increased risk of
liver cancer, but there are few data on long-term use.
In contrast, in areas where cancer of the liver is un¬
common, an association has been established; whereas
the relative risk was 1.0 for women who had ever used
an oral contraceptive, it was 4.4 for those who had
used one for eight years.12
Cancar ot the Cervix
The relation between the use of oral contraceptives
and cancer of the cervix is not clear. Use is associated
with endocervical hyperplasia, which is probably
caused by the progestogen component and is depend¬
ent on the dose and duration of use." Some reports
have suggested a relation between oral contraceptives
and cervical adenocarcinoma in young women, but
the cancer is uncommon. There is a small increase
in the risk of squamous carcinoma of the cervix (rela¬
tive risk, 1.3 to 1.8) in women who have taken an
oral contraceptive for more than five years.14 How¬
ever, both types of cervical cancer are highly corre¬
lated with sexual activity. After differences in sexual
activity and the use of barrier methods of contra¬
ception (which have a protective effect) have been ac¬
counted for, there appears to be no increase in the risk
of cervical cancer among women who take a combined
oral contraceptive.
Breast Cancar
The case for a relation between oral contraceptives
and breast cancer is more difficult to dismiss. Estrogen
stimulates the growth of breast tissue, and long-term
estrogen administration may reasonably be expected
to be associated with an increased risk of breast can¬
cer, as has been reported in postmenopausal women."
A recent meta-analysis of 16 case-control studies con¬
cluded that there was a 1.3-to-l.8-fold increase in the
risk of breast cancer among women taking estrogen for
more than 10 years.16 Despite numerous studies, the
question of an association between combined oral
contraceptives and breast cancer remains unresolved.
Four large prospective studies, two from the United
Kingdom and two from the United States, and a large
case-control study by the Cancer and Steroid Hor¬
mone Study Group in the United States have had the
most influence on our thinking about this subject."'21
In these studies and a meta-analysis of these and all
other studies in the English and French literature
since 1975,22 there was no increase in the risk of breast
cancer in women who had ever taken an oral contra¬
ceptive. The same was true in the studies reported
after 1980, which were performed among women tak¬
ing the oral contraceptive preparations now in use. A
World Health Organization scientific group recently
concurred with this conclusion and recommended no
change in family-planning policies regarding the use
of oral contraceptives.12 Moreover, there has been no
increase in the incidence of breast cancer attributable
to the use of combined oral contraceptives in the Unit¬
ed Kingdom, according to data from various national
cancer registries.23
The same meta-analysis, however, confirmed the
conclusions of the U.K. National Case-Control Study
Group that the risk of breast cancer before the age of
46 years is increased by 46 percent among women who
have taken a combined oral contraceptive for at least
10 years.18,22 The most relevant period of exposure
may be between menarche and the first full-term preg¬
nane)'. In the United Kingdom the cumulative inci¬
dence of breast cancer is 1 in 500 by the age of
36 years. The increase in risk calculated by the U.K.
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National Case-Control Study Group should therefore
be discernible from cancer-registry data, but it is not.23
Furthermore, there is no relation between dose or du¬
ration of use and the risk of cancer.
Cardiovascular Dlsaasa and Lipid Metabolism
Large cohort studies in the United Kingdom have
examined the relation between cardiovascular disease
and the use of combined oral contraceptives.24,25 In
1977 the Oxford Family Planning Association Contra¬
ceptive Study demonstrated a 4.7-fold increase in the
risk of death from cardiovascular disease among wom¬
en using oral contraceptives containing 50 /rg of estro¬
gen.24 It is clear that a reduction in the dose of estro¬
gen is associated with a reduction in this risk. In the
more recent prospective Nurses' Health Study the rel¬
ative risk of cardiovascular disease among women
who had ever used an oral contraceptive was 0.8.26
The risk of cardiovascular disease associated with the
use of combined oral contraceptives is often attributed -
to changes in serum concentrations of lipoproteins,
and there have been more than 100 published reports
on the effect of combined oral contraceptives on serum
lipoprotein concentrations. In a recent review of six
formulations, Fotherby27 concluded that they did not
change total serum cholesterol concentrations but did
increase triglyceride concentrations, and those con¬
taining some of the newer progestogens also increased
serum levels of high-density lipoprotein cholesterol.
There is no evidence that formulations containing
low doses of estrogen are associated with an increased
risk of cardiovascular disease. The issue of changes in
lipid metabolism associated with the use of oral con¬
traceptives is complex, and the association between
the changes in serum lipoprotein levels and cardiovas¬
cular disease is indirect. Each of the three major lipo¬
protein classes contains a number of discrete subfrac-
tions with different biologic characteristics,28 and
much of the evidence of a link between cardiovascular
disease and serum lipoproteins comes from studies
among men rather than young women. Estrogen may
actually protect against cardiovascular disease by a
direct action on arterial walls that protects them
against atheromatous injury. The reversal of the bene¬
ficial effects of estrogen on lipoprotein metabolism
produced by the addition of a progestogen may there¬
fore be irrelevant. Moreover, the risk of cardiovascu¬
lar disease in premenopausal women probably results
not from premature atherogenesis but from thrombo-
genesis, the risk of which is related to many variables.
These variables include not only serum lipoprotein
concentrations but also changes in procoagulants and
platelet aggregation.29 Combined oral contraceptives
increase the production of factor X, factor II, and
plasminogen; decrease the production of antithrom-
bin; and increase platelet aggregation by reducing the
production of prostacyclin.30 These changes are prob¬
ably important only in women who smoke, since
smoking also increases the risk of thrombogenesis.
We conclude that combined oral contraception is
safe in women who do not have preexisting disease of
the circulatory system. It is almost certainly prefer¬
able that they not smoke. In the absence of other risk
factors, however, the combination of smoking and use
of an oral contraceptive is probably safe.
Glucosa Toleranca
In contrast to estrogens, progestogens impair glu¬
cose tolerance, the degree of impairment depending
on both the type and the dose.31 The impairment is
most marked with nandrolone derivatives and least
with medroxyprogesterone acetate.32 The third-gen¬
eration progestogens have little if any effect on carbo¬
hydrate metabolism. Moreover, most women whose
glucose metabolism becomes abnormal after they be¬
gin taking a combined oral contraceptive have normal
glucose tolerance after six months of use. These agents
may increase insulin requirements in women with dia¬
betes mellitus, however. The need to increase the dose
of insulin may be a small price to pay for reliable
contraception in women in whom pregnancy may be
contraindicated.
Hypertension
Combined oral contraceptives cause hypertension
in about 4 to 5 percent of normotensive women and
increase blood pressure in about 9 to 16 percent of
women with preexisting hypertension.33 The effect is
probably due to both hormones, and the risk is related
to race, family history, obesity, diet, smoking, and the
duration of the use of the oral contraceptive agent.
Some of the third-generation progestogens may have
an antimineralocorticoid effect and thus be associated
with a reduced risk of hypertension.6 Monitoring
blood pressure during the first three months of use
allows one to identify affected women. The effect is
almost always reversible.
Contraception with Procestocen Only
Contraception with progestogen alone is the only
hormonal alternative to the use of a combined oral
contraceptive. It would be expected to have fewer sys¬
temic side effects, but it is associated with a high inci¬
dence of disturbances in menstruation, particularly
irregular bleeding.34"36 There arc no data on the long-
term risks of contraception with progestogen alone.
Only 8 percent of the women in the United Kingdom
who use contraception, and even fewer in the United
States, take an oral progestogen-only contraceptive.3,37
Most are older women or women in whom estrogen is
contraindicated.38 The use of progestogen-only con¬
traception by older women is likely to decrease as the
dose of estrogen in combined oral contraceptives is
reduced and as the recommendation that combined
oral contraceptive agents are safe for nonsmoking
women over the age of 35 years becomes widely ac¬
cepted.39 Progestogen-only contraception is widely
used by breast-feeding women in the United King-
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dom, since progestogen — unlike estrogen — does not
affect lactation.40 In the United States and Australia,
lactation is still considered a contraindication to con¬
traception with progestogen only.
Progestogens have no effect on blood clotting or
platelet aggregation and are the contraceptive of
choice for women with hypertension.41 The older pro¬
gestogens impair glucose tolerance slightly but not
enough to increase insulin requirements in women
with diabetes.32
An injectable progestogen-only agent, depot med¬
roxyprogesterone acetate, has been available in the
United Kingdom and was recently licensed in the
United States (Table 1). It offers an extremely effec¬
tive and safe method of contraception.42 In a large
World Health Organization case-control study in¬
volving 869 women with breast cancer and 11,870 con¬
trols, the relative risk of breast cancer among women
who had ever used depot medroxyprogesterone was
1.2(95 percent confidence interval, 1.0 to 1 .5).43,44 The
results of a small study from New Zealand reporting a
significant loss of bone mineral density in long-term
users were confounded by the effects of smoking.45
New Delivery Systems
Steroidal contraceptives are highly effective, rela¬
tively safe, and easy to use._ Prospects for the develop¬
ment of new nonsteroidal methods seem limited. Re¬
cent research has concentrated on the development of
new systems for delivering steroidal contraceptive
agents. Nonoral routes offer the advantage of avoiding
the first pass through the liver, thereby allowing lower
doses of hormone and reducing metabolic side effects,
and they produce constant serum hormone concentra¬
tions and simplify compliance.40 A subcutaneous im¬
plant of levonorgestre! (Norplant) was approved for
use in the United States in 1990 and will probably be
approved in the United Kingdom this year. The im¬
plant, designed to be replaced after five years, consists
of six nonbiodegradable silicone-rubber capsules con¬
taining a total of 36 mg of levonorgestrel47 that release
an average of 30 fig per day. The rates of failure rise
from 0.04 percent in the first year to 1.1 percent in the
fifth year, and they are higher in obese women.48 This
preparation, like all progeslogen-only agents, is asso¬
ciated with a relatively high incidence of menstrual
irregularities, and after three years 50 percent of wom¬
en have discontinued the method, which requires sur¬
gical removal of the implant.
The progestogen-only vaginal ring releases 20 fig of
levonorgestrel per day and is designed to last for three
months. Its use is associated with failure rates similar
to those'of oral progesiogen-only agents.49 Up to 17
percent of women discontinue use because of men¬
strual irregularities. Much better cycle control is
achieved with the combined-agent vagina! ring, which
releases 15 /eg of ethinyl estradiol and 120 fig of deso-
gestrel per day and is worn for 21 days and removed
for 7 days.50 Failure rates are similar to those of com¬
bined oral contraceptives. Many women find the com¬
bined-agent vaginal ring an acceptable method. The
long-term effect of relatively high doses of gonadal
steroids in close proximity to the vagina and cervix is
not known.
Postcoital Contraception
The concept of a method of contraception that
could be used after intercourse is not new and has
many attractions.51 High-dose estrogen alone (e.g., 25
_mg of diethylstilbestrol per day for five days) or com¬
bined with a progestogen (100 fig of ethinyl estradiol
plus 1 mg of levonorgestrel twice a day at 12-hour
intervals) has been successful in reducing the risk of
pregnancy after unprotected intercourse. The efficacy
of these methods is hard to judge, but postcoital con¬
traception probably reduces the risk of pregnancy by
90 to 95 percent.52 There are no serious side effects,
but the relatively high incidence of vomiting and dis¬
turbed menstrual cycles and the fact that the medica¬
tion must be taken within 72 hours after intercourse
have limited the widespread use of these regimens. A
single 600-mg dose of mifepristone (RU 486) appears
to be highly effective as a postcoital contraceptive."
Even if further studies confirm its efficacy, however,
there remains the problem of how to make it widely
available while at the same time preventing its un¬
authorized use as an abortifacient.
Hormone-Impregnated Intrauterine Devices
Hormone-releasing intrauterine devices have at¬
tracted interest for more than a decade. Initial prob¬
lems with an increased risk of ectopic pregnancy ap¬
pear to have been overcome by increasing the dose of
synthetic progestogen.54 A levonorgestrel-impregnat-
ed intrauterine device that releases 20 fig of levonor¬
gestrel per day has been developed in Scandina¬
via.55 The hormone is placed in a Silastic capsule on a
standard polyethylene frame. The cumulative rate of
pregnancy after seven years of continuous use was
reported to be 1.1 percent. As compared with inert or
copper intrauterine devices, the device reduces men¬
strual blood loss, and many women become amenor-
rheic after the first few months of use.56 Amenorrhea
is due to endometrial atrophy, and possibly to the
destruction of endometrial estrogen receptors. Ovar¬
ian function is only infrequently affected, and 75 per¬
cent of women continue to ovulate.5' Thus, amenor¬
rhea is not accompanied by hypoestrogenism. In
addition to being a very effective contraceptive that
may be attractive to older women with menstrual ir¬
regularities, the progestogen-impregnated intrauter¬
ine device opens new possibilities for the noninvasive
management of menorrhagia regardless of the need
for contraception.58
Male Contraception
The development of reliable methods of hormonal
contraception has proved much more difficult for men
than for women.59 The regulation of spermatogenesis
is poorly understood, and the link between sexual ac-
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livity and hormones is much more direct in men than
in women. Any method that compromises the endo¬
crine activity of the testes must also involve testos¬
terone replacement if sexual function is to be main¬
tained. The use of large amounts of testosterone to
inhibit the secretion of follicle-stimulating hormone
and luteinizing hormone and hence spermatogenesis is
not new.49 As early as 1950 azoospermia wa's achieved
by the daily injection of 25 mg of testosterone pro-
prionate.60 It is necessary to give testosterone by injec¬
tion because orally active synthetic androgens such as
mcthyltestosterone may cause liver damage. More re¬
cently, there has been widespread publicity concern¬
ing the use of testosterone enanthate given weekly
in a dose of 200 mg intramuscularly.6' Complete azoo¬
spermia occurred in only 157 of 271 men, and it was
more likely in Asian men than white men. The combi¬
nation of a potent antagonist of gonadotropin-releas-
ing hormone and testosterone causes azoospermia
more often,62 but the need for daily injections of antag¬
onist makes this regimen impractical. Moreover,
potential changes in clotting factors, enlargement of
the prostate, and changes in serum lipoproteins
raise concern about the long-term risks of such a treat¬
ment.63 The prospects for a male contraceptive seem
as distant as ever.
New Developme.vts
The most promising development in the field of
hormonal contraception has been the use of hormone
agonists and antagonists.63 Agonists of gonadotropin-
releasing hormone bind to gonadotropin-releasing
hormone receptors on the anterior pituitary and, after
initially stimulating the secretion of follicle-stimulat¬
ing hormone and luteinizing hormone, produce a hy-
pogonadotropic state by down-regulation of the recep¬
tors. Ovulation is inhibited during chronic intranasal
administration of the gonadotropin-rcleasing hor¬
mone agonist buserelin." This agent could prove par¬
ticularly useful as a contraceptive during breast-feed¬
ing, since minimal quantities pass into the milk.66 If
ovarian activity is completely suppressed, however,
the deleterious effects of a prolonged hypoestrogenic
state on bone and the cardiovascular system would
probably necessitate some form of replacement thera¬
py. On the other hand, incomplete suppression with
residual ovarian activity might lead to an increased
risk of endometrial hyperplasia and cancer due to the
effects of unopposed estrogen.
Antagonists of progesterone offer considerable po¬
tential for the regulation of fertility.67 Progesterone is
essential for a range of reproductive functions, includ¬
ing the establishment and maintenance of pregnancy.
Antagonists of progesterone, such as mifepristone,
block the action of progesterone on the endometrium
and hence produce an environment hostile to preg¬
nancy. Mifepristone in combination with a prosta¬
glandin is a highly effective and safe method for the
termination of early pregnancy.66 The political contro¬
versy surrounding this agent has overshadowed its po¬
tential use as a contraceptive. When given in the early
luteal phase of the cycle it prevents the development
of a secretory endometrium, and preliminary trials
indicate that it may be effective when given at that
time as a once-a-month contraceptive.69,70
The ability of mifepristone to block ovulation when
given in the follicular phase of the cycle" and to pre¬
vent the development of a secretory endometrium in
the luteal phase probably explains its efficacy as a
postcoital agent." Continuous administration in daily
doses as low as 1 mg inhibits ovulation, suggesting
that it may be a useful alternative to contraception
with progestogen alone.72,73
Conclusions
The current methods of hormonal contraception
have been in clinical use for more than 30 years and
have proved to be highly reliable and acceptable to
many millions of women. Overall, the health benefits
of these methods far outweigh their side effects and
risks. Of the many difficulties involved in the develop¬
ment of new methods of contraception, a major hurdle
is the insistence by some regulatory authorities that
there be absolute proof of long-term safety. This ideal
goal is virtually impossible to achieve; it requires, as
Sir Alan Parkes put it, that "no woman should be kept
on the Pill for 20 years until, in fact, a sufficient num¬
ber of women have been kept on the Pill for 20
years."73 In 1993 the evidence suggests that after risk
factors (e.g., smoking, hypertension, and obesity)
have been identified, combined oral contraceptives are
safe for most women for most of their reproductive
lives. The incidence of cancer of the ovary, uterus,
cervix, and breast is related to the pattern of ovarian
and sexual activity throughout reproductive life, not
to the use of contraceptives.71 It has been proposed
that by manipulating the hormonal environment with
gonadotropin-releasing hormone agonists and estro¬
gen-replacement therapy, it may be possible to pro¬
vide contraception while at the same time reducing the
risk of cancer of the reproductive system and death
from cardiovascular disease.76 Although the practical
problems associated with developing such radical ap¬
proaches are considerable, the principal constraints
on the application of novel methods of hormonal con¬
traception are not likely to be medical or scientific. As
Fathalla states, "For research to have an impact on
reproductive health, it must be backed up by political
commitment and by the provision of adequate re¬
sources for health services."77
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8.1.2 Hormonal contraception
Anna Glasier
Hormonal contraception can conveniently be divided into methods
which contain both oestrogen and progestogen and methods which
contain only progestogen.
transdermal patch and contraceptive vaginal ring. The
presently still under development but is likely to become at T
in 2002. Combined injectables are licensed for use in a nu
countries, mainly in South America, but are not marketed! ;tnthe^
Combined oral contraception
Introduced in the early 1960s, the COC has been used by hund|ff
millions of women worldwide. In the United Kingdom around 35




The combined pill contains oestrogen - almost always
oestradiol, although there is still one brand available in the UK
contains mestranol - and a progestogen. The dose of oestrogifl
from 50 to 20 p.g. Most women now use the so-called 'low oraT
containing 30-35 p,g which arc considered to be safer siiif
cardiovascular risks of the pill are mainly due to oestrogen ajf
some conditions, are dose-dependent. However the lower thef
oestrogen, the higher the chance of poor cycle control, breaktB
bleeding and pregnancy if compliance is poor. f§jH
Progestogens are synthetic compounds which bind to tHe'blj
terone receptor and behave like the natural hormone. The prof
gens used in currently available pills fall broadly into thrcey*
first generation progestins such as norethindrone, second j
norgestrel derivatives such as levonorgestrcl (LNG) and
generation series including gestodene, desogestrcl and norgSffl
Different progestogens have different potencies and ecj(ip
contraceptive effectiveness is achieved at different dostili
generation progestogens are less androgenic than their prcdeces
Most COC brands are taken for 21 days followed by a iey|
break (the pill free interval or PFI) during which time Wn||
bleeding usually occurs.
Combined pills arc available in monophasic preparations I
every pill in the packet contains the same dose of steroidal
and triphasic preparations where the dose of both ocstfo
progestogen changes once or twice during the 21 days. Pn
were introduced in order to reduce the total dose of prog
and in the belief that a regimen which mimicked the norf|
would produce better cycle control and fewer side effecj&a
no evidence for better cycle control and some women fbj
preparations confusing, particularly if they want to run a ny
packets of pills together, for example, to postpone menSjL
Every day (ED) preparations are widely used in the
Australia where, rather than seven days without pills, w0IP?|
inactive tablet. In some countries the inactive tablet coiip
It is thought that ED pills improve compliance since it ,SJ|
remember to take a pill every day rather dian for 21 out c
Combined oestrogen-progestogen
contraception
Combined hormonal contraception is available as an oral preparation
(the combined oral contraceptive pill, COC), an injectable preparation,
Mechanism of action
The combined pill acts mainly by inhibiting ovulation,
inhibits pituitary FSH secretion thereby suppressing a
while the progestogen inhibits the development of tl*e lutein
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.„r«c. In some women the seven-day PFI is long enough to
^ H dcgrnwth and 25 per cent of women will have ultrasound
f follicles of 10 mm in diameter on the last dav of the PFI.
rais prolonged beyond seven days, these follicles will continueW2 , and, despite restarting the pill, ovulation may occur. For
who appear" to have conceived as a result of a genuine pillLai«i
ier than as a result of an error in pill taking) and who wishi .. (rather
I * lie using the pill , the PFI can be shortened to 4 or 5 days
r' c suppression of follicular development. In the USA a pill
F- ently been marketed containing 20 |xg ethinyl ocstradiol and
t des°gestr^ ^or 21 days followed by 5 days of 10 pg ethinyl
^jjol alone and two days of a placebo tablet. This regimen
^sses follicular development (as measured by ultrasound) more
Uktivel/u than a regimen with the standard seven day PFI.
I In addition to inhibiting ovulation, the COC alters the char-'
dstics of cervical mucus, thereby impairing sperm transport.
ti transport may be impaired by an effect on tubal motility. The
also probably alters endometrial factors essential for uterine
ptivity, and causes endometrial atrophy, inhibiting implantation.
Jed perfectly, the COC is almost 100 per cent effective (Table 1).
| failure rate with perfect use is 0.1 per 100 woman years (HWY).
'pnicn who do conceive despite perfect use may metabolize ethinyl
&ogen more rapidly than usual (so called 'fast acetylators')
jjfiby reducing the effective half-life of the pill. In practice, because
eiiprs in pill-taking, the typical failure rate is 0.2-3 per HWY or
jjhiirdepending on the population studied.
■
It? ■
dvantages of the combined pill
addition to being a highly effective method of contraception which
men find very easy to use, the COC confers a number of health
Befits.-Menstrual periods tend to be lighter, shorter and more regular
jag pill use and dysmenorrhoea and pre-menstrual symptoms are
^trptiblcsome. The combined pill is often the first choice of treat-
Pf for Menorrhagia, dysmenorrhoea, pre-menstrual syndrome and
P^ry dysfunctional uterine bleeding. In developing countries
Re, anaemia is common, COC use reduces the incidence of iron
pcyanaemia through decreased menstrual blood loss.
Other benefits include a decreased incidence (during pill use) of
P breast lumps, functional ovarian cysts, endometriosis, possibly
f.Inflammatory disease and certainly acne. f
i ■,«1 Percentage of women experiencing unplanned pregnancy

















There is convincing evidence that the COC protects against both
ovarian and endometrial cancer/25 There is a 50 per cent reduction in
the risk of epithelial ovarian cancer after' five years use of the COC
which persists for at least ten years after pill use stops. The mech¬
anism for the protective effect is unclear but may be related to the
reduction in the total number of ovulations, and therefore rupture of
the ovarian capsule, experienced in a lifetime. In the recent analysis
of 25 years of follow-up of 46 000 women who took part in the Royal
College of General Practitioners' (RCGP) Oral Contraceptive Study(3)
which compared 517 519 years of pill use with 335 998 years of
never-use, the relative risk of death from ovarian cancer was reduced
to 0.2 (confidence interval 0.2-0.8, p = 0.01) among women who
were using the COC or who had stopped less than ten years ago.
The COC similarly reduces the risk of endometrial cancer, with an
effect strongly related to the duration of use. The risk is reduced by
20 per cent after one year and by about 50 per cent after four years.
The protective effect seems to be sustained for perhaps as Jong as
15 years after stopping the pill. In the RCGP study, although the risk
of death from endometrial cancer was reduced among current and
recent (within ten years) users, the extent of the reduction did not
reach statistical significance, probably because the sample size was
inadequate and because the average age of the women at the time the
data were analysed was 49 years, relatively young to develop endo¬
metrial cancer.
Contraindications
The absolute contraindications to the COC are listed in Box 1.
Relative contraindications include the presence of serious, or mul¬
tiple, risk factors for arterial disease - hypertension; family history;
diabetes mellitus; smoking; increasing age; obesity and migraine.
Oestrogen stimulates prolactin production and women with hyper-
prolactinacmia wishing to avoid pregnancy should be advised to use
progestogen-only contraception.
In 1995 the World Health Organisation (WHO) produced an
evidence-based document listing all commonly available methods of
contraception together with criteria for their use in the presence of
certain medical conditions. It was revised in 2000 taking into account
new data published since 1995. This second edition of the so called
Medical Eligibility Criteria*45 is a useful resource for anyone trying to
decide whether a particular method of contraception is appropriate
for an individual with a pre-existing medical condition.
Risks and side effects
The combined pill has an effect on almost every system in the body.
Most side effects are minor. Mood change, weight gain, fluid reten¬
tion, nausea or vomiting, headache, chloasma, loss of libido, mastal-
gia, breast enlargement and greasy skin are all quite common
complaints among pill users. Many improve or disappear within six
months of starting the pill but side effects often lead to discontinua¬
tion of the method. Since some may be alleviated by a different dose
of oestrogen or type of progestogen, it is worth trying another brand
if time alone docs not solve the problem.
Contraceptive steroids are metabolized by the liver and affect the
metabolism of carbohydrates, lipids, plasma proteins, amino acids,
vitamins and clotting factors. The COC slightly increases circulating
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Box 1 Absolute contraindications to the combined oral
contraceptive pill
. : ♦' Iscbaernf&Hi
'
•>,' M vJ
♦ Most types i
concentrations of triglycerides and low-density lipoproteins (LDL).
Combined pills containing levonorgcstrel or norethisterone decrease
concentrations of high-density lipoproteins (HDL), however HDL is
slightly increased among women using third generation pills. It is
likely that none of these metabolic effects are clinically significant
among healthy women.
There is a slight reduction in glucose tolerance and an increase in
plasma insulin concentration in healthy non-diabetic women. The
combined pill does not, however, induce diabetes. Long-term follow-
up of 17 000 users has demonstrated no increase in referrals to
hospital for either type 1 or type 2 diabetes.
Serious side effects involve mainly the cardiovascular system and the
pill affects both the venous and arterial circulation. Arterial disease
(myocardial infarction and cerebrovascular accident) is much less
common but much more serious. Although the aetiology and epidemi¬
ology of venous and arterial disease differ, in both cases the increased
risk appears to be related to an increased thrombotic tendency.
Alterations in clotting factors creates a tendency to hypercoagulability
which is partly balanced by an increase in fibrinolysis. The adverse
effect on clotting is related to the dose of oestrogen and lower dose pills
have been shown in some (but not all) studies to be associated with
a reduced risk compared with pills containing 50 p,g oestrogen.
Venous disease
The COC increases the reJativc risk of venous thr iHf
(VTE) by three to six fold compared with women novll|l§l
COC. The risk is unaffected by smoking, age or durjffr||lff
but is higher in obese women (BMI more than 25 k AIDS
Europe, among women with a history of pregnancy-lo<fl||^
tension. The absolute risk of VTE attributable to COGulpfjra
with age, obesity, recent surgery and some thrombophi^^S
ofVTE returns to normal by three months after stoppiri|;j^^B
A number of studies published in 1996 demonstrateda dlilllll
risk of VTE depending on the type of progestogen in tfjBP
Combined pills which contained either gestodene or desog<|l|l|shown to have a roughly twofold increased risk of VTH
pared with pills containing first or second generatiorti|^^SThere is no evidence to suggest that progestogens have
on clotting mechanisms and tin "
between oestrogens and the less androgenic progestin^
antagonize the oestrogens less than l.NG, thereby rend||j|||
generation pills biologically more oestrogenic. It is not cfSfP™
what mechanism the risk of clot formation is increased jit
has recently been demonstrated that acquired resistance0
protein C (which downregulates iti-viiro thrombin forM
more pronounced during use of a pill containing desogcsS
pared with one containing LNG.(6*
The findings of these studies led to widespread publicfj
1995 and in the UK, Germany and Nonvay restrictions w<
on the use of pills containing gestodene or desogestrel, aft
many countries no action was taken. In the UK the Coj
Safety of Medicines (CSM) recommended that COC pills
gestodene or desogcstrel should be regarded as a pill of seedfli
and not used by women with known risk factors for VTE. $ii
been published since the original studies demonstrating a je
ship between the risk of VTE and the type of progestin vv|r'
lished. Data were reviewed by a group of experts meeting a|
in November 1997. The group concluded17* that 'pills conl
desogcstrel and gestodene probably carry a small risk of VTE,i
that of pills containing levonorgestrel'. In 1999 the CSM remd|
restrictions, advising that although the evidence was still suj
of an increased risk of VTE with pills containing dcsogcsjti
gestodene, that women should be given the facts and all<hj
choose a contraceptive pill which suited them best. Recent
ials*8,9* have advised that caution is still justified.
Although the risk of VTE is increased in women with ^p§|
thrombophilias, widespread screening of women wishing
using the COC is not recommended since the prevalence of troy®
philia is relatively low, the tests are complex and expensive rag
large number of women who use the pill would make it an
costly exercise, ll is however well worth screening women
strong family history of thrombotic disease before starting cont,
hormonal contraception.
Arterial disease -0.
The WHO expert group also reviewed the data on
infarction (MI) and stroke, the conclusions are a useful sunui. .-r-j




$' js uncommon in women of reproductive age.
§»
0 do not
of MI. regardless of age, is not increased among pill users
smoke and do not have cither hypertension or diabetes.
hienIn who have hypertension and who take the COC have an
relative risk of MI of at least three times that of women
Ice the COC and are normotensive.
yng increases the risk of MI by 10 times when compared with
•s who do not smoke.
A, insufficient evidence to allow any conclusion on whether
risk of MI is influenced by the type or dose of progestogen.
jjs women who have no other risk factors can be reassured that
'-ye no increased risk of myocardial infarction. There was no
led risk of mortality due to ischaemic heart disease either
"or after COC use in the report of the RCGP study.'3'
oke
emic and haemorrhagic stroke are both uncommon among
ri of reproductive age.
C'rtsic of ischaemic stroke is increased by about 1.5-fold in women
.take the COC who do not smoke and are not hypertensive,
"ntrast, the risk of haemorrhagic stroke is not increased in
"women until they reach the age of 35, after which the increas-
l|atural risk ofhaemorrhagic stroke is magnified by COCP use.
"tension increases the risk of both ischaemic (by three times)
Hemorrhagic (tenfold) stroke when compared with never users.
; increases the risk of ischaemic and haemorrhagic stroke
-:3) compared with pill users who do not smoke.
:
is insufficient evidence to determine whether the risk of either
pfstroke is influenced by the type or dose of progestogen.
the data are reassuring for haemorrhagic stroke, but the risk
pmic stroke is increased by COC use and once again this is
ed by the findings of the RCGP study'3' in which the relative
death from stroke was significantly increased to 1.9 (confid-
jervals 1.2-3.1, p —0.009). After ten years of stopping the pill
of death from stroke is no longer elevated.
.fine is, listed as one of the relative contraindications to the
cause of the association between migraine anyl cerebrovascular
J. The relative risk of ischaemic (but not haemorrhagic) stroke
sed among women with a personal history of migraine (RR
dence intervals 1.30-9.61) in one large study.'10' Odds ratios
.far for classical migraine (with aura) and simple migraine
Sjt aura). Oral contraceptive use increased the relative risk,
Si.< n°t statistically significantly. Pill users who have a history of
on Hormonal Factors in Breast Cancer"" rt
of 54 studies involving over 53 000 women w
100 000 control subjects. The group concludec
was associated with a small increase in breas
increased risk persisted for ten years after si
relative risk for current users was 1.24; for 1-
1.16 and for 5-9 years after stopping 1.07. Sine
breast cancer increase with age, the effect of this
population terms among older women whe
recently taken the COC (Fig. 1). After ten yet
breast cancer was no longer increased. Althoug
higher for women who started the pill at a youi
cancer is rare in this age group) there was little
duration of use, dose or type of hormone. Sc
ever-users were significantly less likely (RR
which had spread beyond the breast even if the
more than ten years earlier. The RCGP study is
respect since the risk of dying from breast can.
increased among current or recent (within 10 yi
The relationship between the pill and breas
explain because the risk appears to increase soo
not increase with duration of exposure an.
10 years after stopping. It has been suggested t
pill may accelerate the appearance of breast
women, that is late stage promotion of existii
possible that women using the pill have tliei
earlier although it is difficult to explain why
diagnosis would persist for years after stopping
lysis, the risk of breast cancer was also increase<
of both the progestogen only pill (RR 1.17) ai
1.07) although the numbers of women using p;
was small. Since there is no evidence that progt
with the pathogenesis of breast cancer, these fi
argument for increased detection rather than k
breast cancer. Nonetheless, a biological effect o




j® Never took COCs
Es) Used GOCs for 5 years
44 48.7
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Cervical cancer
Data on the risk of cervical cancer among pill users is also difficult to
interpret since barrier methods confer some protection, and the
aetiology of cervical cancer is connected with sexual activity with the
risk related to the number of sexual partners a woman has in her
lifetime. More than five years of pill use may well be associated with
an increase in the risk of squamous carcinoma of the cervix. The
RCGP study reported an increased relative risk of death from cervical
cancer of 2.5 (confidence interval 1.1-1.6, p=0.04) but this increase
disappeared once women had been off the pill for more than ten
years. In the UK, COC users arc a captive population for cervical
screening so that it should be possible to diagnose and treat malig¬
nant disease at an early stage.
Recent evidence has suggested an increased risk of adenocarcin¬
oma among long-term users but this is a rare tumour.
Liver cancer
Benign hepatic adenoma is a rare consequence of COC use. In
countries where hepatocellular carcinoma is rare, this disease may
very rarely be associated with pill use. Among populations where it is
common, such as in the Far East, short-term use of the COC docs not
alter the incidence of hepatocellular carcinoma but data on long-term
use are scarce.
Practical prescribing
A full history should be taken to exclude risk factors which might
contraindicate combined pill use or indicate the need for further
investigation. Blood pressure should be measured and it may be
helpful to record baseline weight. Pills containing gestodene or
desogestrcl are currently contraindicated for overweight women in
the UK. Pelvic examination is not routinely indicated at the first visit
unless there is reason to suspect gynaecological pathology. Women
do not like pelvic examinations and some, particularly the young,
may be deterred from starting or continuing with the method if
examination Is seen as a necessary prerequisite.
Cervical smears should be taken in accordance with national
policy. A baseline breast examination is often recommended in new
users over the age of35 years.
New users should start with a low dose (30-35 p,g) pill. If break¬
through bleeding occurs, it usually settles within the first three
months but if it persists, and after excluding a gynaecological cause,
a higher dose pill or one containing a different type of progestogen
may be tried. Women on long-term cnzyme-inducing drugs (for
example, some anticonvulsants) should use a 50 jxg oestrogen
preparation to ensure best efficacy.
Women should be carefully instructed how to use the pill and
what to do when pills are forgotten (Fig. 2). They should also be
informed that some antibiotics are thought to interfere with the
absorption or metabolism of the pill and thereby jeopardize efficacy.
Although the evidence for this is not very convincing/12* the advice
has become standard and there is insufficient evidence to change
the recommendations. Many women choose or are advised to have
a break from using the pill for a few months. While cardiovascular
Are you more than
12 hours late in taking
one pill?
Are you more than
12 hours late in taking
one pill or more?
YES
Take the delayed at
once and further pills
as usual
Take the last missed pill
. now but leave other missed
pills in the pack. Take
further pills as usual,
use extra precautions e.g.
condoms for the next 7 days
_ Are there 7 or more pills




When you have finished
the pack start the next pack
next day, without a break ."fc'
YES )
When you have finished
the pack, leave the usual 7
day break before starting
the next pack
Fig. 2 Rules for missed pills.
risks decline when the pill is stopped, they recur as soon as it is;ife|i
again and unplanned pregnancies commonly occur during
breaks. Most women who stop the pill regain normal fertility
three months. Secondary, so-called post-pill amenorrhoea is ajjiwf
always the result of abnormalities present before the pill wa^lsuS
(such as polycystic ovarian syndrome) but regular COC$P3§
withdrawal bleeds mask these conditions. There is no evidence'o(|J
adverse effect on the fetus as a result of previous pill use. If conceptwl;
occurs during pill use the risk of teratogenesis is tiny or non-exiSt$||
Combined injectables
Combined oestrogen-progestogen injectable contraceptives arej
with women who like hormonal methods but forget to ta|T.
Cyclofem (medroxyprogesterone acetate 25 mg and oestradiolc
5 mg) and Mesigyna (norethisteronc enanthate 50 mg and <
valerate 5 mg) are given monthly and have a very low pregriatj
(0.5 per HWY). Vaginal bleeding occurs around every 35 da)
discontinuation rates for menstrual irregularity and amenorrhea
half those associated with progestogen only injectables. The ri||§j
side effects are the same as for the combined pill
Combined contraceptive vaginal and
transdermal preparations
Non-oral routes of administration of contraceptive steroids avoi^ ^
first pass through the liver allowing lower doses of horm0||/J^used. Constant circulating hormone concentrations niayre
incidence of minor side effects when compared with oral a^p
tion. Most steroid hormones are well absorbed through th^p
mucosa and soft silastic or polyethylenevinylacetate (E-
have been developed which release a combination of oestyf8.
progestogen and can be worn for three weeks and rem° , j|§
days. Efficacy is as good as that of the combined pill but
179
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remember to insert and remove the ring once each month,
cfll?" "^jjvering 15 p-g ethinyl oestradiol and 120 p.g desogcstrel*13*
A{{fih
e available in the USA and much of Europe in 2001.
# h transdermal preparations of oestrogen and progestogen' Allh°"Sh
bl« been
ivailable for menopausal hormone replacement therapy
time, patches have been slow to enter the contraceptive
&
^ seven day patch delivering 25 fig ethinyl oestradiol and
17-deacetylnorgestimate underwent phase three trials^14* in
^^999 and should become available in 2001.
progestogen only contraception
. „cn 0nly contraception is mucii less commonly used than
bined hormonal contraception. It is however available in a wider
ririity ol systems including pills, implants, long-acting injectables
tad hormone-releasing intrauterine devices (IUDs). New delivery
tems include vaginal rings, patches and a gel preparation.
The mechanism of action of progestogen-only contraceptives
Ipcnds on the dose of steroid administered. High doses - for
^mple, injectables - inhibit ovulation. Low doses inhibit ovulation
inconsistently depending on the individual response. By all
pU|W of administration, progestogens affect both the quantity and
jjiyskal characteristics of cervical mucus, reducing sperm penetrab¬
ly and transport. All methods have an effect on the endometrium
bhich probably compromises implantation.
Idvantages and disadvantages
k progestogen-only or mini pill (POP) is usually prescribed for
rcrnen in whom oestrogen is absolutely or relatively contraindicated
for example, women with cardiovascular risk factors, migraine, or
ypcrtension) and for women who are breast-feeding (since ocstro-
eh Impairs milk production). The lack of oestrogen makes progesto-
cn only a much safer hormonal contraceptive but it also has fewer
eallh benefits. For women who like to have amenorrhoea Depo-
rycra (see below) is an attractive method of contraception which is
relatively long acting. Absence of menstruation is of benefit to
omen who suffer from premenstrual syndrome, mcnorrhagia and
^menorrhoea and it is perhaps surprising that Depo-Provera is
rldqm used to manage these problems particularly in women who
Kd contraception. Progestogen-only contraception is also said to
"luce the incidence of pelvic infection, perhaps because the thick-
^ cervical mucus prevents ascending infectiop. Increasingly the
NG-releasing intrauterine system (IUS) (LNG-lUS see below) is
used for the management of menorrhagia and as a means of
divering the progestogen component of hormone replacement
NPT(HRT).
°nti'aindlcations
^indications which apply to progestogen-only methods are
p> lfi Box 2. In many countries regulatory authorities still insist
'th * contra'n^cat'ons which apply to the combined pill
1 ln reality, to progestogen-only methods such as VTE.
Box 2 Contraindications to progestogen-only contraception
♦ Absolute
■ Known or suspected pregnancy - high dose androgenic
progestogens such a$ NET-EN rnay carry a very small
risk of masculinization of a female fetus
■ Undiagnosed irregular vaginal bleeding
• Any serious side effea which is not clearly
oestrogen-related
. Current history of serious cardiovnscular disease
Injectable rnethods should not be used by women
with a bleeding tendency-including long-term
anticoagulation - because of risk of injection-site
.... haematoma . : 1 ■
_
. Relative
. Severe obesity-the efficacy of law dose methods may ■'
% b? reduce^ and Injectable may exacerbate weight gain
' V1 ■ Breast cancer 4, ' < 1 '■
. Molar pregnancy until urine is free of hCG
\ • Severe hypertension k . * * •
•
• History of recurrent ovarian cysts - this does not
|| | appjy to injectable methods
Cj ' « Chronic liver conditions 1 j ' :
Risks and side effects
All low dose progestogen-only methods arc associated with a high
incidence of irregular vaginal bleeding. This is due in part to their
effect on ovarian function. Inconsistent ovulation and fluctuating
endogenous oestrogen production from irregular follicle growth
causes irregular bleeding. Low dose progestogen-only methods also
alter the vasculature of the endometrium perhaps increasing capillary
fragility/15*
The effect of the low dose progestogens on ovarian activity also
results in a relatively high incidence of functional ovarian cysts or,
more accurately, persistent follicles. Some 20 per cent of women
using the POP, LNG-J US and Norplant or Implanon will have one
or more persistent follicles demonstrable by ultrasound. These arc
usually asymptomatic but can cause abdominal pain or dyspareunia.
Most will disappear with menstruation and treatment should
therefore be conservative.
Other side effects include headache, nausea, bloating, breast ten¬
derness and mood change. These often settle with time. If the POP is
being used, minor symptoms may sometimes be helped by changing
to a different progestogen. Oily skin and acne can be a problem with
the more androgenic progestogens - LNG and norethisterone. The
POP is commonly said to be associated with an increased risk of
ectopic pregnancy. Since the failure rate is less than 3 per cent, overall
the incidence of ectopic pregnancy is in fact significantly less than
that among women not using contraception.
In general, progestogens induce fewer metabolic changes than the
combined pill. Effects on lipids are minimal, even with the high dose
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injectable methods. Depo-Provera and NET-EN slightly increase
insulin resistance but the effects are not clinically significant.
also for women with conditions oil which the effect of
on lipids may be detrimental, for example, mild hypertension"'
Long-term risks
There are fewer data on the long-term risks of progestogen only
contraception because the numbers of women using them are
relatively small compared with the combined pill.'16* Since implants
and the progestogen-releasing IUS are both relatively new, data are
even more scarce and it is reasonable to extrapolate from what is
blown about the risks of low dose oral progestogen contraception.
Cardiovascular disease
Since the cardiovascular risks of the combined pill are due to oestro¬
gen it has always been felt that the risks of the POP should be
negligible. This view was confirmed by the publication in 1998 of
a multinational study*17* which demonstrated no statistically signifi¬
cant increase in the risk of acute Ml, stroke or VTE among POP users
or women using Depo-Provera.
Reproductive cancers
As discussed earlier, use of the POP and Depo-Provcra within the last
5 years is associated with a small increase in relative risk of breast
cancer (RR 1.17 and 1.07 respectively). The increase in risk disap¬
pears 5 years after stopping and is only statistically significant for the
POP. The increased risk is likely to be due to increased detection of
tumours rather than to a causative relationship.
There are no data for the effect of the POP on the incidence of
other reproductive cancers such as endometrial or ovarian cancer but
bearing in mind the effect of low dose progestogen on the ovarian
cycle there is unlikely to be a significant effect on malignant disease.
Depo-Provera confers a high degree of protection against endo¬
metrial carcinoma but although it should theoretically also protect
against ovarian cancer there arc as yet no data to support this. There
are also no data on risks of cervical cancer although it is thought that
all hormonal contraception may play a very small promoting role.
Oral progestogen-only contraception
Available preparations
The progestogen-only or mini pill (POP) is available in daily doses of
between 30 and 75 jxg leading to peak concentrations of around
2.5 nmol/1. A number of different progestogens are available includ¬
ing LNG, norcthisterone and ethynodiol diacetate (more than 90 per
cent of which is converted to norethisterooe as the act ive metabolite).
As yet there arc no preparations marketed containing a third
generation progestogen.
Not only do these pills not contain oestrogen, but the dose of
progestogen is often considerably lower than that delivered in the
combined pill. A 28-day course of Microval, for example, exposes the
user to a total dose of 0.84 mg of LNG compared to 3.15 mg during
21 days use of Microgynon or 5.25 mg of Ovranctte. Thus the minipfil
is suitable not only for women with contraindications to oestrogen but
Mechanism of action
*1
Around 50 per cent ofwomen using the POP continue to ovi
menstruate regularly. Ten per cent will experience completeij|j|
sion of follicular development and will have amenorrhp^|
remainder will have inconsistent ovulation, often with a short in,
phase, or follicular development only or both, with the patttl'j
ovarian activity varying from one cycle to the next. This lasted
of women will experience irregular bleeding and up to 20 per cm,
users discontinue the POP for this reason.
Efficacy
Since many women continue to ovulate, the POP has a higher lab
rate than the combined pill (sec Table 1). The POP also has a shjrlt
half-life so that missing even just one pill may interfere with ccsti,
ccptive efficacy. Efficacy tends to increase with age but mayl
reduced by obesity and it is widely recommended that womcitSi
weigh more than 70 kg take two tablets each day.
Practical prescribing
For immediate effectiveness the POP should be started on the
day of die menstrual cycle. It is taken every day and because ofj
shorter half-life the importance of taking the pill at the same lias
each day should be emphasized. If the POP is taken more ihan' jj
late, the rules for missed COC pills should be followed. Siinila||i
has become widespread practice to recommend secondary protecltot
(with a barrier method) in the presence of concurrent antibiotic
orgastro-intestinal upset. 4jJ||
It is not possible to predict the pattern of ovarian actiy(t)|jp
therefore the bleeding pattern) that an individual womai)
expect. If irregular and frequent bleeding is a problem an am
method of contraception should be discussed since bleeding
do not improve with time and nor is the problem relieved
a different progestogen. ®§
Once the POP is stopped normal fertility resumes within/
Injectable progestogen-only methods
Available preparations
Long-acting injections of norethisterone-enanthate (Nbl-JTv-
medroxyprogesterone acetate (DMPA, Depo-Provera) af||
highly effective methods of contraception. NET-EN is rarelyJ||
the UK as the preparation has to be warmed before it can
up into a syringe and it is administered every 8 weeks
initially) as compared with 12 weeks for DMPA (Dcpo-Prove|!
Depo-Provera is given by intramuscular injection, 150
12 weeks.
Side effects
The high dose of progestogen inhibits ovulation and by th||
one year of use 80 per cent of women have either infreq11 ^
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specialized training. Although no longer available in the UK Norplant
has been used by some 60 million women worldwide and is registered
in over 60 countries/235 An implant which uses only two rods
(Norplant 2 or Jadelie) is now licensed in some countries.
Norplant is highly effective (Table 1). It is marketed as a method
which lasts for five years but there are good data demonstrating
efficacy for more than seven years.
Implanon®
Implanon8 is a single rod, 4 mm long and 2 mm in diameter,
containing approximately 68 mg etonogestrel within a EVA mem¬
brane/24,255 Each rod comes individually packed in a sterile dispos¬
able inserter (Fig. 3). Daily release rates are around 67 jig and fall
only very slowly during the life of the implant which is three years.
The dose of progestogen is sufficient to inhibit ovulation in all users
for the durat ion of treatment and this is reflected in both the efficacy
and bleeding patterns. In trials totalling almost 3000 women years of
use, to date there have been no pregnancies reported during the use
of Implanon/265 Since ovulation is inhibited in almost every user
throughout the three years of use amenorrhoea is slightly more
common' among women using Implanon, (21 per cent during
any three-month reference period) compared with women using
Norplant or Jadelle.
Side effects
Minor side effects include weight gain, headache, mood change and
acne. As with all low dose progestogen-only methods menstrual
disturbance is the most frequently reported sidc-effect, and occurs in
nearly all users widi many bleeding irregularly and unpredictably
through three years. Heavy bleeding is uncommon. Many women do
not like the unpredictability of bleeding, and even very light bleeding
is unacceptable if it lasts for days on end. Long-term use is essential for
cost effectiveness, and careful counselling, particularly about men¬
strual irregularities, is vital to avoid premature discontinuation.
Menstrual change accounts for the great majority of discontinuations.
As with the POP, ovarian enlargement due to persistent unrup¬
tured follicles has been noted in some women. The follicles can reach
5-7 cm in diameter but usually regress within 1-2 months. They may
be accompanied by mastalgia and abdominal pain and management
should be conservative.
Most studies demonstrate a slight reduction in circulating trigly¬
cerides^ total cholesterol and LDL concentrations with only a minimal
effect on HDL. No clinically significant changes in clotting factors
have been described and it is likely that the effects of progestogen-only
Fig. 3 Implanon and its disposable inserter.
bleeding or amenorrhoea. Heavy prolonged bleeding may
j,lcm m around 2 per cent of women. The cause is unknown
tig! |eads to discontinuation of the method. Bleeding can be
•°-' ril>' dleviated by the administration of oestrogens (the easiest'# l0 give the combined pill), but it often persists for some
after Depo-Provera is stopped,
gi take up to one year for normal fertility to return following
lion Depo-Provera. Women often complain of 'feeling^ trual' despite continuing amenorrhoea. They can be assured
if^re is no permanent impairment of fertility but this delay
pepo-Provera an inappropriate method for women wishing
toa-term contraception.
Many women wrongly attribute weight gain to the use of hormo-
(' ntraception. Depo-Provera however is associated with weight
■\,w j ^mcn may gain as much as 16 kg after two years of use.
§|lete inhibition of ovulation by Depo-Provera is associated with
flltrogenism and amenorrhoea. Hypo-oestrogenism is associated
llleduction in bone mineral density. Two papers published in the
_j showed that long-term use of DMPA resulted in BMD
w^hich partially recovered after stopping the method/195
ffresponse to the concerns raised, a variety of suggestions were
iaHe-as to how to manage women on long-term DMPA including
Addition of'add-back' oestrogen (for example, an HRT patch).
||g| many women who use DMPA have contraindications to
:pesl«igen and it adds considerably to the cost and complexity of the
IgJ Reassuring data have been published recently. A cross
^jfonal study'205 from the UK of 185 women using Depo-Provera
|orjnore than five years or aroenorrhoeic after one year of use,
;iho$ed only a minimal change in BMD which was thought unlikely
,|o be'of clinical significance. Similarly no significant difference in
demonstrable when past-users are compared with con-
Concerns remain however about the use of DMPA in
^descents who have yet to achieve their peak bone mass. The effect
fpf^ormonal contraception on bone mass is reviewed in a useful
s||§ei|y Meirik (2000)/225
'radical prescribing
efficacy DMPA should be given in the first five days of
illtrual cycle.
,y6«togen-only implants /
?S|J^icontraceptivc implant to become available in the UK was the
'mpl«mt Norplant® which became available in 1993.
pfi!|lg°f Norplant in the UK ceased in 1999 for a number of




P" is a long-acting hormonal method of contraception
J|B of six flexible capsules releasing a low dose of LNG
Bg/24 h after 18 months). The capsules are inserted sub-
iM'-mthe inner aspect of the upper arm under local anaesthesia.
a°d removal are minor surgical procedures which require
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implants on the risks of cardiovascular disease are no different from
those described for the progestogen-only pill.
Long-term (five years) follow-up of over 16 000 women using
Norplant shows no significant excess of any health problems includ¬
ing ectopic pregnancy, cardiovascular disease and neoplasia.*27* Such
long-term safety data are not yet available for Implanon but it seems
unlikely that they would be different. Normal ovulatory cycles return
rapidly after removal ofboth Implanon and Norplant and conception
rates and the outcome of pregnancy following Norplant removal is
no different from that following the use of any other hormonal
method of contraception. As yet there are no data for Implanon.
Progestogen-releasing intrauterine
system
Hormone releasing lUDs were developed in the 1970s but it was not
until 1995 that a LNG-releasing device (Mirena) became available in
the UK. Marketed as an intrauterine system (LNG-IUS) to distin¬
guish it from non-medicated devices the LNG-IUS has a sleeve.of
LNG (52 mg) around its stem (Fig. 4) releasing 20 p.g LNG per day
and lasting for at least 5 years.*28* In the USA an IUS which releases
65 p,g progesterone a day is available. This system is licensed for only
one year.
Mechanism of action
Copper-containing lUDs are thought to have a toxic effect on
gametes (both sperm and eggs) thereby reducing the chance of
successful fertilization. They also stimulate an inflammatory reaction
in the endometrium which will inhibit implantation.*29* The LNG-
IUS probably acts similarly but in addition causes endometrial
atrophy. The dose of LNG is too low to inhibit ovulation in most
women.
Efficacy
The LNG-IUS is more effective than a copper IUD (Table 1) pre¬
sumably because of the additional effects on cervical mucus charac¬
teristics and on endometrial atrophy.
Advantages
Intrauterine devices are long acting methods ofcontraception^
once inserted, can be forgotten about Copper devices are £
cheap. The cost of the LNG-IUS is comparable with the C0C
used for five years.
Copper IUDs increase the duration and quantity of
bleeding in many women and 20 per cent of them will stop v
IUD because of menorrhagia. In contrast the LNG-IUS deci
flow by causing endometrial atrophy. The LNG-IUS is lic<?
xlr«pdf
fIV
Scandinavia, and in the UK, for the treatment of merit)
Fig. 4 Mirena - the levonorgestrel-releasing intrauterine system.
Andersson and Rybo (1990) demonstrated that after one year/
median blood losi fell to 10 ml among 19 women with menon
The LNG-IUS" is said to reduce the risk of pelvic infection
because the progestogen causes thickening of the cervicajf
impeding the passage of infectious agents into the uterine lr
reality the risk of pelvic infection with all IUDs has been'!
emphasized and in women whose lifestyles do not put
increased risk ofsexually transmitted infections, the risk is
In addition to its use as a contraceptive, the LNG-I^fe
licensed (and widely recommended) for the medical manag'"
menorrhagia*31* and the system may also be of value as a '
administration for the progestogen component of postm
HRT. Many women find the side effects of progestogens uijf
and progestogens are only required to oppose the neoplastic e
oestrogen on the endometrium. A very low dose of progestogt
local effects on the endometrium but few systemic side effect
be preferred by many women.
Risks and side effects
The risk of perforation of the uterus (less than 1 per cent) at
of insertion of the LNG-IUS and of expulsion (less than 5 peigl*
probably less than that for copper IUDs because the device i$|'
Many women find that menstrual periods are replaced m
longed light vaginal spotting which may or may not impir
time. Women who have menorrhagia find this quite accept
women who do not have menstrual dysfunction are often «f
with this pattern ofbleeding.
There arc as yet no data on the long term safety of the %
In theory the risks of cardiovascular disease and neoplasia sho^
no different from those of other low dose progestogen contract
The risk ofendometrial cancer may be reduced but it will tSjj
before there are data to support this hypothesis. 1%.-
Practical prescribing
The LNG-IUS is a relatively large device which may be difi
insert in a nulliparous women or in an atrophic uterus
example, prolonged use of the COC or Depo-Provera. lnse^v|fifc
be helped by the use of local anaesthesia or by pre-treatiric£^S
either oral or vaginal misoprostol which has been shown 10
non-pregnant cervix.*32* Insertion should take place durin^Jg
five days of the menstrual cycle and the IUS can be remove
time if pregnancy is desired. Women should be warned--to £4
irregular vaginal spotting at least during the first three
and perhaps for longer. Ten per cent of women will develop .(jsSssg




only vaginal rings have been in development for some
_ are as yet not licensed in any country. Using doses cquiva-
P* ^ose of the POP, side effects, particularly bleeding patterns,
are likely to be similar. The advantage will be in terms of
•T nee since it is likely that rings can be designed to last for at
- f months and can simply be inserted into the vagina and
about.
patches and gels
w Population Council (New York) is presently developing patches
iflj ^or lranst*crma' administration of a non-androgenic
- Nestorone - which is inactive by the oral route.
contraception
^&ncy contraception can be defined as any drug or device which
^'prevent pregnancy after intercourse has taken place. Emergency
l^intracepti°n is useful after unprotected intercourse or withdrawal
ijffiich pccurs too late and for couples who experience and recognize
failure of a barrier method such as a burst condom. It is not usually
Commended when oral contraceptive pills have been forgotten
:'^cc there are established rules for use of a barrier method as
secondary prevention under these circumstances (Fig. 2).
It has been calculated that the widespread use of emergency con¬
traception could prevent substantial numbers of unintended pregnan-
$cs/331 The first method to be described was high dose oestrogen but
jhis approach has largely been abandoned because of a high incidence
Ml^usca and vomiting. From 1984 until 1999 the most widely used
Ihormonal emergency contraceptive - and the only method licensed in
-was a combination of ethinyl oestradiol and LNG (Sobering
In 2000 following a randomized controlled trial by WHO*34*
anstrating similar or superior efficacy and a much better side
profile, LNG alone was licensed for emergency contraception in
iiihe UK, USA and much of Europe. More effective but much less
^convenient to use, the intrauterine contraceptive device prevents up to
|59per cent of pregnancies if used post-coitally.
(.
Combined oestrogen-progestogen
Schering PC4 is a combination of 100 p.g ethinyl oestradiol and
§§tM LNG taken twice with the two doses separated by 12 h. The
tt&Qien's recommended for use within 72 h after intercourse. The
S^; hormones are available in some brands of combined oral
praceptivc pills. It is not known whether COCs containing other
.progestins administered in a similar manner are effective.
gestogen only emergency contraception
alone is an effective post coital agent. Marketed by
Iwjce* ^ea^Karc as LevonelIe-2 it comprises 0.75 mg LNG given
'wi.k.^ ^le two doses separated by 12 h and the first dose givenhlfl 72 h of intercourse.
Recent data suggest that both PC4 and LNG alone may be much
more effective if taken within 24 h and that efficacy falls with time.*35*
Mechanism of action
There is good evidence that Schering PC4*36* and LNG alone*37*
inhibit or delay ovulation in some women some of the time. Unfor¬
tunately they are both probably less likely to do so when a mature
follicle is present in the ovary (and therefore when the risk of
pregnancy is greatest). Although it has been suggested that Schering
PC4 may inhibit implantation the data arc-difficult to interpret and
not very convincing. Recent research*38* has been unable to demon¬
strate any effect of levonorgestrel on the endometrium and it is
possible that either hormonal EC does not work, or works much less
well, if it is used after ovulation has occurred. Since the inconsistent
disruption of ovulation seems insufficient to explain the apparent
efficacy of either Schering PC4 or LNG alone it is possible that other
mechanisms of action (such as the inhibition of sperm transport)
may be involved.*39*
Efficacy
The exact efficacy ofemergency contraception is difficult to calculate.
Most studies include large numbers of young women of unproven
fertility; neither the timing of intercourse nor the date of the last
menstrual period are always accurately recalled; the day of ovulation
may vary by as much as two or diree days each cycle for any indi¬
vidual woman; users are not always honest or accurate about the
number of acts of intercourse that have occurred and unprotected
intercourse often occurs again after emergency contraception has
been used. Using known estimates of the probability ofpregnancy on
different days of the cycle, it is possible to compare the number of
pregnancies that actually occur with the number expected. In this
way it has been calculated that Schering PC4 is between 70 and 80 per
cent effective*'10* however the WHO trial*34* comparing the two
methods (using an intention to treat approach to the analysis of
efficacy) suggested that Schering PC4 prevented less than 60 per cent
of pregnancies while LNG alone prevented over 85 per cent.
Risks and side effects
Nausea (up to 50 per cent) and vomiting (up to 20 per cent) are the
main side effects of Schering POL Both may interfere with compli¬
ance, and vomiting may reduce efficacy if it occurs soon enough
to interfere with absorption of the contraceptive steroids.
Levonorgestrel alone is associated with a much lower incidence of
nausea and vomiting and for this reason has become the method of
choice. With both methods, subsequent menses normally occurs at.
the expected time. There are few data on the safety of the CEP
regimen and none for LNG alone. Although the dose of ethinyl
oestradiol in PC4 is relatively high compared with that in the COC
the exposure is short. Nevertheless many doctors make no distinction
between the known risks of the combined pill and the theoretical
risks of emergency contraception. They worry particularly about
venous thrombosis. A recent case control study demonstrated no
increase in the risk of VTE.*41* Lcvonorgestrel, as discussed above, has
been used for many years in a variety of long-acting methods of
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contraception which are extremely safe. It is unlikely that LNG used
as an EC will have any health risks and since it contains no oestrogen
there are no concerns about VTE. It is probably mainly for this
reason that Levonelle has, after much lobbying by the medical
profession, become available off prescription in the UK. Unfortu¬
nately at £20 it is expensive.
Practical prescribing
Hormonal emergency contraception is safe. 'ITiere are really no
contraindications to its use and the contraindications to the pill
certainly do not apply. When prescribed by a doctor it is common to
take a careful medical history and check the blood pressure. Since it
will not work if a woman is already pregnant, it is as well to exclude
pregnancy by asking about the date (and normality) of the last
menstrual period. It is not necessary to do a pregnancy test or a pelvic
examination unless there is clinical suspicion of pregnancy or patho¬
logy. If there lias been more than one act of unprotected intercourse
in that q'cle pregnancy may have already occurred but emergency
contraception should not be denied as there is no evidence of terato-
genesis. It is perfectly safe to use emergency contraception as often as
it Is required. Since it is only 75-85 per cent effective it is not sensible,
however, to use it as a regular met hod of contraception.
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8.1.3 Premenstrual syndrome
kger Sundstrom and Torbjorn Backstrom
Introduction
jfrdfonstrual syndrome (PMS) or premenstrual dysphoric disorder
jUfPP) is a psychoneuroendocrine disorder. Fluctuations in gonadal
^nhones, psychiatric vulnerability traits and psychosocial factors act
& concert to provoke symptoms in affected women during the luteal
e menstrual cycle. To be able to get a full understanding of
jJMS pr.c has to integrate knowledge from several, clinical disciplines=Mu(|iiig the endocrine, neuroendocrine, psychiatric, and psycho¬
id fields. This review will emphasize aspects gathered from
.^cftin the gynaecological endocrinology and psychiatry fields,
v There is great confusion, and sometimes controversy, among
^fteH and clinicians about what PMS is and what to call it. This is
;|Wdtie to the failure to appreciate that although most women
fSdice mild mood and somatic symptoms premenstrual!/, a
significant number is severely disabled by the disorder.
teg*0*, scient ists in the field of PMS have not agreed on which
"§$°gy to use. The terms PMS and PMDD are used inter-
•Jpply by some researchers. Others claim that there is a distinc-^fwcen PMS and PMDD, where the term PMS should be reserved
somatic symptoms such as breast tenderness, bloating,
&and minor mood changes. However, this presentation will
adhere to the term PMS, as it is more familiar among gynaecologists.
Whenever the term PMS is used in this chapter, the definition will be
according to the criteria stated by the American Psychiatric Associations
Diagnostic and Statistical Manual of Mental Disorders, 4th edition*1'
(DSM-1V) for PMDD.
PMS is a commonly encountered disorder in the western world
and has a substantial impact on several aspects of the daily lives of
women. The disorder is defined by the cyclical recurrence of a cluster
of negative mood symptoms and physical symptoms. Symptoms
develop iinhe tufcat phase of the menstrual ,cyde and remit withinr
a few days after the onset of menstrual bleeding. DSM-IV defines
diagnostic criteria for PMDD, Box 1. To fulfil the criteria for PMS (or
PMDD) a patient needs to present with at least five of the listed
symptoms during the premenstrual week. At least one of these
symptoms must be a mood symptom such as depressed mood,
anxiety, affective lability or irritability. Other symptoms described
Box 1 Summary of PMS criteria
♦ (A) In most menstrual cycles during
;(or mpre) of. the fojlowing symptof
; :most of the time during the last we
began to remit within,a few days afte
^folli.c^r, pbiise'fnd .were absent in






Monthly Focus: Endocrine & Metabolic
New developments in
contraceptive drugs for use by
women
Anna Glasier
Lothian Primary Care NHS That, Enmity Planning cr Well Woman Service & University ofEdinburgh
Department ofObstetrics & Gynaecology 18 Dean Terrace. Edinburgh EH41NL, Scotland. UK
Since the oral contraceptive pill was first marketed in 1959, advances in con¬
traceptive drugs for women have been limited to variations on the theme of
oestrogen in combination with progestogen or progestogen alone. Altera¬
tions to the pill regimen, new progestogens and new delivery systems have
increased choice but while these advances significantly improve acceptability,
side effects and risks remain essentially unchanged. New ideas are in short
supply. Antiprogesterones offer a new approach with a variety of dose regi¬
mens but their development has been seriously hampered by the politics
associated with their abortifacient action. Other hormone antagonists as con¬
traceptives seem a long way off. Immunocontraception is still at a very early
stage. Genes, whose products are uniquely concerned with reproductive
processes, promise new targets but radically new contraceptive drugs for
women appear distant.
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1. Introduction
Throughout time, mankind has taken steps to limit family size. Although the male
condom has been around for thousands of years, modern contraception for use by
women dates only from the 1900s when the intrauterine device (IUD) and cervical
cap were developed. The combined oral contraceptive pill (COC) came onto the
market in 1959, heralding the start of the so-called contraceptive revolution.
In die last four decades, advances in contraceptive drugs have been limited to hor¬
monal methods and specifically to variations 011 the two themes of oestrogen in
combination with progestogen or progestogen alone. The HIV/AIDS epidemic
stimulated research to improve barrier methods ofcontraception. Differently shaped
male condoms made of different materials, condoms for women and modifications
to the design of the diaphragm have almost exhausted the limited potential of bar¬
rier methods for new developments. Much of the research effort in this area is now
concentrated on die development ofvaginal microbicidcs (with or without inherent
spermicidal activity and alone or in combination with existing spermicides) which
will protect against sexually transmitted infections, particularly HIV.
The IUD too has limited scope for improvement. Copper was added to the
inert frame of the IUD in the late 1960s allowing production of a smaller device.
Most clinicians (the author of this article included) and certainly most women, do
not regard copper IUDs as drugs; however, recent advances have focused on its use
as a delivery system for hormones. Odier compounds, such as antihormones and
inhibitors of angiogenesis, represent more exciting potential candidates for intrau¬
terine deliver}'.
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In some developing countries, 'medical methods' of induc¬
ing sterilisation for both women (e.g. using quinacrinc [I j)
and men (e.g. using a preparation of styrene maleic anhydride
dissolved in dimethyl sulphoxide (2]) are used. These advances
have not been considered in this review.
During the two decades following the launch of the pill, a
number of pharmaceutical companies were involved in con¬
traceptive research. Simultaneously, not-for-profit organisa¬
tions such as the Population Council and WHO were actively
working on the development of new methods with the needs
of the developing world predominantly in mind. Since 1980,
the interest of pharmaceutical companies in contraceptive
development has waned 13] for a number of reasons including:
• the high cost of developing new products
• the cost of product liability, particularly in the US
• stringent regulatory requirements with a long and expen¬
sive registration process and a concomitant decrease in pat¬
ent protection
• a dearth of ideas for fundamentally new products
• a hostile political climate, particularly in the US
• competition from the public sector through the provision
of free or low-priced contraceptives in developing countries
• high contraceptive prevalence in developed countries where
pharmaceutical companies make most of their profit
Very recently, even the interest of die not-for-profit organisa¬
tions has dwindled. This is in part due to die commonly held
view that, in the face of die HIV/AIDS epidemic, it borders
on unethical to think ofdeveloping new contraceptives which
do not simultaneously protect against HIV.
2. Mechanism of action of contraception for
women
The control of reproduction in the female is a complex proc¬
ess which is incompletely understood. Gonadotropin-releas-
ing hormone (GnRH) from the hypodiaiamus stimulates the
secretion of lutcinising hormone (LH) and follicle-sdmularing
hormone (FSH) from die anterior pituitary. Stimulation of
the ovary by FSH encourages die development, at the start of
each menstrual cycle, of around 20 follicles. In most cycles
only one follicle reaches maturity, the rest become atretic In
response to rising levels of oestrogen production from the
dominant follicle, a midcycle surge of IJH stimulates ovula¬
tion, releasing die mature egg from the ovary. If sperm are
present, fertilisation usually occurs in the fallopian tube and
the fertilised egg implants in the endometrium, ~ 6 - 8 days
after ovulation. Although the start of pregnancy may be
defined as occurring at any point in this process, in the West¬
ern world most clinicians, scientists and the law, define preg¬
nane)' a$ beginning when implantation occurs.
The interruption of female fertility can potentially be
achieved by interfering widi any one (or more) of these proc¬
esses. Inhibition of ovarian function may be either partial or
complete. 'Hie COC, for example, inhibits both follicular
development and ovulation so there is no egg to be fertilised.
The drawback of this approach is that it is ovulation, followed
by 14 days of progesterone secretion which, unless conception
occurs, determines regular menstruation. In die belief that it
would seem more natural and therefore improve acceptability,
the combined pill was designed in such a way that regular
menses is induced by a seven-day, pill-free interval causing
oestrogen withdrawal bleeding (4). If ovarian activity is com¬
pletely inhibited, by for example die high dose ofprogestogen
in depot medroxy-progesterone acetate (Dcpo Provera^),
amenorrhoea will result. If, however, ovulation is inhibited
but follicular development maintained, irregular bleeding will
result from the effect on the endometrium of fluctuating lev¬
els of oestrogen coming from follicles which develop ro an
immature stage and then become atretic. Low-dose pro-
gestogen-only methods of contraception (oral pills and
implants) inhibit folliculogenesis and ovulation only incon¬
sistently in most women and are associated with irregular
unpredictable bleeding.
Conception may also be prevented by inhibiting fertilisa¬
tion. There are no contraceptive drugs wliich are expressly
designed to prevent fertilisation and will not be until we
have a clear understanding of the normal physiological proc¬
esses involved.
Alterations in tubal motility or in the tubal environment,
which either delay the passage of gametes or interfere with the
conditions required for fertilisation, present a possible
approach to new contraceptives but have the theoretical risk
of inducing ectopic pregnancy.
Preventing implantation by interfering direcdy with the
development of a receptive endometrium is probably pan of
the mode of action of the IUD and perhaps of low-dose pro-
gestogen-only methods. Implantation can also be disrupted
by interfering with progesterone production from the corpus
luteum, although if this is done after implantation has been
completed it is theoretically the induction of abortion.
3. Steroid hormone contraception
3.1 Combined oral contraception
Through the last two decades research in hormonal contra¬
ception for women has centred on four specific areas; altering
the 21 plus 7 day regimen, phased pill regimens, developing
new progestogens with a better side effect profile, and explor¬
ing new routes of administration for hormone delivery.
3.1.1 Altering the 21 plus 7 day regimen
When the pill was first marketed in 1959, the dose of oestro¬
gen was 150 pg/day 14J. When the increased risk of venous
thromboembolism (VTE) was recognised, the dose was
reduced to 50 pg and then to the so-called low-dose 30 pg pill
that is in use today. Pills containing 20 pg of ethinyl oescra-
diol (EE) are probably approaching the threshold of efficacy
and are certainly associated with slightly reduced cycle control
(Le., with more irregular/unscheduled bleeding) [5]. Keen to
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reduce the dose of EE still further but anxious about compro¬
mising efficacy, the pharmaceutical industry has fixed its
attention on the pill-free interval (PFI). The classical 7-day
interval is sufficient to allow die resumption of follicle devel¬
opment in many women. Ultrasonography demonstrates the
presence of follicles of > 10 mm in diameter at the end of the
PFI, some of which have the potential to mature and ovulate
if the start of the next packet of pills is delayed [6j. It is possi¬
ble simply to shorten the PFI and market a pill for say 23 + 3
days. A comparison between a pill containing 20 pg EE in
combination with 75 pg gestodene and given for 23 days fol¬
lowed by a 5-day PFI, with a 21 + 7 day 20 pg EE pill regi¬
men comprising 150 pg desogestrel showed no difference in
pregnancy rates or cycle control but was associated with with¬
drawal bleeds of shorter duration V\. It is likely that die sam¬
ple size of study necessary to demonstrate a significant
difference in efficacy would be prohibitive. Using a 24 + 4 day
pill regimen, a preparation containing 15 pg EE plus 60 pg
gestodenc (Schcring AG, Berlin, Germany) has undergone
Phase III trials in Europe |8j. Contraceptive efficacy appears'
similar to that of30 pg COCs, with a Pearl Index of 0.2. In a
recent study designed to investigate cycle control with this
product, involving 58 women using the pill for one year,
irregular bleeding occurred in 19% of cycles - higher than
diat typical of higher dose pills |9]. Despite die very low dose
of oestrogen, no differences in coagulation markers compared
with higher dose pills could be identified.
A more imaginative solution is to stop the oestrogen/pro-
gestogen combination regimen, inducing a withdrawal bleed,
but to include 4-5 days of low-dose EE to maintain the sup¬
pression of follicle growth, with a PFI ofonly two days. A pill
containing 150 pg desogestrel and 20 pg EE given for 21 days
is followed by two days of placebo and dicn five days EE
lOpg/day (Mircette™,Organon, West Orange, NJ, USA) is
now marketed in the US but not yet in the UK. The Pearl
index among 1143 women over 18 months of use was 1.02/
100 women years [to]. In a randomised study involving
47 women this regimen suppressed follicular development (as
measured by ultrasound) more effectively dian a regimen with
the standard 7-day PFI [llj.
The pill-free interval can simply be removed alcogcdier. Its
only purpose is to confer a regular wididrawal bleed but it
provides opportunities for errors of compliance and probably
accounts for many pregnancies attributed to pill failure. In
Europe for many years, women have run packets of pills
together intentionally to avoid a withdrawal bleed either
purely for convenience or to reduce menstrual side effects like
dysmenorrhoea or premenstrual symptoms [12]. The concept
was first described in the literature in the mid 1970s p3). In a
recent study of 90 women randomised to a 21 + 7 day or a
42 + 7 day pill cycle for one year, 52.4% of women assigned
to the 49 day cycle elected to continue die extended regimen
when the study was finished [i4]. Of die women assigned ro
the 28-day cycle, 16.7% also adopted extended cycles of pill
use. It is only very recendy that the industry has considered
marketing a trimonthly combined oral contraceptive pill. A
monophasic pill containing EE in combination with lev-
onorgestrel (LNG) as 84 + 7 days in a single pack (Seasonale,
Barr Laboratories, USA) is currently under trial in the US L15J.
3.1.2 Phasedpill regimens
The total dose ofhormone administered can be altered slightly
by using biphasic or triphasic regimens in which the dose of
steroids changes twice or tliree times during the 21 days of pill
administration. Despite there being no evidence diat eitlier
cycle control or side effect profiles are any better than with
monophasic pills, it seems that there is still an intcresc in this
approach. A recent publication described a new pill regimen
(Escrostep™) in which the dose of progestogen remains con¬
stant (norethindrone 1 mg/day) but the dose of EE changes
(20 pg/day for 5 days, 30 pg for 7 days and 35 pg for 9 days)
[16]. The intention is to reduce the androgenic impact of the
progescogen by giving a little more (but not much more!) oes¬
trogen. Increased circulating sex hormone binding globulin
(SHBG) and decreased testosterone concentrations suggest
'little if any intrinsic androgen activity* but side effects have
not been evaluated in large studies.
3.1.3 New progestogens
The progestogens most commonly used in contraceptives
(norethindrone, LNG, 3-keto-desogestrel, gestodene and
norgestimate) are derived from 19-nortestostcrone, hind to
androgen receptors and are said to be associated with andro¬
genic side effects'. Acne is indisputably one such side effect.
Others, such as loss of libido, weight gain and changes in
lipid profiles and mood, are often attributed to the andro¬
genic properties of the progestogen but in reality the relation¬
ship is less dear. The seardi for less androgenic progestogens
has occupied the industry for many years. Gestodene and des¬
ogestrel (the so-called third generation progestogens), when
not in combination with oestrogen, certainly have a lower
binding affinity for androgen receptors than LNG. In the
COG, however, any clinically relevant androgenic effects are
often overcome by oestrogen. All combined pills for example
tend to improve acnc and it is likely that only a pill contain¬
ing a specific anti-androgen (such as cyprotcrone acetate) is
significantly superior. Undeterred it would seem by the pill
scare of 1995 in which the apparent increased risk of VTE
associated with desogestrel and gestodene has been attributed
by some to their less androgenic (and thereby more oestro-




3,20-diene, [NES]), formerly known as ST1435, is a potent
19-nor-progesterone derivative which is not active orally. It
has strong progestational activity but lacks androgenic, oestro-
genic or glucocorticoic activity [18]. In steroid receptor bind¬
ing studies, 3-keto-desogestrel showed the highest binding
affinity to progesterone receptors (PR) followed by nestorone,
1241Expert Opin. Investig. Drugs (2002) 11(9)
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LNG and progesterone. The binding affinity of nestorone to
androgen receptors (AR) was 500 - 600-fold less than that of
testosterone and much less than that of LNG or 3-keto-des-
ogestrel. None of the progestogens bound to the oestrogen
receptor (ER). Despite significant binding to glucocorticoid
receptors, nestorone showed 110 glucocorticoid activity in vivo
in adrenalectomised rats.
Concluding that the high progestational potency and lack
of androgenic, oestrogenic and glucocorticoid activity confers
special advantages to nestorone for use in contraception (and
in hormone replacement therapy [HRT]) the Population
Council (New York, USA) has been exploring its potential in
long acting contraceptive delivery systems including implants
and vaginal rings (see section 3.3).
3.1.3.2 Drospirenone
Drospirenone is a progestogen derived from 17a-spironolac-
tone. Receptor binding studies demonstrate progestogcnic
potency similar to progesterone but 110 androgenic, ocstro-
gcnic, glucocorticoid and antiglucocorticoid activity (19). Dro¬
spirenone however has anti-androgenic activity and, in
contrast to all other progestogens currently used in contracep¬
tion, ancimineralocorticoid properties. Drospirenone 2 mg
alone orally for 6 days resulted in a cumulative sodium loss of
84 mmol and a significant rise in plasma renin and aldoster¬
one compared with placebo [20). From cycle days 5 — 25,
2 mg of drospirenone suppressed ovulation and resulted in a
slight natiuresis with 110 change in blood pressure [ 18]. Dros-
pirenone 3 mg/day in combination with 30 pg EE has
recently been marketed in Europe (Schcring AG) and the US
(Berlex Laboratories, Montvillc, NJ) as the combined oral
contraceptive pill, Yasmin™. Its main selling point is the asso¬
ciated reduction in fluid retention (due to the antimineraloco-
rticoid effect) leading to weight loss or at least less weight gain
when compared with a pill containing desogestrel (21). The
difference in weight is small and it is possible that the anci-
androgciiic effect may be associated with a marginally
increased risk of VTE (demonstrated with pills containing
cyproteronc acetate (22]), perhaps made worse by a slight fluid
depleted state.
3.1.3.3 Nomegestrol acetate
Nomegestrol acetate (prcgna-nor-4,6diene-3,20-dione 6-
methyl-17|3-acetoxy-19-) is an orally-active 19-nor-proges-
terone-derived progestogen which has been around for some
time and which is currently used 111 HRT preparations in
Europe (231. Doses of 1.25 mg/day inhibit ovulation in
women without inhibiting follicular maturation perhaps by
disrupting the positive feedback-induced EH surge (24]. It
has been developed as a contraceptive implant (sec section




mcthyl-cstra-4,9-dien-3-one) is a 19-norpregnane progestin
under development for HRT and oral contraception (co-
developed by Hoechst Marion Roussel and Wyeth-Ayerst). It
has a better receptor selectivity profile than medroxyproges¬
terone acetate (MPA) in rat and rabbit models and possess
weak anti-androgenic activity without androgenicity (25).
3.2 Oral progestogen-only contraception
Oral progestogen-only contraception has been available for
decades but is used by only a small number of women world¬
wide. It accounts for — 2% of the hormonal conrraception
market in the UK and is used mainly by women who have
contraindications to oestrogen, particularly breastfeeding.
Until recently, 110 new progestogen-only pills (POP) have
been developed.
3.2.1 Desogestrel-onlypill
A POP containing 75 gg desogestrcl is currently marketed in
some European countries, but not yet in the UK or the US,
by NV Organon (Oss, The Netherlands). This dose inhibits
ovulation much more consistently than other currently availa¬
ble POPs which rely 011 the effect on cervical mucus for their
contraceptive efficacy. In a hcad-to-head comparison with
30 gg LNG, desogcstrcl 75 gg among 64 women randomised
to the method for one year, follicular rupture (confirmed by
ultrasound) occurred in 36% of cycles in the twelfth treat¬
ment period among users of LNG but in only 3% of cycles
among users ofdesogestrel (26].
3.3 New hormone delivery systems
Avoidance of the oral route of administration for contracep¬
tive steroids has the advantage of bypassing the first phase of
metabolism through the liver. This allows the dose of hor¬
mone to be reduced thereby theoretically improving safety.
Non-oral delivery systems also have the potential to deliver
very constant amounts of drug, theoretically reducing side
effects which are sometimes attributed (perhaps naively) to
daily fluctuations in steroid dose. Most importantly, the
new delivery systems provide long-acting contraceptives
which depend less, or not at all, on compliance for their
effectiveness.
3.3.1 Contraceptive implants
Several implants have been developed for female contracep¬
tion [27). Inserted subdermally, under local anaeschesia in the
inner aspect of the non-dominant arm, they begin to release
the progestogen immediately following insertion. The
amount of steroid released drops slowly and progressively with
time. Their effective lives extend from 6 to 84 months.
3.3.1.1 Jadelle
A two rod levonorgesrrel implant (Jadelle®) achieves virtually
the same performance as Norplant® but fewer rods allows easier
insertion and removal. Each rod consists of 75 mg of LNG
crystals embedded in a dimethylsiloxane/methylvinylsiloxane
copolymer [28], LNG serum concentrations fall rapidly from
770 pg/ml to half this value during the first month after inser¬
tion. Thereafter serum concentrations decline slowly to
-275 pg/ml at the end of three years. Effectiveness, side effects,
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continuation rates and return to fertility after removal are not
clinically different from those associated with Norplant.
3.3.1.2 Implanon
Implanon™ (NVOrganon Oss, The Netherlands) is a single
unit implant releasing etonogestrel (ENG, 13P-ethyl-17p-
hydroxy-11-methylene-18,19-dinor-17a-pregn-4-en-20-yn-
3-one), the biologically active metabolite of desogestrel. The
steroid crystals are embedded in a rod of ethylene vinylace-
tate (EVA) copolymer, covered by a thin EVA copolymer
membrane. The implant measures 40 mm long by 20 mm
outside diameter, contains 68 mg of ENG microcrystals and
is marketed for three years of use. Mean maximum serum
levels (813 pg/ml) are attained on day 4 after insertion [28].
Thereafter, ENG concentrations decline to ~ 196 pg/ml at
the end of the first year and to 156 pg/ml at the end of the
third year. Lower body weight is associated with higher
serum concentrations. After removal of Implanon, serum
levels of ENG fall below the detection limit of the assay (20
pg/ml) within a week. The dose of ENG is sufficient to
inhibit ovulation in almost everyone for the full three years
(28]. Implanon is highly effective (29]. Marketed in Europe
and in some developing countries for a few years, there has
as yet been 110 method failure reported. Bleeding patterns
are similar to those associated with Norplant, i.e., irregular
bleeding is common.
3.3.1.3 Nestorone implants
Subdermal implants containing nestorone arc being devel¬
oped by the Population Council and by South-to-South
cooperation in Reproductive Health (Salvador, Baliia, Bra¬
zil), the latter using the trade name Elcometrine [28]. The
Population Council implant contains a central core rod of
nestorone and a silicone elastomer. An efficacy study of an
early prototype f30] using two implants each containing
~ 80 nig nestorone reported no pregnancies during
1570 women months of use. A redesigned implant wfdi an
in vitro release of 110 - 115 pg/day is currently in clinical tri¬
als designed to determine whether full contraceptice effec¬
tiveness continues for 3 — 6 months beyond the 2 year life
intended for the product [31]. By the end of February 2001,
151 women years of use had resulted in no pregnancies and
there had been no first year failures. The current trials will be
completed in early 2003.
An NES implant delivering -100 pg NES/day has been
tested for efficacy in breastfeeding women 132]. One hundred
women in Chile used the implant (designed to last for two
years) which was inserted between days 55 and 60 postpar¬
tum. 100 breastfeeding women using a standard copper IUD
acted as die controls. During more than 2100 women months
of exposure with each method there were no pregnancies. Dis¬
continuation rates were similar but 25% of die NES discon¬
tinuations were for irregular bleeding. There was no effect of
either method on infant feeding patterns but the mean dura-
uon of lactational amenorrhoea was higher among the
implant users. NES serum concentrations reached a mean of
-175 pmol/1 during the first month after insertion and
decreased to - 60 pmol/1 at the end of the first year. Concen¬
trations in breast milk over the same time fell from 135 to
54 nmol/1.
Elcometrine contains 50 mg of crystalline steroid in a sin¬
gle silicone rubber capsule 4 cm long widi a wall thickness of
0.8 mm and a diameter of 2.4 mm. Both ends are sealed widi
medical grade silicone adhesive [28]. Its effective life is only
6 months. It was registered as a contraceptive in Brazil in
1998 and is under study as a contraceptive implant for breast¬
feeding women.
3.3.1.4 Uniplant
Uniplanr (South-to-South cooperation in Reproductive
Health) is a single-unit implant delivering nomegestrol acetate
from a single silicone rubber tube 39 mm long and 2.4 mm in
diameter, sealed at both ends widi medical grade silicone adhe¬
sive [28]. The current version contains 55 mg of finely ground
steroid. The estimated release rate of the original version that
contained 38 mg of steroid is - 100 ug/day during the first
3 mondis of use, widi a decline to 70 pg/day during the last
9 months of use. It is recommended that each capsule be used
for not longer than 1 year. A trial among 1803 women from
nine countries contributing 19,900 months of use gave a one-
year cumulative pregnancy rate of 0.94% [33] (Pearl Index 0.9/
hundred women years). The discontinuation rate was 15.7%
3.3.2 Contraceptive vaginal rings
Steroid-releasing contraceptive vaginal rings were first
described in the 1970s. The)'have the characteristics of other
methods which avoid the oral route, but are under the control
of the user who can remove, insert and discontinue the
method at will.
33.2.1 Ethinyl oestradiol and etonorgestrel
NV Organon has developed a combined contracepdve vaginal
ring releasing etonogestrel 120 pg/day and EE 15 pg/day over
a period of three weeks of use (NuvaRing®). The ring is made
ofsoft EVA copolymer, has an outer diameter of 54 mm and a
cross-sectional diameter of 4 mm. Maximum concentrations
of etonogestrel are reached after - 1 week after insertion fol¬
lowed by a gradual linear decrease to 21 days. If the ring
remains in the vagina for 35 days, die linear decrease contin¬
ues. Ethinyloestradiol concentrations show a similar pattern
but reach their maximum - day 2 or 3 [34]. Suppression of
ovarian activity is said to be similar to that achieved with an
oral combined pill containing 30 pg EE and 150 pg des¬
ogestrel. In a one-year muld-centre study of contraceptive
efficacy involving 1145 women using the ring for
12,109 cycles, there were six pregnancies, giving a Pearl Index
of 0.6 (95% CI 0.24 - 1.41). Three of the six pregnancies
were diought to have resulted from user failures [35]. Irregular
bleeding, mainly spotting, varied between cycles but was
never > 6.4%. Absent withdrawal bleeding occurred in a max¬
imum of only 2.1% of cycles. Mean body weight increased by
0.43 ± 3-35 kg over the 13 cycles of rreatment and the most
frequently reported adverse events were vaginitis (13.7%),
headache (11.8%) and leukorrhoea (5.9%). This method was
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discontinued by 15% of women due to an adverse event. In a
comparison with an oral COC containing 30 pg EE and
LNG 150 jig (Microgynon 30; Sobering) the incidence of
irregular bleeding in the Nuvaring was significantly less (1.9
versus 38.8%; p < 0.001) (361.
3.4 Ethinyl oestradiol and norethindrone acetate
The Population Council has tested a silicone elastomer vagi¬
nal ring releasing 20 or 15 pg EE and ~ 1 mg norethindrone
acetate. In a Phase II trial involving 61 women from three
sites using the ring as a 21 + 7 day regimen for four months
there were no pregnancies [37]. Serum progesterone concentra¬
tions indicated luteal activity consistent with ovulation in
only one cycle but levels consistent with deficient luteal func¬
tion occurred in 6% of cycles with the 15 pg EE ring which
was associated with poorer cycle control.
3.4.1 Ethinyloestradiol and nestorone
The Population Council has tested a similar contraceptive'
vaginal ring using nestorone (100 pg) in combination with
EE (30 pg) |38]. Phase II studies with a variety of dose regi¬
mens are ongoing.
3.4.2 Nestorone-only vaginal ring
Progestin-only pills have a half-life of- 19 h and demand a
high degree of compliance for their effectiveness. The use of
a vaginal deliver)' system allows the development of a low-
dose progestogen-only method which does not rely on
remembering to take a pill each day and which is under the
control of the user. The Population Council has undertaken
Phase II studies of a vaginal ring made of elastomer
LSR 25 - 10:1 (Applied Silicone Corp, Ventura, CA, USA)
containing a 3 mm diameter solid core of NES mixed with
elastomer R2602 (NuSil Silicone Technology, Carpintera,
CA, USA). Rings were designed to release 50, 75 or 1Q pg/
day [39]. Eighty-seven women volunteered for a 6-month
study. Peak NES concentrations varied from 300 to 150
pmol/l according to the amount of NES and fell to between
220 and 100 pmol/l at the end ofsix months. All three doses
inhibited ovulation. Luteal activity, detected in up to 2.6%
of cycles, was usually suggestive of insufficient luteal func¬
tion and was independent of dose. Serum oestrogen levels
remained within the physiological range but tended to be
lower widi the highest dose. Like the nestorone-only
implants the Population Council sees a role for NES rings
for lactating women.
3.4.3 Combined injectable contraception
A once-monthly injectable contraceptive consisting of 25 mg
medroxyprogesterone acetate (MPA) and 5 mg oestradiol
cypionate has been developed by WHO [4o]. Injections are
administered intramuscularly every 28 days. The method has
been licensed in some parts of the world for some years but is
not yet licensed in Europe and is due to be launched in the
US in 2002 as Lunelle™ (Pharmacia, Peapack, NJ, USA). In a
direct non-randomised comparison of Lunelle with a widely
used OC in the USA (Ortho-novum® 7/7/7 containing 35 pg
EE in combination with 7 days each of 0.5» 0.75 and 1 mg
norethindrone acetate), there were no pregnancies among
728 women in over 8000 cycles of use (compared with 1 preg¬
nancy in 3400 cycles of pill use — Pearl Index 0.4) [41] this dif¬
ference is not statistically different. Bleeding patterns were
comparable widi the COC. Bleeding episodes can be antici¬
pated 18-22 days after injection and are induced by a
decline in oestrogen concentrations to < 50 pg/ml. Approxi¬
mately 70% of women experience one bleeding episode per
month, with only 4% experiencing amenorrhoea over three
treatment cycles.
3.4.4 Transdermal contraceptive patch
Although HRT administration by transdermal patch has been
available for more than a decade, the development of a contra¬
ceptive patch has lagged behind. A combined contraceptive
patch has been very recently launched in the US (Ortho
Evra™, Ortho McNeil) delivering 150 pg norelgestromin and
20 pg etliinyloestradiol daily [42J. A matrix patch consisting of
three layers (an outer protective layer of polyester, a medicated
adhesive middle layer and a polyester release liner removed
before application) measuring 20 cm2, each patch lasts 7 days.
One patch per week for three consecutive weeks is followed by
a patch-free week. In a Phase III crial comparing the patch to
a triphasic oral contraceptive pill containing LNG,
571 women completed 13 cycles ofpatch use. The overall and
method failure Pearl Indices were 1.24 and 0.99 respectively,
not significantly different from those of the pill. For the
patch, the cumulative probability of pregnancy after cycle 13
was 1.3 (0 — 2.7). After cycle 2 there was no difference in the
rate of irregular bleeding when the patch was compared with
the pill. In the first two cycles of patch use irregular bleeding
and breast tenderness were bodi significantly more common
than among pill users. The patch was also associated with a
higher increase in total cholesterol and triglyceride concentra¬
tions at die end of treatment. In both groups, body weight
had increased by 0.41 kg. Of women, 29.7% discontinued
the patch or were lost to follow-up, 26% of these withdrew
because of application site reactions.
3.4.5 Intrauterine delivery systems
In contrast to copper IUDs, the LNG-releasing intrauterine
system (LNG-IUS) marketed in the UK and US as Mirena®
(Leiras, Turku, Finland) is associated with a significant reduc¬
tion in menstrual blood loss. Many women experience, and
enjoy, amenorrhoea. Mirena now accounts for > 11% of the
hormonal contraceptive market in the UK. Mirena is a rela¬
tively large device which can be difficult to insert into a
small, nulliparous uterus. Attracted by the concept of using
the I US as a means of delivering the progestogen for HRT,
Leiras has been working on developing a smaller frame. Widi
a similar market in mind, odicrs have been working on a
frameless device.
1244 Expert Opin Investig. Drugs (2002) 11(9)
Glasier
3.4.6 Frameless LNG-IUS
Fibroplant-levonorgestrel (Concrel Research, Belgium) con¬
sists of a 3 an long by 1.2 mm wide fibrous delivery system
releasing 10 pg LNG/day or a system of 4 cm in length deliv¬
ering 14 jig LNG/day. The system is fixed to an anchoring
thread by a metal clip 1 cm from the anchoring knot which is
implanted into the myometrium. The tail of the thread pro¬
trudes through the cervical canal. The rate of release is con¬
stant over 5 years [43J. The 'system' has been tested in a small
number of perimenopausal and postmenopausal women (43)
and in women of reproductive age complaining of dysmenor-
rhoea (44). The system was associated with amenorrhoea in all
of the jx>st menopausal women and most of those in the peri-
menopause. Women of reproductive age mostly reported
reduced menstrual blood loss and dysmenorrhoea. Contra¬
ceptive efficacy has yet to be tested.
3.4.7 3-Keto-desogestrel IUS
The Mulriload Cu250 IUD (Organon) lias been used as a'
device on which to mount three different doses of 3-keto-des-
ogesrrel with daily release rates of 1.5, 3 and 6 Jig of pro¬
gestogen 145]. The aim is to reduce menstrual blood loss,
adequate contraception being provided by the copper IUD.
Two hundred and three women participated in a double-blind
study in which all three doses of 3-keto-desogestrel reduced
menstrual blood loss by up to 40 ml after 12 months of use.
4. Antiprogesterones
4.1 Mifepristone
In 1980 a group of chemists at Roussel Uclaf, while looking
for a glucocorticoid antagonist, discovered a synthetic steroid
which was a potent antagonist of progesterone and Cortisol
but which had no antiestrogenic activity. They named it
RU38486, abbreviated to RU486 or mifepristone. Mifepris¬
tone has a binding affinity five times that of progesterone and
three times that of dexamediasone at the respective receptors.
Over 400 compounds with antiprogesterone activity have
been synthesised (46]. Only a handful have been tested on
humans including mifepristone (formerly Roussel-Uclaf,
now Exelgenc), onapristone and lilopristone (Schering AG),
the compound developed by the National Institute for Hor¬
mone Research (NIH), CDB 2914 and die Organon com¬
pound (sec section 4.2).
Mifepristone (and the other antiprogestins) bind to proges¬
terone receptors in the hypodialamus, anterior pituitary and
uterus (both endometrium and myometrium). Once bound
to die progesterone response elements of progesterone respon¬
sive genes, andprogesterones render die gene transcriprionally
inactive. The effects of antiprogestins depend on the dose and
the time of the ovarian cycle when they are administered.
4.1.1 Emergency contraception
The contraceptive effects of mifepristone have been demon¬
strated most clearly in trials of post coital (or emergency) con¬
traception. A single dose of 600 mg given within 72 h of
intercourse was shown to be 100% effective in preventing
pregnane)' (47). The efficacy of emergency contraception can
only be estimated since it is impossible to exclude conception
of the pregnancy either before or after treatment. In a second
study of 600 mg, the single pregnane)' identified was deemed
to have occurred with an act of intercourse which occurred
after mifepristone treatment (48]. In a later dose-finding study,
10, 50 and 600 mg mifepristone all appeared to be equally
effective in prevendng pregnancy even up to 120 h after inter¬
course (49]. Side effects were independent of dose but men¬
strual delay (suggestive ofdelayed ovulation) was significantly
less likely with the 10 mg dose. The mode of action of mife¬
pristone used as an emergency contraceptive depends when it
is taken. Given before ovulation it prevents it, given after ovu¬
lation the effect on die endometrium is highly suggestive of
impaired implantation.
4.1.2 Daily low-dose mifepristone
Mifepristone has been tested as a conventional contraceptive
using a variety of regimens (daily, once-weekly and once-
mondily). The theoretical advantages ofonce-weekly or once-
monthly regimes include exposure to lower total doses of the
drug but may be more difficult to remember. In each case,
inhibition of ovulation and/or significant disruption of the
normal endometrial histology is taken as an indication of con¬
traceptive efficacy. It is fair to assume that anovulation will be
contraceptive but die relationship between endometrial his¬
tology and the prevention of pregnancy is not clear. Exactly
how abnormal' the endometrium has to look before implan¬
tation will fail is unknown and minor dianges may not in fact
be associated widi contraceptive efficacy.
Doses of mifepristone from 10-0.1 nig have been tested as
a once-daily regimen. Three doses, 10, (50], 5 and 2 mg (51-53]
daily, have all been shown to inhibit ovulation. In a double-
blind randomised trial comparing 2 and 5 mg in 90 women
over 120 days in Scotland and China (533, Brown and col¬
leagues (2002) demonstrated inliibition of ovulation in 90%
of cycles with 2 mg and 95% with 5 mg. Sixty-five percent of
women taking 2 mg/day and 88% taking 5 mg/day experi¬
enced amenorrhoea. Although follicular activity (and there¬
fore oestrogen secretion) continued during treatment, the
endometrium was rendered largely atropic suggesting diat,
even if ovulation did occur, implantation and conception
would have been very unlikely. A dose of 1 mg/day of mife¬
pristone inhibits ovulation only inconsistently but profoundly
disturbs endometrial development (54], while 0.5 mg/day has
no effect on follicle growth, ovulation, hormone secretion or
die timing of menses but the endometrium appears retarded
and glandular diameter significantly reduced (55]. The contra¬
ceptive efficacy of daily low-dose mifepristone lias been dem¬
onstrated in only two studies. In the study from Scotland and
China (using 5 mg mifepristone), 50 women used no method
ofcontraception and there were no pregnancies (53). In a study
of 32 women using 0.5 mg mifepristone daily, 16 women
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Figure 1. Centchroman.
completed six months of use. In 141 cycles, diere were five
pregnancies [56].
4.1.3 Once-weekly mifepristone
An alternative approach has been once-weeldy administration
of mifepristone. Doses of 50, 25 and 10 mg 157.581 were associ¬
ated with variable inhibition of ovulation while doses of 5 and
2.5 mg [59| did not inhibit ovulation. All doses, however,
caused apparent desynchronisation of endometrial develop¬
ment and impaired secretory activity of the endometrium.
The efficacy of a once-weekly regimen has been tested in only
one study involving 18 women [60]. In over 63 cycles, rhree
pregnancies occurred.
4.1.4 Once-monthly mifepristone
The administration of mifepristone once-monthly is thought
to prevent pregnancy by inhibiting implantation. A number
ofstudies have demonstrated that 200 mg mifepristone given
in the early luteal phase retards endometrial development
without altering die timing of next menses. It also alters uter¬
ine contractility [61]. Two studies have tested die contraceptive
efficacy of 200 nig mifepristone given within 2 days of the
LH surge [61,62). Efficacy in both studies was > 95%. The lim¬
iting factor to this approach is the accurate detection of the
LH surge as the timing of mifepristone is critical. Given too
early, it will delay ovulation resulting in prolonged cycles and
a risk ofpregnancy when ovulation does occur. Given too late,
mifepristone induces endometrial bleeding and is probably
much less effective in preventing pregnancy. The technology
currently available to allow accurate detection of the LH surge
demands a degree of compliance which appears to be beyond
most women [631-
4.1.5 Mifepristone plus progestogen
The administration of an antiprogesterone alone may theoret¬
ically be associated widi the inhibition of ovulation while fol¬
licle development (and therefore unopposed oestrogen
secretion) is maintained. This hormone environment is asso¬
ciated widi an increased risk of endometrial hyperplasia and
malignancy. These concerns have prompted trials of a variety
progestins in combination with mifepristone, the progestin
being given to protect the endometrium and to promote a
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regular bleeding pattern. A number of regimens have been
tried including 25 nig mifepristone for 14 days followed by
5 mg norethisterone from days 15-24 [6-11; 25 mg mifepris¬
tone for 21 days then 5 mg norethisterone or 5 mg MPA for
days 22 - 31 [65). However, most women ovulated in the pro¬
gestin phase of treatment, presumably jeopardising contracep¬
tive efficacy and irregular bleeding was common. 50 rug
mifepristone on days 9-11 and 27-29 with 10 rng MPA on
days 17 - 26 (66|; and a regimen comprising 5 mg mifepris-
tone/day for days 1-15 with MPA 10 mg from days 16 - 28
[67). A regimen comprising 10 nig mifepristone per day on
days 1 — 15 with noniegestrol acetate 5 mg on days 15 — 28
did manage to confer regular cyclical bleeding but again ovu¬
lation was incompletely suppressed [68|.
4.1.6 Progestogen plus mifepristone
The opposite approach has also been tested, hypothesising
that the administration of an antiprogesterone to women
using progestogen-only mediods may improve bleeding pat-
teens and thereby enliance acceptability and continuation
rates. In a double-blind placcbo-conrrolled trial of 50 mg
mifepristone taken once every 4 weeks by women experienc¬
ing troublesome irregular bleeding while using Sino-implant
(Chinese Norplant) mifepristone shortened bleeding episodes
but did not reduce their frequency [69], Similar studies funded
by WHO are ongoing.
4.2 Other antiprogesterones
Onapristone and lilopristone (Schering AG, Berlin), were
both tested in humans for their potential effect on reproduc¬
tive function but onapristone was abandoned after Phase I
studies demonstrated changes in liver function and lilopris¬
tone has not been taken forward.
Organon has published data about two antiprogesterones,
Org 31710 and Org 31806 [70). Org 31710 is a potent anti¬
progesterone with low antiglucocorticoid activity and weak
androgenic/anti-androgenic and anabolic properties. Single
administration of 150 mg given every 28 days to 48 women
using a desogestrel-only POP appeared to induce ovulation in
15% of subjects [71], A trial of the effect on bleeding patterns
of this regimen (akin to that of Cheng et al. with sino-plant
[69]) has been completed but awaits publication.
C.DB 2914 is an antiprogesterone developed by the
National Institute of Child Health and Development
(NICHD). It is a synthetic steroid analogue structurally simi¬
lar to mifepristone. Doses of up to 200 mg have been shown
to have no adverse effects in normally cycling women [72). A
single oral dose of 10, 50 and 100 mg of CDB-2914 given in
the presence of a maturing ovarian follicle (14 - 16 mm in
diameter) caused a dose-dependent delay in ovulation or folli¬
cle atresia and disruption of endometrial histology similar to
that seen with mifepristone (73). A trial of CDB-2914 as an
emergency contraceptive is presendy ongoing.
A new group of compounds called mesoprogestins (includ¬
ing J867, J956, J912 and J1042) have been synthesised and












3 FSH receptor antagonist
4 Arrest of oocyte maturation
5 Blockage of follicle rupture
6 Inhibition of fertilisation
7 Block of implantation
8 Spermicides
Figure 2. Potential targets for contraception in women.
Reproduced with permission from Baird and Glasier J82i.
FSH: Follicle-stimulating hormone; GnRH: Gonadotropin-releasing
hormone; LH: Luteinising hormone.
characterised (Jenapharm GmbH & Co, Jena, Germany).
These compounds bind strongly to the PR but have mixed
agonistic, and antagonistic activities at PR in vivo [74]. Their
antiproliferative effect on endometrium is being investigated
in animal models including primates but no studies on
humans have yet been published.
Although antiprogesterones hold much promise for a new
approach to contraceptive development, progress is severely
impaired by politics. Mifepristone is licensed in many parts of
the world as an abortifacient and the anti-abortion lobby has
been remarkably successful in scaring off both the pharmaceu¬
tical industry and the not-for-profit organisations, both of




GnRH antagonists cause an immediate, rapid and reversible
suppression ofgonadotropin secretion inhibiting folliculogen-.
esis and ovulation. These effects are clearly contraceptive but
induce hypo-oestrogenism and, used long-term, oesrrogen
replacement would be required. There is great interest in the
development of GnRH antagonists, including orally-active
non-peptide compounds, with acceptable safety and 'com¬
mercial' profiles [75]. Already in use for short-term ovarian
suppression in assisted reproduction, the market for these
compounds will be benign gynaecological conditions such as
endometriosis and fibroids and breast and prostate cancer.
They will be expensive and die pharmaceutical industry
appear reluctant to make diem available for contraceptive
development (for cither men or women).
5.2 Anti-oestrogens
Anti-oestrogens arc being developed for HRT and it is to be
hoped that, in the not roo distant future, a selective oestrogen
receptor modulator can be developed for use in contracep¬
tion. A compound which will inhibit ovarian activity without
binding to receptors in breast or hepatic tissue would over¬
come the increased risks of breast cancer and VTE associated
with the COC.
5.2.1 Centchroman
Centchroman (ormeloxifene, Figure l) trans-l-[2-[4-(7-mcdi-
oxy-2,2-dimcdiyr-3-phenyl]-phenoxy)-ethyi] pynolidine is a
non-steroidal oestrogen antagonist with weak oestrogenic
activity which prevents pregnancy in the rat, mouse, dog and
rhesus monkey when administered widiin 24 h of coitus. It
was developed at the Central Drug Research Institute in Luc-
know, is marketed in India as a regimen comprising 30 mg
twice-weekly for 12 weeks and once-weekly thereafter. It
reaches peak concentrations in women within 4 - 6 h of
administration and has a half-life of 7 days [76].
It has no effect on the hypothalamus-pituitary-ovarian axis,
and doses as high as 120 mg/wcek fail to inhibit ovulation or
disturb cyclical ovarian activity. It is thought to act by inhibit-
ing implantation, specifically by accelerating ovum transport
through the fallopian tube and preventing endometrial decidu-
alisation, thus causing asyncrony between the arrival of die
blastocyst in the uterine cavity and endometrial receptivity [77J.
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Centchroman has been reported to be effective in women
as a postcoital contraceptive using a single dose of 60 mg. In a
study of 103 parous women, using the method for
650 months only one pregnancy occurred 177). Given once
weekly 30 mg of centchroman used by 992 women for almost
14,000 months gave a cumulative pregnancy rate of 3.42 at
12 months. Prolongation of cycles was the commonest side
effect associated within both post coital and monthly use.
Since most pregnancies occurred during the first 12 weeks of
the study the regimen was changed to allow twice-weekly dos- _
ing for the first 3 months successfully reducing the one year
CPR to 1.63 (771- The contraceptive effect is readily reversible.
Prom time to time various not-for-profit organisations have
flirted with the idea of exploring centchroman in detail but
none has yet done so.
6. Immunocontraceptive vaccines
The idea of a contraceptive vaccine has been around for a -
long time. Targets indude sperm, oocyte and embryo. To
date, immunisation against a variety of sperm proteins and
against the zona pellucida of the oocyte have only been tested
in animal models including primates (78). Although there arc
more than 30 vaccines under development, many of them
targetting male reproductive function, only a handful have
been tested in women and all are anti-hCG vaccines. A vac¬
cine using the unique CT peptide portion of BhCG as the
antigen has been tested in India. Phase II studies have been
published and demonstrate both contraceptive efficacy and
reversibility 179.80J. WHO and one pharmaceutical company
(Aphton, Miami, Florida) are undertaking Phase I trials of an
anti-hCG vaccine. Progress with contraceptive vaccines has
been hampered by a variety of factors including uncertainty
about the long-term effects of immunising against human
tissues and fears, perhaps ironically from women's groups,
that contraceptive vaccines too easily lend themselves to coer¬
cive family planning policies. There also concerns about
whether vaccines would ever achieve the effectiveness associ¬
ated with long acting hormonal methods (such as implants)
or modern IUDs.
7. Expert opinion & the future
As our understanding of reproductive biology increases there
is now much interest in looking at genes whose products are
solely concerned with reproductive processes and which there-
fore present prime targets for inhibiting conception (Figure 2).
Methods which much more specifically target reproduction
should produce contraceptives with fewer side effects. For
review of potential targets see (81,821.
Bibliography
Papers of special note have been highlighted as
cither of interest (•) or ofconsiderable interest (••)
to readers.
1. LIPPES J: Quinacrinc sterilization:the
imperative need for amcrican clinical trials.
Fertil SteriL (2002)77:1106-1109.
2. CUBA SK. SI NG H G, SCRIVASTAVA A el
al\ Two-year clinical efficacy trial with dose
variations of a vas deferens injectable
contraceptive for the male. Contraception
(1998) 58:165-174.
3. VAN LOOK PFA: Contraceptives of the
future In: Handbook ofFamily Planning and
Reproductive Healthcare. Glasicr A, Gcbbie A
(Eds), Churchill Livingstone, Edinburgh.
Scotland. (2000):397-398.
4. PINCUS G: The control of fertility.
Academic Press, New York, USA (1965).
5. AKERLUND M, RODE A,
WESTERGAA.RD J: Comparative profiles of
reliability, cycle control and side effects of
two oral contraceptive formulations
containihg 150pg desogestre! and either 30
Pg or 20 pg ethinyl ocstradiol. Br. J. Obstct.
Gynaecol (1993) 100:832-838.
6. SPONA J. El .STEIN M. FEICHTINGER
W cc a!.: Shorter hormone free interval in
combined oral contraceptives decreases
follicular development. Br. Med. J. (1996)
54:1-74.
7. ENDRIKATJ, CRONIN M, GERLINGER
C, RUEBIG A. SCHMIDT W,
DUSTERBERG B: Open, multi-centre
comparison of efficacy cycle control and
tolcrability of a 23-day oral contraceptive
regimen with 20 mg ethinyl estradiol and 75
mg gesrodent and a 21-day regimen with 20
mg ethinyl estradiol and 150 mg desogestrcl.
Contraception (2001) 64:201-207.
8. GESTODENE STUDY GROUP 322: The
safety and contraceptive efficacy of a 24-day
low dose oral contraceptive regimen
containing gestodene 60 |tg and
ethinylocstradiol 15 pg. Eur J. Contracep.
Reprod. Health Care (1999) 4(Suppl.):9- l 5.
• A study ofa combined pill containing 15 pg
EE.
9. FRUZETTI F, GENAZZANIAR, RICCl
C, DE NEGRI F, BERSI C, CARMASSI F:
A 12-month clinical investigation with a 24-
day regimen containing 15pg
cthinylocscradiol plus 60pg gestodene with
respect to hacmostasis and cycle control.
Contraception (2001) 63:303-307.
10. THE MIRCETTE STUDY GROUP: An
open-label, tnu11icentre,noncom parative
safety and efficacy study of Mircette TM, a
low-dose cstrocn-progestin oral
contraceptive. Am. J. Obstct. Gynecol. (1998)
179:S2-S8.
11. KlLUCK SA, FITZGERALD C, DAVIS A:
Ovarian activity in women taking an oral
contraceptive containing 20 pg ethinyl
cscradiol and 150 pg dcsogestrel: effects of
low estrogen doses during the hormonc-frcc
interval. Am. J. Obstet. Gynecol. (1998)
179-.S18-S24.
12. DEN TONKELAAR1, ODDENS BJ:
Preferred frequency and characteristics of
menstrual bleeding in relation to
reproductive status and contraceptive use and
hormone replacement therapy use.
Contraception (1999) 59:357-362.
13. LOUDON NB. FQXWELL M, P07TS
DM. GUILD AL. SHORT RV:
Acceptability of an oral contraceptive that
reduces frequency of menstruation : the rri-
cyclc pill regime. Br. Med. J. (1977) ii:487-
490.
14. MILLER L, KNOTTER KM: Menstrual
reduction with extended use ofcombined
oral contraceptive pills: randomized
controlled trial. Obstet. Gynecol (2001)
98:771-778.
15- KAUNITZAM: Menstruatiomchoosing
whedicr and when. Contraception
(2000) 62:277-284.
• A review discussing COC use to induce




16. BOYD RA. ZEGARAC AE, POSVAR EL.
F1ACK MR: Minimal androgenic acriviry of
a new oral contraceptive containing
norethindronc acetate and graduated dose of
ethinyl estradiol. Contraception (2001)
63:71-76.
17. SKEGG DCG: Third Generation Oral
Contraceptives. Br. Med. J. (2000) 321:190-
191.
18. KUMAR N. KOIDU SS. TSONG Y-T,
SUNDARAM K: Ncstoronc*: a progestin
with a unique pharmacological profile.
Steroids (2000) 65:629-636.
• A review of Ncstoronc.
19. MUHN P. KRA7TENMACHER R. BEIER
S et aL: Drospirenonc a novel progestogen
with antiinincralocorticoid and ami
androgenic activity. Contraception (1995)
51:99-110.
20. OELKERS W: Drospirenone -- a new
progestogen with antiinincralocorticoid
activity, resembling natural progesterone.
Eur. J. Cantracept. Reprod. Health Care
(2000) SCSuppl. 3): 17-26.
21. POIDART JM. WUTTKE W, BOUW GM,
GERLINGERC, HEITHECKER R: A
comparative investigation of contraceptive
reliability, cycle control and tolerance of two
nionophasic oral contraceptives containing
either drospirenone or desogcstrcl. Eur. J.
Contracept. Reprod. Health Care (2000)
5:124-134.
• A comparison of combined pills containing
dcsogcstrcl or drospirenone.
22. VASILAKIS-SCARAMOZZA C. JICK H:
Risk of venous thromboembolism with
cyprorerone or icvonbrgestrel contraceptives.
Lancet (2001) 358:1427-1429.
23. SITRUK-WARE R: Progestogens in
hormone replacement therapy; new
molecules, risks and benefits. Menopause
(2002) 9:6-15.
24. BAZJN B, THEVERIO I' R. BURSAUX C.
PARIS J: Effect ofnomcgcstro! acetate, a new
19-nor-progcsteronc derivative, on pituitary
function in women. Br. J. Obstet. Gynaecol.
(1987) 94:119-1204.
25. ZHANG Z. LUNDEEN SG, ZHU Y.
CA RVER JM, WINNEKER O In vitro
chractcrization of trimcgestone : a new
potent and selective progestin. Steroids
(2000) 65:637-643.
26. RICE CP. KILIJCK SR. DIEBEN T,
COELINGH BENNINK HC: A
comparison of the inhibition of ovulation
achieved by dcsogcstrcl 75 pg and
Icvonorgcstrel 30 pg daily. Hum. Reprod.
(1999) 14:982-985.
27. MEIRIK O: Implantable contraceptives for
women. Contraception (2002) 65:1-3.
28. CROXATTO HB: Progestin implants for
female contraception. Contraception (2002)
65:15-19.
• An overview of implants.
29. CROXATTO HB, URBANCSEK J,
MASSAI R, COELINGH-BENNINK H,
VAN BEEK A. IMPLANON STUDY
GROUP: A multicentre efficacy and safety
study of the single contraceptive implant
Implanon. Hum. Reprod (1999) 14:976-981.
30. DIAZ S. SCHIPPACASSA V. PEREZ M et
aL Clinical trial with Ncstoronc subdcrmal
contraceptive implants. Contraception (1995)
51:33-38.
31. SIVIN I, MOO-YOUNG F: Recent
developments in contraceptive implants at
the Population Council. Contraception
(2002) 65:113-119.
32. MASSAI RM, DIAZ S. QUINTEROS E et
aL: Contraceptive efficacy and clinical
performance of Ncstorone implants in post
partum women. Contraception (2001)
64:369-376.
33. COUTINHO E, DE SOUZA JC,
ATHAYDE C et aL: Multicentre clinical trial
on the efficacy and acceptability of a single
contraceptive implant of nomegcstrol acetate.
Contraception (1996) 53:121-125.
34. TIMMER C, MULDERS TMT:
Pharmacokinetics of etonorgcstrel and
cthinylcstradiol released from a combined
contraceptive vaginal ring. Clin.
Rlmrmacoki'het. (2000) 39:233-242.
35. ROUMEN FJME, APTER D, MULDERS
TMT, DIEBEN TOM: Efficacy, tolerability
and acceptability of a novel contraceptive
vaginal ring releasing etonorgcstrel and
cdunyloescradiol. Hum. Reprod. (2001)
16:469-475.
• Clinical trial of the combined contraceptive
vaginal ring.
36. BJARNADO'lTIR RJ, TUPPURA1NEN
M, K1LLICK SR: Comparison of cycle
control with a combined contraceptive
vaginal ring and oral Icvonorgestrcl/cthinyl
estradiol. Am. J. Obstet. Gynecol. (2002)
186:389-395.
37. WEISBERG E, FRASER IS, MISHELL DR,
LACARRA M, DARNEL P, JACKANICZ
TM: A comparative study of two
contraceptive vaginal rings releasing
norethindronc acetate and differing doses of
ethinyl oesrradiol. Contraception (1999)
59:305-310.
38. ALVAREZ-SANCHEZ F, BRACHE V,
JACKANICZ T, FAUNDES A: Evaluation
of four different contraceptive vaginal rings :
steroid scrum levels, luteal activity, bleeding
control and lipid profiles. Contraception
(1992) 46:387-391.
39. BRACHE V. MISHELL DR.
LAFTIEENMAKI P et aL: Ovarian function
during use of vaginal rings delivering three
difference doses of Ncstoronc®. Contraception
(2001) 63:257-261.
40. WORIX) HEALTH ORGANIZATION
TASK FROCE ON LONG-ACTING
SYSTEMIC AGENTS FOR FERTILITY
REGULATION: A multiccntred Phase III
comparative study of two hormonal
contraceptive preparations given oncc-a-
ntonth by intramuscular injection :
contraceptive efficacy and side effects.
Contraception (1988) 37:1 -20.
41. KAUNrrZ AM, GARCEAU RJ, CROMIE
MA, LUNELLE STUDY GROUP:
Comparative safety, efficacy and cycle control
of Lunelle monthly contraceptive injection
(medroxyprogesterone acetate and estradiol
cypionatc injectable suspension) and Ortho-
Novum 7/7/7 oral contraceptive
(norcthindronc/cthinyl estradiol triphasic).
Contraception (1999) 60:179-187.
42. AUDET MC, MORIAN M. KOLTUN
WD et aL: for the ORTHO/EVRA/EVRA
study group: Evaluation of contraceptive
efficacy and cycle control of a transdermal
contraceptive patch versus an oral
contraceptive. A randomized controlled trial.
JAMA (2001) 285:2347-2354.
♦ Clinical trial of the combined contraceptive
patch.
43. WILDEMEERSCH D. SCHACHT E:
Endometrial suppression with a new
'franielcss' levonorgcsrrel releasing
intrauterine system in pcrimenopausa! and
postmenopausal women: a pilot study.
Afatvritos (2Q0Q\ 36:63-68.
44. WILDEMEERSCH D, SCHACHT E,
WILDEMEERSCH P: Treatment ofprimary
and secondary dysmenorrhoca with a novel
'fraindess' intrauterine Icvonorgestrcl-
rcleasing drug delivery system: a pilot study.
Eur. /. Contracep. Reprod. Health Care (2001)
6:192-198.
45. JANSSEN CAH, SCHOITEN PC,
HEINTZ I'M: The effect of low-dose 3-
keto-desogcsocl added to a copper-releasing
intrauterine contraceptive device on
menstrual loss : a double-blind dose-finding
placebo-controlled study. Am. J. Obstet.
Expert Opin. Investig. Drugs (2002) 11(9) 1249
197
New developments in contraceptive drugs for use by women
Gynecol. (2000) 182:575-581.
4<>. IIODGEN CD: Anriprogestins : The
political chemistry of RU486. Fertil Stcril.
(199 1)56:394-395.
47. CLASIER A, THONG KJ, DEWAR M,
MACKIE M, BAIRD DT: Comparison of
mifepristone and high doscocstrogen-
progestogen for emergency post coital
contraception. N. Engl J. Med\\ 992)
327:1041-1044.
48. WEBB AMC, RUSSELJ, ELSTEIN M:
Comparison of the Yuzpc regime, danazol
and mifepristone in oral post-coital
contraception. Br. Med. ]. (1992) 305:927-
931.
49 TASK FORCE ON POSTOVULATORY
METHODS OF FERTILITY
RF.GULATION: Comparison of three single
doses of mifepristone as emergency
contraception: a randomised trial. Lancet
(1999)353:697-702.
• Effectiveness of mifepristone as an
emergency contraceptive.
50. CROXATTO HB. SALVATIEKJtA AM.
CROXATTO HD, FUF.NTEALBA B:
Effects ofcontinuous treatment with low
dose mifepristone throughout one menstrual
cycle. Hum. Rcprod. (1993) 8:201-207.
51. LEDGER WI, SWEETING VM, HILLIF.R
H, BAIRD DT: Inhibition of ovulation by
low-dose mifepristone (RU486). Hum. Rep.
(1992) 7:945-950.
52. CAMERON ST. THONG KJ, BAIRD DT:
Effect of daily low dose mifepristone on the
ovarian cycle and on the dynamics of follicle
growth. Clin. Endocrin. (1995)43:407-414.
53. BROWN A. CHENG L, LIN S. BAIRD
DT: Daily low-dose mifepristone lias
contraceptive potential by suppressing
ovulation ami menstruation: A double-blind
randomized control trial of 2 and 5 rng per
day for 120 days./ Clin. Endocrinol. Metab
(2002) 87:63-70.
• An efficacy study of low-dose daily
mifepristone.
54. CROXATTO HB. KOVACS L. MASSAI R,
RESCH BA: Effects of long-term low-dose
mifepristone on reproductive function in
women. Hum. Reprod. (1998)13:793-798.
55. GEMZELL-DANIF.LSSON K. SWAHN
ML, WESTLUND P, JOHANNISSON E.
SEPPALA M. BYDEMAN M: Effect of low
daily doses of mifepristone on ovarian
funcrion and endometrial development.
Hum. Reprod. (1997)12:124-131.
56. MARIONS I, V1SKI S, GEMZELL-
DANIELSSON K et al: Contraceptive
efficacy of daily administration of 0.5 tng
mifepristone. Hum. Rcprod (1999) 14:2788-
2790.
• An efficacy study of very low-dose daily
mifepristone.
57. SPITZ IM, CROXATTO HB. ROB BINS A:
Antiprogestins: mechanism of action and
contraceptive potential. Ann. Rcu Pharmacol
Toxical (1996) 36:47-81.
58. CH EN X, XI AO B: Effect of once weekly
administration of mifepristone on ovarian
function in women. Contraception (1997)
56:175-180.
59. GEMZEU.-DANIELSSON K,
WESTLUND P. JOHANNISSON E,
SWAHN M l, BYD F.MAN M.SEPPALA
M: Effect of low weekly doses ofmifepristone
on ovarian function and endometrial
development. Hum. Rcprod. (1996)11:256-
264.
60. MARIONS L, G EMZELL-DANIELSSON
K. SWAHN M-L. BYDEMAN M:
Contraceptive efficacy of low doses of
mifepristone. Fertil SteriL (1998) 70:813-
816.
• An efficacy study of oncc-wcckly
mifepristone.
61. hapangamadk.glasieraf,
BROWN A. BAIRD ITrTeasibility of
administering mifepristone as a once a
month contraceptive pill. Hum. Reprod.
(2001) 16:1145-1150.
• An efficacy study ofonce-monthly
mifepristone and useful review of the
literature.
62. G RMZELL- DANIELSSON K, SWAHN
ML, SVALANDER P AND BYGDEMAN
M: Early Luteal phase treatment with
mifepristone (RU 486) for fertility
regulation. Hum. Reprod. (1993) 8:870-873.
63. HAPANGAMA DK. GIASIER AF. BAIRD
DT: Non-compliance among a group of
women using a novel method of
contraception. Fertil SteriL (2001) 76:1196-
1201.
64. kekkonf.n R. alfthan H,
hackkamaa m. he1kinheimo o.
luukkainen t. lahteenmak1 P:
Interference with ovulation by sequential
treatment with the antiprogestcrone RU486
and synthetic progestin. Fertil. Steril (1990)
53:747-750.
65. KEKKOKEN R. 1AHTEENMAKI P.
LUUKKAINEN T, TUOMINEN J:
Sequential regimen of the amiprogesterone
RU486 and 5)11111060 progestin for
contraception. FcrtiL SteriL (1993) 60:610-
615.
66. KEKKONHN R. CROXATTO HB.
LAHTEENMAKI P. SALVATlERRA AM,
TUOMINEN J: Effects of intermittent
antiprogestin RU486 combined with cyclic
medroxyprogesterone acetate 011
folliculogencsis atid ovulation. Hum. Reprod.
(1995) 10:287-292.
67. CROXATTO HB. MASSAl MR.
SALVATl ERRA AM, FUENTEALBA B,
CROXATTO HD, IAHTEENMAKI P:
Effects of a sequential regimen of
rnifepristone-medroxyprogesterone acetate
011 ovarian function, endometrial
development and hormonal parameters.
Contraception (1996) 54:79-86.
68. CROXATTO HB. SALVATTERRA AM.
FUENTEALBA B, MASSAl R:
Contraceptive potential of a mifepristonc-
noincgcstrol acetate sequential regimen in
women. Hum. Reprod. (1998) 13:3297-
3302.
69. CHENG I, ZHIJH, WANG A. REN F,
CHEN J. GLASIER A: Once a month
administration of mifepristone improves
bleeding patterns in women using subdcrmal
contraceptive implants releasing
Icvonorgestrcl. Hum. Rep. (2000) 15:1969-
1972.
• A study of mifepristone to improve bleeding
patterns with LNG implants.
70. KLOOSTERBOER HJ, DECKERS GH.
SCHOONEN WJ: Pharmacology of two
new very selective antiprogestagens: Org
31710 atid Org 31806. Hum. Reprod. (1994)
9:47-52.
71. VAN HEUSDEN AM, KILUCK SR.
COELINGH BENNINK HJ F. FAUSER
BCJM: Single monthly administration of the
and-progestagen Org 31710 in users of the
75 Rg dcsogcstrcl progestagen-only pill:
effects on pituitary ovarian activity. Hum.
Reprod. (2000) 15:629-636.
72. PASSARO M. P1QUION J. MULLEN N et
ah Safety and luteal phase effects of the
antiprogestin GDB—2914 in normally
cycling women. Proceedings ofthe 79th
meeting ofthe Endocrine Society (1997)
Endocrine Society. Minneapolis, USA.
73. STRATTON P, HARTOG B. HAJIZADEN
N ctal.:A single mid-fbllicular dose of CDB
- 2914, a new antiprogestin inhibits
folliculogcnesis and endometrium in
normally cycling women. Hum. Reprod.
(2000) 15:1092-1099.
74. CHWA1.ISZ K, BRENNER RM.
FUHRMANN UU. HESS-STUMPP H.
ELGER W: Antiproliferative effects of
progesterone antagonists and progesterone
1250 Expert Opin. In vestig. Drugs (2002) 11(9)
198
Glasier
receptor modulators on the endometrium.
Steroids (2000) 65:741-751.
• An overview of progesterone antagonists
and receptor modulators.
75. HUIRNE JAI'. LAMBALK CB:
Gonadotrophin-releasing hormone -
receptor antagonists. Lancet (2001)
358:1793-1803.
76. LAL J, ASTHANA OT, NITYANAND S,
GUP TA RC: Pharmacokinetics of
centchronian in health/ female subjects after
oral administration. Contntccption (1995)
52:297-300.
77. KAMBOJ VP, RAY S, DHAWAN BN: New
Products : centchroman. Drugs Today (1992)
28:227-232.
78. FENG H. SANDLOW JI, SPARKS AET,
SANDRA A: Development of an
imntunoconrraccprivc vaccine. Current
status./ Rcprod. Med. (1999) 44:759-705.
79. TALWAR TP: Fertility regulating and
inimunotherapcutic vaccines reaching
human trials stage. Hum. Rcprod. Update
(1997) 3:301-310.
80. SINGH M. DAS SK, SURIS et ah. Regain
of fertility and normality of progeny born
during below protective threshold anti-body
ticrcs in women immunized with the HSD-
hCG vaccine. Am. J. Rcprod. Immunol
(1999) 39:395-398.
81. HARRISON PR ROSENFIELD A:
Contraceptive technology and the state of
science: New Horiz.ons. In: Contraceptive
research and development. National Academic
Press. Washington DC. USA (1996): 125-
165.
• A detailed review ofboth broad and detailed
issues of contraceptive development.
82. BAIRD DT, GI-AS1HR A: Science, Medicine
and the future; Contraception. Br. Med. J.
(1999)319:969-972.
• A succinct review of the prospects of




Lothian Primary Care NHS Trust, Family
Planning & Well Woman Service & University of
Edinburgh Department of Obscerrics &
Gynaecology, 18 Dean Terrace, Edinburgh F.H4
1NL, Scotland. UK.
Tel: +44 (0)131 332 7941;
Fax: +44 (0)131 332 2931;
E-mail: a.glasicK'Ped.ac.uk




ELSEVI ER Conlraeepiion 65 (2002) 29-37 .
Original research article
Implantable contraceptives for women: effectiveness, discontinuation
rates, return of fertility, and outcome of pregnancies
Anna Glasier*
Lothian Primary Care NHS Trust and University of Edinburgh. Department of Obstetrics and Gynaecology. Edinburgh, UK
Received 28 June 2001; accepted 8 October 2001
Abstract
Piogexlogen-only contraceptive implants are highly effective. In most studies, 5-year cumulative pregnancy rates are less than 1.5/100
women for Norplant and Norplant II. No study has yet reported any failures with Implanon. Weight over 70 kg and age at insertion under
25 years both increase the failure rate of Norplant and Norplant II; however, data arc as yet lacking for Implanon. The effectiveness of other
progeslogen-only implants for which there are as yet few data are unlikely to he any different. Continuation rates arc high compared with
other hormonal methods and with the intrauterine device. In most cohorts at least 35% of women, and often many more, are still using
Norplant by the end of 5 year.,. Rates vary according to a number of factors, including population studied, age, and parity. Menstrual
disturbance is by far the most common reason for discontinuation, with headache, acne, weight gain, and desire for pregnancy accounting
for other common reasons for implant removal. Fertility returns rapidly following implant removal, and pregnancy rates (76-100% I year
after removal) arc usually no different from those following discontinuation of any other contraceptive method. There is no increase in the
risk of ectopic pregnancy, fetal malformation, or impaired infant health in pregnancies conceived either during implant use or after removal.
© 2002 lilsevicr Science Inc. All rights reserved.
Keywords: Contraception; Implants; Effectiveness: Continuation rotes; Fertility
I. Introduction
Norplant was the first implantable contraceptive for
women to be developed and is currently the most widely
used. First tested in 1966, clinical studies have involved
more than 55,000 women, and Norplant is registered in at
least 60 countries. Norplant consists of six small, llexible,
sealed capsules each containing 36 mg levonorgestrel
(LNG). The initial studies were done with so-called "hard
tubing" Silastic implants, but the currently used "soft tub¬
ing" results in a greater daily release and is associated with
lower pregnancy rales 111. Norplant is approved for use for
5 years. Norplant 11 (Jadelle) consists of two rods containing
a total of 150 mg LNG and is licensed for use for 5 years of
use. It is now registered in several countries in Europe. Two
LNG implants, one composed of six capsules and the other
♦Tel.: +44-131-332-7941; fax: +44-131-332-2931.
Ii-inail address: a.glasier@ed.ac.uk (A. Glasierj.
two rods, are available in the People's Republic of China
12].
Implanon is a single implant that contains etonogeslrel
and provides contraception for 3 years. Implanon is regis¬
tered in Australia, Indonesia, and in many counlries in
Europe.
Uniplant is a single implant delivering the progestogen
nomegestrel acetate. It has been developed as a contracep¬
tive, but is not yet registered in any country.
The Population Council is undertaking studies of the
progestogen Nestorone as a contraceptive implant. A single
nestorone implant (Elcomelrine) is registered in Brazil for
the treatment of endometriosis. For a detailed description of
all (be implants discussed in this article, see Croxalto, 2(X)2
[3].
There has been a large number of studies of the efficacy
of Norplant in a wide variety of different countries and in
different population groups. There is a reasonable body of
data on Norplant 11; however, fewer data are available for
Implanon and still less for Uniplant, Nestorone, and the
Chinese implants.
(XII(1-7824/02/$ - see from matter© 2002 Elsevier Science Inc. All rights reserved.
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2. Efficacy
']'lie effectiveness of a method of contraception is deler-
mined by how it works and how well and consistently it is
used. A method that inhibits ovulation in every cycle in
every woman who uses it will be 100% effective if it is used
perfectly. Because most modern methods of contraception
must be highly effective when used perfectly (or they would
not be licensed), many of the pregnancies that occur during
contraceptive use are the result of imperfect (or typical) use.
Norplant, Norplant II, and Uniplant, and probably Nestor-
one, prevent normal sperm transport through the female
genital tract; impair normal development of the endome¬
trium; and in some, but not all, cycles inhibit ovulation |4|.
Implanon has been developed by using a dose of progestin
sufficient to inhibit ovulation in every cycle throughout
almost the entire 3 years of use |4|. It also has an effect on
sperm trimsport and endometrial development, but if there is
no egg present to fertilize or to implant, these mechanisms -
of action are superfluous. Because all implants currently
available are nonbiodegradable and have to be inserted and
removed by a minor surgical procedure, compliance is guar¬
anteed. Differences in failure rates between population
groups are. therefore, unlikely unless there are significant
differences in reproductive physiology or in the absorption
or metabolism of the drug. This has not deterred the com¬
pletion and publication of dozens of trials of efficacy in
different countries and different settings throughout the
world, all of which have reported similar results. A wom¬
an's age appears to influence the pregnancy rates of all
reversible methods of contraception and may be a reflection
of coital frequency (and of the inevitable decline in natural
fertility with age) rather than of any inherent relationship
between aging and the mode of action of the method. Be¬
cause implant use makes no demands on compliance, the
effect of age cannot be attributed to more reliable use, in
contrast to, for example, oral contraceptives. The only other
physiological variable known to consistently influence the
efficacy of low dose progeslin-only contraception is the
weight of the user. Higher failure rates in some studies from
some countries reflect a difference in the age and weight of
the population participating in the trial.
2. I. Norplant and Norplant II
There is a vast literature on Norplant, although only the
most recent studies have used the soft tubing formulation. In
studies undertaken by the Population Council |l| in which
recruitment was completed by 1986 (using hard tubing
implants) and involving 2470 users, annual pregnancy rates/
100 women were 0.2, 0.5,1.2, 1.5, and 0.8 through Years 1
to 5, respectively. In developmental studies undertaken
from 1986 until registration of the drug, 1530 women using
soft tubing implants were studied. There were no pregnan¬
cies during Years 2 and 5, and rates of only 0.1/100, 0.4/
100, and 0.5/100 in Years I. 3. and 4, respectively. The
average pregnancy rate was thus significantly lower for the
soft tubing implants. The risk of pregnancy was higher for
women weighing more than 70 kg (1.7/100 in total) for the
hard tubing implants. Prescribing information for currently
available soft tubing Norplant implants describe the 5-year
cumulative pregnancy rate as 3.9/100.
Much of the published data on soft tubing Norplant
comes from studies comparing it with Norplant II. Different
publications often overlap, and results from a group of
women studied in one particular center and published in one
particular article may also appear in another publication
included in a different cohort of subjects.
In a multinational study undertaken in seven centers [5],
1198 women were randomized to Norplant (598 women) or
Norplant II (600 women). There were no pregnancies during
the first 4 years of use of either implant. During the fifth
year, annual pregnancy rates were 1.0/100 women for Nor¬
plant II and 0.7/100 for Norplant, and because there were no
pregnancies in the first 4 years, these arc also the cumulative
pregnancy rates. Both pregnancies occurring during Nor¬
plant use were in women weighing 70 kg or more at admis¬
sion to the study, whereas the three pregnancies occurring
among users of Norplant II were in women who weighed
less than 70 kg. Thus, women weighing 70 kg or more when
they first started using Norplant were more likely to expe¬
rience a method failure (p < 0.001) than were lighter
women. Among women aged under 30 years at the lime of
admission into the study, pregnancy rates were 0.15/100
women-years for the LNG rod and 0.16 for Norplant. For
both methods there were fewer pregnancies among women
aged 30 or over (0.11 and 0.00/100 years of exposure for
LNG rod and Norplant, respectively).
In a study from North America |6| of 511 women, the
cumulative pregnancy rate among Norplant users was 1.3/
100 users. Three pregnancies occurred during Norplant use,
two during Year 5 and one at Month 35 in it woman taking
rifnmpicin—all three women weighed over 70 kg at the lime
of Norplant insertion. For women weighing 70 kg or more
at die time of insertion, the cumulative 5-year pregnancy
rate was 4.2/100, corresponding to an average life table rate
below 1/100. Women under 25 years of age at time of
insertion had a cumulative 5-year pregnancy rale of 2.8/100
compared with 0.7/100 for women aged 25 or over.
A large number of studies has been carried out in single
centers or reported as findings from single centers. Five-
year cumulative pregnancy rates range from 0 to 4.7/100 in
these publications, which are summarized in Table I
[6-16J.
In a large study designed to undertake post-marketing
surveillance [ 171, 7977 women using Norplant were fol¬
lowed prospectively alongside a cohort of women using
locally available intrauterine devices (IUDs; 6625 women)
and a cohort of women who had been sterilized (1419
women). Participants were recruited from 32 clinics in eight
developing countries. Annual pregnancy rates each year for
all three methods were less than 1/100 women-years. From
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Tabic 1
Comparison of pregnancy rates*
Country Authors Rcf Number of users Cumulative 5-year
pregnancy rale/KM) users
Peoples' Republic of China Gu et al. 8 10,718 1.5
Taiwan Tseng et al. 9 567 1.2
Singapore Singh et al. 10 100 0.0
Thailand Chomopootawccp el al. 11 308 4.2
Indonesia Affandi 12 437 1.8
Nepal Chetri el al. 13 407
-
Bangladesh AkJiter el al. 14 600 0.0
Egypt Shaaban 15 3,000 1.8
Belgium Vekcinans ei al. 16 612 3.7
US Sivin ct al. 6 511 1.5
Pakistan Rehau et al. 7 265 2.5
* From reference 17].
Year 2 Che annual cumulative pregnancy rate among Nor¬
plant users increased very slightly (0.08 in Year 2, 0.33 in-
Year 3, 0.35 in Year 4, and 0.59 in Year 5), and the overall
cumulative pregnancy rate at 5 years was 1.46 ±0.16.
Although Norplant was developed and is licensed as a
method that lasts 5 years, there is good evidence for high
efficacy persisting well beyond that time. In a study of
Chinese women IS J involving 10,718 women in total, 3622
continued using hard tubing Norplant for a sixth year and
2433 for a seventh year. There were 18 pregnancies in the
sixth year and 12 in the seventh, giving an annual gross
pregnancy rate of 0.4/100 for both years. Beyond the fifth
year, women aged less than 25 years at admission and those
weighing more than 70 kg at the time of implant insertion
were most at risk of pregnancy. Cumulative pregnancy rales
at the end of 5 years were 1.53/100 and had increased only
very slightly at the end of 7 years to 2.32/100.
in a second study of 1210 women using soft tubing
Norplant for 7 years [18], the cumulative pregnancy rate
was 1.1/100 at the end of 5 years, whereas at the end of 7
years it was 1.9/100. In the course of 7 years of use there
was only one pregnancy among women aged 30-40 years
at admission and that was in a woman who weighed 100 kg
when she had the implants inserted (cumulative life table
pregnancy rate of 0.4/100). No woman who weighed less
than 50 kg at admission became pregnant during the study.
Annual pregnancy rales were less than 1/100 continuing
users in the sixth and seventh years of Norplant use.
2.2. Implanon
Data from studies undertaken during the development of
Implanon [19] include a core data set of 13 studies that met
the requirements for good clinical practice (GCP). These
studies, involving 1716 women in at least 10 different coun¬
tries, contributed 4103 women-years of use of Implanon in
which no pregnancies occurred. An additional four studies
not compliant with GCP bring the total exposure to 5629
women-years with no pregnancies. Ten of the studies used
Norplant as a comparator, and over a total of 2155 women-
years no pregnancies occurred during 3 years of Norplant
use. Although obese women were purposely excluded from
the studies, a small number of women (175) weighing over
70 kg participated in the developmental studies with no
pregnancies during Implanon use.
Other publications also reported no pregnancies, but
probably included data from some of the women who par¬
ticipated in the studies making up the core data set. Croxatto
et al. [20] reported no pregnancies among 635 women using
Implanon for 2 years and reported none among a group of
147 of these same women in whom use was extended to 3
years. Affandi et al. [21] also reported no pregnancies
among 200 Indonesian women using Implanon for up to 4
years. Similarly, no pregnancies occurred among 100 Chi¬
nese women exposed to Implanon for 341 women-years
[22].
2.3. Uniplant
Among 1803 women from nine countries contributing
19,900 women-months of use of Uniplant, there were 15
pregnancies, giving a 12-month cumulative pregnancy rate
of 0.94% [23].
2.4. Nestorone
Among 1570 women-months of use of one of two pro¬
totype implants containing 76-82 mg nestorone each, there
were no pregnancies [24], Similarly, no pregnancies were
reported among a cohort of breastfeeding women [25].
2.5. Efficacy of contraceptive implants compared with
other methods of contraception
In a systematic review of implantable contraceptives, the
National Health Service Research & Development Health
Technology Assessment Programme (HTA) in the UK [26]
searched relevant electronic databases for material on sub-
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dermal contraceptive implants that was published between
1972 and July 1998. The publications were reviewed in the
now standard manner for systematic reviews (for details, see
French el at. 2000 |26|). All randomized, controlled trials
(RCTs) and controlled clinical trials comparing implants
with other forms of reversible contraception (including
other implants) and all nonrandomized prospective cohorts
were considered for inclusion in lite meta-analysis. A total
of 34 comparative studies met the inclusion criteria, includ¬
ing 15 RCTs and 19 nonrandomized prospective cohort
studies. Most of these (59%) were carried out in community
settings, although three studies recruited women while in
the hospital (after childbirth or abortion). Two studies lim¬
ited recruitment to adolescent women, and two others in¬
volved breastfeeding women. Data from 18 of the 34 studies
were included in the meta-analysis, some of which have
been referred to earlier in this review. Six studies compared
Norplant with Norplant II, showing similar efficacy over 3
years of use. In the seven trials of Implanon versus Nor¬
plant, there were no pregnancies in either group and, there¬
fore, no difference between the methods. Although the dif¬
ferences were not significant, there was a trend toward «
lower failure rate among users of Norplant during both I
and 2 years of follow-up when compared with women using
either the combined pill or the copper-T IUD containing
<250 mm2. A comparison of Norplant II with the LNG-
IUS (intrauterine system) |27| showed no difference in
pregnancy rates, and one study comparing Uniplant with the
CuT 380A IUD (28| reported no pregnancies in just over
1200 women-months of use for each method.
In the study of soft tubing Norplant use for 7 years [18],
pregnancy rates were compared with those among women
who had been sterilized in the US Collaborative Review of
Sterilization [29]. For women aged 18-34, the efficacy of
Norplant was equal to that of sterilization. For women aged
over 34 years, Norplant was more effective.
In the post-marketing surveillance study [17]. Norplant
was compared with copper and noncopper lUDs and with
sterilization. The annual pregnancy rates fell year after year
among IUD users, who had a cumulative pregnancy rate at
5 years of 4.19 ± 0.28 for copper IUD (13.0 ± 1.39 for
noncopper IUDs) compared with 1.46 ± 0.16 for Norplant.
Women who had been sterilized had a cumulative rate ol
0.72 ± 0.23 til 5 years.
3. Continuation rates
Although there should be no difference in efficacy be¬
tween different population groups of the same age and
weight using the same method of contraception perfectly,
differences in continuation rates are to be expected. For
most methods of contraception, women taking part in pro¬
spective trials often have relatively high continuation rates
because the inclusion criteria for trials lend to bias toward a
willingness/likelihood to continue the method. Regular fol-
Tablc 2
Cumulative continuation rates with Norplant among per l(X) US women
by age in years*
Age (years) Year
i 2 3 4 5
<25 91.6 70.1 52.6 40.8 29.0
25-29 86.4 74.2 60.0 45.3 37.8
>30 87.0 77.7 72.2 61.4 51.7
* i "mm reference |(i|.
low-up visits often serve as positive reinforcement (al¬
though for some participants the demands of too frequent
follow-up are a cause of premature discontinuation). In
many countries where health care is expensive, provision of
free contraceptive supplies and services through clinical
. trials ensures good compliance. Data from "real life" are
harder to come by, and loss to follow-up is common; even
women taking part in the post-marketing surveillance study
[17] were followed-up more assiduously than in average,
normal practice. For most methods continuation rates vary
between countries. Specific population groups (such as ad¬
olescents), too, may have a much greater tendency to dis¬
continue a contraceptive method than other groups.
3.1. Norplant and Norplant II
Sivin el al. 15] reported in 1998 cumulative life tabic
continuation rates of 71% for both Norplant and Norplant II
at the end of 3 years; 61 % and 63%, respectively, at 4 years
and 53% and 55%, respectively, at 5 years. Participating
centers were in the US, Chile, Thailand, Finland, Singapore,
and Egypt. Continuation rates were related to age, parity,
and family formation factors. Menstrual disturbances were
Ibe most common reason given for discontinuation for both
types of implant. Cumulative 5-year life tabic discontinua¬
tion rates for menstrua) problems (including amenorrhea)
were 16.4/100 for Norplant II and 19.2/100 for Norplant.
Cumulative 5-year discontinuation rates for other medical
reasons were 15.0 and 12.0/100 for Norplant 11 and Nor¬
plant, respectively. Headaches, weight gain, and acne to¬
gether accounted for more than 50% of these other medical
reasons for removal, with removals for acne and headache
(but not for weight gain) varying significantly between
clinics. All other medical reasons accounted for less than
1% of removals, with the exception of depression, which
was cited by 1% of Norplant users as the primary reason for
discontinuation.
In the study of Norplant in the US |6J, the cumulative
5-year continuation rate was 39/100. Continuation rates
varied with age and from Year two onwards were consis¬
tently lower among women under 25 years (Table 2). Five-
year removal rales for specific complaints were 17.5/100 for
menstrual irregularities, 3.9/100 for weight gain, 2.2 for
headache, and 1.8 for mood change. Removal rates for all
other medical reasons, including acne, were less than 1%.
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Table 3
Cumulative continuation rates of Norplant in various countries*
Country Authors Rcf Number of Continuation Rate/100 users
Peoples' Republic of China Gu el al. 8 10.718 94 72
Taiwan Tseng el al. 9 567 90 42
Singapore Singh ct al. 10 100 - 60
Thailand Choinopootaweep et al. II 308 98 71
Indonesia Affandi et al. 12 437 96 78
Fisher c( al. —34— 2979— - 34
Tuladliar el al. 32 1283 - 33
Nepal Chetri.et al. 13 407 - 62
Bangladesh Akhter et al. 14 600 - 41
Kgypi Salah et al. 33 250 58
Shaahan 15 3000 51
Scandinavia Sivin 34 - 76 33
US Sivin et al. 6 511 - 39
Pakistan Rehan et al. 7 265 86 46
Belgium Vckcmans ct al. 16 612 87 36
* From reference |7|.
In the cohort of women described by Sivin ct al. in 1997
(centers in the USA, Chile, Thailand, Finland, Singapore,
and Egypt [30]), continuation rates were 93.1/100 after 1
year, 83.3/100 at 2 years, and 71.3/100 al 3 years for
Norplant compared with 93.8/100 at I year, S1.7/100 at 2
years, and 71.3/100 at 3 years for Norplant 11. Once again,
menstrual problems were the most common reason for re¬
moval, with acne, headache, weight gain, and depression
being the most commonly cited other medical reasons.
Continuation rates have been shown to be particularly
high in the People's Republic of China, where annual av¬
erage rates of 90% have been reported with more than 70%
of women still using Norplant at 5 years [8]. Half the
women still using the method at 5 years opted to continue
for a sixth year, and two thirds of those still using it after 6
years opted to continue for a seventh.
Although study design and recruitment criteria vary
making published trials difficult to compare, there is a
tendency for women in developing countries to have higher
continuation rates with most methods of contraception when
ccftnpared with women from developed countries (Table 3)
16,8 — 11,16,17,31-34], As discussed earlier, the acceptabil¬
ity of a method varies considerably between cultures, and
many oilier practical issues (access to other methods; cost of
each method; and access to facilities for, and cost of, re¬
moval) besides the incidence of side effects, influence ihe
likelihood of discontinuation. In a retrospective audit of
continuation rates among new 1UD and Norplant acceptors
in Scotland [35], where all contraception is provided free
with no consultation fee for insertion or removal of either
method,,2-year continuation rates among Norplant users
were 72/100 compared with 55/100 among 1UD users. None
of these women were taking part in a trial. In a similarly
designed retrospective audit undertaken in Belgium [16],
612 women had life table continuation rates of 87/100 at I
year, 71/100 at 2 years, 53/100 at 3 years, 44/100 at 4 years.
and 36/100 at 5 years. Twenty-three percent of removals
were for menstrual irregularities.
3.2. Implanon
In a review of bleeding patterns drawn from data from
the core data set, Affandi [36] reported an overall discon¬
tinuation rate for Implanon that varied dramatically in dif¬
ferent parts of the world. Among 1716 Implanon users,
discontinuation rales were 30.2% over 3 years ill Europe
and Canada, compared widi only 0.9% in South East Asia.
Similar findings were reported for Norplant use (22.5%
versus 1.4%, respectively). Bleeding irregularities provided
the most common reason for discontinuation of the method.
Drawing from the same data set, Edwards and Moore 137]
reported discontinuation rates for Implanon of 5.3% in the
first 6 months, 6.4% in the second 6 months, 4.1% during
months 13-18, and 2.4% during Months 19-24; thus, dis¬
continuation tended to occur more frequently during the first
year of use. In Indonesia, a total of 27% of women prema¬
turely discontinued from the trial of Implanon, but only
3.5% discontinued during the first 2 years of use, and
women continuing beyond that time chose to continue be¬
yond the original study duration. In the cohort described by
Croxatto et al. [20], 31% of women discontinued Implanon
in the first 2 years of use, but only 6% in the extended third
year.
3.3. Uniplani
Discontinuation rates for Uniplant were 15.7% at 1 year.
Of the 276 women who stopped using the method prema¬
turely, 37 (13%) did so to become pregnant [23].
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3.4. Continuation rales compared with oilier methods
In the HTA meta-analysis [26], no difference in contin¬
uation rates over lime could be identified between Norplant
and Norplant II. However, at 1 year, Norplant users were
nearly twice as likely to continue the method when com¬
pared with pill users (rate ratio 1.9; 95% CI 1.4-2.5) or with
women using progesterone vaginal rings (rate ratio 1.8; 95%
CI 1.3-2.4); and more than two-and-a-half times more
likely to continue using the method than were women using
Depo Provera. Continuation rates for Norplant did not differ
when compared with the 1UD. A comparison of Norplant II
with the LNG-IUS 127] showed no difference in discontin¬
uation rates. In the one study comparing Uniplanl with the
CuT 380A 1UI) |28] there were no differences in the dis¬
continuation rates. In a recent paper analyzing the results of
the 1995 USA National Survey of Family Growth [38], the
percentage of women discontinuing Norplant by the end of
I year was 12% compared with 22% for copper IUDs and'
30% for injectable contraception. In a randomized, multi-
center trial comparing Implanon with Norplant in Indonesia
[39] involving 899 women, cumulative continuation rates
were over 90% for both methods; 1.1% of Implanon users
and 0.9%' of Norplant users discontinued the method be¬
cause of bleeding problems (including amenorrhea).
In the post-marketing surveillance study [17], women
choosing Norplant continued with the method for an aver¬
age of 4.2 years compared with 4.1 for IUD users (and
5.0—unsurprisingly—for women who were sterilized). By
5 years, 66.8% of women were continuing to use Norplant
compared with 69.5% of those using a copper IUD. Men¬
strual problems accounted for the most common reason
(13.7% discontinuations over 5 years) for removal of Nor¬
plant.
3.5. Continuation rates among special groups
There are no data for continuation rates of Implanon or
Uniplant except for those from standard trials including
women of reproductive years. There are, however, data for
Norplant for specific population groups in the US. In a study
of 181 poor teenage mothers who had Norplant inserted at
some time during the first year after childbirth, 36%' of
women had the implants removed within 20 months [40].
"Concerns about adverse events'' was given as the most
important determinant of Norplant removal. In a study of 56
adolescents [41] choosing Norplant compared with 56
choosing the oral contraceptive pill, and despite 73% of
women reporting menstrual irregularities, 1-year continua¬
tion rates for Norplant were 91/100 compared with 34% for
the pill. Continuation rates from this group are extremely
high, although of course users of implants are to some
extent a captive population because the implants can only be
removed by a health professional. Finally, in a study of
urban minority women also from the US 142] the cumula¬
tive continuation rate among 197 black and Hispanic
women were 83% at 6 months, 68% at 1 year, 39% at 2
years, 24% at 3 years, and only 13% at 4 years. Reasons for
discontinuation included menstrual irregularities (44%),
weight concerns (32%), headache (34%), and hair loss
(23%).
4. Return to fertility
Women using Norplant, Jadelle, Uniplant, and Nestorone
have incomplete and inconsistent inhibition of ovulation. As
circulating concentrations of the steroid in Norplant de¬
crease with time, ovulatory cycles are more likely to occur
[43], and this is probably true of the other implants in this
group. Implanon inhibits ovulation during most, if not all, of
the 3 years of use for which it is registered. After removal
of Implanon, serum concentrations of etonogestrel decline
to below the limit of detection of the assay (20 pg/mL)
within 1 week [44]. Ovulation [45] and fertility [46] are
reported to return within 3 months alter implant removal. In
a pilot study of Implanon undertaken in Thailand [46] 6
women out of 29 who slopped using the implant and used
no other method of contraception conceived within 3
months. AH implants deliver low doses of progestogen that
clear rapidly from the circulation when the implant is re¬
moved, with the consequent resumption of regular men¬
strual cycles and normal ovulatory ovarian activity in
women who had normal ovarian function at the time of
insertion. Fertility declines with age, and as with any
method of contraception, some women who have used con¬
traceptive implants for a number of years will have become
naturally less likely to conceive after implant removal than
they were at the time of insertion. Some may even have
entered the perimenopause or menopause. For these rea¬
sons, there may be a few women who complain of infertility
after implant removal, but use of the implant per se should
have no detrimental effect on subsequent fertility.
In a study comparing the return of fertility following
Norplant use with Norplant II, 9 out of 10 women using
Norplant and 6 out of 11 women using Norplant II had
conceived during I year of follow-up [47]. In a similar study
comparing Norplant with the IUD, 11/14 ex-Norplant users
conceived after I year and"i/5/78 after 2 years compared
with three quarters of ex-IUD users after I year and 38/38
after 2 years |48|. When ex-Norplant users were compared
with ex-depot medroxyprogesterone acetate (DMPA) users
[49] pregnancy rates were no different (39/51 at 1 year and
46/51 by 2 years after removal of Not plant compared with
33/47 after 1 year and 42/47 after 2 yetirs after stopping
DMPA). The above studies were entered into the HTA
meta-analysis [26], which could demonstrate no significant
differences in pregnancy rates between Norplant, after re¬
moval, and all other methods of contraception, including
DMPA.
Affandi el al. [49] undertook a prospective study of 51
Indonesian women who had Norplant removed because they
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wished to conceive. Pregnancy rates among a cohort of
ex-IUD andex-DMPA users were simultaneously collected.
There was no difference in the cumulative pregnancy rates,
76.5% of ex-Norplant users had conceived by 12 months
(compared with 74.7% of ex-IUD users and 70.2% of cx-
DMI'A users), and 90.2% had conceived by 2 years (86.7%
for ex-IUD users and 89.4% for ex-DMPA users). In a
similar study in which 372 women were followed up after
stopping contraception for planned pregnancy [50], preg¬
nancy rates at 2 years were 87/100 for Norplant and 92/100
for Norplant II (compared with 88% for both Ihe LNG-IUS
and TCu380 Ag).
In only two published trials have pregnancy rates after
removal of Norplant been below those accepted as "nor¬
mal." In the post-marketing surveillance study of Norplant
[17], 436 women using Norplant and 559 women using the
1UD had their method removed because they wished to
conceive. Two hundred fourteen women who had used
Norplant (55.6%) and 291 women who had used the IUD
(63.9%) became pregnant in the first year. Both these rales
are low, and the difference between Norplant and the 1UD
was significant. However, pregnancy rates varied by site,
and in four sites there were no differences in pregnancy
rates between the two methods. The female/male sex ratio
of newborn infants was significantly elevated, and under¬
reporting of pregnancies terminated for selective abortion
may have occurred in some countries explaining the appar¬
ently low pregnancy rates for both lUDs and implants. The
other study [51] reporting apparently low pregnancy rates
after implant removal reported 1-year cumulative pregnancy
rates after removal of Norplant of only 37.5/100 women and
for Implanon of 48.8/100 women. Under-reporting of ter¬
minated pregnancies may also be the explanation for these
apparently low rates.
5. Outcome of pregnancy
5.1. Outcome, of pregnancy during implant use
5.1.1. Norplant
In seven studies undertaken by the Population Council
using hard tubing implants (I), 8 out of 46 pregnancies that
occurred were ectopic, a 17% probability that a pregnancy
would be ectopic and significantly higher than the rate for
non-contracepting women. Subsequent studies with hard
tubing implants, however, reported tin ectopic pregnancy
rate of only 1.3/1000 women-years [1].
In the study published by Sivitt et al. in 1998 [5] com¬
paring Norplant and Norplant 11, there were no ectopic
pregnancies among women using Norplant. From the US
data set [6], also published in 1998, two pregnancies con¬
ceived during Norplant use went to term with the delivery of
normal babies, and one was an ectopic pregnancy, giving an
ectopic rate of 0.6/1000 woman-years.
In the post-marketing surveillance study 117], a total of
1737 pregnancies were recorded. Most (1134, 65.3%) were
among women who has stopped using contraception. Six
hundred three occurred while women were using a method
(89 among Norplant users), and most of these ended in
induced abortion. Seven pregnancies among women using
no method were ectopic, giving a rate of 2.7/1000 women-
years. For women who conceived while using Norplant,
copper IUDs, or sterilization, the ectopic pregnancy rates
were 0.3, 0.68, and 0.13/1000 women-years, respectively.
One thousand one hundred nineteen pregnancies ended in
childbirth, and 10 of them were multiple births. The mean
birth weight of babies (49 live births) conceived during
Norplant use was not different from that of babies con¬
ceived while no method was being used, and there were no
malformations.
5.1.2. Norplant 11
An ectopic pregnancy rate of 0.4/1000 was recorded by
Sivin et al. [5], giving an 80-90%i reduction in the risk of
ectopic pregnancy compared with that observed for women
using no method of contraception.
5.1.3. Implanon
There have as yet been no published reports of pregnan¬
cies conceived during the use of Implanon.
5.1.4. Uniplant
In the one published study of Uniplanl, 15 women con¬
ceived during method use. Eight of the pregnancies were
terminated. Seven went on to delivery, and all the babies
were reported to be healthy [23].
5.2. Outcome ofpregnancy conceived after removal of
implants
The outcome of pregnancy conceived after implant re¬
moval is no different from normal limits. There is no in¬
crease in the prevalence of malformations, birth weight, or
the health of the infant 11,50-52],
6. Conclusions
In conclusion, low-dose progestogen-only implants pro¬
vide a highly effective, reversible method of contraception
with failure rates equivalent to those of sterilization. In the
somewhat artificial context of clinical trials, continuation
rates are good and are often belter than those for other
hormonal contraceptives or IUDs. By far, the most common
reason for removal is menstrual disturbance. The return of
fertility after discontinuation is rapid, and there is no evi¬
dence for any increased risk of adverse outcome (including
ectopic pregnancy) of pregnancies conceived either during
use of Norplant or Norplant II or shortly after stopping.
More data are needed for Implanon and other implants that
have been available for only a relatively short time or are
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still under development, but any adverse effect would seem
highly unlikely.
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Edinburgh Healthcare NHS Trust Family Planning and Well Woman Services
Abstract
Objective
To determine the uptake, acceptability and
continuation rates of a new contraceptive implant,
Norplant.
Design
Review of case notes of all acceptors during the two
years following the introduction of the implant.
Setting
A large family planning clinic in Edinburgh.
Subjects
All women choosing Norplant.
Results
508 women chose Norplant, many as an alternative
to sterilisation or because they had experienced
problems with other methods of contraception. 9%
of women were lost to follow-up. Of the remainder
continuation rates were 84% at one year and 80%
after 18 months of use. 43% of women gave bleeding
problems as the reason for removal. However the
combination of weight gain, mood swings,
depression and headache was frequently reported as
unwanted side effects by women seeking removal. No
major problems were experienced with either
insertion or removal of Norplant.
Conclusions
Norplant is an effective method of contraception
which many women find attractive. The incidence of
erratic bleeding is high but many women tolerate
this problem because the method is easy to use and
lasts five years. Careful counselling is essential for
high continuation rates.
Methods
A record was kept of all patients who were counselled
at length about Norplant and proceeded to insertion.
Counselling was undertaken by both doctors and trained
family planning nurses, and included a detailed descrip¬
tion of the method, its advantages and disadvantages,
with particular attention being given to bleeding
problems. A description of the insertion and removal
procedures followed. Each patient was then assessed for
their suitability for the method and an appointment
given for insertion at least two weeks in advance. Dis¬
cussion of side effects was repeated at the insertion visit.
Insertion and removal was carried out in all cases by
fully trained doctors, or doctors training under
supervision, in Family Planning Clinic premises, and an
appointment given for follow up in three months.
Patients were asked to return at regular intervals for
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Results
508 women had Norplant inserted in the two years
following its introduction in July 1993. Many more
came to the clinic for information and approximately
25% of those decided against the method for a variety
of reasons, or were considered unsuitable. The age
distribution ranged between 15 and 42 years with a
mean of 26.7 years. 71% of women had live
children.
Introduction
Norplant is a long-acting hormonal method of
contraception which was introduced into the United
Kingdom in 1993. Six flexible capsules releasing a low -
dose of levonorgestrel (30-35 mcg/24 hours after 18
months) are placed subdermally in the inner aspect of
the upper arm under local anaesthesia. Insertion and
removal are minor surgical procedures which require
specialised training.
Norplant is a highly effective method of contraception
with a cumulative failure rate over five years of 1.6 per
100 woman years' compared with a typical failure rate
of the combined oral contraceptive pill after one year of
use of 5.9/hwy.! The implant lasts for five years and
fertility returns rapidly after removal.
Menstrual disturbance is the most frequently reported
side-effect, and occurs in nearly all users. At £179
Norplant is expensive even if used for five years
(£2.75/28 days against £1.52 for the most widely used
modern pill). The additional cost is justifiable as the lack
of need for compliance guarantees low failure rates.
However long-term use is essential for cost
effectiveness, and careful counselling, particularly
about menstrual irregularities, is vital to avoid
premature discontinuation.'
The launch of Norplant in the UK was accompanied by
immense media interest and clinics in some parts of the
country were said to have been 'inundated' with
enquiries. We report the experience of a large family
planning clinic in Edinburgh and describe the
characteristics of those women who have accepted
Norplant in the two years since its introduction.
18% (94) of women had a history of termination of
pregnancy, with 6% (30) women having more than one
termination, including one woman who had five.
Most women were using hormonal methods of
contraception immediately prior to Norplant insertion.
Women commonly chose Norplant as an alternative to
sterilisation or because they had experienced problems
with all other available methods of contraception.
Insertion problems. The insertion procedure was
carried out using strict aseptic technique and usually
took less than ten minutes. Most women found it an
acceptable procedure. Two patients developed infection
at the insertion site, both were treated with systemic
antibiotics. In one of these women two capsules were
expelled spontaneously from the insertion site. Blisters
at the insertion site were reported by three patients,
probably due to local reaction to the dressing strips.
Hyperpigmentation of the skin over the site after sun
exposure was experienced by two women who
nevertheless chose to continue using the method.
Failure rate. No pregnancies have resulted from
method failure, although two women were later found
to have been pregnant at the time of insertion.
Side effects and continuation rates. 280 women had
Norplant inserted more than one year ago. 27 women
(9%) have never returned to the clinic on any occasion
since insertion. 71 women (25%) are very satisfied with
the method and have no perceived problems including
30 who had regular cycles and 14 who had amenorrhoea
at one year. The incidence of side effects is shown in
Table I. The most commonly repotted side effect was
altered vaginal bleeding, which was experienced by at
least 70% of patients, and varied from complete
amenorrhoea to continuous bleeding. There were no
reports of heavy bleeding, the most common complaint
being of irregular loss (25%'). No diary cards were
issued and no attempt has been made to quantify
bleeding patterns. Only 30% of those reporting bleeding
problems described the bleeding as troublesome. 45
women (16%) have requested removal, giving
continuation rates after one year of 84%. 51 women
have now had Norplant for 18 months, and 10 of these
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Removals. Since the service started a total of 66
removals have been carried out in the clinic. Nine of
these had Norplant inserted elsewhere but were referred
from general practitioners or hospital doctors who
lacked the expertise to remove Norplant themselves.
The average duration of use was 39 (range 4-92) weeks.
Most women gave more than one reason for requesting
removal, and although bleeding problems were the
commonest complaint, the combination of weight gain,
mood swings, depression and headache occurred
frequently, and accounted for 56% of removals
(Table 1.1). Difficulty was experienced with only two
removals, one which resulted from poor placement at
insertion and one required a second attempt before
removal was complete. Most removals were achieved
in under 30 minutes.
Discussion
Widespread publicity about Norplant led to many
requests for information about the method. Women












were attracted by the simplicity of use, the low failure
rate, and the long-acting nature of Norplant. Just over
half of them were looking for an alternative to
sterilisation, but many had experienced problems with
other contraceptive methods, in particular with
compliance—many stated that they found it hard to
remember to lake a pill every day. Inevitably there were
also those women who, having used a variety of
methods in the past, had never found their ideal
contraceptive.
In the first two years since Norplant has been available
in the UK continuation rates have remained high. 84%
at one year compares extremely favourably with
continuation rates of other methods4 (Table III).
Norplant has to be removed surgically and women must
attend the doctor if they wish to discontinue the method.
It is much easier for example simply to stop taking the
pill; indeed over 50% of women using the oral
equivalent of Norplant, the progestogen-only pill, have
discontinued by the end of one year. Continuation rates
are also higher than those for the IUD and
discontinuation of that method also entails a visit to the
doctor. Moreover at least 70% of women in our series
reported side effects but persisted with the method. It is
possible that continuation rates are higher because pre-
insertion counselling is more thorough. There is no
doubt that the cost of Norplant, the time required to
insert and remove the capsules, and unfortunately the
fear of litigation have all played their part in
encouraging a counselling routine that is often absent
from discussions about other contraceptive methods. In
contrast to all other methods of contraception a short
trial of Norplant is financially prohibitive. Most women
in our series persisted with Norplant often despite very
disrupted and unpredictable bleeding patterns.
Table III: Continuation Rates of All Contraceptive
Methods at One Year—USA
%
Combined oral contraceptive pill 50-75
Norplant 82-92
Dcpo-Provera 60
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Tolerance began to expire after six months but many
women were prepared to continue for at least one year
before requesting removal. It is common for these
women to express regret that such a good method has
not worked for them. They would nevertheless still
recommend it to their friends.5
Recently there has been widespread publicity about
difficulties with Norplant removal," particularly when
attempted by untrained personnel, some possibly
resulting in litigation. An easy removal depends entirely
on correct placement of the capsules at insertion, and a
comprehensive training programme in both insertion
and removal techniques has been available free of
charge from Hoechst-Roussel who market the drug. We
have had no patients in whom removal has been -
impossible, and as described earlier, only two of which
could be classed as difficult, both caused by
inexperience of the technique at insertion.
Two doctors in our clinic are Norplant trainers and have
been responsible for most of the insertions and nearly
all removals, although the majority of medical staff are
fully trained in insertion. As trainers, we have taught
more than 300 other family planning doctors and
general practitioners, and have inevitably accumulated
more experience than others in removal. Those doctors
who have inserted relatively few Norplant have not yet
acquired removal experience, and may never do so,
preferring instead to refer to a specialist centre, not only
for removals but also for insertions in the future; If
recurrent adverse publicity, particularly from the USA
continues,' doctors will be deterred from offering the
method to their patients, and women will be deprived of
a safe, effective, and increasingly available method of
contraception.
Advances on a six-capsule system are imminent.
Implanon, one capsule containing a 3-keto-desogestrel
and lasting two to four years, and Norplant 11 consisting
of two capsules and lasting three to five years, are in the
late stages of development und may be marketed in the
next two years. Insertion and removal will be much
quicker and easier. Careful counselling however will
still be necessary as the side effects appear to be similar
to original Norplant. Until the problem of menstrual
disturbance is solved, it is difficult to see contraceptive
implants gaining in popularity, particularly in younger,
nulliparous women.
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Limitations
Figure 2: Incidence of HIV infection over 2 years by age and sex in
intervention and comparison communities
Training support, supervision, and monitoring
The syndromic strategy requires a new way of thinking from
doctors and hetdth workers. This ctin best be developed
through short training seminars, followed by supervisory
visits to health facilities during which the training is
reinforced and errors in application of the flow charts are
discussed.6 Regular supervision is essential for success.
Another thing to he monitored is the effectiveness of the flow
charts in use. The system therefore requires at least one reference
clinic in place with access to microbiological laboratory services.
Advantages ol the syndromic strategy
Some critics have dismissed the syndromic strategy as
unscientific', 'second class' or even 'quack medicine'.
Although the strategy certainly lias limitations, such
statements arc simply wrong. Unlike any other approach, it
allows integration of STD services into the primary care
structure and treatment of patients at the place and time of
first contact with the health system. Waiting time is
minimized; referral to a distant laboratory or specialist can be
avoided. This in itself increases patient compliance
dramatically. Many people in developing countries cannot
spend money on transport or take hours off work.
The sensitivity of the approach is high, since hy definition
the diagnosis of a particular causal agent cannot be missed.
What about cost-effectiveness? Because of the
standardization, ineffective prescriptions (and thus drug
wastage) are avoided. The increase in expenditure generated
by the need to give combination treatments is by far
outweighed by the savings on laboratory costs.'
The syndromic strategy has been adopted by many
countries, particularly in Africa, where it has been well
accepted and cure rates have been favourable. In Tanzania a
randomized controlled trial showed thai improved STD
treatment using the syndromic strategy reduced the
transmission of HIV infection in a rural population by 409b
(figure 2). The rate of new HIV infections was substantially
lower in all villages where the intervention had been applied,
and that was true for all sex and age groups." A reduction was
also seen for syphilis and the urethritis syndrome.'
What are the drawbacks of the syndromic strategy? Most
patients will be overtreated, since they are infected with only
one of the microbes covered by the respective algorithm. Drugs
need to be selected carefully with respect to side-effects.
One objection to syndromic management is the possible
encouragement of bacterial drug resistance. However,
bacterial resistance is usually caused by underdosage rather
than over-treatment.
The main difficulty relates to the vaginal discharge
syndrome, and to the frequently symptomless but dangerous
infections of the cervix. Some vaginal infections are difficult
to treat, and vaginal symptoms are not predictive for cervical
infections. Here there is an urgent need for simple and cheap
diagnostic tests.
STD control is one of the mailt pillars of HIV prevention,
and the syndromic strategy can be instrumental in achieving it.
One day. simple and low-cost diagnostic tests will be available.
Until then, the syndromic strategy seems the best alternative.
Dr liciner Grosskurth is a senior lecturer at the Department of
Epidemiology and Population Sciences, London School of Hygiene
ami Tropical Medicine, London WC1E 7HT, UK.
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One of the drawbacks of existing Intrauterine devices (lUDs)
is the effect they have on menstruation: menstrual periods
tend to become heavier and last longer, and this is a common
reason for requesting removal. The levonorgestrel-releasing
intrauterine system (LNG-1US) does not have this
disadvantage. Developed by the Population Council, it was
approved for use in Finland and Sweden in the early 1990s
and in the United Kingdom in mid-1995, where the trade
name is Mirena. The manufacturers refer to the device as a
"system" to distinguish it from copper-bearing lUDs that do
not release hormone.
The system has the stune polyethylene frame as the Nova T
IUD, but wrapped around the stem is a column of
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levonorgestrel within a rate-limiting membrane (Figure I).
The column contains 46 mg levonorgestrel released at a rate
of about 20 pg/24 h (compared with 50-80 [.lg/24 h for
Norplant and 30 pg in Microvai, an oral gestagen-only Pill
marketed in the UK). The release rate falls to about 15 p.g/24
h after 5 years. The LNG-IUS is marketed for use for 5 years
in Scandinavia and 3 years in the UK. Trials have shown no
decline in efficacy after 7 years' use.
Efficacy
The LNG-IUS is at least as effective as modern copper-
containing lUDs. In a randomized trial, cumulative
pregnancy rates after 7 years were 0.5 per 100 woman years
for the LNG-IUS and 1.0 for the Coppei T38()Ag.' Expulsion
rates, at around 7 per 100 woman-years, are about the same as
those for modern copper devices.
Mechanism of action
The LNG-IUS exerts a strong progestational effect on
cervical mucus and on the endometrium. The mucus becomes
thick and irapenncablc to sperm while endometrium becomes
thin and inactive. Another effect that, as with copper lUDs.
may contribute to the contraceptive action is a localized
inflammatory-type response in the endometrium.
Side-effects
The local action of the LNG on endometrium accounts for the
strong effect on menstruation. In women with monorrhagia
(menstrual blood loss > 80 mL) the LNG-IUS reduced loss by
86% at 3 months and 97% at 12 months.2 Discontinuations
for prolonged bleeding or dysmenorrhoea are less titan those for
copper lUDs; nevertheless, many women do report spotting,
which particularly in the first 3 months can be irregular,
prolonged and troublesome. By the end of one year up to 20%
of women have become amenorthoeic. Many see this as a benefit;
but, if women are not warned that it may happen, amenorrhoea
can paradoxically be a reason for requesting removal.'
The risk of pelvic infection in association with the LNG-llIS
is even lower than that with the modem copper IUD, perhaps
because of the "impermeable" cervical mucus.3 As with the
copper lUDs, if failure occurs there is a small risk of ectopic
pregnancy (ectopic pregnancy rales with the progesterone-
releasing intrauterine devices were much higher).
The LNG-IUS does not inhibit ovarian activity but, as with
the progeslagcn-only Pill and Norplant, ovulation may be
inhibited and persistent ovarian follicles (sometimes large
enough to he called cysts) come and go. In general these
cause no symptoms.
Although the 1US delivers only a small dose of LNG into
the uterine cavity, the steroid is absorbed and up to 30% of
women who stop using the method do so because of
metabolic side-effects such as acne, nausea, breast tenderness
and mood changes.4
Gynaecological applications
The LNG-IUS is an effective contraceptive which has the
potential for other gynaecological applications.5 It can be
useful in (lie management of metrorrhagia; it is said to reduce
the incidence and growth of fibroids; and. surprisingly it
seems to lessen the incidence of dysmenorrhoea (among
those who continue to menstruate). Another possible
Figure 1: The LNG-IUS
application is in the management of endometrial hyperplasia
and dysplasia, and it.may alleviate premenstrual syndrome.
The system is being tested as a route for administering
progestagen directly to the endometrium in women receiving
oral or transdermal oestrogen for hormone replacement
therapy, in the hope that the low dose will have few systemic
side-effects.6
Conclusions
Despite its considerable merits,7 the LNG-IUS does have
drawbacks. It is expensive, just under £100 ($160) in the UK
compared with under £10 for all copper IlJDs. The barrel of
steroid makes it big, the inserter is fat and insertion can be
painful and difficult; some clinicians routinely use local
anaesthesia for insertion but, even if this allows placement in
a nulliparous uterus, immediate post-insertion discomfort
may necessitate removal. The prolonged vaginal spotting can
be troublesome. In our clinic we reserve Mirena mainly for
parous women who have heavy periods and who regard more
days of vaginal spotting as preferable to fewer days of heavy
loss. The 20% who become amenorrhoeic think it is a
wonderful contraceptive.
With time, technological advances will surely result in a
smaller, perhaps even frameless, device. Though not quite the
perfect contraceptive we were looking forward to, the LNG-
IUS is an excellent method as well as having great potential
for the management of certain gynaecological disorders.
Dr Anna Glaaier is director, Family Planning and Well Woman
Services, Edinburgh Healthcare NHS Trust, Scotland.
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hormone(LH)peakorfprogest ronetdia osvulation.Eth e maynothelpthew manithirr gularcycles,asnyfthk redesigned(and-priced)forusj tafewd ysa oundthanticipated timeofovulationandwouldbimpracticalf rseprol gedp riods oftime. Barriermethods Diaphragmshavedeclin dsig ificantlyi popul ritsin ethe1960snd arenowadaysnlyus dba ound1-290fsexuallyactiveomen(Off ce ofPopulationCensusesandS rveys,1991).How ver,th yrer latively morepopularamongldwomen,yfwhomablong-term satisfieduserswhora elyconsultm dicadvis rs.Altho ghqu ted failureratesofthdiaphragmrelativelyhigh,theri koff i urs substantiallylowerinolderom nasnatufer ilitdecli es(V sey al,1982).Useofdi phragmrequiresinitialfit ingbytra n dh lth professional.Ther afteritentirelyunderthcont olfindivi ual woman,andsustainedmo ivationiessentialf rcorr ctu .Thpr se ce ofabnormalpelvica atomy,par icularlyprolapsefthev gin lw lls,c n makesecurefittingandr te tionofhdi phragmmoreiff cult.C rvical caps,whicharemorepre iselyfitt ddi ctontoc iwix,ra ngdiaphragmsmayovercomet iproblem. Useofandjunctivespermic dalpreparationialwaysrecommendedt improvetheefficacyffemalebarri rmethods.Thisaddt 'messiness'ofthemethod,whichmanywomedislike,buta beneficiali providinglubricationdurint coursev g nald yne sis aproblemforthold rwoman. Useofspermicidealonf rcontraceptioni lyrecommendedti s ofextremelyl wfertility,suchasrwomenaitingthca ndary ar followingtheirlastm nsesrinconjunctionwi hhormoner placement therapy(HRT).The'Today'contraceptivespongipolyure hanefo m impregnatedwiththspermicidalagentnonoxynol-9,wh chipl cedhig withinthevagina.Alt oughmethodatwomeng nerallyfindi acceptable,ith sn verbe nwidelyadvocatedithUKb ausof reportedlyhighfa lurerat .Nor hAmericanstudies,howev r,vnot foundsuchaig ificantdifferenceifa lurratesbetwe ndiaphr gmd spongeusers(Tru selletal,1993). Condomsarewidelyavailablendoff rpr t ctionag instp eg ancy, sexuallytransmissibleinfectionandcervicaln oplasia.Olderplesar generallymoreprofici ntith irC r ctusage,andfailu erat sf condomsfallconsiderablywithin rea ingagfthu .S eo r menfindcondomshelpte ablehm i tainarection,although othersfindt ymaexac rbateer ctilimpot nc .Hy ersensitivityo latexrubbercanoccasionallydevelopinitherp rtner,a dno - allergenicsheathscabobtained.Alls xuallyactivewom n,irre pec¬ tiveofage,should,wh nembarkingon wrelatio ship,considert e needforcondomsasp rs nalprotectionagai ts xuallytr n m ssible infection.
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Progestogen-onlycontraception Hormonalmethodsfcontracepti nthcontainprogest genal e particularlyusefulfowomenithrelativcontra-indicationstoestrogen suchasobesityrcigarettesmoking,whichbeco em resignificantwhe combinedwithadvancingage.ThPOP(ormini-pill)hasadded advantageinthaetot ldosfprogestogenislethat tne equivalentcombinedpreparation.Microgyno ,forexample,isaCOCpill thatcontains30} goestrogenand0.15nnorethisterone.Thdailyos ofnorethisteroneithequivalentprogest gen-onlypre arat n,Microval, is0.03mg.Evenallowingfor21daysfc mbinedpiusecomparedwith 28ofPOPuse;thetotaldosfnoret i teroneov28daysfMicr val (0.84mg)islessthanonet irdt tfthecomb edpreparatio(3.15mg). Atpresent,thereanooralpr gestogen-onlypre arationsmarketed containingonefthethird-generationprogestogens. Whilet ePOPisa sociatedwithanoverallfailurer tof2-3pe hundredwomanyears,Vess yta(1985)demonstrat dara eofly0.3 perhundr dwomanyea s(asgo dt atofthecombinedpill)amo g womenover40yearsfage. Long-actingprogestogen-onlycontraceptiv(injectabiesandimplants) arelessikelytobprescribedtn wus rovthagf35.Indeed,th currentdatasheetfoNorplantintheUKdescrib siab ingsuitablefo womenaged18-40.Thre sonsfortheupperaglimitarnotclear,since theverynatureofNorplantmakesiausefulmethodfoco pl swhoant nom rechildrenbutwarenoyetrea ytoco sidersterilization. Allprogestogen-onlypreparationsa eassociat dwithmen trual disturbance—aproblemal eadyfacedbymanyol rwomen.Ut20% ofwomenwillst pus ngthePOPbecau eofirregular,unpredict b ea oftenfrequentbleeding.Th rislittleevid ncethatbleedi gpat erns improvewithtime,andchangingbrandsofpillsdoesnotsethel . SimilarpatternsarfeaturoftheLNGimpl nt(Norpl n )use,andi isunlikelythatenewimpla tcontai ingdesogestr l(Implanon)will beanyb tter.M ywom ntoler t'fhemenstrualchaosassociat dwit Norplantbecausefthereli bi ity,conv niencea dlong-act gaturef themethod.Iislikely,too,hatw narbettercounselledaboutthe side-effectsoNorplant,anmoreoverthc stoft emeth d(£179in theUK)preclud sashorttrialofacceptability.Incontr st,irregular bleedingisuncommonamongwo enusingDepo-Provera(DM A), aroundS0%ofwh millhavemertorr oeaoinfrequ ntsc typ riods after1yearofuse.Thism ybeseenaparticularadv n agbywomen troubledbymenorrhagiaopolymenorrhoeaass ciat dwiththeperi- menopause. Therearemuchfewdataonlong-terms fetythePOPthanoft COC.However,therearnokno nlong-termrisksfmalignancyr cardiovasculardisease.Fom nyyear ,concernthatDMPAmight increasether skofbreastcancerlimi editavailabilityinycountries. IntheUK,althoughlicensedi1984,itsu ewaslimit duntil1995to womenforwht ermet dsofcontrac ptionwerinappropriatnd
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HORMONEREPLACEMENTTHERAPY( T) ANDCONTRACEPTION Manywomanrenowstarting(HRT)f menopausalsym tomsa d prophylaxisagainstosteoporosisbef et emen pau e.Thwom nne d
tocontinuec ntraceptionand,ili issituatiw hthcombinedp ll, becomesimpossibletgiveaccuratead icnwh nontraceptionb safelydiscontinu dsHRTwillinducereg arwithdrawalbl edsn masktheriseinFSHconcentrations.Ifwomapr p redts pHRT for6weeks,anFSHconce trationanbch ckedaftert attima womanadvisedaccordingly.Ifshiunwi lingtdis nti ueHRT,tr ¬ ceptionanbarbitrarilycontinueduntilsheach st eagf55year . Contraceptionshouldbcontinuediwom nt k gHRThoh vot yetreachedthmenopausebec usn turaloes rogensont in di HRTpreparationsa eoflow rot cyndd sththsy hetic oestrogenwi hithCOCanddn treliablyin ibitovulat o .Osm ll studydemonstratedbiochemicalevidencefovul tioni60%wom givenconventio aloralHRTwhprev uslyhadregularycles(G bbiet al,1995).E rlystudiessuggestedthatdaoralsfbout4mg oestradiolwasn ce sarytobt nacceptablecontr ceptivefficac(S rup etal,1981)—moststandardHRTpreparati nsco t ior2mgo st d ol. Incontrast,erecentstudythaic mbined1gmicronizeo stradiol with150mgdesoges relreportedva iansu pressionv rt ocycl sin2 women,asmonitor dbyultras unexaminatioicombi ti nth hormoneassays(Wenzitl,1993),Inwomentreatedithsubcut n ous oestradiolimplantscombinedwithcyclicalrnorethister ne,signif ant folliculargrowth(meas redbyultrasound)continuedtilthfo rttrea ¬ mentcycle(Magoset,1987). Thereisconsiderablenteresttdev lopm ntfacontraception usingnaturaloes rogens.which,bytureftheireak rpo ency,hav feweradv rseeff ctsonfibrinolysisndcoagulationmechani msthad syntheticoestrogens,a dwhichther bycarrle sri ktldom nn thosewithcardiovascularriskfa t fs. Methodsofcontraceptionav ilabletwoment ki gHRThrequ re additionalcontraceptionin ludebar rme hodsndIUTXThPOP giveninconjunctionwithHRT,althoughtherersci tificd taup¬ portitsu enthisway.Al oughdo fadditionalrogestogenHRT couldtheoreticallybr d ceifPOPwerea d d,tsnpracticeasi¬ esttor c mmendthabothprep rationsarakesimulta eouslywithout alteringprogestogedos s.Aiscussedearli r,he lthywomitni k factorsmaytakeCOCuphgof50yearsgiveffectivecontra¬ ception,excellentyclecon r la dr lievearlym nopausalsymptoms. FUTUREDEVELOPMENTS Manyofthefuturedevelopmentsinc ntrac ptivet ch ology(review d VanLook,1995)willbeppropriatef olderm n.S efthn w
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Original Research Article
Incidence of Ovulation in
Perimenopausal Women Before and
During Hormone Replacement Therapy
Ailsa E. Gebbie, Anna Glasier, and Vicky Sweeting—
Once hormone replacement therapy (HRT) has been com¬
menced, it becomes extremely difficult to advise women
approaching the menopause on the need for contraception.
In this study of twenty women, neither the regularity of
their pre-existing menstrual cycle nor a random FSH con¬
centration predicted the likelihood of subsequent ovula¬
tion whilst taking HRT. HRT is not reliably contraceptive ■
and women commencing HRT whilst still menstruating
spontaneously must be advised on the need for additional
contraception. Contraception 1995;52:221-222
key words: ovulation, hormone replacement therapy,
contraception, perimenopause
Introduction
Women become less fertile as they approachthe menopause. There is nevertheless stillthe potential for conception if ovul tion oc¬
curs. Normal practice is to advise women to continue
to use contraception for one year following cessation
of menstruation if this happens at age 50 years or
above, and for two years if menses stop before 50
years. Many women experience symptoms that they
attribute to the menopause while still menstruating
and they frequently request and commonly receive
hormone replacement therapy (HRT). The prescribing
of HRT is likely to increase further as there is growing
awareness of the favourable effects of HRT, particu¬
larly on postmenopausal osteoporosis and coronary
artery disease.1 There is very little information on the
contraceptive efficacy of HRT2 and many doctors are
unsure about the need for contraception in perimeno¬
pausal women who are using HRT. We report the
incidence of ovulation, and by implication therefore
the need for contraception, in a group of women be¬
fore and during oral HRT.
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Materials and Methods
Twenty women aged between 42 and 52 years attend¬
ing a community-based menopause clinic complain¬
ing of vasomotor symptoms and requesting HRT were
recruited to the study. None had contraindications to
HRT, had used hormonal contraception within the
past year or had a history of anovulatory infertility.
On questioning, ten women described having regular
cycles while ten were menstruating irregularly with
last menstrual periods ranging from one week to ten
months earlier (median 4.6 weeks). Circulating serum
FSH concentration was checked randomly prior to
commencing the study. The women collected a spec¬
imen of early morning urine once per week for eight
weeks before and for twelve weeks after starting
HRT. Ovulation was monitored by measurement of
pregnanediol,3 the metabolite of progesterone, which
is unaffected by the concurrent administration of
progestogens in HRT.
All women took Prempak-C 1.25 mg/day (conju¬
gated oestrogens 1.25 mg daily with cyclical nor-
gestrel 150 ug for 12 days out of 28). Urine samples
were stored at -4°C and later analysed in batches
using in-house ELISA4 and results are expressed as a
ratio of the creatinine concentration to allow for vari¬
ations in urine output. A pregnanediol concentration
of >0.5 mmol/g creatinine was taken as the definition
of ovulation. FSH was measured using radioimmuno¬
assay. The results were analysed using the Student's
t-test for unpaired observations with log transformed
data.
Results
The women with irregular cycles were significantly
older (47.3 years + 1.0 SEM, p < 0.02) than those still
menstruating regularly (45.5 years + 0.75 SEM) and
they had significantly higher (p < 0.001] mean FSH
concentrations (26.0 + 6.5 SEM (range 3-67) IU/L
versus 14.2 + 6.0 SEM (range 3-61) IU/L). FSH con¬
centrations in the two groups are demonstrated in
Figure 1.
Prior to starting HRT, ovulation was detected in all
© 1995 Elsevier Science Inc.
















IRREGULAR CYCLE REGULAR CYCLE
Figure 1. FSH concentrations in women with irregular cy¬
cles and women with regular cycles.
ten women who had regular menses. Six of them con¬
tinued to ovulate while taking HRT.
Prior to starting HRT, ovulation was detected in
four of the ten women with irregular cycles. Three of
these women subsequently had anovulatory cycles
whilst taking HRT. Of the six women with irregular
cycles who failed to ovulate during monitoring before
HRT, three resumed ovulation during treatment.
Discussion
This small study demonstrates that the oral admin¬
istration of Prempak-C does not reliably inhibit ovu¬
lation even at the higher of the two available doses.
Although pregnancy is uncommon in women over 45
years, when it does occur it is associated with in¬
creased perinatal mortality, maternal morbidity and a
well recognised increase in fetal chromosomal abnor¬
malities. The pregnancy may well be catastrophic
psychologically and socially to the woman concerned.
Although in our study women over the age of 45 years
were more likely to have irregular anovulatory cycles,
ovarian activity fluctuated and spells of anovulation
were followed by spells of ovulation, clearly putting
these women at some risk of pregnancy.
Some of the symptoms experienced by these
women may in fact be unrelated to the menopause
and could be related to life stresses and the premen¬
strual syndrome. Use of low-dose, combined oral con¬
traception in healthy, low risk women in this age
group can offer reliable contraception and will also
relieve many of the symptoms experienced by these
women.
The measurement of FSH either before starting
HRT or during a break from hormonal contraception
is widely used to diagnose the menopause and some¬
times is the basis for advising women about the need
for contraception. From our study, it is clear that ran¬
dom FSH measurements are variable and that an ele¬
vated FSH does not necessarily mean that ovulation is
not occurring or will not occur in the future. One
woman had an FSH concentration of 67 1U/L before
entering the study, yet she ovulated in the next cycle
with urinary pregnanediol measurements, suggesting
entirely normal ovarian function.
Clearly, neither age, regularity of menstrual cycles
nor the measurement of FSH can reliably be used to
predict the need for contraception in perimenopausal
women using HRT. To be absolutely safe, it is prob¬
ably still best to advise women taking HRT to con¬
tinue to use some form of contraception until one or
two years after their last spontaneous menstrual pe¬
riod. This study highlights an important clinical area
and further research on larger numbers of women is
definitely indicated.
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Figure7.3 (A)Hulka-Glemensclip. Figure.7.3 (B)Filshieclip. recanalization,a dthereforefailure.TNd:Y gl s r,althoughprobably moreeffective,isextrem lyxpensive. Non-surgicalmethods Anumberofche icalagentshavebeet st dforth irb lityc lude thefallopiantubwhinstilled;tothubeith rd rectlyorv athe
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184HANDBOOKOFF MILYPLANNING contraceptionw sanIUDillnoticeimpr vem ntth rbleedi gpa ¬ terns.D spitehiherhaveb nnumb rofst di swh chdemon¬ stratedanincre side ceofhy ere tomymongwom nhav beensterilized(Hil istal1998).B aringinmindthenevitabchang s menstrualble dingpatte nsassociatedwi hadv cingtstop¬ pingthecombi edll(tmostmmonlyus dethoofreversib ec n¬ traception),itmaybeh twomehh vbe nsteriliz dorlik ly toseekhysterectomyrmo ewillingacc pti ,fh yl adin¬ capableoffurtherhildbearing. 2.Thetermpost-tubalsterilizationsyndromewasc n dde c bea varietyofsymptomsth thavebeenrepo tedaftert riliza ionndwhich womenmayattributethpr ced r .Thessymptomsincluabdo inal pain,dys areu iaexacerbationofprem ns rualsynd omedysmeno - rhoeaandem tionalpsychos xu lproblems.Lap r scopyf ilt demonstrateanypathology.Arecentr vi wfthlite ture(Ge tilt 1998)concludedthatsterilizationinoassoci edwithnincreasedi kf theseproblemsexceptamongwo nst rilizedbef ragof30in whomthesympto smayso e imesbaanifes ationfregr t. 3.Bowelbstructionfr madhesionsiv ryrarcomplicati . 4.Ectopicpregnancyhasbereportedinupt50%offail resfo lowing cauteryandin4%followingmechanicaloc lus vt ods.Alargeoll b¬ orativestudyundertakenithUSAandnvol i gver10000womens reportedin1996(Pet rsonal996).The0-yearcumula iveprob bilityof ectopicpregnancywas7.3r1000rocedure . Womenshouldbeadvisethatifymi sper odndhavsymptoms ofpregnancyth yshouldeekm dicaladv eurgently. 5.Severalstudieshavuggestedthaubateriliz tionm yr duc riskofvariancancer.Ila gAmericanstudy/theh zr tiow s0.64 (Miracle-McMahilltl1997).Ther asonfort iassociatioin lle r VASECTOMY Techniques Vasectomyinvolvesthdi isionrocclusionfaeferenpr ent thepassageofsperm.Itc nberformedunderLAG .Av i ty techniquesforvasocclusionisa ailablebuthepri ciplt samn ofthem. Divisionandligati Thevasispalpatedthrough.skinfup rscrotumandf xeeither instrumentallyorbe weethf g rsandhumb.Tvaswithii sfa cial sheathiexposedthrougham llkinincisio ,fascopenedlo git¬
STERILIZATION185













































































































































































































































































































































































































































































































































































































































































































































































































































































188HANDBOOKOFF MILYPL NING informationleaflet(Append x7.2«isse touwiththfirstap int ent informingthec upleaboutcomplicationsandthefa lurr tbef et y attendforcouns lli g.Th yarsk dtsignformst i gth eyhav readandunderstoodthinformationsh etadditionthstand dfor consentingtoperation. Complications Immediate 1.Bruisingandhacmatoma.Al teveryonewillexperiences ro albruis¬ ingbut1-2%ofmenp stop rativebleed gwillsufficienttcaus haematoma.Localsupportandnalgesiru u lydequatetre t ent butasmallnumberofmenwillrequiradmissionthospitaf rdrain ge ofthehaematoma. 2.Woundinfectionoccursupt5%fmeandaytre tm ntwith antibiotics. 3.Failure-upto2%fmenfailachi veazoospermia.Ifsperconfinue toappearinhejaculatef rmonths,thevasectomycbre-don .Th timingofa're-do' rexploratioismatterfdiscu si nbetw enth patientandsurgeo .Thcontinuprese ceofspermm ybdutinfre-
^quentejaculationbuifthisdonoappeartbhcasandifm ny
Ojspermarepres nt,itse mslittlha dtokthpatientprovidspeci-
Chmensmonthafteronthbef readmittingdefeat. Late 1.Spermgranulo as-smalllumpsyforatthcutendsfthevasa resultofalocainflamma oryresponsetleak dsperm.Themayb painfulandpalpableandcpers stforye rs.Excisionu u l ysolve theprobl m.Spermgranulomasm yalsphysicallunitethcutendof thevasandincre set a ceoffailure. 2.Chronicintrascrotalpainanddiscomfor(po t-vasectomyynd ome)- somemencomplainofadullheinthscr tuwhichmaybeexace bated bysexualexcitementandejaculation.Ths mpto sarprob blyduto distensiona dgra ulomaform ti nintheepididymisandv sdeferen . Painmaylsoresultfromscartissu To mingaroundsmallne v s.Chronic painassociatedwithprogressivinduration,tubul rdistensiona dgra ¬ lomaformationintheepididymismayquireexcisionftheepididym s andobstructedvasdefere . 3.Laterecanalization-failurc noc urupt10yearsftvase tomy despitetwonegativsamplesofse inalfluidfoll wingthproc dure.Iis rare(1in1000)butp egnancyasresultoflatreca aliz tionisalw ys sensitiveis ue.Itnottac fuloca ydoubthp t rnfthpreg¬ nancy.Semi alanalysisc nbeoff redutinosp rmarithej cu¬
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194HANDBOOKOFFAMILYPLANNING findingsfromtheU.S.CollaborativeReviewfSteriliz t n.AmericaJourn lfObs trics andGvnecology174:1161-1170 PetersonHB,owa dsSS1998Vas ctomyndpr statec ncer:thevide cetodate.Fertili y andSterility70:201-203 RoyalCollegefObstetricansandGynaecologists(R OG)1999Mala dfemsterilisation. Evidence-BasedClini alGuidel nesNo4.R OG,Lon o StraderCH,WeissNSDalingJR1988Vasectomyndthincide ceoftesticulcan r. AmericanJournalfEpidemiology128:56-63 VesseyMP,Lawles,YeatD1982Efficacyofdifferentcontraceptivemethods.Lan ti: 841-842









































































































































































































































































































































198HANDBOOKOFF MILYPL NING andtheratewhichishappensde e dsowftyouvint rcourse.Ywillb askedtosena-sp cimenofsemi alfluidthlaboratory12w e saft ry uoperationd againt16weeks.Inmostcase ,boths mplesi lfre fsp rma dwilleyoukn w thatyouroper tionisc mplete.Insomas s,ttakesmorh n16we kfotsp r clearandyouwillbasketcontin ese dsampl sev y4weekun ilt cons cut ve samplesarfreeofspe m.Inut2%c s s(2i100m n),sperco tinuap ard youwillbeadvisedthahvasectomyexpl r d,usua lynd rg eralan esth t cihos¬ pital.Un iyouhavebeentoldhatourerationiscompl e,y rurp rtnes oul continuetuseano hermethodofcontracepti n. In1i000casesthvasectomyfailstl terd t-ttwoe dofhvh li htim andrarelythec ale-op ns(so-c ll'latrec n lization').Ifthishappe s,youp t erm y becomepregnantd spity uhav gadtwosperm-freesam lesnb ingtoldth tyou operationwascomplete.Latre- analiz tionm yhapp nsy a saft ruh vdyou vasectomy.Bcomparison,sterilizationinthfem lefailaround3p r1000cases. Arethereanyproblems? Complicationscanbedividedintothosewhichightccurimmedia elyaft rtvas tomy andthosewhichdnotoccurf rsomeyea . Immediatecomplications Allsurgicaloperat onscarrysomeriskandvasectomyinex eptionbuthproble sa usuallyminor. Between5and10%ofm nexperi ncei orlocalpr blemsaft rthprocedu .Ont localanaesthetichwornoff(aft rab u2hour ),y uillprob blyfees medisc mfort whichisusuallyhelpedbytak ngmildpainkiller(paracetamolorspirin).M tmnot c certainamountofswellingndbruisi garoundthoperati nsitwhichla tfedays. Sometimesthesitcanbe oinfec dandy uayr quireantibio ics.Iyoot cp rsist¬ ingpain,swellingorredn ssyoush uldcont ctugeneralpractitioner.Occa ion l y, moderateamountofblee ingoccursanthebl osl wlyc l ctsthasoftscr tum causinglargeswellorhaematoma.1in00enrequireshospi altre tm ntft is complicationandlthoughthiscanber erfrigh e ingev t,idoesnotcauseanylo - termproblems. Long-termconsequences In10-15%ofmen,leakagespermfr mthcutendoftvasc us ssominflamm tiond occasionallysm llpainfullump(spermgranulomas)ya pear.Verarelthp im y lastforyearsafterva ec omybutfurths rgeryusuallyc r sthp bl m. Alargeamountofresearchh sbe nc rriedoutnthlong-t meff ctofv s tomyi ordertestablishwheth repr ce urehasnyeff ctogenerahealth.Whilth rse m benogo dvidencefora yseriouslong-termeff ct ,numbfstudi shavraiseth possibilityoftherebeingalinkbetw eprostatcancera dvasect my. Cancerofthprostateisrelativelyc mmonnmenalt ughr rebel wthgof65.I Scotlandabout650mendifr mthiseaseeachye ro paredw thabout2700m ndying fromlungca cera dbout1300womenho(lifrb e stc ncer.Thc usofpr statcan¬ cerisnotknownbuttsomewaydependenonthmalhort st terone. Mostcancersarssociatedwithcertainri kfact rs,e.g.menwhhavework diths m chemicalsaremuchorlik lytdev lopbladdercanceth noswn t.Wot' knowwhatriskfact rsarerelat dtp ostateance . Doeshavingvasectomyincreasey urhancoflat rdevelopi gc nc rftprost te?A lotfme.dicalresearchhasinvestigatedthpo sibilityfr lations ipbe we nvas ctomy andprostateca cer.Anumboflargst diesiChinaa dt eUSAh vsuggestedth thereisnoli kbetweenvas ctomyandtriofpro tatc nc .Inde ,ithChin
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Objectives I. To produce a list of evidence-based criteria for good quality care relating to female laparo¬
scopic sterilisation. 2. To assess the level of agreement with each criterion among gynaecologists in
Scotland. 3. To obtain an overview of current sterilisation practice for comparison with the agreed
criteria.
Design 1. Agreement with criteria assessed by questionnaire survey; 2. Overview of current practice
obtained by questionnaire survey and by casenote review.
Setting Scotland.
Sample 1. Questionnaire survey: all 132 consultant gynaecologists in NHS practice. 2. casenote review:
988 consecutive women sterilised in 12 representative hospitals.
Results The response rate to the questionnaire survey was 94%. A list of 15 evidence-based criteria
was produced, covering patient selection, information and counselling, techniques of tubal occlusion
and timing of sterilisation. All 15 suggested criteria gained an overall balance of support among
responding gynaecologists. Similar impressions of current practice were gained from the question¬
naire survey and from the casenote review. Aspects of practice which measured up well to the agreed
criteria included: only 6% of women sterilised were younger than 25 years of age; over 85%
of casenotes included clear documentation that women had been counselled regarding failure
rate and intended permanency; 88% of sterilisations were performed, or directly supervised by, a
gynaecologist of consultant or senior registrar status; and only 2% of sterilisations were undertaken
in combination with induced abortion. Aspects of practice which compared poorly with the agreed
criteria, and for which recommendations for change have been made, included: only 22% of
caseuotes mentioned that the option of vasectomy had been discussed; only 30% of gynaecologists
indicated that they provide locally produced information leaflets as an adjunct to counselling;
four methods of tubal occlusion (including .unipolar diathermy) were in use; and there were wide
variations among hospitals in the use of day-case care, ranging from 19% to 99%.
Conclusions A list of criteria for good quality care in relation to sterilisation has been validated by
agreement among Scottish gynaecologists. Current practice (as assessed by questionnaire survey and
casenote review) has been compared with the criteria and some recommendations for change in
practice have been made. Following dissemination of these results and recommendations, re-audit
will be undertaken in order to identify any changes.
INTRODUCTION
Laparoscopic sterilisation is a major component of
the Scottish NHS gynaecological workload. Around
7700 such procedures arc undertaken annually and
comprise almost 10% of total gynaecology inpatient
plus day-case discharges (Information and Statistics
Division, NHS in Scotland, 1993). Complications
and faihires of sterilisation arc a common cause of
litigation against gynaecologists, and there is concern
Correspondence: Dr G. C. Penney, Room 64, Top Floor. Maternity
Hospital, Cornhill Road, Aberdeen AB9 2ZD, UK.
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regarding the frequency of requests for reversal;
329 reversals of female sterilisation were performed
in Scotland, in 1993 (Information and Statistics
Division, NHS in Scotland, 1993).
Despite the frequency of sterilisation and the
concerns regarding litigation and patient-regret, there
are no agreed guidelines within Scotland covering
selection of patients, pre-sterilisation counselling or
appropriate techniques for tubal occlusion. Ii was
therefore decided to address the topic of female
laparoscopic sterilisation within a national audit
project, the Gynaecology Audit Project iivScotland.
As part of this project the views of gynaecologists
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Table 1. Suggested criteria lor good quality care in relation to laparoscopic sterilisation plus references from the literature on which they arc
based. Where no references are given, the statement summarised the views of the discussion panel.
Criterion Supporting references
Patient selection
1. In almost all cases, sterilisation should be refused to women under the age of 25 and reversible methods of contraception advised 2 6
2. Prior to sterilisation it should be verified, by gynaecological history taking and examination, that a more radical operation
is not indicated —
Patient information and counselling
3. Prior to female sterilisation, it should be ascertained that the option of vasectomy lias been fully discussed with
married/cohabiting couples. 7. 8,35
4. Pre-stcrilisation counselling should include discussion of failure rate (including risk ofectopic pregnancy) and
complications and should emphasise that the procedure is intended to be permanent. 34
5. Prc-sterilisation counselling should include enquiry into any disharmony within the current relationship. 3 6,13, 32.36 38
6. The fact that the palieni has been counselled regarding failure rate, complications and irreversibility should bo
documented in the case notes as well as appearing on a printed consent form. 34
7. Prior to sterilisation, women should be given an information leaflet summarising the various factors covered
in the counselling.
8. The likelihood ofa less acceptable menstrual pattern following sterilisation should be discussed with current users
of the contraceptive pill. 9 12.39
9. Women should be advised to continue with their current method of contraception (including the contraceptive pill)
until their admission for sterilisation.
Techniques for sterilisation ^
10. Filsliie clips represent the tubal occlusion technique ofchoice. 9. 13-22,40 44
11. Fxcopi where there are medical, social or geographical contra-indications, laparoscopic sterilisation should he
performed as a day-enso. 45,46
12. A post-MRCOG gynaecologist should perform, or he present at, all laparoscopic sterilisations and should confirm
occlusion of both fallopian tubes. 34
Timing of sterilisation
13. For almost all patients, sterilisation should be undertaken as an interval procedure rather than in association
with pregnancy (ie post- natally or combined with induced abortion). 13. IS, 23 31. 33. 34
14. Patients requesting sterilisation in association with pregnancy should he informed that this increases
the failure rate at least three-fold. This wanting should he documented in the ease notes. 34
15. On admission for sterilisation, co-existing pregnancy should be excluded by taking a mcnsli ual and
contraceptive history. A sensitive pregnancy test should be performed in cases of doubt. 34
about a list of evidence-based criteria for good
quality carc relating to sterilisation were sought by
means of a postal questionnaire survey, and addi¬
tional questions were asked about current sterilisation
practice. Information about current practice ' in
Scotland was obtained by means of eascnote review
in 12 representative hospitals.
The results of these exercises are presented in this
paper and will be disseminated among gynaecolo¬
gists in Scotland. In due course re-audit will
be undertaken in order to identify any changes in
practice. The criteria for good quality care discussed
here may provide a basis for the development of
formal clinical practice guidelines.
METHODS
A review of contemporary medical literature relating
to laparoscopic sterilisation provided the basis for a
provisional list of statements, or criteria, regarded
as summarising essential elements of good practice.
The criteria covered four broad aspects of patient
management: patient selection, information and
counselling, techniques for tubal occlusion and
timing ofsterilisation, the provisional list of criteria
was modified and refined following discussion by a
panel of clinicians, comprising three gynaecologists
with a special interest in fertility control and three
generalists. The final list of 15 criteria with a
summary of references from the literature review in
support ofeach is shown in Table I.
A questionnaire was then designed to assess level
of agreement with each criterion. Recipients were
asked to indicate their level of agreement with each
statement, as representing an important criterion for
good quality care, on a five-point scale. The scale
was graded strongly agree, agree, neither agree nor
disagree, disagree, and strongly disagree. Other
questions addressed aspects of current practice
related to the same four broad aspects of care covered
by the 15 criteria.
In November 1994 the questionnaire was mailed to
all 132 consultant gynaecologists in NHS practice in
Scotland at that time. The mailing list was based on
names and addresses obtained from the Royal
College of Obstetricians and Gynaecologists and
updated by telephone enquiry to all 26 gynaecology
units in Scotland. A second copy of the questionnaire,
ift RC'OG 1097 Br J Ohstet Gynaecol 104, 71- 77
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Table 2. Levels of agreement with criieria for good quality care. For each criterion (numbered as in Table I), the lable shows llie ranking in
importance assigned, the agreement score (on a scale ranging front > I (10 to -100) and the percentage of consultants who agteed or strongly
agreed.
Rank Criterion No. Abbreviated criterion Agreement score % agreed
1 4 Content ofcounselling +91 I0O
-) 6 Documentation of counselling +80 98
3 9 Continue contraception pre-sterilisntion + 80 98
4 15 Exclude co-existing pregnancy +78 94
5 14 Document increased failure rate for sterilisation in association with pregnancy +5X 83
6 11 Day-case care • 55 82
7 2 Ere-sterilisation history and examination i-50 81
8 13 Interval procedure rather than concurrent with abortion i49 78
9 3 Vasectomy discussed +46 72
10 8 Post-pill altered menstrual pattern +43 76
II 5 Enquiry into disharmony in relationship +37 67
12 12 Post-MRCOG gynaecologist present +36 64
13 7 Information leaflet • 36 59
14 10 Fiishie clip: method of choice +22 54
15 1 Age cutoffof 25 years +7 46
with a letter of reminder, was sent to those
consultants who did not respond within three weeks.
Data from the questionnaires were entered into a
database using Paradox (Borland) software on an
IBM-compatible I'C.
In order to quantify the overall balance of agree¬
ment with the suggested criteria, an agreement score
was allocated to each criterion. The agreement scores
were calculated as previously described1 by allocat¬
ing each response of strongly agree a score of+2; of
agree + 1; of neutral 0; of disagree -1 and ofstrongly
disagree -2. The scores for each criterion were
summed and expressed as a percent of the maximum
possible score had all participants strongly agreed.
Thus, any positive score indicates a balance of agree¬
ment, + 100 is the maximum possible score and -100
is the minimum possible score.
Twelve hospitals throughout Scotland were
recruited into the casenote review audit. These
were selected as being representative of Scotland
as a whole in terms of teaching/district general,
large/small and geographical spread. A casenote
review document was designed for the transfer of
information relating to the agreed criteria from
patients' records. Audit assistants with a medical
secretarial background in each hospital received a
training session from one of the Research Fellows
(V.S./G.C.P.) on transferring information from
sample casenotes to the document. Thus, data were
collected in a standardised manner in all 12 partici¬
pating hospitals. Commencing in June 1995, the audit
assistants began identifying 100 consecutive cases of
laparoscopic sterilisation undertaken in each hospital,
completed the casenote review documents and retur¬
ned them to the project office for computerisation.
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RESULTS
Response rates
As a result of the two mailings, 124 completed
consultant survey questionnaires were received (a
response rate of 94%). One consultant indicated that
he never performed laparoscopic sterilisation and
answered no further questions. Thus, the resulting
overview of current opinion and practice is based on
the replies of 123 gynaecologists who undertake
female sterilisation in the course of their routine Nl IS
practice.
The intention was to review the notes of 100
consecutive patients in each of the 12 participating
hospitals. However, in the funded data collection
period of approximately four months, fewer than 100
sterilisations were performed in some hospitals. A
total of 988 cases were reviewed (mean 82 cases per
hospital; range 41 to 100 cases).
Opinion on suggested criteria for good quality care
Table 2 summarises all 15 criteria arranged according
to agreement scores. The scores represent an attempt
to indicate the strength of support for each criterion,
giving additional weighting to responses of strongly
agree or strongly disagree rather than simply agree or
disagree; however the level of agreement with each
criterion is also shown in terms of the percentage of
respondents who agreed or strongly agreed.
All 15 criteria gained positive agreement scores,
indicating a balance of support among consultants.
However, the level of support ranged from universal
agreement with "Presterilisation counselling should
include discussion offailure rate (including risk of
242
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ectopic pregnancy) and complications and should
emphasise that the procedure is intended to he
permanent" to a meagre balance of agreement witlt
"In almost all cases, sterilisation should be refused
to women under the age of25 and reversible methods
ofcontraception advised".
Overview of current practice
Patient selection
Consultants were asked whether or not they adopt an
age cutoff below which they would usually refuse
sterilisation. Only 27 (22%) indicated that they do so;
the most popular minimum age selected was 25 years
(as suggested in the audit criterion), ranging from 16
to 30 years. Among the 988 patients studied in the
casenole review, only 56 (6%) were younger than 25
years of age and 280 (28%) were younger than 30. -
Among individual hospitals the proportion of women
sterilised under 25 and under 30 years of age ranged
from 2% to 10% and 18% to 43%, respectively.
With regard to adequacy of pie-sterilisation
gynaecological history taking and examination, the
findings of a pre-operative pelvic examination were
documented in only 512 (52%) of casenotes, and the
result of a cervical smear within the previous three
years was documented in only 613 (62%).
Patient information and counselling
No respondents indicated that they routinely insist on
counselling women requesting sterilisation along with
their partners, although 29 (24%) would ask the male
partner to attend if there were particular medical con¬
traindications to female sterilisation; and 57 (46%)
would include the male partner in counselling "ifhe
happened to be present". Thirty-seven individuals
(30%) indicated that they never see the male partner.
Consultants also were asked if they include discus¬
sion of vasectomy in pre-sterilisation counselling and
whether for couples in stable, long term relations,
they usually advocate vasectomy as the method of
choice. Sixty respondents (49%) said they always
discuss vasectomy, 52 (42%) in "selected cases" and
11 (9%) never do so. Only 25 (20%) said they usually
advocate vasectomy as the method of choice.
Despite the universal agreement that women should
be fully informed about failure rate, complications
and irreversibility, only 37 consultants (30%) indi¬
cated that a sterilisation information leaflet produced
within their own department was available. A further
34 (28%) indicated that standard leaflets (e.g. Family
Planning Association) were available and 52 (42%)
said that they do not provide information leaflets.
Table 3. Usual method of tubal occlusion used al laparoscopic sterili¬
sation. Values are given as n (%).
Method ofocclusion Reported usual practice* Actual method usedf
Filshie clip 73 (59) 617 (62)
Falope ring 35 (29) 244 (251
Hulka Clemens clip 9 (7) 85 (9)
Diathermy methods 6 (5) 31 (3)
Unclassified 11 (1)
TOTAL 123 (100) 988 (100)
*n = 123 gynaecologists responding to questionnaire survey,
t'l - 9X8 cases of laparoscopic sterilisation reviewed.
Results from the casenote review exercise relating
to documented counselling mirrored those of lite
questionnaire survey. Discussion of the option of
vasectomy was documented in only 148 cases (15%).
However, formal documentation in addition to infor¬
mation on the printed consent form relating to
irreversibility and failure rate was found in over
86% of casenotes, although increased risk of ectopic
pregnancy among failures was mentioned in only
59%. Evidence of any enquiry into the stability of the
current relationship was found in only 45% of
casenotes.
Techniquesfor sterilisation
Consultants were asked which method of tubal occlu¬
sion they use most often. Responses are summarised
in Table 3. Over half of respondents usually use the
Filshie clip with the Falope ring the next most popu¬
lar method. Of 105 consultants who ever use a clip
method of sterilisation, 17 (16%) apply two clips to
each tube as a routine. Most of the others (78, 74%)
occasionally use two clips when accurate placement
of the lirst clip is in doubt.
The methods of tubal occlusion used in the 988
sterilisations reviewed are also summarised in
Table 3. Among the 702 sterilisations where clip
methods were employed, more than two clips were
applied in 34% of cases. Among individual hospitals
the rates ofapplying more than two clips ranged from
1% to 96%, reflecting the variations in consultants'
reported practice.
The vast majority of respondents (104, 84%) indi¬
cated that they routinely treat sterilisation as a day
case procedure in the absence of medical, social or
geographical contraindications. Among the 988
patients reviewed, 714 (72%) were managed as day
cases. Of the remainder, 180 women (18%) stayed
one night, 81 (8%) stayed two nights and the others
for variable, longer periods. Among individual hospi¬
tals, day case care rates ranged front 99% down to
45 RCOG 1997 Br J Ohstct Gynaecol 104, 71-77
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19%. These variations were not entirely explicable on
geographical grounds as the two hospitals with the
lowest utilisation of day case care (19% and 40%) are
both located in the central belt of Scotland.
Overall, 738 (75%) of the 988 sterilisations
reviewed were performed by a consultant or senior
registrar, and it was evident front the operation note
that a further 127 procedures (13%) had been directly
supervised by a gynaecologist of these grades.
Among the 12 individual hospitals studied, the.
percentage of sterilisations performed, or directly
supervised, by a gynaecologist ofconsultant or senior
registrar status ranged from 76% to 100%.
Timing oj sterilisation
One hundred and eight consultants answered a ques¬
tion about their usual policy for women requesting
both induced abortion and sterilisation; the remaining-
15 respondents indicated that they do not perform
abortions. Of these 108, 30 (28%) would usually
perform the two procedures concurrently whereas 78
(72%) would arrange interval sterilisation at least
six weeks after abortion. In practice, among the 988
sterilisations reviewed only 17 (2%) were undertaken
as combined procedures with induced abortion.
DISCUSSION
The questionnaire provided an informative overview
of current opinion and practice in relation to laparo¬
scopic sterilisation among gynaecologists in Scotland.
A list of evidence-based criteria for good quality care
has been validated by an overall balance of agree¬
ment among participating clinicians and was adopted
as the basis of standards for the casenote review
audit. In due course, the criteria may also serve as a
foundation for the development of a national clinical
practice guideline.
The first suggested criterion that in general women
younger than 25 years of age should be advised
against sterilisation is based on evidence that younger
women have a higher incidence of post-sterilisation
regret and of request for reversal2 In a study of
some 6000 post-sterilisation patients Wilcox el al.5
found that those who were younger than 30 years at
the time of sterilisation were twice as likely to seek
information on tubal reanastamosis as those aged 30
to 34. In view of this evidence, and the fact that the
number of reversals of sterilisation undertaken annu¬
ally in-Scotland amount to around 5% of the total
number of sterilisations (Information and Statistics
Division, NHS in Scotland, 1993), it is disappointing
that this criterion was the least strongly supported of
the 15 suggested.
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Criterion 3 suggests that all couples requesting
sterilisation should be fully counselled about the
option of vasectomy on the basis that this procedure
is safer, cheaper and no less effective than female
sterilisation7-8. Again, it is perhaps disappointing that
no gynaecologists insist on counselling pre-sterilisa-
tion patients along with their partners and that only a
fifth regard vasectomy as the method of choice for
most couples.
Reviews of failure rates associated with different
methods of tubal occlusion suggest that diathermy
carries the lowest overall failure rale (around 2-3 per
1000), whereas Fajope rings and clip methods carry a
somewhat higher failure rate of around 4 per 1000".
However the apparent advantage of tubal diathermy
is counterbalanced by the high incidence of ectopic
pregnancies among diathermy failures. Ectopic
rates of over 50% are reported among pregnancies
following tubal diathermy, whereas ring and clip
method failures are associated with ectopic rates of
less than 5%". Another major drawback of diathermy
sterilisation is the potential for serious intra-operative
complications, principally bowel burns which may
result in the need for bowel resection or even in
death®-14 l7. There seems to be little to choose
between ring and clip methods of tubal occlusion
in terms of failure and ectopic rales. However,
ring methods are associated with more serious intra¬
operative complications, in the form of tubal avulsion
and haemorrhage®-1*-1® and with a higher incidence of
peri-operative pain2". Another factor to consider
when selecting a tubal occlusion technique, par¬
ticularly for younger women, is the potential for
reversibility. Diathermy sterilisation damages up
to 5 cm of tube, resulting in a very low potential for
successful reversal. Clips damage only around 5 mm
of tube, thus providing the optimum chance of suc¬
cess if reversal is required1®. The project's discussion
panel ofclinicians therefore agreed that a clip method
of tubal occlusion was to be preferred. The Filshie
clip was suggested as the tubal occlusion technique
of choice on the basis of evidence relating to failure
rate, incidence of ectopic pregnancies among
failures, peri-operative complications and potential
reversibility. The project panel favoured the Filshie
rather than the Hulka clip on the basis of one study21
which directly compared the two, and concluded that
the Filshie clip was preferable because its larger
capacity facilitated the occlusion of thick tubes and
the applicator was easier to use and maintain. The
panel strongly supported the views of a British
Medical Journal editorial written in 198022 which
expressed surprise that "relatively uncontrolled
unipolar electrocoagulation is still used; even in
soma teaching centres in Britain ". The survey has
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19%. These variations were not entirely explicable on
geographical grounds as the two hospitals with the
lowest utilisation of day case care (19% and 40%) are
both located in the central belt ofScotland.
Overall, 738 (75%) of the 988 sterilisations
reviewed were performed by a consultant or senior
registrar, and it was evident from the operation note
that a further 127 procedures (13%) had been directly
supervised by a gynaecologist of these grades.
Among Hie 12 individual hospitals studied, the
percentage of sterilisations performed, or directly
supervised, by a gynaecologist of consultant or senior
registrar status ranged from 76% to 100%.
Timing ofsterilisation
One hundred and eight consultants answered a ques¬
tion about their usual policy for women requesting
both induced abortion and sterilisation; the remaining
15 respondents indicated that they do not perform
abortions. Of these 108, 30 (28%) would usually
perform the two procedures concurrently whereas 78
(72%) would arrange interval sterilisation at least
six weeks after abortion. In practice, among the 988
sterilisations reviewed only 17 (2%) were undertaken
as combined procedures with induced abortion.
DISCUSSION
The questionnaire provided an informative overview
of current opinion and practice in relation to laparo¬
scopic sterilisation among gynaecologists in Scotland.
A list of evidence-based criteria for good quality care
has been validated by an overall balance of agree¬
ment among participating clinicians and was adopted
as the basis of standards for the easenote review
audit. In due course, the criteria may also serve as a
foundation for the development of a national clinical
practice guideline.
The first suggested criterion that in general women
younger than 25 years of age should be advised
against sterilisation is based on evidence that younger
women have a higher incidence of post-sterilisation
regret and of request for reversal- ". In a study of
some 6000 post-sterilisation patients Wilcox cl al.s
found that those who were younger than 30 years at
the time of sterilisation were twice as likely to seek
information on tubal reanastamosis as those aged 30
to 34. In view of this evidence, and the fact that the
number of reversals of sterilisation undertaken annu¬
ally in Scotland amount to around 5% of the total
number of sterilisations (Information and Statistics
Division, NHS in Scotland, 1993), it is disappointing
that this criterion was the least strongly supported of
the 15 suggested.
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Criterion 3 suggests that all couples requesting
sterilisation should be fully counselled about the
option of vasectomy on the basis that this procedure
is safer, cheaper and no less effective than female
sterilisation78. Again, it is perhaps disappointing that
no gynaecologists insist on counselling pre-sterilisa-
tion patients along with their partners and that only a
fifth regard vasectomy as the method of choice for
most couples.
Reviews of failure rates associated with different
methods of tubal occlusion suggest that diathermy
carries the lowest overall failure rate (around 2 -3 per
1000), whereas Fajope rings and clip methods carry a
somewhat higher failure rate of around 4 per 10()0IJ.
However the apparent advantage of tubal diathermy
is counterbalanced by the high incidence of ectopic
pregnancies among diathermy failures. Ectopic
rates of over 50% are reported among pregnancies
following tubal diathermy, whereas ring and clip
method failures are associated with ectopic rates of
less than 5%'\ Another major drawback of diathermy
sterilisation is the potential for serious intra-operative
complications, principally bowel burns which may
result in the need for bowel resection or even in
death'''14 I7. There seems to be little to choose
between ring and clip methods of tubal occlusion
in terms of failure and ectopic rates. However,
ring methods are associated with more serious intra¬
operative complications, in the form of tubal avulsion
and haemorrhage''18'1'' and with a higher incidence of
peri-operative pain70. Another factor to consider
when selecting a tubal occlusion technique, par¬
ticularly for younger women, is the potential for
reversibility. Diathermy sterilisation damages up
to 5 cm of lube, resulting in a very low potential for
successful reversal. Clips damage only around 5 mm
of tube, thus providing the optimum chance of suc¬
cess if reversal is required1''. The project's discussion
panel of clinicians therefore agreed that a clip method
of tubal occlusion was to be preferred. The Filshie
clip was suggested as the tubal occlusion technique
of choice on the basis of evidence relating to failure
rate, incidence of ectopic pregnancies among
failures, peri-operative complications and potential
reversibility. The project panel favoured the Filshie
rather than the liulka clip on the basis of one study21
which directly compared the two, and concluded that
the Filshie clip was preferable because its larger
capacity facilitated the occlusion of thick tubes and
the applicator was easier to use and maintain. The
panel strongly supported the views of a British
Medical Journal editorial written in 1980" which
expressed surprise that "relatively uncontrolled
unipolar electrocoagulation is still used, even in
some teaching centres in Britain The survey has
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Continuation Rates of Long-Acting
Methods of Contraception
A Comparative Study of Norplant® Implants and
Intrauterine Devices
Diana Fleming, J. Davie, and A. Glasier
ELSEVIER
Following adverse widespread publicity in the United
Kingdom and the United States, it is commonly believed
that discontinuation rates for the contraceptive implants
Norplant® in the UK are high.
We have compared discontinuation rates between new
intrauterine device (IUD) users (253 women) and new
Norplant implant users (502 women) over 33 months
following the introduction of Norplant implants among a
population of women attending the same clinic and coun¬
seled in the same manner by the same group of providers.
Women choosing the 1UD were slightly older and were
more likely to be changing their contraceptive method
because of dissatisfaction with their current method. Nor¬
plant implant users were more likely to have completed
their families. Continuation rates for Norplant implants
were significantly higher than for 1UD at 12, 18, and 21
months after insertion. At 21 months, continuation rates
for Norplant implants were 72% compared with rates of
55% for 1UD users. Higher continuation rates may be
related more to factors associated with the providers than
with the users of these two long-acting methods.
Contraception 1998;57:19-21 © 1998 Elsevier Science Inc.
All rights reserved.
key words: Norplant® implants, intrauterine device, con¬
tinuation rates
Introduction
Norplant® implants became available in tbeUnited Kingdom in August 1993. Their intro¬duction was accompanied by widespr ad pu ¬
licity in the popular press. The pharmaceutical com¬
pany who marketed Norplant implants had in place a
national training program to ensure that a cohort ol
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doctors were competent to insert and remove the
rods. Adverse publicity in 19951"3 in both the UK and
the United States resulted in a number of women
requesting removal of implants, which, together with
removals for side effects, led to the widespread im¬
pression that "everyone was having their implants
removed." We audited continuation rates among
women who had had Norplant implants inserted in a
large community family planning clinic in Edinburgh
and demonstrated continuation rates of 84% at 1 year
and 80% after 18 months of use.4 Despite these data
and national figures5 showing similar continuation
rates, anecdotally, many medical and nursing staff
responsible for delivering contraceptive services in
the UK had expressed the view that the Norplant
implants launch had been a failure.
We present a study comparing continuation rates
among women choosing a copper intrauterine device
(also requiring insertion and removal by a doctor),
provided in the same clinic setting and during the
same time span, with continuation rates among
women choosing the Norplant implants.
Materials and Methods
A retrospective review of the case records was carried
out of all women (n = 370) who had had nonhormonal
IUD inserted from August 1, 1993, to May 1, 1995, in
a large Family Planning clinic in Edinburgh, Scotland.
Only first time users of the method (2,53) were in¬
cluded in the study; all those who had used an IUD in
the past were excluded, as the comparison was made
with the new users of Norplant implants. There were
no other exclusion criteria.
If a patient had not attended the clinic for a fol¬
low-up within 1 year of the review, a standard letter
of inquiry was sent out to the patient. If the patient
failed to reply, a letter was sent to her general practi¬
tioner (family doctor) to ascertain whether an IUD
was still being used as a method of contraception. If
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tacted by telephone to establish whether he/she had
further information as to the patient's current contra¬
ceptive use. Those patients for whom no further
information could be collected were recorded as lost
to follow-up. Information collected from women who
returned their questionnaires included age, parity,
date of 1UD insertion and removal (if applicable), prior
method of contraception, reason for the IUD being
requested as a method of contraception, and reasons
why removal of the IUD was requested. The same
data on new Norplant implants users were collected
from the same family planning center, prospectively
from August 1, 1993, to May 1, 1995.'1
Both IUD and Norplant implants users had been
counseled before the insertion of the device. Advan¬
tages, disadvantages, and suitability of the method
were discussed at a general contraceptive clinic. The'
insertion of the device was undertaken at a second
visit in a dedicated IUD or Norplant implants clinic,
at which time the suitability for the method was
confirmed and counseling reinforced.
Results were analyzed using the xl test for discreet
variables. A p <0.01 was considered to be significant.
Results
From August 1, 1993, to April 30, 1995, 502 women
had Norplant implants inserted and were followed-up
until the removal of the implant or to April 30, 1996;
45 (9%) of these women were lost to follow-up. A
total of 253 new users of nonhormonal IUD were
identified, of which 42 (16%) were lost to follow-up.
Characteristics of Users
Women who chose an IUD tended to be slightly older
than women choosing Norplant implants (mean age
30.7 vs 27.2 years, respectively). Fifty-four percent of
IUD users |p <0.001) were over 30 years of age at the
time of insertion compared with 30% of Norplant
users. There were no differences in parity or number
of liveborn children between women choosing differ¬
ent contraceptive methods. Women who chose Nor¬
plant implants were more likely to have been using
the combined oral contraceptive pill at the time of
choosing their new method than were IUD choosers
(p <0.001) who were more likely to be using condoms
(p <0.01). The most common reason for choosing
Norplant implants was as an alternative to steriliza¬
tion whereas that for choosing the IUD was because
of dissatisfaction with other contraceptive methods.
Insertions and Removals
Figure 1 shows the cumulative number of insertions
and removals of the two methods over the 33-month
Months of the Study Period
Figure 1. Cumulative number of insertions and removals
of Norplant implants and nonhormonal IUDs over the
33-month study period (August 1, 1993 to May 1, 1995) in a
large family planning clinic in Edinburgh, Scotland.
study period. An average of 10.3 (SD 4.0) IUD were
inserted each month compared with 24 (SD 13.8)
insertions of Norplant implants. Although a higher
percentage of IUD were removed during the study,
they were removed steadily at an average of 3.2 (SD
1.8) per month. Removals of Norplant implants in¬
creased with time with a mean monthly removal rate
of 1.4 (SD 2.2) in the first 18 months and a mean of 7.8
(SD 3.8) in the subsequent 15 months.
Continuation Rates
Continuation rates were higher at all time points
among users of Norplant implants. At 12 months,
continuation rates were 84% for Norplant users com¬
pared with 70% for the IUD users, and at 18 months,
were 80% for Norplant and 63% for the IUD. By 2
years after insertion, 71.8% of women were continu¬
ing to use Norplant implants compared with only
54.6% for IUD users (p <0.001).
Reasons for Discontinuation
More than one reason was often cited for discontinu¬
ation of a method. For both methods, the predomi¬
nant reason for removal was bleeding problems (Table
1). Users of Norplant implants experienced menstrual
irregularity, whereas for IUD users menorrhagia was
common. In 10 of the 16 cases in which pain was
cited as a reason for IUD removal, this was associated
with menorrhagia. Other reasons for removal of Nor¬
plant implants included mood swings, weight gain,
and headaches. Only one woman having the Norplant
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Table 1. Reasons for removal of norplant implants (n =
142) and iud |n = 104)
Reason Norplant IUD
Removed Removals Removals
Bleeding problems 64 40
Pain 6 16




Preferred sterilization 6 4
Postcoital insertion 0 6t
Mood swings 47 0
Weight gain 23 0
Headache 19 0
Acne 11 0
Hair problems 5 0
Relationship ended 3 2
Adverse Publicity 1 0
'Pregnancy undiagnosed at time of insertion.
1IUD inserted post coitaliy, initially planned to continue hut changed
mind.
Discussion
Continuation rates among women using Norplant
implants were much higher than those for IUD users,
which is reassuring to both providers and users par¬
ticularly as the 1UD is regarded as a very useful
(although not widely used) method of contraception
in the UK. There were no differences in the manner in
which the two groups of women were counseled
about their choice of method and counseling was
undertaken by the same staff in the same clinic.
Women using Norplant implants tended to be a little
younger than IUD users but, implicit in their choos¬
ing between sterilization and Norplant implants, they
were perhaps more likely to have completed their
families. This is reflected in the higher number of
removals among IUD users who were planning an¬
other pregnancy.
Although the cost of the chosen method, together
with fees for removal or insertion, may play a part in
continuation rates in other countries such as the US,
this is not the case in the UK where contraception is
free to the user. However, providers do pay for the
cost of contraception in their clinic budgets and they
have become much more cost conscious in recent
years. A "trial" of an IUD (at < $16.50 pet device)
may be regarded as acceptable, whereas a trial of
Norplant implants (at $280) would be quite unaccept¬
able. The threshold for insertion and removal of IUD
may thus be lower.
Access to removal may also have influenced con¬
tinuation rates. Although no fees are charged for
either insertion or removal of cither method, whereas
most doctors are capable of removing an IUD, only a
small number have been trained to remove the Nor¬
plant implants. A woman wishing to have her 1UD
removed can be seen by her family doctor or by a
doctor at a family planning clinic. For Norplant
implants users, removal requires a visit to one partic¬
ular clinic that may be much less geographically
convenient, thus encouraging women to postpone
removal for a little longer. However, easy access to
the implant clinic by telephone, by self-referral, or at
the request of her general practitioner was offered at
the time of insertion. Assurance was given that re¬
moval could be undertaken, if necessary within 1
week.
In conclusion, comparison of discontinuation rates
between Norplant implants and the IUD demonstrate
that, contrary to popular belief, women who have
been well counseled will manifest high Norplant
implants continuation rates.
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Menstrual bleeding patterns and
contraception
Introduction
Disruption of the cyclical pattern of menstrual bleeding presents
a major obstacle to the widespread continued use of many types
of contraceptive. These disturbances range from amertorrhoea to
heavy irregular bleeding throughout the time of administration.
Irregular bleeding is the commonest reason for the
discontinuation of all types of progestagen-only contraception
including Pills (30-40%); injectable methods (50%); vaginal
rings (3B-40%) and implants (50%).' Similarly, excessive'
menstrual blood loss (MBL) is the usual cause of premature
removal of the 1UD.
Natural menstrual bleeding is the result of biochemical and
structural changes in the endometrium induced by alterations in
ovarian steroids. In the follicular phase of the cycle the high
levels of oestradiol stimulate the repair and proliferation of the
stroma and epithelial layers of the endometrium. During this
time of unopposed oestrogen, the synthesis of receptors for
oestradiol and progesterone is stimulated so that maximum
concentrations are achieved around midcycle. thus making the
endometrium responsive to progesterone. Following ovulation,
the synthesis of steroid receptors is inhibited by progesterone.
Thus, priming with oestrogen is necessary before progesterone
can induce secretory changes. Normal menses occurs in
response to the decline in the concentration of progesterone
which happens when the corpus luteum regresses. Any
alteration in the cyclical exposure of the endometrium to
unopposed oestrogen, followed by oestrogen and progesterone,
is likely to result in disturbances in the menstrual pattern. Drugs
which have an effect on the ovarian cycle or which themselves
contribute to the fluctuations in oestrogen and progesterone, as
well as devices or drugs which interfere with the orderly
development of the endometrium, are likely to affect the pattern
of menstrual bleeding.
Combined oral contraceptives (COCs)
Since the combined Fill inhibits ovulation and replaces the
normal ovarian cycle, in the absence of erratic Fill taking, it is
not likely to be associated with disturbances of menstrual
bleeding. Indeed, one of the reasons why the COC is so popular
is because the majority of users experience a highly predictable
pattern of regular menstrual bleeding (actually withdrawal
bleeding), during the Pill-free week. Nevertheless,
intermenstrual bleeding is reported in some 2-2(1% of cycles
and amenorrhoea in up to 8%. A World Health Organization
Multicentre Study" reported, in 1982, a discontinuation rate for
bleeding disturbances of 9.7% after one and 14.9% after two
years of use of a combined oral .ontraceptive Pill containing
30 /xg of ethinyl oestradiol. Abnormal bleeding is more likely
with low-dose Pills and is said to improve with time. As a first
approach to the management of breakthrough bleeding, a
change of Pill to one containing a higher dose of oestrogen is
worth trying and makes sense physiologically. The triphasic Pill
was developed in an attempt to improve cycle control, but there
~Ts no good evidence to suggest that it is any better in this respect
than monophasic Pills, particularly after the first three cycles.'
The reason why some women fail to bleed during the Pill-
frce week and develop amenorrhoea is not clear. It is possible
that their ovaries may be totally suppressed and that in contrast
to the majority of women on COCs there is no rise in the level of
endogenous oestradiol during the Pill-free week. In most
women on COCs the brief time unopposed oestrogen is present
is likely to stimulate the development of steroid receptors which
permit the endometrium to respond to oestrogen and
progestagen. Women who develop amenorrhoea while on the
Pill may have endometrial atrophy because of a lack of
endogenous oestradiol sufficient to develop steroid receptors.
Injectable pragestagen-oestrogen contraceptive methods
have been developed by WHO and allow a single defined
bleeding episode.4 While these combined preparations are as
effective in preventing pregnancy as injectable progestagen-
only methods, the rale of discontinuation for bleeding
irregularities after 12 months is low (6.3-7.5%). as is that lor
amenorrhocu (1.6-2.1%). Combination vaginal rings releasing a
progestagen and an oestrogen have been tested by tire
Population Council. In a multicentre study4 there was no
difference in the incidence of intcnncnstrual bleeding or
spotting when the ring was compared with a 30 /ig combination
Pill, and both methods produced similar bleeding patterns.
Progestagen-only contraception
All methods of progestagen-only contraception are associated
with a relatively high incidence of bleeding disturbances.
Around 40% of women taking the progestagen-only Pill (POP)
continue to ovulate regularly,'1 while the remainder will have
anovulatory cycles (23%); cycles with insufficient luteal phases
(21 %); or amcnorrhoea (15%).
When continuous exogenous progestagens are superimposed
on irregularly fluctuating concentrations of endogenous steroid
hormones it is hardly surprising that irregular bleeding patterns
occur.' It is more difficult to explain the occurrence of
breakthrough bleeding in the presence of high doses of
progestagen (with DMPA or during the first year of Norplant
use). In this case the mechanism is probably a result of
endometrial factors, such as the inadequate development of
steroid receptors. There is little evidence to suggest that
irregular bleeding associated with POP use improves with a
change to a different brand of POP if the dose of gestagen is
equipment, nor does it improve with time.
In contrast, women using injectable methods tend to develop
amenorrhoea with increasing duration of use (30-50% after one
year and a higher percentage with long-term use). In some
societies, it may be culturally unacceptable, however, to have
amenorrhoea. despite the potential health benefits. Cyclical oral
oestrogen administration in combination with DMPA has been
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shown lo be effective in producing better cycle control,' but
converts the regimen into a much more complicated method of
contraception, and may cause more side-effects and increase the
risk of cardiovascular complications.
Gestagen-only subdermal implants and vaginal rings release
constant amounts of steroid hormone, hut are nevertheless
associated'with disturbances of bleeding patterns. The situation
with Norplant does improve with time." but in one study 26% of
women abandoned the method within the first year." The
progestagen-only vaginal ring is associated with a similar
discontinuation rate for menstrual disturbances as the POP
(15%), but in studies undertaken to dale, amenorrhoea appears
lo be an uncommon complication.1"
Intrauterine devices
That the use of the 1UD is associated with increased MBL is
undisputed. However, the mechanism underlying the
phenomenon remains unclear. A local inflammatory response
may cause injury to small blood vessels, alter prostaglandin
synthesis and release, increase fibrinolytic activity and impair
haemostasis." Efforts have been concentrated on designing
devices which would reduce the problem. The addition of
copper to lUDs allowed a reduction in (heir size, while
maintaining or even improving their contraceptive efficacy.
Copper [UDs are associated with fewer bleeding problems than
inert devices,14 but their use still results in a higher MBL and
longer duration of menstrual bleeding than occur in the natural
cycle. The new flexible IUD." consisting of small copper beads
threaded on nylon embedded into the myometrium of the
fundus, may be associated with reduced MBL, but (he
progeslagen-releasing I UDs probably offer the best possibility
of overcoming (he problem. Alter a high incidence of
bleeding/spotting days in the first three months there is a
reduction in the duration and amount of bleeding in association
with endometrial atrophy and. indeed, one of the commonest
reasons for discontinuation in early trials was amenorrhoea.1
Conclusion
It has lo lie remembered that the acceptance of disturbances,of
menstrual bleeding varies among women, depending on a
number of factors including cultural considerations and the
availability of alternative methods. The number of women
discontinuing a method for a particular reason probably
represents only a fraction of the number experiencing and
tolerating that side-effect. The development of new and
improved methods of contraception should not rely on a high
level of tolerance of so-called 'nuisance side effects'. However,
there is a real need for further research lo increase our
understanding of the mechanism of normal menstruation so that
future contraceptive methods with a low incidence of menstrual
disorders may be developed. Dr Jose Barzelatto. in his
welcoming address lo participants attending a WHO
Symposium on contraception and mechanisms of endometrial
bleeding held in 1988, doubted whether "it is possible at all to
develop steroidal contraceptives which do not cause any
bleeding irregularities" — unfortunately, lie may be right.
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The use of progesterone vaginal rings
as contraceptives for lactating
women
The contraceptive efficacy of breast feeding is high during the
time of lactational amenorrhoea, but the risk of pregnancy
increases rapidly once the menstrual cycles recommence or
when mothers start supplementing their infant's diet or when
they are more than six months postpartum.3 Lactating women
who want to avoid pregnancy need to start using contraceptive
methods that should not interfere with lactation and maternal or
infant health. At the present lime, (he selection of appropriate
methods for nursing women is restricted to very few alternatives
because several of the methods available have a negative
influence on lactation or hold potential risks for the infants.4 For
this reason, we have proposed and tested lite efficacy of
progesterone, the natural hormone, as a fertility regulation
method during lactation.5
Use of progesterone
Progesterone has no biological activity when given orally unless
it is specially formulated or is given in very high doses.6 Thus,
the risk of infant exposure to progesterone is minimized in
comparison with orally active compounds. To be active, the
hormone must be given by a different route.
Silastic vaginal rings have proved useful for the
administration of synthetic progestagens3'8 arid of
progesterone.""' Rings delivering 5-15 trig per day of
progesterone have been tested in postpartum clinical trials lo
assess their contraceptive efficacy, clinical performance and
influence on lactation.
The initial studies were performed in our clinic with
encouraging results. The contraceptive efficacy of the
progesterone vaginal ring (PVR) is similar to that of copper
intrauterine devices (T-Cu) as shown in Table I. In addition, the
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This study has examined endometrial tissue in 14 normal
women prior to insertion of a levonorgestrel-releasing
intrauterine system (LNG-IUS) and thereafter longitudin¬
ally for up to 12 months post-insertion. The specific end-
points examined by immunohislochemistry were progester¬
one receptor (PR) subtypes A + B, oestrogen receptor
(ER) and prostaglandin dehydrogenase (PGDH). Two anti-
progesterone receptor antibodies, one specific to PRp sub¬
type and the other to PR subtype A + B, were employed
to examine the localization of both PR isoforms. The
activity of PGDH, a progesterone dependent enzyme, was
also measured. ER and PRA + B and PR subtype B were
significantly down-regulated in glands and stroma in the
presence of continuous intrauterine LNG delivery. There
was an apparent increase in PItA immunoreactivity in
endometrial glands between 6 and 12 months post-insertion.
Consistent with down-regulation of both isoforms of PR
was reduced glandular PGDH immunostaining following
LNG-IUS insertion, and PGDH activity (as measured by
metabolism of excess substrate in vitro). Furthermore,
PGDH activity, known to be localized in the glands, signi¬
ficantly increased (P < 0.05) at 12 months post-insertion,
coinciding with the observed increase in glandular PRA+B
immunoreactivity at this time. Since the ENG-IUS sup¬
presses the PR|i so strongly, PRA is likely to be the subtype
that mediates long term LNG action in the endometrium.
PRIt is the more suppressed of the two subtypes, and only
PRA rises along with PGDH activity. Alterations to norma)
endometrial morphology and function, e.g. perturbation of
normal sex steroid receptor expression, following exposure
to high concentrations of local LNG, may play a role in
the aetiology of bleeding disorders associated with the
LNG-IUS. Further elucidation of local uterine mediators
involved in the mechanism of bleeding problems is required.
Key words: intrauterine levonorgeslrel/PGDH/progestin recep¬
tor isoforms
Introduction
All progestogen-only contraceptives, including the levonorges¬
trel-releasing intrauterine system (LNG-IUS, Mirena, Leiras
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Oy, Finland) are associated with the problem of break-through
bleeding. Even though the LNG-IUS is an extremely effective
contraceptive which dramatically reduces menstrual blood loss
(Andersson and Rybo, 1990; Milson et al., 1991) its use is
associated with frequent and recurrent break-through bleeding
in many women. Since the acceptability to women of modern
approaches to fertility control, especially hormonal methods,
is dependent upon the extent of menstrual bleeding disturbance
associated with such methods (Odlind and Fraser, 1990),
„ improvements in break-through bleeding rates with the LNG-
IUS are highly desirable.
The aetiology of menstrual aberration associated with pro-
gestogen-only contraception is not understood. In fact, there
are very limited data on the local effects of levonorgestrel
on endometrial physiology. Well documented fluctuations in
steroid receptor concentration take place during endometrial
exposure to sex steroids in the normal cycle (Sullivan et al.,
1988). Briefly, concentrations of glandular progesterone recep¬
tor (PR) increase in the follicular phase under the influence of
oestradiol and decline following ovulation due to secretion of
progesterone. There is no substantial change in endometrial
stromal PR expression across the cycle (Snijders et al., 1992)
and in first trimester decidua (Shi et al.. 1993). Oestrogen
receptor concentrations are also maximal in the proliferative
phase and decline in both the glandular and stromal compart¬
ment in the secretory phase of the cycle (Garcia et al., 1988;
Snijders et al., 1992). In an interesting exception, endometrium
exposed to long-term systemic LNG delivered by sub-dermal
implant (Norplant®) exhibits an increase in immunoreactivity
of the stromal progesterone receptor when compared with
control endometrium at all stages across the menstrual cycle
(Critchley et al., 1993).
There are two distinct subtypes of the human progesterone
receptor, PRA and PRB (Clark et al., 1987). PRA subtype is
the shorter form, lacking 164 amino acids from the N-terminal
fragment (Tung et al,, 1993), Our studies of progesterone
receptor localization have involved two antibodies: a rabbit
polyclonal against PRB isoform and a monoclonal antibody
that detects both A + B subtypes. Thus we refer to PRA + B
as the receptor detected by antibody that recognizes both
subtypes of the PR and PRB as the receptor detected by
antibody specific to the B-isoform. It is not possible to raise
an antibody specific to the PRA isoform. We assume that PRA
is the subtype responsible for positive immunoreactivity when
the PRb cannot be detected. Our group has recently described
the presence of PRB immunoreactivity in the nuclei of endomet¬
rial glandular and stromal cells throughout the normal men¬
strual cycle and in decidua of early pregnancy. PR subtype B
is preferentially expressed in the mid-proliferative phase, and
© European Society for Human Reproduction and Embryology
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declines dramatically in the secretory phase. By inference, the
PRa subtype is the subtype responsible for all immunostaining
during the secretory phase, premenstrually and immediately
post-menstruation. Further, preferential expression of PR sub¬
type A was observed in first trimester decidua (Wang et al.,
1998). It is not known whether this differential expression of
the two forms of progesterone receptor in endometrium results
in different responses to steroid exposure. There are no data
on progesterone receptor subtype expression in levonorgestrel-
exposed endometrium.
The local release of vasoactive substances such as prosta¬
glandins has been implicated in the contraceptive actions
of intrauterine contraceptive devices. The presence of an
intrauterine device (IUD) increases the production of prosta¬
glandin E2 (PG.E2) in secretory endometrium (Hillier and
Kasonde, 1976). In studies of decidua exposed to antigestogens,
blockade of the action of progesterone results in a decrease in
prostaglandin metabolism and an increase in prostaglandin E,
which in turn may facilitate leukocyte traffic in the endomet¬
rium. The interaction between progesterone, prostaglandins
and leukocyte traffic arc of relevance to the contraceptive
effects of the IUD. The main prostaglandin metabolizing
enzyme, prostaglandin dehydrogenase (PGDH), has been
shown to be progesterone dependent (Casey et al.» 1980).
This study has therefore examined endometrial tissue in
normal women prior to insertion of a levonorgcstrcl-releasing
intrauterine system (LNG-1US) and thereafter longitudinally
for up to 12 months post-insertion in order to ascertain changes
in endometrial sex steroid receptor localization and activity of
PGDH, a progesterone dependent enzyme, during local delivery
of levonorgestrel to the uterine cavity.
Materials and methods
Ethical approval for the siudy was obtained from Lothian Research
Ethics Committee (reference: 1702/94/6/44). Informed consent was
obtained from 14 women aged between 32 and 48 years (median'age
37 years). All subjects were fertile, had reported regular menstrual
cycles (cycle length 25-35 days) and had not used hormonid or
intrauterine conlraception in the 6 months prior to inclusion in the
study. The indication for insertion of the LNG-IUS was either for
contraception (n — 10) or heavy menstruation (n — 4). The study
was longitudinal, with each subject acting as her own control. All
subjects underwent a pre-insertion endometrial biopsy cither in the
proliferative (n = 7) or secretory (n = 7) phase of the cycle,
immediately after which the LNG-IUS was inserted. The stage of the
cycle prior to insertion of the LNG-IUS was defined with reference
to serum sex steroid concentrations and histological dating, according
to the criteria of Noyes ei al. (1950). Biopsies were performed in an
outpatient setting with a Pipclle suction curette (Laboratoire CCD,
Paris, France). Further endometrial samples were collected 1, 3, 6
and 12 months following insertion of the LNG-IUS. Since histological
appearances were indistinguishable in the follicular or luteal phase,
once the LNG-IUS was in situ, data at each time period (i.e. 1. 3, 6
or 12 months) post-lUS insertion were pooled regardless of cycle
stage. All endometrial tissue samples were fixed overnight in 10%
neutral buffered formalin at 4°C, rinsed and stored in 70% ethanol
and thereafter routinely wax embedded. Sections 5 pm thick were
cut for routine histopathology (haematoxylin and eosin staining) and
immunohislochcmistrv (progesterone receptor, subtypes A + B.
progesterone receptor subtype B, oestrogen receptor and PGDH
imrnunoloculizution). Tissue was also transported to the laboratory in
ice-cold RPMi 16/40 medium for measurement of PGDH activity in
the endometrial eytosol. A venous blood sample was collected at the
time of biopsy. Serum was separated and frozen at ~20*C for
subsequent radioimmunoassay of oestradiol and progesterone (Yong
ei at, 1992). The inter-assay coefficients of variation (CV) for these
assays were 11.0 and 10.0% respectively; intru-assay CV were 8.0
and 8.0%- respectively.
ln-vitro measurement of PGDH activity
Tissue was washed in ice-cold saline, weighed, chopped with scissors
and homogenized for 20 s in 0.5 ml of ice cold metabolism buffer
[20% glycerol, 2 mM dithiolhreitol (Sigma, Dorset, UK) in 0.1 M
phosphate buffer, pH 8.41. Homogenate was centrifuged at 2000 g in
a refrigerated centrifuge at 4°C and supernatant was stored at -40°C
until assayed. PGDH activity in all samples was determined at the
same time.
Frozen supernatant was thawed on ice and diluted in metabolism
buffer. Samples of 100 pi of enzyme were incubated in I ml
metabolism buffer containing 1 mM NAD (Sigma) and 5 pg PGE2.
After 30 min, the reaction was stopped by adding 2 ml of methoxy-
amine hydrochloride (10 mg/ml) in acetate buffer pH 5 to dcrivatize
keto groups to their methyl oxime form. 15-Keto PGE was measured
as its methyl oxime by ELISA, using a specific antibody and 15-kcto
PGE conjugated to horse radish peroxidase.
Immunohistochemistry procedures
All inimunohistochemical protocols were optimized to determine the
correct conditions for maximal specific staining, and all negative
controls displayed absent immunostaining.
Progesterone receptor (subtypes A +• B) immunoreactivity with
NCL-PGR antibody
Tissue sections were dewaxed and rehydrated in descending grades
of alcohol to water. Tissue sections were washed in distilled .water
and 0.1 M Tris buffered saline (TBS, pH 7.4-7.6, for 10 mini.
Non-specific endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in distilled water for 5-10 min at room temperature.
An antigen retrieval step was performed. Tissue sections were
microwaved at high power in 0.01 M sodium citrate buffer (pH 6.0)
for 10 min and then allowed to stand in the microwave oven for a
further 20 min. After a further wash in buffer, tissue sections were
exposed to a 20 min non-immune block using diluted normal
horse serum. The primary antibody raised in mouse against human
progesterone receptor was used at a dilution of 1:40 (NCL-PGR.
recognizing A + B subtypes, Novocastra Laboratories, Newcastle.
UK). Following primary antibody binding, the sections were incubated
for 30 mill at room temperature with hiotinylatcd horse anti-mouse
IgG (Vecta stain, PK-4002; Vector Laboratories, Peterborough. UK).
Sections were thereafter incubated for 30 min at room temperature
with a mixture of avidin and biotin complex coupled to a horseradish
peroxidase enzyme (Vecta stain elite, PK 6101; Vector Laboratories).
The site of bound enzyme was identified by application of 3.3-
diaminobenzidine in H202 (DAB Kit, SK-4100: Vector Laboratories).
Thereafter tissue sections were washed in distilled water and counter-
stained with Harris' haematoxylin, a non-specific nuclear stain.
Sections were rinsed with tap water, dehydrated and cleared in
xylene before mounting in Pertex (Cellpath, Hemel Hempstead, UK).
Negative controls were included by replacing the primary antibody
with mouse immunoglobulin (at a matching concentration) at a
dilution of 1:6000 in PBS.




subtype B (PRB). oestrogen receptor (ER) and PGDH. Specific
features in each immunostaining protocol were as follows.
Progesterone receptor subtype B (PRr) inunuiwliistochemistry
No antigen retrieval step was required to expose the epitope. A non¬
immune block was conducted with normal goat serum. Tissue sections
were incubated with a 1:200 dilution of and progesterone receptor B
antibody (rabbit anti-human polyclonal antibody, raised against a 19
amino acid sequence from the N-terminal end, unique to PRB
subtype -DQQSLSDVEGAYSRAEATR- and coupled through a C-
tcrminal cysteine to keyhole limpet haemocyanin) in. TBS for 60 min
at 37°C. Western blotting of endometrial tissue samples collected
during the periovulatory phase revealed a strong band at expected
molecular mass of 120 kDa (Wang et al., 1998). Primary antibody
binding was detected with an avidin-biolin peroxidase detection
system. Sections were incubated with a biotinylated goat anti-rabbit
IgG antibody made up in dilute normal goal serum for 60 min at
room temperature. Thereafter the protocol was as described above
for localization of the progesterone receptor. Negative controls were
performed by replacing die primary antibody with non-immune scrum
of the equivalent concentration.
Oestrogen receptor (ER) inununohistochemistry
Pretreatmcnt of the sections was necessary for localization of the
oestrogen receptor. Tissue sections were microwaved at high power
in 0.01 M sodium citrate buffer (pH 6.0) for 10 min then allowed to
rest in the microwave for 20 min. The protocol was thereafter
conducted as described above lor the progesterone receptor. Primary
antibody ERID5 (DAKO Laboratories, High Wycombe, UK) was
used at a dilution of 1:25. Negative controls were included by
replacing primary antibody by non-immune mouse immunoglobulin
at the equivalent concentrations.
Prostaglandin dehydrogenase (PGDH) immunohistochemistry
Detection of PGDH imniunoreactivity employed a rabbit polyclonal
antibody (Cascade Biochem Ltd. Reading, UK) with an avidin-biolin
peroxidase detection system. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide in distilled water for 10 min
al room temperature. A non-immune block was conducted using 10%
normal swine serum for 20 min at room temperature. Sections were
incubated overnight with the primary antibody (dilution 1:500) at
4*C. Biotinylated secondary antibody (biotinylated swine anti-rabbit)
and ABC complex (Vecta stain, ABC Kit, PK 4002; Vector Laborat¬
ories) were then applied for 30 min each at room temperature. The
peroxidase substrate diaminobenzidinc (DAB) was used to visualize
the reaction (SK4I00; Vector Laboratories). Slides were lightly
counter stained with Harris haematoxylin. Rabbit immunoglobulin at
a dilution of 1:500, i.e. the equivalent concentration as primary
antibody, was substituted for negative control sections.
Scoring and immunohistochemistry analysis
A semi-quantitative scoring system was employed for assessment of
intensity and localization of immunoreactivity in entire tissue sections.
The score of zero indicated an absence of immunoreactivity; 1 =
faint immunoreactivity; 2 = strong immunoreactivity and 3 = very
intense immunoreactivity. We have previously reported in endometrial
tissue sections a high correlation (0.963) of objectively measured
immunoreactivity (measured by computerized image analysis) and
subjective sbmi-quantitative scoring of immunostaining patterns. Such
data supports the subsequent statistical analyses performed on the
semi-quantitative scores of sex steroid receptor immunoreaclivity
(Wang et al, 1998).
A one-way analysis of variance (ANOVA) with Fisher's PLSD
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Table I. Serum oestradioi (pmol/l) and progesterone (nmol/1) concentrations
at time of endometrial biopsy, prior to and following insertion ol' a LNG-
IUS
Biopsy time n Serum oestradioi Scrum progesterone
range range
mean (SE) mean (SE)
Pie-insertion: proliferative 5* 62-343 0-10
phase 145 (53) 3.4 (1.9)
Pie-insertion: secretory 7 166-614 6-28.6
phase 300 (52.7) 17.7 (2.9)
Post-insertion 1 month 11 217-2281 0-23.2
637 (201) 3.7(1.1)
3 months 13 49-813 0-19.9
380.7 (105.8) 3.8 (I.1)
6 months 14 69-1929 0-16.3
446.2 (120.6) 3.7(1.0)
12 months 14 67-1288 0-56.6
460.4 (124.4) 11.6 (3.1)
♦Serum oestradioi and progesterone concentrations were unavailable from
two patients whose biopsies prior to I US insertion were collected in the
proliferative phase (hence n = 5).
coefficient was used to evaluate whether or not there were significant
differences in the expression of epitopes. The results with a P value
of ^0.05 or *&().() I were considered significant differences.
Results
Prior to insertion of the LNG-IUS, endometrial biopsies
conducted in the follicular and luteal phases of the ovarian
cycle displayed normal proliferative and secretory features
respectively. All subjects in whom biopsies were performed
in the follicular phase (proliferative histology) had circulating
progesterone concentrations of =£10 nmol/l (range 0-10, mean
3.4, SEM 1.9). Women in whom biopsies were performed in
the luteal phase (secretory histology) had serum progesterone
concentrations ranging between 6 and 28.6 nmol/1 (mean 17.7,
SEM 2.9) (see Table I).
Insertion of a LNG-IUS produced widespread morphological
changes in endometrial histology: a pseudo-decidualized
stroma with atrophic glands was observed in all biopsies
collected following insertion of the LNG-IUS.
PRa+u immunoreactivity
Prior to LNG-IUS insertion, all proliferative phase biopsies
displayed positive PRa+b immunoreactivity in both glands
and stroma. Secretory phase endometrial biopsies collected
prior to I US insertion showed reduced PRA,.B immunostaining
in glands (P 0.001) but no reduction in stromal PRA+B
immunoreactivity. However, a significant decrease in PRa+b
immunoreactivity was observed in the stromal and glandular
compartments of endometrium (see Figure la-c) following
insertion of a LNG-IUS. Figure 2 illustrates the change in
glandular and stromal PRa+b immunoreactivity in endomet¬
rium following insertion of a levonorgestrel IUS.
There were significantly lower (P 0.001) PRA+B immuno¬
staining levels in the glandular epithelium 1. 3 and 6 months
after insertion of a LNG-IUS compared to progesterone recep¬
tor immunoreactivity in biopsies prior to insertion of the
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Figure 1. Progesterone receptor (PRA + PRB) and progesterone receptor subtype B stromal and glandular immunoreactivity in endometrium
exposed to inuauterine LNG. (a) Strong positive PR (A + B) immuuostaining in proliferative endometrium prior to insertion of a I.NG-
IUS. (b) Reduced endometrial PR (A + B) immunostaining I month post-insertion of a LNG-IUS. (c) PR (A + B) immunostaining 12
months post-LNG-IUS insertion. Note increased immunostaining in glands and stroma, (d) Strong positive PRB immunoreactivity in
proliferative endometrium prior to LNG-IUS insertion, (e) Low intensity PRB immunostaining 1 month post-insertion of a LNG-IUS. (0
Persistent low PRB immunoreactivity 6 months following insertion of a LNG-IUS. Scale bar for a, b, d, e (shown in d) = 50 pm. Scale bar
for c and f (shown in f) = 25 pm.
intrauterine system collected in the proliferative phase. These
levels were equivalent to those seen in the luteal phase.
However, between 6 and 12 months following insertion, there
was an increase in PRa+b immunostaining in endometrial
glands (P < 0.05). In the endometrial stroma, PRA, B immuno¬
staining. was also significantly decreased I, 3, and 6 months
following insertion of the LNG-IUS when compared to pre-
insertion stromal immunoreactivity (P < 0.05), but, unlike the
glands, there was no increased staining evident in the 12
month samples.
PRi, immunoreactivity
PR subtype B immunostaining was evident in glands and
stroma in proliferative phase biopsies prior to IUS insertion,
although immunostaining was much less intense than when an
antibody recognizing A + B subtypes was employed. Glandular
PR subtype B immunoreactivity was significantly reduced in
the secretory phase (P < 0.01) but persisted in the stromal
compartment of secretory phase biopsies collected pre-IUS
insertion. Figure ld-f and Figure 3 illustrate a decrease or
absence of progesterone receptor subtype B immunoreactivity
in both glandular and stromal (P < 0.01) compartments of
endometrium 1, 3, 6 and 12 months following insertion of a
LNG-IUS, with no indication of an increase in immunostaining
in the 12 month samples.
Oestrogen receptor (ER) immunoreactivity
ER immunoreactivity was also confined to the nuclei of
endometrial glands and stromal tissue. Positive strong immuno¬
staining was displayed in glands and stroma of proliferative
phase biopsies prior to LNG-IUS insertion. Pre-insertion biop¬
sies collected in the secretory phase displayed reduced glandu¬
lar (P < 0.05) and stromal immunoreactivity (not significant).
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Figure 2. Mean PRA + p immunostaining scores (± SEM) in
endometrium prior to and after insertion of a LNG-IUS. Prolif.
proliferative; Secret. — secretory; M - months.
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Figure 4. Mean oestrogen receptor (ER) immunostaining scores (r
SEM) prior to and after LNG-IUS insertion. Prolif. = proliferative;
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Figure 3. Mean PRp immunostaining scores (± SEM) prior to and
following insertion of a LNG-IUS. Prolif. ® proliferative;
Secret. ~ secretory: M — months.
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Time of LNG-IUS Insertion
Figure 5. In-vitro prostaglandin dehydrogenase (PGDH) activity
(|ig/ml per mg tissue) ± SEM. Pre-insertion biopsies (n ~ 8;
proliferative n = 3, secretory n - 5); Post-insertion biopsies
(at I month n ~ 8; 3 months n = 12; 6 months n = II; 12
months n — 7).
inimunoreactivity in the glandular compartment of endometrial
biopsies collected at I, 3, 6 and 12 months post-insertion,
when compared with endometrial tissue collected pre-insertion
in the proliferative phase (Figure 4). Oestrogen receptor
immunoreactivity in stromal endometrial tissue was signific¬
antly reduced (P < 0.01) 1, 3, 6 and 12 months following
insertion of the IUS when compared with stromal endometrium
collected from subjects prior to insertion in the proliferative
phase (Figure 4). These levels were equivalent to those
seen in the luteal phase, and showed no increase in the 12
month samples.
PGDH metabolism
PGDH activity, as measured by metabolite (fig/mJ per mg
tissue) was greater in endometrial samples collected in the
secretory phase. Low levels of PGDH activity were observed
following insertion of a LNG-IUS both 1 and 3 months post-
insertion. Metabolism significantly increased (P < 0.05) at 12
months post-IUS insertion (Figure 5).
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Positive immunoreactivity for PGDH was observed in the
glandular cytoplasm from all endometrial biopsies collected
prior to insertion of the LNG-IUS during the secretory phase
of the cycle. Reduced PGDH immunostaining was observed
in endometrial tissue collected following insertion of the LNG-
IUS (data not shown).
Serum oestradiol and progesterone concentrations
Circulating serum oestradiol and progesterone concentrations
at the time of endometrial biopsy are documented in Tabic I.
Discussion
This study describes a significant decline in immunostaining
of ER and PR (subtype A + B) in glands and stroma in
endometrium exposed to intrauterine levonorgestrel. Further¬
more, the availability of an antibody directed against a sequence
at die N terminal end, unique to PRB subtype, has demonstrated
a more substantial and sustained down-regulation of the
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PRh subtype in ihe glands and stroma of the LNG-exposed
endometrium, whereas a distinct increase in staining with the
PUA + B antibody was evident in tlie glands at 12 months.
Consequently, the data herein show by inference that the PRA
subtype is likely to be the isoform mediating LNG action in
the endometrium.
The observation of down-regulation of PRB (see Figure 3)
in endometrium exposed to intrauterine levonorgestrel is con¬
sistent with our own observations of progesterone receptor
subtype expression in the normal cycle and in early decidua
(Wang et al.. 1998). It would appear that regardless of whether
the exposure of the endometrium to high concentrations of
progestin was endogenous (as in luteal phase or early preg¬
nancy) or exogenous (LNG-IUS) PRB is suppressed to a greater
extent than the PRA subtype.
We previously reported that PRA is the predominant subtype
in secretory endometrium and decidua of early pregnancy, that
is, in a progesterone dominated steroid environment (Wang
et ul., 1998). PRa protein is also the dominant isoform, as
determined by Western blot analysis in human myometrium-
(Viville ei oL. 1997). The significance of the predominance of
PRA is not known. Morphologically, the endometrium in the
presence of a LNG-IUS shows features of decidualized stroma
(Nilsson cl al., 1978; Silverberg el al., 1986). Hence in the
presence of 'pseudo-decidualization'. the predominance of
PRa is consistent with observations of PR subtype expression
in early decidua (Wang el at., 1998). Differential expression
of PR subtypes is likely to determine response to progestins,
although the action of ligand occupied PRB receptors may
work through an alternative mechanism (Tung el al.. 1993).
In endometrium exposed to a local exogenous LNG (LNG-
IUS), sufficient PRA isoform is maintained to mediate the long
term morphological and functional characteristics of progestin
action, for example dccidualization.
There was an interesting apparent increase in PRA immuno-
reactivity in endometrial glands between 6 and 12 months
post-insertion. Further, this apparent rise in PRA was related
to increased PGDH activity between 6 and 12 months following
insertion of die intrauterine system. However, there was an
apparent discrepancy between PGDH activity (Figure 5) and
PR concentration (Figure 2) during the secretory phase. This
may have been due to the chronic high exposure of the
endometrium to local progestins. Nevertheless, the observations
described here concerning prostaglandin metabolism (reduced
PGDH immunostaining and reduced in-vitro PGDH activity
post-LNG-IUS insertion) support the hypothesis that with a
down regulation of PR, the endometrium is less responsive to
progestin-mediated events.
The observations of elevated PGDH imntunoreactivity in
endometrial biopsies collected in the secretory phase prior to
insertion of a LNG-IUS arc consistent with reported data
concerning PGDH enzyme activity in the secretory phase and
premenstrually (Casey el al.. 1980). The decline in PGDH
immunostaining following insertion of a LNG-IUS is consistent
with our observation of reduced PRA + B and PRB immunoreac-
tivity post-insertion of a LNG-IUS. From a functional view¬
point. if reduced steroid receptor is available to bind the ligand
then only a limited functional response can be initiated (that
is. reduced induction of PGDH activity). This study has
thus demonstrated a consistent functional response of the
endometrium to the reduced number of progesterone receptors.
The continued suppression of PRB by exogenous LNG is by
inference, at least in part, mediated by the PRA subtype.
The in-vitro data for PGDH activity arc in keeping with
these observations. Prostaglandin metabolism is elevated in
tissue collected in the secretory phase, prior to insertion of
a LNG-IUS and reduced thereafter. Small sample numbers
(n = 3) precluded estimation of a significant difference when
compared with secretory phase biopsies. The observation is,
however, entirely consistent with the literature (Casey el a!.,
1980). Following insertion of the LNG-IUS, metabolism
was low al 1 month and 3 months. This is consistent with
die down-regulation of PR in the glands of LNG-exposed
endometrium. However, there was a significant increase in
metabolism (PGDH activity) 12 months post-LNG-IUS'
insertion. This coincided with the observed significant
increase in glandular PR immunorcactivity fwhich by
inference was presumably PRA subtype) 12 months following
insertion of die LNG-IUS.
In the present study, a significant reduction in ER
immunoreactivity has been reported up to 12 months
following insertion of the LNG-IUS. In the normal cycle
there is a significant decline in the ER of the glands and
stroma in the functional layer of endometrium, with the
transition from proliferative to secretory phase of the cycle.
However, there is no significant fall in ER (or PR)
immunoreactivity in the stromal compartment of the basal
endometrium (Snijders et al., 1992). The endometrium of
users of a LNG-IUS is atrophic, but is morphologically
distinct from normal basal endometrium (own observations).
At any time, die steroid environment within the endometrium
will reflect die local progestogen (LNG) levels and the
circulating serum oestradioi and progesterone concentrations.
Mean serum oestradioi concentrations remained in the mid
follicular range (Critchley et al., 1990) during the 12 months
following LNG-IUS insertion. Mean serum progesterone
levels were indicative of the fact that biopsies were collected
during either the follicular or luteal phases (see Table 1).
Short-term administration of synthetic progestogens
decreases the PR content of both endometrial epithelium
and stroma in pre- and post-menopausal women (Lane et al,
1988). Continuous delivery of levonorgestrel exerts part of
its contraceptive action via PR in endometrium and thus
subsequent biological activity is presumed to be dependent
upon the concentrations and availability of functional PR
CLau el al.. 1996). The observations reported here on
PR expression in endometrium exposed to intrauterine
levonorgestrel are completely opposite to observations in
endometrium from Norplant® users (sub-dermal LNG). In
die presence of elevated circulating progestogen concentra¬
tions, PR immunoreactivity was persistently raised in
Norplant® exposed endometrium. The mechanism by which
this observation may be. explained and whether the observed
increase in stromal PR immunoreactivity is associated with
an increased number and concentration of functional PR is




(1996), Norplant results in a decrease in PR mRNA levels
as measured by in-situ hybridization, which implied a change
in turnover rate of PR mRNA and protein. Similar data on
PR mRNA levels in endometrium exposed to intrauterine
delivery of levonorgestrel are not yet available.
Pekonen et al. (1992) have also observed functional differ¬
ences between continuous local intrauterine and subdermal
levonorgestrel delivery. Intrauterine LNG was a potent stimul¬
ator of stromal cell IGFBP-1 production. IGFBP-1 is a product
of decidualized stromal cells (Bell, 1991). Subdermal delivery
of LNG produced no such effect. This observed difference is
likely to reflect dose-dependency effects of LNG. Intrauterine
LNG produced endometrial LNG levels 1000 times greater
than serum concentrations. The latter are of the same order of
magnitude with subdermal implants (Nilsson et al., 1982;
Pekonen et al., 1992). In the presence of such high local
progestin concentrations, endogenous, systemic progesterone
would be masked, despite circulating progesterone concentra¬
tions remaining in the normal follicular-luteal phase range
(Table I). Women using a LNG-IUS usually have normal
ovulatory cycles (Luukkainen, 1991) and there is no reduction
in oestradiol concentrations (Luukkainen et al., 1990). LNG,
however, is not progesterone and the ligand (LNG)-receptor
complexes may not necessarily reproduce all the classic
4progesterone' actions.
Insertion of a LNG-IUS produced widespread morphological
changes in endometrial histology. In this study, a pseudo-
decidualized stroma, with atrophic glands, was evident in all
biopsies collected post-insertion of the IUS. These observations
are consistent with earlier reports (Nilsson et al., 1978;
Silverberg et al., 1986). A more detailed description of the
histological features in biopsies in this series will be reported
elsewhere.
The dramatic reduction in menstrual blood loss (Andersson
and Rybo, 1990;.Milson et al.. 1991) described in users of a
LNG-IUS has been considered to be due to epithelial and
glandular endometrial atrophy (Nilsson et al., 1978; Silverberg
et al.. 1986) associated with the LNG-IUS. However, disturb¬
ances in endometrial bleeding associated with the intrauterine
system remain a major problem for users. It is likely that
subtle endometrial mechanisms responsible for the control of
normal uterine bleeding have been disturbed. The present data
provide novel information on the perturbation of local sex
steroid receptor expression (down-regulation) in die presence
of a LNG-IUS and evidence to support interference with
normal function (PGDH activity). Thus disturbance of sex
steroid receptor expression, as described in this study, may
play a role in the control of mechanisms responsible for
aberrations in normal bleeding patterns. Interestingly, bleeding
patterns are reported to improve (Luukkainen. 1991) 6 months
or so following insertion of a LNG-IUS, at a time when at
least PR (by inference subtype A) had somewhat increased.
Further work is necessary to elucidate the mechanisms respons¬
ible for this major problem of menstrual aberration with
progestin-only contraceptive methods. Examination of more
local mechanisms in endometrium exposed to an intrauterine
levonorgestrel system should help explain some of the potential
mechanisms regulating endometrial bleeding.
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Irregular bleeding remains a common reason for the
discontinuation of progestin-only contraception. The levo- -
norgestrel releasing intrauterine system (LNG-IUS) has
profound morphological effects upon the endometrium.
Specific features are gland atrophy and extensive decidual
transformation of the stroma. Morphological changes in
the endometrium may be associated with perturbation of
mechanisms regulating normal endometrial function. This
study describes endometrial stromal and glandular features
prior to and up to 12 months following insertion of
the LNG-IUS. Comparison is made with first trimester
dccidua. In order to elucidate further mechanisms govern¬
ing endometrial function with local intrauterine delivery
of LNG, we here report histological features consistent
with decidualization; a significant increase in granulocyte-
macrophage colony stimulating factor (GM-CSF) immuno-
reactivity in decidualizcd stromal cells; glandular and
stromal prolactin receptor expression and an infiltrate of
CD56+ large granular lymphocytes and CD68+ macro¬
phages. We are unaware of previous reports which have
documented longitudinally both morphological and func¬
tional observations in endometrium exposed to local intra¬
uterine levonorgestrel delivery. These studies demonstrate
that long-term administration of intrauterine levo¬
norgestrel results in features of altered morphology and
function. No correlation was apparent between the end
points in the study and the bleeding patterns described by
the subjects. Further evaluation of these features in the
context of menstrual bleeding experience may contribute
to a better understanding of this troublesome side-effect
which often leads to dissatisfaction and discontinuation of
the intrauterine system.
Key words: decidualization/GM-CSF/intrauterine levonorges-
trel/leukocytcs/prolactin receptor
Introduction
Irregular bleeding remains the single most common indication
for discontinuation of progesterone-only methods of contracep-
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tion (Findlay, 1996) and the aetiology of this frequent complaint
is not understood. Few data exist concerning endometrial
stromal changes in users of progestin-only contraception.
Indeed attention has been drawn to the fact that the 'short
phase of decidualization' observed following commencement
of progesterone-only contraception may be transient and thus
the cells are not 'true decidual cells' with the consequence
that factors not normally associated with decidual cells may
be produced (Findlay, 1996).
Steroid releasing intrauterine devices have profound morpho¬
logical effects on the endometrium. Specific features are
suppression of proliferative activity and atrophy with extensive
decidual transformation of the stroma (Silverberg el at., 1986;
Sheppard, 1987). Intrauterine devices elicit characteristic local
changes in leukocyte populations within the endometrium,
including infiltration of macrophages, lymphocytes and neutro¬
phils which appear in the stroma and epithelium (Sheppard,
1987). Mechanisms concerned with leukocyte distribution in
the endometrium of IUD users are not known. During the
normal menstrual cycle there is a late secretory phase increase
in stromal leukocytes (Bulmeref at., 1988)withapre-menstrual
increase in stromal macrophages (Kamat and Isaacson, 1987).
Both the late secretory phase endometrium and early decidua
contain a significant population of leukocytes, the majority of
which are CD56+ large granular lymphocytes (LGL) (King
and Loke, 1991).
The temporal expression of prolactin in the uterus implicates
a role for this hormone in decidualization and hence implanta¬
tion (Wu et at., 1995). Prolactin is an immunoregulating agent
and may play a role in leukocyte function. Our group (Jones
el at., 1998) has recently reported the localization of the
prolactin receptor protein in glandular epithelium and some
stromal cells from the mid to late secretory phase of the
menstrual cycle and in first trimester decidua, coinciding with
the onset of decidualization.
Few data are available concerning endometrial cytokines
and their role in mechanisms concerned with endometrial
bleeding. Granulocyte-macrophage colony stimulating factor
(GM-CSF) is an activating growth factor for granulocytic and
monocytic cells. Human GM-CSF is considered to be steroid-
regulated (Sharpe-Timms el at., 1994). GM-CSF is synthesized
by epithelial cells in the murine pregnant and non-pregnant
uterus (Robertson el at., 1992) and is likely to be regulated in
the mouse primarily by oestrogen. In the human, epithelial
cells are the major contributor to production (Giacomini
el at., 1995) and variations are reported in the level of
immunohistochemical expression of GM-CSF in endometrial
epithelial cells (Shaqpe-Timms el at., 1994). Furthermore,
GM-CSF production by resident leukocytes (macrophage and
© European Society for Human Reproduction and Embrvoloev
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large granular lymphocytes) has been demonstrated (Jokhi
et al, 1994). A potential role for endometrial GM-CSF in
macrophage recruitment into the stroma has been reported in
rodents (Robertson and Seamark, 1992).
This study describes endometrial stromal and glandular
features prior to and up to 12 months following insertion of a
Ievonorgestrel-releasing intrauterine system (LNG-1US;
Mirena, Leiras Oy, Finland). The LNG-IUS has an inert frame
on which a silastic capsule has been attached to the vertical
arm, releasing 20 Jig levonorgestrel every 24 h to the uterine
cavity from a total load of 52 mg LNG (Luukkainen et al,
1990). A comparison has been made with the morphological
features of first trimester decidua.
Materials and methods
Ethical approval for the study was obtained from Lothian Research
Ethics Committee (reference: 1702/94/6/44). Informed consent was
obtained from 14 women aged between 32 and 48 years (median age
is 37 years). All subjects were fertile, described regular menstrual
cycles (cycle length 25-35 clays) and were not using hormonal or
intrauterine contraception in the 6 months prior to inclusion in the
study. The indication for insertion of the LNG-IUS was either for
contraception (n -■ 10) or heavy menstruation (n = 4). The study
was longitudinal with each subject acting as her own control. All
subjects underwent a pre-insertion endometrial biopsy either in the
proliferative (// - 7) or secretory (/t = 7) phase of the cycle. The
stage of the cycle prior lo LNG-IUS insertion was defined according
(o the criteria of Noyes et cil. (1950). Biopsies were performed in an
outpatient setting with a pipelle suction curette (Laboratoirc CCD,
Paris. France). Further endometrial samples were collected 1, 3, 6
and 12 months following insertion of the LNG-IUS. Once the LNG-
IUS was in situ, rhe histological appearance of endometrium samples
was indistinguishable whether collected in the follicular or luteal
phase, hence data at time period of I, 3, 6 and 12 months were pooled.
In addition decidual tissue was collected from ten women (8-10
weeks amenorrhoea) undergoing surgical termination of pregnancy.
Decidual biopsies were stained with a monoclonal antibody against
cytokeratin to confirm absence of trophoblast tissue (decidua
parictalis). All endometrial and decidual tissue samples were fixed
overnight in 10% neutral buffered formalin at 4°C. rinsed and stored
in 70% ethanol and thereafter routinely wax embedded. Sections 5
pm thick were cut for routine histopathology (haematoxylin and
eosin staining) and immunohislochemical localization of granulocyte
macrophage colony stimulating factor (GM-CSF), prolactin receptor.
CD56+ large granular lymphocyte (LGL), macrophage (CD68) and
neutrophil elaslase immunoreactivity. Our laboratory has recently
described the localization of progesterone receptors (subtypes A +
B) and oestrogen receptors in normal endometrium and decidua
(Wang c.t al1998) and in endometrium exposed to intrauterine LNG
(Critchley et at.. 1998).
Immunohistochemistry procedures
Prolactin receptor immunolocalization
Paraffin sections were dewaxed and rehydrated through descending
grades of elhanol to distilled water. The sections were then washed
twice in 0.1 M phosphate buffered saline (PBS) for 5 min. Endogenous
peroxidase activity was quenched by immersion in 3% hydrogen
peroxide (H1O2, BDH Laboratory Supplies, Poole. UK) in distilled
water for 5 min and then sections were again washed. Non-specific
binding was reduced by a 20 min incubation with non-immune goat
serum (Vector Stain Elite®; Vector Laboratories, Peterborough, UK)
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in a humidified chamber at room temperature, following which the
excess was carefully removed and the primary antibody (Nevalainen
et al, 1996) (rabbit polyclonal raised against u rat peptide sequence
common to the short and long form of the receptor, kindly supplied
by Dr P. Inglelon, University of Sheffield) was applied at a dilution
of 1:50. Slides were incubated overnight (17 ± I h) at4°C Antibody
binding was detected by the sequential application of biotinylated
goat anti-rabbit IgG and an avidin-biotin-peroxidase complex (ABC
Vector Stain®; Vector Laboratories).
The substrate 3.3' diarninobeiizidine (DAB, Vector Laboratories)
was then utilized to visualize positive immunorcaclivity. Finally,
sections were counter-stained with Harris' haematoxylin (Pioneer
Research Chemicals Ltd, Colchester, UK), dehydrated and cleared in
xylene before mounting in Pcrtex® (Cellpath, Hemel Hempstead, UK).
Positive controls included for the prolactin receptor immunohisto¬
chemistry were sheep pituitary sections (Tortonese ct al, 1996) and
human term fetal membranes (Maaskanl et al, 1996). Negative
controls had an equivalent concentration of non-immune rabbit
immunoglobulin substituted for the primary antibody to exclude the
possibility of non-specific binding.
Granulocyte macrophage colony stimulating factor (GM-CSF)
Immunolocalization
A similar protocol as above was used for die localization of GM-
CSF. The primary antibody was raised in the mouse against human
GM-CSF J GM-CSF (ZM-213), Genzvme Diagnostics, Kent. UK].
Incubation with the primary monoclonal antibody at a dilution of
1:75 took place for 90 min at 37°C. Thereafter the protocol was
similar to that employed for prolactin receptor. Tris buffered saline
(TBS) was used throughout instead of PBS. The second antibody
was a horse anti-mouse antibody (Vector Laboratories) and the
avidin-biotin-peroxidase complex ABC Elite® (VecLor Laboratories).
Negative controls were performed by replacing the primary antibody
with mouse immunoglobulin at the same dilution (1:75).
The positive controls were a GM-CSF expressing cell line (MG-
63 cells, derived from a male osteosarcoma cell line and gift of Dr
Fouad Habib, Western General Hospital, Edinburgh). MG-63 cells
were grown up on Chamber slides (Nunc Inc. Naperville, IL, USA).
After hxation, the MG-63 slides were stored in 70% ethanol until
use. Cells were first washed separately in TBS for 5 min and then
included as a positive control.
Leukocyte invnunolocalization
Sections (5 pm) from formalin-fixed, paraffin embedded biopsies
were cut for immunohistochemical localization of (i) macrophages
(CD68, DAKO, Code M876); (ii) CD56+ lymphocytes (Zymed, San
Francisco, CA, USA); (Lai) neutrophil elastase (DAKO Neutrophil
Elastase. Code M752). Tissue sections were dewaxed and rehydrated.
Non-specific endogenous peroxidase activity was blocked by treatment
with 3% hydrogen peroxide in distilled water for 5 min at room
temperature. Prc-treatment of the sections was necessary for localiz¬
ation of macrophages and CD56+ lymphocytes as described below.
For macrophage (CI) 68) immunostaining. tissue sections were
exposed to an enzyme digestion with 0.1% trypsin in 0.1% calcium
chloride at pH 7.8. The digestion was conducted at 37°C for 25 min
and subsequent enzyme activity removed by washing in lap water.
For CD56+ lymphocyte immunoslaintng, tissue sections were
microwaved at high power in 0.01 M sodium citrate buffer (pH 6.0)
for 20 min then allowed to stand for a further 20 min. Sections were
washed in buffer prior to a non-immune block.
Thereafter all sections were exposed to a non-immune block with
normal horse serum for 20 min at room temperature. Tissue sections




Figure 1. Photomicrograph of endometrium exposed to intrauterine Figure 2. An example of the spindle-celled pattern of pseudo-
levonorgestrel for 3 months. The glands are narrow and inactive decidualizalion of die stroma. The central gland is very narrow and
and the stroma is typically dccidualizcd. There is a scanty inactive. Levonorgestrel intrauterine system in siru for 12 months,
granulated lymphocyte infiltrate. Original magnification XI85. Original magnification XI85.
(i) macrophage antibody (CD68) dilution 1:50 for 60 min at 37°C;
(ii) CD56 antibody dilution 1:250 for 60 min at 37°C;
(iii) neutrophil clastase antibody dilution 1:50 for 60 min at 37°C.
Sections were labelled with an avidin-biotin-peroxidase detection
system (Vector Stain®; Vector Laboratories). Colour development
employed diaminobcnzidinc (DAB) solution for 2-10 mill. Sub¬
sequently tissue sections were counlerstained with haematoxylin,
dehydrated and cleared in xylene and mounted in Pertex. Negative
controls were conducted by replacing the primary antibody with non-
immunized mouse immunoglobulin at the same concentration as the
primary antibody.
lmmunosiaining intensity and distribution of epitopes in all tissue
sections were assessed semi-quantitativcly, on a four point scale: 0 =
no staining, 1 — faint staining. 2 - moderate staining, 3 — intense
staining. Scoring was performed blind by two observers. The mean
and standard error of mean (±SEM) was calculated. The data were
analysed by one-way analysis of variance (ANOVA), using Fisher's
PLSD coefficient to'assign significance.
Results
Histology
The LNG-IUS produced widespread morphological changes
in the endometrium (Figures 1 and 2). The histological changes
were not limited to the contact site although typical contact
site changes were observed in the majority of cases. The
superficial part of the endometrium formed cushions of rather
((edematous, spindle-celled, pseudo-decidualized stroma
(Figure 2) and occasionally, microscopic, oedemalous, surface
micropapillae were seen. In biopsies where the progestational
effeel was long-standing, the endometrial decidualization
remote from the device was spindle-celled and diminished in
intensity whilst the decidualization nearest to the device
remained more typical with 'rounded' cells rather than spindle
cells. Glands in the superficial part of the endometrium were
extremely narrow, whilst those in the deeper layers were
slightly wider and lined by an epithelium which was cubo-
columnar in contrast to the cells lining the superficial glands
which were flattened cuboidal. In a small number of biopsies
1220




Positive immunostaining (brown) for GM-CSF was observed
in the cytoplasm of glandular and surface epithelial cells in
normal endometrium. In early decidua (Figures 3A and 4)
positive unmunoreactivity in epithelial and decidualized
stromal cells, especially in a perivascular location, was noted.
Immunoreactivity tended to he heterogeneous. Regions where
decidualization was marked demonstrated strongest immuno¬
reactivity. Strong cytoplasmic glandular and stromal immuno¬
reactivity, particularly in a perivascular location, was also
evident following insertion of the LNG-IUS (Figures 3B and
4). There was a significant increase (P < 0.05) in GM-CSF
immunoreactivity in the stromal compartment of LNG-exposed
endometrium at 1, 3, 6 and 12 months post insertion compared
with 'pre-insertion' endometrium biopsied in both the prolifer¬
ative (P < 0.01) and secretory phase IP < 0.05) of the cycle
(Figure 4). Immunoreactivity in normal decidual stromal cells
was similar to secretory phase endometrium (see Figure 4,
lower panel).
Prolactin-receplor inununostuining
Minimal positive immunostaining was observed in pre-inser-
tion endometrial biopsies collected in the proliferative phase.
However, in pre-insertion endometrial biopsies from the secre¬
tory phase, positive immunoreactivity was evident in the
cytoplasm of glandular epithelium and in some stromal cells.
Biopsies of first trimester decidua displayed strong immuno¬
reactivity in glands and deciditulized stromal cells (Figure
3C). Consistent with these features of prolactin receptor
immunoreactivity in early decidual tissue, biopsies collected
post insertion of the LNG-IUS displayed positive immuno¬
staining both in the glandular epithelium and in pseudo-
decidualized stromal cells (Figure 3D). A significant increase
(P < 0.05) in stromal prolactin receptor immunostaining
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Figure 3. (A, B) Photomicrographs of granulocyte-macrophage colony stimulating factor (GM-CSF) immunoslaining. (A) First trimester
dccidua. Positive inimunoreactivity (brown staining) is noted particularly in lite cytoplasm of large decidualizcd cells often in a perivascular
location. (B) Endometrial biopsy from patient I month after insertion of levonorgeslrel releasing intrauterine system (I.NG-IUS). Strong
cytoplasmic immunorcactivity is evident in the stroma. (C, D) Photomicrographs of prolactin receptor immunostaining. (C) First trimester
dccidua. Positive immunoreactivity (brown) is clearly visible in deciduatized stromal cells. (D) Endometrial biopsy collected 3 months post
LNG-IUS insertion displaying positive immunostaining in both glandular epithelium and decidualized stroma. Scale birr = 25 pni.
was evident following insertion of Ihe LNG-IUS (Figure 5.
lower panel).
Leukocyte immunostaining
Intense positive immunostaining of CD56+ LGL was evident
in all endometrial biopsies collected following insertion of the
intrauterine system. There was significantly greater (P < 0.05)
CD56+ immunoreactivity in the stroma of secretory compared
to proliferative endometrium, prior to insertion of the LNG-
IUS (Figure 6B). The significant increase (P < 0.05) was still
evident at 1 and 3 months post insertion of the LNG-IUS
when compared to proliferative endometrium prior to LNG-
IUS insertion (Figure 6B). Strong CD56+ immunostaining
was observed however in normal decidua. especially in areas
of full decidualization. Positive immunoreactivity for CD68 +
macrophages was also obtained in all endometrial biopsies
following insertion of the LNG-IUS (Figure 6A). There was
a significant increase in macrophage immunostaining between
proliferative endometrium pre-insertion and the 1st month post
insertion (P < 0.05). A significant decrease (P < 0.05) in
CD68 + macrophage immunoreactivity was noted from 1-12
months post insertion. There was negligible immunostaining
for neutrophil elastase (polymorphonuclear leukocyte marker)
in all post insertion endometrial biopsies (data not shown).
Discussion
In order to elucidate further local mechanisms governing
endometrial function with local intrauterine delivery of
levonorgestrel, the present study has reported histological
features consistent with decidualization. We have observed a
significant increase in GM-CSF immunoreactivity, particularly
in the decidualized stromal cells observed in LNG exposed
endometrium, plus glandular and stromal prolactin receptor
expression and an infiltrate of CD56+ large granular lympho¬
cytes and CD68+ macrophages. We are unaware of any
previous reports which have documented longitudinally both
morphological and functional observations in endometrium
exposed to local intrauterine LNG delivery.
The endometrial morphological features following intra¬
uterine levonorgestrel delivery are typical of those seen in
long-term users of a progestogen (Silverberg et a!.. 1986:
Buckley and Fox, 1989). The features of pseudo-dccidualiz-
ation closely resembled the morphology of early pregnancy
decidua.
The progestational effects observed in this study occurred
diroughout the endometrium and are consistent with an earlier
report (Nilsson el al., 1978), and were not limited to the


















Prolif. Secret. 1M 3M 6M 12M Decidua
Preinsertion Post Insertion
Time of LNG-IUS insertion
Figure 4. Granulocyte-macrophage colony stimulating factor
(GM-CSF) immunosiainmg scores (mean ± SHM) in endometrial
glands (upper panel) and stroma (lower panel) prior to and
following insertion of levonorgestrel releasing intrauterine system
(LNG-IUS). Prolif. = proliferative phase. Secret. = secretory
phase, M - months.
examined in the present study did not display the micropolyps
described by Silverberg et al. (1986) where the median duration
of use was 48 months and women using a device releasing
20 )ig daily were all examined after at least 12 months of use.
The hick of observation of micropolyps in our study may be
due to the fact that the levonorgestrel intrauterine system' had
only been in situ for up to 12 months.
In a few biopsies haemorrhagic infarction, necrobiosis and
coagulative necrosis were present. These features are indicative
of spontaneous tissue breakdown but differ from that seen in
normal menstruation, in that the features were usually focal
or multifocal. All subjects in this study had recorded details
of daily bleeding (if present) for the full 12 months study
period. On review, the biopsies with evidence of spontaneous
tissue breakdown were not from subjects who had described
break-through bleeding (unpublished data).
Any agent which modifies endometrial morphology is likely
also to modify the normal intrauterine processes regulating
function. The stromal GM-CSF immunoreactivity in the local
levonorgestrel treated endometrium closely resembled GM-
CSF immunostaining in Ihe epithelial and stromal cells of first
trimester decidua. Particularly of note was the localization
of immunostaining to large perivascular decidualized cells.
Appreciable amounts of GM-CSF are known to be produced
by first trimester decidua (Jokhi et al., 1994) and a potential
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Figure 5. Prolactin receptor immunoslaining scores (mean 4: SEM)
in endometrial glands (upper panel) and stroma (lower panel) prior
to find post insertion of a levonorgestrei releasing intrauterine
system (I.NG-IUS).
role in leukocyte recruitment has been proposed (Robertson
and Seamark, 1992).
Prolactin receptor protein has been immunolocalized to the
glandular epithelium and stromal cells of pseudo-decidualized
endometrium following intrauterine levonorgestrel delivery.
Our observation is consistent with data from our group (Jones
el at.,. 1998) concerning expression of the prolactin receptor
in both normal endometrium and first trimester decidua. Locally
derived growth factors and cytokines are likely to regulate
prolactin receptor expression (Gu et al., 1994), and the detection
of strong immunoreactivity for the receptor in both epithelium
and stroma in pseudo-decidualizcd endometrium suggests a
paracrine role for prolactin.
The pseudo-decidualized endometrium associated with local
levonorgestTel delivery displayed a significant increase in
CD56 + LGL when compared with proliferative phase endo¬
metrium and has a persistent population of macrophages.
Normal decidua has a similar leukocyte population (Loke and
King, 1995). The mode of recruitment of these cell types
remains under investigation, although, under the influence of
progesterone, neither cell type to date has been reported
to express sex steroid receptors (King et al., 1996). Local
intrauterine levonorgestrel delivery results in a down-regulation
of stromal progesterone receptors (Critchley ct al., 1998) at a
time where, in the current study, we have observed strong
prolactin receptor immunoreactivity that increased significantly
1 month post insertion of the LNG-IUS.
From the above data it must be concluded that the stromal
Stroma »
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Figure ft. Mean (± SEM) immunostaining scores for
(a) macrophages (CD68-L) and (hi large granular lymphocytes
tCD56 l ) in endometrial stroma before and after exposure to
intrauterine lcvonorgcstrcl.
comparlinent of the endometrium does indeed undergo changes
consistent with decidualization for at least up to 12 months
post insertion of LNG-IUS. Previous examination of the state
of the endometrial stroma in progestin-only contraeeptive users
was limited (Findlay. 1996). Furthermore, it has been suggested
(Findlay, 1996) that there may be a short phase of decidualiz-
ation following commencement of the method. In this study
evidence is presented that GM-CSF and prolactin receptor
proteins immunolocalize to the pseudo-decidualized cells in a
similar manner to the true decidual cells of first trimester
pregnancy. It is notable that GM-CSF protein localized particu¬
larly to large decidualized perivascular cells. Findlay (1996)
has noted that in progestin exposed endometrium the decidual¬
ized cells may produce factors not normally associated with
true decidualized cells which may have the potential to be
detrimental to blood vessels.
It is worth noting that in normal decidua immunoreactivity
was heterogeneous, and was most marked for GM-CSF,
prolactin receptor and CD56 where decidualization was
apparent. In these early pregnancy biopsies some regions still
displayed a marked glandular morphology. It is recognised
that during the first trimester, two histologically distinguishable
zones may be observed (Bell, 1991).
The presence of a marked and persistent population of
CD56+ LGL is also consistent with the observation that
uterine LGL are the predominant lymphocytes reported in first
trimester decidua (Loke and King, 1997). Furthermore, in this
study macrophages were evident throughout the 12 months
following insertion of a LNG-IUS. In this context Clark et al.
(1996) reported a reduced frequency of CD68 + cells in
the atrophic endometrium of Norplant®1 users (sub-dermal
levonorgestrel). The number of CD68+ cells was significantly
increased in those women using Norplant with abnormal
bleeding. In the context of the present study there was a
significant increase in macrophage immunoreactivity at I
month post LNG-IUS insertion and proliferative phase endo¬
metrium. Interestingly, thereafter a significant decrease in
macrophage immunostaining was observed between I and 12
months following insertion of LNG-IUS. No formal quanti¬
fication of immunostaining was undertaken due to the small
size of many of the later biopsies, and hence the description
was subjective.
Bleeding disorders remain a major problem and a primary
reason for discontinuation of progestin-only methods of contra¬
ception (Findlay. 1996). A previous irregular menstrual history
has been raised as a potential contributing factor to bleeding
disorders. In the present study all women recruited described
a regular bleeding history. Many of them went on to experience
irregular bleeding with the LNG-IUS in situ. A minority (n =
4) also described heavy loss. Nine out of 14 women (64%)
experienced light menstrual blood loss each month and only one
subject achieved amenorrhoea with the LNG-IUS (unpublished
data). Despite detailed scrutiny of the several end points in
this study, no correlation was established with the menstrual
bleeding patterns described by the subjects.
A detailed understanding of the local endometrial mechan¬
isms which are disturbed by the presence of high dose
intrauterine progestagen are also important willi respect to the
contraceptive action of the LNG-IUS. Recently Mandelin et al.
(1997) described inappropriate glycodelin A mRNA and protein
expression before and at mid cycle in women using a LNG-
IUS. This untimely production of glycodelin A has been
implicated in the contraceptive action of the LNG-IUS. In this
context glycodelin A is usually absent from the endometrium
in the proliferative and immediate postovulatory phases, i.e.
at a time when glandular progesterone receptor expression is
maximal. It is interesting to note that the inappropriate produc¬
tion of glycodelin A coincides with the down-regulation of
progesterone receptor reported (Critchley et al., 1998) with
intrauterine levonorgeslrei administration.
In summary, the present study has described features consist¬
ent with endometrial decidualization in the presence of an
intrauterine levdnorgeslrel-rcleasiftg system. It is not possible
to determine whether these decidualized cells are 'true decidual
cells' (Findlay, 1996) although several of the features described
herein are almost indistinguishable from normal decidua.
Further study of the decidualized nature of the stromal cells
in the levonorgestrel exposed endometrium should contribute
to a greater understanding of the mechanisms responsible for
break-through bleeding, a major reason for discontent with
progestin-only contraception.
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Remodelling of endometrial tissues is fundamental to the
cyclical changes that occur during the menstrual cycle,
implantation and, in the absence of pregnancy, at menstru¬
ation. The enzyme matrix metalloprotcinasc-9 (MMP-9) is -
recognized as important in these processes but its regulation
is not well defined. These studies have demonstrated that
MMP-9 activity is present in die endometrium and exhibits
cyclical changes in its distribution in the glandular and
stromal cells. MMP-9 protein is present throughout the
cycle with highest expression, as determined by semi¬
quantitative analysis of specific MMP-9 iinmunoreactivity,
in glandular cells during the mid secretory phase. A similar
distribution was observed in first trimester decidua. In
women with a levonorgestrel intrauterine system (bNG-
IUS), which delivers high local concentrations of progesta¬
gen to the uterine cavity, MMP-9 is highly expressed in
both endometrial glandular and stromal cells, and ill the
vasculature (in endothelial and perivascular cells). II can
lie concluded that MMP-9 is stimulated directly or indir¬
ectly by progesterone. Furthermore, MMP-9 may play a
role in the remodelling of the endometrium that occurs
during the menstrual cycle and in the aetiology of the
morphological changes and breakthrough bleeding associ¬
ated with long-term progestagen administration via a
I.NG-IUS.
Key words: eontraception-LNG/endometrium/matrix nietallo-
proteinases/menstruation/tissue remodelling
Introduction
Tissue remodelling in the uterus is ail important process during
the normal menstrual cycle for the sequential destruction and
reconstruction of die endometrial t'unctionalis, for implantation
processes and subsequent development of the placenta and
fetal-maternal interface (Hulboy el til.. 1997). The matrix
metalloproteinases (MMP) are a family of zinc-dependent
enzymes (bat are important for these tissue remodelling pro¬
cesses by degrading components of the extracellular matrix
(ECM). basement membrane and interstitial matrix
(Rawdanowicz et al„ 1994). To date there have been 16
distinct MMP cloned and characterized ill die human and the
European Society of human Re[mxiuctioii and Embryology
family member MMP-9 is a 92 kDa gelatinase enzyme that
degrades components of the extracellular matrix and basement
membrane components, specifically, collagens IV and V, elastin
and gelatin (Hulboy et at., 1997). MMP-9 is expressed in the
uterus and cellular sources include endometrial glandular and
stromal cells, macrophages, neutrophils and first trimester
cytotrophoblast cells (Jeziorska el al„ 1996; Salamonsen and
VVoolley, 1996; Bischof ci tv/., 1998). The gelatinase MMP-2
is also expressed and secreted by human endometrium (Irwin
el til., 1996; Salamonsen et al„ 1997). There is increasing
evidence for a role for MMP in the tissue remodelling events
of implantation and, in the absence of pregnancy, subsequent
menstruation (Rodgers et til., 1994; Marbaix et ai, 1995;
Salamonsen and Woolley. 1996).
The regulation of MMP-9 is not well understood but it is
controlled, at least in part, by progesterone. Maximal intralumi¬
nal secretion of MMP-9 by glandular epithelial cells occurs at
a lime when progesterone concentrations are highest during
the 'implantation window' of early to mid secretory phase
(Jeziorska et til.. 1996) although its release from endometrial
explains is inhibited by progesterone in vitro (Rodgers et a!.,
1994). This control of MMP-9 and indeed uterine function by
progesterone is clearly complex, demonstrated by these dif¬
fering responses found in vivo and in vitro. A compounding
factor of this regulation is that the two isoforms of the
progesterone receptor (PR), PRA and PR8. are present in
epithelial and stromal cells during the proliferative phase. In
the secretory phase both receptor subtypes decline in the
glandular compartment and PRB decreases in the stroma (Wang
era/., 1998).
The levonorgestrel-releasing intrauterine system (LNG-IUS;
I-eiras Oy, Finland) is associated with a 97% reduction in
menstrual blood loss (Andersson and Rybo. 1990; Milson
el ah, 1991). However, the most common indication for
discontinuation of use of this method and indeed other proges¬
terone-only systems of contraception, with its associated dra¬
matic reduction in menstrual bleeding, is the occurrence of
the troublesome side-effect of unpredictable breakthrough
bleeding (Findlav, 1996). The long-term administration of
intrauterine levonorgestrel results in features ofaltered morpho¬
logy and function of the endometrium (Critchley et ul., 1998a)
and down-regulation of receptors for oestrogen and both
isoforms of the progesterone receptor (Critchley el til., 1998b).
The paracrine mechanisms which account for the disturbance
in bleeding patterns associated with intrauterine levonorgestrel
delivery remain to be elucidated. Endometrium obtained from
women using a LNG-iUS provides an opportunity to study the
effect of high-dose local progestagen delivery upon endometrial
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Normal endometrium was collected from women (n - 40) aged
38 years (median, range 25-47) undergoing minor gynaecological
procedures (including laparoscopic sterilization, diagnostic laparos-
copy for pelvic pain, endometrial sampling for regular but dysfunc¬
tional uterine bleeding) collected by Pipelle suction curette
(Laboratoire CCD, Paris, France). All women described regular cycles
(25-35 days). Endometrial samples were designated as menstrual,
early proliferative, mid proliferative, late proliferative, ovulatory,
early secretory, mid secretory and late secretory phase (n = 5 for
each stage of cycle). Dating was based on the histological criteria of
Noyes et at. (Noyes et at., 1950) and all biopsies were consistent
with the date of the last menstrual period. No subject had received
exogenous hormones or had used an intrauterine device in the 3 ^
months prior to biopsy. A 10 ml sample of venous blood was collected
at the time of each endometrial biopsy for estimation of serum
oestradiol and progesterone concentrations by radioimmunoassay.
Circulating concentrations of serum oestradiol and progesterone at
the time of endometrial biopsy in women using a LNG-IUS have
been previously reported (Criichley et at., 1998b) and reflect continued
ovarian activity in subjects with a LNG-IUS in situ.
Endometrial tissue was collected from 14 women aged between
32 and 48 years (median 37) who provided informed consent for an
endometrial biopsy prior to, and following, insertion of an LNG-IUS.
All participants were fertile, described regular menstrual cycles (cycle
length 25-35 days) and were not using hormonal or intrauterine
contraception in the 6 months prior to inclusion in the study. The
indication for insertion of the LNG-IUS was either for contraception,
often also in association with heavy menses (;i = 10), or heavy
menstruation (« = 4). The study was longitudinal with each subject
acting as her own control. Seven subjects underwent a pre-inserlion
endometrial biopsy in the proliferative phase and seven subjects in
the secretory phase of the menstrual cycle prior to insertion of the
LNG-IUS. The stage of the cycle prior to LNG-IUS insertion was
defined according to the criteria of Noyes el at. (1950). All biopsies
were performed in an outpatient setting with a Pipelle suction curette.
Subsequent endometrial biopsies were collected I, 3,6 and 12 months
following insertion of the LNG-IUS. Once the LNG-IUS was in situ,
the histological appearance of the endometrium samples was indistin¬
guishable whether collected in the follicular or luteal phase of the
cycle, hence data at dine periods of I. 3. 6 and 12 months were
pooled. The sex steroid receptor expression in this longitudinal scries
of biopsies has been previously reported (Criichley el at., 1998b).
A further five women (8-10 weeks amenorrhoea) provided decidual
tissue at the time of planned surgical termination of pregnancy.
Decidual biopsies were collected following dilatation of the cervix
and curettage of the uterine wall prior to vacuum aspiration of
products of conception. Placental biopsies were also collected at this
time. Decidual and placental villous biopsies were immunostained
with a monoclonal antibody against cytokeratin (Dako M0821, High
Wycombe. 'Bucks. UK) to confirm absence of trophoblasl tissue
(decidua parielalis).
Ethical approval for this study was granted by die Lothian Research
Ethics Committee (reference: 1702/94/6/44 and 1702/93/6/73) and
all tissue samples were obtained with informed written consent from
all patients.
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For zymography. endometrium was snap-frozen immediately after
collection and stored at -70°C. For immunohistochemistry, all endo¬
metrium and decidua samples were fixed overnight in 10% neutral
buffered formalin at 4°C, rinsed and stored in 70% ethanol and
thereafter routinely waxed embedded. Sections (5 (im) were cut and
mounted on 3-aminopropyItrieihoxysilane-coated slides (Sigma. St
Louis, MO, USA) for routine histopathology (haematoxylin and eosin
staining) and immunolocalization of MMP-9.
Zymography
Gelatina.se activity was detected by zymography using methods
described previously with minor modifications (Rawdanowicz ci at.,
1994). Briefly, tissues were homogenized [extraction buffer 0.2%
sodium dodecyl sulphate (SDS) in H^O; 100 jig tissue wet weight/ml
buffcrj and protein concentrations measured. Samples were separated
(50 jig protein loaded) by SDS-polyacrylamide gel electrophoresis
(PAGE) using gels (7.5%) containing gelatin (1 ing/ml) using non-
reducing conditions. Gels were washed (2.5% Triton X-100) and
incubated in zymography digestion buffer (50 mM Tris, 0.2 M NaCl,
5 mM CaCh, J jtM ZnC.l2, 0.02% Brij-35. pH 7.6) at 37°C for 18
h. Gels were then stained (0.5% Coomassic blue R250 in 30%
methanol/10% glacial acetic acid) at 23°C for 3 h, destained (staining
solution omitting the Coomassie blue) to reveal the discrete areas
where gelatinase activity had hydrolysed the substrate.
Immunolocalization of MMP-9
Immunoreaciive MMP-9 was localized using standard techniques. In
brief, sections were dewaxed, rehydrated and endogenous peroxidase
activity blocked by incubation with ILOi (3% v/v for 20 min; Sigma).
Sections were washed extensively and a further blocking step of
normal horse serum (5% v/v for 20 min) applied. Tissue sections
were then incubated (17 h at 4°C) with the primary mouse monoclonal
antibody (2 jig/ml final concentration) raised against a peptide
sequence corresponding to amino acids 624 to 644 in the carboxv-
terminal domain of MMP-9 (Insight Biotechnology Ltd. Wembley,
Middlesex. UK). The primary antibody was detected using a biotinyl-
ated horse anti-mouse antibody and an avidin-peroxidasc complex
(Vector Laboratories, Burlinghame. CA, USA), then visualized with
3,3'-diaminobenzidine as chromagen (Vector) according to the manu¬
facturers instructions. Sections were counterstained, dehydrated and
mounted.
The specificity of the MMP-9 antibody used for immunohistochem-
istry was confirmed using immunoblotting techniques. In brief,
conditioned medium samples collected from endometrial explants
were dialysed and concentrated by lyophilization. Secreted proteins
were separated by PAGE (7.5% gels) and transferred to a nitrocellulose
membrane (0.45 (tm pore size; Biorad, Hcmel Hempstead. Herts,
UK) by wet blotting. The membrane was blocked with 5% bovine
serum albumin, before application of the MMP-9 antibody, which
was delected using the same methods used for immunohistochemistry.
Negative controls were performed by replacing the primary antibody
with non-immune mouse immunoglobulin at a concentration of 1:500
in diluted horse serum (purified MMP-9 antigen was not available).
Sections of placenta collected at term were used as a positive control,
which demonstrated strongly positive and consistent immunolocaliz-
ation of MMP-9 in cytotrophoblast and extra villous trophoblasl cells
throughout all the experiments performed, as described previously
(Riley et at.. 1997).
Scoring and analysis of immunoreactivity
Immunostaining intensity and proportion of positive immunoreactivity
of epitope in all tissue sections was assessed semi-quantilatively, on





Figure 1. Gelatin zymogram demonstrating matrix mcliillo-
proteinase (MMP)-9 (92 kOa gclatinase B) and MMP-2 (72 kDa
gclalinase A J in liomogenatcs of endometrium from die
proliferative (Pr), ovulatory (Ov) and secretory (S) ptiases of the
menstrual cycle and decidua collected from the first trimester of
pregnancy (D). Amniotic fluid (AF) collected at term after
spontaneous delivery was used as a positive control.
>95% for the cell types, that is, glandular or stromal cells examined.
Scores of I turd 2 indicated weak or moderate immuitostainiug,
respectively. A score of zero indicated an absence of immunoreactivity.
The scoring was performed blind by a single observer, without prior
knowledge of phase of the menstrual cycle. The mean ± SEM was
calculated. The data were analysed by one-way analysis of variance
(ANOVA) using Fisher's PLSD (protected least significant difference)
coefficient to assign significance.
Results
MMP-9 activity in endometrium and decidua
Gelatin zymography demonstrated that MMP-9 activity, corres¬
ponding to 92 kDa, was detectable in endometrium tissue
samples from throughout the menstrual cycle and also from
decidua collected during the first trimester of pregnancy
(Figure I), In addition. MMP-2 enzyme activity (corresponding
to 72 kDa) was evident in endometrium and decidual samples
(see Figure I), The specificity of this activity as being derived
from MMP was confirmed by incubation with EDTA (5 ruM)
or o-phenanthroline (2,5 mM), with both treatments inhibiting
activity of all bands (data not shown).
Imnuinolocalization of MMP-9 during the menstrual cycle
The specificity of the MMP-9 antibody was confirmed by
immunoblol (Figure 2). A single band at the expected 92 kDa
molecular weight was identified as a secreted product in culture
medium conditioned by tissue explains of endometrium. This
aligned with the strong single band in the amniotic lluid
positive control.
Positive immunoreactivity for MMP-9 was predominantly
visualized in the cytoplasm of the majority of glandular
epithelium in both the proliferative, secretory and menstrual
phases of ihe cycle (Figure 3a--c). In endometrial stromal
cells, a heterogeneous distribution of lower intensity MMP-9
immunoreactivity was observed, with immunostaining more
marked in the secretory phase (Figure 3b), especially in the'
MMP-9 in endometrium
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Figure 2. Immuuoblot demonstrating Ihe presence of matrix
metalloproleinase (MMP)-9 immunoreactivity, identified at 92 kDa
molecular weight (niw), in samples of conditioned medium
collected from explains of endometrium (cm) and also as a positive
control in amniotic lluid (af) obtained at active labour at term.
late secretory stage. The intensity of MMP-9 immunostaining.
expressed by serni-quantitative analysis during the proliferative
and secretory phases of the cycle is demonstrated in Figure 4.
There was no significant difference in the intensity or distribu¬
tion of MMP-9 immunoreactivity between these phases of
the menstrual cycle. In the endometrial vasculature, MMP-9
immunoreactivity was localized in endothelial cells and also
in perivascular cells in some vessels throughout the menstrual
cycle (Figures 3a-c). All negative control sections consistently
demonstrated no positive staining (representative section.
Figure 3d). All biopsies collected during lite normal menstrual
cycle were from the functionalis layer, since a Pipelle sampling
device (suction curette) was employed,
Immunolocalization of MMP-9 in decidua and placenta
during early pregnancy
MMP-9 immunoreactivity was localized in decidual tissue in
a similar pattern of distribution and intensity to that seen in
the mid and late secretory phases of the cycle (Figure 30-
Maximal MMP-9 immunostaining was present in glandular
epithelial cells, whereas in stromal cells staining was heterogen¬
eous from strong to less intense and absent. The localization
of MMP-9 in the vasculature was similar to that found
during [he menstrual cycle, evident in endothelial and some
perivascular cells (Figure 30. In placenta. MMP-9 was local¬
ized in villous tissue predominantly in syncytiotrophoblast.
but not in cytolroplioblast cells (Figure 3g).
Iinmiinolocaiization of MMP-9 in endometrium exposed to
intrauterine levnnorgestrel
Endometrial biopsies collected prior to insertion of the LNG-
IUS demonstrated normal morphology consistent with features
of the proliferative or secretory phase described, and localiz¬
ation of MMP-9 immunoreactivity was comparable to normal
tissues collected from the same stage of the cycle as
reported above.
All subjects in whom biopsies were collected in the follicular
phase (proliferative histology) had circulating progesterone
concentrations of =510 ntnol/1 (range 0-10, 3.4 ± 1.9 nmol/1,
mean ± SEM). Subjects in whom biopsies were collected in
the luteal phase (secretory histology) had serum progesterone




Figure 3. Localization of matrix metailoproteinase-9 imnuinoreactivity in endometrium collected from the menstrual cycle in the
(A) proliferative phase, predominantly in glandular epithelium, (B) early secretory phase, predominantly in glandular epithelium, in the
vasculature and in some stromal cells and (C) during (he menstrual phase in glandular epithelium and vasculature (note stromal breakdown):
(I)) a representative negative control section demonstrating no positive non-specific staining; (E) from a woman with a levonorgeslrel
intrauterine system in situ strongly in decidualiz.ed stromal cells with less immunostaining in atrophic glands (F) in dccidua collected from
the first trimester of pregnancy in glandular epithelium, stromal cells and vasculature, and (G) in placenta in villous tissue in
syncytiotrophoblast. v = vasculature; s — syncytiotrophoblast; c ~ cytotrophoblast; g — glandular epithelium: ag — atrophic gland; si =
stromal cells. All scale bars = 50 pm.
insertion of the LNG-IL'S serum progesterone and oestradiol
concentrations were within normal follicular and luteal concen¬
trations as expected, and have been previously published
(Critchley er al., 1998b).
Following insertion of the LNG-IUS, endometrial morpho¬
logy was modified with widespread pscudo-dccidualization
evident in all biopsies. MMP-9 immunoreactivity remained
marked in,the glandular compartments, although it became
less evident with increased atrophy of these glands (Figure 3e).
In contrast to the normal cycle, following insertion of the
LNG-IUS regardless of the time period at which the biopsy
was taken, intense MMP-9 immunoreactivity was present in
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the stromal ceils of all biopsies (Figure 3e). There was a
significant (/' < 0.05) increase in MMP-9 immunoreactivity
in the endometrium collected following insertion of the LNG-
IUS, compared with biopsies collected in both the proliferative
and secretory phases of the cycle (Figure 5).
Discussion
In normal endometrium MMP-9 enzyme activity is present
throughout the menstrual cycle. MMP-9 immunoreactivity wits
localized predominantly in glandular epithelial cells with the
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Figure 4. Immtinostaining scores assessed by scnii-quunlilativc
analysis of matrix metalloproteinasc-9 immunorcactivity in glands
and stromal cells of endometrium throughout the early (E) mid (Mi
and late I'M stages of the proliferative (P), ovulalory (Ov),
secretory CS) and trtenstntal (M) phases of the menstrual cycle D =
decidua from early pregnancy In - 5 tissue samples collected front
different women at each time jxuni). Open bars ~ glands; solid
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Figure 5. Immunostaining scores assessed by semi-quantitative ,
analysis of matrix metalloproteinase-9 immunoreactivity in glands
and stromal cells of endometrium collected from women in the
proliferative (prolif) and secretory (secret) phases of the menstrual
cycle prior to and I. 3. 6 and 12 months (M) after the insertion of
a L.NG-1US. Open bars = glands; solid bars = stromal cells.
peri-menstrual phases of the cycle. In decidua in early preg¬
nancy. MMP-9 was present iri glands and also in decidualized
stromal cells. These findings indicate a role for MMP-9 in the
remodelling processes that occur during menstruation and at
implantation (Marbaix etui., 1992; Salamonsen and Woolley,
199ft) Following intrauterine delivery of levonorgestrel by a
LNG-IUS there was tt significant increase in endometrial
stromal MMP-9 immunoreactivity, indicating that progesterone
may be involved, at least indirectly, in the control of MMP-9
expression. In addition. MMP-2 enzyme activity is present in
endometrium obtained throughout the menstrual cycle and
during early pregnancy, as demonstrated by kymography.
The findings in this study demonstrate that in the normal
menstrual cycle MMP-9 protein was imnnuiolocalized lo
glandular epithelial cells throughout the menstrual cycle with
maximal intensity in the glandular epithelium. A previous study
which examined MMP-9 localization in human endometrium
(Jeziorska el til., 1996) showed similar findings in the proliferat¬
ive phase. As in this present study, intraluminal secretion was
evident with peak concentrations in glandular secretion and
uterine lluid at the peri-implantation period. However, Jeziorska
ct al. (Jeziorska el ul„ 1996) observed a disappearance of
MMP-9 immunoreactivity in the late secretory phase and
perimenstrually. contrary to our findings. Furthermore, Rodgers
or cil. (Rodgers el til., 1994) repotted that expression of M.MP-
9 mRNA was roost evident in lale secretory and menstrual
endometrium. Such observations support a role for MMP-9 in
remodelling of the extracellular matrix and in the production
of glandular secretions which may be associated with blastocyst
recognition and implantation. In stromal cells, MMP-9 inimu-
noreaetivity was generally low throughoul the cycle with only
an increase in the late secretory phase, where it may have a
role in the profound changes in morphology during decidualiz-'
alien as well as at menstruation. By dual immunolocalization,
Jeziorska el al. (Jeziorska el ill.. 1996) noted that MMP-9
immunoreactivity was present in polymorphonuclear leuko¬
cytes and macrophages, with little MMP immunoreactivity in
stromal cells and resident leukocytes, including mast cells.
The observation of MMP-9 expression in subpopulations of
leukocytes within the endometrium at critical times, for
example pre- and peri-menstrually, is consistent with a role
for these cell types as a source of endometrial MMP-9
expression (Jeziorska el al., 1996).
Immunoreactivc MMP-9 was localized in file endometrial
vasculature in endothelial and perivascular cells throughout
the menstrual cycle and may play a role in the angiogenesis
and development of the vasculature, as well as the breakdown
of vessels during menstruation. Roberts el al. (Roberts el al..
1992) in an electron microscopy study demonstrated extensive
breakdown of the vascular basal lamina prior to menstruation.
Specifically in the pre-menstrual period structural interactions
between endothelial and neighbouring pericytic cells are
impaired. This endothelial cell hypertrophy evident in the luteal
phase of the cycle has been attributed to rising concentrations of
progesterone in combination with oestrogen. In late secretory
endometrium the necrosis evident in stromal tissues is distinct
from that in capillary endothelial cells (Roberts el al.. 1992).
In women using an intrauterine device (IUD), overall
secretion of gelatinase activity increases throughout the cycle,
with increased MMP-9 secretion during the proliferative phase
(Martelli et al., 1993). This activity was attributed to bone
marrow-derived cells, in agreement with the findings of
Jeziorska et al. (Jeziorska el a!., I996J. This may be involved
in the rise in blood loss al menstruation associated with
IUD use.
The role of progesterone in the regulation of endometrial
MMP-9 expression is unclear. These and previous studies
(Jeziorska et al.. 1996) have demonstrated that glandular
MMP-9 production increases at a time when progesterone also
increases, but it is maintained when progesterone concentra¬
tions fall in the perimenstrual period. The LNG-IUS releases
20 pg of levonorgestrel daily directly lo the uterine cavity
and this results in the typical morphological changes in the




(Silverberg ct al., 1986; Buckley and Fox. 1989) including
pseudo-decidualization resembling the morphology observed
during die first trimester (Critchley et al.. 1998a). This study
has shown an increased MMJP-9 immunoreactivity in associ¬
ation with this decidualizatioa within one month post insertion
of LNG-JUS which persisted throughout the study period
following LNG-IUS insertion. This high expression of MMP-
•9 may be involved in the tissue remodelling that occurs during
reduction of the functionalis layer of the endometrium with
long-term treatment with progestagen contraceptives (Marsh
ct al., J 995). MMP-9 may also have a role in the aetiology
of breakthough bleeding (since MMP-9 is localized in the
vasculature) which is the major problem with this contracept¬
ive method.
In women using a LNG-IUS, both isoforms of the progester¬
one receptor (PRA and PRr) are down-regulated and there
is a reduction in some progesterone-dependent endometrial
markers (Critchley etal., 1998b) including glycodelin (Mande-
lin ct al., 1997). Interestingly PRj, isoform is the more
suppressed of the two subtypes and thus PRA is likely to be
the subtype that mediates long term levonorgestrel action in
the endometrium (Critchley ct al., 199Sb: Wang ct al.. 1998).
Similarly, studies in vitro demonstrate that after several days
in culture, more MMP-9 is secreted by stromal than epithelial
cells in culture (Salamonsen ct al., 1997) and progesterone
withdrawal is the optimal stimulus for inducing MMP-9
expression in these cells. Nevertheless, this study and others
(Jeziorska et al.. 1996) indicate that the stromal cells are not
the principal source of MMP-9 during the normal menstrual
cycle and that these alterations in stromal cell MMP-9 expres¬
sion do not occur in vivo during the normal cycle but are a
response to decidualization during early pregnancy or exogen¬
ous progestogen treatment, or to in-vitro culture (Salamonsen
ct al.. 1997). There is recent evidence for the cell specificity
of progesterone receptor regulation (Tseng and Zhu, 1997)
with progestin stimulating progesterone receptor mRNA in
cultured human endometrial stromal cells. This stromal-decid¬
ual cell system is novel in that progestin induces numerous
factors, such as specific cytokines and prolactin, that in turn
regulate the concentration of progesterone receptor. Hence
differential pathways are involved in the regulation of PR
isoforms in endometrial stromal cells.
MMP are also controlled after secretion by inhibition of
enzyme activity by endogenous tissue inhibitors of metallo-
proteinases (TIMP). TIMP-L -2 and -3 are localized in
endometrium and are secreted by decidualized stromal cells
in culture, but it is proposed that they are not regulated
during the menstrual cycle and their role would appear to be
maintenance of tissue integrity (Hulboy ct al.. 1997; Zhang
and Salamonsen, 1997).
In placenta during the first trimester, MMP-9 is localized in
svncytiotrophoblast, but not cytotrophoblasl, cells. However,
cytotrophoblast cells collected at this time and maintained in
culture secrete MMP-9, although this may be due to alterations
in phenotype in vitro (Librach et al., 1994). At this stage,
interactions between trophoblust and decidua are important for
the establishment of the fetal-maternal interface. An as yet
unidentified factor in medium conditioned by decidualized
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stromal cells stimulates gelatinase activity and MMP-9 release
by first trimester trophoblast cells (Bischof ct al.. 1998). This
may be an important component of the control of trophoblast
invasion at this time.
The antibody used in this study does not distinguish between
the latent and active forms of MMP-9. so care must be taken
in the interpretation of these data, although the major form of
MMP-9 detected by zymography was the latent 92 kDa form.
The concentrations of total protein as assessed here by semi¬
quantitative analysis of immvinohistoche.misr.ry does not estab¬
lish enzyme activity within tissues.
In summary, this study confirms that MMP-9 activity is
present in normal endometrium and decidua with an increased
MMP-9 expression in levonorgestrel-exposed endometrium.
Maximal MMP-9 immunoreactivity was evident at times when
progesterone exposure was highest during the early and mid
secretory phases, that is, around the time of anticipated
implantation. MMP-9 may also have a role in menstruation
Ayith its expression maintained in the late secretory phase in
association with progesterone withdrawal. Regulation of MMP-
9 is clearly complex and it is likely to involve progesterone
either directly or indirectly via other local mediators. High
quantities of MMP-9 immunoreactivity were present in endo¬
metrium exposed to intrauterine progestagen delivered by the
LNG-IUS, and MMP-9 may have a role in the aetiology of
breakthough bleeding associated with the use of this intrauter¬
ine contraceptive system.
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Objective: To determine the effect of a single dose of mifepristone (200 mg) on endometrial estrogen and
progesterone receptors in Norplant™ users.
Design: A prospective single-blind placebo-controlled pilot study.
Setting: Women were recruited from a large family planning clinic and were studied cither at the clinic or
in a clinical research unit attached to a teaching hospital gynecology department.
Patient(s): Eight women using Norplant™ and experiencing vaginal bleeding more often than once every 24
days. All completed the study.
Intervcntion(s): Endometrial biopsies were taken after treatment with both placebo and 200 mg of mife¬
pristone, both given at the start of a bleeding episode.
Main Outcome Measure(s): Expression of endometrial progesterone (PR) and estrogen (ER) receptors,
ovulation, and vaginal bleeding.
Result(s): Mifepristone administration was associated with down-regulation of PR receptor subtype B and
up-regulation of ER. Women treated with mifepristone showed a tendency to increased ovulation rates and
reduced vaginal bleeding.
Conclusion(s): The effect of mifepristone on endometrial steroid receptors was consistent with functional
inhibition of progesterone. The findings warrant further investigation of this regimen as a strategy to reduce
frequent bleeding. (Fertil Steril® 2002;77:366-72. ©2002 by American Society for Reproductive Medicine.)
Key Words: Norplant™, mifepristone, bleeding, endometrium, contraception
Irregular or breakthrough bleeding is per¬
haps the most frequent side effect of oral con¬
traceptives (1); in some parts of the world, it is
the commonest reason for discontinuation (2).
Irregular bleeding is particularly associated
with low-dose progestogen-only contraception
(pills, implants, and progestogen-releasing in¬
trauterine systems), which in most women do
not completely inhibit endogenous ovarian ac¬
tivity. In a recent review of first-year continu¬
ation rates of Norplant™ contraceptive im¬
plants in the United Kingdom (3), over 50% of
women who had the implants removed cited
menstrual change as the reason. By 18 months
after insertion, 20% of women attending a large
family planning clinic in Scotland (4) had
stopped using Norplant™, with 43%; of them
attributing discontinuation to irregular bleed¬
ing.
The mechanisms responsible for irregular
bleeding are not well understood. The occur¬
rence of erratic bleeding episodes does not
clearly correlate with fluctuations in circulating
concentrations of endogenous or exogenous
steroids, nor with any particular pattern of en¬
dometrial histology. It is thought that break¬
through bleeding is probably related to molec¬
ular changes in the endometrium that disrupt
vascular growth, function, and repair and dis¬
turb hemostatic mechanisms (5). Estrogen re¬
ceptors have now been clearly demonstrated in
the endothelium of the endometrial vasculature
(6), and thus these changes may be mediated by
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a direct or indirect effect of steroids on the vasculature acting
via cytokines or cheiuokines (7).
Whatever the cause of breakthrough bleeding, it is well
recognized that the addition of ethinyl estradiol to a proges-
togen-only contraceptive regimen reliably improves bleed¬
ing patterns (8, 9). More recently it has been demonstrated
that the addition of an antiprogesterone to progestogen-only
contraception reduces the incidence of unscheduled bleeding
in monkeys (10), and we have shown that once a month
administration of mifepristone improves bleeding patterns in
Chinese women using the levonorgestrei-releasing sino-im-
plant (11). The mechanism for this effect of botli estrogen
and mifepristone is unknown. In the normal cycle, after
menstruation, a period of unopposed estrogen stimulation
(during lite follicular phase) appears to be necessary for the
regeneration of endometrial progesterone receptors. Al¬
though the endometrium of women using Norplant™ has
been shown to have an increased concentration of proges¬
terone receptors (PR) (12, 13), exposure to progestogens can
lead to refractoriness to the steroid (see 14 for review). It is
possible that both add-back estrogen, acting directly on the
endometrium, and antiprogesterone, through a direct effect
on steroid receptors allowing the regeneration of functional
PR, mimic this physiological process.
In an attempt to determine whether the addition of an
antiprogesterone to a progestogen-only regimen of contra¬
ception might alter the expression of endometrial steroid
receptors, we undertook a small pilot study of women expe¬
riencing troublesome bleeding while using the contraceptive
implant Norplant™.
None of die authors has any vested interest of a commer¬
cial nature relevant to this study.
PATIENTS AND METHODS
Eight women who had been using Norplant™ for at least
4 months and who were experiencing vaginal bleeding more
than once every 24 days were recruited to the study from a
large family planning clinic in Edinburgh. All eight women
took both placebo and mifepristone treatment, and all com¬
pleted the study. None complained of any side effects asso¬
ciated with either treatment. Women kept a daily diary of
menstrual bleeding and spoiling throughout the study.
Ovarian activity was monitored for 8 weeks by measuring
estrone and pregnanediol/creatinine ratios in early morning
specimens of urine collected three times every week. Sam¬
ples from individual women were run in a single batch.
Urinary estrone-3-glucuvonide was measured using a spe¬
cific radioimmunoassay and pregnanediol-3-glucuronide us¬
ing an enzyme-linked immunosorbent assay (ELISA) (for
full details see 15). A pregnanediol/creatinine ratio of 0.5 or
more was taken as an indication of ovulation. On the third
day after the onset of the first bleeding episode to occur after
8 weeks of baseline monitoring, a single placebo tablet
FERTILITY & STERILITY®
(vitamin C, 50 mg) was given and urine collection was
increased to daily (Fig. I). In a similar manner, 200 mg of
mifepristone was taken on day 3 of the first bleeding episode
to occur at least 3 weeks after placebo treatment. Daily urine
collection continued until 4 weeks after the administration of
mifepristone. Participants were blinded to the treatments.
Between 3 and 5 days after administration of both placebo
and mifepristone an endometrial biopsy was taken using a
Pipelle endometrial sampler. On the day of the biopsy a
single venous blood sample (10 m.L) was taken for the
measurement of estradiol and progesterone by RIA using
methods that have previously been published from our center
(16). A sample of cervical mucus was also collected using a
tuberculin syringe (15). Cervical mucus score was assessed
using lite criteria established by the World Health Organi¬
zation (17) wherein scores of 0 to 3 were given for mucus
volume, consistency, l'erning, spinnbarkeit, and cellularity
(total score possible = 15).
All endometrial tissue samples were fixed overnight in
10% neutral buffered formalin at 4°C, rinsed, and stored in
70% ethanol and thereafter routinely wax embedded. Sec-
lions 5 gm thick were cut for routine hislopathology (hema¬
toxylin and eosin staining) and immunolocalization of pro¬
gesterone receptor (subtypes A and B), progesterone
receptor subtype B, and estrogen receptor.
Local ethics committee approval was obtained for the
study and all participants gave written, informed consent.
Differences in bleeding patterns were analyzed using the
Wilcoxon signed rank lest and by paired t test.
Imniunohistochemical Procedures
Localization of progesterone receptors was undertaken
with (lie use of two antibodies, a rabbit polyclonal antibody
against PRU subtype, and a monoclonal antibody that detects
both A and B subtypes. It is not possible to raise a specific
subtype antibody against the A form of the receptor. Hence,
we refer to PRA tc as the receptor detected by die antibody
that recognizes botli subtypes of the PR, and PRB as the
receptor detected by antibody specific to the B form of the
receptor. Furthermore, we assume PRA is the subtype re¬
sponsible for positive immunostaining when the B subtype
cannot be defecled. (For full details of the immunoliisto-
chemical protocols used in our study, see 18, 19).
Briefly, paraffin-embedded tissue sections were ireated
with primary antibodies raised against tire A and B subtype
of die progesterone receptor (1:40 Novocastra Laboratories,
Newcastle, United Kingdom), the B form of the progester¬
one receptor (1:200 "in house" rabbit anti-human antibody
[18]), and the estrogen receptor (I in 25 ER1D5, DAKO
Laboratories, High Wycombe, United Kingdom). An anti¬
gen-retrieval step (tissue sections microwaved in citrate
buffer, pll 6.0 [18]) was necessary for localization of epitope
representing the A and B form of the progesterone receptor
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detection methods were employed (avidin-biotin-peroxidase:
Vectastain, PK-4002, DAB kit, SK-4100, Vector Laborato¬
ries, Peterborough, United Kingdom). Negative controls
were included by replacing the primary antibody with non¬
immune serum of. equivalent concentration.
Scoring of Inimunohistochemical Staining and
Statistical Analysis
Immunostaining intensity and distribution of epitopes in
all tissue sections were assessed semiquantilatively, on a
four-point scale where 0 = no staining, 1 = mild staining,
2 = moderate staining, and 3 = intense staining. Scoring
was performed "blind" by a single observer. As we reported
elsewhere, in endometrial tissue sections, a high correlation
(0.963) of immunostaining was measured objectively by
computerized image analysis and by subjective semiquanti¬
tative scoring of immunoreactivity (18). These published
data support the subsequent statistical analyses performed'on
semiquantitative scores of sex steroid immunostaining. As
the data were noncontinuous, analysis employed a Mann-
Whitney lest.
RESULTS
The characteristics of the women and their responses to
treatment with mifepristone and placebo are shown in Table
1. The amount of tissue from one woman following placebo
I TABLE 1 I
Menstrual bleeding pattern reported with mifepristone and placebo.
Bleeding/spotting days Dry days
Women
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Semiquantitative immunostaining scores (median value) of progesterone receptor (PgR) (A and B isoforms), progesterone
receptor B (PgR(3) isoform, and estrogen receptor (ER) in endometrium after placebo and after mifepristone. 0 = no
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treatment, and front the same woman and one other follow¬
ing mifepristone administration was inadequate for analysis;
thus, seven biopsies were available after placebo treatment
and six after mifepristone.
Steroid Receptor Imniunostaining
The response of receptor expression to the administra¬
tion of mifepristone in endometrium exposed to Nor¬
plant™ is shown in Figure 2. Levonorgestrel-exposed
endometrium displayed intense immunostaining for PR
subtype A + B in both stromal and glandular cells. Admin¬
istration of mifepristone was not associated with any
change in this pattern. Endometrium exposed to levonorg-
estrel displayed a lower level of immunostaining for PR
subtype B than for PRA+B in both glands and stroma; PRB
expression was significantly further reduced following
mifepristone (P<.05) (Fig. 3).
Estrogen receptor immunoreactivity was intense in
both glandular and stromal components of the Norplant™
(levonorgestrel-treated) endometrium. Mifepristone ad¬
ministration was followed by a significant increase in ER
immunoreactivity in glandular cells (P<.05).
FERTILITY & STERILITY®
Bleeding Patterns, Ovarian Activity, and
Cervical Mucus Characteristics
Both placebo and mifepristone were administered on the
third day of an episode of vaginal bleeding. The mean
number of days during which women continued to experi¬
ence bleeding or spotting after treatment was slightly less (4
days, range: 0 to 6) following mifepristone than after placebo
treatment (6 days, range: 0 to 21). The mean number of days
when no bleeding or spotting occurred (dry days) following
the end of the "treatment episode" until the onset of the next
episode of bleeding or spotting was slightly longer following
administration of mifepristone (17 days, range; 8 to >25)
than after placebo (14 days, range: 8 to 39). Neither of these
observations reached the level of statistical Significance.
Because the study ended 4 weeks after mifepristone treat¬
ment, it was not possible to determine the total number of
dry days in every woman; two had experienced no further
bleeding by the time the study ended.
Following mifepristone administration (see Table 1),
three women ovulated and two others had an increase in
pregnanediol/creatinine ratio, which did not reach a value
consistent with normal ovulation (>0.5). In comparison,
only two women showed signs of ovulation during the
3(59
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Strong positive nuclear progesterone receptor (PgR) immunostaining (brown) was observed in glands and stroma of endo¬
metrium treated with (a) Norplant™ and (b) mifepristone-Norplant™, (c), Lower positive progesterone receptor B (PgRB)
immunostaining was apparent in glands and stroma of Norplant™treated endometrium, (d), Positive progesterone receptor B
(PgRe) immunostaining was present in few cells of glands and stroma of mifepristone-Norplant™treated endometrium, (e),
Strong estrogen receptor (ER) immunostaining was observed in glands and stroma of Norplant™treated endometrium, (f),
Intense estrogen receptor (ER) immunostaining was observed in glands and stroma of endometrium treated with mifepristone-
Norplant™.
8-week pre treatment period and only one woman ovulated in
the 4 weeks following placebo. There were no clear dif¬
ferences identifiable in endometrial steroid receptor im-
munostaining between the women who did or did not
ovulate. In no woman did ovulation occur before the time
of the biopsy.
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No cervical mucus was detectable in any of the women on
the day of placebo treatment. On the day of mifepristone
administration, cervical mucus was detectable in only one
woman, in whom the total score was 6.
There were no pregnancies during the course of the study.
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DISCUSSION
The findings of this pilot study lend support to our hy¬
pothesis that the administration of an antiprogeslerone might
functionally inhibit the actions of levonorgestrel, despite its
continued delivery from Norplant™ implants. A possible
mechanism for this is as follows. The predominant steroid
receptor pattern in levonorgestrel-exposed endometrium is
characterized by maximal expression of subtype A with a
reduction in expression of both PR subtype B and estrogen
receptors. This is a similar pattern to that observed during the
luteal phase of the normal cycle and one where it is associ¬
ated with endometrial breakdown and vaginal bleeding.
Thus, the chronic exposure to low-dose levonorgestrel is
associated with an endometrium constantly liable to degen¬
erate. Mifepristone administration causes further reduction
of the expression of PRU receptors, amplifying the lack of
progesterone action and inducing menstruation. The simul¬
taneous up-regulation of estrogen receptors induces the fac¬
tors responsible for endometrial proliferation, causing ces-'
sation of bleeding and a period of bleed-free days until
endometrial shedding recurs as the background pattern of
endometrial receptor status associated with Norplant™ (high
PRa, low PRb, and low ER) is restored.
The actual mechanism by which the steroids act on the
endometrial vasculature is unknown. However, increased
immunostaining for matrix metalloproteinases (MMPs),
which are involved with tissue breakdown, has been de¬
scribed in the endometrium of Norplant™ users (20) and
these enzymes have been implicated in endometrial break¬
down at the onset of menstruation in the normal cycle (7).
Like other investigators (12, 13), we have shown in this
study that PR concentrations are high in both the glandular
and stromal cells of the endometrium of women exposed to
levonorgestrel delivered by Norplant™. We have also dem¬
onstrated, for the first time, the presence of PR subtype B
receptors in endometrium exposed to Norplant™. It is clear
from Figure 3 that PR,, immunoreactivity in glandular and
stromal cells is much lower than the immunoreactivity for
PRa+b, which we infer to represent PR subtype A (18).
Mifepristone administration resulted in further depression of
the B subtype receptor. The simultaneous tip-regulation of
estrogen receptors as a result of mifepristone administration
may be an indication of the functional withdrawal of pro¬
gesterone and its effects on the endometrium.
There are no data on endometrial vessel changes in
women using Norplant™, who have been exposed to an
antigeslogcn. We and others have reported that the PRA
isoform is likely to be the dominant isoform in the secretory
phase of the cycle (18, 21). Moreover, PRA is the dominant
form in differentiating stromal cells in vitro. The abundance
of PRa declines in vitro during the decidualizalion process
(22). A decline in PR levels, either PRA or PR„, will be of
functional importance as there is differential gene activation.
FERTILITY & STERILITY®
Moreover, PRA may act as a repressor of PRri function, and
the expression ratios of the two subtypes will determine the
response to progesterone/progestogen (21, 23).
Mifepristone may also have an effect on the hypothala¬
mus, stimulating positive feedback by blocking the inhibi¬
tory action of progesterone and inducing ovulation (16), an
action which, independent of any direct effect on the endo¬
metrium, would be sufficient to improve bleeding patterns.
Certainly there was a suggestion in our study that ovulation
was more likely to occur during the 4 weeks after mifepris¬
tone administration than during the weeks before and after
placebo.
Cheng et al. (11) demonstrated an improvement in bleed¬
ing patterns when mifepristone was administered to women
experiencing bleeding dysfunction while using the levonorg-
estrel contraceptive implant. In that study ovarian activity
was not monitored, so we do not know whether the improve¬
ment was due to induction of regular ovulation or to some
other direct effect on the endometrium as described above.
Bleeding patterns tend to improve with the duration of use
of Norplant™ (11, 24), probably because as circulating
concentrations of levonorgestrel fall ovulation becomes
more frequent—about one-third of women ovulate regularly.
The altered endometrial vessel morphology described by
Hickey et al. (25) coincides with the time when bleeding
problems arc most common. In our study, the duration of
Norplant™ use varied between 4 and 24 months, but only
two women showed evidence of ovulation during the pre-
treatmenl period (S weeks) and all were experiencing fre¬
quent bleeding episodes. It is possible that mifepristone may
have a different effect depending on the duration of Nor¬
plant™ use, but the sample size in this small pilot study was
insufficient to assess this.
It is possible then that the regular administration of an
antiprogesterone—for example, once each month—might be
a useful strategy for reducing the side effects of low-dose
progestogen-only contraceptives, thereby increasing both ac¬
ceptability and continuation rates.
Norplant™ is a highly effective method of contraception
that has three mechanisms of action. It inhibits ovulation,
prevents normal sperm transport through the female genital
tract (particularly through the cervix), and is associated with
endometrial atrophy (24). If mifepristone administration in¬
creases the number of ovulatory cycles, it might reduce the
contraceptive efficacy of Norplant™ at the expense of in¬
ducing more tolerable bleeding patterns. Ovulation is infre¬
quent during the first 2 years of Norplant™, but it increases
with time as discussed earlier. However, the cumulative
pregnancy rate at the end of 5 years is only 1.1%, and thus
it would seem unlikely that an increase in the frequency of
ovulation following mifepristone would significantly in¬
crease the failure rate of Norplant11,1.
In the clinical trial of once a month mifepristone admin-
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istration (11), there were 110 pregnancies during 300 woman-
months of use. Contraceptive efficacy could also be reduced
if antiprogesterone improved the quality of cervical mucus.
No woman showed any evidence of having fertile mucus at
the time when placebo and mifepristone were given. It is
however possible that the functional inhibition of progester¬
one by mifepristone might induce fertile mucus, which we
failed to detect as we did not collect samples within days of
mifepristone administration.
Although ours was only a small pilot study, our observa¬
tions suggest that further investigation of the effects of an
antiprogesterone on the endometrium, and 011 vaginal bleed¬
ing patterns, in women using long-acting low-dose proges-
togen-only contraceptives would be worthy of future study.
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Once a month administration of mifepristone improves
bleeding patterns in women using subdermal
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It has been suggested that the administration of an anti-
progesterone might improve bleeding patterns in women
with irregular bleeding while using low-dose progestin-
only contraception. We report the findings of a double-
blind, randomized, placebo-controlled trial of mifepristone
50 mg taken once every 4 weeks in 100 Chinese women
(50 subjects and 50 controls) complaining of frequent and
irregular bleeding while using a levonorgestrel-releasing
subdermal contraceptive implant. In all women, regardless
of treatment, the frequency of bleeding decreased signific¬
antly over 360 days of observation. Women recorded
significantly shorter episodes of bleeding (P < 0.0002)
during mifepristone treatment than during the 90 days
before treatment started. In contrast, the duration of
bleeding episodes fell more gradually in placebo-treated
controls. Women using mifepristone were more likely to
find treatment acceptable than women receiving a placebo
tablet (/' < 0.01). Despite concern that anti-progestogenic
effects may jeopardize contraception, there were no preg¬
nancies. This approach may offer a useful strategy to
improve continuation rates by alleviating unwanted side-





Progestin-only contraceptive implants offer highly effective
contraception that is long-acting and does not require compli¬
ance for effectiveness. The major side-effect is an irregular
pattern of uterine bleeding (Fraser et al., 1998). At the end of
5 years, some 25% of Norplant users will have requested
removal of the implants because of a bleeding problem (Sivin
et al., 1998). In the People's Republic of China, levonorgestrel-
releasing implants account for only a very small amount of
contraceptive use, in Shanghai <1% of women use the Sino-
© European Society of Human Reproduction and Embryology
implant (Shanghai Dahua Pharmaceutical Plant, Shanghai,
China). In a multicentre study (undertaken in China) of
two types of levonorgestrel releasing implants, menstrual
disturbance accounted for 90% of the reported side-effects and
led to a discontinuation rate of 11% al the end of 1 year (Fang
et al., 1998).
Although the mechanisms underlying menslrual disturbance
are not completely understood (Fraser et al., 1997; Hickey
et al., 1999a,b) a variety of approaches have been tested to
reduce irregular bleeding in association with progestin-only
contraception and thereby to improve continuation rates
(Frascr, 1983).
It has been demonstrated that the addition of an antiprogester¬
one to progeslin-only contraception reduces the incidence of
unscheduled bleeding in monkeys (Williams et al., 1997). In
a small pilot study among women using Norplant®, wc have
demonstrated that a single dose of mifepristone 200 mg induces
changes in endometrial progesterone and oestrogen receptors
which are consistent with the functional inhibition of progester¬
one. There was a suggestion that anti-progesterone treatment
might improve bleeding patterns, either by a direct effect on
the endometrium or by inducing ovulation (Wang et al., 1997).
In an attempt to see whether the monthly administration of a
single dose of anti-progesterone might confer a clinically
significant improvement in bleeding patterns, we undertook a
double-blind randomized trial of once a month administration
of mifepristone to women using the Chinese levonorgestrel-
releasing implant (Sino-implant).
None of the authors has any vested interests of a commercial
nature relevant to this study.
Materials and methods
One hundred women aged 18-40 years were recruited from three
family planning clinics on the outskirts of Shanghai. All had hecn
using, for at least 3 months (range 3-43, median 15 months), a
contraceptive implant (Sino-implant; Shanghai Dahua Pharmaceutical
Plant) comprising two rods, each containing 75 mg levonorgestrel,
delivering a total dose of 30 pg/day for 3 years. All women were
attending the clinic complaining of frequent vaginal bleeding, defined
as a bleeding episode occurring more often than once every 24 days.
None was receiving any medication and all were fit and well with
no history of any gynaecological disease. Local ethical committee
approval was obtained for the study and informed consent was given
by all participants.
Women were randomized (50 in each group), using random number
tables, in blocks of eight attending each clinic, to receive either 50 mg
mifespristone (two tablets of 25 mg each) or two placebo tablets
(both placebo and mifepristone were provided by the Shanghai
Hualian Pharmaceutical Co. Ltd, Shanghai, PR China). Treatment
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Figure 1. Study design and reference periods for analysis of bleeding patterns. Mife = mifepristone 50 mg or placebo.
All women were instructed to keep a daily diary of bleeding and
spotting. Spotting was defined as vaginal blood loss not requiring
sanitary protection. After being enrolled in the study, a record of
bleeding was kept for 90 days prior to starting treatment. After
completion of 90 days of record-keeping, women were instructed to
attend the family planning clinic for the first treatment on the third
day after the start of a bleeding/spotting episode. After the first
treatment women were given a date to return to the clinic once every
28 days for 5 months (a total of six treatments in all). Treatment was
always given at the family planning clinic, where pill taking was
observed by a doctor after urinary P-human chorionic gonadotrophin
(HCG) had been measured to exclude pregnancy. At this visit the
bleeding diary was checked. Bleeding diaries were continued for a
further 90 days after completion of the last cycle of treatment.
Urinary HCG was measured using a kit (Surestep™ HCG; Applied
Biotech Inc., San Diego, CA, USA), the lower level of sensitivity of
which was 25 IU/I.
Statistical analysis
Since we had no meaningful data on which to base power calculations
the sample size was chosen to give sufficient power to detect as
significant a mean difference of 0.6 standard deviations. Menstrual
diaries were analysed using the MDS Menstrual Diary Analysis
Programme (World Health Organization, Special Program of Research,
Development and Research Training in Human Reproduction,
Statistics and Data Processing Unit, Version 3.0. 1993) (WHO, 1996).
Bleeding patterns were analysed in blocks of 90 days (reference
periods) (Figure 1). For each reference period the number of days of
bleeding and spotting, the number of episodes of bleeding and
spotting; the mean duration of spotting and bleeding episodes and
the number of 'dry days' (free of bleeding and spotting) were
calculated. Thus reference period 1 includes 90 days before the first
treatment (mifepristone or placebo). Reference periods 2 and 3 cover
a total of 180 days from the first treatment and together include 6
treatment months and the first 12 days of month 7. Reference period
4 started 39 days after the last treatment and ended 90 days later
(Figure 1).
In the final analysis, bleeding and spotting days were combined
and the data analysed using the Mann-Whitney (/-test.
Results
There were no differences in age (29.5 years for subjects, 30
years for controls) or parity (2.6 for each group) between
subjects and controls nor in the mean duration of implant use
(15.8 ± 2 months for subjects and 16.5 ± 2 months for
1970
Table I. Degree of satisfaction with treatment [numbers (and percentages)
of women]
n Satisfied Neutral Dissatisfied
Subjects 48 18(37) 21 (44) 9(19)
Controls 49 9(18) 20 (41) 20 (41)
controls). All women completed the study and there were no
pregnancies.
The effect of treatment on bleeding patterns is shown in
Figure 2. There were no statistically significant differences
between subjects and controls in any of the parameters assessed
during the 90 day period before treatment was started. Women
in both groups tended to show a similar decrease in the number
of bleeding days (and therefore an increase in the number
of dry days) with time (Figure 2A). Women treated with
mifepristone bled for a mean of 48 ± 15 days (range 21-88)
during the first 90 days, falling to 29 days in reference period
2 (P < 0.0002) with a further decrease to 23 days during
reference period 3. Women treated with placebo recorded a
mean of 51 ± 15 days (range 27-89) of bleeding in reference
period 1, falling to 33 days (P < 0.0002) during reference
period 2. By reference period 4 (after treatment), there were
no significant differences between subjects and controls in any
of the bleeding parameters measured. The mean number of
bleeding and spotting episodes also fell with time (Figure 2B),
with no significant difference between women treated with
mifepristone and controls. The most marked difference between
the two groups was in the average duration of bleeding episodes
(Figure 2B) which, among the subjects, fell from a mean of
14 days before treatment to 6.5 days after the first 90 days of
treatment CP < 0.00001). Among controls, the mean duration
of bleeding episodes also fell significantly with time from 15
days during the 90 days before treatment to 11.1 days at the
end of the first 90 days of treatment (P = 0.0003) and 8.2
days after the completion of all six treatment cycles. The mean
duration of bleeding episodes almost halved for both groups
of women when the number during the pre-treatment period
was compared with that post-treatment, regardless of whether
they had been treated with placebo or mifepristone.
Forty-eight subjects and 49 controls completed the post-
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Figure 2. Mean number of bleeding and dry days (A) and number and duration of bleeding episodes (B) among mifepristone-treated women
and controls over the four reference periods (RP).
treatment satisfaction questionnaire. Women treated with
mifepristone were more likely to rate their treatment as
satisfactory than those who received placebo (P < 0.01,
Table 1).
Discussion
In all women using the Sino-implant, bleeding patterns
improved during the 360 days of follow-up. The number of
bleeding days decreased (and inevitably therefore the number
of dry days increased) and both the number and duration of
bleeding episodes was reduced to a similar extent regardless
of treatment. This tendency for bleeding patterns to improve
has been observed with Norplant (Shoupe et al., 1991) and
has been attributed to an increase in the frequency of ovulation
as concentrations of levonorgestrel delivered by the implant
gradually fall. We analysed the number ofbleeding and spotting
days and number of bleeding episodes (among both subjects
and controls and both groups combined), comparing women
who had been using the implants for durations of less than
the median with those who had been using them for longer




Table II. Mean number of bleeding and spotting days and mean number of bleeding episodes per 90 day
reference period among women with shorter (less than median) or longer (longer than median) durations of
implant use
Patient Duration of implant use n Mean number of Mean number of
bleeding/spotting days bleeding episodes
Subjects More than median 24* 44.0 ±16 4.1 ± 1
(median 13.5 months) Less than or equal to median 24* 51.2 ± 14 4.3 ± 1
Controls More than median 25 46.2 ±13 4.3 ± 1
(median 15 months) Less than or equal to median 25 54.9 ±15 4.4 ± 1
All patients More than median 45" 45.6 ± 14 4.3 ± I
(median 14 months) Less than or equal to median 53 52.1 ± 15 4.3 ± I
♦Data inadequate for one subject in each group.
to be a slight improvement (Table II), the differences were not
statistically significant, in contrast to the differences seen in
response to mifepristone administration. The incidence of side-
effects also has been reported to decrease with time among
women using the Sino-implant (Fang et al., 1998), although
whether this is due to an increase in ovulatory cycles is
not known.
The only significant effect of mifepristone treatment was
on the average duration of bleeding episodes, which more than
halved in length during mifepristone-treated cycles but changed
much more gradually in women receiving placebo tablets. The
duration of bleeding episodes during mifepristone resembled
a 'normal' menstrual period. Since ovarian activity was not
monitored during the study, it is not possible to determine
whether induction of ovulation was the cause of the improve¬
ment in bleeding patterns. Further studies, with monitoring of
ovarian activity, need to be undertaken.
While these results may seem somewhat disappointing, the
women clearly found mifepristone to be of benefit. It hardly
needs scientific methodology to confirm that a bleeding episode
of shorter duration has to he more acceptable than one that
continues for days on end.
Levonorgestrel contraceptive implants act mainly by chan¬
ging the quality of cervical mucus and inhibiting normal sperm
penetration (Croxatto et al., 1987). Abnormal endometrial
development will prevent implantation, should fertilization
occur. Any intervention designed to improve bleeding patterns
which 'inhibits' the action of the progestogen might theoretic¬
ally jeopardize contraception. Reassuringly, no woman con¬
ceived during 300 'cycles' of use of mifepristone in
combination with the Sino-implant. In the event that adminis¬
tration of an anti-progesterone might reverse the contraceptive
effects of the progestogen, mifepristone itself at a dose of 50
mg has both contraceptive and abortifacient effects and the
risk of pregnancy may in fact be reduced still further.
The results of this study suggest that the once a month
administration of mifepristone may be an effective and accept¬
able way to ameliorate bleeding irregularities and 'tide women
over' until bleeding patterns improve with time as a con¬
sequence of an increasing frequency of ovulatory cycles. It is
possible to achieve a similar effect with the combined oral
contraceptive pill (Diaz et al., 1990), but most women find
the idea of using two hormonal contraceptives simultaneously
hard to understand and many have chosen a long-acting implant
1972
because they do not like - or cannot remember - to take a
pill every day. Further, and more detailed, studies of the
mechanism of action of this regimen are warranted.
References
Croxatto, H.B., Diaz. S., Salvatierra, A.M. el al. (1987) Treatment with
Norplant subdcrmal implants inhibits spenn penetration through cervical
mucus in vitro. Contraception, 36. 193-201.
Diaz, S., Croxalto, H.B., Pavez. M. et al. (1990) Clinical assessment
of treatments for prolonged bleeding in users of Norplant implants.
Contraception, 42, 97-109.
Fang. K-J., Guan. Y-M., Fan, H-M. el al. (1998) A multicentre study of two
types of Sino-implant (expanded application) (two year follow-up). Chinese
J. Fam. Plan., 33. 11-14.
Fraser, l.S. (1983) A survey of different approaches to management of
menstrual disturbances in women using injectable contraceptives.
Contraception, 28. 385-397.
Fraser, l.S., Hickey. M. and Song, S.Y (1997) Mechanisms of menstrual
bleeding: dysfunctional uterine bleeding and breakthrough bleeding. Hum.
Repmd., 11, 165-178.
Fraser, I.S., Ttilincn. A., Al'fandi, B. et al. (1998) Norplant® consensus
statement and background review. Contraception. 57, 1-9.
Hickcy, M., Sintbar, M., Markham, R. et al. (1999a) Changes in endothelial
cell basement membrane in Norplant users. Hum. Reprod., 14, 716-721.
Hickey, M.. Sinlbar, M., Markham, R. et al. (1999b) Changes in endometrial
vascular density in Norplant users. Contraception, 59, 123-129.
Shoupe, D., Horenstcin, H., Mishell, D.R. Jr et al. (1991) Characteristics of
ovarian follicular development in Norplant users. Fertil. Steril., 55.766-770.
Sivin, 1., Mishell, D.R. Jr. Dantcy. P. el al. (1998) Efficacy, side effects and
acceptability of soft tubing Norplant® implants in the United States: a 5-
year study. Obstel. Gynecol., 92, 337-344.
Wang, H.. Critchicy, H.O.D.. Kelly. R.W. el al. (1997) Docs the monthly
administration of an antiprogestogen improve bleeding patterns in women
using Norplant? 13^ Annual Meeting ESHRE - Edinburgh, June 1997.
Hum. Reprod., 12 (Abslracl book 1). P125.
Williams, R.F., Kloosterbocr. J.H., Vcrbosl. P.M. and Hodgen, G.D. (1997)
Once monthly antiprogestin controls menstrual bleeding during progeslin-
only contraception in primates. J. Soc. Gynecol. Invest.. 4. 134A. Abstract
no. 221.
World Health Organization Task Force on Long-Aciing Agents for Fertility
Regulation (1996) Clinical evaluation of the therapeutic effectiveness of
ethinyl oeslradiol and ocstrone sulphate on prolonged bleeding in women
using depot medroxyprogesterone acetate for contraception. Hum. Reptvd.,
11. 1-13.
Received on December 20, 1999: accepted on May 23, 2000
284
Clinical review
Science, medicine, and thefuture
Contraception
David 1 Baird, Anna F Glasier
The prevalence of contraceptive use Is increasing
worldwide, and in many countries over 75% ofcouples
use effective methods.1 However, existing methods of
contraception are not perfect, and their acceptability is
limited by side effects and inconvenience. Even in
developed countries where contraception is freely
available, many unplanned pregnancies occur. There
is tints a real need for new methods of contraception
to be developed that are more effective, easier to use.
and safer than existing methods. This article discusses
current research into new forms of contraception
and predicts what methods are likely to be used in
the future-
Social influences
Demographic forces, prevalence of disease, and social
and cultural factors influence not only die use of
contraceptives but also the development of new
methods. 'Hie age of onset of sexual activity is frilling,
while childbearing is being delayed or, in many
developed countries, forgone altogether. There is
pressure from the public for die use of more "natural
products." which arc perceived to be safer, but at the
same time demand that contraceptives have almost
perfect efficacy.
Those concerned with the development of new
drugs and devices take efficacy as read and are now
seeking positive health benefits—methods that prevent
riot only pregnancy but also sexually transmitted
disease and, in the long term, common diseases such
as breast cancer. Heterosexual intercourse is now the
main route of transmission of HIV. While barrier
methods such as condoms reduce die risk of trans¬
mission. there is a pressing need for additional and
complementary methods ol protection in die form
of topical virucidal agents, which ideally would also
be spermicidal.
Hormonal contraception for women
Methods involving steroid hormones have dominated
new developments in contraception, and in the past
40 yeah more than 200 million women worldwide
have taken "die pill."* Recent data confirm its excellent,
safety profile, and in many respects die pill will be hard
to beat. In the past 15 years new developments in
contraception have come mainly from tinkering with
hormonal methods—new delivery systems (implants
Predicted deyclqpfaents > (V- ■'
•^Njew'delivery systfenis ofc'onvenfionaJcontraceptives.
Kudi as yaginal rings, transdermal patches, and gels
«^Gdntra«pi|y^iftaf also protecta^flhst^ually
.;transipid^;Hi§caii? : •„;• •••" 1 ..fg; . - .
t&rm;(<fOyeat'S^^ ••
Uiifinhibits im|i(ahtaiic|h . ;!'
;v 7 .,7^' u.f ' i>
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•' spe^n maturation
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phosphodiesterase inhibitors ' '* ' -'f:
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and hormone releasing intrauterine devices), better
progestogens, and lower doses of oestrogen.
New delivery systems and selective receptor
modulators
The early 21st century will probably witness the licens¬
ing ofcontraceptive vaginal rings, transdermal patches,
and gels. In the longer term it seems likely drat selective
modulators of hormone receptors will replace
currently available oestrogens and progestins in order
to avoid their risks, particularly venous thrombosis,
while also reducing the incidence of common diseases
such as breast cancer. Study of the molecular structure
of hormone receptors has revealed drat each ligand
induces an almost unique conformational change and,
hence, has slightly different biological effects/1 It Is
therefore likely that organ specific drugs, which
produce the desired effect only on critical reproductive
processes, will become available.
Antiprogestins
'Hie most exciting development in die past 20 years
has been die discovery of compounds that antagonise
die action of progesterone. Progesterone is necessary
for die establishment and maintenance of pregnancy.
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implantation—depend on the secretion of progester¬
one by the ovary at the appropriate time. It is nearly 20
years since die discovery of the first antagonist of pro¬
gesterone (mifepristone), which was shown to interrupt
pregnancy The political controversy surrounding die
"abortion pill" has impeded research into other poten¬
tial uses of these compounds, including contraception.
Some years ago we showed that a single close of
600 mg mifepristone was highly effective as an
emergency contraceptive after unprotected inter¬
course.' The compound both inhibits ovulation and
prevents implantation, properties which suggest that it
could be used as a regular form of contraception. AT
daily close of2-5 mg (less than a hundredth of die close
required to induce abortion) inhibits ovulation and
prevents the formation of a secretory endometrium.*'
Oestrogen secretion bv the ovary is maintained at the
level of that found in die follicular phase of die
menstrual cycle. Preliminary data suggest that most
women are amcnorrhoeic while taking the antiproges-
tin, which could be a considerable advantage
compared with other forms of oestrogen-free contra¬
ceptives such as gestogen only pills.
Antigestogens might also be used for "once a
month" pills. If rhey are given in the early luteal phase
of the cycle die formation of a secretory endometrium
is retarded without affecting the regular pattern of
menstruation, hi a pilot study of 21 women in Sweden
who used this method as their sole means of
contraception there was only one pregnancy in 153
menstrual cycles." A major practical problem with this
approach is the difficulty in detecting ovulation so diat
the pill can be taken at the correct rime of the cycle.
A once a month pill that prevented ovulation or
implantation would be welcomed by many women
from various countries and cultures.' In contrast, only a
minority of women would be prepared to use a pill
taken around the time of expected menses, when
implantation of the embryo would already have
occurred. In any case, current evidence suggests that
mifepristone alone or in combination with misoprostol
would result in tot) high an incidence ot pregnancy to
be useful as a regular method of inducing early
menses"
Contragestion
It has also been proposed that mifepristone could be
taken only if the menses was overdue ("contragestion").
An inducer of a missed menses acts by disrupting an
implanted embryo and induces a very early abortion. A
pilot study supported by the World Health Organis¬
ation reported very few ongoing pregnancies in
women given a combination of 600 mg mifepristone
and 1 mg gemeprost within 10 clays of their expected
menses." Although this study showed "proof of
concept," there are legal, political, and ethical issues
dial make it unlikely that this approach would receive
widespread acceptance. Moreover, in the above study
there was considerable variation in die timing of the
onset of the next menses, which would make it difficult
for women to decide whether to take die pill again in
subsequent cycles. However, for those women who find
it ethically acceptable, a pill diat induced missed men¬
ses might be more attractive than a monthly pill to
induce early menses, perhaps because it would be
required only two or three times a year.
Hormonal contraception for men
Evidence from different countries and cultures shows a
growing demand for more effective and convenient
methods of contraception for men.10 A recent survey in
Scotland, South Africa, Hong Kong, and China found
that most men would consider using a "male pill".
Although it has been known for nearly 50 years that
azoospermia can be induced by the administration of
large doses of testosterone, progress in the develop¬
ment of hormonal male contraception has been slow
for several reasons. The supraphysioiogical dose of
androgen required to induce azoospermia causes side
effects, including prostate hypertrophy and unfavour¬
able changes in plasma lipids, precluding wide scale
use in otherwise healthy men."
Current research therefore focuses on lower physi¬
ological closes of androgen in combination with
gestogens (such as desogcstrel and cyproterone
acetate) or gonadotrophs releasing hormone antago¬
nists.1* Orally active non-peptide antagonists of
gonadotrophin releasing hormone or a depot prepa¬
ration could provide a practical method ofsuppressing
gonaclotrophins in combination with androgen
replacement. J-Iowever, there are presently no conven¬
ient. safe preparations of androgen for replacement
therapy, although this is the subject of research by sev¬
eral pharmaceutical companies. Encouraging progress
is being made in die development of new androgens
(such as 7«-methyl nortestosterone (MENT)) chat have
potential health benefits and in new methods of long
term delivery of steroids in implants (such as
Implanon).w Development of a sate, acceptable
treatment that is as effective as the combined oral con¬
traceptive pill lbr women (Pearl index < 1 per 100
women years) is at least five years away.
Beyond 2010
In die long term there are several potential approaches
for contraception in men and women (see figure)."
Meiotic arrest
hi bodi sexes die formation of gametes (spermatogen¬
esis and oogenesis) involves the process of meiosis,
whereby die number of chromosomes in a diploid
nucleus is halved to the haploid state by cell division.
Meiosis occurs only in germ cells, and, hence,
substances that interfere with meiotic division should
be specific for the gonad. Specific genes are expressed
at different stages of spermatogenesis, and antagonism
of their prevducts (stiCh as activin) could lead to sterility.
In the female, meiosis is almost completed during
fetal development, but the final stages of meiotic
division are delayed into adulthood, until just before
ovulation. If we knew die mechanism by which meiosis
was arrested in die oocyte it might be possible to acti¬
vate a similar mechanism to inhibit spermatogenesis in
men. Arrest of meiosta in the oocyte involves at least
one protein specific to germ cells (c-mos), which is also
transcribed in the male during meiosis. A high concen¬
tration of cyclic AMP is apparendy important in
preventing final maturation of die oocyte, and specific
inhibition of phosphodiesterase 3 (the enzyme that
catalyses the breakdown of cyclic AMP) is contracep¬
tive in rats, preventing the oocyte from acquiring
developmental competence.


















Potential targets for contraception in men and women
Blockage of follicle stimulating hormone
Blocking the follicle stimulating hormone receptor or
inhibiting secretion of follicle stimulating hormone
with analogues of inhibin will interfere with sperma¬
togenesis, although whether sperm production can be
maintained by testosterone alone in men. as it can in
rodents, is not known. A minimum concentration of
testosterone within the testis is probably required tor
spermatogenesis, so that inhibitors of androgen
synthesis or action will be conuaceplive. 'Hie key to
successful use of these approaches is again specificity. It
may be possible to use the follicle stimulating hormone
receptor as a target to deliver another agent specifically
to the testis.
Munitions of the follicle stimulating hormone
receptor have been described in women who present
with primary amenorrhoca due to lack of follicle
development. Inhibitors of follicle stimulating hor¬
mone synthesis or action could prevent fertility but
would require oestrogen replacement to prevent die
consequences of hypo-oestrogenism. Arresting final
maturation of die oocyte before ovulation or follicle
rupture would be an attractive method of contracep¬
tion that did not disrupt the endocrine events control¬
ling the ovarian cycle.
Preventing implantation
Progesterone induces the transcription of various
endometrial gene products involved in implantation—
for example, leukaemic inhibitory factor, calcitonin,
vitronectin, integrin, and a4pt intcgrin.1*Specific
antagonists of these products would be promising as
new contraceptives because they should only act at the
litems.
The formation of new blood vessels (angiogenesis)
is usually restricted in adults to repair of injury, but in
the ovary and litems there is extensive angiogenesis
each month during die formation of the follicle,
corpus luteum, and endometrium. A potent antagonist
of vascular endothelial growth factor prevented
pregnancy in mice without producing major systemic
side effects in the long term.
Immunisation
Other likely targets for new contraceptives arc proteins
involved in fertilisation.17 w The sperm attaches to die
egg through die interaction of specific: antigens on the
sperm surface with the zona pellucida proteins of the
egg (such as ZP3). Immunisation of female monkeys
widi zona pcllucicla proteins prevents pregnancy, but
unfortunately produces a form of autoimmune
oophoritis with loss of oocytes and premature
menopause. Unforeseen consequences resulting from
autoimmunity are a potential hazard of antifertility
vaccines. Immunisation of women against sperm
antigens should avoid such problems, but research is
still at the initial stages.'*
Another possibility is disrupting the synthesis or
delivery of proteins such as fcrtiiin that are important
for the function of sperm membrane, thus leading to
incompetent spermatozoa. Interfering with the final
maturation of the spermatozoa has die attraction dial
it would result in sperm that were incompetent to ferti¬
lise an egg without running the risk of producing
genedcally mutated germ cells. However, concerns
have been raised about the potential misuse of contra¬
ceptive vaccines, particularly if they are not fully
reversible.
Because of these political concerns and doubt
about long term consequences of immunisation, diere
is little commercial enthusiasm for further develop¬
ment of this approach in spile of the scientific
potential.





Compared wiih many drugs, die product develop¬
ment of a new contraceptive is expensive and
relatively high risk. It is unlikely that die pattern of
contraceptive use will change radically in the next 10
years. No one method will be suitable fur everyone,
and individuals' preferences will probably change
through their reproductive life. In the next five years
more sophisticated systems for die delivery of steroid
hormones, through or under the skin and into die
uterus, will extend the range of options available. Ill
five to 10 years new steroid antagonists such as
antiprogestins will replace some current contraceptive
methods, such as gestogen only pills, and probably
lead to new approaches like a "once a month" pill. By
10-15 years, the dream of an effective safe male pill
will probably become a reality, shifting the burden of
responsibility for coiitrucepdon more equally between
men and women. Only then will women have tnilv
achieved "the fifth freedom"—freedom from the
burden of excessive fertility*
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When 1 use a word,..
That's show business
The names of drugs are usually coined from words related to
their chemical structures. For example, the full chemical name for
a popular analgesic is A'-acci.yl-/tfra-aminophcnol. Simpler to use
the British Approved Name, paracetamol, which is just a
contraction of the full name, as is acetaminophen, the United
Slates Adopcd Name.
Bui some drug names have unusual origins. For instance, it few
are derived from die entertainment business.
V Sensi and his colleagues at Lcpetit Research Laboratories in
Milan hat! the habit of giving new compounds nicknames, later
substituting names thai would be acceptable to scientific journals.
Malantycin, for example (Antibini Chemother 1959^):76),was
originally nicknamed Mata Mart. And when in 1957 they isolated
a group of antibiotics from the fungus Strefflomyccs nud'uei mnei
(now called Ntrrctului medilcrranm) ihey cnlled them rifamycins,
from the title of the French gangster film, Rifiji. directed byJules
Dassin (1955). Rifampicin was the N-atnino-A-'-mcthylpiperazine
(AMP) derivative—liciice rit-amp-kin, Rifili is French argot for
trouble, and the original title of tlte film was I)u Rififi Chez In
Homnws, which we might nowadays translate as Men tichavhig
Hodly.Tlic chief feature of the film was the half hour
dooumcntary-like sequence during which a bank robbery is
staged in total silence. The startling effect of the return of sound
to the screen was harnessed again by Dassin in another account
of an unsuccessful heist, Toj>kapi096i), based on Eric Ambler's
novel 'Che Light ofDay.
Then there is opera. In 1977 several novel compounds were
isolated from a substance known as bohemic acid complex ill.
Their discoverers named thein marcellomycin, musctinmyciri.
rudolphornycin. mimimyrin, colliriemycin, alcindoromycin, and
schaunardimycin. Another compound was called bohetuamine.
Recall the plot of Puccini's opera I.a Boh'cme. Rodollb artd
Marcello, poet and painter respectively, trying to work in their
bitterly cold garret, are joined by their fellow lodgers. Golline (a
philosopher) and Schaunard (a musician). Rodolfo meets a
neighbour, Mimi, with whom he tails in love. Marcello's former
lover, Musctta, gets rid of her ageing admirer. Alcindoro. «uid
rejoins Marccllo. bul they later separate again. Rodolfo leaves
Mimi k«), but they are reunited just before she dies.
Unfortunately, ignoring the symmetry of the plot, niimimycin is
the HI cphner of marcellomyrin and collinemyciu the 1') epimer
of muscttantycin—not the proper pairings at all. The spelling uf
rudolphomvcin is also curious. In Henri Murger's original stories,
Sihies tie la Vic dc tlohtmc, the poet's name is Rodolphe, while
Puccini, being Italian, spelt the name Rodolfo. Perhaps the
discoverers of these compounds (/ ATal Prod 1980;43:242-58 and
1984;47:098-701) just made a mistake.
These -mycins are all anrhracydine antibiotics, effective against
cancers. But I wonder if they might have cured Mimi of her
tuberculosis.
JelTAronson, clinical phai macologisU Oxford
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Feasibility of administering mifepristone as a once a month
contraceptive pill
Dharani K.Hapangama, Audrey Brown, Anna F.Glasier and David T.Baird1
Contraceptive Development Network, Department of Reproductive and Development Sciences, The University of Edinburgh,
Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh, EH3 9ET, UK
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Many women find the idea of a once-a-month contraceptive pill an attractive concept. Mifepristone has been shown
to be effective as a contraceptive if administered in the early luteal phase. We tested the contraceptive efficacy of
200 mg of mifepristone on day luteinizing hormone (LH) J- 2 in a group of 32 women who used a fertility monitor
to identify the LH surge. We also recruited a control group, comprising 20 women who were trying to conceive. In
this group, 12 women conceived during a total of 50 control cycles (probability of pregnancy 0.25-0.32). Women in
the treatment group contributed to a total of 178 cycles and there were two pregnancies (probability of pregnancy
0.01). An LH surge was not detected in 34 cycles (19.1%). In 20 cycles (11.2%) this was due to imperfect use while
14 were monitor method failures (7.9%). Treatment with mifepristone in the early luteal phase did not disrupt the
cycle length but women reported slight vaginal bleeding in 15% of the cycles. The combination of a home-use
fertility monitor with once-a-month administration of mifepristone (especially if mifepristone is administered at the
early luteal phase) is an acceptable contraceptive option with minimal side effects. Unfortunately, it is difficult to
envisage how an easier way of defining the correct timing, which required less compliance, could be devised.
Key words: contraceptive/home use fertility monitor/LH surge/Mifepristone/once-a-month pill
Introduction
Hormonal contraception is used by almost 100 million women
world-wide. However, many women are deterred from using
it because of perceived risks to health such as breast cancer
or side effects such as weight gain. Most of the risks and the
side effects arc the results of prolonged exposure to steroids
and many women, in a variety of cultural settings, find the
idea of a pill which they need take only once each month, an
attractive concept (Rimmer et al, 1992; Glasier et al., 1999).
Progesterone is essential for the establishment and mainten¬
ance of human pregnancy. The anti-progesterone mifepristone
is a synthetic 19-norsteroid, which acts by blocking the action
of progesterone at the receptor level (Spitz and Bardin, 1993),
and thus, has multiple potential anti-fertility actions. When
administered in the early luteal phase mifepristone retards
endometrial development, without disturbing the timing of
menses (Swahn el al., 1988; Berthois et al., 1991; Maentausta
et al., 1993). It also alters uterine contractility to a pattern
more usually seen in the late luteal phase (Gemzell-Danielsson
et al., 1990). In 1993 Gemzell-Danielsson and colleagues
conducted a pilot study in which a single dose of 200 mg of
mifepristone was given in the early luteal phase [2 days
following the surge of the lutenizing hormone (LH) in urine].
Out of 124 cycles in which coitus took place during the fertile
period, only one pregnancy was observed (Gemzell-Danielsson
© European Society of Human Reproduction and Embryology
et al., 1993). There was no disruption of the timing of the
subsequent menstrual bleed, although in 35% of the cycles
slight vaginal bleeding was reported 2-3 days after treatment.
The main problem in developing a oncc-a-month contra¬
ceptive is finding a means that, both reliably and easily,
identifies the start of the LH surge. Gemzell-Danielsson tried
to solve this problem by using the LH sticks for home urine
testing (Ovu-quick; Organon). In their study 12 out of 169
cycles were deemed to be anovulatory. However, it is not
possible to determine if the LH surge truly was absent, or if
the method failed to detect a surge. The woman may have
read the test result wrongly or even failed to perform a lest
on the appropriate day.
Unipath (Bedford, UK) have developed a technology that
can be used in the home to monitor changes in urinary
hormones. This system comprises disposable test sticks and a
hand held monitor, which together are used to detect changes
in the levels of oestrone-3-glucuronide (E3G), a urinary
metabolite of oestradiol, and LH, to indicate the potentially
fertile days leading up to ovulation. The time from the first
significant rise of LH in the urine to ovulation is reported to
be around 24-48 h (Collins, 1996). The monitor thus should
provide a convenient method of identifying the early luteal
phase. Summary data for up to six consecutive cycles can be




We investigated the contraceptive efficacy of 200 mg of
mifepristone on day LH + 2 in a group of women who used
this monitor to identify the LH surge.
Materials and methods
This was a single centre study in healthy female volunteers,
approved by the Lothian Research Ethics Committee. All subjects
gave written informed consent to participation. Fifty-two sexually
active women, with regular (25-32 day) menstrual cycles were
recruited trom a large Family Planning Clinic lit Ediubuigli. If the
women had a significant medical condition or if they or their partners
had a history of fertility problems, they were excluded from the study.
Treatment group
Thirty-two women were recruited to the treatment group. None had
been taking hormonal preparations within the 2 months prior to the
start of the study and all had had at least two spontaneous menstrual
periods since stopping hormonal contraception. All women underwent
screening at the time of recruitment including a routine physical and
gynaecological examination. A venous blood sample was taken for "
full blood count, serum biochemistry and liver function. The study
started on day I of the menstrual period following screening, and
lasted for up to seven consecutive menstrual cycles in which subjects
took 200 mg mifepristone once per month.
Control group
The control group consisted of 20 healthy women with regular
menstrual cycles who were trying to become pregnant (for less than
6 months prior to the enrolment in to the study) and hence, were not
using contraception. They were provided with a monitor, which they
used according to the manufacturer's instructions. Women were
advised that their chance of conception would be higher if they were
to have sexual intercourse during the fertile period, identified by the
monitor. The controls took part in the study until pregnancy occurred
or for a maximum of six cycles if they did not conceive.
Procedure
All subjects and controls were provided with a home use hormone
monitoring system (Unipath, Bedford, UK). The system comprises a
hand-held monitor and disposable dual-assay urine test sticks, and is
used to simultaneously detect LH and E3G levels in early morning
urine. The monitor optically measures the intensity of the lines that
form on the test sticks after sampling, and the system will delineate
three levels of fertility (Low, High and Peak Fertility) according to
the optical signal changes detected. Low fertility will be displayed
from day 1 of the cycle, until the hormone levels rise above the
baseline levels. A change from low to high fertility is triggered by
detection of elevated E3G levels, to concentrations typically
between 20 and 30 ng/ntl. The change from high to peak fertility is
triggered by the detection of an LH surge, typically with a concentra¬
tion >30 IU/1.
Peak fertility is displayed on the day of the LH surge and on the
following day. Subsequently high fertility is displayed for I day prior
to a return to low fertility. At the start of each menses, the subjects
pressed the'm' button on their monitor to initiate that cycle of use,
at a time suitable for testing the first urine of the day. For the rest of
the month, the subjects were required to consult the monitor display
each morning (3 h either side of the time when'm' button was set)
to determine whether they needed to perform a test that day. Beyond
this 6 h time window the monitor would not accept a test. The system
requests one test every day for up to a total of 10 or 20 tests,
depending on the length of the woman's cycle, and the timing of her
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LH surge. Embedded software within the monitor collects and analyses
data from each cycle to identify and display fertility status to the
user, and stores data for several months.
Mifepristone (Laboratories Exelgyn. Paris, France) was taken 2
days after the day of the first day of peak fertility (LH surge). With
each cycle, subjects followed the same protocol, and were reviewed
by the investigator monthly, on day LH + 2. Just before taking the
200 mg tablet of mifepristone, a venous blood sample was taken,
and later assayed for progesterone. At the beginning of the study, if
the LH surge was not identified by day 21 of the cycle, the subject
was instructed rn continue, testing, hut mifepristone was not given in
that cycle. The subject was also advised to use barrier contraception
from day 21 until the onset of the next menses. After the second
pregnancy (which occurred due to a failure in detecting an LH surge),
we changed this practice. We calculated the estimated day of LH
surge for each month based on information from the previous cycles.
If the women did not detect an LH surge either within 3 days after
the anticipated day of LH surge or by day 19, a blood sample was
taken for rapid serum progesterone assay. If the progesterone level
was >5nmol/l and if the woman was at risk of pregnancy, mifepristone
was administered.
All subjects and controls kept a menstrual record card, recording
all vaginal bleeding experienced during the study and the days on
which they had sexual intercourse. Subjects also marked the first day
of the peak fertility as identified by the monitor and the day of taking
the study medication.
Ifmenstruation was overdue by more than one week the investigator
performed a pregnancy lest. Provided this was negative, the subject
continued in the study and the next cycle was deemed to start with
the onset of menses. Since the effect of mifepristone taken in very
early pregnancy is unknown, and teratogenic effects could not be
ruled out. women who would not consider terminating any pregnancy
were not recruited to the treatment group.
At the end of the study, the subjects attended for a final visit, when
a routine physical and gynaecological examination was performed.
Full blood count, serum biochemistry and liver function were
reassessed.
The following definitions were created for the purpose of the study.
Imperfect use: was defined as failure to delect an LH surge
through performing the test inconectly (e.g. dipping a test slick in
urine 30 or more min before it being read by the monitor), or failing
to perform tests as requested by the monitor.
Monitor method failures: were defined as failure to delect an LH
surge despite performing all tests as requested.
High fertile days: days preceding the urinary LH surge as indicated
by the monitor to be potentially fertile.
Peak fertile days: The first day of a significant rise in urinary LH
detected by the monitor, and the following day.
The fertile period: of the cycle was defined as 3 days before until
2 days after the urinary LH surge (LH-3 to LH+2).
Exposure cycles: were cycles in which women reported having
sexual intercourse at least once during the fertile period.
Statistical analysis
Cycle lengths and serum progesterone concentrations were compared
by two-sample r-tests. Confidence limits for efficacy were derived
from confidence limits for relative risk calculated by the Greenland
and Robins method (Greenland and Robins, 1985).
Results
Table I shows the demographic characteristics of the women
who took part in the study.
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Table I. Demographic data.
Treatment group Control group
(»i « 32) (« = 20)
Age
Range 18-39 26-40
Mean (± SD) 30 (± 5.4) 32.9 (± 4.5)
BMI
Range 19-38 21-29
Mean (± SD) 23.6 (± 4.3) 23.8 (± 2.7)
Smokers (%) 7 (21.9) 1(5)
Non-smokers (%) 21 (65.6) 16(80)
Ex-smokers (%) 4(12.5) 3(15)
Previous pregnancies
!+(%> 19 (59.4) 14 (70)
Never been pregnant (%) 13 (40.6) 6(30)
Ever abortion (%) 15 (46.9) 5(25)
Marricd/Co-habiting (%) 28 (87.5) 20 (100)
Single (with a regular boy friend) (%) 4 (12.5) 0(0)
The women in treatment group were slightly younger (mean
age 30 years) than those in the control group (mean age 32.9
years). Otherwise there were no differences between subjects
and controls.
The probability ofpregnancy in the control group
Twenty women were recruited to the control group and three
withdrew before completing the study. Two withdrew from
the study as they found using the system 'too stressful' and
one withdrew because she no longer wished to plan a pregnancy.
Data were collected from 50 control cycles during which 12
pregnancies occurred. Average frequency of intercourse was
1.7 episodes per week in the 39 control cycles in which the
women kept a record of their sexual activity. In 37 cycles
women had intercourse at least once during the fertile period
(FP). In two cycles intercourse did not occur during the FP,
while in 11 cycles the exposure status was unknown, as women
failed to keep a record of sexual activity. Eight pregnancies
occurred in the first exposure cycle.
If we assume that all 11 cycles from which information
on sexual activity was lacking were exposure cycles, the
probability of pregnancy was 0.25. However if those cycles
were all non-exposure cycles, the probability of conception
would be 0.32. Therefore among the control group the overall
probability of pregnancy if sexual intercourse took place at
least once during the fertile period lies between 0.25-0.32.
Contraceptive efficacy of the method
Thirty-two volunteers were treated with a single dose of
200 mg of mifepristone administered in the luteal phase
of the cycle as their sole method of contraception between
one and seven cycles. They contributed a total of 178 cycles,
and in 167 cycles mifepristone was administered. Eight women
withdrew from the study before completion; two women
moved out of the area, three ended their relationship, two
conceived during the study and one lost confidence in the
method.
Two clinical pregnancies occurred in the 178 cycles
studied. The first pregnancy was a true treatment failure.
which occurred in a woman (para 1) who took mifepristone
on day 14 (LH + 2) of her first treatment cycle. She opted
for a surgical termination of pregnancy, which was performed
at 8 weeks of gestation (confirmed by ultrasound scanning).
In the second woman (para 3), an LH surge was not identified
in her third study cycle hence she did not receive treatment
with mifepristone, menses did not occur and on day 37 after
her last menstrual period an ectopic pregnancy was diagnosed
and treated surgically. In a third woman a biochemical preg¬
nancy was diagnosed (serum [5HCG only rising to 34 IU/1),
which was spontaneously and completely aborted by day 34 of
the third study cycle after taking mifepristone on day 14 (LH
+ 2). This woman continued in die study and completed six
treatment cycles.
The mean frequency of sexual intercourse was 1.8 episodes
per week in 167 treatment cycles in which sexual activity was
recorded. If we assume the probability of pregnancy in the
treatment group is similar to the control group (0.25-0.32),
the expected number of clinical pregnancies during the 178
cycles (in which 140 were exposure cycles) studied should be
between 35-48.3. The observed number was two. Therefore,
the efficacy of the method is 94.3% (95% confidence interval
75.4-98.7) - 95.9% (95% CI 82.5-99.0).
When calculating the efficacy of die method, we excluded
the 29 cycles during which women were not exposed to a risk
of pregnancy, and the three cycles in which mifepristone was
taken in the follicular phase.
Contraceptive efficacy of luteal phase administration of
mifepristone
In 145 cycles in which mifepristone was taken in the early
luteal phase (within 2 days of the urinary LH surge) 117 were
exposure cycles (Table II). Exposure status was unknown in
eight cycles and in 20 cycles women were not at risk of
pregnancy. In the 117 exposure cycles, there was only one
clinical pregnancy.
In 19 (10.7%) cycles, no LH surge was declared by die
monitor but mifepristone was given as coitus had taken
place during the fertile period of the cycle (calculated according
to the usual cycle length and usual day of LH surge).
Occurrence of ovulation was confirmed by serum progesterone
of >5 nmol/1 in all 19 cycles and treatment was administered
prior to day 21 of the cycle in each case [between day 13-21
of the cycle, mean 16.9 (SD ± 2.1) days]. There were no
pregnancies in these cycles.
If the probability of pregnancy in all exposure cycles in
the study is 0.25-0.32 (the same as diat of the control group),
between 34-46 clinical pregnancies would be expected in
the 136 ovulatory cycles in which mifepristone was taken in
the luteal phase. The observed number was one. Hence, the
contraceptive efficacy of luteal phase mifepristone is between
97.1% (95% CI 78.00-99.6) - 97.8% (95% CI 83.9-99.7).
Performance of the home use hormone monitor
in 140 treatment cycles an LH surge was identified by the
monitor, which equates to 90.9% LH surge detection when
calculated for perfect use cycles; and 80.5% when imperfect




Table II. Treatment cycle details.
Total no. Exposure Unknown No
cycles cycles exposure Exposure
Mifepristone administered 167 136 8 23
In follicular phase 3 0 0 3
In luteal phase 164 136 8 20
Early luteal phase 145 117 8 20
LH + 2 127 100 7 20
LH + I 17 16 1 0
LH + 0 1 1 0 0
In luteal phase (unknown LH status) 19 19 0 0
Mifepristone not given 11 5a 0 6b
Total 178 140 8 29
"LH surge missed, at risk of pregnancy but after day 21.
bAnovulatory cycle n = 1, LH surge missed and no risk of pregnancy n = 5).
was confirmed by a subsequent rise in serum progesterone of
>5 nmoi/1 in the early luteal phase. This information was _
not available from nine cycles (blood samples lost or not
collected). In the remaining four cycles serum progesterone
was between 2-5 nmol/1, 1 or 2 days following the urinary
LH surge as detected by the monitor. This may have been due
to an early detection of the first significant rise in urinary
LH. None of these five cycles were prolonged after taking
mifepristone, hence it is unlikely that they were anovulatory.
There was a total of 38 (21.3%) cycles in which an LH
surge was not detected. Among them, one (0.6%) was an
anovulatory cycle, defined by serum progesterone not rising
above 5 nmol/l in the mid-luteal phase. In three (1.7%) other
cycles we administered mifepristone on day 19, before the
monitor had identified an LH surge. Serum levels of progester¬
one (taken on the day of administering mifepristone) confirmed
that in these cycles mifepristone was administered in the
follicular phase. AH three cycles were prolonged (43-52 days).
In the remaining 34 cycles an LH surge probably occurred
(as suggested by a rise in serum progesterone of >5 nmol/l)
but was not identified by the monitor. Fourteen were missed due
to monitor method failure (7.9%) and 20 were a consequence of
imperfect use of the system (11.2%).
Cycle length
Mifepristone when given in early luteal phase did not signi¬
ficantly affect the cycle length (P = 0.35). The mean of
the usual cycle length was 28.3 days (SD ± 1.3) and during
the treatment cycles it was 28.0 days (SD ± 1.9).
Side effects
Women kept a record of vaginal bleeding in 139 out of the
total 144 cycles where mifepristone was taken on LH + 2.
Mifepristone induced vaginal bleeding within 72 h in 21 cycles
(15%). In a further 19 cycles, our volunteers took mifepristone
in the luteal phase but the LH status was not known. In 17 of
those cycles (>89%), mifepristone induced a vaginal bleed.
Serum progesterone values in blood samples taken just
prior to mifepristone administration were available for 136
cycles. The mean serum progesterone value was significantly
(P < 0.0001) higher in those cycles where mifepristone
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induced bleeding when compared to the mean value for the
cycles without bleeding [21.72 (SD ± 9.04) nmol/l versus
13.33 (SD ± 6.23) nmol/l].
Two women spontaneously reported improvement of their
pre-menstrual symptoms during cycles in which mifepristone
was administered, while one reported worsening. In one woman
hepatic alanine aminotransferase (ALT) was elevated at 103
IU/1 (normal range 10-40 IU/1) at the end of the study but
returned to normal within 2 months. One woman complained
of diarrhoea 12 h post mifepristone in one cycle, three reported
menstrual cramping within 72 h of taking mifepristone; two
women reported a reduction in menstrual blood loss.
Discussion
A single dose of 200 mg of mifepristone administered
once a month is an effective contraceptive method with an
overall efficacy of 95% increasing to 97% if administered
at the correct time (i.e. the early luteal phase). Thus our
results are in agreement with the findings of a previous study
(Gemzell-Danielsson et at., 1993).
One criticism of previous work in this field has been
the lack of a suitable control group for the subjects studied.
Unlike the Gemzell-Danielsson study, we were able to compare
the results with a contemporaneous control group using the
same methodology in the same cultural setting. In this control
group, if sexual intercourse took place on a fertile day the
probability of a pregnancy was 0.25-0.32. The calculated
probability of pregnancy in a cohort of couples monitored
during a study of natural family planning (WHO, 1983) was
0.486 if intercourse took place 3 days prior to and a day after
the peak day of mucus discharge. The difference in the
probability of pregnancy between our study and a variety of
other published series (Table III) may be explained by the fact
that we have extended our definition of the fertile period to 6
days (3 days prior to the urinary LH surge until 2 days after).
Other authors (Wilcox et al., 1995) have calculated that the
likelihood of conceiving during an ovulatory cycle to be 0.37
(95% confidence interval 0.31-0.48) if daily sexual intercourse
took place during a 6 day fertile period (four days before and
a day after ovulation). The lower frequency of intercourse in
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Table III. Probability of clinical pregnancy.
No. of No. of Probability of
exposure pregnancies pregnancy
cycles
Wilcox et aL, 1995b 129 34 0.26
Our control groupb 37-48 12 0.25-0.32
Our treatment groupb 140-151 2 0.01
(monitor + mifepristone)
Our treatment groupb 136-143 I 0.007
(mifepristone in luteul phase)
Gcmzeli-Daniellson et al., 1990* 124 I 0.008
WHO study1 72 35 0.48
"The length of (he fertile period defined its 4 days.
*Thc length of the fertile period defined as 6 days.
LH surge not identified by the monitor
a) within 3 days of the expected day of the surge
or
b) by day 19 of the cycle
Figure 1. Algorithm for administering mifepristone when the LH
surge is not identified
our group (untimed intercourse averaging 1.7 per week) may
also explain the lower probability of pregnancy.
The limiting factor in this once-a-month approach to
administering anti-progesterone is the accurate detection of
the LH surge. Clearly, the failure to detect accurately the
LH surge has a big impact on the overall effectiveness of
the method. Using laboratory assay of LH in blood or urine
to identify ovulation is neither practical nor convenient for
long term use in the general population. The monitor
provided us with an opportunity to overcome these problems.
Gemzeil-Danielsson el at. (1993) reported 49% accuracy using
home LH detection sticks (Gemzeil-Danielsson el al., 1993).
Although the monitor performed better (over 80.5% accuracy),
both of these methods remain below the required standard.
We studied 32 women over a total of 178 cycles. Imperfect
use of the system accounted for failure to identify an LH surge
in 11.8% cycles while 7.9% were due to monitor method
failure. Compliance difficulties are associated with all contra¬
ceptives and non-compliance in -12% of cycles is probably
no worse than with any other method which demands action
from the user, for example, compliance rates reported from
oral contraceptive pill users range from 3.4-100% (Wheble
el al., 1981; Molloy el at., 1985; Hamilton and Hoogland,
1989). Although our study population consisted of women
who were motivated and committed and some of them already
had experience in using natural family planning methods, they
found the short, inflexible testing window set on day 1 of the
cycle to be particularly demanding. This is inconsistent with
couples using the monitor in order to get pregnant (Bonnar
et al., 1999). The prevalence of imperfect use is likely to rise
in the general population compared with that typical of a
research study.
During the course of the study we developed an algorithm
(Figure I) for the administration of mifepristone if an LH
surge was not identified. In 19 exposure cycles (out of 28
cycles in which an LH surge was not identified) mifepristone
was administered using this algorithm and there were no
pregnancies. Given that the methods available to be used in
real life to time the administration of mifepristone cannot be
100% accurate, such an algorithm will be essential to deal
with a missed LH surge.
In our study, mis-timed administration of mifepristone
led to predictable effects. When administered during the
proliferative phase of the menstrual cycle, mifepristone
inhibited follicular development, and delayed the mid cycle
" LH surge, leading to a delay in ovulation and subsequent
prolongation of the menstrual cycle (Liu et al., 1987;
Luukkainen el al., 1988; Swahn et al., 1988). Ovulation
may occur later in that cycle, leaving women at risk of
conception. In our study, when administered in the late
follicular phase (in error) in three cycles, mifepristone pro¬
longed the cycle length (43-52 days). The women were advised
to use condoms for the remainder of that cycle and none of
the three cycles resulted in pregnancy.
Administration of mifepristone in the mid or late luteal
phase induces a bleed within a few days of treatment, which
may or may not be followed by a second bleed at the time of
expected menstruation (Shoupc el al.. 1987; Swahn et al.,
1988). In our study, in 17 out of the 19 cycles where
mifepristone was taken after ovulation (the LH status
unavailable and probably later than on LH + 2), inter¬
menstrual vaginal bleeding occurred (89.5%). Moreover, there
was an increased risk of bleeding seen in those women who
may have taken mifepristone slightly later in the LH + 2
window. The mean serum progesterone concentration was
significantly higher in those women who had bleeding after
taking mifepristone within LH + 2, when compared with those
who did not. The higher serum progesterone value in some on
LH + 2, could be due to a delayed identification of the first
significant rise in urinary LH, or because of a more rapid
increase in serum progesterone due to early ovulation. Never¬
theless, in our group of women, in all cycles where mifepristone
induced a vaginal bleed, a second bleed occurred at the time
of the expected menses. Therefore, while the bleeding may
have been inconvenient, it did not jeopardise efficacy or
continued use of the method. There was less inter-menstrual
bleeding (15% of the cycles) reported in our study when
mifepristone was taken within LH + 2, less than half of
that reported by Gemzell-Danielsson et al. (32%) (Gemzell-
Danielsson et al., 1993). This is possibly due to the fact that
the majority of women in our study received mifepristone at
the correct time. In their study, in 51%> of the cycles, mifepri¬
stone was taken between 3 and 5 days after the LH surge.




fertility monitor with once-a-month administration of
mifepristone (especially if mifepristone is administered at the
early luteal phase) is an attractive contraceptive option with
minimal side effects. However, to be an effective contraceptive
method, the women have to be committed to using a device,
which identifies the LH surge, in order that the pill can be
taken at the correct time in the cycle. Whilst this regimen may
be acceptable to motivated women, it may be regarded as too
complicated for others to adopt on a routine basis. There was
evidence of such non-compliance in this study, with 11.2% of
LH surges being missed as a consequence of imperfect use of
the monitor. Unfortunately, it is difficult to envisage how an
easier way of defining the correct timing, which obligated less
compliance, could be devised.
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MIFEPRISTONE (RU 486) COMPARED WITH HIGH-DOSE ESTROGEN AND PROGESTOGEN
FOR EMERGENCY POSTCOITAL CONTRACEPTION
Anna Glasier, M.D., K.J. Thong, M.R.C.O.G., Maria Devvar, B.Sc., Mav Mackie,
and David T. Baird, D.Sc.
Abstract Background. Mifepristone (RU 486) is a syn¬
thetic steroid with potent antiprogestational and antigluco-
corticoid properties that provides an effective medical
method of inducing abortion in early pregnancy. Since pro¬
gesterone is essential for implantation, we tested the use
of mifepristone for emergency postcoital contraception.
Methods. We studied 800 women and adolescents re¬
questing emergency postcoital contraception who had had
unprotected intercourse within the preceding 72 hours. A
total of 398 women and adolescents were randomly as¬
signed to treatment with 100 pg of ethinyl estradiol and
1 mg of norgestrel, each given twice 12 hours apart
(standard therapy), and 402 women and adolescents were
randomly assigned to receive 600 mg of mifepristone.
Results. None of the women and adolescents who re¬
ceived mifepristone became pregnant, as compared with
four of those who received standard therapy; the differ¬
ence in failure rates between the two regimens was not
statistically significant. The number of pregnancies in each
group was significantly lower than the number expected
according to calculations based on the day of the cycle
during which intercourse had taken place (P<0.001). In
many subjects the stage of the cycle as calculated by
menstrual history was inconsistent with measurements of
plasma progesterone or urinary pregnanediol excretion.
The subjects treated with mifepristone reported less nau¬
sea (40 percent vs. 60 percent) and vomiting (3 percent
vs. 17 percent) on the day of treatment, as well as lower
rates of other side effects, than the subjects treated with
the standard regimen, but they were more likely to have a
delay in the onset of the next menstrual period (42 percent
vs. 13 percent).
Conclusions. Mifepristone is a highly effective postcoi¬
tal contraceptive agent that, if used more widely, could
help reduce the number of unplanned and unwanted preg¬
nancies. (N Engl J Med 1992;327:1041-4.)
DESPITE the availability of highly effective meth¬ods of contraception, many conceptions are un¬
planned.' Many women who request an abortion have
become pregnant as a result of either the lack of fore¬
thought or contraceptive failure.
The report by Yuzpc and Lancee2 that a combina¬
tion of a large dose of estrogen and a progestogen
prevented pregnancy after intercourse led to the devel¬
opment of the now standard regimen of 100 p.g of
ethinyl estradiol and 1 mg of norgestrel, each given
twice 12 hours apart, for emergency contraception.
Fasoli et a!.,3 in a review of the results of published
studies of this regimen, reported a wide variation
(from 0.2 to 7.4 percent) in the rate of failure. The side
effects of the combined administration of estrogen and
progestogen are those commonly associated with es¬
trogen; most studies report nausea in 50 percent of
women and vomiting in up to 25 percent. When these
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symptoms occur within the first 12 hours after treat¬
ment is initiated, they may impair compliance and
efficacy. The postcoital insertion of an intrauterine
device is highly effective in preventing pregnancy (fail¬
ure rate, 0.1 percent), but the process of insertion is
invasive and associated with side effects. Other oral
agents used for this purpose include danazol and high-
dose levonorgestrcl, but the failure rates of these
agents have been as high as 10 percent.4,5
Progesterone is necessary for the formation of secre¬
tory endometrium and therefore for the establishment
and maintenance of pregnancy. Mifepristone (RU
486) is a synthetic steroid with potent antiprogesta-
tional and antiglucocorticoid activity. When given in
combination with a prostaglandin, it has proved to be
a safe, convenient alternative to surgical termination
of early pregnancy.6"9 Reflecting the importance of
progesterone in many biologic processes, mifepristone
has many other potential uses, such as the inhibition
of ovulation,l0,n prevention of the development of
secretory endometrium,12 induction of labor,13 and
treatment of endometriosis and breast cancer.14
We compared the efficacy and side effects of a 600-
mg dose of mifepristone with those of the standard
regimen of estrogen and progestogen as emergency
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postcoital contraceptive agents in a randomized trial
of 800 women and adolescents. A preliminary report
describing the results in the first 379 subjects in this
study has been published.1^
Methods
Wc studied 800 women and adolescents ranging in age from 16 to
45 years who were recruited from the Dean Terrace Centre in Edin¬
burgh (732 subjects) and the Accident and Emergency Department
of the Royal Infirmary of Edinburgh (48 subjects). All the women
and adolescents were seeking emergency postcoital contraception.
All had a history of regular menstrual cycles of 21 to 35 days for the—
preceding three months, were seen within 72 hours after a single act
of unprotected intercourse, and were willing to use a condom or
abstain from intercourse for the rest of the current cycle. We ex¬
cluded women and adolescents who were taking an oral-contraccp-
tive preparation, had a medical contraindication to the standard
esirogen-progestogen regimen (a history of cardiovascular disease,
thromboembolism, or liver disease), were regularly using prescrip¬
tion drugs (anticonvulsant medications or insulin), were certain
that they would continue with the pregnancy if emergency contra¬
ception failed, or would be unavailable for follow-up.
The project was approved by the local ethics committee, and ^
written informed consent was obtained from each subject, who was
informed that there was a risk of failure no matter which treatment
she received. Mifepristone was supplied by the World Health Or¬
ganization, and the use of the drug for emergency contraception
was approved by the Medicines Control Agency of the United
Kingdom.
A careful menstrual history was obtained from each subject, and
the interval between intercourse and presentation was recorded.
The estimated day of ovulation was calculated as being 14 days
before the estimated day of onset of the next menstrual period; each
subject's usual cycle length was taken into account. On the basis of
these data we determined whether a subject was treated at midcycle
(one day before or after ovulation), in the follicular phase of the
cycle (two or more days before ovulation), or in the luteal phase of
the cycle (two or more days after ovulation). A pelvic examination
was undertaken only if clinically indicated. Each subject's height
and weight were recorded.
To allow for differences in fertility and therefore possible differ¬
ences in failure rates with age, the women and adolescents were
divided into three age groups: 16 to 25 years, 26 to 34 years, and 35
to 45 years. The women and adolescents in each age group were
randomly assigned to receive cither 600 mg of mifepristone as a
single dose taken at the time of enrollment or two 100-/rg doses of
ethinyl estradiol and two l-mg doses of norgcstrel. the second dose
of each being taken at home 12 hours after the first.
Blood or urine samples were collected at the time of enrollment
for the measurement of the plasma progesterone concentration and
urinary pregnanediol excretion. Each subject was asked to complete
a diary chart recording the occurrence and severity of nausea, vom¬
iting. breast tenderness, headache, and vaginal bleeding each day
for seven days after treatment, and each made an appointment to
return to the clinic within five days of the expected date of the next
menstrual period. Each subject was given a stamped, addressed
envelope in which to return the diary chart and to inform the clinic
of the date of the next menstrual period should she be unable to
return. Attempts were made to contact the women and adolescents
who did not return or mail in a completed diary chart. Alter three
unsuccessful attempts the subject was classified as lost to follow-up.
At the follow-up visit the diary chart and date of menstrual bleed¬
ing were checked by a member of the clinic staff. If menstrual
bleeding had not occurred, blood was taken for the measurement
of the beta subunit of chorionic gonadotropin in the plasma
and another appointment was made. The subject returned for addi¬
tional follow-up every two weeks until she had a normal menstrual
period.
Assay Methods
Urinary pregnancdiol-3-glucuronide was measured by enzyme-
linked immunosorbent assay.""' The sensitivity of the assay was 0.17
ng per milliliter (0.5 nmol per liter), and the intcrassav and intraas-
say coefficients of variation were 12 percent and 10 percent, respec¬
tively. Plasma progesterone was measured by a radioimmunoassay
in which l-anilino-8-naphthalencsulfonaic (pH 4.0) was used to
displace progesterone from plasma binding proteins.1' The intcr-
assay and intraassay coefficients of variation were 10 percent and
8 percent, respectively. Plasma progesterone concentrations of more
than 3 ng per milliliter (>9 nmol per liter) or urinary prcgnanediol
excretion in excess of 0.5 mmol per mole of creatinine (>2.17 ihg
per gram of creatinine) were considered to be compatible with ovu¬
lation; plasma progesterone concentrations ranging from 1.6 to 2.9
ng per milliliter (5 to 9 nmol per liter) or urinary pregnanediol
excretion of 0.3 to 0.4 mmol per mole of creatinine (1.3 to 1.7 mg
per gram of creatinine) were considered periovulatorv; and plasma
progesterone concentrations below 1.6 ng per milliliter (<4 nmol
per liter) or urinary pregnancdiol excretion below 0.2 mmol per
mole of creatinine (<0.9 mg per gram of creatinine) were consid¬
ered consistent with the absence of ovulation.
Statistical Analysis
Fisher's exact test (two-tailed) was used to compare the efficacy
of the two regimens, and chi-squarc tests were used to compare the
incidence of side effects in the two groups.
Results
A total of 402 women and adolescents were treated
with mifepristone, and 398 were treated with the
standard regimen of ethinyl estradiol and norgestrel.
Of the 800 women and adolescents, 566 were 16 to 25
years of age, 192 were 26 to 35 years of age, and
42 were 36 to 45 years of age. Twenty-six women
and adolescents (3 percent) were lost to follow-up,
of whom seven had had intercourse within three days
before or after the estimated day of ovulation and
might be considered genuinely at risk for conception;
three of these subjects received mifepristone. A fur¬
ther 16 women and adolescents failed to reply to let¬
ters or telephone calls but returned for follow-up with¬
in three months after treatment. Although unable to
recall the date of menstruation, none had become
pregnant.
Efficacy
Four women became pregnant, all of whom had
received the standard regimen; there were no mifepris¬
tone failures. The overall failure rate in the standard-
therapy group was 1.0 percent (95 percent confidence
interval, 0.3 to 2.5 percent). All four women chose to
have the pregnancy terminated. The difference in fail¬
ure rates between the standard regimen (1.0 percent)
and mifepristone (0 percent) was not statistically sig¬
nificant (P = 0.12). The characteristics of the four
women who conceived are shown in Table 1.
Accurate cycle data were obtained for 733 women
and adolescents, of whom 322 (44 percent) had had
intercourse within three days before or after the esti¬
mated day of ovulation. One hundred sixty-seven of
these subjects received mifepristone. All 4 of the wom¬
en who became pregnant were among the 155 subjects
in this group of 322 who were treated with the stand¬
ard regimen, for a failure rate of 3 percent.
Side Effects
A total of 693 women and adolescents returned
completed diary charts. The incidence of side effects is
shown in Table 2. All side effects were significantly
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Table 1. Characteristics ot the Four Women Who
Became Pregnant aher Receiving the Standard
Regimen tor Postcoital Contraception.
Body- Da> of Inter¬ Time nam Plasma
Subject Mass course/Normal Intercourse to Proges¬
No age Index* Cycle Length Treatment terone*
yr days hr nf/ml
1 32 25 13/28 13 1.0
2 25 26 15/28 14 1.6
3 23 22 15/28 40 6.6
4 24 23 15/30 40 1.3
•Body-mass index is expressed as tiic weight hi kilograms divided by ihe
square of the height in meters.
1To convert values for progesterone to namomoles per liter, multiply
by 3. IS.
(P<0.00l) more frequent ftmong the subjects treated
with the standard regimen, and more of the women
and adolescents who were treated with mifepristone
reported having no side effects (P<0.00l). Among the
subjects who had nausea ort the day of treatment, I 7
percent of those who received the standard regimen
described the nausea as being severe, whereas only
2 percent of those who received mifepristone did so.
Timing of Menses
The timing of the onset of menstrual bleeding after
emergency postcoital contraception is shown in Table
3. A subject who reported bleeding within three days
before or after the expected day of menstruation was
described as having menstruated on time. Significant¬
ly more (P<0.00l) of the women and adolescents who
were treated with mifepristone had a delay in the onset
of menstruation (range, 4 to G3 days).
Discussion
Most published studies of the efficacy of postcoital
contraception report failure rates in terms of the num¬
ber of pregnancies as a function of the total numberof
women treated, and do not report the number lost to
follow-up. Not all women given emergency postcoital
contraception are genuinely at risk for pregnancy,
since unprotected intercourse that occurs in the early
follicular phase or in the luteal phase of the cycle is
unlikely to result in conception. On the basis of cycle
dales, 44 percent of the women and adolescents in this
study were treated within three days before or after the
estimated day of ovulation. Silvestrc et al.'" argued
that the true failure rate should take into account the
timing of unprotected intercourse and therefore the
probability that a pregnancy will occur. Using a table
that provides a probability of pregnancy for each day
of the cycle,'9 Silvestre et a!.'8 recalculated the failure
rates of the standard estrogen and progestogen regi¬
men reported in a number of studies. Failure rates
reported as ranging from 0.2 to 5 percent on the basis
of the number of women treated ranged from 6 to 44
percent when the table was used and the probability
of pregnancy taken into account. Using the table in
the same way, we calculated that we should have ex¬
pected 23 pregnancies in each treatment group in our
study, which would mean a failure rate of 17 percent
for the standard regimen and, of course, 0 percent
with mifepristone. Both regimens resulted in signifi¬
cantly fewer pregnancies than would have been ex¬
pected had no treatment been given (P<0.001).
The validity of using the table depends on the accu¬
racy of the menstrual-cycle data. The measurements
of plasma progesterone or urinary pregnanediol in 780
women and adolescents on the day of treatment pro¬
vided the opportunity to determine whether the cycle
data were compatible with the biochemical evidence
of ovulation. Of the 368 women believed on the evi¬
dence of cycle data to be in the luteal phase of the
cycle, 187 (51 percent) had a plasma progesterone or
urinary pregnanediol value indicating that ovulation
had not occurred. Forty-four of the 205 women and
adolescents (21 percent) considered to have been
treated in the follicular phase had biochemical evi¬
dence of ovulation. Ninety women and adolescents
who had intercourse four to nine days after the esti¬
mated day of ovulation, and who were therefore ex¬
cluded from our calculations of the fertile phase of the
cycle, had not in fact ovulated when they were treated
and could therefore have been genuinely at risk for
pregnancy. Most women do not keep a record of their
menstrual periods, and it is well recognized that esti¬
mated dates are likely to be inaccurate. In our study
the dates appeared more likely to be accurate in the
follicular phase of the cycle when menses had recently
occurred.
Regardless of the method by which failure rates are
calculated, the fact remains that none of the women
and adolescents who were treated with mifepristone
conceived. Although the difference in the failure rates
was not statistically significant, mifepristone was-un¬
questionably as effective as the standard estrogen-
progestogen regimen as emergency postcoital contra¬
ception. Although the subjects were aware or which
treatment they received, they were not advised that
there might be any difference in side effects. It is clear,
however, that mifepristone was associated with fewer
side effects. Moreover, since it was taken as a single
Table 2. Incidence ol Side Effects among Women
and Adolescents Treated with Mifepristone or the
Standard Estrogen-Progestogen Regimen for
Postcoital Contraception*
Mifepristone Standard Regimen
Side Eitect in = 347> in » 346) P Value
number (percent!
No symptoms 132 <38) 45 (13) <0.001
Nausea on day of
treatment 137 (40) 207 <60) <0.002
Nausea after day
of treatment 98 (28) 184 (53) <0.001
Vomiting on day
of treatment 9 (3) 59 (17) <0.001
Headache at
any lime 170 (49) 242 (701 'sO.OOl
Brcasi tenderness
at any time 94 (271 158 (46) <0.001
*A total of 693 women and adolescent completed diary charts; 34?
treated with mifepristone and .346 treated with the standard regimen
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Table 3. Timing ol Menses among Women
and Adolescents after Postcoital Contracep¬
tive Treatment with Mifepristone or the
Standard Regimen.*
Onset of slandaad
Menses Regimen mlff.pkistone P Value
Early 142 76 <0.001
On timet 166 111 <0.001
Late 45 137 <0.001
•Sixteen women and adolescents were excluded because they
could not recall the date of menstruation.
tMenses considered to be on time were those that occurred
within three days before or after the expected date.
dose, there was no possibility of noncompliance if side
effects occurred.
The only apparent disadvantage of mifepristone -
was that more of the women and adolescents who took
it had a delay in the onset of the next menstrual period
— an occurrence that would undoubtedly be stressful
to a woman who was worried that she might be preg¬
nant. In contrast to the standard regimen, however, it
is possible to make some prediction about the timing
of the onset of the next menses after the administra¬
tion of mifepristone. Of the women and adolescents
who were treated with mifepristone in whom both cy¬
cle and biochemical data suggested that they were in
the follicular phase, 52 percent had bleeding more
than four days after the expected date of their next
menstrual period, indicating that mifepristone inhibit¬
ed ovulation.10 Of those who were treated in the luteal
phase (confirmed biochemically), 84 percent either
bled before the estimated date of their next menstrual
period or menstruated on time. The administration of
mifepristone in the luteal phase is associated with ear¬
ly bleeding in 100 percent of women.20-21
In conclusion, we confirmed our preliminary re¬
port15 that mifepristone is an effective postcoital con¬
traceptive agent with advantages over the standard
estrogen-progestogen regimen. A dose of 600 mg is
probably higher than necessary, but no studies have
yet been done to determine the optimal dose. The real
problem with emergency postcoital contraception is
not its failure rate or its side effects but the fact that so
few women and adolescents who have had unprotect¬
ed intercourse actually use it.
Mifepristone has been a center of controversy since
the report of the initial clinical study demonstrating
its efficacy as,an abortifacient agent.13 Research into
alternative uses of mifepristone is severely restricted
in many countries, including the United States, large¬
ly as a result of the activities of those who are opposed
to abortion. The results in this paper demonstrate that
the drug has the potential to avert unwanted and un¬
planned pregnancy. More widely available contracep¬
tive services that included mifepristone as a postcoital
agent would help reduce the demand for therapeutic
abortion.
We are indebted to the medical and nursing staff of the Family-
Planning Service, without whose help the study would not have
been possible; to Ms. Vicky Sweeting and Mrs. Sanjukta Chatteijee
for technical support; and to Mrs. Maureen Lipscombe for assist¬
ance in the preparation of the manuscript.,
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The attitudes of women of reproductive age in Scotland,
Romania and Slovenia to the idea of a contraceptive pill which
is taken only once each month or only when menses are
delayed was investigated. In all three centres, the great
majority of women fell positive towards the idea of a once-a-
month pill which inhibited ovulation and >50% found a pill
which inhibited or interfered with implantation an acceptable
idea. Only 24% of women in Scotland were attracted to the
idea of a pill which was taken only if menstruation was
delayed by 1 or 2 days, that is a pill which would cause an
abortion, while in contrast 58% of women in Slovenia and
80% in Romania thought that such a method of controlling
fertility would be acceptable. Attitudes were not related to
age, social class or marital status but were influenced by-
religious belief and in Scotland by a history of abortion. In
countries where the availability of contraception is limited and
abortion is common, women would seem to welcome another
method of fertility regulation—even one which disrupts the
very early stages of pregnancy.
Key imrds: contraceptive pill/contraceplion/delaycd menstruation
Introduction
The most reliable currently available contraceptive methods
depend for their efficacy on "continuous' use. Innate human
fertility in the absence of contraception is notoriously difficult
to quantify (Shon, 1976) but the chance of conception has been
calculated from both demographic data (Sheps, 1965) and
mathematical models (Tietzc and Potter, 1962) to be at most
~28% per cycle. In order, then, to prevent perhaps one chance
of conception every 3 months, women using 'continuous' methods
of contraception do so for between 274 and 365 days each year.
The administration of the anti-progesterone RU486 at or shortly
after the time of expected menses will induce menstruaJ-like
leeding aqd/or abortion in 85% of women (Van Look and
yRdernan, 1989). More recently it has been demonstrated that
^ fciven to women shortly after the LH surge results in
608
changes in endometrial histology and hormone receptor content
compatible with the inhibition of implantation (Swahn el al.,
1990). With the advent of anti-hormones and anti-implantation
agents, a pill which is effective in preventing pregnancy and yet
which is taken only once each month may become a reality. In
October 1991, Swahn and colleagues in a letter to The Lancet
reported only one pregnancy in 80 cycles of use of RU486 taken
only once a month as a contraceptive.
While a once-a-month pill may be a technical feasibility, an
individual's choice of contraceptive method is influenced by a
variety of factors including 'intensely fell individual values'
(Mastroianni et al., 1990). In this study, we have tried to
determine whether a once-a-month pill is an attractive concept
to three groups of women of reproductive age in three different
countries where availability of contraception and availability and
rates of abortion vary dramatically. In Scotland, contraception
is widely available and free of charge and while abortion is legal;
and relatively easy to obtain, abortion rates are low. In Slovenia,
the availability of contraception is more limited, abortion is legal
and much more prevalent than in Scotland. In Romania contra¬
ceptive prevalence is extremely low and abortion, illegal for the
past 25 years, was only legalized in 1990. We have also tried
to establish whether the mechanism of action, and therefore the
lime when it may affect the potential pregnancy, significantly
influenced the acceptability of such a method.
Materials and methods
Twenty questions were devised to investigate the attitudes of
women to the concept of a pill taken only once each month and
to the possible modes of action of such a pill. Told that it was
now technically possible to produce a pill which need be taken
only once each month in order to prevent pregnancy (oncc-a-
month pill) women were asked how, in principle, they felt about
the idea. Details of previous contraceptive use and fear of side
effects were recorded. The final question asked how women
would feel about the idea of a pill which they would take only
if their period was 2 to 3 days late (missed-period pill). It was
made clear that no other method of contraception would be used;
that the pill would work by dislodging an early embryo; and that
they would probably only be in a position to need to use such
a pill three or four times each year.
The questionnaire was administered during the second half of
1990 and the first half of 1991 to: (i) 400 women consecutively
attending clinics at a large family planning centre in Edinburgh,
Scotland (Dean Terrace); (ii) 400 women attending an outpatient
gynaecology clinic (-40% attending for family planning) in
Tirgu-Murcs, Romania (Tirgu-Murcs); and (iii) 100 women
© Oxford University Press
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attending a family planning clinic in Ljubljana, Slovenia
(Ljubljana).
When the data from the women atlending the family planning
clinic in Edinburgh were analysed, il became clear that women
who had children had slightly different attitudes than women who
had not. Il was therefore decided to involve a group of women
who were pregnant at the time of completing the questionnaire
and forms were distributed to women attending an antenatal clinic
at the Simpson Memorial Maternity Pavilion (SMMP) in
Edinburgh. Results were analysed after fifty questionnaires had
been completed. Since there were no significant differences—
between the pregnant women and those atlending the family
planning clinic, no further questionnaires were distributed.
Every effort was made to simplify the questionnaire and to
make it intelligible to all concerned. All questions were worded
to allow a range of expression of opinions to be recorded and
a five-point Likert scale was used. A pilot version of the
questionnaire was given to 20 women at Dean Terrace and as
a result of subsequent discussion with these women, modifica¬
tions were made and a final version prepared. The questionnaire -
was translated locally into the Slovenian and Romanian languages.
In Romania, many of the women have little or no understanding
of the way in which contraceptive methods work and the
questionnaire was administered by a trained interviewer who gave _
detailed explanations, with the aid of diagrams, where necessary.
The questionnaire took 10- 15 min to complete and no means
of identification of the women was recorded. In Dean Terrace,
no woman refused a questionnaire but 1% had no time to
complete it: 88% of women answered all 20 questions. In
Slovenia and Romania, all women asked to take part in the study
did so.
Responses were coded and analysed in Edinburgh on an IBM
PC usfng a Minitab Statistical program [Minitab data analysis
software Version 5.1.1. (1986) 3081 Enterprise Drive, State
College. PA 16801, USA] and in Tirgu-Mures, using Epi Info
version 5.0. Significance values were obtained using the
chi-squarc lest for the two groups of 400 women (Dean Terrace




The demographic characteristics of the women taking part are
shown in Table I. It is a little surprising that only 35% of the
women in Tirgu-Mures had had an abortion when the rale in
Romania is over twice that of the rate in Yugoslavia. However,
abortion has only been legal in Romania since 1990; moreover
it may be that many women are reluctant to admit to having had
a pregnancy terminated before 1990.
Because il seemed likely that religious beliefs may influence
women's attitudes towards contraception, we asked about both
religious denomination and strength of belief. In the Slovenian
sample, 54% of women were Roman Catholic compared with
only small numbers in both the other centres. Most of the women
in Scotland and 32% of the Romanian women were Protestant,
48% of the Romanians were Orthodox, the predominant
denomination in the country and one which docs not allow
abortion. Despite the preponderance of Roman Catholics in
Ljubljana, only 2% held strong religious beliefs and indeed 43%
described themselves as atheist.
Of the women attending the family planning clinics in
Edinburgh, a slightly but not significantly higher proportion than
in the general population came from social classes I and II. We
were unable to obtain any comparable details for women from
the Eastern European countries; 85 of the 100 women questioned
in Ljubljana were employed while 50% of the sample from
Romania were described as 'factory workers' and 15%, as
'intellectuals'.
Questionnaire replies
Altitudes to once-a-month and missed-period pills
The percentage of women in each group who said that they felt
positive or very positive and negative or very negative towards
the idea of taking a once-a-month pill and towards the idea of
taking a missed-period pill is shown in Table fl. A small number
of women in each centre said that they were neutral or did not
know. Over 70% of women in all three centres were attracted
to the idea of a oncc-a-month contraceptive pill. However, <25%
of women in Edinburgh felt that they would be prepared to use
no method but to take a pill which would disrupt a very early
pregnancy; many in fact were actually negative about the concept.
In contrast, over half of the sample in Ljubljana and 80% of the
women in Tirgu-Mures fell positive towards litis approach to the
regulation of fertility.
Mechanism of action
In respect of the once-a-month pill (and before the misscd-pcriod
pill had been mentioned), women were asked whether they would













Table IL Attitudes of the three groups of women to the idea of a oncc-a-





% Positive 71 6 81 3 94.0
$ Negative 9.5 4 1 3.0
Misscd-pcriod
% Positive 24.2 80.0 58.0
% Negative 53.8 10.0 10.0
609




% Ever had a baby
% Ever had an abortion
% Roman Catholic
% Holding slrong religious beliefs
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find such a pill more or less acceptable depending on whether
it prevented ovulation, prevented implantation or acted after
implantation. It is clear from Table III that women in all three
countries do discriminate between modes of action and that all
the women found a pill which inhibited ovulation significantly
more acceptable than one which inhibited implantation. However,
a method which works after implantation has occurred becomes
unacceptable to the majority.
Relationships between variables
It was hypothesized thai social characteristics and previous
experience of contraception would influence attitudes. We
predicted that older women with perhaps a lower frequency of
exposure to the risk of pregnancy would find the concept of a
oncc-a-month pill more attractive, while women who had
undergone pregnancy termination would be more positive towards
a "missed-pcriod pill. It was also hypothesized that women with
strong religious beliefs and women who took into account the
mode of action of a contraceptive when choosing a method may
be more negative towards the idea of any pill which acted after
ovulation had occurred. In fact neither age, social class, mariial
status, religion nor previous method of contraception used
influenced women's attitudes to cither of the proposed pill types
in Scotland, Romania and Slovenia.
There were few significant correlations between the variables
tested. Women who held strong religious beliefs were less positive
(P < 0.005) about the idea of a oncc-a-npnth pill in both
Scotland and in Romania although this relationship was only
maintained among the Scottish women in respect of the misscd-
period pill. Women in Edinburgh who had been deterred in the
past from using either an intrauterine contraceptive device or
post-coital emergency contraception were significantly more
negative about the concept of a oncc-a-inonth pill (P < 0.01)
and about the concept of a missed-pcriod pill (P < 0.001).
Women who had ever had a pregnancy terminated were
significantly more likely to be positive about a misscd-period pill
than the women who had never had an abortion (P < 0.01 ,in
Table III. Acceptability (% of women feeling positive) of a once a month




Edinburgh (DT) 90.4 64 I 15.7
Ljubljana 77.3 54.2 33.4
Tirgu-Murcs 81.0 68.0 31.3
Edinburgh and P < 0.05 in Ljubljana); however a history of
abortion had no effect on attitudes towards cither pill in Romania.
Women in Edinburgh who had children were less likely to be
positive about the idea of a oncc-a-month pill than nulliparous
women (P < 0.05).
Discussion
Since the introduction of die oral contraceptive pill some 30 years
ago. there have been no major developments in the field of
contraceptive research and no radically new methods of
contraception have become available to the population at large.
A oncc-a-monlh pill is an attractive concept to those of us working
in the field of contraception. The currently available and more
reliable methods of contraception have unwanted side-effects and
risks which arise as a result of their 'continuous' use. Less total
exposure to pharmacologically active contraceptive methods
should reduce side-effects. Fccundability decreases significantly
with age and frequency of intercourse (Lcridon. 1979) and a oncc-
a-month pill might be a particularly attractive proposition lo older
women, a large group for whom currently available methods may
be particularly inappropriate.
It is clear from our study that the vast majority of women—
whether they live in Scotland, Romania or Slovenia—are indeed
attracted towards the idea of a oncc-a-month pill. Many women
do a,ppear to understand the implications of the mode of action
of a method of contraception at least in terms of when during
the reproductive process it has its effect. In the Dean Terrace
sample, a small number of women said that they had been
deterred from using both the intrauterine contraceptive device
and post-coital contraception because of how the mcdiod worked
The same women were consistent in feeling significantly more
negative titan the rest of the women towards a pill which acted
after implantation had occurred.
In all three countries, women preferred die idea of a pill which
inhibited ovulation and for many die idea of using a method which
acted after implantation would be unacceptable. It is hard to see
how a once-a-monlh pill which inhibited ovulation could be
developed since the inevitable dcsynchronization of the ovarian
and endometrial cycles would not only result in an unacceptable
bleeding patterns but would make the liming of pill-taking
impossible to determine in all but the first cycle. Even the correct
liming of a compound which acted early in the luteal phase prior
to implantation would be difficult to achieve. However, a
significant proportion of women tvould seem lo find a pill which
inhibited implantation an acceptable method of contraception, at
least in principle.
Tabic IV, Contraceptive use among ihc sample and naiional abortion nucs
Contraceptive method ever used Edinburgh Ljubljana Tirgu-Murcs
Combined oral contraceptive % 87.9 65.0 38 3
Gestogcn only pill % 23.5 3.0 0.0.
Intrauterine contraceptive device % 10.6 31.0 5.2
Post-coiuJ contraception % 68.2 33.0 9.5
Abortion rate/1000 women 15-44 years 9.1 36.9 176.0
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Do women want a orKf-«-monlh pill?
While most women in Scotland seemed lo like (he idea of a
nncc-a-month pill. <25% found the idea of a misscd-pcriod pill
acceptable and indeed the majority admitted to having negative
feelings aboul ii. In contrast, in Slovenia the majority, and in
Romania, 80% of women asked found the idea of a misscd-pcriod
pill attractive. In Edinburgh, women who had undergone a
termination of pregnancy were more positive about the idea of
both types of proposed pill. Contraceptive use and abortion rates
(Table IV) vary widely between the three countries. In a country
where a variety of contraceptive methods are easily available and
arc supplied free of charge and where the abortion rate is low,
the idea of taking no precautions against pregnancy but wailing
lo act until a delay in menstruation bas occurred is not widely-
acceptable Opponents of abortion arguing against the so-called
'abortion pill' RU486 would have us believe that if abortion is
made easier, more women will have abortions: our study would
seem to suggest (hat this is not the ease. Given the opportunity
lo induce menstruation after a missed period, most women in
Edinburgh are not happy with the idea; whatever an individuals
views on the rights or wrongs of abortion, this approach may
seem somewhat cold-blooded. However, in societies where the
availability of contraception is limited and where abortion is more
common than childbirth, such a simple solution to controlling
one's own fertility can only be an attractive one. In an unpublished
study of contraceptive prevalence and attitudes towards abortion
undertaken in Romania by Dr M.Horga.i>6% of women asked
fell that to use a method of contraception to prevent pregnancy-
was preferable to having an abortion. However, faced with the
realities of an unwanted pregnancy, it would seem that women
in Eastern Europe arc prepared to renounce cultural, moral and
religious beliefs and will accept almost anything. It is unlikely-
thai this attitude is peculiar to Eastern Europe. The women in
Edinburgh who had had an abortion were more positive about
the idea of a pill which acted by disrupting an early pregnancy.
Perhaps a woman who has never had to face an unwanted
pregnancy can afford the luxury of discriminating between
methods of contraception according to their mode of action.
Attitudes may be modified by personal experience of an
unplanned and unwanted pregnancy.
In conclusion, it is clear to us that most women in Europe
would be interested in using a contraceptive pill which they need
lake only once each month, However, the acceptability of a pill
which could be used for menstrual induction will vary between
populations depending on the availability of methods which can
be used to prevent a woman from becoming pregnant at all.
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Totals of 450 women attending family planning clinics in
Hong Kong, Shanghai and Edinburgh, and 468 in Cape
Town, completed a questionnaire designed to seek their
views on a contraceptive pill which would be taken only
once each month. At least two-thirds of the women in all
centres liked the idea of a once-a-month pill. In Hong
Kong, Cape Town and Edinburgh, women preferred a pill
which inhibited ovulation to one which inhibited implanta¬
tion, while in all centres a pill which worked after implanta¬
tion (early menstrual inducer) was considered unacceptable
by over half the women. A pill which was taken after a
missed menstrual period was considered preferable in all
centres, perhaps because it would not be used every month
but rather only ifpregnancy had occurred. No demographic
characteristics, contraceptive experiences or beliefs were
consistently correlated with attitudes towards a once-a-
month pill, except that women who would not consider
having an abortion were more likely to dislike a method
that either prevented, or worked after, implantation. A
once-a-month pill Is now technically possible, although the
major drawback is the need to determine when it should
be taken. It is reassuring that many women from a variety
of different cultures and with widely different experiences,
would find this an attractive approach to contraception.
Key words: contraception/contraceptive pill/mifepristone
Introduction
Contraceptive prevalence is increasing globally: 56% of
couples in developing countries and 73% in the developed
countries of the world were using contraception in 1995. With
population growth, however, the number of contraceptive users
will need to increase by 50% by the year 2025 even to maintain
prevalence at the current level (World Health Organization,
1998). In many countries, abortion rates are also rising. In
developed countries, where contraception is easily available
at minimal or no cost, roughly 50% of unwanted pregnancies
3018
arise from the failure of a method (usually less than perfect use),
while 50% occur in women who have not used contraception
(Griffiths, 1990; Yimin et at., 1997). Despite an apparently
wide choice of contraceptive methods, many couples are either
unable to find one that suits them, or they persevere with a
method with which they are somewhat dissatisfied. Despite
reassuring data on safety, many women are concerned about
the long-term exposure to steroid hormones, believing the
daily ingestion of hormones to be 'unnatural' and unsafe
(Oddens et al., 1994). In 1991, a study was undertaken
_ (Rimmer et al., 1992) to assess the attitudes of women in
three European countries (Scotland, Slovenia and Romania) to
the concept of a pill which would be taken only once each
month. Women were generally in favour, although the majority
found the idea of a pill which acted after implantation to be
unacceptable.
Since 1991, the development of a once-a-month pill has
become feasible. In a pilot study (Gemzell-Danielsson et al.,
1993), it was reported that only one pregnancy occurred among
21 women who had taken a single dose of 200 mg mifepristone
at midcycle during 124 cycles in which intercourse occurred
during the fertile period.
In 1995, the UK Medical Research Council and Department
for International Development jointly funded a programme of
basic research in the development of new contraceptive
methods in a network of centres in Shanghai and Hong Kong
in China, Cape Town in South Africa, and Edinburgh in
Scotland. Since one of the main areas of research was to be
on the contraceptive effects of antigestagens, and recognizing
that the acceptability of different methods of contraceptives
varies widely in different cultural sellings, it was decided to
revisit the issue of the acceptability of a once-a-month pill in
an international setting with widely disparate cultures and
contraceptive practices.
Materials and methods
The questionnaire used in the previous study (Rimmer et al., 1992)
was revised to investigate the attitudes of women towards a once-a-
month pill, the possible mechanism of action, and practicalities for
use, A pilot version of the questionnaire was administered to 25
women at the Edinburgh centre, and the final version was prepared
as a result of discussions with these women. The questionnaires were
administered by trained interviewers who gave detailed explanations,
with the aid of diagrams where appropriate. The questionnaire
took approximately 10-15 min to complete, and subjects remained
anonymous. All questions were worded to allow a range of expression
of opinions to be recorded, and a five-point Likert scale was used
(Streiner and Norman, 1995). The questionnaire was administered to
450 women attending clinics at a large family planning (FP) clinic
© European Society of Human Reproduction and Embryology
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in Edinburgh (The Dean Terrace Centre), to 450 women attending
clinics of the Maternal and Child Health Centres in Hong Kong, and
to 450 women attending clinics at the Shanghai Institute of Family
Planning Technical Instruction. In Shanghai and Hong Kong, more
than 97% of the respondents were Chinese, while in Edinburgh over
97% were of Caucasian origin. In Cape Town, a total of 468 women
were interviewed at a variety of FP clinics selected to obtain equal
numbers of the three main ethnic groups; black, coloured and white
women (156 in each group). Within each setting all patients were
invited to take part. The questionnaires were translated locally into
Cantonese and Mandarin in Hong Kong and Shanghai respectively,
and into Xhosa and Afrikaans for the Cape Town centre. During
19%, recruitment took place over 3 months in Edinburgh and
Shanghai, and over 6 months in Hong Kong and Cape Town. Less
than 10 women in Hong Kong and Shanghai declined to complete
the questionnaire. In total, 162 women in Edinburgh, and 356 in
Cape Town, declined to participate in the study. The over-riding
reason was lack of time, but in Cape Town almost half the refusals
were due to the patient speaking a different language from the
interviewer.
Brief demographic data, details of previous contraceptive use and
concerns about possible side effects of contraception were noted. The
women were then advised that it was now technically possible to
produce a pill to prevent pregnancy which need only be taken once
monthly, and were asked—in principle—how they felt about the idea.
It was then explained that such a pill may act in one of three ways:
by preventing ovulation; by preventing implantation; or by disrupting
implantation. The acceptability of each method was recorded. The
final question addressed how women would feel towards a pill which
they would take only if their period was 2-3 days late. It was made
clear that this pill would act by dislodging an early embryo, and that
they would probably need to take such a pill only three or four times
each year.
Statistical methods
The responses were coded and entered into databases at the individual
centres and returned to Edinburgh for quality control checking and
statistical analysis. The significance of associations between different
variables was tested by y2, Mann-Whitney, Kruskal-Wallis or Spear¬
man rank correlation tests as appropriate. Multiple linear regression
was used to test the effect on ordinal responses of several factors
adjusted for one another, since the sample sizes were considered to
be large enough to justify the normal approximations involved. The
complete range of five-point Likert scales was used for significance
testing, omitting those who did not know, but the percentages of
women quoted as having 'positive* attitudes in the results refer to
the combined numbers of those who were positive or very positive




The demographic characteristics of the women who took part
in the study are shown in Table I.
Women in Edinburgh and Cape Town were similar in age,
marital status and smoking habits. Some 65% of women in
Edinburgh had never been pregnant, compared with 48% in
Cape Town. In Hong Kong and Shanghai, where family
planning clinics are used almost exclusively by married women,
over 90% of women were parous. A history of induced abortion
was most common in Shanghai (68%) and least likely (at least
Acceptability of a once-a-month pill
Table I. Demographic characteristics from each centre
Edinburgh Cape Town Hong Kong Shanghai
No. of women 450 468 450 450
Mean ± SD age (years) 26 ± 6 26 ± 5 34 ± 5 34 ± 8
% Marricd/co-habiting 41 40 99 92
% Smoker 28 30 6 2
% Ever pregnant 35 52 99 95
% Ever abortion 20 1 23 68
% Strong religious 11 54 3 9
beliefs
Table II. Contraceptive use
Contraceptive method Edinburgh Cape Tbwn Hong Kong Shanghai
ever used®
Combined oral 92 62 67 16
contraceptive
Gcstogcn-only pill 14 7 0.7 0.2
Intrauterine contraceptive 9 5 22 64
device
Injcctablcs 6 74 19 4
Male condom 93 44 82 40
Post-coital contraceptive 53 16 1 2
Would consider changing 80 60 20 22
method
"Values are percentages.
Table III. Attitudes of the women (% positive) towards a once-a-month pill
and a misscd-pcriod pill
Type of pill Edinburgh Cape Town Hong Kong Shanghai
Oncc-a-month 84 76 76 68
Missed-period 32 44 44 9
to be admitted to) in Cape Town (1%), where at the time of
the study abortion, although officially legal, was extremely
difficult to obtain. There were major differences in past
contraceptive use between the centres (Table II).
Altitudes towards the concept of a once-a-month pill
In all centres more than two-thirds of women were in favour
of the concept of a once-a-month pill (Table III). Womens'
attitudes were independent of any of the demographic variables
listed in Table I or, in Edinburgh, by past use or beliefs about
contraception. In Hong Kong, women who had used the oral
contraceptive pill in the past were more likely to be positive
(P < 0.05), while in Shanghai women under 25 years of age
(P < 0.025), and in Cape Town women over 25 (P < 0.05),
were more likely to be positive to the concept.
Mechanism of action of a once-a-month pill
Attitudes towards a once-a-month pill differed according to
the mode of action (Table IV). There were no consistent factors
which correlated with womens' preferences. In Shanghai,
women who were better educated (P < 0.025) and older (=s30
years of age) (P < 0.001) were more likely to be positive
about a pill which inhibited ovulation. In Cape Town, while





Table IV. Allitudes (%■ positive) towards a once-a-month piil according to
its mode of action
Mode of action Edinburgh Cape Town Hong Kong Shanghai
Prevent ovulation 88 82 80 65
Prevent implantation 44 53 63 78
Disrupt implantation 20 33 49 7
regardless of their educational level (P < 0.001). Among black
and coloured women there was a weaker correlation between
educational achievement and preference for a pill which
inhibited ovulation.
In Edinburgh, Cape Town and Hong Kong, acceptability of
the method was much less if a pill was designed to inhibit
implantation, with the greatest decline being in Edinburgh
(Table IV). In contrast, in Shanghai women found a pill which
inhibited implantation more acceptable (78% positive) than
one which inhibited ovulation (65% positive). In Edinburgh
and in Hong Kong, the difference in acceptability of the
method according to whether it inhibited implantation or
ovulation was influenced by knowledge or beliefs about the
mechanism of action of existing methods commonly believed
to inhibit implantation, such as the intrauterine device (IUD).
Women in Hong Kong who found an IUD an acceptable
method were more likely to be positive towards a pill which
prevented implantation (P < 0.001), while in Edinburgh
women who said they were unaffected by the way in which
contraceptive methods worked were more likely to be positive
(P < 0.01), and women who disapproved of emergency
contraception were more likely to be negative (P < 0.001).
In South Africa, a pill which inhibited implantation was more
likely to be favoured by black women (P < 0.05) than by
white or coloured women.
Acceptability declined in all centres, especially Shanghai,
if the pill was said to dislodge an embryo which had already
implanted (Table IV). Approval of this method was significantly
related to approval of IUD use (P < 0.001 in Hong Kong and
P < 0.001 in Cape Town) and neutrality about the mode of
action of any method (P < 0.01) in Edinburgh. Attitudes
towards abortion also correlated with attitudes towards the
mode of action of a once-a-month pill which dislodged an
embryo. In Hong Kong, women who would consider having
an abortion if they had an unplanned pregnancy were more
likely to be positive (P < 0.001), while women who would
not consider an abortion were likely to have a negative attitude
in Edinburgh {P < 0.001) and Cape Town (P < 0.05). In
Shanghai, there was no effect of views on abortion. In Cape
Town, white women (independently of their level of education)
were least likely to approve of a method which dislodged an
already implanted pregnancy (P < 0.001). Those coloured
women who had received more years of education were also
not in favour of this method (P < 0.01).
Missed-period pill
Women were asked how they felt about using, as a regular
method of contraception, a pill which was taken only if a
period was missed. No other contraception would be used and
(based on estimates of fecundability) women were informed
that their period was likely to be late only three or four times
a year. In Hong Kong and Cape Town, 44% of women were
positive towards this idea (Table III). In Hong Kong, women
were more positive if they were older (P < 0.05), less well
educated (P < 0.001) and happy to use an IUD (P < 0.001).
In Cape Town, in contrast, older women found the idea less
acceptable (P < 0.05), but single women were more positive
(P < 0.05), as were black women (P < 0.01). In Edinburgh,
where only one-third of women found relying on an abortifa-
cient acceptable, single women (P < 0.01) and those whose
views were unaffected by the mechanism of action of any
method (P < 0.05) were most likely to be positive. In Shanghai,
where only 9% of women were positive, women who were
separated were more likely to approve (P < 0.05) than those
who were married or co-habiting.
Discussion
Despite vastly different cultures, beliefs and experience with
contraception, women in China, South Africa and Scotland do
not differ substantially in their attitudes towards a pill which
needs to be taken only once a month. In all centres more than
two-thirds of the women who were asked thought that the idea
was a good one. Attitudes towards how such a pill might work
were also surprisingly similar. In all centres except Shanghai,
most women would prefer to use a method of contraception
which inhibited ovulation rather than one that inhibited
implantation. This preference is likely to reflect personal views
about the niceties of the stage in development when conception
is interrupted. Indeed, women who expressed prejudices about
the mechanism of action of a contraceptive method were
consistent in the pattern of approval and disapproval. In
Shanghai, hormonal contraception is not widely used (only
16% of women in this study had ever taken the oral contra¬
ceptive pill). It is commonly held that interference with the
menstrual cycle leads to 'hormonal' side effects including
obesity and hirsutism. It is possible that these beliefs explain
the preference for a pill which inhibits implantation.
In all centres women expressed a strong dislike of a method
which dislodged an already implanted embryo. Interestingly,
on this issue the two Chinese centres—where abortion was
most common—held the most extreme views, with over 90%
of women in Shanghai disapproving of a pill acting after
implantation compared with only 51% in Hong Kong. This
observation is difficult to explain. While it may seem paradox¬
ical that women might find a missed-period pill more acceptable
than a pill which dislodged an embryo, it is possible that
women might dislike a method which intentionally aimed to
dislodge an embryo every month and may be more pragmatic
or fatalistic about taking action after a pregnancy had actually
occutTed. These findings are in contrast to the suggestion that
expected menses inducers (EMI) are more acceptable than
missed menstrual inducers (MMI) (Harrison and Rosenfield,
1996). There was some consistency in wontens' attitudes,
as those who would not consider an abortion under any
circumstances were most positive about contraception which
Acceptability of a oncc-a-montii pill
Table V. Percentages of women positive towards different methods of contraception in each centre according
to whether they would or would not consider an abortion. Results from Shanghai are excluded as only one
woman would not consider abortion
Attitude towards Edinburgh Cape Town Hong Kong
abortion
No. of women who would consider abortion 232 124 304
No. of women who would not consider abortion 17 21 57
Prevent ovulation (%) + 89 81 82
- 94 29 78
Prevent implantation (%) + 48 54 66
- 35 24 61
Disrupt implantation (%) + 26 37 55
- 18 9 40
Missed period (%) -f 40 64 50
- 29 86 39
Table VI. Differences among the three ethnic groups in Cape Town in
responses to key questions
White (%) Black (%) Coloured (%) _
Positive about a oncc-a-monlh pill 74 85 68
Positive about inhibiting implantation 53 52 54
Positive about dislodging an embryo 36 23 37
Positive about a missed-period pill 56 35 40
Held strong religious beliefs 45 47 70
Would consider abortion 38 28 12
prevented ovulation, and were increasingly negative about
intervening as the stage of pregnancy advanced (Table V).
Despite overall similarities, demographic differences might
be expected to cause some minor variations in views. Women
in the two Chinese centres, almost all of whom were married,
were much less likely to consider changing their current
method of contraception than women in Scotland or South
Africa. A similar degree of satisfaction with their current
method was described among men in Shanghai and Hong
Kong who took part in a questionnaire study about male
contraception (C.W.Martin el al., personal communication). It
is possible that contraceptive users in Shanghai have more
faith in their doctors' advice than men and women in the West,
where a tendency to question or actively disagree with figures
in authority is more common.
Although different demographic characteristics correlated
with different preferences in different cities, there was no one
factor, or pattern of factors, which determined contraceptive
choice. In general throughout their responses, women were
consistent in the beliefs which they hold strongly, but even in
South Africa—where ethnic differences might be expected to
reveal marked contrasts in contraceptive preference—there
was no clear pattern of response (Table VI). An individual's
choice of contraceptive method is probably influenced by
many factors, including past experience (of both contraception
and reproductive events), technical or scientific knowledge,
and beliefs about efficacy and side effects. Different methods
suit different women at different times in their lives and given
the choice, a once-a-month pill which acted before implantation
would almost certainly be a well-used method of contraception.
Our findings suggest that an EMI and MMI would probably
be regarded as something of a last resort.
Table VII. Frequency of urine testing found acceptable (% of women)
Edinburgh Cape Town Hong Kong Shanghai
Never 20 8 19 31
Once per month 4 21 16 54
Once per week 31 49 30 11
5-6 days per month 9 3 4 1
Every day 13 8 11 1
The results of this survey were not substantially different
from those of the survey undertaken in 1991 which involved
only European centres. Only in Edinburgh was the study
repeated (in the same setting), and it is interesting to note that
the percentage of women in favour of a once-a-month pill had
increased from 72% in 1991 to 84% in 1996. There was also
an increase in the number of women finding a missed-period
pill an acceptable concept (24% in 1991 versus 32% in
1996). Perhaps this reflects a general liberalization of society's
attitudes, and helps to explain the differences between Europe,
Africa and Asia in the current survey.
If a once-a-monlh pill is to become available, it is likely
that it will need to be taken at a precise time in the cycle. To
do this, women will have to use a method of detecting
ovulation, such as the measurement of luteinizing hormone
(LH) in urine. It is likely that several tests will need to be
done over a number of days, as accurate timing will be vital
for the efficacy of the method. We asked the respondents
whether they would be prepared to do this, and the results are
shown in Table VII. In all centres <15% of women would be
prepared to test their urine as frequently as would almost
certainly be required (5-6 days/month) if ovulation were to
be detected reliably. A method of contraception is already
available in the UK which requires urine testing for up to 10
days each month (Bonnar et al., 1999). The method—a fertility
regulation monitor known as Persona (Unipath, Ltd., Bedford,
MK44 3UP, UK)—is favoured by women who want to avoid
using hormonal contraception. Given the option to use a
method which exposes them to these dmgs only 13 times a
year, many more women may be prepared to endure the
inconvenience of urine testing if the method were highly
effective. With time, it may be possible to develop similar
convenient monitors which measure indicators of ovulation in




It is difficult to predict how many women would actually
use a once-a-month pill were one to become available. Many
other factors (e.g. related to compliance, cost, and provider
acceptability) are involved in the process that leads to effective
and safe use of a new contraceptive method. While it would
be unwise to extrapolate precisely from the findings of this
survey, the positive attitudes of so many women from such
different cultures should nevertheless be reassuring to any
pharmaceutical company interested in turning the concept into
a reality.
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Abstract
Surveys undertaken in the 1970s and 1980s suggested that amenorrhea was unacceptable to most women, especially in developing
countries. More recent research suggests that increasing numbers of women in the developed world prefer to menstruate less often. In a
questionnaire survey of 1001 women attending family-planning clinics and 290 contraceptive providers in China, South Africa, Nigeria and
Scotland, only among black women in Africa did the majority like having periods. In all other groups, most women disliked periods, which
were "inconvenient" and associated with menstrual problems. Given the choice, the majority of Nigerian women would prefer to bleed
monthly. Elsewhere, women would opt to bleed only once every 3 months, or not at all. In all except the Chinese centers, the majority of
women would be willing to try a contraceptive which induced amenorrhea. Providers tended to overestimate the importance of regular
menstruation to their clients. This is an important observation for scientists and funding agencies involved in developing new methods of
contraception. © 2003 Elsevier Science Inc. All rights reserved.
Keywords: Contraception; Amenorrhea; Acceptability
1. Introduction
When Pincus and colleagues developed the combined
oral contraceptive pill, they purposely introduced a regimen
which would confer a monthly withdrawal bleed because
"ihese artificial menstrual cycles give assurance to the con¬
traceptive user of'normal' genital function" [1]. In contrast,
the 3-monthly injectable method of contraception, depot
medroxyprogesterone acetate (Depo Provera®), which be¬
came available a decade or more later, inhibits cyclical
ovarian activity, doing away with menstrual periods in most
users. For many years, amenorrhea was widely regarded as
* Corresponding author. Tel.: +44-131-332-7941; fax: +44-131-322-
2931.
E-mail address: Anna.glasior@lpct.scot.nhs.uk (A.F. Glasicr).
the price women had to pay for the clear advantages of the
method in terms of efficacy and duration of action. When
the levonorgestrel-releasing intrauterine device (Mirena®)
came onto the market in the 1990s, the amenorrhea com¬
monly associated with its use was heralded by the manu¬
facturer, providers and users as a positive benefit of the
method. There is no medical advantage to menstruation per
se. On the contrary, the morbidity associated with menstru¬
ation is impressive. Menstaial dysfunction is one of the
most common reasons for which a woman consults her
general practitioner and in some countries up to 20% of
women will undergo hysterectomy for excessive menstrual
bleeding [2],
In the developed world, the gradual acceptance of
amenorrhea associated with contraception has recently at¬
tracted interest. Surveys suggest that increasing numbers of
0010-7824/03/S - see front matter © 2003 Elsevier Science Inc. All rights reserved,
doi; 10.1016/S0010-7824(02)00474-2
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women welcome methods which induce amenorrhea and
indeed many manipulate their pill-taking to achieve it [3,4],
The debate has been taken a step further recently by the
suggestion that whether to menstruate or not should be a
matter of choice [5-7]. However, perceptions of menstrua¬
tion vary according to culture and religion and women's
attitudes to changes in bleeding patterns associated with
contraceptive use vary widely. Research undertaken by the
World Health Organization (WHO) published in 1981 sug¬
gested that most women (even in the UK, but particularly in
the developing world) preferred to have a monthly bleed
and were unwilling to use a method of contraception which
induced amenorrhea [8], These findings have strongly in¬
fluenced not-for-profit agencies involved in contraceptive
development, which have tended to shy away from explor¬
ing such methods. Since much of the research on attitudes to
menstruation was carried out decades ago, we have under¬
taken a survey among women attending family-planning
clinics, and among their providers. The study was designed
to explore attitudes towards menstruation and willingness to
use a method of contraception which induces amenorrhea.
2. Materials and methods
The survey was undertaken in two centers in the People's
Republic of China (Shanghai and Hong Kong), two centers
in Africa (Sagamu in Nigeria and Cape Town in South
Africa), and in one center in Scotland (Edinburgh).
Two questionnaires were developed, one for women at¬
tending family-planning clinics (clients) and another for
health professionals responsible for providing contraception
(providers). Pilot versions of the relevant questionnaire
were administered to 20 clients and five health-care provid¬
ers at each center. Both questionnaires were modified ac¬
cording to the consensus of comments received and a re¬
vised version of the questionnaire for providers (which was
changed quite extensively) was piloted before being final¬
ized. The questionnaires were translated into local lan¬
guages where appropriate and independent back-translation
was performed to validate interpretation. The client ques¬
tionnaire contained questions concerning gynecological his¬
tory; methods of contraception ever used and reasons for
slopping; clients/partners views towards menstruation; atti¬
tudes towards amenorrhea and, in particular, towards a
method of contraception which may result in amenorrhea.
The questionnaire for health-care providers probed factors
which influenced their choice of contraception for a partic¬
ular client and their perception of the importance to clients
of menstruation during contraceptive use.
2.1. Subjects
In each center, clients were recruited from one or more
family-planning clinics. In each clinic all clients were in¬
vited to participate and recruitment coutinued until 200
questionnaires had been completed. In Cape Town, to en¬
sure that the views of all groups were well represented,
clinics were selected to yield equal numbers of the three
main ethnic groups (black, colored and white). Recruitment
took place in all centers between December 2000 and June
2001. Following an explanation about the study and after
obtaining verbal consent, the questionnaires were adminis¬
tered to the clients by trained interviewers and took approx¬
imately 5-10 min to complete. Questionnaires were posted
(or hand-delivered) to health-care providers together with a
return envelope. The number of refusals/nonreturns from
each center was noted. All respondents (clients and health¬
care providers) remained anonymous. Ethical approval was
obtained for this study by local ethics committees in each
center.
2.2. Statistical analysis
Samples of 200 clients in each of the five centers allowed
for the prevalence of moderately common attitudes to be
estimated to within a standard error of 4% within centers,
and gave high power to detect true differences in prevalence
of the order of 15% between centers. The precision of
estimation for attitudes of the health-care providers was
lower, resulting in estimates with standard errors of the
order of 8% within centers.
The responses to the questionnaires were coded and
entered into databases at each of the centers and returned to
Edinburgh for quality-control checking and statistical anal¬
ysis. The significance of associations between binary or
nominal variables were tested by chi-squared tests, with
Yates' correction in the case of 2 X 2 tables, while appro¬
priate nonparametric methods (Mann-Whitney, Kruskal-
Wallis or Spearman rank correlation tests) were used for
analyzing ordinal or quantitative variables.
'5. Results
The questionnaire was administered to 200 clients in
each of the five centers. In Edinburgh, Shanghai and Nige¬
ria, no one refused to participate. In Hong Kong, 4 women
and in,Cape Town, 12 women declined to take part, mainly
<jue to lack of time. At least 50 providers in each of the five
centers were sent a questionnaire. All questionnaires were
returned in Cape Town, Shanghai and Nigeria. In Hong
Kong, 50 of 76 questionnaires were returned. In order to
obtain 50 returned questionnaires from Scotland, a further
50 were distributed to the medical staff of the Sandyford
Institute, Family Planning and Reproductive Health Center,
in Glasgow. A total of 71 questionnaires were returned from
100 distributed to health-care providers in Edinburgh/Glas¬
gow.
The demographic characteristics of the clients are illus¬
trated in Table 1. As expected, there were significant dif¬
ferences between the various centers reflecting the different
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Table I
Demographic characteristics of clients from all centers"
ED CT HK SH NG Significance of
(n = 200) (n = 201) (n = 200) (n = 200) (n = 200) difference between
centers
Age (years) (%)
20-29 53 56 24 49 13 p < 0.001
30-39 33 33 44 36 62
>40 11 7 31 16 26
Marital status (%)
Married/Cohabit 49 33 84 81 99 p < 0.001
Single 48 62 15 20
Ethnic group (%)
B - 34 - - 100
W 97 33 - - p < 0.001
Cb - - 92 99 -
C - 34 - - -
Religion (%)
Christian 35 84 9 1 78 p < 0.001
Muslim 0.5 9 0.5 1 23
Buddhist - 0.5 7 ' 2 -
No religion 64 6 74 96 -
No. of children (%)
0 76 46 31 42 2 p < 0.001
1 11 26 28 55 5
2-3 13 25 41 4 36
>4 1 4 0.5 59
a ED = Edinburgh; CT = Cape Town; HK. = Hong Kong; SII = Shanghai; NG = Nigeria; B = black; W = white; Ch = Chinese; C = colored.
cultures. Clients in Edinburgh, Cape Town and Shanghai
tended to be younger than those in the other two centers (p
< 0.001) and more clients in Hong Kong, Shanghai and
Nigeria were married. In Edinburgh most clients did not
have children, whereas in Nigeria the majority of clients had
four children or more. In contrast to the other two centers,
the majority ofclients in Edinburgh, Hong Kong and Shang¬
hai stated that they had no religion.
The vast majority of women had regular menstrual cy¬
cles of average length (26-35 days) and menstrual bleeds of
average duration (4-7 days). In no center did more than 4%
of women have menstrual periods lasting more than 7 days.
At least half of the women in every center reported their
menstrual flow as being "normal." Two percent of women
in Hong Kong, 10% in Edinburgh and 29% in Cape Town
had no periods—most of them were using Depo Provera as
their method of contraception. Of those women who stated
that they experienced menstrual problems, the most com¬
mon complaint in all centers was dysmenonhoea
(32-40%).
Table 2 illustrates the methods of contraception currently
used by clients. The patterns of use were similar to those
observed in previous studies from these centers [9,10], In
Edinburgh, the oral contraceptive pill was the most popular
choice, while in Africa, injections were the most commonly
used method (Depo Provera in South Africa and norethis-
terone enanthate in Nigeria). Nearly 40% of clients in Hong
Kong and Shanghai used condoms.
Except for black women in the two African centers, more
than half the women said they did not like having periods
Table 2
Current contraception (%)—clients"
ED CT HK SH NG
COC 40 35 28 6 17
POP 7 5 - - 0.5
Condoms 21 2 38 39 23
1UCD 9 - 12 17 27
Inject/implant 10 53 9 2 30
None—at risk 0.5 4 2 13
None—no need 4 2 4 6 -
Planning pregnancy 3 - 2 0.5
-
4 ED = Edinburgh; CT = Cape Town; HK = Hong Kong; SH = Shanghai; NG = Nigeria; COC = combined oral contraceptive pill; POP ~
progestcronc-only pill; IUCD ~ intrauterine contraceptive device.
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Table 3
Attitudes and experience of clients towards contraception and amenorrhea®
ED CT-B CT-W CT-C HK SH NG Significance of difference between centers
Do you like having
periods? (%)
Yes 26 75 35 42 50 33 81 p<0.00l
No 74 25 65 58 51 63 19
Don't know - - - - - 5 -
If you could choose, how
often would you like
to have a period? (%)
Monthly 33 49 30 42 42 43 71 p<0.001
3-monthly 20 27 26 15 39 30 12
Never 37 9 29 36 6 15 13






Provided your periods and
your fertility returned
to normal immediately
after you stopped using it,














Yes 65 52 64 61 37 48 73
No 25 41 26 33 32 35 24
Undecided 11 7 11 6 32 18 4
a ED = Edinburgh; CT-B = Cape Town (black); CT-W = Cape Town (white); CT-C = Cape Town (colored); HK = Hong Kong; SJ1 = Shanghai; NG
= Nigeria.
(Table 3). In South Africa, white or colored women were
significantly more likely to say they disliked periods com¬
pared with black women (p < 0.001). The most common
reason for not liking periods was because they were "incon¬
venient" (65-85%). In Edinburgh and Hong Kong, 33% and
13% of women, respectively, disliked periods because of
associated menstrual problems. In contrast, 81% of women
in Nigeria said they liked having periods, the most common
reason cited was "to get rid of bad blood." They also liked
having a period to reassure them that they were not preg¬
nant. In all other centers, the most common reason for liking
periods was because they were perceived as "natural."
Offered the choice of how often the clients would like to
have a period, there were significant differences between
centers (fable 3). More than one-third of all women in
Edinburgh and colored women in Cape Town preferred
never to menstruate, compared with fewer than 10% of
women in Hong Kong and of black women in Cape Town.
The proportion of women preferring a monthly bleed ranged
from 30% among white women in Cape Town and 33% in
Edinburgh, to 71% in Nigeria.
With the exception of Cape Town, the majority of clients
in all centers had no experience with use of a method of
contraception which stopped periods (Table 3). Within
Cape Town, there were, however, differences between eth¬
nic groups (p = 0.002). The majority (60%) of black clients
had used a method of contraception which had stopped
periods (Depo Provera) compared with fewer than one third
of white women and 37% of colored women.
More than half the clients in Edinburgh, and all three
ethnic groups in Cape Town, said that they would consider
using a contraceptive method which resulted in temporary
cessation of menstruation. In Shanghai and Hong Kong,
more than one-third of women would be willing to use such
a method. In Edinburgh, Cape Town and Shanghai, women
who did not like having periods were more likely (ban those
who did to consider a method of contraception which
stopped periods (p < 0.001), but this was not the case in
Hong Kong or Nigeria. Even amongst women in Nigeria,
and black women in South Africa, most of whom had
expressed a preference for having periods (Table 3), more
than half of the women were favorable to the idea of using
a method of contraception which would temporarily end
menstruation.
The acceptability of a contraceptive which induced
amenorrhea was unrelated to age, parity, education or reli¬
gion except in Shanghai, where younger women (52%, p =
0.015) and women who wanted children (p = 0.017) tended
to be more positive than those who did not. There was also
no correlation between willingness to use this method and
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Table 4
Demographic characteristics of providers from all centers
ED cr HK SH NG Significance of
s II (n = 50) (n = 50) (n = 50) (n = 69) difference between
centers
Age (years) (%) p<0.0l
20-29 17 13 20 26 10
30-39 36 29 53 42 36
>40 47 58 27 32 54
Marital status (%) p<0.001
Married/cohabit 75 64 70 84 93
Single 24 28 30 16 7
Ethnic group pCO.OOl
B - 31 - - 100
W 92 35 - - _
Ch - - 100 100 _
C - 35 - - -
Religion (%) pCO.OOl
Christian 71 80 34 86
Muslim 3 8 - 14
Hindu 3 2 - - -
No religion 23 - 62 100 -
No. of children (%) pCO.OOl
0 41 24 46 30 7
1 14 28 24 68 5
2-3 43 40 30 2 58
>4 3 8 - - 24
ED = Edinburgh/Glasgow; CT = Cape Town; 1 IK = Hong Kong; SH = Shanghai; NG = Nigeria; b = Black; w = White; Ch = Chinese; c = Colored.
how the client perceived her own menstrual period (i.e.,
normal, heavy or light).
There were significant differences between centers in the
demographic characteristics of the health-care providers
(Table 4). In all centers, over 70% of the providers were
women and most were married. However, providers in Ed-
inburgli/Glasgow, Cape Town and Nigeria were older than
those in China (p = 0.0013) and the majority in Scotland
and Hong Kong did not have children. In Scotland and in
Hong Kong, providers were much more likely than their
clients to describe their religion as Christian.
The attitudes of the health-care providers towards con¬
traception and amenorrhea are illustrated in Table 5. Most
providers in Nigeria, Shanghai and Hong Kong thought that
it was important for women to menstruate while using
contraception. In all the centers at least 75% thought their
clients considered that menstruating whilst using contracep¬
tion was important. Despite this, in all centers except
Shanghai, more than half the providers would recommend a
method which stopped menstruation.
4. Discussion
Regular monthly periods are a relatively recent phenom¬
enon [11]. Until modern contraceptives became available,
most women spent much of their lives pregnant or breast¬
feeding and, therefore, amenorrheic. Menses only returned
briefly at weaning, which was rapidly followed by another
pregnancy. The epidemic of menstrual cycles coincided
with the demographic transition from developing to devel¬
oped country status with low fertility rates. Faced with the
inevitable inconvenience of repeated menstrual periods,
women perhaps unsurprisingly adopted a positive attitude.
Thus, periods were seen as "normal," a means of "getting
rid of bad blood" and a sign of fertility. Amenorrhea could
indicate ovarian failure and a sign of the end of reproductive
potential at the menopause.
These ingrained cultural attitudes may explain the results
of previous surveys. In a questionnaire survey of over 5000
women from 10 countries (Egypt, India, Indonesia, Jamaica,
Korea, Mexico, Pakistan, Philippines, UK and Yugoslavia)
undertaken in the late 1970s, the majority of women in all
cultural groups were unwilling to accept a contraceptive
which induced amenorrhea [8]. The size of the majority
varied from 50% in Korea and 53% in the UK to 85% in
India and 91% in Pakistan. Women in this survey were said
to feel that amenorrhea was "unnatural" and that menstru¬
ation was "an outlet for bad blood." In a qualitative study
undertaken in the early 1990s using focus discussion groups
involving 576 women from seven countries (Cambodia,
India, Mexico, Pakistan, Peru, South Africa and USA), a
majority of women in every site strongly expressed their
overall dissatisfaction with available methods of contracep¬
tion [12]. The authors reported that, when directly asked,
"women were largely dismayed by the prospect of a con¬
traceptive method causing amenorrhea." Women were con¬
cerned about the negative health effects, fear of pregnancy
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Table 5
Providers' attitudes towards contraception and amenorrhea
ED CT-B CT-W CT-C HK SH NG Significance of difference
between centers






Yes 18 47 13 18 65 82 74
No 82 53 88 82 35 18 26
How important does the
client herself think
it is to menstruate
whilst using
contraception? (%)
Very important 18 60 25 24 26 28 79
Quite important 74 33 56 65 72 62 17





Yes 92 71 100 77 66 36 52 p<0.00l
No 8 29 24 34 64 48
ED - Edinburgh/Glasgow; CT-B -
NG = Nigeria.
Cape Town (black); CT-W = Cape Town (white); CT-C = Cape Town (colored); HK = Hong Kong; SH = Shanghai;
and the difficulties that amenorrhea caused with keeping
contraception secret from husbands.
In contrast, in our study, more than 50% of women in
Edinburgh, Cape Town and Sagamu (Nigeria), and more
than one-third of women in Hong Kong and Shanghai,
would consider using a contraceptive method which in¬
duced amenorrhea. The proportion was high even among
population subgroups of women (or cultures) in which the
preference for having periods was widespread.
Why should our results be so different from those re¬
ported by the two earlier studies? Neither study described
the source of the respondents but there is no indication that
they were recruited from a health-care setting. Both sought
only the views of married women with children. The women
who took part in the questionnaire study [8] were markedly
older than women participating in our study—in all but two
cultural groups, at least one third were aged over 35 and in
nine fewer than 15% were aged under 24. In the focus
discussion groups [12], the mean age of participants was 32,
and although the upper age limit was said to be 35, the
reported range was much greater. In our own study, all die
participants were attending family-planning clinics, many
(76% in Edinburgh) had no children and more than 49% in
Shanghai, •Edinburgh and Cape Town were aged under 30.
The differences could be due, therefore, to the type of
women participating in the studies. However, in our survey,
the women most likely to consider using a contraceptive
which induced amenorrhea were the women from Nigeria
(73%). Yet, these were the women who were most likely to
like having periods (81%); most likely to choose to have a
monthly withdrawal bleed (71%) and tended to view peri¬
ods as a way of "getting rid of bad blood." They were also
most likely to be married with children. So, in every respect,
this group of women was more similar to those who partic¬
ipated in the two earlier studies. The study by Snow and
colleagues [12] included 98 women from Cape Town and
the WHO study [8] included a center in the UK. While the
former study gave no absolute numbers, in the latter 53% of
women front the UK were unwilling to accept a method of
contraception which induced amenorrhea (compared with
only 25% in Edinburgh in 2000). Perhaps a more likely
explanation for the difference between the findings of our
Study and those of WHO and Snow is the effect of the
passage of time. In a questionnaire survey of 178 pill users
in Sydney, Australia, although 83% of women believed that
a monthly bleed was necessary, 27% would choose to bleed
every 3 months, 4% every 6 or 12 months, and 15% never
[3], Participants for this study were recruited from family-
planning clinics or general practice, two thirds of the
Women were between 20 and 29 years, and almost half had
hever been married. Thus, these Australian women were
more like our own respondents. Furthermore, this survey
was done in the late 1980s when it is possible that women
\vere becoming more accustomed to the concept that amen¬
orrhea might have some benefits and that they do not have
to bleed each month. The results may also reflect an increas¬
ing willingness of women to accept therapeutic interven¬
tions if the benefits are seen to be real.
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In a more recent study undertaken in the Netherlands [4]
published in 1999, the majority of women aged 15-34
preferred a bleeding frequency of less than once a month,
and 26% of women aged 15-19 and 31% of those aged
25-34 would have preferred never to bleed. Given the
opportunity to design their own pill regimen, one third of
women aged 15-19 opted for a bleed once every 3 months
and between 22% (aged 15-19) and 26% (aged 45-49)
would design a regimen that induced amenorrhea.
Although neither the WHO survey [8] nor the Snow
study [12] specifically asked women whether or not they
liked having periods, WHO did ask women about physical
discomfort and mood change and whether they would be
willing to accept less bleeding. Although more than half of
the women in every cultural group admitted to physical
discomfort, and many to mood change in association with
menses, in every center more than 60% (and in seven groups
over 80%) of women were unwilling to accept less bleeding.
In contrast, in 2000 in our study, only among black women
(in both Cape Town and in Nigeria) did more than 50% of
women say that they liked having periods. In Edinburgh,
Cape Town and Shanghai, women who did not like having
periods were more willing to try a contraceptive method
which stopped periods.
There are data which testify to women's willingness to
use the oral contraceptive pill (OC) to induce amenorrhea.
More than 25 years ago, it was demonstrated in a Scottish
study that the majority of women given the opportunity to
use an OC continuously for 3 months found the regimen
acceptable [13]. Ninety-one percent of the 107 women who
completed the study (out of 195 women who started) re¬
fused to revert to the monthly regimen. Most of the women
participating in similar trials of extended OC cycles in
Australia [14], Sweden [15] and the USA [16] welcomed
infrequent menses. Recognizing an increasing tendency for
women to manipulate bleeds, a phase III trial of a combined
oral contraceptive formulation taken continuously for 84
days followed by 7 days of placebo (Seasonale, Barr Lab¬
oratories) is underway in the USA. A similar study of
continuous use of the combined contraceptive transdermal
patch (ORTHO EVRA/EVRA, R.W. Johnson Pharmaceu¬
tical Research Institute, Raritan, NJ, USA) is also ongoing.
Anecdotal evidence from developed countries suggests
that it is becoming increasingly common for women to
manipulate their cycles to avoid a withdrawal bleed. In the
study of Rutter and coworkers [3], 43% of women had used
the pill to alter the timing of withdrawal bleeding for special
occasions, holidays and weekends. Even women who are
not using the OC look for ways to postpone menstruation. A
review of prescribing patterns among general practitioners
in Oxfordshire (UK) which showed clear peaks of prescrib¬
ing every year for 4 years over the summer holidays, led the
authors to describe norethisterone as a lifestyle drug [17].
Many factors influence a couple's choice of contracep¬
tion. Providers, both through which methods they make
available and accessible, and by their own attitudes and
preferences, have a major influence. Few studies have
looked at the influence of providers. Indeed, Snow [12]
expressed regret at not probing further about the effect that
providers have on determining women's preferences. In the
Scottish study of tricycling the OC, while 82% of women
who used the regimen welcomed the reduction in the num¬
ber of periods, half of the doctors who worked in the
participating clinic preferred to stick to the monthly regimen
of prescribing [13]. Some 16 years later in the Australian
study, 20 female doctors working at a Sydney teaching
hospital answered (he same questionnaire as the OC users
[3]. The doctors were young (mean age: 24) but 40% were
married. Sixty percent of them believed that a monthly
bleed was necessary on the pill but more than half opted for
less frequent bleeding episodes when given the choice of
how often they personally would prefer to bleed and 30%
chose never to bleed. In our own study, in every center
except in white Cape Town, at least 90% of providers
thought that clients felt that regular menses were cither quite
important or very important, while a much lower percentage
of the clients themselves seemed to choose a monthly with¬
drawal bleed. In Nigeria, only 52% of providers, and in
Shanghai only 36%, would recommend a contraceptive
which induced amenorrhea, yet 73% of women in Nigeria
and 48% of women in Shanghai said they would be pre¬
pared to try one. Thus, there was a tendency for providers'
recommendations to correlate far more closely with their
own views about menstruation than with the views of the
women they treat. It is possible that the phenomenon of
Westernization which is underway in major Chinese cities
like Shanghai enhances the ability of clients to disagree with
their providers and to adopt their own views of contracep¬
tion as they become better informed. In black Africa, even
in Cape Town, perhaps women have yet to become eman¬
cipated in this respect.
The acceptability of a method is often inferred from
continuation rates. However, since most women using con¬
traception are highly motivated to avoid pregnancy, they are
prepared to tolerate side effects and the chosen method may
be the "least worst alternative." Continuation rates may only
be a reflection of the characteristics of the "best" method
available rather than of those of a method which women
would be truly happy to use were there more choice. Our
study measures the hypothetical acceptability (or desirabil¬
ity) of one feature of a method of contraception—amenor¬
rhea. Responses to a questionnaire survey may not be a true
reflection of the number of women who would be prepared
to try a method of contraception which induced amenorrhea
if the method was actually available nor how many would
continue to use it having tried it. However, our survey does
suggest that attitudes may be changing. Scientists and fund¬
ing agencies involved in developing new methods of con¬
traception [18] and improving existing ones should be re¬
assured that amenorrhea could be a popular option.
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The prospect of a hormonal male contraceptive is no longer
distant. Data on the potential impact of this improvement
in contraceptive provision, however, is limited, particularly
between different cultures. We have therefore carried out
a multi-centre study to assess men's attitudes to proposed
novel hormonal methods. Questionnaire-based structured
interviews were administered to men in Edinburgh, Cape
Town, Shanghai and Hong Kong. Approximately 450 men
were interviewed in Edinburgh, Shanghai and Hong Kong,
and a slightly larger group (n = 493) in Cape Town to
give samples (n > 150) of black, coloured and white
men. Knowledge of existing male and female methods of
contraception was high in all centres and groups. The
majority of men welcomed a new hormonal method of
contraception, 44-83% stating that they would use a male
contraceptive pill. Overall, a pill was more acceptable than
an injectable form (most popularly given at 3-6 month
intervals); long-acting implants were least so except in
Shanghai. Familiarity with comparable female methods
appeared to influence acceptability, for both oral and
injectable methods. Hong Kong was the only centre where
a male method (condom) was currently the most commonly
used; men there appeared to rate the convenience of
condoms highly while being least likely to think that they
provided effective protection against pregnancy compared
to other centres, and were least enthusiastic about novel
male methods. The acceptability of potential male hormonal
methods of contraception was high in some groups but
showed wide variability, determining factors including
cultural background and current contraceptive usage.
These results suggest that the emerging emphasis that men
should have greater involvement in family planning will
be substantiated when appropriate contraceptive methods
become available.
© European Society of Human Reproduction and Embryology
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Introduction
Access to a wide range of effective methods of contraception
is an important element of reproductive health. The develop¬
ment of new methods of contraception, such as the combined
oral contraceptive pill in the 1960s and more recently medicated
intrauterine devices (IUD) and long term implants, has been
mainly female-directed. Despite this one-sided approach to
contraceptive provision, a third of couples practising contracep¬
tion world-wide use a male method (United Nations, 1994).
Lack of demand for more advanced reversible male methods
is frequently advocated as a reason for limiting the already
meagre research effort in this field (Potts, 1996). The wide¬
spread usage of male methods, however, suggests that any
lack of demand is more perceived than real, but there are
limited data on this subject (Ringheim, 1993).
The prospect of a clinically available hormonal male contra¬
ceptive has been considerably advanced in recent years. The
contraceptive efficacy of a prototype, testosterone-based,
method has been demonstrated [World Health Organization
(WHO), 1996]. Combinations of testosterone with a progest¬
ogen (Bebb el al., 1996; Handelsman et al., 1996; Meriggiola
and Bremner, 1997) may show more rapid and consistent
suppression of spermatogenesis, and long-acting testosterone
preparations are becoming available (Behre et al., 1995).
Formulations may therefore include oral, injectable and implant
preparations.
In view of this divergence between perceived need and
actual usage, we have investigated men's attitudes to contracep¬
tion. The progress in development of potential methods allows
inclusion of likely specific formulations to address their poten¬
tial impact, and the wide global variations in contraceptive
usage necessitate that this be addressed in different cultures.
Materials and methods
The participating centres in this study were Edinburgh, UK; Cape
Town, South Africa; Shanghai and Hong Kong. People's Republic of
China. A total of 1829 men (-450 per centre) was recruited between
October 1995 and December 1996. The study group was recruited from
(i) new or expectant fathers (exclusively new fathers in Shanghai); (ii)
fire-fighters in Edinburgh, Hong Kong and Shanghai and army
personnel in Cape Town; and (iii) men attending Blood Transfusion
Services to donate blood. These groups were selected to achieve a
sample population at different stages of their reproductive careers,




to be compared. Equal numbers of men were recruited from these
three groups except in Cape Town: very few black men were recruited
from Blood Transfusion; thus, to ensure approximately equal numbers
from the coloured, black and white ethnic groups, additional men
were recruited from the odier two groups.
Data were collected through structured interviews using a question¬
naire filled in by a trained interviewer. The questionnaire look -30
min to complete. In each centre the questionnaire was translated from
English to the appropriate local language by a fiuent interpreter
and checked by back-translation. Interviews were conducted in the
subject's first language: English in Edinburgh, English, Afrikaans or
Xhosa in Cape Town, Mandarin in Shanghai, and Cantonese in Hong
Kong. In each centre, permission to conduct the study was granted
from the local ethical committee. Informed consent was given by all
subjects before interview.
The questionnaire aimed to assess the attitudes of men to currently
available male methods of contraception and their opinion about oral,
injectable and implant preparations which may become available in
the future. The questionnaire therefore covered three main areas: (i)
sociodemographic data, including religious beliefs; (ii) knowledge of
contraception and current use: (iii) attitudes towards hormonal^
methods for men.
In Edinburgh, 80 men refused to complete the questionnaire, 34
refused in Hong Kong and 76 men in Cape Town, mainly due to lack
of time. There were 45 refusals in Shanghai mainly because these
men objected to the idea of a questionnaire about contraception.
Statistical methods
All data were returned to Edinburgh for analysis. In general, com¬
pleteness of data was high, typically 98-100%, with the exception of
black Cape Town men for questions concerned with attitudes to
contraceptive methods where completeness was -93%. Associations
between pairs of variables were tested by t-tests, %2 or Spearman
rank correlation tests as appropriate.
Multivariate linear regression was used to analyse the likelihood
of men using novel hormonal male methods (5-point score ranging
from 'definitely would' to 'definitely would not' use). Multivariate
logistic regression was used to analyse men's first choice between
condoms, a daily pill, injection or implant. For both linear and logistic
regressions, the following factors were assessed for significance: age.
having children (yes/no), wanting children in the future (yes/no),
married/co-habiting (yes/no), and having a higher qualification (yes/
no). Variables were selected for the model using forward selection
with age given priority over the other variables since age was likely
to affect other variables rather than vice versa. The analysis of men's
first choice tested whether current contraceptive method influenced
their preference.
Preliminary analysis demonstrated that there were only minor
differences in attitudes between the three sources of recruitment (new
and expectant fathers, blood donors and firemen/soldiers), thus these
groups were combined.
Results
Characteristics of study population
In Cape Town, 493 men were interviewed (153 black, 171
white and 169 coloured), 450 men in Hong Kong and Shanghai
and 436'in Edinburgh. Demographic details and reproductive
status are shown in Table 1. Men in Shanghai were older than
in the other centres and the majority (70%) had completed
their families. Only a small number of men declared no interest
in having a family at any stage (2-6%).
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Current contraceptive usage
Table II shows the current contraceptives used by men or their
partners in the four centres, excluding new or expectant fathers
who would not have a current contraceptive requirement.
There were marked differences (P < 0.001) between centres
and between ethnic groups in Cape Town. The majority
of men, other than black men, were using some form of
contraception: 74% overall, 41% among black men. Female
hormonal methods were the most widely used method of
contraception in Edinburgh and all ethnic groups in Cape
Town. Very few partners of Edinburgh men, white Cape Town
men or Chinese men were using injectable methods. The IUD
was the most common method in Shanghai, and uncommon
in other centres. Only one couple in Shanghai was relying on
female hormonal methods. Condoms were the most common
method in Hong Kong, and the second or third most common
method in other groups, accounting for 17-62% of current
- jisage. Vasectomy was relatively common among white men
In Cape Town and in Edinburgh, particularly in comparison
With female sterilization, but was used very little in the
other centres.
Knowledge ofand attitudes to existing contraceptive methods
Men were asked to give as many female and male contraceptive
methods as they could think of, without prompting. Table III
shows the proportions of men who recalled the major current
female and male methods, and the proportions of men who
had used those methods.
There was a highly significant difference (P < 0.001)
between centres and ethnic groups with respect to knowledge
of current male contraceptive methods. While knowledge was
generally high, black men in Cape Town were unlikely to
recall other than commonly used methods (condom, pill,
and injection). Shanghai men had the greatest knowledge of
methods of which they had no direct experience.
There were differences between centres in men's views on
condoms for effectiveness (P < 0.001) and convenience (P <
0.001) but less so for decreasing sexual satisfaction (P <0.01)
(Table IV). Men in Edinburgh were most likely to regard
condoms as effective but least likely to find them convenient
to use whereas the opposite was found for Hong Kong men,
where usage was highest: men there were least likely to think
them effective for preventing pregnancy but most likely to
regard them as convenient. This difference between Hong
Kong and other centres also applied to men who were current
condom users rather than just the group overall: only 72% of
Hong Kong current users agreed that condoms were effective
for preventing pregnancy compared to 92-95% of users in the
other centres.
1
Attitudes to potential contraceptive methods
Men were asked a series of questions about male methods
which may be available in the future, i.e. a daily pill and
injectable/implant contraceptives, and their answers were com¬
pared to their views on condoms (Table IV). In the introduction
to the questions on proposed male methods, subjects were told
that these methods would provide reliable contraception, would
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Table I. Demographic details of participating centres
Edinburgh Cape Town Hong Kong Shanghai
(n = 436) (n = 450) (n = 450)
Black Coloured White
(n = 153) (n = 169) (n = 171)
Ethnic origin 99% white 31% 34% 35% 98% Chinese 99% Chinese
Age (years)
Median 31 27 31 29 32 40
(range) (18-52) -419-57) (18-52) (19-r60) . 116—59) (21-59)
Marital status:
Married/cohabiting 79 56 72 73 70 88
Regular partner 9 41 12 9 14 5
No regular partner 12 3 16 18 15 7
Children:
Yes 52 72 62 50 59 83
Elective childless 5 2 2 4 6 6
Family not yet started 42 26 35 45 34 12
Family in progress 19 46 25 17 29 13
Family complete 33 27 38 33 30 70
Values are median (range) for age, and percentages of respondents in each centre for other variables.
Reproductive status was categorized as follows: elective childless, no children, none wanted; family noi yet
started, no children but would like some; family in progress, some children but want more; family complete,
some children, no more wanted.
Table II. Current contraception (excluding new or expectant fathers)
Edinburgh Cape Town Hong Kong Shanghai
Black Coloured White
(n = 79) (n « 119) (n = 121)
Currently using 72 41 61 71 74 92
contraception
Female hormonal method
Pill 41 25 28 43 15 0
Implant/Injection 1 38 18 2 3 0
Condom 28 31 17 17 62 22
Female sterilization 7 3 1 13 13 9 3
Vasectomy 14 1 8 19 5 1
IUD 4 0 3 2 2 62
Rhythm 2 0 0 0 2 7
Other 4 3 8 2 1 5
Are you happy with your 71 97 80 88 83 92
current contraception?
(Yes)
Values are percentages of respondents in each centre. Data for those using particular methods of
contraception arc percentages of those currently using some form of contraception.
1UD = intrauterine device.
not carry significant risk of side-effects and would take 3-4
months to become effective. Questions were therefore designed
to assess men's attitudes to these novel preparations separate
from concerns about safety and efficacy although questions
regarding these issues were included. Despite these reassur¬
ances, many men appeared to remain sceptical about the safety
and efficacy of the proposed methods although there were
large differences between centres. Thus there were differences
between centres for perceived contraceptive efficacy, conveni¬
ence, reduction in sexual satisfaction and reduction in masculin¬
ity (P < 0.001 in each case for both a male pill and an
injectable contraceptive). This was particularly the case with
Hong Kong men, of whom only 36% and 38% felt that a male
pill and injection respectively would be effective at preventing
pregnancy. As discussed above, however, Hong Kong men
also had doubts as to the efficacy of condoms (only 60%
believing them to be effective) despite the finding that they
were the most widely used form of contraception in that centre
and that 79% of condom users were happy with their current
form of contraception.
Men had more positive attitudes to the convenience of novel




Table III. Contraceptive knowledge and past usage
Edinburgh Cape Town Hong Kong Shanghai
Black Coloured While
Existing methods recalled:
Rhythm (safe period) 26 10 20 41 36 68
Diaphragm/cap 61 10 34 64 19 38
Pill 99 75 96 99 92 87
IUD 73 22 47 67 45 81
Implant/injection 25 75 86 71 56 47
Sterilization 22 35 70 72 48 66
Female condom 47 8 26 34 29 25
Condom 100 82 97 97 98 100
Withdrawal 24 29 62 68 26 83
Vasectomy 36 20 75 82 50 76
vcr used:
Rhythm (safe period) 5 3 9 15 17 31
Diaphragm/cap 11 I 2 6 0 4
Pill 78 16 49 66 24 14
IUD 9 2 10 8 2 50
Implant/injection 3 22 36 11 6 1
Female sterilization 3 1 6 8 4 3
Female condom 6 1 0 0 0 1
Condom 90 49 74 80 75 72
Withdrawal 14 17 39 46 11 44
Values arc percentages of respondents in each centre. Subjects were asked to name as many contraceptive
methods as they could, unprompted. They were then asked whether they had used any of the listed methods
at any time.
IUD = intrauterine device.
to use than condoms in Edinburgh and in Cape Town. Men in
the Chinese centres, however, regarded condoms as more
convenient, particularly in Shanghai where only 38% of men
thought a male pill would be convenient compared to 61% for
condoms. Similar results were obtained when men were asked
whether a male pill or injectable form would be inconvenient
to obtain, with a minority (23-34%) of men in Edinburgh
and Cape Town stating that an injectable form would be
inconvenient, whereas 64% of men in Hong Kong and 46%
in Shanghai felt it would be inconvenient.
Condoms were consistently regarded as decreasing sexual
satisfaction in all centres (by 48-63% of men). While both a
male pill and an injectable form were thought to be more
satisfactory in tills respect, 16-34% of black men in Cape
Town and in the Chinese centres thought that a new hormonal
pill or injection would decrease their sexual desire or masculin¬
ity. Men in all centres regarded condoms as safer for health
reasons: this question was deliberately phrased in a non-specific
manner to allow the subject to interpret it as they wished.
The preferred frequency of administration of potential
injectable methods was investigated (Table IV). Proposed
frequencies varied from monthly injections to implants lasting
3 years. The most popular intervals were 3 and 6 months
except in Shanghai where 42% said they would prefer implants
which lasted 3 years.
Men were asked whether they would use the proposed novel
male methods (Table IV). Despite the above reservations, a
majority of men said they would definitely or probably use a
male pill (from 44% in Hong Kong to 83% among white Cape
Town men). Responses to the same question regarding an
640
injectable form were less positive in all groups, varying from
32% in Edinburgh and Hong Kong to 62%' among white Cape
Town men. There was a strong correlation (r = 0.76; P <
0.001) in all centres between men's willingness to use a pill
and an injectable form, with nearly all men willing to use a
male injection also willing to use a pill. Factors considered in
Table IV were closely related to whether men thought they
would use a novel male method. The strongest predictor for
both pill and injectable methods was found to be whether the
men thought their partner would wish them to use that method
(P < 0.001 in all groups in each case with the sole exception
of black Cape Town men for prediction of pill use, n.s.).
Concern that novel methods would affect sexual desire was
found to be a predictor of use of a male pill in Edinburgh,
among black men in Cape Town and in Shanghai (P < 0.01
in each case) and for an injectable form in ail groups (P <
0.01 except for black and white men in Cape Town, P < 0.05).
Relationships between demographic data and likely usage
were investigated. In Edinburgh older men were more likely
to consider a male pill (P = 0.023) whereas younger men in
Hong Kong and white men in Cape Town were more likely
to consider a male pill (P < 0.001 and P - 0.026 respectively).
Edinburgh men were more likely to consider using an injectable
contraceptive if they did not have a higher qualification (P =
0.004) whereas in Hong Kong men with a higher qualification
(P = 0.033) were more likely to consider this method. Although
there was no relationship between strength of religious belief
(on a 5-point scale) and likelihood of using novel methods in
any centre/group, all three ethnic groups in Cape Town were
more likely to say that they would use a male pill if they
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Table IV. Men's views on male methods
Do you think that these Edinburgh Cape Town Hong Kong Shanghai
methods:
Black Coloured White
Are effective for preventing pregnancy?
Condoms 91 75 77 87 60 80
Male pill 74 65 85 91 36 52
Injection 69 74 79 88 38 46
Are safe for health reasons?
Condoms 82 76 73 73 82 75
Male pill 30 55 47 46 11 36
Injection 27 60 40 38 11 33
Are convenient to use?"
Condoms 59 71 76 74 79 61
Male pill 83 73 88 95 61 38
Would be inconvenient to obtain?"
Male pill 5 29 14 10 21 43
Injection 26 31 34 23 64 46
Decrease sexual satisfaction/dcsire?b
Condoms 59 48 , 55 63 52 60
Male pill 2 26 8 4 25 17
Injection 2 30 10 3 26 16
Lessen your masculinity?
Male pill 3 34 10 7 23 16
Injection 2 30 11 4 24 17
Would you use this method? (definitely/probably)
Male pill 66 55 66 83 44 50
Injection 32 48 55 62 32 35
How often would you like an injcctable/implant to be given?
Monthly 8 18 7 15 8 6
Every 3 months 25 40 39 41 19 8
Every 6 months 32 15 21 29 24 19
Once a year 15 8 12 5 9 18
Every 3 years 16 7 9 7 10 42
"Different questions were asked to compare the self-administered methods (condom and pill), and methods
requiring interaction with a service provider (pill and injection).
^Satisfaction' when related to condoms, 'desire' when related to inalc pill and injection.
Values are percentages of respondents in each centre.
attended religious services (P = 0.003, P = 0.022, and P —
0.040 for black, coloured and white men respectively). There
was no such relationship in the other centres.
Contraceptive preference
The data in Table IV suggest that all groups would prefer to
use a pill than an injectable form, particularly in Edinburgh
where twice as many men would consider using a pill than a
injection. The order of preference was tested more directly by
asking men to rank condoms, a daily pill, a 3-monthly injection
and a long-term implant (Table V). The proportion of men
rating each method as first choice varied significantly between
centres (P < 0.001 for all four methods). Condoms were first
choice for over 60% of men in both Chinese centres, other
methods being first choice for less than 20% of men. Condoms
were also the first choice of 44% of black Cape Town men,
but novel methods were first choice for men in Edinburgh and
for coloured and white men in Cape Town. Edinburgh men
showed a preference for a male pill (33% first choice), although
this centre showed the most even distribution between methods.
A 3-monthly injection was the most prevalent first choice for
both coloured and white Cape Town men (41 and 39%
respectively), with a pill being second choice in both groups.
A 3-monthly injection was second most prevalent choice with
black men. A longer acting implant was the least prevalent
first choice among all groups except in Shanghai, but it was
still only first choice with 17% of men in that centre.
Factors associated with contraceptive method of first choice
were obtained by multivariate logistic regression. Condoms
were more likely to be the choice of younger men in Edinburgh,
white men in Cape Town, Hong Kong and Shanghai (P <
0.05 in each case). Black men in Cape Town were more likely
to pick this option if they wanted (more) children in the future
(P < 0.01). Current users of condoms were more likely to
choose condoms except in Edinburgh and coloured men in
Cape Town (P < 0.01 for black and white men in Cape Town,
P < 0.05 for Hong Kong and Shanghai).
In Edinburgh, having a higher qualification was the only
factor associated with ranking the male pill as the first choice
(J° < 0.05). For black and coloured men in Cape Town, none
of the factors investigated show a significant correlation with
choosing the pill. Current pill usage was predictive for this
choice among white men in Cape Town and in Hong Kong




Table V. Contraceptive preference
Edinburgh Cape Town Hong Kong Shanghai
Black Coloured White
First choice
Condom 28 44 19 16 68 61
Pill 33 19 29 30 12 8
3-monlhIy injection 24 28 41 39 11 14
Implant 14 9 11 15 9 17
Who decides which method of contraception to use?
You 7 20 10 8 18
Your partner 13 26 18 11 15
Both of you 78 48 66 80 54
Do you think that 42 72 81 90 59
responsibility for contraception
falls loo much on women?
(Yes)
Method characteristics:
Need for semen analysis
Agree* 33
Disagree" 45



























Values arc percentages of respondents.
"Agree/disagree strongly or very strongly.
man indicated that his current method of contraception was
the pill; however, men who were using methods other than
the two main methods in that centre (condom and IUD) were
more likely to choose the male pill.
An injectable form was more likely to be chosen by those
men who were married or cohabiting in Edinburgh and among
black and white Cape Town (P < 0.05 for Edinburgh and
white men in Cape Town, P < 0.01 for black Cape Town
men). This was not a predictive factor in Hong Kong, where
current use of methods other than condoms was associated
with men being more likely to pick this option. Not wanting
any (more) children was a strong predictive factor among
black Cape Town men (P < 0.001). No significant associations
were found between any of the factors investigated and
choosing this option among men in Shanghai.
Age was the main factor associated with first choice of an
implant. Thus being older in Edinburgh, Hong Kong (P <
0.01) and Shanghai (P < 0.05) and having children in
Edinburgh (P <0.01) showed significant positive associations
with this method. Current contraceptive usage was also a
significant predictive factor for IUD users in Hong Kong and
Shanghai (P < 0.05 and P < 0.01 respectively), using the pill
in Edinburgh (P <0.01) and among coloured Cape Town men
(P < 0.01), and using injectable forms among black men in
Cape Town (P < 0.05). These factors, however, did not show
significant associations among white men in Cape Town.
Sharing responsibility
The sharing of contraceptive decision-making was investigated.
In all centres the majority of men reported that decisions
regarding contraceptive usage were made jointly, varying from
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54% in Hong Kong to 80% of white men in Cape Town (Table
V). A majority of men in all centres except Edinburgh
thought that the responsibility for contraception fell too much
on women.
The need for semen analysis and delay in onset of efficacy
It is likely that the use of male hormonal contraception Will
require analysis of one or more semen samples, therefore men
were asked whether the necessity to supply a semen sample
would be acceptable to them (Table V). There were significant
differences between centres, men in Cape Town being most
likely to find this acceptable and Chinese men in Shanghai
and Hong Kong least likely (P < 0.001). Similar results were
obtained when men were asked about the acceptability of a
3-4 month delay before the method became effective, with
the exception of Cape Town where this was regarded as less
acceptable than the need for semen analysis by all three
ethnic groups.
Discussion
Although a third of all couples world-wide rely on a male-
dependent method of contraception (United Nations, 1994;
Ringheim, 1996), there is an emerging emphasis that men
should be involved in family planning (ICPD, 1994). The use
of male methods also appears to be increasing in many
developing countries (Drennam, 1998). Although many know¬
ledge, attitudes and practice surveys relating to contraception
have been carried out, few contain comparable data on men
in different countries (Ezeh et al., 1996; Drennam, 1998). This
survey therefore sought to investigate men's attitudes to novel
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hormonal forms ofcontraception which would provide effective
male-dependent methods. While it is acknowledged that inten¬
tion may not predict behaviour (Keller, 1979), the information
obtained may be of value in the design of future products
by biomedical scientists and the eventual introduction of a
real method.
The recruitment of men from approximately the same three
sources in the four different centres was designed to increase
comparability between the centres. This design was adopted
in preference to attempting to recruit a random sample from
the local population. Blood donors and firemen/soldiers would
not be expected to reflect the views of the wider population,
but the third group, recent fathers, would be more likely to do
so. Importantly, we did not find significant differences between
the three recruitment groups in any of the centres, strengthening
the validity of these data as representative of the population
from which they are drawn. Although there will inevitably be
differences between such diverse populations, the demographic
details shown in Table 1 show considerable similarities in the .
composite variable of 'reproductive status', i.e. whether the
men had or were planning children, or whose families were
complete. Men in Shanghai, however, tended to be older, and
consequently were more likely to have completed their families.
The overall similarity in the responses of men in Hong Kong
and Shanghai compared to the other two centres indicates that
this had little impact, in agreement with the result of the
detailed analysis showing the generally modest influence of
reproductive status.
The major finding of this study is that the majority of men
surveyed welcomed new hormonal methods of contraception
even though they were mostly happy with their current method.
Indeed 44-83% said that they would definitely or probably
use a male pill. Attitudes to existing and novel methods,
however, differed greatly between centres. Hong Kong was
the only centre where a male-directed method (condom) was
the main method currently used, and men in that centre were
least keen on novel methods despite the high prevalence of
reduction in sexual satisfaction with condoms (52%, similar
to other centres) and low belief in their contraceptive efficacy
(60%, lower than all other centres). Lack of belief in contracept¬
ive efficacy also extended to novel hormonal methods despite
being assured of this in the introduction to those sections of
the interview. Condoms, however, were highly regarded for
convenience. Conversely, men in Edinburgh were least likely
to regard condoms as convenient although most likely to regard
them as effective. These data therefore illustrate differences in
factors influencing contraceptive usage in different societies.
Thus the finding that a male pill was regarded as more
convenient than condoms in Edinburgh and among all ethnic
groups in Cape Town but not in Hong Kong or Shanghai may
indicate large differences in potential usage. Similarly an
injectable form was regarded as more inconvenient in Hong
Kong and Shanghai than Edinburgh and Cape Town.
In addition to convenience, concern over interference with
sexual functioning and partner's attitudes were strong pre¬
dictors of potential use of novel methods. Both a male pill
and an injectable form were perceived as having a much lower
impact on sexual desire/satisfaction than condoms in all centres,
particularly in Edinburgh and among coloured and white men
in Cape Town. Similar differences between centres were
apparent for concern as to whether novel methods would affect
self-perceptions of 'masculinity'. However, compared to all
other factors tested (Table IV), anticipated endorsement by the
man's partner of usage of both oral and injectable novel
methods was the most powerful predictor of potential usage.
Men's knowledge of both male and female existing contra¬
ceptive methods was generally high. The only exception was
that knowledge among black men in Cape Town was largely
restricted to past or present usage of methods. Conversely
men in Shanghai had the widest knowledge. There are thus
differences not only in knowledge and usage in different
cultural settings, but also in the relationship between them.
The high prevalence of men's knowledge of both male and
female methods found here is consistent with an analysis of
men's and women's knowledge and usage in 10, mostly
African, countries (Hulton and Falkingham, 1996). In that
study, usage of male methods was generally low, e.g. the
highest rate of ever-use of condoms was 35% (in Ghana)
compared to the lowest figure from the current data of 49%
among black Cape Town men.
Relationships between age and willingness to use novel
methods varied greatly between centres. Thus older men were
more likely to use a male pill in Edinburgh, while this was
more likely among younger men in Hong Kong who were
also more likely to use an injectable form. Having a higher
qualification also showed variable correlations, being less
likely in Edinburgh men who would use an injectable form
but more likely among such Hong Kong men. Age and level
of education have frequently been found to have a significant
influence on the acceptability of family planning methods in
demographic and health surveys carried out in developing
countries (Drennam, 1998). Reproductive status was generally
not an important predictor of potential usage of a novel method
in any centre. These findings demonstrate the importance of
local and specific investigation of factors influencing uptake
of family planning methods.
A second question to assess the potential impact of novel
methods involved asking men to rank condoms and three novel
methods: a daily pill, an injectable form lasting 3 months, and
a long-acting implant. The most consistent finding was of the
rejection of novel male methods in tire two Chinese centres,
with <15% of men ranking a pill or injection first choice. In
contrast a significant proportion of men in Edinburgh and
Cape Town would choose a pill, injection or implant demon¬
strating that, as in female contraception, user satisfaction is
most likely to occur when a range of methods is available.
Injectable methods appeared to be relatively more popular
than a pill, in contrast to when men were directly asked
whether they would use either method. This may be because
in this section men were asked to rank four methods, none of
which might have been acceptable. Current use and familiarity
with comparable female methods appeared to affect acceptabil¬
ity, similarly to findings in the accompanying study of the
acceptability of novel male methods to women (Glasier el al.,
2000): thus female pill use was highest in partners ofEdinburgh




was also highest. Similar relationships were also apparent for
injectable method use, with both current female usage and
proposed male usage highest in Cape Town. Current contracept¬
ive usage was dominated by a single method in the two
Chinese centres, over 60% using condoms in Hong Kong and
1UD in Shanghai, and men in these centres were markedly
less interested in novel male methods. Perhaps related to
familiarity with the IUD, long-duration methods were relatively
popular among Shanghai men: the lowest frequency of adminis¬
tration was most popular and an implant was rated as first
choice by 17%.
One potentially valuable area of information from acceptabil¬
ity studies such as this is the identification of barriers to
widespread usage of a method. Two relevant areas to novel
male methods are the need for semen analysis to confirm azoo-
or severe oligozoospermia, and the delay before adequate
suppression of spermatogenesis is achieved. The need for
semen analysis was regarded as acceptable by a small majority
in Cape Town, but by only 17 and 27% in the two Chinese
centres. These figures are lower than the proportions of men, '
even in the Chinese centres, who indicated that they would
use a male pill or injection. As the question of semen analysis
was raised towards the end of the questionnaire, it is possible
that if it had been included earlier, it might have reduced the
apparent acceptability of the methods. Men, however, were
told that there would be a delay of 3 months before the
methods would become effective in the introduction to the
questions on each method. This was also regarded as a
significant disadvantage to a novel method. It therefore appears
that both a delay in onset of effectiveness and a need for
semen samples would be significant barriers to the introduction
of novel male methods of contraception. These are also key
features of vasectomy, however, and do not preclude its
widespread use.
Partners' altitudes to novel methods were a strong influence
on acceptability to men, and the majority of men in all centres
agreed that decisions about family planning should be taken
jointly. This finding is in agreement with other studies in a
variety of settings (Keith et al., 1975; Davidson et al., 1985;
Grady et al., 1996; Drennam, 1998) and emphasizes the
importance of our finding of very positive attitudes to hormonal
male methods in a parallel study in women (Glasier et al.,
2000). The addition of further contraceptive options potentially
adds to the total of contraceptive use, and the female partner's
encouragement has been a major factor in men's willingness
to volunteer for prototype male contraceptive trials (Ringheim,
1995). This finding, from participants in mostly Western
urban locations of WHO studies, complements findings from
developing countries of the importance of women as the
principal sources of information about contraception for their
partners (Ringheim, 1993).
While acceptability is recognized to be culture specific,
failure to find new methods acceptable should not be attributed
to cultural bias until access to the method is observed to be
easy and appropriate education and information channels have
been used to best effect (Ringheim, 1993). However, the present
results suggest a major dichotomy between the acceptability of
hormonal male methods in the two Chinese centres compared
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to the other centres. The similarity in the responses to this
questionnaire between Hong Kong and Shanghai is despite
major differences in current contraceptive usage as well as in
economic/political terms, as this study was conducted shortly
before Hong Kong became part of the People's Republic of
China. The acceptability of novel methods among black Cape
Town men was relatively high despite the finding that they
had the lowest knowledge of current male methods, and is
encouraging as to the potential widespread applicability of
such methods.
Female-dependent methods have been the subject of consid¬
erable scientific advance, offering effective and male-independ¬
ent contraception. Recent advances in tire field of hormonal
male contraception provide models for the characteristics of
hypothetical preparations and although they remain experi¬
mental, the recent announcements of intent by major pharma¬
ceutical companies adds credence to their successful
development. The acceptability of potential male hormonal
methods of contraception was generally high but showed
significant variability between centres, determining factors
including cultural background and current contraceptive usage.
These results suggest that the current emphasis that men
should have greater involvement in family planning will be
substantiated when appropriate contraceptive methods are
made available.
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Would women trust their partners to use a male pill?
A.F.GIasier1-5, R.Anakwe1, D.Everington1,
C.W.Martin1, Z.van der Spuy2, L.Cheng3,
P.C.Ho4 and R.A.Andersonl
Contraceptive Development Network at 'Department of Obstetrics
and Gynaecology, Centre for Reproductive Biology, The University
of Edinburgh, 37 Chalmers Street, Edinburgh EH3 9EW, UK,
2Department of Obstetrics & Gynaecology, University of Cape
Town. Medical School, Anzio Road, Observatory, South Africa
7925, Shanghai Institute of Family Planning and Technical
Instruction, International Peace Maternity & Child Health Hospital,
China Welfare Institute, 145 Guangyuan Road, Shanghai 200030.
People's Republic of China and 4Department of Obstetrics &
Gynaecology, The University of Hong Kong. Queen Mary Hospital,
Pokfularn Road, Hong Kong
^o whom correspondence should be addressed at: Family Planning
& Well Woman Services, Edinburgh Primary Care NHS Trust,
18 Dean Terrace, Edinburgh EH4 1NL, UK
Despite a renewed interest in the development of hormonal
contraceptives for men, many discussions about the poten¬
tial acceptability of a 'male pill' end by speculating whether
women would trust their partners to use the method
reliably. To determine the views of women, we undertook
a survey of 1894 women attending family planning clinics
in Scotland (450), China (900) and South Africa (544). In
all centres over 65% of women thought that the responsibil¬
ity for contraception falls too much on women. More than
90% in South Africa and Scotland thought that a 'male
pill' was a good idea, with Chinese women (71 % in Hong
Kong and 87% in Shanghai) only slightly less positive.
Only 13% of the total sample did not think that hormonal
male contraception was a good idea and only 36 women
(2% of the total) said that they would not trust their
partner to use it. 78% of Scottish women, 71 % of Shanghai
women, and 78% of white women and 40% of black and
coloured women in Cape Town thought that they would
use the method. This survey should dispel the myth that
women would not trust their partners to use a 'male pill'
reliably and illustrates the potential market for the method.
Key words: hormonal contraception/male/women's attitudes
Introduction
Increasing emphasis on the role of men in reproductive health
has led to a renewed interest among scientists, funding agencies
and policy makers, in the development of hormonal contracept¬
ives for men [United Nations Family Planning Association
(UNFPA), 1994; Harrison and Rosenfield, 1996], Even in
countries where the prevalence of male methods (condom and
vasectomy) is low, the majority of men who have been surveyed
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claim to believe that they should take more responsibility for
contraception [Ringheim, 1993; United Nations Development
Programme (UNDP)/UNFPA/World Bank Special Programme
of Research, 1999], In surveys in which they have been
specifically asked, a significant proportion of men from both
developed and developing countries have expressed a will¬
ingness to use a hormonal method if and when it became
available (Ringheim, 1993).
Recognizing that contraceptive failure has far greater
personal consequences for the woman, many discussions about
the need for, and acceptability of, hormonal contraception for
men end by speculating whether women would trust their
partners to use a method reliably (Ringheim, 1993; Potts,
1996). As part of a programme of research on the development
of new contraceptive methods for men, we have undertaken
two separate surveys in a number of different cultural settings.
The attitudes of men towards a hypothetical hormonal contra¬
ceptive are to be published separately (Martin el al., 2000). In
this paper we report the findings of a survey designed to seek
the views of sexually active women and specifically to ask
whether they and their partner would use hormonal male
contraception if it became available.
Materials and methods
A total of 450 women aged 16-50 years attending family planning
clinics for contraceptive advice and supplies was recruited from each
of three centres in Edinburgh (UK), Shanghai and Hong Kong
(People's Republic of China). In a fourth centre in Cape Town (South
Africa), a larger group (n = 544 women) was recruited in order to
provide a representative sample of the three main ethnic groups,
black (n = 286), coloured (n = 151) and white (n = 107). In all
centres patients were unselected, and consecutive attendees were
invited to complete the questionnaire. In Hong Kong and Shanghai
no one refused to participate, in Edinburgh 18 women and in Cape
Town 16 women declined to complete the questionnaire, almost all
for lack of time. Recruitment took place during 1996 over 3 months
in Edinburgh, Shanghai and Hong Kong and over 7 months in Cape
Town. A simple questionnaire, piloted in a family planning clinic in
Edinburgh and translated into local languages, was administered by
a trained interviewer. Questionnaires were completed non-attributably
and sought information about demographic characteristics of the
interviewees, satisfaction with current contraception and attitudes
towards hormonal male contraception and its possible use. Local
ethical committee approval was obtained in all four centres.
Statistical methods
Descriptive analyses, including cross-tabulations of each question, by
centre were performed first. Associations between pairs of categorical
variables within centres were tested by y2-test.
© European Society of Human Reproduction and Embryology
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Table I. Demographic characteristics, current contraceptive use and response to the idea of hormonal contraception for men
Edinburgh Cape Town (n = 544) Hong Kong Shanghai
Black Coloured White
(n = 450) (n = 286) (n = 151) (n = 107) (n = 450) (n = 450)
Mean age (years) 27.6 30.0 29.2 28.0 31.3 30.9
% <20 18 15 14 4 11 2
% >40 4 11 9 4 14 12
% with higher 42 13 32 69 3 19
qualification"
% married/ 49 35 61 56 71 96
co-habiting
% with rcgulur 44 58 27 25 25 3
partner
% with children 31 80 72 25 67 65
Contraceptive method
% using oral contraception 72 9 47 72 28 4
% using injectable 4 90 48 22 7 0
% using IUD 3 0 1 0 10 36
% using condom 15 0 1 4 40 34
Other including NFF 2 I 2 1 7 II
None 5 0
'
2 I 8 15
% happy with methodb 64 93 84 79 59 44
% unhappyb 18 7 9 8 21 23
Male contraception 94 93 91 97 71 87
a good idea (%)
*An additional 15% of women in Edinburgh and 5% in Hong Kong were students; in other centres no more than 1% were students.
hOnly those women who recorded that they were currently using a method were asked this question.
IUD - intrauterine device; NFP = Natural Family Planning.
Results
The demographic characteristics of the respondents, together
with their current method of contraception, are shown in Table
1. There were marked differences between the centres. For
example 96% of women in Shanghai were married or cohabit¬
ing compared with only 49% in Edinburgh. The results of the
survey have therefore been analysed on a within-centre bpsis.
Women who were using a method of contraception at the
time of the survey were asked whether they were 'entirely
happy' with that method (Table I) and if not, why not. Only
44% of women in Shanghai said that they were happy with
their method, while in all other centres the majority of women
were happy (59-93%). The condom was the method associated
with the most dissatisfaction, with 48% of women in Edinburgh
who used it (15% of the sample), 31% in Hong Kong (where
40% of women used the condom) and 23% in Shanghai (34%
condom users) saying that they were unhappy. The main
reasons for dissatisfaction were failure of a method (mentioned
by 96 women, 58 of them condom users) and side-effects or
long term risks (mentioned by 117 women, almost half of
them in relation to oral contraceptives). A few women remarked
on the inconvenience of having to remember to take the pill.
Women were told by the interviewer that it was now possible
to produce a hormonal contraceptive for men which would
not interfere with male sexual function and which, if used
correctly, would be as effective as the female contraceptive
pill. In all four centres the great majority of women thought
that in principle this was a good idea (Table I). Asked why
they thought so, over 84% of these women in each centre
agreed that it would allow a more equal sharing of responsibility
for contraception. In Shanghai 39% of them thought a hormonal
method would be more effective than the male condom.
Women in Hong Kong were least likely to think that
hormonal contraception for men was a good idea (131 women
(29%) were either negative or unsure, Table 1], Fifty-eight
women in Shanghai (13%) and only 37 in Cape Town (7%)
and 28 in Edinburgh (6%) said they were unsure or did not
think it a good idea. Chinese women were most likely to be
concerned about associated side effects and health risks,
whereas women in Edinburgh and Cape Town were more
likely to say that they would not trust their partner to use a
hormonal method. Between 18% (Hong Kong) and 67%
(Shanghai) of these women said simply that they would not
want to rely on a hormonal male method. Very few women,
even in South Africa, were concerned about the spread of
sexually transmitted infections.
Women who currently had a partner were asked whether, if
a hormonal method for men was available, they would use it
either now or in the future. They were also asked whether
they thought their partner would use such a method and if so
which route of administration he might prefer. Responses are
shown in Table II. In Edinburgh, Cape Town (regardless of
ethnic group) and Shanghai one-third or more of women with
partners said that they would use a male hormonal method
immediately, whereas in Hong Kong only 13% of women
would do so. Asked if they would use the method at some
time in the future, the percentages rose to over 70% of white




Table II. Responses of women with current partners to the idea of hormonal contraception for men. Values are percentages of women giving each response
Edinburgh Cape Town (n = 486) Hong Kong Shanghai
Black Coloured White
(n = 416) (n = 267) (/i = 132) (n - 87) (« = 432) (n = 447)
Use now
Yes 38 33 36 45 13 33
No 23 29 30 21 44 25
Use in (he future
Yes 78 43 46 78 14 71
No 5 22 18 6 30 6
Would partner use it
Yes 69 48 53 79 28 56
No 12 33 24 8 30 17
Partner's choice of method
Doily pill 55 21 17 23 23 24
Monthly injection 32 39 40 51 22 41
Long-term implant 6 2 11 16 13 23
Don't know 7 38 32 10 41 13
-
Table III. Reasons why women who did not think a male hormonal contraceptive 'a good idea' fell this way. Values are percentages of women giving each
response
Edinburgh Cape Town Hong Kong Shanghai
Black Coloured White3
(n = 28) (/» - 21) (" = 13) ('» - 3) (n = 131) (n = 58)
Not trust partner 50 38 46 5 2
Health risks 21 0 23 60 95
Female responsibility if 21 29 15 5 16
method fails
Do not want to rely on 64 19 46 18 67
a male method
Infrequent intercourse 4 5 23 5 17
Concern about STD 11 0 15 5 0
"Only three white women in Cape Town did not think male hormonal contraception a good idea, one because of health risks and infrequent intercourse and
two because the responsibility for failure fell to the woman.
STD = sexually transmitted diseases.
The percentage for possible future use rose less markedly
among black and coloured women in Cape Town while in
Hong Kong women who would not use the method now would
not use it in the future either. Women in Edinburgh and in
Cape Town appeared confident that their partner would be as
happy as they themselves were to use a hormonal male
contraceptive at some time. In Shanghai, while 71% of
respondents felt that they would like to use the method
themselves at some time in the future, only 56% felt that their
partner would want to. In contrast, in Hong Kong women
seemed to feel that their partner would be more likely to want
to use a male hormonal method than they themselves.
Fifty-five per cent of women in Edinburgh felt that their
partner would be most comfortable taking a daily pill while a
monthly injectable was die most popular preparation in Cape
Town and Shanghai (Table II). A long-term implant was
considered the best mode of administration by only a few
women except in Shanghai where 23% thought that their
partner would feel most comfortable with an implant.
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Discussion
The idea of hormonal contraception for men appears to be
extremely popular. In all four centres, despite vastly differing
cultures, beliefs and personal contraceptive experience, more
than two-thirds of women thought it was a good idea. One-
third or more of women who currently had a partner, in all
centres except Hong Kong, said that they would use a hormonal
male method now, and more than 70% of women in Shanghai
and Edinburgh and white women in South Africa would use
it in the future. Black and coloured women in South Africa
were somewhat less likely than white women to think they
they might use the method; nevertheless 40% of women with
partners believed that they and their partner would use a
hormonal male contraceptive at some time. Although they
liked the idea, and although 28% of women in a relationship
thought that their partners would use it, very few women in
Hong Kong thought that they would ever rely on a hormonal
method for men.
Despite what has been suggested, lack of trust really did
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not seem to be much of an issue. Only 36 women (2% of the
total sample) said that they would not trust their partner to
use hormonal contraception (Table III). Only among black
women in South Africa was lack of trust the most important
reason for not liking the idea. Even in Hong Kong, where the
idea of the method was least popular, only seven women said
that they would not trust their partner to use it. In Shanghai
the main reason for not liking the method was because of fear
of side-effects. Hormonal methods are not widely used by
women in China, with fear of side-effects accounting to some -
degree for their unpopularity. While we did not ask all women
directly whether they would trust their partner to use a
hormonal method we must assume that, if they foresaw that
they would use such a method now or in the future, they
would trust their partner.
Although there have been a number of studies in which
men have been asked their views of hormonal methods for
themselves (including our own in the same four settings
(Martin el al„ 2000), we know of only two other studies which -
have sought the views of women. In a study undertaken in the
late 1960s in the USA, Bardwick (Bardwick, 1973) interviewed
107 women, some attending a family planning clinic (FPC)
and others students from the University of Michican. Women
attending the FPC were planning to start using the combined
oral contraceptive pill. The interviews were designed to predict
psychological and psychosomatic responses to pill use. One
question asked 'if there was a pill for men like the pill
for women, who would you prefer to be responsible for
contraception'? Seventy-two per cent of women said they
wanted to be in control of contraception themselves, 16%
preferred the man to take responsibility while only 12% felt
that responsibility should be shared. Women were not asked
anything more about male methods and were not asked
specifically if they would use hormonal male contraception.
A great deal has changed since the 1960s, however, and the
responses contrast with a later study also carried out in the
USA. In a randomized telephone survey of 1005 Americans
(502 women) aged 3=18 years, more than 70% of both men
and women said that they thought men should play more of a
role in using contraception. This study was undertaken by the
Henry J.Kaiser Family Foundation (HJKFF, 1997) and was
published in 1997. Forty-five per cent of women thought that
men would take a 'male pill1, fewer thought that they would
use injectables or implants, while 36% of women in the survey
doubted that men would use a hormonal method at all. The
apparent lower popularity of a hormonal method for men in
the USA compared with tire only developed country in our
survey (Scotland) may reflect the different populations sur¬
veyed since women in our study were currently using contra¬
ception, actively seeking advice or supplies and were asked
whether they thought their partner, rather than just men in
general, would use a method. On the whole many women
have rather cynical views of men in general which do not
reflect their views of individual men — especially their partner.
The choice of route of adminstration of a hormonal method
for men varied between centres and probably reflects familiarity
with the most popular delivery system for hormonal contracep¬
tion for women in each centre — pills in Scotland and Hong
Kong, injections in South Africa. In Shanghai, where hormonal
contraception is not very widely used, an injectable method
was favoured.
Despite the widespread belief that women would not want
a 'male pill' because they would not trust their partners to use-
it reliably, our study suggests that a hormonal method for men
would be extremely popular and that many women, regardless
of culture, would trust their partners to use it. Presently a male
pill is likely to be less popular in the Far East than in the
West but, despite what many might predict, it may certainly
have an important role in Africa. More choices of contraceptive
methods for men will allow increasing numbers of men in all
countries to accept more responsibility for reproductive health,
and certainly their womenfolk are keen that they should do
so. Approval of, and intention to use, a hypothetical method
of contraception is unlikely to be accurate in predicting
behaviour when such a method becomes available. However,
even if the number of potential users is overestimated by a
factor of 10, a hormonal method for men would still represent
a greater share of the market than contraception implants,
injeclablcs or the progestogen-only pill in the UK, and no
one would dream of questioning their important role in
contraceptive choice.
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Noncompliance among a group of women
using a novel method of contraception
Dharani K. Hapangama, M.B., Anna F. Glasier, M.D., and David T. Baird, D.Sc.
Contraceptive Development Network, Department of Reproductive and Development Sciences, The University
of Edinburgh, Centre for Reproductive Biology, Edinburgh, United Kingdom
Objective: To compare the incidence of noncompliance measured objectively by a home use fertility monitor
with the traditional self-reported incidence of compliance in a study of a new method of contraception.
Design: Prospective cohort study.
Setting: A large family planning clinic in Edinburgh.
Paticnt(s): Thirty-two healthy women who took part in a trial assessing the efficacy of a novel method of
contraception involving accurately timed administration of a single dose of mifepristone.
Intervention(s): Mifepristone was administered orally and a blood sample was collected on the same day.
Main Outcome Measurc(s): Percentage of missed tests detected by the monitor against the self-reported
percentage during the critical period.
Rcsult(s): Women failed to perform 24.2% (95% confidence interval, 16.5-31.5) of the tests in the 162 cycles
analyzed. They missed tests at an absolutely vital time for contraceptive efficacy in 42% of cycles according
to the monitor while admitting to missing tests in 14.8%. Poor compliance was associated with younger
women, those who discontinued the study before completion, and cycles in which women were not relying on
the contraceptive method.
Conclusion(s): The use of microelectronic monitoring systems may improve our understanding of the extent
of patient noncompliance, providing objective information that no other monitoring technique can produce.
This understanding provides the opportunity to make the optimum use of potentially effective treatments while
validating research evidence. (Fertil Steril® 2001 ;76:1196-1201. ©2001 by American Society for Reproduc¬
tive Medicine.)
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Since the first woman on earth chose to
contradict the instructions ofher Provider in
the Garden of Eden, expecting her descendants
to comply perfectly with a contraceptive regi¬
men may seem rather unrealistic. However,
noncompliance with a particular contraceptive
method is linked with an increased risk of
unintended pregnancy (1). Conventionally, it
has been assumed that the users of contracep¬
tion are highly motivated because the conse¬
quence of noncompliance —pregnancy—is so
obvious, and so significant. Studies involving
organ transplant recipients have shown, how¬
ever, that no consequence of poor compliance
is severe enough—not even the rejection of a
transplanted kidney—for all patients to reliably
follow their prescribed regimen (2).
Poor compliance—in both clinical practice
and research—is associated with a number of
factors. Though several patient characteristics
(e.g., age, education, socioeconomic back¬
ground) (3-5), characteristics of the treatment
regimen (e.g., frequency of dosing, side ef¬
fects) (6-8), and outcome characteristics (e.g.,
treatment of incurable or terminal illnesses) (9)
have been associated with nonadherent behav¬
ior, there are no reliable and universally appli¬
cable predictors of noncompliance. In addition,
there is no gold-standard measurement for pa¬
tient compliance (10).
Prevalence of noncompliance ranges from
0-96.6% in oral contraceptive pill users (11—
13). Although extremely common, there is a
dearth of information available on patient non¬
compliance with die use of different contracep¬
tive methods. What data exist commonly come
from self-reporting. When undetected, poor
compliance can invalidate results of efficacy
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studies (14, 15), yet it is commonly overlooked in clinical
research (16).
We observed behavior of 32 women who took part in a
trial assessing the efficacy of a novel method of contracep¬
tion (17). The women took 200 mg of mifepristone 2 days
after the midcycle LH surge (measured in urine) as a once-
a-month contraceptive pill. Mistimed administration of mife¬
pristone can disrupt the menstrual cycle and can also leave
the women at risk of conception. A home use fertility mon¬
itor that could store data on daily testing events was used to
time the administration of mifepristone. Although it made
minimal demands on the users, the method provided objec¬
tive, long-term data on their routines. Because investigators
saw participants once each cycle throughout the study, we
were able to compare the results of this method with the
traditional self-reported incidence of compliance.
MATERIALS AND METHODS
Data were collected during a study assessing the feasibil- -
ily of administering mifepristone as a once-a-month contra¬
ceptive pill, and detailed study methodology has been re¬
ported elsewhere (17). Thirty-two sexually active women
(age range, 18-39 years) were enrolled from a large family-
planning clinic in Edinburgh. (The mean body mass index
was 24 ± 4.3, and 66% were nonsmokers.) All subjects gave
written informed consent to participate, and the Lothian
Research Ethics Committee approved the study. Data were
collected from a total of 178 cycles, with each subject
contributing between one and eight cycles. It was not pos¬
sible to retrieve compliance data from the monitors in 28 of
the study cycles because of infrequent downloading from the
monitor and lost or broken devices.
The study started on day 1 of the menstrual period after
screening and lasted for up to eight consecutive menstrual
cycles. The subjects were relying on once-a-month treatment
with mifepristone as their sole method of contraception
during 150 of the cycles analyzed. In addition, it was pos¬
sible to retrieve data from a further 12 cycles during the
study suspension period, during which women did not rely
on our method for contraception but only used the monitor.
During the cycles in which mifepristone was administered,
the timing of mifepristone depended on detection of the LH
surge, which in turn depended on compliance with daily
urine testing.
Procedure
All subjects were provided with a home use fertility
monitor (Unipath, Bedford, UK). The system comprises a
hand-held monitor and disposable dual-assay urine test
sticks and is used to detect simultaneously LH and eslrone-
3-glucuronide levels in early-morning urine. The system
delineates three levels of fertility (low, high, attd peak fer¬
tility) according to the optical signal changes detected. At the
start of each menses, the subjects pressed the m button on
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their monitors to initiate that cycle of use at a time suitable
for testing the first urine of the day..
For the rest of the month, the subjects were required to
consult the monitor display each morning (3 hours on either
side of the time when the m button was set) to determine
whether they needed to perform a test that day. Without this
6-hour time window, the system would not accept a test. The
monitor requests one test every day for up to a total of 10 or
20 tests, depending on the length of the woman's cycle and
the timing of her LH surge. Embedded software within the
monitor collects, analyzes, and stores data for several
months.
The correct way to use the monitor (including the impor¬
tance of the testing window) was demonstrated to all sub¬
jects at the time of recruitment, and written information was
given. Subjects were advised to contact the investigator
immediately if they were not able to perform a test during a
critical period. The investigator was available by telephone 7
days a week.
In each cycle, subjects were reviewed by the investigator
monthly, on day LH+2. A sample of venous blood was
collected before taking the tablet of 200 mg mifepristone and
was later used for the analysis of progesterone. The infor¬
mation collected by the monitor was later analyzed using
special computer software. The estimated day of LH peak for
each month was calculated based on information from all the
previous cycles monitored. If an LH surge was not detected
either within 3 days after the anticipated day of LH peak or
by day 19 of the cycle, a blood sample was taken for rapid
serum progesterone assay, and the information from the
monitor was downloaded. Mifepristone was administered
only if the woman was at risk of pregnancy (i.e., had been
sexually active) and if the progesterone level was >5nmol/L.
All subjects kept a menstrual record card, recording all
vaginal bleeding experienced during the study and the days
on which they had sexual intercourse. They also marked the
day of the LH surge as identified by the device and the day
of taking the study medication.
The following definitions were created for the purpose of
the study. The period of time between the calculated earliest
day an LH peak was likely to occur (based on the usual cycle
length and the day of the LH surge in previous cycles) and
the day of the actual LH surge >in each cycle was defined as
the critical period for each patient. The fertile period of the
cycle was defined as 3 days before until 2 days after the
urinary LH surge (LH—3 to LH + 2). Exposure cycles were
cycles in which women reported having sexual intercourse at
least once during the fertile period. Noncompliance was
defined as a urine test that was requested by the monitor but
missed.
Statistical Methods
Some of the compliance data were summarized for de¬
scriptive purposes using numbers of cycles or tests as de¬
ll 97
330
nominators. However, statistical inference was carried out
on data aggregated to patient level, to take account of pos¬
sible heterogeneity in behavior among patients that might
have invalidated analyses using data from individual cycles
or tests. Thus, percentages of tests missed were calculated
for each patient, and these were tested for association with
demographic data using Pearson correlations. Testing was
done on data aggregated to patient level. Thus, for example,
correlating each patient's age with the percentage compli¬
ance over all her cycles tested the association between age
and compliance. Similarly, percentages of tests missed at
different stages of the cycle, and when on and off the
treatment regime, were compared by paired /-tests. A two-
sample /-test was also used to compare the percentage of
tests missed in patients who dropped out and those who did
not.
RESULTS
One hundred sixty-two cycles were analyzed, of which
150 were study cycles. Data collected during the 12 cycles „
during which subjects were using a barrier method through¬
out the cycle and did not receive mifepristone were analyzed
separately.
Ill total, 2,013 tests were requested by the monitor during
the 162 cycles analyzed (12.4 tests per cycle, 95% confi¬
dence interval [CI], 11.8-13.0), and 494 were missed
(24.2%; 95% CI, 16.5-31.5). On average, three tests (95%
CI, 2.4-3.6) per cycle were missed.
Compliance During the Intention-(o-Treat
Cycles
During the 150 cycles in which women were relying on
the study method as their only contraception, a total of 1,816
tests was requested by the monitor, and 411 tests were
missed (22.6%; 95% CI, 15.2-30.1).
Compliance Before and After Identifying the
Peak
In the days before the women knew an LIT surge had
occurred, 23% of the requested tests were missed (95% CI,
16-30; 260 of 1,160). Women were not more likely to miss
tests before the LH surge than after it (/ = 0.57, NS).
Concordance of Monitor Data With the Self-
Reported Data
In 68 cycles (42%), women failed to test at all on a day of
the cycle, which was critical to the accurate detection of an
LH surge. In 27 of these cycles, the monitor did not delect ait
LH peak, in the remaining 41 cycles, despite critical tests
being missed, the monitor did detect an LH peak. Women
admitted to not performing tests in 24 cycles (14.8%). In the
other 44 cycles, women did not report missed tests and only
admitted to it once the investigator showed the downloaded
monitor data to them.
Some women actively fabricated the information that they
reported to the investigator. In one of these cycles, when
contacted, a woman declared detecting an LH peak on a day
(day 13 of the cycle) when she had not performed a lest at
all. Another woman performed the tests correctly and iden¬
tified an LH peak on day 13 but forgot to inform the
investigator and failed to obtain the mifepristone tablet as
per protocol. When contacted on day 19 of the same cycle,
she claimed that the monitor ltad not detected an LH peak.
Compliance During the Critical Days
Noncompliance with urine testing as monitored by the
system was significantly lower during the critical period
(15.6%; 95% CI, 9.5—21.7) when compared with during the
noncritical days (27.5%; 95% CI, 17.9-37; paired /-test, / =
3.64, P<.01). The self-reported percentage of missed tests
during the critical period was 2.7% (95% CI, 1.0-4.3),
which was significantly lower than that detected by the
monitor (/ = 4.48, PC.OOl).
Compliance During the Study Suspension
Interval
After a pregnancy that occurred because of a failure in
detecting a LH peak, the study was suspended for a month.
However, some women continued to use the monitor only,
while using a barrier method for contraception. Therefore, it
was possible to retrieve data from the monitors for 12 cycles
in which the women were not using our method as their
contraceptive.
In six of these 12 cycles, the monitor was not able to
identify an LH peak because of its imperfect use. During this
period, a significantly high percentage of tests (41.2%; 95%
CI, 22.4-60.0) were missed when compared with the study
cycles (22.6%; 95% CI, 15.2-30.1; / = 2.9. P=.015).
Compliance and Sexual Activity
There was no correlation between the frequency of sexual
intercourse per cycle and the number of missed tests per
cycle (correlation coefficient was 0.01). The percentage of
missed tests were compared between the exposure and non-
exposure cycles in 12 women who had at least one exposed
and one unexposed cycle. There was no significant differ¬
ence (paired /-test, t = 0.06, NS; 95% C'.l for differences
between exposed and unexposed, -8.3 to +7.8) in compli¬
ance during exposed and nonexposed cycles.
Demographic Features and Compliance
Age was negatively correlated with the percentage of
missed tests—younger women missed more tests (r =
-0.36, /><.Q5). There was no apparent relationship between
compliance with the method and the number of pregnancies,
number of previous abortions, or number of living children.
Compliance Among Dropouts
We analyzed cycle data from the seven women who
discontinued the study before completion. They missed a
significantly higher percentage of tests (44.4%) when com¬
pared with the other 25 women who completed the study
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Information collected from the monitor and the diary card from a woman with a 31-day cycle in which the LH surge was
identified. Mifepristone was administered on day 20 (LH+2). (A), Information downloaded from the monitor. Level of fertility
displayed to the woman on each day of the cycle: open block, low fertility; partially closed block, high fertility; closed block with
circle, peak fertility. Data on testing events appears as a narrower bar underneath: open block, test performed; closed block,
test missed. (B), Data recorded on the diary card by the woman (self-report). B, days of vaginal bleeding; check mark, tests
done during the critical period; X, days in which sexual intercourse occurred; T, day when mifepristone was taken. (C),
Downloaded information on signal levels of LH and estrone-3-glucuronide (E3G) levels. Closed circle, LH; open square, E3G;
M, missed tests. Note that on several days (comparing panels A and B), the woman reported performing the test (check mark)
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(17.4%; 95% CI of the differences between the two percent¬
ages, 10.6-43.3; t = 3.39, P-.002). The dropouts missed
tests on a critical day in 16 of the 22 cycles, although they
admitted to missing tests in only four. Therefore, the self-
reported incidence of noncompliance during the critical pe¬
riod was 18.1%, whereas the monitor-detected incidence was
72.7%.
DISCUSSION
The home use fertility monitor offered us an important
methodological advance in providing reliable data on the
incidence and the magnitude of noncompliance with the
contraceptive method studied and on information about ex¬
actly when the imperfect use occurred. We sought to achieve
significantly high compliance rates with employing this
monitoring system in a contraceptive regimen, which ap¬
peared to be acceptable to women (18, 19). Women were
counseled at the start of the study regarding the importance
of performing urine tests accurately to identify the time to
administer mifepristone. They were aware that if mifepris¬
tone was not taken, they would be at risk of pregnancy.
Because the teratogenic effects of mifepristone are not
known, women considering participation in the study were
advised that if pregnancy occurred, they should consider
termination. Despite this, the information collected from the
monitor demonstrates that women failed to perform 24.2%
of the tests in the 162 cycles analyzed. Moreover, in 42% of
tlje cycles, women missed tests during a day that an LH
surge was likely to have occurred, in other words, at an
absolutely vital time for contraceptive efficacy.
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FIGURE 2
Information collected from the monitor and the diary card from a 35-day cycle in the same woman as illustrated in Figure 1.
As a consequence of missed tests, the monitor did not identify the LH surge, and mifepristone was not administered. (A),
Information downloaded from the monitor. Level of fertility displayed to the woman on each day of the cycle: open block, low
fertility; closed block, high fertility. Data on testing events appears as a narrower bar underneath: open block, test performed;
closed block, test missed. (B), Data recorded on the diary card by the woman (self-report). B, days of vaginal bleeding; check
mark, tests done during the critical period; X, days in which sexual Intercourse occurred. (C), Downloaded information on signal
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Although noncompliance is common, by inviting only a
selected group of women who appeared to be motivated and
committed, we sought to exclude those who might be poor
compilers. Interestingly, the medical profession is reportedly
poor in identifying noncompliers (20). Users of our method
were reasonably young (mean age, 30 years) and were healthy.
The serious outcome of noncompliance (pregnancy) was rare.
Women may have found the daily requirement for urine testing,
using the monitor on a long-term basis, to be complicated or
inconvenient. Side effects of the method (although fewer than
in most other methods available) may not have been acceptable
to them, or they may not have had faith in the effectiveness
of the method although this seems unlikely because they did
not revert to condoms. Considering these odds, it is not
difficult to infer why compliance problems were frequent.
Common sense suggests that with increasing experience,
the women may trivialize the need for testing on days during
which an LH surge was unlikely to have occurred. All women
were made aware of the critical period for testing urine at the
stait of the study, and as expected, women missed fewer tests
during this period. Incomplete understanding of how to be
compliant with a regimen hits been suggested as a common
reason for poor compliance (21). Women in our study were
given detailed verbal and written information on using the
monitor at the start of the study. The importance ofaccurate use
of the device according to manufacturer's guidelines was
stressed at each monthly visit. Because there was no significant
difference in the percentage of missed tests between the first
study cycle and the hist study cycle, it is difficult to support
the suggestion that in the earlier cycles, women were less
confident about how to use the method or more confident in
their ability to guess the correct time for testing (22).
There was a highly significant difference between the patient
self-reported percentage of missed tests (2.7%) and that de¬
tected by the monitor (15.6%) during the critical period. Figures
1 and 2 illustrate this discrepancy during two cycles contributed
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by one woman. This discrepancy was even greater among the
seven women who discontinued the study before completion
and is consistent with results of previous studies that reported
significant overestimation of compliant behavior with self-
regulation (23). Patients tend to tell doctors what they think
the doctors wish to hear. If they assume that doctors perceive
patient nonadlierence as a judgmental disappointment, they
may feel guilty and fail to report noncompliance.
Although older women tended to miss fewer tests, the other
demographic characteristics such as parity, previous abortions,
number of living children, and educational background did not
correlate with the number of missed tests. Neither did frequency
of sexual activity or exposure to the risk of pregnancy
correlate with the missed tests. However, because the infor¬
mation about sexual activity was only collected by self-
reporting, this association should be accepted with caution.
Most investigators work on the assumption that a patient
who complies with one aspect of a clinical protocol (e.g.,
attending the clinic as directed) also adheres to all other aspects
of the study, though this might not always be the case. The *
monitor supplied data on daily testing of urine, which was only
one part of the contraceptive method. We cannot infer from
those data how well the women in our study complied with the
rest of the protocol, such as recording daily events (sexual
intercourse, vaginal bleeding). With no means of testing this,
for validity of our results, we had to depend on our volunteers
being truthful. Therefore, in the future, we have 110 other option
but to work toward forming a true therapeutic alliance with our
volunteers and to come to an agreement with our patients rather
than to impose a prescription or a protocol upon them.
In conclusion, the use of microelectronics monitoring
systems such as the home use fertility monitor may improve
our understanding of the extent of the problem of patient
noncompliance,.providing precise objective information that
no other monitoring technique can produce. This understand¬
ing will empower us as health care providers to adopt a
no-fault approach to behavior relating to noncompliance and
establish "a tailored consensual regimen" with the user that
she is able to adhere to (24). This provides the opportunity to
make the optimum use of potentially effective treatments
and legitimate research evidence. Perhaps a small price to
pay for such a return!
Acknowledgments: The authors thank Unipath Ltd. for the provision of
monitors and data collected from the monitors, Rob Elton, Ph.D., for his
assistance and advice on statistics, Mrs. Ann Mayo, S.R.N., for helping with
the recruitment of patients, and Mrs. Martha Urquhart for laboratory assays.
References
1. Rosenberg M, Wnugh MS, Long S. Unintended pregnancies and misuse
and discontinuation of oral contraceptive. J Rcprod Med 1995;40:355—
60.
2. Rovclli M, Palmeri E, Bartus S, Hull D, Schweizer R. Non-compliance
in organ transplant recipients. Transplant Proc 1989;21:833-4.
3. Mcichcnbaum D, Turk DC. Facilitating treatment adherence: a.practi¬
tioner's guidebook. New York: Plenum Press, 19S7.
4. Potter LS. Oral contraceptive compliance and its role in the effective¬
ness of the method. In: Cramer JA, Spilker B, eds. Patient compliance
in medical practice and clinical trials. New York: Raven Press. 1991:
195-231.
5. Rapoff MA, Barnard MU. Compliance with pacdiatric medical regi¬
mens. In: Sackett DL, Haynes RB, eds. Compliance with therapeutic
regimens. Baltimore, MD: John Hopkins University Press, 1986:73-98.
6. Puller T, Birtwcll AJ, Wiles PG, Hay A, Fcely MP. Use of a pharma¬
cologic indicator to compare compliance with tablets prescribed to be
taken once, twice, or three times daily. Clin Pharmacol Ther 1988;44:
540-4.
7. Rapoff MA. Compliance with treatment regimens for paediatrics rheu¬
matic disease. Arthritis Care Res 1989;2:S40-7.
8. Cromer BA, Steinburg K, Gardner L, Thornton D, Shannon B. Psy¬
chological determinants of compliance in adolescents with iron defi¬
ciency. Am J Dis Child 1989;143:55-8.
9. Spilker B. Methods of assessing and improving patient compliance in
clinical trials. In: Cramer JA, Spilkcr B, cds. Patient compliance in
medical practice and clinical trials. New York: Raven Press, 1991:37-
56.
10. Rudd P. In search of the gold standard for compliance measurement
[editorial]. Arch Intern Med 1979;139:627-8.
11. Wheblc AM, Street P, Whcble SM. Contraception: failure in practice.
Br J Fam Plann 1981;7:41-4.
12. Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic study of
the ovarian suppressive activity of a low dose triphasic oral contracep¬
tive during correct and incorrect pill intake. Am J Obstct Gynecol
1989;161:1159-62.
13. Molloy BG, Coulson KA, Lee JM, Watters JK. "Missed pill" concep¬
tion: fact or fiction? Br Med J 1985;290:1474-5.
14. Probstficls JL, Russell ML. Insull W, Yusuf S. Dropouts from a clinical
trial, their recovery and characterization: a basis for dropout manage¬
ment and prevention. In: Shumakcr SA, Schron EB. Ockene JK, eds.
The handbook of health behaviour change. New York: Springer, 1990:
376-400.
15. Urquhart J. Non-compliance: the ultimate absorption barrier. In: Prcs-
cott LF, Nimmo WS, eds. Novel drug delivery and its therapeutic
application. New York: Wiley, 1989:127-37.
16. Dahlstrom B, Eckernas S-A. Patient computers enhance compliance
with completing questionnaires. In: Cramer JA, Spilker B, cds. Patient
compliance in medical practice and clinical trials. New York: Raven
Press, 1991:233-40.
17. Hnpangama DK, Brown AH, Glasier AF, Baird DT. Feasibility of
administering mifepristone as a once a month contraceptive pill. Hum
Reprod 2001;16:1145-50.
18. Rimmer C. Horga M, Ccrar V, Alder EM, Baird DT, Glasicr A. Do
women want a once-a-monlh pill? Hum Rcprod 1992;7:608-11.
19. Glasicr AF, Smith KB, Cheng L, Ho PC, van der Spuy Z, Baird DT. An
international studv on the acceptability of a oncc-a-month pill. Hum
Rcprod 1999;14:3018-22.
20. Gilbert JR. Evans CE, Haynes RB, Tugwell P. Predicting compliance
with a regimen of digoxin therapy in family practice. Can Med Assoc
J 1980;123:119-22.
21. Rosenburg MJ, Waugh MS, Meehan TE. Use and misuse of oral
contraceptives; risk indicators for poor pill taking and discontinuation.
Contraception 1995;51:283-8.
22. Lusher TF, Vclter H, Siegcnthaler W, Velter W. Compliance in hyper¬
tension: facts and concepts. J Hypcrtcns l985;3(Suppl I ):3—9.
23. Potter L, Okiey D, de Leon-Wong E, Caneonar R. Measuring compli¬
ance among oral contraceptive users. Fam Plann Perspcct 1996*28:
154-8.
24. Fink DL. Tailoring the consensual regimen. In: Sackctt DL, Hayncs
RB, cds. Compliance with therapeutic regimens. Baltimore, MD: John
Hopkins University Press, 1976:110-8.
FERTILITY & STERILITY® 1201
Therapeutic termination of
pregnancy
Anna Glasier bscmd frcog
. - R, 1 \ ,1 ■:
Introduction
Abortion is common. It has been
estimated that 50 million
abortions occur worldwide
annually - 40% are illegal and
around 20 million unsafe.
Abortion accounts for between
60 and 120 000 maternal deaths
each year (20% of total maternal
deaths); almost all are in
developing countries and almost
all arc preventable.
Abortion rates are usually
expressed as the number of
abortions per 1000 women of
reproductive age (15-44 years).
Worldwide the average abortion
rate is thought to be 32-46/1000
and 10-30/1000 in developed
countries. There are wide
variations in abortion rates with
the lowest being found in the
Netherlands (5/1000) and the
highest in parts of the former
USSR (186/1000). in 1990, in
the USA and UK, the rates were
24/1000 and 15.8/1000,
respectively.
Abortion rates are related to
contraceptive prevalence.
Countries with low contraceptive
prevalence tend to have higher
rates than those where
contraceptive use is widespread.
In a recent review of the subject,
Kulcyzyki and colleagues (1]
point out that 'no society has
achieved low fertility without
recourse to abortion'. Abortion
is an intrinsic element of fertility
regulation and, as contraceptive
prevalence rises in developing
countries, so eventually abortion
rates fall. However, even in
countries where contraceptive
prevalence is high and couples
have access to methods with low
failure rates, abortion is still
common. In the UK, where
contraception is free ofcharge
and without consultation fees, it
has been estimated that 47% ofall
pregnancies are unintended and
43% of these are terminated [2],
amounting to one in five
conceptions ending in an
abortion. In England and Wales, a
woman's average lifetime risk of
abortion was calculated by the
UK Dirth Control Trust to be
43% based on 1995 figures.
After the 1967 Abortion Act in
England and Wales, there was a
rapid rise in tire abortion rate
which reached a plateau in the
late 1980s. Since then there has
been a gradual rise in the rate
each year until 1993 when a small
downward trend began. In 1994,
166 876 abortions were
performed in England and Wales,
a 1.1% fall compared with 1993.
However, since 1972 the
proportion ofabortions to
conceptions has remained
constant at 8% for married
women and 37% for single
women [3]. In 1996, England and
Wales witnessed an 8.3% rise in
abortions compared with 1995
(Figure 25.1). The rise was
attributed to the 'pill scare' of






The risk ofabortion is related to
age, parity, ethnicity and
socioeconomic status. Cultural
values, laws and policies obviously
also play a role. In Western
countries the peak age for
abortion is 20 and the tendency
for young women to be most at
risk ofabortion is universal.
Women over the age of35 are
also more likely to have a
pregnancy terminated, perhaps
because of the catastrophic
domestic and medical
consequences ofunplanned
pregnancy for many women and
the decline in the prevalence of
effective contraception among
this age group.
Marital status also has an effect
on abortion risk. In Europe, most
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Fig. 25.1 Abortion rates in England and Wales 1968-1996.
unmarried. In England and Wales
in the early 1990s, eight
pregnancies were terminated for
every 100 births among married
women compared with 52 per
100 births among unmarried
women. In contrast, in Asia, most
women are married, while in
Africa and Latin America, slightly
more married than unmarried
women are at risk. The effect of
parity is closely related to marital
status.
Although data on
socioeconomic status are scarce,
in general it is true to say that
women who are better educated
and those who live in urban areas
are most likely to undergo
abortion. In a recent Scottish
survey, Smith and co-workers |4|
demonstrated that unplanned
pregnancies are commoner
among teenagers who live in
socially deprived areas than
among teenagers from more
affluent areas, who, when they do
conceive, are more likely to have
their pregnancy terminated than
their economically deprived
peers. In the USA, non-Whites
are nearly three times more likely
to have a therapeutic abortion,
while in the Netherlands,
immigrants are significantly more
at risk than Dutch women.
With the legalization of
abortion and improvements in
service delivery, the average
gestation at which abortion is
performed has fallen. Figures may
be misleading, however, since in
some countries, abortion may be
illegal after,12 weeks, while
elsewhere, although legal, it may
be much more difficult to obtain
after the first trimester.
Legal issues
From the mid-19th to the mid-
20th centuries most developed
countries had restrictive or very
restrictive abortion laws.
Concern about the harmful
effects ofillegal abortion led to
liberalization of the laws.
Abortion became legal for 'social
reasons' in the USSR in 1920 and
in Iceland, Sweden and Denmark
in the 1930s, with almost all
developed countries, together
with China and India, following
in the 1960s and 1970s. In the
USA, access to abortion, at least
during the first trimester, became
a constitutional right in 1973.
More recently, a swing towards
less liberal attitudes and laws has
occurred in the USA, and in
some central and eastern
European countries, particularly
Poland and Hungary. Most
developing countries have
restrictive abortion laws. In
Bangladesh, while abortion is
illegal, menstrual extraction is
available in government clinics up
to 8-9 weeks' gestation as long as
the pregnancy has not been
confirmed.
It has been estimated that 63%
ofwomen in the world have
access to abortion on request,
12% on broad medical grounds
only, while 25% ofwomen must
continue the pregnancy unless
their life is endangered. Most
countries in which abortion is
legal require assessment and
agreement by at least one doctor,
although this may change in the
future at least for abortions in the
first trimester. In South Africa,
recent abortion legislation does
not require agreement by a
doctor for pregnancies of less
than 8 weeks' gestation.
Legalized abortion does not
guarantee access to safe abortion.
In some countries, such as India,
services may be inadequate or too
expensive to meet the demand.
In the USA, 84% ofcounties have
no specialist medical provider of
abortion services. In contrast, in
Brazil, where abortion is illegal, it
is available in clandestine but safe
clinics to women who can afford
to pay. In the UK, the law defines
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specific indications for abortion
which reflect the reasons why a
woman finds herselfwith an
unwanted pregnancy. The 1967
Abortion Act and its amendment
in the Human Fertilisation and
Embryology Act of 1990, states
that abortion can be performed if
two registered medical
practitioners acting in good faith,
agree that the pregnancy should
be terminated on one or more
of the grounds shown in Box
25.1.
The 1990 amendment reduced
the upper limit from 28 to 24
weeks' gestation for clauses C. and
D, reflecting the lowering of the
limits of fetal viability resulting
from advances in neonatal care. It
also included selective reduction
in multiple pregnancy cases and
authorized the Secretary ofState
for Health to licence premises for
the sole purpose ofproviding
medical termination of
pregnancy.
The 1967 Abortion Act does
not apply to Northern Ireland,
where abortion is only legal
under exceptional circumstances,
e.g. to save the life of the mother.
The law recognizes that some
doctors have ethical objections to
abortion. Doctors who do have
objections should refer women to
another colleague who does not
hold similar views.
Adolescents
One-fifth of the world's
population is aged between 10
and 19 years, and in some
developing countries the
majority of the population is
under 20 [5]. Everywhere age at
first intercourse is falling, while
age at marriage is increasing. As a
result, teenage pregnancy is
becoming common and is widely
regarded in many countries as a
significant sociontedical problem.
In the USA, one million women
under 20 become pregnant each
year and 82% of these pregnancies
are unintended. In Kenya, the
percentage ofpregnancies among
15-19-year-olds which are
mistimed or unwanted is 47%
among married women and 74%
among those not married.
Young people are less likely to
use contraception because they
do not expect to have sex, do not
know about contraception, lack
access to it or lack the ability or
Box 25.1 Clauses under which abortion is legal in the UK
A. The continuance of the pregnancy would involve risk to the life of
the pregnant woman grpaterthan if the pregnancy were
terminated.
8. The termination is necessary to prevent grave permanent injury to
' " the physical or mental health of the pregnant woman.^ ~~« >
C. The pregnancy has not exceeded its 24th week and the continuance
of the pregnancy would involve risk, greater than if the pregnancy
were terminated, of injury to the physical or mental health of the
'■
. pregnant woman.
D. The pregnancy has not exceeded its 24th week and that the
A: continuance of the pregnancy would involve risk, greater than if the
pregnancy were terminated, of injury to the physical or mental
k:'health of the existing child(ren) of the family of the pregnant
■ woman.
E. There.js substantial risk that if the child were born it would suffer
. from such physical or mental abnormalities as to be seriously
handicapped.
power to make decisions. In
developing countries, adolescents
are more likely to suffer
pregnancy-related complications
and to die in childbirth than
women in their 20s. Abortion-
related complications and deaths
are also thought to be more
common among adolescents than
older women. In many countries
unwanted pregnancy in an
adolescent presents problems
with the issue ofconsent, since
the law may require parental
consent for the procedure.
However, in the UK, if the
termination is lawful, consented
to by a competent patient and if
considered in the teenager's best
interests, then a doctor may
proceed with the operation if
forbidden or unable to obtain
parental consent. The issue of
competency ofminors to give
consent is defined in the UK in
the Children's Act.
Counselling for abortion
The decision to have a pregnancy
terminated is never an easy one.
All women should have access to
abortion counselling, which
should provide opportunities for
discussion, information,
explanation and advice in a
manner which is both non-
judgemental and non-directive.
The way in which counselling is
provided will vary; in some
developed countries it is
mandatory. Whatever the format
of counselling, every woman
should be given the opportunity
to explore her feelings and
anxieties, and to make an
informed choice. She may be sad
about her decision but she should
have no long-term regrets. Box








Box 25.2 Management and care of the unplanried pregnancy
1. 'Counselling' - risks and alternatives; inform fjer that she can change
herinind. : * " ' ' ■ -•*.
2. Assessment of gestation:
• History
• Clinical examination
• Pregnancy test, if indicated
• Ultrasound, especially if discrepancy between dates and size,
suspected adnexal mass or questionable viability
3. Explain: .







• Reason for termination of pregnancy
• Gestational age and date of pregnancy test
• Informed choice with alternatives
• Discussion of complications and possible sequelae
• Contraceptive care - ,
• Tests carried out/offered
5. Tests: . > , , : . - - ■
• Mandatory - haemoglobin, blood group and rhesus status, sickle
screen (if indicated) and rubella screen (if indicated, and if follow-
up immunization, if required, is feasible)
• Chlamydia and other STD screening, especially in women under 25




GA = general anaesthesia; LA = local anaesthesia; STD = sexually transmitted disease;
HIV = human Immunodeficiency virus.
and care of the unplanned
pregnancy at die abortion facility.
Counsellors should encourage
the woman to think ofboth the
practical and emotional
consequences ofall the possible
options: abortion, continuing
with the pregnancy and adoption.
Unless a woman is quite certain
ofher decision, she will be more
likely to regret it later. A few
women will need more time and
perhaps more counselling to help
them make up their minds. Some
women will change their minds.
The incidence oflong-term
regret/emotional sequelae is low.
Even in countries where
abortion is legal and accessible,
many women fear they may be
refused an abortion and, perhaps,
for some, it is not possible to
make the final decision until they
are quite certain that they really
do have a choice. For others, the
reality ofabortion may not
become apparent until they are
faced with the practicalities of
undergoing the procedure. In
some countries, such as France,
statute demands a waiting period
between the time the abortion
has been agreed and the time it is
carried out. to allow women the
opportunity to reflect on their
decision free from the worry that
the request may be refused.
The majority ofwomen
(around 80%) have made their
decision before they see a doctor.
Seeing the doctor is usually a
necessary part ofobtaining an
abortion and women attend
expecting confirmation of their
pregnancy, information and
referral to an abortion provider.
The skill of the counsellor lies in
the ability to detect those women
who need lengthy discussions and
more support, and diose who
may be at risk ofsevere regret.
The different techniques,
together with their advantages
and disadvantages, should be
discussed to enable a choice to be
made where available and
appropriate. The risks ofabortion
together with the effect of
abortion on future fertility should
be covered. Women also need to
receive information about what
happens after the abortion, the
expected duration ofbleeding,
when to have intercourse and
even such details as when to have
a bath. The decision to have a
termination has often arisen
because a relationship has ended
and the woman may not see an
immediate need for future
contraception. While discussion
about future contraception prior
to or even immediately after the
abortion may not be ideal, in
some cases it may be the only
chance the professional has.
Contraception is an important




Particular attention should be
paid to conditions such as asthma,
which may influence the choice
ofmethod ofabortion, and to
factors which may increase the




Gestation should be determined
by menstrual history and pelvic
examination. A pelvic ultrasound
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scan is unnecessary unless there is
doubt about the gestation or
ectopic pregnancy is suspected.
Genital tract infection
(particularly Chlamydia)
Whether screening is performed
or everyone is treated with
prophylactic antibiotics depends
on the background incidence of
infection in the local population
and on the relative costs. Ifscreen
is positive, antibiotic therapy
should be started before the
abortion is performed. 111 high-
risk populations, both screening
(and wherever possible, contact
tracing) and antibiotic prophylaxis
may bejustified. Antibiotic
prophylaxis should comprise anti-
chlamydial and antianaerobic
infection agents. There is evidence
that antibiotic prophylaxis for
high-risk cases reduces the
incidence ofinfection [6],
Hepatitis B and HIV
Women considered to be at high
risk of hepatitis B or HIV should
be offered screening with
appropriate counselling. Women
who refuse screening should be
treated as high risk during the
abortion procedure.
Cervical screening
Cervical screening is not essential
and may not be practical, but
should be offered in accordance




blood group should be
determined. Women who are
rhesus negative should be
injected with anti-D
immunoglobulin (1250 1U)




Box 25.3 Methods for inducing abortion





Medical ; > _ .
• Antiprogesterones ± prostaglandins
• Methotrexate + prostaglandins
• Prostaglandins alone (not currently recommended)
Late first trimester (9-14 weeks)
Surgical
• Vacuum aspiration
Second trimester (beyond 14 weeks)
Surgical
• Dilatation and evacuation
• Hysterotomy








There is a variety ofmethods
available for termination of
pregnancy (Box 25.3). The
method chosen depends largely
on gestation and availability of
methods (Figure 25.2). The
woman's parity, medical history
and her wishes are other issues to
consider.




In some countries women who
have missed a menstrual period
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*No anaesthesia required to 6 weeks, local anaesthetic thereafter.
tMifepristone is also licensed in UK for medical termination of pregnancies 12-20
weeks' gestation.
♦Can be done under local or general anaesthetic. Cervical priming using
prostaglandins, mifepristone or hydrophilic dilators is recommended for nulliparous







have access to menstrual
regulation, when suction
evacuation of the uterine cavity is
performed usually withouc
confirmation ofpregnancy. This
method is common in China,
where abortion is legal, and in
Bangladesh up to 6-9 weeks of
amenorrhoea. Usually
undertaken very soon after the
missed menstrual period, it is
done with a hand-held syringe
attached to a manual or electrical
aspiration pump.
Vacuum aspiration
Vacuum aspiration has been the
method ofchoice for early
surgical termination ofpregnancy
in most developed countries for
over 20 years. Dilatation and
curettage is not recommended as
it requires a greater degree of
cervical dilatation, and is
associated with a significantly
higher incidence of uterine
injury and of retained products of
conception. Vacuum aspiration
can be performed under either
local paracervical block (LA) or
general anaesthesia (GA). Some
evidence suggests that local
anaesthesia may be safer: in the
USA, the mortality rate is 2-4
times greater when general rather
than local anaesthesia is used for
first-trimester abortion. In the
UK, where most abortions are
performed under general
anaesthesia, there has not been an
abortion-related maternal death
in many years. In developing
countries, economic
considerations and the availability
ofskilled personnel may
influence the choice of
anaesthetic.
Preoperative treatment with a
cervical priming agent reduces
the risk ofhaemorrhage and
genital tract trauma.
Prostaglandins, bougies and the
antiprogesterone RU486
(mifepristone) are all effective,
but prostaglandins probably have
a faster onset ofaction.
Pretreatment of the cervix
increases the cost of the
procedure and may be difficult to
organize when abortion is
performed as a day case. As
cervical trauma is commoner in
women under the age of 17 years
and uterine perforation is
associated with increasing parity
and increasing gestation, efforts
to arrange cervical ripening
should be concentrated on very
young women, highly parous
women antidrose presenting at
later gestation.
A curette of6—10 mm internal
diameter is passed through the
cervix and the contents of the
uterus aspirated using negative
pressure. It is advisable to use the
smallest diameter curette which is
adequate for the gestation -
8 mm at 8 weeks, 10 mm at 10
weeks. The curette may be nude
ofmetal or plastic, curved or
straight, and either flexible or
rigid.
Vacuum aspiration at this stage
ofpregnancy is safe, with an
incomplete abortion rate of less
than 2%. Failure is more likely to
occur before 7 weeks1 gestation
when the fetus may be missed by
the curette. Thus it may be better
to defer operation until after 7
weeks or to use medical methods.
The mortality from vacuum
aspiration in the first trimester is
less than about 1 per 100 000,




A variety ofcompounds have
been used to induce abortion




contractions, and can be
administered orally, vaginally,
extra-amniotically, intra-
amniotically or by intramuscular
injection. In the early first
trimester, prostaglandins alone
will induce complete abortion
in up to 95% of cases, but the
duration of treatment and the
incidence ofside effects militate
against their routine use.
Antiprogesterones
Antiprogesterones are synthetic .
steroids which block the action of
progesterone by binding to its
receptor. Mifepristone (RU486,
Mifegyne) is the only such
compound yet marketed and is
used in France, China, UK and
Sweden. In 1996 it was
recommended to the US Food
and Drugs Administration as a
safe and effective means of
inducing abortion, although it is
as yet not available for use in the
USA. Mifepristone also binds to
the glucocorticoid receptor and
blocks the action ofCortisol.
When mifepristone is used
alone, for pregnancies with up to
63 days ofamenorrhoea,
complete abortion only occurs in
around 60% ofcases. The
antiprogesterone itselfstimulates
some uterine contractility but
also greatly enhances the
sensitivity of the myometrium to
prostaglandins. The rate of
complete abortion rises to over
95% if a prostaglandin analogue
is given 36 or 48 h after the
administration ofmifepristone.
In the UK, tire recommended
regimen is mifepristone given as a
single oral dose of600 mg (3 X
200 mg tablets) followed 48 h
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later by a 1 mg vaginal pessary of
the prostaglandin Cervagem
(gemeprost) (Figure 25.3).
Mifepristone 200 nig has been
shown to be equally effective and
since this makes the regimen
considerably cheaper, the lower
dose is now widely used. In the
UK, mifepristone is also licensed
for use with gemeprost for
termination ofsecond-trimester
pregnancies and for management
ofdeath in utcro in the third
trimester. Its use in the
pretreatment of the cervix prior




marketed for the treatment of
peptic ulcer, has been shown to
be effective in combination with
mifepristone, although efficacy
may decline after 7 weeks'
gestation. Unlike gemeprost, it
does not require refrigeration and
'thawing' for an hour prior to
administration. Misoprostol can
be administered vaginally or
orally, and may be more effective
vaginally, but randomized
controlled studies are few. In the
Box 25.4 Contraindications to first-trimester medical abortion using
antiprogesterone + prostaglandins
Absolute cpntraindicatipns
• > 9 weeks' gestation "
• Suspected ectopic pregnancy
• Active asttima
.• Liypr arid/or renal disease ,, . v *, .;•?
• Suspected adrenal insufficiency ,v.
• Heavy smoking (>15,cigarettes per day) and >35 years
• Unavailability for follow-up within 2 weeks
• Anaemia (Hb < 10 g/dl)
• Haemolytic disease or taking anticoagulants
Relative contraindications
• > 8 weeks' gestation
• Hypertension (diastolic pressure > 100 mmHg)
• Heavy smoking (>15 cigarettes per day) ■
• > 35 years
• Women taking systemic steroids
UK, misoprostol is not licensed
for termination ofpregnancy. The
cost ofmisoprostol is 50 times less
than gemeprost. Misoprostol has
also been used with mifepristone
in the termination ofsecond-
trimester pregnancies.
Not all women are suitable for
medical abortion. The
contraindications are shown in
Box 25.4.
There are very few side effects
following the administration of
mifepristone. The fetus is usually
aborted following the
Fig. 25.3 Protocol for medical termination of early pregnancy (< 63 days'
amenorrhoea)
600 mg oral mifepristone OR Given in abortion facility OR
200 mg oral mitepristone outpatient clinic linked to such facility
500 mg vaginal gemeprost OR
400 pg vaginal or oral misoprostol
repeated 2 h later
Given 48 h after mifepristone
in abortion facility
Observe patient for 4 h (unless opiate
analgesia is required)
Follow-up within 2 weeks
administration ofprostaglandins,
and this is accompanied by
bleeding and pain. The bleeding
is usually like a heavy period,
although rarely (<1%) there may
be very heavy bleeding requiring
resuscitation. The amount of
bleeding is related to gestation,
since the size of the placental site
increases as-pregnancy advances.
Nulliparotis women and those
with a history of dysmenorrhoea
are more likely to experience
severe pain and 10-20% of
women may need opiate
analgesia; the rest will cope with
paracetamol alone. Prostaglandin
synthetase inhibitors, such as
aspirin or meferramic acid, should
be avoided. Bleeding can
continue for up to 20 days after
the abortion, although in most
women bleeding stops after 10
days. The total amount ofhlood
lost is similar to that occurring at
the time ofvacuum aspiration.
A follow-up visit about 2
weeks after administration of the
prostaglandin is essential because
30% ofwomen do not pass an
identifiable fetus and/or placental
tissue. Ongoing pregnancy occurs
in only 1% of cases; however,








necessary in up to 5% because of
incomplete abortion. These
figures are no different from those
associated with surgical abortion.
The risk of fetal malformation
following RU486 alone or in
combination with prostaglandins
is unknown. Women should be
advised that medical abortion is a"
two-stage procedure, and that it is
not possible to have a change of
heart after taking RU486 and
before prostaglandin
administration. In the event ofa
failed medical abortion, the
woman must be strongly advised
to have vacuum aspiration,
although babies born to the few
women who have chosen to
continue with the pregnancy,
after medical abortion has failed,
have been normal. Misoprostol
is teratogenic; however, any
congenital defect may partly be
the consequence of the failed
abortion.
In France and the UK, around
20-25% prefer medical abortion.
Women often choose the medical
method because it usually avoids
an anaesthetic and because they
feel more in control of the
situation. Some women,
however, find the two stages a
disadvantage. The incidence of
serious complications is probably
similar to that associated with
surgical abortion but, because
95% ofwomen need neither
anaesthesia nor instrumentation
of the uterus, large randomized
trials may eventually show
medical abortion to be safer.
Methotrexate
The cytotoxic drug methotrexate
has recently been used in the
medical management ofectopic
pregnancy. In the USA,
methotrexate has been proposed
as an effective adjuvant to
prostaglandins used for first-
trimester abortion. Unlike
RU486, methotrexate is known
to be teratogenic, thus risking
fetal malformation and inevitable
litigation in the event of ongoing
pregnancy.
Late first trimester (9-14
weeks)
Ac this stage ofpregnancy, the
method ofchoice is vacuum
aspiration, which can be done
under local or general
anaesthesia. Although abortion
can be induced by antigestagens
and prostaglandins, the incidence
of incomplete abortion is high.
The cervix should be pretreated
at gestations ofgreater than 10
weeks in nulliparous women.
Although vacuum aspiration is an







In some countries, including the
USA, D&E is commonly used for
terminating pregnancies up to 20
weeks' gestation. It should only
be performed by experienced
surgeons. Under local or general
anaesthetic, the cervix is dilated
to 14 mm or more to allow
removal of relatively large fetal
parts. Pretreatment cervical
priming is essential and an
oxytocin infusion during D&E is
advisable to reduce blood loss.
Fetal parts should be kept so that
the completeness ofthe
procedure can be checked before
evacuating the cavity with a 12
mm suction curette. D&E is
thought to be safer than intra-
amniotic instillations up to 16
weeks' gestation, although the
procedure has not been compared '
with vaginal prostaglandins.
Hysterotomy
The removal ofthe uterine
contents via laparotomy and a
vertical or transverse uterine
incision is associated with
relatively high mortality and is
rarely necessary, particularly as




Hypertonic saline and urea can
he administered intra-
amniotically to induce late
abortion. The procedure is
prolonged but can be shortened
by pretreatment cervical priming
and the use of intravenous
oxytocin to enhance uterine
contractions. The incidence of
infection, haemorrhage and
retained products of conception
is higher than with
prostaglandins but the fetus is
rarely delivered alive. Rarely,
disseminated coagulopathy may
occur and the inadvertent
systemic administration of
hypertonic saline may lead to
cardiovascular collapse. Another
agent, ethacridine lactate
(Rivanol) is an acridine dye
which can be inserted into the
extra-amniotic space. It is cheap,
safe and weakly antiseptic and,
for these reasons, is popular in
some developing countries.
There is some evidence of acute
toxicity in animals and, for this
reason, WFIO has denied
permission for clinical trials.
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Prostaglandins
prostaglandins alone have been
widely used in the termination of
second-trimester pregnancy.
Intra-amniotic administration
requires skilled personnel. Rarely,





interval is prolonged with a
concomitant increase in the risk
ofinfection. The experience is
painful. The vaginal
administration ofpessaries
containing a prostaglandin E,
analogue or misoprostol is safer
and less unpleasant. In the UK,
this approach is now routinely
preceded by pretreatment with
the antiprogesterone RU486
(mifepristone), which
significantly shortens the interval
between administration ofthe
prostaglandin and abortion of the
fetus to 6-8 hours. Mifepristone
600 mg is given 36 h before
vaginal insertion ofa 1 mg
gemeprost pessary repeated at
intervals of3 and 6 h until
expulsion ofthe fetus occurs.
Infusion ofprostaglandin E, into
the extra-amniotic space can be
used ifpessaries are not available.
Overall, 30% ofwomen retain all
or part of the placenta, and require




in combination with mifepristone,
is very effective and associated with
a very low incidence of
complications. Because it requires
less surgical skill, the potential for
serious complications is probably
less than for D&E and hence, it will
continue to be used in many parts
ofthe world.
Abortion beyond 18 weeks'
gestation is rare and is usually
reserved for pregnancies
complicated by severe fetal
malformation. Particularly
distressing for both the mother
and the staff, these late abortions
are often effectively managed with
vaginal prostaglandins in
combination with RU486, with
intra-amniotic urea or fetal
intracardiac injection ofpotassium
to minimize the chances of
expulsion ofa live fetus (see
Chapter 33 for information about
anaesthesia for termination of
pregnancy). Box 25.5 gives details
ofcervical preparation.
Sequelae of abortion
In developed countries where
abortion is legal, associated
mortality and morbidity have
fallen over the last two decades.
In Europe and the USA, the risk
ofdeath is less than 2 per 100 000
procedures; in Sweden, abortion
is ten times safer than childbirth.
The risks rise with gestation.
Serious complication rates for
first-trimester abortions are less
than 1% (Box 25.6), with fewer
than 1 in 1000 women needing
hospitalization; beyond 10 weeks'
gestation the health risks of
abortion rise with each week.
The risk oflate second-trimester
abortion is up to four times
higher than that for first-trimester
abortion. Complications are
usually divided into immediate
(during or within 3 h ofthe
procedure), delayed (3 h to 28





Box 25.5 Preparation of the cervix
I. Hydrophilic dilators
Reduce the force needed for dilatation
(a) Laminaria tents;
• Stems of seaweed
• Radial force on the cervix
• Swell to 3-4 x their size
• Cheap
• Never 100% sterile
• Slow action (6-48 h)
(b) Synthetic dilators:
• Rapid dilatation ....»' „.(
(i)Lamicel „.J-
• Polyvinyl sponge containing 450 mg of MgSO,; 3 and .5,mm sizes
• Force not radial, therefore not useful for late abortions
Maximum action after 2 h '*'*'['■ 'V ; •
(ii)Dilapan y:1.' ' ,yj' " ; '
• Hypan urAififtf ''urifltftornwirifftTVn i
• Quick action
• 4-8 mm in 30 min
• 12 mm ill 1h
II. Prostaglandins
e.g. Gemeprost 1 mg pessary 1-3 h preoperatively produces dilatation
of 7-9 mm; or misoprostol orally -;V-"'y'-'i V ■"■ TV.
III. Fo|ey catheter
Inserted intracervically and balloon inflated With 20-30 ml of water;
* ■ (*': :.•■ ' ■ ... '* ' 5 N"






















Cervical laceration occurs usually
when the tenaculum pulls off the
cervix during dilatation. The risk
is reduced by preoperative
cervical priming and by placing
the tenaculum vertically with one
tooth in the os and the other high
on the anterior hp, taking a 'big
bite' of tissue. Iflaceration occurs,
it may require suturing but. more
commonly, simple postoperative
observation is all that is needed.
Uterine perforation probably
occurs more commonly than is
apparent: perhaps as many as one
in six- perforations goes
undiagnosed. When recognized,
perforation is usually without
complications and the patient
should simply be observed.
If intra-abdominal trauma is
suspected - more likely during


















termination - laparoscopy and/or
laparotomy should be performed
and the damage repaired by a
competent surgeon.
Haemorrhage
The true incidence of





and internal compression of the
uterine cavity with the balloon of
a Foley catheter or with a pack




This is a rare but potentially fatal
complication ofsecond-trimester
abortion. The risk may be
reduced by draining the amniotic
fluid at the beginning of the
procedure.
Anaesthetic complications
In the TJSA, complications of
general anaesthesia are the
leading cause ofabortion-related
death. In a recent review of die
subject, Grimes [7] concluded
that abortion under local
anaesthesia is preferable in terms
ofboth safety and cost. Abortion
in the UK is still predominantly
managed with general
anaesthesia. Offered the choice,
some women would certainly
find the idea of being awake
during the procedure quite
unacceptable. However, up to
30% ofwomen in the first
trimester chooie local anaesthesia
when offered.
Venous thromboembolism
Pregnancy increases the risk of
diromboembolism; so does
general anaesthesia. Most women
undergoing termination of
pregnancy are young and
physically fit, and surgical
abortion is rarely a prolonged
procedure. Nonetheless, the risk
ofvenous thrombosis should
never be overlooked and a
previous history of
thromboembolism might
determine the choice of
anaesthetic and, ifpractical and





following abortion is the
persistence ofplacental and/or
fetal tissue. Up to 5% ofwomen
undergoing first-trimester
medical abortion will require
surgical re-evacuation of the
uterus within the first month.
The incidence of incomplete
abortion after vacuum aspiration
rises with gestation. Bleeding 2.
weeks after a medical or surgical
abortion is not in itself an
indication to evacuate the uterus.
Ultrasound scans often show
residual trophoblastic tissue even
in women who have stopped
bleeding. Although an ultrasound
scan of the uterus and the
measurement ofbuman
chorionic gonadotrophin (HCG)
in plasma may be helpful in
diagnosing an ongoing
pregnancy, the decision to
evacuate the uterus should be
made on clinical grounds, i.e.
continued heavy or persistent
bleeding from a bulky uterus in
which the cervix is still dilated.
The majority ofwomen with an
incomplete or missed abortion
will pass the residual tissue with
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time if they will wait. The belief
that all women with an
incomplete abortion have a high
risk of intrauterine infection until
the uterus is evacuated probably
stemmed from the time when




for chorionic villi and fetal parts
should reduce the risk of
unrecognized ectopic pregnancy
which may be fatal. Microscopic
(pathological) examination of the
specimen is only indicated ifa
molar pregnancy is suspected.
Infection
Post-abortion infection is
probably also under-reported but
should be suspected in a woman
with prolonged heavy vaginal
bleeding as well as those with
classical symptoms ofpain and
pyrexia. Established pelvic
inflammatory disease with
pyrexia, abdominal pain and
offensive vaginal discharge occurs
in around 1% ofwomen
whatever method ofabortion is






Almost all studies [8,9], agree that
neither vacuum aspiration nor
second-trimester prostaglandin
abortion is associated with a
significant increase in secondary
subfertifity. There is a 30% risk of
tubal infertility following severe
post-abortion infection. The
latter is uncommon occurring in
<0.5% of cases. There are as yet
insufficient data on first-trimester
medical abortion, but there is no
reason to suspect that the risk will
be different. Uncomplicated
induced abortion does not
increase the risk ofectopic
pregnancy, nor ofspontaneous
abortion unless sharp curettage is
used. Abortion has no effect on
the outcome ofsubsequent
pregnancies continued to
childbirth, such as low birth
weight or premature delivery.




syndrome is a rare complication
ofabortion where intrauterine
adhesions follow vigorous
curettage of the uterine wall.
Management is hysteroscopic
division of the adhesions,
placement ofa Foley catheter or
an intrauterine device in utero and
treatment with a short course of
oestrogen/progestogen.
Psychological sequelae
Many women feel emotional for
a few days following the abortion.
Many studies have, however,
demonstrated a significant
improvement in psychological
well-being by 3 months after,
compared with before the
abortion [10], There is no
evidence ofan increase in the
incidence ofserious psychiatric
problems following abortion:
indeed a recent review of the
subject [11] concluded that 'there
is, as yet, no credible evidence for
the existence ofpost-abortion
syndrome'. In contrast, the
incidence ofdepression, suicide
and child abuse is higher in
women who have continued
with the pregnancy because
abortion was refused [12], In the
same study, the children born to
women refused abortions had
higher incidences of
psychopathology and educational
and social problems than their
matched contemporaries, and
these differences persisted into
adulthood.
Breast cancer
Induced abortion does not seem
to increase the risk ofbreast
cancer [13].
Follow-up
All women should have their
questions answered and receive
contraceptive advice (Table 25.1)
and, ifappropriate, supplies before




Table 25.1 Post-TOP contraception
Method When to start? , .
Combined pill Day of operation or following day
Progestogen-only pill Day of operation or following day
Condom Advisable whenever intercourse occurs for STI
prevention
IUD At Operation (if £ 12 weeks) orat ne?ct menses
Diaphragm ChecMze £ 2 weeks post-TOP
Depo-Provera Within 5 days of TOP
Norplant At operation
Sterilization • Discussecj as for interval procedures i
STI = sexually transmitted infection; IUD = intrauterine device; TOP = termination of pregnancy
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should be given a follow-up
appointment within 3 weeks,
either with the clinic which
carried out the abortion or with a
suitable alternative doctor. At
follow-up, a pelvic examination
should aim to confirm complete
abortion and the absence of
infection. Discussion should




In the foreseeable future, the
important changes in the
management ofunwanted
pregnancy are likely to be
political rather than clinical.
Clinical scientists will continue to
tinker with regimens for medical
abortion in an attempt, for
example, to find the 'perfect'
prostaglandin, which is free from
side effects or to develop slow-
release prostaglandins to be given
at the same time as mifepristone.
A number ofpharmaceutical
companies have antiprogesterone
drugs which may be superior to
mifepristone. Most, however,
seem reluctant to develop them as
abortifacients because of the
politics ofabortion.
Women's health advocates and
some non-governmental
organizations are pressing for
widespread availability of
medical abortion, particularly in
developing countries where
surgical techniques may be
dangerous, and where abortion-
related morbidity and mortality
are high". In this context, there is
also a move to facilitate the use
of medical methods by
individual women in their own
homes. Many doctors have
concerns about the safety of do-
it-yourself medical abortion but,
seen as a wider public health
imperative, persuasive arguments
can be made at least for reducing
the need for medical supervision
for some stages of medical
abortion procedures. There is,
however, a risk that moves to
allow abortion at home will
increase popular support of the
anti-abortion lobby and, in
developed countries, where safe
abortion is available and
accessible, it may be sensible not
to 'rock the boat'.
Finally, it is likely that abortion
legislation will continue to
change throughout the world. In
developing countries, where
abortion is currently illegal, the
inevitable processes of
liberalisation — as in South Africa
- may result in legalisation. In
Europe, where birth rates have
fallen in some countries to below
replacement level, it is equally
possible that governmental
concerns about demographic
changes may result in abortion
becoming less easily available.
Whatever happens, we can rest
assured that in no country will
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Mini-symposium: Therapeutic ibortion
The organisation of abortion services
A. Glasier
The availability and genuine accessibility of abortion varies widely throughout the United
Kingdom depending mainly on the commitment and interests of local gynaecologists. In most
districts in England and Wales availability falls far short of that recommended by successive
governments. Arguments can be made in support of the provision of abortion either as part of
general gynaecology services or within dedicated units. Within each district one consultant
should have a special responsibility for all aspects of fertility control including abortion. The
establishment of a service for medical termination of pregnancy in each district is desirable
and may reduce the burden on surgical gynaecology. Medical abortion is only available to
women referred in early pregnancy, so that efficient referral is in the interests of the patient
and the service. This may be best achieved by some form of centralisation of appointments.
Introduction
Induced abortion. has been legal throughout the
United Kingdom for 25 years. The number of women
undergoing pregnancy termination rose in England
and Wales from 24000 in 1967 to 184000 in 1989.
In this review the overall provision of services will
be described and the organisation of each stage of
the procedure discussed.
Provision of services
The provision of abortion services varies enormously
across the country. In Scotland over 97% of the
10 192 abortions performed in 1989 were done in
NHS premises, compared with only 41.5% in England
and Wales, where just over 50% of abortions were
done privately and 9% by agencies who are paid by
the NHS. In the West Midlands Health Authority
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less than 14% of abortions were done on NHS
premises.
In 1974 the Lane Committee,1 set up by the
government to review the working of the 1967
Abortion Act, recommended that contractural
arrangements with other agencies should only be
used, if at all, to provide temporary facilities. In 1979
the Merrison report2 recommended that 75% of
abortions should be provided free in NHS facilities.
In England and Wales that target has never been
reached. With the current changes in the NHS. even
thi.v,level of service is under threat. An article in the
Health Service Journal published in 1990J reported
that abortion services were facing widespread
reductions and cited West Lambeth Health Authority
where the number of abortions paid for by the NHS
had been reduced from 26/week to 9/week. In a
country where abortion is legal, the adequate pro¬
vision of services depends on governments, health
authorities and gynaecologists recognising that abor¬
tion is a fundamental component of a woman's
ability to control her own fertility. A genuinely
accessible service can be provided - as appears to be
the case in Scotland - if the commitment is there.
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Maresh" found no relationship between the number
of beds or of gynaecological sessions and the regional
variation. In a more recent study undertaken in I9895
few gynaecologists appeared to think that there was
a problem of clinical resources. In reality the uneven
spread of abortion services across the country reflects
the varying degree of commitment and it is largely
the local gynaecologists who decide how accessible
abortion is. Throughout the 1960s and 1970s the
professor of obstetrics in Grampian was a strong
supporter of abortion6 and the service provided was
and still is - comprehensive. In contrast the
professor in Glasgow during the same years was
totally against abortion and it is only recently that
the majority of abortions have been done within the
NHS in the West of Scotland.
Some gynaecologists dislike doing abortions5,7
which they regard as occupying outpatient and
theatre time otherwise available for 'real gynae¬
cology'. In the Francontbe survey 60% of gynaecolo¬
gists questioned wanted to see abortion split from
general gynaecology and 45% favoured regional
abortion units. The majority of gynaecologists in
Scotland, however, did not wish to see abortion
being carried out separately from general gynae¬
cology. Gynaecologists in Scotland provide an
ethcient abortion service within a general gynaecologi¬
cal setting perhaps when the system works well the
benefits are more obvious.
In some parts of the country dedicated abortion
units do exist and they work well, however the Lane
Committee did not favour the establishment of
separate units but rather recommended a general
improvement of all gynaecological services. In her
report on Patterns of Hospital Medical Staffing,
Dowie8 argues that the workload of gynaecologists
has changed dramatically since 1974. New services
such as colposcopy have been introduced and depart¬
ments providing the full range of services including
abortions are overstretched. One solution, suggests
Dowie, would be to transfer work associated with
pregnancy termination to dedicated units. There are
advantages to dedicated units. On general gynaeco¬
logical operating lists suction terminations tend to be
left until the end when they are often done by juniors
who may be unsupervised, the consultant having left
to fulfil another commitment. Abortions done within
the NHS are associated with a higher morbidity than
those done in the private sector.9 Abortions done
privately are more likely to be done at an earlier
gestation but it may also reflect the relative inexperi¬
ence of those most likely to perform the surgery
under the NHS. Those in favour of specialised
abortion units argue that the volume of work -
usually undertaken by one or two interested surgeons
means that it is being done by experts. This may
be particularly important when less commonly used
procedures such as dilatation and evacuation for
second trimester abortion are called for. The estab¬
lishment of abortion clinics also avoids the necessity
for women undergoing abortions occupying beds
next to women undergoing other procedures
infertility investigations for example. It is also argued
that the staff working in these units are inclined to
be much more sympathetic and that they are better
placed and more likely to undertake contraceptive
counselling.
However, this approach separates abortion from
all other areas of reproductive health care turning it
into something special and different. Counselling for
and performing abortions should be part of the
training of all gynaecologists and in a general
gynaecological setting medical students and doctors
planning to enter general practice are exposed to all
aspects of the care of women with unplanned
pregnancy. Few people want to spend all their time
doing abortions and, moreover, general gynaecologi¬
cal services are better equipped to cope with compli¬
cations of abortion. The district general hospital is
often more accessible to women and more acceptable
~
to those who wish to conceal the fact that they are
having an abortion. Perhaps more importantly, if
abortion is provided locally and is recognised as a
local issue, it is more likely to highlight local needs
in all areas of fertility control. Finally, a separate
abortion unit becomes an easy target for the anti-
abortionists as has happened in the USA. In their
Working Party Report on Unplanned Pregnancy10
the Royal College of Obstetricians and Gynaecolo¬
gists (RCOG) recommends that a senior specialist in
each Health Authority should oversee the provision
of contraception, sterilisation and legal abortions.
The report suggests that community gynaecologists
may fulfil this role. At present there are very few
community gynaecologists and they come from a
variety of backgrounds. If abortion is to be provided
as part of the general gynaecological service the
specialist responsible for its organisation must have
status equivalent to those who are providing the
service but the status of community gynaecologists is
as yet undefined.
If there was more widespread recognition of the
size of workload undertaken by gynaecologists, the
great majority of whom have a substantial obstetric
case-load, a significant increase in consultant numbers
together with the appointment of one consultant in
each Health Authority with responsibility for fertility
control would ensure the organisation of efficient
abortion services. In the conclusions to her Report
on Medical Staffing Dowie suggests the establishment
of centres to undertake gynaecological procedures
that can be performed on an outpatient or day care
basis including abortion, colposcopy, sterilisation
and the investigation of infertility.8
Centres for Women's Health could include all these
services together with well woman and family plan¬
ning clinics, breast screening and facilities for health
education and health promotion. Such centres would
provide opportunities for training and for integrated
349
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research into all aspects of women's health including
abortion.
Organisation of the service
In 1991 the Birth Control Trust (BCT) published a
specification for a model abortion service." The
document reminded Health Authorities that the
overall aim is To provide an efficient, eflective and
comprehensive service which is of demonstrably
high quality'.
A comprehensive service begins with the initial
presentation of the woman with an unplanned
pregnancy.
Initial presentation
The majority of women requesting pregnancy termin¬
ation initially seek help from their general prac¬
titioner. Others present to community family planning
clinics or to organisations such as Brook Advisory
Centres or the British Pregnancy Advisory Service.
The government has always recognised the need for
women to be able to discuss and obtain contraception
and fertility regulation from someone other than
their general practitioner. Unfortunately, the wide¬
spread reduction in NHS community family planning
clinics in some parts of the country12 jeopardises this
aspect of an accessible abortion service. Not only are
such clinics known to provide special services for
women under 20 - a group in whom the abortion
rate is high - but they are also seen as an essential
resource in reducing the number of unwanted preg¬
nancies particularly by providing emergency
contraception.
Pregnancy diagnosis, advice and counselling are
undertaken at the first visit. Not all general prac¬
titioners have the capacity to undertake pregnancy
testing in their surgeries. David Paintin" reported
that only 30% of GPs were able to do immediate
pregnancy testing. Waiting for test results can lead
to delays of up to 1 week before a woman is referred.
In the absence of pregnancy testing facilities, a
history of amenorrhoea and symptoms of pregnancy
are sufficient to warrant referral if the pregnancy is
unwanted.
Most women seeking abortion are fairly certain of
their decision at the lime of initial presentation.
Nevertheless, every woman should have the oppor¬
tunity to discuss her feelings about the pregnancy,
the alternatives and to obtain information about
procedures involved in abortion.
It has been estimated that about 10% of women
will need further counselling at the time of referral
and a small number may require help front a trained
counsellor with more time and skills available than
the average GP. In a review of 735 referrals to an
Edinburgh hospital in 198914 10% of women either
cancelled an appointment at some stage during the
referral procedure, defaulted, or informed their
doctor that they had decided to continue with the
pregnancy. Arguably it is this group of women who
require advice front a social worker rather than the
great majority who are certain of their decision.
Referral procedures
The mechanism by which a woman requesting
abortion is referred to a gynaecologist varies widely
throughout the UK. In many areas the referring
doctor has to contact the gynaecologist personally,
often a time consuming procedure. There are fre¬
quently long delays before a woman is seen by a
gynaecologist and before the operation is done. In
their study on late abortions in England and Wales15
the RCOG reported that 45% of women operated
on at between 13 and 16 weeks gestation had
consulted their GP before 13 weeks. There have been
improvements since 1985 and gradually the number
of mid trimester abortions is falling (in 1989 over
80% of abortions were performed before 13 weeks).
However, this is as a result of a reduction in the
delay at all stages, including the stage of pregnancy
at which women first present.
In their model specification the BCT recommend
that women should be seen within 5 days of receipt
of a letter of referral. One way to achieve this
standard is to set up a centralised referral service as
has been tried successfully in both Newcastle16 and
in Edinburgh.14 In Edinburgh, gynaecologists reserve
a specific number of appointments each week for
termination referrals. The number is calculated to
match the demand. A central agency holds all the
appointments and offers the first available one to the.
referring doctor. Used for all referrals below 18
weeks gestation, this has significantly reduced the
average wait for a referral from 11.2 days to 4.7 days
in Edinburgh. The success of such a system depends
on the continued commitment of the gynaecologists
involved. It has been suggested that doing away with
the need for two doctors agreeing to there being
grounds for abortion may hasten the referral process.
Unless women were able to refer themselves directly
to the doctor performing the abortion this would not
make any real difference to waiting times.
Abortion procedure
The BC.T recommends that 95% of abortions should
be performed within 5 working days of a woman
being seen by the gynaecologist and that most should
be done as day cases. In the UK the majority of
abortions are still performed surgically. Availability
of theatre time, gynaecological case load, emergency
case load and individual consultant's policies all
influence the speed with which any gynaecological
patient reaches the operating theatre. There is no
doubt that a commitment to providing an efficient
service and the establishment of an efficient referral
system helps. In Edinburgh the waiting time for
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theatre fell in parallel with the wait for referral from
7 to 4 days. While gynaecological workload is
increasing, changes in practice are altering the need
for theatre time. Many units, for example, have
replaced routine D & C under general anaesthesia
with outpatient endometrial biopsy and the increasing
use of minimally invasive surgical procedures will
further reduce the need for both inpatient beds and,
in some cases, operating theatre time.
It is surprising that of 54 health districts surveyed
in the late 1980s and reported in I99017 the median
figure for terminations performed as day case pro¬
cedures was only 15%. Certainly admission as a day-
case makes life considerably easier for the patient.
Perhaps one of (he most important developments
with the potential to influence the wait for surgery is
the introduction of a medical abortion service.
RU486 (mifepristone) was granted a licence for use
in medical termination of pregnancy in the UK in
July 1991. In France where the treatment is only
licensed for use up to 7 weeks gestation, 30% of '
terminations are now done using a combination of
RU486 and prostaglandins (PG). For women suitable
for medical abortion and where the service is offered,
counselling for pregnancy termination should include
a discussion of the advantages and disadvantages of
medical versus surgical techniques.
Because of the current limitations on the avail¬
ability of RU486 it is at present given on hospital
premises, although this part of the procedure can be
combined with the referral visit. Readmitted 48 h
later, women stay in hospital for 6 h after PG
administration. It is not necessary for them to be
kept in bed or to wear night clothes or hospital
gowns although beds must be available for women
needing opiate analgesia or wishing to lie down.
In the UK the development of medical abortjon
services has been slow. By December 1991 only 35
units were purchasing RU486 (Roussel Uclaf -
personal communication). Most Health Boards are
facing a reduction in funding and some are burdened
with a large financial deficit. Few have funding for
so called 'developments' and the establishment of a
medical abortion service is seen as such. Although
medical termination of pregnancy removes the need
for theatre time and. once set up, can be largely
staffed by nurses, the organisation of a service
requires commitment from managers and gynaecolo¬
gists. The establishment of the service may require
some funding or at least transfer of funds. Referrals
still need to be seen and discussion of a choice of
method - medical versus surgical - may lengthen the
consultation. The 48 h gap between RU486 and
prostaglandins limits the availability of the service to
certain days of the week in most units and some
effort has to be put into tracing women who default
after taking RU486 but before receiving prostagland¬
ins. At present follow-up to confirm that the abortion
is complete is mandatory when medical methods are
used to terminate pregnancy. Moreover, the cost of
medical abortion at present is nol significantly
different from that of surgical techniques. In a recent
letter to the British Medical Journal, Henshaw &
Templeton18 estimated the cost of a medical abortion
at £400 compared with £480 for a surgical procedure.
Nevertheless, medical abortion is an attractive option
to many women and should be available throughout
the UK. Only women referred early in gestation will
be eligible for medical methods so that the potential
for improving abortion services will only be realised
in Health Authorities where an efficient referral
service exists. The manufacturers of mifepristone,
concerned about the dangers of misuse of the drug
will only sell it to NHS hospitals or (o other premises
currently licensed to carry out abortions. Clause 37
of The Human Fertilisation and Embryology Acl
(1990) does allow the licensing of other types of
premises to undertake abortions. With time it may-
become possible for family planning clinics to offer
medical abortion or to make arrangements with a
nearby hospital to share the load with the counselling,
administration of RU486 and follow-up taking
place in the Family Planning Clinic while the
hospital provides the facilities for prostaglandin
administration.
Follow-up
Most gynaecologists do not see abortion patients
after their discharge from hospital and follow-up is
left - often only tacitly - to the referring doctor.
Many women are given appointments at the time of
the initial consultation with the GP and are usually
seen 4-6 weeks after referral. Significant numbers
fail to keep these appointments. It should be the
policy of all hospitals and agencies discharging a
woman after a termination of pregnancy to make
sure that she leaves with sufficient and appropriate
contraceptive supplies.
In addition to ensuring that the abortion is
complete, the woman is free from side-effects and
clear about her future contraceptive plans, post
abortion consultations should give women the oppor¬
tunity to discuss their feelings about the experience.
While more than 90% of women have no significant
psychological problems following abortion a few will
have difficulty coming to terms with their decision.
If the referring doctor feels unable to help, many of
the agencies such as the Brook Advisory Centre offer
skilled counsellors.
1 in 5 women who have an abortion will have
another at some stage in their life. Sensitive discussion
of the reasons for becoming pregnant, failure of
contraception and future intentions could go some
way to reducing this figure.
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Summary
In 198S a centralised referral service for termination of pregnancy was established in
Edinburgh. This has led to a significant reduction in the time women who have requested
termination wait to see a gynaecologist (mean 4.7 days) and in the time it takes before
suction termination of pregnancy is undertaken (total wait 10.2 days). In 1988 only 40%
of induced abortions in Edinburgh were carried out at 9 weeks gestation or before while
in 1989 that figure had risen to 60 %. In 1989 less than 10 % ofpregnancies were terminated
at or after 12 weeks gestation, compared with 21 % in 1988. Reasons for delays in obtaining
an abortion are multifactorial but rapid referral once a woman has made the decision
to seek help will be essential if she is to avail herself of the advantages of medical
termination—only available until eight weeks of pregnancy.
Introduction
The number of terminations is rising annually throughout the United Kingdom. In 1989
in Scotland 10,159 pregnancies were terminated, a rate of 9.1 terminations per thousand
women of reproductive age. While the mortality rate associated with therapeutic abor¬
tion has fallen—there have been no deaths from abortion in Scotland since 1981—major
complications, haemorrhage, infection, operative trauma and thromboembolism, occur
in over 2% of cases'. It is quite clear that the morbidity associated with the procedure
increases with the gestation of the pregnancy at the time when it is terminated. The risk
of major complications doubles when termination is carried out at 15 as compared with
8 weeks gestation2.
Complete abortion can be induced medically in 97% of women with up to 56 days of
amenorrhoea (8 weeks gestation) with a combination of an antiprogesterone (mife¬
pristone) and a prostaglandin1. In France 30% of therapeutic abortions are now done
using this method. Mifepristone is the subject of a current application for a product
licence for use in the United Kingdom in early 1991 but only for the induction of abortion
in women who are eight weeks pregnant or less at the time of termination.
While some women may take a long time to reach the decision to seek a termination
of pregnancy, in many cases much of the responsibility for the delay lies with the medical
254
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profession. There are frequently long delays before a woman is seen by a gynaecologist
and again before the operation is actually done4. In their confidential study on late
abortions in England and Wales, the Royal College of Obstetricians and Gynaecologists
reported that 45% of women operated on at between 13 and 16 weeks gestation had
consulted their General Practitioner (GP) before 13 weeks5.
The establishment of a centralised service for the referral of termination requests has
been shown to reduce significantly the delay between referral by the GP and the out¬
patient consultation6. Such a centralised abortion referral service was set up in Lothian
in the latter half of 1988. In this paper we review the impact of the service on referral
times and the mean gestation of termination of pregnancy in Lothian.
Methods
In 1988, 2,204 and in 1989, 2,210 pregnancies were terminated in the Lothian Region.
While some 250 of these abortions were done in West Lothian the vast majority were
undertaken in three main hospitals in Edinburgh. All the consultant gynaecologists
working in these three hospitals agreed to participate in a centralised abortion referral
service; the consultants in West Lothian wished to continue to operate their own local
referral system. Each of 16 consultant gynaecologists working in the city of Edinburgh
identified a number of out-patient appointments reserved exclusively for requests for
termination of pregnancy. General practitioners and doctors at family planning clinics
within the area wishing to refer for termination a women who is less than 18 weeks
pregnant, telephone the Lothian Centralised Abortion Referral Service (LARS) which
is based at the local family planning centre. The appointments clerk offers the first
available appointment and at the end of the day contacts the out-patients' department
at each ofthe three hospitals involved giving details of appointments issued. Termination
appointment slots remaining unused twenty-four hours before the clinic may be used
for other referrals. Referring doctors wishing to specify a particular hospital or consultant
are offered the next appropriate appointment and some patients choose to delay, usually
for domestic reasons. Doctors referring women beyond 18 weeks gestation or more
contact the gynaecologist personally, as before. Referrals have been accepted through
LARS since the first of November 1988.
All referrals through LARS to the Royal Infirmary of Edinburgh during the first six
months of 1989 have been analysed to determine the mean waiting time between referral
and consultation with a gynaecologist. By referring to ward operation books and indivi¬
dual patient's notes the waiting time between the out-patient consultation and operation
has also been determined. Patients referred for a medical termination of pregnancy have
been excluded from analysis and only women referred for a routine suction termination
of pregnancy have been analysed. Data have been analysed using the Chi Square test
of statistical significance.
In 1989,2,262women were referred through LARS requesting termination ofpregnancy.
Less than 2% of abortions are done privately in Scotland and we are confident that LARS
handles at least 97% of termination referrals up to 18 weeks of gestation in Edinburgh.
255
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Results
Mean waiting times between a woman being referred by her GP or other doctor for
gynaecological consultation and between referral and the surgical procedure are shown
in Table I. Requests for appointments have been subdivided into requests for a first
trimester termination (< 12 weeks n = 507) and requests for a mid trimester termination
(12-18 weeks n = 137). First trimester requests have been subdivided into those who took
the first available appointment (n = 402) and those who, for some reason, chose to delay
(n = 105). Only 29 women (7%) who took the first available appointment waited more
than seven days before being seen by a gynaecologist and none waited longer than ten
days. A total of 73% of women who were seen at the earliest available appointment
underwent a suction termination ofpregnancy within seven days ofseeing the gynaecolo¬
gist and only 11.7% waited more than ten days. Women who for some reason chose
not to take the first available appointment waited slightly but not significantly longer
to see a gynaecologist but did not have a longer wait for operation once they had been
seen. Women referred for a mid trimester appointment passed through the system
slightly more quickly than requests for first trimester termination—the median wait
between the request for referral and initial consultation was nine as compared with 12
days.
Table I: Mean Waiting Time Between Initial Consultation and Referral to the Gynaecology Clinic for
Abortion and Between Initial Referral and Operation Among Patients Referred Via LARS to the RIE from












402 4,7±2.1 (range 1-10) 5.6±4.0 (range 0-23) 10.2±4.1 (range 1-23)
median 12.
105 5.5 + 2.8 (range 1-19) 5.6±3.7 (range 0-20) 10.8 + 4.3 (range 1-22)
median 12.
137 5.7±3.0 (range 1-12) 4.2±3.1 (range 0-15) 9.8±4.2 (range 1-23)
median 9.
Referral times have been further analysed in a small subgroup of patients referred
from Lothian Health Board community family planning clinics to the Royal Infirmary.
Referral times during the first six months of 1989 are compared with the wait for referral
during the first six months of 1988 before LARS was set up. Results are shown in Table
II. Patients referred for pregnancy termination in 1988 waited significantly longer both
for an appointment to see a gynaecologist (p<0.002) and for operation (pcO.Ol). In
1988 76% of women waited more than one week to be seen and 41% of them waited
more than two weeks, while in 1989 over 85% of referrals were seen within one week
and none waited more than ten days.
The percentage of pregnancy terminations undertaken in Lothian at each week of
gestation from 5-22 weeks during 1988 until November when LARS came into operation
and from its inception until the end of 1989 is shown in Figure 1. Before a centralised
referral service was established just over 40% of terminations were being undertaken
at nine weeks gestation or earlier and 21% at 12 weeks or later. During 1989, 60% of
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Table II: Mean Waiting Time Between Initial Consultation and Referral to the Gynaecology Clinic for
Abortion and Between Initial Referral and Operation Among Patients Referred from Family Planning Clinics
to the RIE from 1 January-30 June 1988 and 1989
Appointment requested n Wait for referral Wait for operation Total wait
(days) (days) (days)
1989— 1st trimester 54 4.6 + 2.9 (range 1-8) 4.6±3.4 (range 0-17) 9.2 + 3.3 (range 1-18)
1989—Midtrimester 17 6.4 ±2.7 (range 1-12) 4.9 ±4.4 (range 0-14) 11.3± 3.9 (range 1-14)
1989—All 71 5.3 ±2.4 (range 1-12) 4.9±3.6 (range 0-17) 10.1 ±3.1 (range 1-17)
1988—All 88 11.2 ± 4.7 (range 0-21) 6.8±4.7 (range 0-20) 18.0 ±4.7 (range O-20)
pregnancy terminations were done at nine weeks or before and less than 10% of all
terminations were done beyond 12 weeks gestation.
Discussion
The introduction of a centralised abortion referral service in Edinburgh appears to have
made a significant difference to the time women seeking pregnancy termination wait
for referral to a gynaecologist—on average they wait one week less than they did before
the service was set up. There has also been a significant decrease in the wait—having
been seen by a gynaecologist—for the operation to be carried out. These improvements
have led to a dramatic change in the average gestation atwhich termination ofpregnancy
is being performed in Lothian.
Other factors may have contributed to these changes. For some years now the Depart¬
ment of Obstetrics and Gynaecology in Edinburgh has been involved with research in
medical methods of termination including the use ofanti-progesterones. Womensuitable
for medical termination are often referred directly to the clinician involved—bypassing
LARS. Equivalent numbers of medical terminations were done during 1988 and 1989
and they have been excluded from analysis. Knowledge of the availability of medical
termination among both general practitioners and women seeking termination may have
led to earlier referrals since the procedure is only suitable for women who are eight weeks
pregnant or less. Increasing discussion in the media about abortion and the abortion
law and changing attitudes towards abortion may make it easier for many women to
confront the problem of an unwanted pregnancy sooner than they tended to in the past.
These and other unrecognised factors may lead to earlier referrals.
The wait for operation during the period studied also appears to be shorter than it has
been in the past. This may simply be a reflection of a better organised referral system
leading to better organised operating lists. There is no evidence ofa fall in the demand for
other surgical gynaecological procedures to permit an improvement in the termination
service, but it is possible that earmarking a number of out-patient appointments for
termination referrals may make it more difficult to get an urgent appointment for other
gynaecological problems such as post menopausal bleeding; this too may have an impact
on the operating lists.
Women considering abortion occasionally change their minds during the referral pro¬
cedure. Of the 735 women referred through LARS to the Royal Infirmary during the
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Figure 1: Percentage of Terminations Being Undertaken in Lothian in Weeks of Gestation Before □ and After ■ LARS
was Established. Scottish Health Service Information and Statistics Division (Used with permission).
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first six months of 1989 10% (73), either cancelled an appointment at some stage during
the referral procedure (26), defaulted (31) or informed their doctor that they had decided
to continue with the pregnancy (16). Too short a referral time may push some women
into having an abortion which they may later regret. In France the law demands that
there must be seven days between the doctor agreeing to terminate a pregnancy and
actually doing so, in order to allow women time to reflect on the decision. However
16.6% (67) of the women taking the first available appointment to see a gynaecologist
at the RIE had had the pregnancy terminated within six days of first consulting their
GP; some would argue that this is too quick. Nevertheless if a significant number of
women are to be able to take advantage of medical termination of pregnancy, they will
have to decide to have an abortion within two weeks of missing a period in order to
allow the system to cope. In many parts of the UK there appears to be no system and
in England and Wales as a whole only 41% of abortions are carried out within the NHS,
although a substantial further number are carried out with NHS funding on private
premises. In Scotland, where less than 2% of abortions are done in the private sector,
the need for a well organised community service is vital if termination of pregnancy is
to be undertaken as early and therefore as safely as possible.
Update
A product licence was obtained in June 1991 for the use of mifepristone (RU486) for
termination of pregnancy up to 9 weeks gestation.
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Multicentre criterion based audit of the management ofinduced
abortion in Scotland
Gillian C Penney, Anna Glasier, Allan Templeton
Abstract
Objectives—To assess and improve the quality
of care provided to women undergoing induced
abortion.
Design—Two rounds of prospective, criterion
based case note review audit.
Setting—Ten NHS gynaecology units throughout
Scotland.
Subjects—2004 patient episodes of abortion care
identified consecutively during two rounds of audit.
The first round comprised 967 cases and the second
round 1037.
Interventions—Dissemination of results from the
first round ofaudit and recommendations for change
in the form of a written report and at postgraduate
meetings in participating hospitals.
Main outcome measures—Improvements in
quality of care as assessed against I"6 previously
agreed criteria, both overall across the 10 study
hospitals and within individual hospitals.
Results—Overall, four significant improvements
occurred: increased availability of early medical
abortion, decreased utilisation of surgical abortion
at very early gestation, increased use ofmifepristone
priming before second trimester medical abortion,
and increased provision of follow up. At the indivi¬
dual hospital level 42 of 150 elements of carc studied
were "close to optimal" at the time of the first round
of audit, rising to 54 at the second round (NS). A
total of 31 significant improvements in individual
elements of care occurred, but 11 significant
deteriorations also occurred (at the P < 0-05 level).
Conclusions—The prospective multicentre audit
proved feasible and achieved the aims of any form
of audit in terms of identifying deficiencies and
variations in care. The audit results prompted
objective review of local abortion services in partici¬
pating hospitals. At least for some elements of care
in some hospitals significant improvements were
detectable.
Introduction
Induced abortion is one of the commonest com¬
ponents of the Scottish NHS gynaecological workload,
accounting for around 11 000 procedures per year.'
Abortion carc was therefore considered to be a particu¬
larly appropriate topic for medical audit and was
recently addressed by means of a criterion based
approach in the gynaecology audit project in Scotland.-
Methods
A list of criteria for good quality care was agreed by a
combination of objective review of contemporary
medical publications, panel discussions, and postal
survey of all consultant gynaecologists in Scotland
(response rate 92%), as described." The lb criteria
which were addressed in the multicentre audit arc
listed in the box.
Ten hospitals throughout. Scotland representing 10
different health board areas and employing around half
of all consultant gynaecologists in Scotland were
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Criteria for good quality care addressed in case note review audit and
agreed among consultant gynaecologists in Scotland
Organisation ofservice
• (1) All women requesting abortion should be offered appointment with gynaecolo¬
gist within five days of referral
• (2) Induced abortion should be undertaken within seven days of appointment with
gynaecologist
• (3) In absence of specific medical or social contraindications women undergoing
abortion should be managed as day cases
Preabortion investigations
• (4) Woman's Rh status should he ascertained and Rh prophylaxis given after
abortion if indicated
• (5) Gestation need not routinely be confirmed by ultrasound scan
• (6) Cervical smear history should be recorded for all women undergoing abortion
• (7) Women undergoing abortion should be screened for genital tract infection and
treated if indicated
Methods ofabortion
• (8) Women presenting early in pregnancy (<9 weeks' gestation) should have option
of surgical or medical abortion
• (9) Suction termination should not he undertaken in very early pregnancy
( « 6 weeks' gestation) because of high incidence of failure
• (1(1) In selected women undergoing surgical abortion, technique for cervical
predilatation should be used
• (11) All surgical abortions at gestations >10 weeks should be carried out by
experienced gynaecologist (post-MRCOG or equivalent)
• (12) For second trimester medical abortions presentment with mifepristone
reduces induction abortion interval
Postabortion care
• (13) Before being discharged each patient should have agreed a contraceptive plan
• (14) Before being discharged each patient should be offered contraceptive supplies
• (15) A follow up appointment, either at hospital or with referring doctor, should be
given to every patient
• (16) Follow up appointment should he within two weeks of abortion procedure
assistant (with a medical secretarial background)
in each hospital identified al! patients undergoing
induced abortion. Mothers undergoing abortion
because of fetal abnormality were excluded as they
were thought to raise different care issues. Data
relating to the agreed criteria were collected in a
standardised manner in all 10 hospitals by transfer of
information from case notes on to a review document.
. Each audit assistant was trained by the research fellow
(GCP) in data transfer. Data from all hospitals were
entered into a purpose designed database by using
Paradox (Borland) software on an IBM compatible
personal computer. Statistical significance testing by
analysis (unless otherwise indicated) was performed
with Instat 2 (Graphpad) software.
After the first audit period results and recommcnda-
l aim.r i—First round of audit. Results of individual hospitals in relation to 15 of agreed audit criteria
tions for change were disseminated as a written report
mailed to all consultant gynaecologists. In addition, in
seven of the 10 hospitals a postgraduate meeting was




A data collection period of six months (beginning in
October 1992) was available for the first round of
audit. It was planned to review 100 consecutive cases
managed in each hospital during this time. In the larger
hospitals 100 cases were identified during as little as six
weeks, whereas in one of the smaller hospitals only 67
cases presented during the whole six months. Thus in
total 967 cases were studied. Owing to constraints of
the project timetable and funding, data collection for
the second round ofaudit was restricted to a two month
period (beginning in August 1993). All cases managed
in each hospital during this time were identified and
reviewed. The mean number of cases per hospital was
104 (range 20 to 266), and in total 1037 cases were
studied.
overa l j. improvements
At the time of the second round of audit four
significant overall improvements across the 10 hos¬
pitals were detected:
• The use of medical abortion for women at <9
weeks' gestation (criterion 8) rose from 39 to 516
(7-6%) to 172 of 541 (31-8%) (P< 0 0001)
• The inappropriate use of surgical abortion in women
at < 7 weeks' gestation (criterion 9) decreased from
68 to 85 (80 0%) to 56 of 98 (57-1%) (P=0-0017)
• The use of mifepristone cervical priming before
midtrimester medical abortion (criterion 12)
increased from 15 of 64 women (23*4%) to 64 of 102
(62-7%) (P< 0 0001)
• The recording of a follow up arrangement in the
case notes (criterion 15) increased from 52% to 69%
of cases (Wilcoxon signed rank test, P=0 037), and
the advising of follow up within the recommended
interval of two weeks after abortion also increased
(from 5% to 32%; Wilcoxon signed rank test,
P=0-0645).
There were no overall deteriorations in relation to
any elements of care.
IMPROVEMENTS IN INDIVIDUAL HOSPITALS
Fifteen of the agreed criteria were addressed on an
individual basis in each of the 10 hospitals. (Criterion 9
was omitted in view of the small numbers of patients
presenting at weeks in any one hospital.) Thus 150
individual elements of care were assessed. Results from
HospitalNo (No of casc> studied)
I 23456789 10
Criterion No Element ofcare In" IPO) (n-100) (n-100) (n-100) (ii-|00) (nHW) (n«100) (n«lt30) (n~ 100) (n->67)
1 % Of cases seen within five days 10 29 so 52 42 64 40 55 30 54
2 "•# Of procedures done within seven days 7.4 49 49 80 93* 70 6.3 (>7 92* 89
3 % Of patients managed as day cases B9 61 93* 95* 44 91* 70 7 72 48
4 "/» Of cases where Rh status was recorded 95' 99* 9R' 100* u«« 99' 100* 86 94* 97*
5 Of cases having ultrasound scan 33 •16 17' 17* 25' 37 97 83 13* 9'
6 Vt- Of eases whet c cervical enicitr history was recorded ft 3 21 55 t3 77 77 84 64 0 12
7 Of cases where genital tract swabs were taken 92* 14 2 1 2 88 15 1 t) 0
S Early medical abortion service available (yes (Y), n«> (N)) Y* Y* N N Y* N N N N N
10 */«0(high risk surgical abortions having prrdilatatinn 61 69 25 71 o2. 10 13 62 10 87
11 % (Xsurgical abortions at > 10 weeks performed by senior registrar
or above 67 54 57 87 100* 100* 100* 79 100' 100*
12 Mifepristone used in second trimester medical abortion (yes (Y),
no (N)) Y* Y* N N N N N N N N
13 1» Of cases where contraceptive plan was recorded Q5« 57 100* 96* 98' 98* 8S 98* 96' 94*
14 % Of cases where contraceptive supplies were given by hospital 20 16 43 24 83 20 16 12 80 81
15 % ( Xcases where follow up arrangements were recorded 74 25 100* 99* 91* 7 37 55 26 6
16 *'o Of case* where follow tip within two weeks was advised 13 4 1« 0 1 3 0 4 6 0
'Asterisk indicates element of care where performance was "close to optimal"
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TAHUi ii—Second roundofaudit. Remits of individual hospitals in relation to 15 ofagreed audit criteria


















66' 26 89 171 33 29i 53 49 6~T 51
78 86 84 77 751 75 75 73 85 80
85 821 96" HGi 94* 9(J* 72 271 82 65
98* 95* 95* 100* 100* 99* 100* 98* 91* 95'
29 6/1 13* 22' 31 25* 100 98 i 18* 15*
«|T 101 381 99'T 96*1 70 76 80 51 * 55t
Q2» 6 0 12 86t 88 10 0 0 0
V* y* y*t N y* n y*? n n n
77 86 53 74 100* 44 t 0 22 67 100*
59 75 33 100' 100" 100* 1(h)* 57 100* 100*
y' v' y*t N y*t y*t y't n n n
°2* 46 99* 100' 100* 99* 95* 100* ' °7* 85
42? U 52 44t 96* T 18 26 17 97*1 504
52 r 94* 100* 98* 14 80t 98*1 12 551
59? )5t 19 03*1 2 0 2 66 t 5 401
*-i Of caws seen within five days
V« Of ptnccdures done within seven days
% Of patients managed as day cases
% Of eases where Rh status was recorded
% Of eases having ultrasound scan
% Of eases where cervical sntear history was recorded
% Of cases where genital Iraft swain were taken
Haily medical abortion service available (yes (Y), no (N»
% Of high risk surgical abortions having prcdiloiation
% Ofsurgical abortions at > 10 weeks performed by senior registrar
or nlKive
Mifepristone used in second trimester medical abortion (yes (Y),
no (N))
% Of eases where contraceptive plan was recorded
% Of cases where contraceptive supplies were given by hospital
5v Of cases where folknv up arrangements were recorded
"Vo Of cases where follow up within two weeks was advised
'Asterisk indicates element of care where performance was "close to optimal." f Indicates significant improvement (P< 0 05). [Indicates significant deterioration (I* < 0 05).
the first round of audit are summarised in table I. Of
these 150 elements of care, 42 (28 0%) were judged to
be "close to optimal" (arbitrarily defined as 55 90% of
eases meeting the criterion, or (for criterion 5) ^25%
of eases undergoing ultrasound scanning, (for criteria 8
and 12) mifepristone being available).
Performance was particularly good in relation to
recording of Rh status (nine hospitals achieved >90%)
and recording of patient's contraceptive plan (eight
hospitals achieved >90%). No hospital achieved close
to optimal performance in relation to seeing patients
within five days of referral, recording of cervical
smear history, providing contraceptive supplies, or
suggesting follow up within two weeks of the abortion.
The results from the second round of audit are
summarised in table II. Fifty four elements of care
(36 0%) were judged to be close to optimal. This
increase over the first round failed to reach significance
(P-O I732). However, major improvements occurred
in relation to 31 individual elements of care. These
comprised the introduction of a new service (cither
early medical abortion or the use of mifepristone for
second trimester medical abortion) in six instances or
significant (P<0-05) improvements in the proportion
of cases meeting a given criterion in 25 instances.
The most common significant improvements were
in relation to recording of cervical smear history,
recording of a follow up plan, and advising early follow-
up (each occurred in five hospitals).
Hlcvcn significant deteriorations in the proportion of
cases meeting a given criterion also occurred. The most
common deterioration was in relation to the proportion
of cases seen by a gynaecologist within five days of
referral (three hospitals).
There was no" significant difference between the
number of improvements occurring in the seven
hospitals in which a postgraduate meeting was held (23
improvements out of a possible 105) and the three
hospitals in which results and recommendations were
disseminated us a report only (eight out of a possible
45) (P-0-6632).
Discussion
The multicentre audit proved feasible and achieved
good cooperation among gynaecologists. While ack¬
nowledging the theoretical advantages of clinical rather
than medical audit we perceived that this project
engendered a strong sense of ownership as a result of
being a confidential single discipline exercise initiated
by the Scottish branch of the Royal College of Obste¬
tricians and Gynaecologists, of which ull participants
were members.
The first round of audit enabled variations and
deficiencies in care to be identified and undoubtedly
prompted open and objective discussions about local
abortion services in participating hospitals. It might be
argued that some of the changes detected in the second
round were unrelated to the audit feedback exercise.
However, one of the most dramatic improvements (the
increase in mifepristone priming before midtrimcstcr
abortion) occurred at a time unrelated to new publica¬
tions on the topic and before the granting of a product
licence. Medical audit can never be the sole stimulus to
change; it acts alongside other educational initiatives.
In this instance, however, we believe the audit was
instrumental in changing practice.
It is clear that in order to maximise the benefits from
the national investment in clinical audit attention must
be directed at identifying the most effective strategies
for disseminating audit results and for implementing
change. Russell and Grimshaw have provided sugges¬
tions for the effective dissemination and implementa¬
tion of clinical practice guidelines4 (to which audit
recommendations are closely related)/ They suggest
that dissemination is best accomplished by "specific
educational intervention" rather than simply "mailing
targeted groups." However, in this study no more
improvements occurred in those hospitals where a
postgraduate meeting was held specifically to address
the audit findings than in those where a postal report
only was provided.
Implementation entails encouraging clinicians to
adopt the audit recommendations. The only imple¬
mentation strategy employed in this study was fore-
Clinical implications
• The quality of care provided to women
requesting abortion was assessed by means of
criterion based audit in hospitals throughout
Scotland
• Deficiencies in care and variations among
hospitals were detected
• Participating clinicians responded to the
audit results and to recommendations made by
the audit team
• Medical audit can act along with other educa¬
tional initiatives in increasing awareness of
effective treatments and in providing a stimulus
to change
• This audit exercise prompted open and
objective discussions among clinicians about
many aspects of patient care and is believed
to have been instrumental in stimulating signifi¬
cant changes in relation to some
BMJ volume 309 2 jui.y 1994
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warning participants that a second round of audit
was imminent. A more effective strategy might have
been to incorporate recommendations in a structured
patient record document for use while managing
abortion referrals, a technique which has proved
successful in implementing guidelines for the manage¬
ment of infertility."
The modest success of this national audit has
confirmed an interest and willingness to participate in
medical audit among Scottish gynaecologists. Refine¬
ments in audit methodology arc required to translate
this good will into substantial improvements in patient
care.
VCe acknowledge the cooperation of flic following con¬
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Agreeing criteria for audit of the management of
induced abortion: an approach by national
consensus survey





















Objective—To obtain a national con¬
sensus view of suggested criteria for good
quality7 care in induced abortion to serve
as a basis for standards for audit to assess
current clinical practice.
Design—Postal, questionnaire survey
assessing consensus agreement with
criteria identified from a literature review
and refined by an invited panel of four
gynaecologists and the gynaecology audit
project in Scotland (GAPS) committee.
Sett ing—Scotland.
Subjects—All 132 practising consultant
gynaecologists.
Main measures—Overall level of agree¬
ment with each of 20 suggested audit
criteria.
Results—121 completed questionnaires
were received (response rate 92%), of
which 119 were returned in time for
analysis; 107 came from consultants who
practised abortion routinely and were
included in the analysis. Nineteen of 20
suggested criteria were validated by an
overall balance of agreement. The most
strongly supported criterion (agreement
score +93) was for ascertaining rhesus
status of the woman and prophylaxis after
abortion, if indicated. The only criterion
to elicit a negative agreement score (-27)
was that dilatation and evacuation is the
best method of abortion at 12-15 weeks'
gestation. The ranked and prioritised
criteria resulting from this exercise are
being used within a national audit
project.
Conclusions—A postal questionnaire
survey among interested clinicians
resulted in a good response rate and
enabled the audit criteria to be validated
and ranked more objectively and among
more clinicians, than would have been
possible by group discussion.
(Quality in Health Care 1993;2:167-169)
Introduction
Criterion based audit has been described as
offering a valuable and realistic method of
audit based on review of medical records.1 3 In
this approach key elements of clinical manage¬
ment (audit criteria) are agreed by partici¬
pating clinicians. Case notes can then be
reviewed by non-medical audit assistants who
extract selected data relating to the agreed
criteria. Shaw suggested that around 15 such
criteria can be addressed in a single audit.1
The practical difficulties of establishing
audit criteria acceptable to all participating
clinicians are acknowledged,' and it has been
suggested that criteria should be based on the
findings of a literature review combined with
discussion by the audit group. Discussion by
all participating clinicians is clearly impractical
for large scale audit projects undertaken
regionally or nationally. This paper describes
an approach to agreeing audit criteria,
incorporating a postal questionnaire survey of
all involved clinicians, which has been
developed and used successfully in a national
audit project.
The gynaecology audit project in Scotland
(GAPS) was initiated by the Scottish
Executive Committee of the Royal College of
Obstetricians and Gynaecologists with the aim
of auditing three topics (induced abortion,
endometriosis, and carcinoma of the vulva)
nationally. The audit of each topic is seen as
an end in itself, but, in addition, the project as
a whole is seen as an opportunity to develop
approaches to the methodology of audit which
can be applied subsequently to further
topics.
'Hie approach to establishing audit criteria
which has been developed within this project
is described with reference to the first topic,
induced abortion.
Methods
A review of contemporary medical literature
relating to the management of induced
abortion provided the basis for a provisional
list of statements, br criteria, which were seen
as summarising essential elements of good
quality care. The criteria covered four,
previously agreed broad areas of abortion care:
organisation of the service, investigations
before abortion, methods of abortion, and care
after abortion.
For example, Criterion 1 - Women requesting
induced abortion should be offered an appointment
with a gynaecologist within five days of referral
This criterion was taken from the Birth
Control Trust model service specification'1
which provided the basis for several of the
suggested criteria under the "organisation of
the sendee" heading. The provisional list of
criteria was then modified and refined by
means of discussions with two separate groups
of clinicians: an invited panel of four
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gynaecologists (two with a special interest in
abortion care and two generalists) and also the
GAPS steering committee.
A questionnaire was then designed to assess
"level of agreement" with each of 20 criteria in
the final list. Respondents were asked: "The
following list of statements relating to the
management of induced abortion has been
drawn up following a literature review and
discussion with a panel of clinicians. We would
like you to indicate your level of agreement
with each statement as representing an
important criterion for good quality care on a 5
point scale graded as follows: 1 strongly agree,
2 agree, 3 neither agree nor disagree, 4
disagree, or 5 strongly disagree."
In September 1992 the questionnaire was
sent to all 132 consultant gynaecologists
practising in Scotland. The mailing list was
based on names and addresses provided by the
college and updated by means of telephone
inquiry to all 26 gynaecology units in
Scotland. A second copy of the questionnaire,
with a letter of reminder, was sent to those
consultants who had not responded within two
weeks. Data from the questionnaires were
entered into a purpose designed database
using Paradox (Borland) software on an IBM
compatible personal computer.
Each criterion was allocated an "agreement
score" in order to convey the overall balance
of agreement with each criterion among
consultants. In allocating the agreement scores
each response of "strongly agree" scored +2,
"agree" +1, "neutral" 0, "disagree" -1, and
"strongly disagree" -2. The scores for each
criterion were then summed and expressed as
a percentage of the maximum possible score
had all consultants strongly agreed (that is, of
204) to give die final "agreement score".
Thus, any positive score indicates a balance of
agreement, +100 is the maximum possible
score and -100 is the minimum possible
score.
Results
As a result of the two mailings, 121 completed
questionnaires were eventually received (a
response rate of 92%), 119 in time for
analysis. Of the 119 respondents, 12 indicated
diat they never accepted abortion referrals and
answered no further questions. Thus, die
opinions on abortion care of those 107
respondents who manage induced abordon in
die course of their routine practice were used
to validate the audit criteria.
The table shows all 20 criteria, in summary
form, ranked according to the agreement score
allocated to each. The agreement scores
represent an attempt to indicate tHe balance of
agreement with each criterion, giving
additional weighting to responses of strongly
Suggested criteria for good quality abortion care rartlecd bv level of agreement among 107 Scottish consultants
Ranking Agreement score Consultants who Abbreviated criterion
(Possible score agreed or
+ 100 to -100) srronglv agreed
(%)
1 +93 100 Rhesus status should be determined before abortion
2 +69 95 Cervical predilatation indicated for selected patients
3 +61 90 Surgical abortion at gestation > 11 weeks requires an
experienced operator (beyond member of Royal
College of Obstetricians and Gynaecologists or
equivalent)
4 +60 88 If indicated, oral contraception should begin immediately
a Her abortion
5 +59 87 Surgical abortion should be managed on a day case basis
6 +58 82 Contraceptive advice and supplies should be provided
after abortion
7 +56 83 Advice on "emergency contraception" should be provided
after abortion
8 +51 79 The "appointment to abortion" interval should be
<7 days
9 +50 81 The "referral to appointment" interval should be £5 days
10 +44 68 There should be a policy for treating potential genital
tract infection
1 i +43 80 Routine ultrasonography is unnecessary before abortion
12 +41 78 "Induction to abortion" interval should be <21 hours at
>15 weeks' gestation
13 +40 72 Abortion patients should begin cervical screening
regardless of age
14 +39 74 Surgical evacuation should not he routine after medical
abortion
15 +34 63 Women at <9 weeks' gestation should have a choice of
surgical/medical abortion
16 +25 40 Mifepristone reduces the induction to abortion interval in
the 2nd trimester
17 +23 59 All abortion patients should be offered a follow up
appointment
18 + 14 41 Surgical abortion should be avoided at gestations <6
weeks
19 +6 33 The follow up appointment should be widiin 14 days of
the abortion
20 27 19 At gestations of 12-15 weeks dilatation and evacuation is
the method of choice
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agree or disagree. The percentage of
respondents who agreed or strongly agreed
with each criterion is also shown. Nineteen of
the 20 suggested criteria gained positive
agreement scores, indicating an overall
balance of agreement. However, the ranked
criteria may be viewed as forming a range in
terms of their agreement scores and thus in
terms of the importance that can be attached
to them as a basis for acceptable audit
standards against which current practice may
be judged and towards which clinicians might
aspire.
The most strongly supported criterion, with
an agreement score of 93 out of a theoretical
maximum of 100 was: The woman's rhesus
status should be ascertained and Rh prophylaxis
given after the abortion if indicated. All
respondents agreed with this criterion, almost
85% strongly agreed. This fundamental
component of abortion care is clearly
acceptable to all as a target to be met in
providing an abortion service.
Among the least strongly supported of those
criteria gaining positive scores were those
relating to follow up after abortion. A follow up
appointment, either at the hospital, or with the
referring doctor, should be given to every patient
was ranked only 17 out of 20, and less than
60% of respondents agreed with it. The follow
up appointment should be within 14 days of the
abortion was ranked 19/20; only a third of
respondents actively agreed with it, most felt
"neutral". Thus, although die Birth Control
Trust and also the Scottish Home and Health
Department's Study Group on the manage¬
ment of gynaecological services emphasise that
the abortion service should encompass such
aftercare,4 5 these criteria were not given high
priority by Scottish consultants.
Only one of die suggested criteria gained a
negative agreement score (-27): At gestations of
12-IS weeks surgical abortion dotation and
evacuation) is the method of choice. This
criterion is well supported by results from
large series of patients managed in the United
States0 7 but is clearly not acceptable in
Scotland at present as a criterion for good
quality care.
Discussion
The results of the national survey have
enabled us to produce a list of criteria, ranked
according to their relative importance to
Scottish gynaecologists. It seems reasonable to
regard the 19 statements for which there was
an overall balance of agreement as valid
criteria for audit against which to measure
current practice. This process is currently
underway in the form of a prospective, case
note review audit of induced abortion in 10
representative hospitals throughout Scotland.
The ranking of the criteria according to
dieir relative importance will enable those
aspects of care which fail to measure up to the
criteria to be similarly ranked. This will be
helpful in deciding which aspects of care
warrant change and in prioritising such
changes for the allocation of resources. For
example, if it were found in the course of
169
prospective audit that the rhesus status of
abortion patients was not being routinely
measured, then participating clinicians, who
judged this to be of fundamental importance
would be expected to give high priority to
implementing change in this aspect of care
whereas this would not be so if it were found
that abortion patients were not routinely being
given follow up appointments within 14 days
of their procedure.
For aspects of care (such as follow up
arrangements) in which the views of
"specialists" in abortion care4 5 * differ from
those of the generality of consultants, the low
ranking of relevant criteria serves to highlight
appropriate topics for educational initiatives.
For such aspects of care opinion must be
changed before there can be hope of changing
practice. In this study the views of consultant
gynaecologists have been used to estimate the
relative importance of different aspects of
abortion care. Consultants seem to rank
"technical" aspects of care more highly than
the "supportive" aspects such as follow up.
Other interested groups such as nursing staff
and consumers might have ranked the
different elements of care differently.
This approach to establishing audit criteria
could be applied to other topics by surveying
clinicians on a geographical basis, as was done
here, or by sun-eying the membership of
specialist professional groups and societies
with regard to more specialised topics.
The survey described was undertaken to
establish criteria for audit rather than to
develop formal clinical practice guidelines.
However, a recent working group document
from the Scottish Home and Health
Department has highlighted the close relation,
between audit and development of guidelines
(Clinical Resource and Audit Group, 1992,
unpublished), and the consensus approach
used here could appropriately be applied to
the validation of guidelines and local
protocols.
In addition to the authors, the following gynaecologists served
on the two discussion panels: Philip Myerscough, Sheila
l.-awson, Richard Henshaw, Marion Hall, Henry Kitchener, Ian
Duncan. Ian Russell and Barbara Thompson gave methodo¬
logical advice; Elaine Stirton typed die questionnaire and
manuscript. The GAPS project is funded by a grant from the
Clinical Resource and Audit Group of die Scottish Office
Home and Health Department. \Vc thank die consultant
gynaecologists who responded to the questionnaire for their
cooperation.
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Objective To assess the impact of the introduction of new medical methods on the provision of
therapeutic abortions at the Royal Infirmary Edinburgh.
Design A review of the total number of abortions performed by medical and surgical means between
1989 and 1995 (inclusive); a prospective survey of the terminations of pregnancy (< 9 weeks of
gestation) performed over the six-month period of January to June 1994; and a questionnaire of the
reasons why women chose a particular method.
Setting Large teaching hospital in Scotland.
Subjects One thousand and seven women seeking early pregnancy termination between January and
June 1994.
Main outcome measures Proportion of pregnancies terminated by medical means; comparison of
complete abortion rate, incidence of complications and morbidity following both medical and
surgical methods (< 9 weeks of gestation); reasons for preference of the method of abortion.
Results Since 1991 there has been a progressive increase in Ihe number of medical abortions performed
at the Royal Infirmary of Edinburgh, and by 1994 the majority of women (57%) seeking abortion at
< 9 weeks chose a medical method. Women who chose medical abortion had more years at full-time
education and were less likely to smoke (P < 0 04). Both medical and surgical methods were highly
effective (> 96% complete abortion) with a low incidence of complications and morbidity. However,
women who had chosen the medical method were less likely to receive antibiotics for suspected
endometritis than their surgical counterparts (%2, P = 0 0001).
Conclusions If this trend towards medical methods in Edinburgh is repeated elsewhere, it will inevitably
have an impact on gynaecological services by releasing staff and operating time for other puiposes.
INTRODUCTION
Unwanted pregnancy is a universal phenomenon
which occurs in all societies irrespective of their
religious beliefs and cultural background. Even in
Scotland where there is relatively easy access to free
contraception, unwanted pregnancy resulted in 10 in
1000 women of reproductive age having a legally
induced abortion in 1993'. Vacuum aspiration is one
of the most common gynaecological procedures per¬
formed in the UK and can account for a substantial
proportion of a gynaecologist's operative workload.
Modern techniques of vacuum aspiration, including
priming agents which facilitate cervical dilatation,
have made a contribution to the overall safety and
Correspondence: Professor D. T. Baird, Department of Obstetrics
and Gynaecology, Centre for Reproductive Biology, University of
Edinburgh, 37 Chalmers Street, Edinburgh EH3 9 EW, UK.
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efficacy of this method so that major morbidity
occurs in < 1% of cases, and the complete abortion
rate approaches 98%2'4. The development of non¬
surgical methods of inducing an abortion, however,
eliminates the requirement for an operation and
anaesthesia and in addition the success of the method
is not dependent on the skill of a surgeon. In July
1991 the antiprogestin mifepristone (RU 486)
(Hoechst-Roussel Ltd, Uxbridge, Middlesex, UK)
was granted a licence in the UK for the purpose of
inducing a medical abortion in the first nine weeks
of pregnancy. In combination with a suitable
prostaglandin analogue, it has been shown to be an
effective and safe alternative to vacuum aspiration5'6.
Although this method is reported to be acceptable
to women as a means of terminating a pregnancy7'"9,
it has not as yet been widely adopted in the UK. A
survey of all Scottish Consultant Gynaecologists
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undertaken in September 1992 revealed that only half
of the gynaecology units in Scotland offered such
a medical abortion sen-ice10. The reasons for its
relatively low use include a lack of awareness that
this method exists, the misconception that it has a low
efficacy and. in addition, the conditions imposed by
the Department of Health may make its provision, at
least in the private sector, actually more expensive
than vacuum aspiration1'.
The Royal Infirmary of Edinburgh is a major
teaching hospital which has offered a medical abor¬
tion service for the termination of early pregnancy
since July 1991 when mifepristone was licensed for
use in the UK. In 1993, 69% of all abortions and 84%
of medical abortions (< 9 weeks) in Edinburgh and
the surrounding district (Lothian) were performed at
the Royal Infirmary1. The purpose of this study was
to assess the impact that new medical methods have
made on the provision of therapeutic abortions at the
Royal Infirmary of Edinburgh. This was assessed by"
determining 1. the numbers of abortions performed
by medical and surgical means since 1989; 2. the
numbers ofwomen (< 9 weeks of gestation) choosing
a medical method and their reasons for doing so;
3. comparing the efficacy, complications and mor¬
bidity associated with both medical and surgical
methods (< 9 weeks).
METHODS
The number of vacuum aspirations and medical
abortions performed each year at the Royal Infirmary
of Edinburgh between 1989 and 1995 was obtained
from the log books of the Gynaecology Operatiug
Theatre and the Medical Abortion Unit, respectively.
The figures obtained with this method agreed to
within 5% with the official hospital statistics for each
year. Since each type of gynaecological procedure
performed at the hospital is given a specific code
number, the latter statistics were easily obtained from
the hospital computer database from the code for
'termination of pregnancy'.
A detailed prospective study of all terminations of
pregnancy performed in the Royal Infirmary was car¬
ried out over the six month period of January to June
1994. Although one aim of the study was to deter¬
mine the total number of abortions and the gestations
at which they were performed, the main aim was to
compare the efficacy, complications and morbidity
associated with both medical and surgical methods of
inducing an abortion up to 9 weeks of gestation.
Approval for the project was obtained from the local
Ethical Subcommittee. Termination of pregnancy
was carried out under the conditions of the United
Kingdom 1967 Abortion Act.
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Since 1993 most women in Lothian have been
given a standard information sheet when they attend
their general practitioners or family planning doctors
requesting a termination of a pregnancy (< 9 weeks
amenorrhoea)12. This information sheet has been
approved by Ihe hospital medical and nursing
staff and describes in simple tenns the medical and
surgical methods used to terminate a pregnancy, the
conditions for being suitable for a medical abortion
and the symptoms likely to be experienced after both
procedures. Thus women who are suitable for either
method can consider the merits of both procedures
before referral to the hospital. After further coun¬
selling with the gynaecologist, women of < 9 weeks
amenorrhoea, if medically suitable, are offered a
choice between medical abortion and vacuum aspira¬
tion. An endoccrvical swab is routinely taken at this
visit to screen for chlamydial infection. Women who
have positive swabs are treated with appropriate
antibiotics on the day of the abortion procedure and
contact tracing ofpartners is arranged.
Throughout the study period women (< 9 weeks of
gestation) who chose a medical abortion were given
200 mg mifepristone orally (Mifegyne, Hoechst-
Roussel Laboratories Ltd, Uxbridge, Middlesex, UK)
and returned 36 h to 48 h later to the Medical Abor¬
tion Unit to receive the prostaglandin analogue13. The
prostaglandin analogue used was either half (0-5 mg)
of a gemeprost vaginal pessary (Cervagem, Pari lion,
Romford, Essex, UK) or 600 pg oral misoprostol
(Cytotec, Searle, High Wycombe, Bucks, UK).
Women remained in the unit for 4 h under the super¬
vision of nursing staff. A vaginal examination was
performed prior to discharge to determine if fetal
tissue had been passed and a follow up appointment
was arranged for two weeks later. Vacuum aspiration
was almost always performed as an outpatient proce¬
dure under general anaesthesia. Nulliparous women
routinely received cervical preparation by inserting a
1 mg gemeprost vaginal pessary into the vagina 3 h
before surgery. Vacuum aspiration was also the
method used to terminate pregnancies between 9 and
12 weeks of gestation. A minority of pregnancies
between 12 and 14 weeks were also evacuated surgi¬
cally after cervical priming with a gemeprost vaginal
pessary, as described above. The majority of women
of more than 12 weeks of gestation, however, had an
abortion induced medically with 200 mg of oral
mifepristone followed 36 h later by a gemeprost
pessary (0-5 mg or 1 mg) every 6 h14.
The gestations at which all abortions were per¬
formed were derived from the case notes and were
calculated on the basis of menstrual history and pelvic
examination, or pelvic ultrasound if the clinical find¬
ings were uncertain. For the putposes of the morbidity
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study, however, data was collected prospectively on
all women (< 63 days amenorrhoea) undergoing a
medical abortion (« = 329) or a vacuum aspiration
(n = 215) performed as a day case procedure. A
further 31 surgical abortions (< 9 weeks of gestation)
were performed in other locations within the hospital
during this time and so were excluded from the
detailed prospective study. Information regarding
patient characteristics, parity, past medical history
and details of the abortion procedure was recorded on
pre-tested data sheets on the day of admission to hos¬
pital. Information on the morbidity following each
method was collected at a follow up appointment two
weeks later by one of the investigators. This appoint¬
ment was given to all the women who had a medical
abortion (n = 329) and to all the women who had a
vacuum aspiration and lived within Lothian (n =
194). At this visit, women were questioned about the
severity of vaginal bleeding, complaints related to the
abortion procedure and whether they had sought
medical advice or required treatment following
discharge from hospital. When women failed to
attend for follow up on two occasions, the general
practitioner or referring doctor was contacted by
postal questionnaire to ascertain whether the patient
itad any significant morbidity relating to the abortion
procedure and if so what treatment was required.
Data were thus available on the wellbeing of all those
in the study who had a medical abortion and 96% of
those who had a surgical abortion. In addition, the
hospital admissions computerised database was
searched to determine whether any woman who had
defaulted from follow up had been readmitted to the
Royal Infirmary within four weeks of the procedure
and the circumstances for admission.
Throughout the study period, a questionnaire
was also conducted to determine the factors which
influence a woman's decision to choose a particular
abortion method. Women seeking a termination of
pregnancy (< 63 days amenorrhoea) (n = 207) were
invited prior to vacuum aspiration (n = 103) or admin¬
istration of mifepristone (n = 104) to complete a
questionnaire which consisted mainly of a series of
questions with answers which required women to inti¬
mate their response by placing a pencil mark in a box
alongside the most appropriate answer. Because of
the pressure of work it was not possible to ask every
woman who presented to complete the questionnaire
which was given to up to five women per day until
the desired number had been obtained. Eighty-six of
103 women seeking vacuum aspiration and 90 of 104
women who had a medical abortion completed the
additional section of the questionnaire which con¬
tained several open ended questions asking women to
state their reasons for choosing a particular method.
1989 1990 1991 1992 1993 1994 1995
Fig. I. The number of abortions performed in the Royal Infirmary of
Edinburgh from 1989 to 1995. Mifepristone was licensed in Great
Britain for induction of abortion in July 1991. M = surgical; ED =
medical < 9 weeks; □ = medical > 12 weeks.
Statistical analysis
For the purpose of statistical analysis a %2 test of sig¬
nificance was used to compare data between groups.
RESULTS
The total number of abortions performed in the Royal
Infirmary rose slightly from 1,645 in 1989 to 1,872 in
1995 (Fig. 1). Since 1991 when mifepristone was
licensed for use in the medical termination of early
pregnancy, the number of first trimester abortions
induced using medical methods increased annually
from 219 in 1991 to 748 in 1995. The small number of
medical abortions in early pregnancy performed prior
to 1991 were conducted as part of clinical research
studies with mifepristone. Since new medical meth¬
ods were introduced, the total number of vacuum
aspirations performed has decreased and by 1995 rep¬
resented only 53% of the total. The number of mid-
trimester abortions induced medically (> 12 weeks of
gestation) have remained fairly constant at about 200
per year until 1995 when the number fell to 129.
Over the six-month period of more detailed study
(January to June 1994) a total of 1007 terminations of
© RCOCi 1996 Br J Obstet Gynaecol 103, 1222-1229
368















Included in study 215













Fig. 2. Numbers of women undergoing medical and surgical methods ofabortion at the Royal Infirmary of Edinburgh between January and June
1994 and numbers of those attending follow up as part of detailed prospective study.
pregnancy were performed at the Royal Infirmary
(Fig. 2). In 14 women case notes were missing and so
the gestation at which these abortions were performed
could not be determined. Of the remaining 993
induced abortions, 13% were > 12 weeks; 29% were
9 to 12 weeks and 58% were < 9 weeks of gestation.
The majority of pregnancies > 12 weeks of gestation
were terminated by medical means (83%, n — 1 11),
with the remainder terminated by vacuum aspiration.
All terminations between 9 and 12 weeks of gestation
were performed using vacuum aspiration. Of the 575
women < 9 weeks of gestation, 329 (57%) chose to
have the pregnancy terminated by the medical
method (Fig. 2). These women were of similar ages,
marital status and parity to those undergoing vacuum
aspiration, but were more likely to be nonsmokers
(X2 = 4-5, P < 0-04) and to have a higher level of
education (x2 = 8-6, P < 0-04) (Table 1). In addition,
a higher proportion of women who chose medical
abortion had previously had an induced abortion
(32-5% and 24% for medical and surgical, res¬
pectively; x2 = 4-4, P < 0 04). The incidence of
chlamydial infection was similar in both groups
(-5%) and all women were known to have received
appropriate antibiotic therapy on the day of the abor¬
tion procedure.
© RC.OG 1996 BrJObsiet Gynaecol 103, 1222-1229
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Tabic I. Characteristics of women (< 9 weeks of gestation) choosing
medical and surgical methods of abortion. Values for characteristics
are given as n! total (%) except for mean age which is shown as
years -rSEM.
Medical Vacuum aspiration
Characteristics n ~ 329 n~ 215
Mean ace 25-5 ±0-3 25-3 ±0-5
Single status 230/329(70) 135/213(63)
Piitnignividae 220/329(67) 130/215(60 5)
Previous induced abortion 107/329 (32-3)* 52/215(24)
Nonsmoker 187/310(60)* 101/199(51)
Finished education > 19 years 56/308(18-5)* 22/174(13)
'Difference from vacuum aspiration P < 0 04.
The efficacy of medical and surgical methods (< 9
weeks of gestation) were similar with complete abor¬
tion rates of 96-4% and 97-9%, respectively. Four
women (2-1%) following vacuum aspiration and five
(1-5%) following medical abortion required further
surgical evacuation of the uterus because of retained
products of conception. In addition seven women
(2-1%) had vacuum aspiration of the uterus to termi¬
nate an ongoing pregnancy following attempted
medical abortion. There was one woman in whom it
was suspected that the uterus had been perforated
during vacuum aspiration (< 9 weeks of gestation)
but this was not confirmed at subsequent
laparoscopy. The incidence of complications follow¬
ing both methods was low. Complications arising
from the medical method consisted of two cases of
persistent heavy bleeding after prostaglandin admin¬
istration, which required the uterus to be evacuated.
There was also one case of a drug-induced skin erup¬
tion following mifepristone (erythematous macular
rash on upper body) which resolved spontaneously.
At the follow up visit, we wished to assess the inci¬
dence of post-abortal pelvic infection and blood loss
as indices of morbidity. Of those women who were
offered a follow up appointment. 129 (67%) from the
surgical group and 317 (96%) from the medical
group attended. A greater proportion of women who
had undergone vacuum aspiration had already sought
medical advice in the interim from their general prac¬
titioner or referring doctor for complaints related
to the abortion procedure [18 (14%) and II (3%) of
the women in both groups, respectively; x2 = 16-6,
P - 0 0001]. Although we were unable to assess the
true incidence of pelvic infection, we were able to use
the information from the referring doctors to deter¬
mine the use of antibiotics for suspected endometri¬
tis. Women who had undergone vacuum aspiration
(< 9 weeks of gestation) received antibiotics for sus¬
pected endometritis more frequently than their med¬
ical counterparts [18/187 (9-6%) and 4/329 (1-2%),
respectively; %2 = 20-6, P = 0 0001 ]. Subjective blood
loss after the abortion was assessed by asking women
in whom bleeding had ceased by the follow up visit
[116 (90%) in the surgical and 176 (55%) in the
medical group] to describe how the entire episode of
bleeding compared with their normal menses.
Bleeding was more often reported as 'heavier than
normal menses' after a medical [117 (66%)] than after
a surgical abortion [13 (11%); x2= 134-9, P = 0-001].
Women who completed questionnaires were repre¬
sentative of all the women in the prospective audit
with respect to age, marital status and parity. Most
women stated that they were first aware that a
medical method existed when they made professional
contact with the referring doctor [43 (41%) and 52
(51%) of those undergoing surgical and medical
methods, respectively] and most had already decided
on their preferred method of abortion before the con¬
sultation with the hospital gynaecologist [60 (59%)
and 75 (74%) of the surgical and medical groups,
respectively]. Women in both groups agreed that the
two most important sources of information regarding
the methods used were medical staff [n = 174 (87%)]
and the information sheet [n = 80 (40%)]. All the
women having a medical abortion had been offered
a choice of method, but 13 of the women having a
vacuum aspiration (13%) had not been offered
a choice due to the presence of a pre-existing medical
condition (such as asthma) which constitutes a
contraindication to prostaglandins. Most women
expressed a definite preference for their chosen
method and only a small number (six in each group)
stated that the decision had virtually been based on
the result of'tossing a coin'.
The majority of women completed the section in
the questionnaire containing open-ended questions
on their reasons for their choice of method (Tables 2
and 3). While many women chose a medical abortion
in order to avoid surgery or anaesthesia, those who
preferred vacuum aspiration did so because they
wished to be unconscious and unaware of the proce¬
dure, since they felt they would be distressed at the
prospect of seeing the products of conception. In con¬
trast some of the women chose the medical method
because they felt it to be 'more natural' and would
allow them to remain 'in control' of the process.
DISCUSSION
Despite ready access to free contraceptive advice
from both general practitioners and a network of fam¬
ily planning clinics, the number of unwanted pregnan¬
cies terminated annually by abortion has not fallen
during the period surveyed (1989-1995) in Lothian
or Scotland (over 2000 and 11,000, respectively)1.
© RCOG 1996 Br J Obstet Gynaecol 103, 1222-1229
370
IMPACT OF NEW METHODS ON THERAPEUTIC ABORTIONS AT THE ROYAL INFIRMARY EDINBURGH 1227
Table 2. Vacuum aspiration: main reasons tor preference. Values are Table 3. Medical method: main reasons for preference. Values arc
given as n (%).The total is more than 100% due to the fact that some given as it (%). The total is more than 100% due to the fact that a few
women stated more than one reason for preference. women stated more than one reason for preference.
Reason n - 86 Reason it — 90
Only single visit required 34 (40) Avoid anaesthesia 32(36)
Unconscious and unaware of procedure 34(40) Avoid surgery 30(33)
Quicker completion of abortion 25 (29) More natural 22(16)
Distress at prospect of seeing products ofconception 22(26) In control 10(11)
Perceived higher failure rate ofmedical method 13(15) Future infertility after vacuum aspiration. 6 (81
Perceived more common method 10(12)
Possible side-effects of drugs used in medical method 3(4)
Part of the continued demand can be explained by
demographic changes as the young women born
during the baby boom of the 1960s pass through their
period of maximum reproductive activity15. In our
study throughout this period there has been a gradual
increase in the proportion of women requesting
abortion at an earlier gestation and in the Royal
Infirmary the majority of pregnancies (58%) are now
terminated before the ninth week of gestation. Since
new medical methods of inducing abortion were
introduced in 1991 the number of women requesting
this method has increased annually, representing by
1994 the majority (57%) of pregnancies under nine
weeks. Including those pregnancies in the mid-
trimester, 45% of all abortions in the Royal Infirmary
are now terminated medically. As the complication
rate of abortion is related to gestation, it is desirable
that the pregnancy be terminated at the earliest possi¬
ble gestation. If women seeking an abortion are to
be given a choice of method, an efficient system
ensuring speedy referral from general practitioner
to gynaecologist, such as exists in Edinburgh, is
necessary16.
Our results, demonstrating that the majority of
women opt for medical abortion ifgiven a choice, are
similar to a study of French women7. The main
reasons for choosing the medical method are to avoid
surgery and anaesthesia or because it is perceived to
be a more natural experience9. A small number of
women in our survey stated that they would prefer
this method because it puts them, rather than the
surgeon, in 'control' of the procedure. In agreement
with the results of others9 we found that some women
request vacuum aspiration because they wish to be
unaware of the abortion procedure or because the
abortion is completed quickly and only requires one
visit to hospital. It has previously been reported that
women who live at a distance from the hospital lend
to prefer vacuum aspiration as a method of abortion9,
which may explain why almost one-third of the
women who were offered a follow up appointment
after vacuum aspiration failed to attend.
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Women who chose a medical abortion had more
years of full-time education and were less likely
to smoke, suggesting that, as in France, women
choosing medical methods tend to be of a higher
socio-economic status7. The reason for this difference
is uncertain but may be related to the fact that they
have a greater ability to understand fully the choices
available and seek medical advice at an early stage.
In contrast to previous studies7-9 we found that
women choosing the medical method were more
likely to have had a previous induced abortion than
those who chose the surgical method. The reason for
this is unclear, but one possibility is that having had a
previous abortion, they may recognise the symptoms
of pregnancy at an early stage and seek termination
of an unwanted pregnancy without delay. Thus,
having presented at an earlier gestation they can avail
themselves of the option of a medical abortion. Since
most women decided on the preferred method of
abortion after consultation with the referring doctor,
it would appear that die initial abortion counselling
exerts a major influence on the woman's choice of
method. It is therefore important that general practi¬
tioners and family planning doctors remain well
informed of all aspects of treatment including new
developments. As die information sheets were shown
to be a valuable source of information for helping
women decide upon the preferred method of
abortion, it is appropriate that they are provided at
this early stage of the abortion counsell ing.
Both methods of abortion were sfiown to be highly
effective. The cases of ongoing pregnancy following
medical abortion during the study period occurred as
part of a larger randomised study comparing the effi¬
cacy of different prostaglandins, which confirmed
previous suspicions that oral misoprostol is less
effective than gemeprost when used at gestations of
50 to 63 days13-17.
The results of the detailed prospective study
demonstrated that both medical and surgical methods
of abortion have a low incidence of complications.
An interesting finding, however, was that women
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who had a surgical abortion received antibiotics for
suspected endometritis eight times more often than
their medical counterparts. Similar findings have also
been observed among women who expressed no
preference for a particular abortion method and were
randomly allocated to either vacuum aspiration or
medical abortionls. A lower incidence of infection
might be expected following a medical abortion since
this method is noninvasive, involves 110 instrumenta¬
tion and thus there is a lower likelihood of pathogens
being introduced into the uterine cavity. It is also pos¬
sible that the medical method may confer protection
against ascending infection through the pharmaco¬
logical effects of mifepristone. Previous animal
studies have demonstrated an increase in leucocytes
in the antiprogestin-treated pregnant cervix19, and it
is therefore possible that this could enhance local
immunological defences against infecting organisms.
However, women who chose vacuum aspiration
attended follow up less often than their medical
counterparts and had often seen a doctor in the
interim and commenced antimicrobial therapy. Thus
the increased use of antibiotics in this study may to
an extent reflect different practitioners' prescribing
policies. It is also possible that the higher incidence
of use of antibiotics following vacuum aspiration
could be due to the fact that women with complica¬
tions would be more likely to attend the hospital for
follow up. This seems unlikely, however, because
there was no difference in the use of antibiotics in
those women who attended for follow up at the
hospital (13/129) compared with those who defaulted
but were treated by their general practitioner (5/58).
Although subjective blood loss was greater follow¬
ing the medical method, we have previously demon¬
strated in a quantitative study that the actual blood
volume lost (-80 mL) following both methods is
similar30. The difference between the objective or
measured blood loss and the subjective or reported
blood loss is likely to be accounted for by the fact
that with a surgical abortion most of the blood is lost
at the time of vacuum aspiration, whereas blood loss
occurs more gradually following a medical abortion.
This study demonstrated that the introduction of
new medical methods of inducing an abortion has
made a significant impact on the clinical services
involved in providing therapeutic abortions at
the Royal Infirmary of Edinburgh. Not only has it
given women a choice of abortion method where
none previously existed, but medical abortion has
proved to be the more popular method which is both
safe, effective and highly acceptable as a means of
terminating an early pregnancy. In addition, the
reduced demand for vacuum aspirations has
inevitably served to release operating theatre time for
other gynaecological procedures to be performed. If
this trend towards medical methods continues and is
repeated in other gynaecological units throughout the
country, it will have important implications for the
provision ofabortion services nationwide.
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This paper summarises the views on their care of 688 women undergoing induced
abortion in 10 Scottish hospitals. Over 80% were satisfied with care provided by
medical and other staff and 75% felt they had received enough emotional support.
Hospital staff discussed contraception with 92% but offered contraceptive supplies to
only 54%. Only 24% of patients eligible for early medical abortion were offered a
choice of methods and only 44% of all patients were offered any form of follow-up,
although 83% felt follow-up was worthwhile. Over a quarter of women reported
health problems in the month following abortion. These women could not be predicted
on the basis of age, gestation, parity or method of abortion. Significant differences
among study hospitals were measurable in relation to satisfaction with care by nursing
and ancillary staff, perceptions of emotional support and provision of contraceptive
advice and supplies. Better care appeared to be provided where women were managed
in a special abortion unit rather than where care was integrated into the general
gynaecology workload.
Introduction
Induced abortion is the second most common procedure in the Scottish NHS gynaecological
workload, accounting for 12% of inpatient plus day case discharges (around 11,000
procedures per year).1 In view of its numerical importance, abortion care may be considered
a particularly appropriate topic for medical audit and was included among three topics
addressed by the Gynaecology Audit Project in Scotland (GAPS).
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In 1983, the NHS Management Inquiry^ emphasised the importance of eliciting the views
and experiences of NHS users and subsequent discussions as to how the quality of health
care should be measured have included patient satisfaction as an important dimension
However, most surveys which followed the Management Inquiry initiative were
managerially led and focused on 'hotel' aspects of hospital care rather than clinical
treatment.
The GAPS audit of abortion care included a postal questionnaire survey of patients, seeking
their views on various elements of their clinical management. The results of the survey are
presented in this paper.
Method
Ten hospitals throughout Scotland were recruited into the audit. These comprised a mixture
of teaching and district general hospitals, large hospitals and small and represented 10
different Health Board areas. Thus, the participating hospitals represent almost the full
spectrum of settings in which NHS gynaecological care is delivered in Scotland and employ
around half of all consultant gynaecologists.
Consecutive women undergoing induced abortion were identified in all 10 hospitals during
two audit periods (during 1992 and 1993) and their case notes reviewed as described
elsewhere.5 Each patient was asked by ward staff if she was willing to participate in a
survey about her care. A questionnaire was sent to the home address of each consenting
patient four weeks post-abortion. The questionnaire addressed the following topics:
1. General satisfaction with care provided by doctors and by other hospital staff.
2. Provision of emotional support .
3. Provision of contraceptive advice and supplies.
4. Views on the availability of a choice of abortion methods and of follow-up.
5. Post-abortion health problems.
Completed questionnaires were returned (using a S.A.E. provided) to the project office
where data were entered into a purpose-designed database using Paradox (Borland)
software on an IBM-compatible PC. Statistical significance testing (using the chi squared or
t tests as appropriate) was performed using SPSSPC software.
Results
Response. A total of 2,002 patients were identified in the course of die audit exercise. Of
these, 1,073 (54%) consented to participate in the patient survey and were sent a
questionnaire. A total of 688 completed questionnaires were returned, a response rate of
64% of those who consented to participate and 34% of the total.
Responders have been compared with non-responders in terms of age, gestation, painty and
method of abortion. Responders were slightly older (mean age 26.0, SD 6.8 years vs 24.7,
SD 6.3 years; p < 0.001); were less likely to be primigravidae (270 of 688 [40%] vs 604 of
1,325 [46%]; p = 0.028) and were more likely to have undergone surgical rather than
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medical abortion (574 of 688 [86%] vs 1,028 of 1,325 [78%]; p < 0.001). There was no
significant difference in gestation between responders and non-responders.
General Satisfaction. Patients were asked to indicate their level of satisfaction with care
provided by doctors and by nursing and ancillary staff on a five-point scale ranging from
'very satisfied' to 'very dissatisfied'. Responses are summarised in Figures 1 and 2.
Overall, more patients were 'satisfied' or 'very satisfied' with care by nursing and ancillary
staff than with care by doctors (604 [88%] vs 569 182%]; p = 0.008). There were no
significant differences among the 10 hospitals in the percentage of patients satisfied with
care by doctors (range 73% to 91%; chi squared test, p = 0.543). However there were
LEVEL OF SATISFACTION
Figure 1. Overall Satisfaction with Care Provided by Doctors
LEVEL OF SATISFACTION
Figure 2. Overall Satisfaction with Care Provided by Nursing and Ancillary Staff
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significant differences in satisfaction with care by nursing and ancillary staff (range 70% to
99%; chi squared test, p < 0.001).
Provision of Emotional Support. Patients were asked three questions in an attempt to
assess the adequacy of counselling and emotional support. Responses are summarised in
Table I. There were significant differences among the 10 study hospitals in relation to the
percentage answering 'yes' to question 3, relating to overall perception of emotional
support (range 57% to 93%; chi squared test, p < 0.001).





1. During your clinic appointments, did you have enough time and help
in reaching your decision to have an abortion? 592 86
2. Do you fee] now that your decision was right for you? 613 91
3. Overall, do you feel that you received enough emotional
support from the hospital staff during your clinic visits and
hospital treatment? 502 75
Contraceptive Provision. Patients were asked if hospital staff had discussed contraception
and if they had offered to provide contraceptive supplies. Of 675 patients who answered
these questions, 619 (92%) indicated that contraception had been discussed and 364 (54%)
that supplies had been offered. Again, there were significant differences among hospitals:
'contraception discussed' ranged from 78% to 100% (p < 0.001) and 'supplies offered'
ranged from 22% to 90% (p < 0.001).
Patients were further asked: 'What are you doing about contraception just now?' Of 684
who answered, 589 (86%) had adopted a contraceptive method at four weeks post abortion
(the pill in 55%). Forty women (6%) responded that they 'did not need contraception just
now' and 55 (8%) that they were 'using nothing but planned to start soon'.
Women were also asked if they were aware of the availability of emergency contraception.
Of 682 who answered, 504 (74%) answered 'yes'.
Choice of Methods. Gestation data were available for 668 respondents. Of these, 346
(52%) were < 9 weeks gestation when first seen at die hospital and were potentially eligible
for early medical abortion. Of these, 84 (24%) indicated that they had been offered a choice
of method and 45 of these (54%) had undergone a medical procedure.
Of the 84 women who were offered a choice, 74 (88%) felt that 'being offered a choice was
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Follow-up. Patients were asked if a follow-up visit either at the hospital or with the
(referring doctor) had been arranged for them. Of 681 who answered, 385 (56%) were
offered no follow-up. Where follow-up was arranged, it was with the general practitioner in
most cases (203; 69%). Women were also asked if they felt a follow-up appointment was
worthwhile. Of 618 who answered, 511 (83%) answered 'yes'.
Post-Abortion Health Problems. Women were asked: 'In the last month, since your
abortion, have you had any health problems connected with your treatment?' Of 681 who
answered, 181 (27%) indicated that they had experienced a total of 257 problems. The
problems described are summarised in Table II.
Table II: Post-Abortion Health Problems Described by 181 Patients
Problem No. ofpatients
Excess bleeding 88






Those responders who reported health problems have been compared with those who did
not in terms of age, gestation, parity and method of abortion. There were no significant
differences between the two groups in relation to any of these factors.
Discussion
The response rate to this survey was (not unexpectedly) low at 64% of those who agreed to
participate. Many patients were reluctant to receive questionnaires sent to their home
addresses and the need to obtain written consent produced some administrative difficulties
for ward staff. However, responders did not differ greatly from non-responders in terms of
age, gestation, parity or method of abortion and may be viewed as fairly representative of
women undergoing abortion in Scottish NHS hospitals.
It is reassuring that, in general, women seem very satisfied with care by doctors and, even
more so, by other hospital staff. It is, however, disappointing that a quarter of patients felt
they had not received enough emotional support from hospital staff although in the 'best'
hospital 93% were satisfied with this aspect of care.
National recommendations advocate that abortion care should include contraceptive
provision and the prevention of further abortions.6"4 It is disappointing, therefore, that
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almost half of the patients indicated that they were not offered contraceptive supplies by
hospital staff. Again, in the 'best' hospital, 90% were offered supplies. It is reassuring that
the vast majority of women had obtained a contraceptive method from some source and had
adopted it at 4 weeks post-abortion. Only a small group appeared to have an unmet need for
contraception.
National guidelines also advocate that abortion services should encompass aftercare1 but
almost half of the patients indicated that they had been offered no follow-up. It was not
possible to identify those patients who experienced post-abortion health problems on the
basis of age, gestation, parity or method of abortion and, therefore, it appears that the
opportunity for follow-up should be offered to all.
Abortion care is offered in a variety of settings in the 10 study hospitals. In some, abortion
patients are integrated into general gynaecology clinics and wards whereas, in others, the
patients are managed in clinics and wards dedicated to abortion care. In this survey,
significant differences among hospitals were measurable in relation to satisfaction with care
by nursing and ancillary staff, perception of emotional support provided and discussion and
provision of contraception. In each instance, the best results occurred in hospitals where
women are managed in abortion-dedicated clinics or wards.
Thus, the multicentre survey revealed that, in general, abortion patients are satisfied with
their care but there is scope for improvement in terms of provision of emotional support,
availability of a choice of abortion methods, provision of contraceptive supplies and follow-
up. Abortion care may be best provided in units dedicated to this purpose.
Acknowledgements
The authors acknowledge the co-operation of the following gynaecologists who co¬
ordinated the project in each hospital: Aberdeen Royal Hospitals NHS Trust/Dr P Terry;
Dumfries & Galloway Infirmary/Dr G Gordon; Ninewells Hospital, Dundee/Dr N Patel;
Hairmyres Hospital, Glasgow/Dr John Grant; Royal Infirmary, Edinburgh/Dr G Smart;
Southern General Hospital, Glasgow/Dr M Carty; Inverclyde Royal Hospital, Greenock/Dr
L Cassidy; Raigmore Hospital, Inverness/Dr M Hulse; Ayrshire Central Hospital, Irvine/Dr
S Prigg; Victoria Hospital, Kirkcaldy/Dr M Hill. Elaine Stirton typed the manuscript and
also computerised the data. The GAPS project is funded by a grant from the Clinical
Resource and Audit Group (CRAG) of the Scottish Office Home and Health Department
(SOHHD) (but the views expressed are those of the authors and not necessarily those of
CRAG or the Department). We are particularly grateful to all ward medical, nursing and
secretarial staff who sought consent from patients and, of course, to the women who
participated in the survey.
References
1. Abortion statistics 1991. Health Briefing 1992; 92/04.
2. Department of Health and Social Security. NHS management inquiry. DHSS, London 1993.
3. Maxwell R. Quality assessment in health. British Medical Journal 1984; 288: 1470-2.




Health Bulletin 52(6) November 1994
5. Penney G C, Glasier A, Tempteton A. A multi-centre, criterion-based audit of the management of
induced abortion in Scotland. British Medical Journal 1994; 309: 15-18.
6. Scottish Office Home and Health Department. Scottish Health Service Advisory Council. Report
of the Study Group on the management of gynaecological services in Scotland. Edinburgh: HMSO.
1991.
7. Birth Control Trust. Model Service Specification: Services for women requesting abortion. 1992/3.












































































































































































































































































































































































































































































































































































































































































































































































tohegynaecologistfail doke pirappointments mtageduring theproc ss.Someleftitasminutea ds mplydidnotturnf r theoperation.Manywomeaf idtmabrefus abortionndperhapsfosomeitn tp ss bletmakhei ldeci i untiltheyarequi ecertainatr llydoh vh c .F roth s, therealityofabortionmn tbecomeapp rentunt lfacedwi h thepracticalitiesofattendingf rsurg rynin tl sm u e theycannotgohroughwitit.Is meuntri scasFr ,sta ute demandswaitingperiodb t eenthiabortioh seg ed andtheimitscarriedoutllowwom nopportunityrefl ctn theirdecisionfreeomw rryatrequestmaybfus d.La minutechangesofi dayausep rticularroblemsw thfirst-trime t medicalabortionwhereth48-hdelaybetweentiprogesteronend theprostaglandintreatmentallowsimforch ngefh rt. IntheUKev rywomanseekinganbortiomustedoctors, bothfwhommustsignaformtatingthererlegiti ategrounds forterminatinghepregnancy.Moswomenst irg eralpractit o er (GP)firstandthengynaecologistwhprovi eseseco dig ature performstheabortion.Professi nalinvolvedw hab rtioftfeat theGPisbestpersonoc unselwomaah rshmostlikely
wtoknherandpersonalcircumsta ces.Sow m n,o ev r
o®prefertosadoctowhosnotkn whem—thisppliparticularly toeenagersandm rriedwom nhosepre nancyaybhresultf anextramaritalrelatio ship.Thesewo enm yendc munity familyplanningcli c(althoughnotlinicsareblt akedire t referraltogynaecologists),oh ymay,f s nfp rceivedivacy choosetgprivately,huha ingforeabortion.Tm j rity ofwomendnotattendthoctorf rhelpithmaki gtde isio (only12%didsoitheAllentudy[5Jrf emotionalupport( l3%). Seeingadoctorisnecessarypartofg ttingabortiondw me attendexpectingpreg a cyt s ,informationref rr l.Iorder satisfythemselvesateraregroundfot rminationo td ct r andcou sellorsdiscusthrea onwhytpregnancyunwa teda thepracticalandemo ionalconseque cesflopti s:abortion, continuingwiththepreg ancya dkeepitb bynadopt o .M st usuallyexplorewheth rthom niabs lutelycer ib th decisions nceuncertaintymayb orelik ltadreg t.Byh timeheyseseconddoct rostwomenarc rtaith ywa t anabortionndfewexpecth lpwithdecisi n-makingrothgy ae¬ cologist.Sincethgynaecologistalshs tisfyims lfrer lt a therearlegitimategroundsfothb rtion,h rshusuallyxplor s




































































































































































































































































































































































































































































































































































































































































































































































































































































118CHAPTER7 availableonrequestrwh resocialf ctorscanbindic tion[11]. However,25%ofwomenstillhaaccesstoabortionlyipreg ancyi life-threatening.Lib ralizationofthebortionl wsle dsbutd est guarantees fabortionserv ce.Im stcountriesiwhichabor ioni legalon ylicensedmedicalp rsonnelpr videit,althoughthpoliciesand practicesregardingthsett gvarywidely. Inmanydevelopedcountries,theismoveawayfromthprovision ofabortionwithih spitaletting.F rxample,i eNethe lands,NorwayandtheUSA,specializedabortionclinicshaveb eestabli hed. IntheUSA,larg rclinicshavecaseloadofm rethan10000abortions eachyear[12],InFr nce,N wZealandntUKbortionisprovided almostonlyinhospital.Abor ionwithindedicatedc inicsmayore economicala dtheserviceiprovid dbyexpertswhomayb ore sensitiveandsympath tictowomenun rgoingr g ancyte ination. However,thisapproachs par tesabor ionfr mtherasp ctsfepro¬ ductivehealthar .InScotland,whereover95%fabo tionse performedinNati nalHealthS vicehosp tals,counsellingrd performingabortionsispartfthetra ningfllgynaecologistsu leh yhavemoraloreligiousobjections.Med calstudentsddoctorspl nning
ootentergen ralpracticearelsoexposedt lasp ctsfunwanted
o®pregnancy[13].Incou trieswhereabortionislarg lyc finedtsp ial¬ izedclinicssu hastheUSA.abortioni otalwayspartfgynaecological training.Withoutexp sureduringt eirrai ingthrelevants uesa d towomenhoarse kingabort on,d ct rsayb c mein e singly reluctanttobeinvolvedwiththprovisionfservices. Whilet mannerinwhichabortionserv cesarprovidedari s widelybetwe ncountriesitspossibletdev satfguidelinesforahigh-qualityservicethatiuniversallyapplicabletolrovid rs.Such templateforabo ionservicesshouldmf rsafe,ffici ntnd comprehensiveservicthatallowsw m ntexercisecho covert ei treatmentndwhichrespectsth irdignity.Thtemplateanbedivid intofourelements: 1pregnancydiagnosisa ddet rminationfgestatio alge;2information,med calassessmentndcouns lling; 3provisionftheabortion; 4post-abortionervices. Pregnancydia osisanddeterminationfge tatio alge Anabortionse viceshouldeab etoff rimmediatebi chemical
COUNSELLING119




































































































































































































































































































































































































































































































































































































































































































































































































































































































1ZZUt-lAt'Jr.rS/ Second-trimesterabortionisl common—itacc u tsf10-15%f alllegabortionsintheUK—but,sass ciatedwi hdisproportionately highlevelofmorbidity,witanthcompl cationsrel i g specificmethodusedtoer inatehpreg ncy.Th rearv rf w largerandomizedstudi sandidifficulttete minwheth rther a'bestmethod'f rmid-trimesterabortion.D&Eist twid lyused methodinanycountriesin l di gthUSA,Ca a aDen rk EnglandandWa es,NewZe lanor aythform rst Germany,andthemethodh sprovebconsi tentlysaf rth instillationprocedures(ale stthUSAgest tionsup16weeks). Thelatterinvolvethinstillation,ei hi tra-orex r -amniotically.f prostaglandins,hype tonicsali e,ureorethacridi elac e.Skill personnelarer quiredtoca ryo tthpr cedur sndabo t o (thewomanisconscious)tendsbepainfula dr l ged.With exceptionofethacridinelac teallthsubstancesrpot tiallyto i(f r reviewse[21J.Thdevelopm ntfstablepr staglandinanalo u sh s allowedthevaginaladministrationofprostagl ndins,r utim ch saferth ninstill tion.In1990,ScotlandandFin nwer ly countrieswi hasignificantincide cfmedi allyduced—rat rthan
wsurgical—second-trimesterabortion .InScotland,thdministrationf
oopr staglandinvagi allyithemethodofchoice,nstilla onbeingr rely used.Thinduction-abortiontervals gnifica tlyr ducedbypre- treatmentwithRU486[22],andherehcompou disavailable combinationfvaginalprostaglandinswithantiprogestero eet eat- mentaybrecomme ded. Abortionbeyond18weeksges ationirareannm ycountries is eitherill galornlyavailab ef pre nci scomplicat dbys ver fetalmalformation.Particularlydistressi gorb ththet eand staff,thesela eabortionsroftef ectivelymanag dwi hv g nal prostaglandinsincombin tiowithRU486ntra-am ioticurear fetalintracardiacjectionofpotass umminimizehech ncesliv birth. Whatevertmethodused,aborti nsh ulbvailablesday-c s orfficep oceduresinth sminimiz sinconveniencwo an concerneda dreducesthst.T eisworldwidetr no a shorterho pitaltaysinthoscoun ri swhereab r ionperfo m d withinahospitalet ing.Overn ghtyshouldbpossiblef rome whohavetotra llongdist c srru fitgoomft rh procedureiscompleted.
COUNSELLING
123


































































































































































































































































































































































































































































































For the great majority ofwomen the decision to have a pregnancy terminated is a difficult and
painful one. The circumstances surrounding the need for abortion, such as the end ofa
relationship, are often distressing. Many women feel guilty about destroying the fetus and most
arc fearful about the abortion procedure. Since the development ofa medical method for inducing
abortion - mifepristone ( first known as RU486) plus prostaglandin - in countries where the two
drugs are licensed and in settings where medical techniques are available, women are being
given a choice as to how they would prefer theirpregnancy to be terminated. The freedom to
choose the method ofabortion may help to alleviate some oftheir anxiety and it is interesting to
review why women choose one method rather than another. This paper reviews existing studies
and discusses the potential limitations on the development ofmifepristone for contraceptive use,
for emergency contraception and otherpossible indications because ofanti-abortion pressure.
y '\|HE acceptability of medical abortion using' 'mifepristone has been assessed in a number
of cultural settings - Scotland,1-2-3 England,4
Sweden,5 France,6 Denmark,7 Hong Kong,6-9
and the USA.10 The studies differ quite sig¬
nificantly, however, and are difficult to compare.
Most were undertaken when RU486 was new and
at a time when RU486 was unlicensed in the
particular country where the study was done.
Many vyornen are understandably hesitant to
opt for a new and relatively untested treatment in
whatever field of medicine, and this almost
certainly affects not only which method they
choose but also colours their experience of it.
Many of the studies were undertaken as part of a
trial of the efficacy of the method. In the Oxford
study,4 for example, women were invited either
to participate in the study or to undergo routine
surgical abortion. They were not simply
choosing between two methods, but also
whether to participate in a trial or not.
Where an acceptability study is tacked on to
an efficacy study, the demands of the study itself
undoubtedly influence the woman's choice of
method too. In Tang's pilot study,8 for example,
women choosing medical abortion bad to attend
the study site on seven separate occasions while
those choosing surgical abortion had to attend
only twice.
Comparability of the studies is also com¬
plicated by significant differences in the details of
the abortion method. Surgical abortion may be
done under local or general anaesthetic, while
medical abortion may involve the use of
prostaglandins administered vaginally rather
than intramuscularly. One of the studies' used
mifepristone alone.
The duration of hospital stay also varied
considerably, in one Scottish study,2 the women
were asked to stay in hospital for only four hours
on the day of prostaglandin administration,
compared with six hours in Hong Kong.8 Again,
in the Hong Kong centre8 surgical abortion
involved an overnight stay in hospital which was
not required in Scotland.3
Despite these major differences there are
nevertheless enough similarities to allow some
general comments about the acceptability of
medical abortion with RU486. Most studies
determined the reasons why women chose either
medical or surgical abortion, whether women
who chose one or other method had certain
characteristics in common, and tried to make
some standard assessment of acceptability by
asking which method a woman would
recommend to a friend or opt for in the future
should the need arise.




have chosen medical abortion as opposed to
vacuum aspiration is the perception that the
former is a more 'natural' procedure, which
avoids exposure to general anaesthesia. In Hong
Kong8 some women felt less guilty about having
an abortion because the medical method seemed
more like a natural miscarriage. The fear of
general anaesthesia is obviously not an issue if
surgical abortion is performed under local
anaesthesia, in the French study6 only nine per
cent of women chose vacuum aspiration under
general anaesthesia while 27 per cent chose
vacuum aspiration under local anaesthesia. Even
when local anaesthesia was available, however,
the great majority of women (62 per cent) opted
for medical abortion.
A minority of women, on the other hand,
chose surgical abortion in the Hong Kong study8
because they wanted to be unconscious and
unaware of events. For some women the anxiety
associated with 'seeing the baby' prompted a
choice of general anaesthesia. In fact, this is not
the case during first trimester medical abortion,
when only blood and tissue are visible, so this
fear is unfounded, a point which can be made
during counselling.
In most studies, some women's choice of
method has depended on their perception of its
safety. Perceptions have varied considerably,
with some women concerned about the safety of
the drugs used for medical abortion and others
concerned about the use of instruments for
surgical abortion. As medical abortion becomes
more widespread, the fear of the drugs will most
likely decrease for many women.
Medical abortion currently requires more
visits to the hospital or clinic and a 48-hour wait
between the two parts of the procedure. Many
women have chosen surgical abortion because it
appears to be quicker and to demand less time
off work, unless an overnight slay is required,
which is still the case in some countries.
Moreover, the 48-hour wait inherent in medical
abortion is a time of anxiety which some women
feel unable to cope with.
For some women the fear of side effects has
deterred them from choosing medical abortion.
In the multicentre study undertaken in the United
Kingdom,11 21 per cent of women complained of
severe pain in the two days following prosta¬
glandin administration and around 30 per cent of
all participants required non-narcotic analgesia.
In addition, between 13 and 37 per cent needed
narcotic analgesia, but this depended both on
parity and also highly significantly on the centre
where the abortion took place. Twenty-five per
cent of the women vomited and 13 per cent
experienced diarrhoea after prostaglandins were
given.
Thong and colleagues2 working in Edinburgh
found that the need for analgesia was related to
length of gestation, parity and a history of
dysmenorrhoea - all factors which can be
determined during the time of counselling a
woman about her choice ofmethod.
Medical abortion is thought to involve more
blood loss post-operatively and a longer
duration of bleeding than with surgical abortion.
In fact, the total blood loss is not greater.
However, with a surgical procedure much of the
bleeding occurs acutely at the time of operation
and is unnoticed by the woman.
In most studies, medical abortion seemed
more likely to be chosen by women who were
younger, single, better educated and of a higher
socio-economic status. In an as yet unpublished
audit from Edinburgh12 women who smoked
were more likely to choose surgical abortion.
In all the published studies, the vast majority
of women were happy with whichever method
they had chosen, said they would choose the
same procedure again if the need for abortion
arose, and would recommend it to a friend. It is
difficult for a woman to choose between two
methods unless she has experienced both and is
faced with a choice on a third occasion. Even
then, the circumstances surrounding the
unplanned pregnancy and the professional staff
involved with counselling and carrying out the
abortion will almost certainly be different, and
both will have a major influence on a woman's
feelings about the procedure.
Perhaps the most helpful study of accept¬
ability comes from Aberdeen3 in which the 54
per cent of women who felt unable to choose
between the two procedures were randomised.
As with other studies, around 90 per cent of the
women who made a choice were happy with the
outcome, but there were significant differences
in the extent of dissatisfaction among those
who were randomised. Only two per cent of
randomised women were unhappy with surgical
abortion, but 22 per cent were unhappy with the
medical method. In contrast, in another study
148
390
Reproductive Health Matters, No 6, November 1995
from Aberdeen,'1 ten out of 13 women who had
experienced both surgical and medical abortion
said that they preferred medical abortion. This
study is the only one which reported psychiatric
morbidity associated with abortion, but it found
no difference between medical and surgical
methods.
Given the choice between surgical and
medical methods of inducing abortion, many
women seem to prefer the medical approach.
Whatever method they choose, a small minority
of women find the experience unsatisfactory and
it is possible that this is more likely when medical
abortion is chosen. When any new therapy is
introduced - particularly with the amount of
publicity that surrounded RU486 abortion -
expectations may be unrealistically high, lire
provision of accurate and detailed information
about all abortion procedures should overcome
this problem. Indeed, the very fact that women
themselves have a say in how the abortion is
performed probably increases the acceptability
of the method they choose.
Other uses of Mifepristone
RU486 has great potential for use as a
contraceptive method and a number of
approaches - very low dose daily administration,
once-a-week pills, once-a-month pills, and
emergency post-coital contraception - are all
being investigated. To date, researchers have
concentrated on the efficacy of these methods
rather than acceptability.
Protocols for the development of new
contraceptive techniques are complicated and
entail a multitude of frequent and often invasive
investigations, such as blood tests, cervical
smears and endometrial biopsies, which are not
necessary when the method becomes available
for routine use. Moreover, phase 1 studies are
often undertaken on women who are not at risk
of pregnancy, women who are sterilised or using
a barrier method of contraception, so true
acceptability is almost impossible to measure.
We undertook a survey13 of women in
Scotland, Slovenia and Romania to determine
the theoretical acceptability of a once-a-month
pill. The once-a-month concept was acceptable,
but in Scotland, and to a lesser extent in Slovenia,
the acceptability depended on the mode of
action. Only 24 per cent of the women in
Edinburgh were prepared to use a pill which
acted after implantation had occurred and only
33 per cent in Slovenia.
Iij two studies of 600 mg RU486 as an
emergency post-coital contraceptive14-15 the
incidence of side effects was highly significantly
less in women who took RU486 in comparison
with those given the standard combined
oestrogen-progestogen (Yu/.pe) regimen. More¬
over, the Yuzpe regimen requires the ingestion of
two doses of pills separated by 12 hours, while
RU486 needs to be taken only once. Although
this was not specifically measured, it is likely that
the single dose and reduced side effects with
RU486 given in this manner would make it more
acceptable than the Yuzpe regimen.
RU486 has great potential for development as
a contraceptive and indeed, for other uses such
as the treatment of breast cancer. Yet the use of
RU486 and any other anti-progestin that may be
developed will be limited if it is only thought of as
an 'abortion pill'. Thus, the introduction of an
anti-progestin, for whatever other therapeutic
use, into a country where abortion is illegal or
where RU486 has not been licensed as an
abortifacient may be extremely difficult. Even in
countries where RU486 is licensed for the
induction of early abortion, it is currently subject
to more controls than perhaps any other drug. In
the United Kingdom, for example, both the drug
licensing authority and the manufacturers are
responsible for a set of stringent restrictions on
its provision.
In some countries, such as the USA, drug
regulatory authorities have a legal mandate to
consider a product application only for the
therapeutic purposes for which approval is
sought. Nevertheless, ideological pressure,
which may even come from the government
itself, may be hard to resist. A review of the
science and politics of 1311486 in 1989 in the USA
says:
..As long as the deadlock on RU4S6 continues,
its other potential lifesaving applications will
remain unexplored/'16
This review points out the fear that the
licensing of the drug for one purpose would
inevitably lead to it ultimately being used for
abortion as well. This would almost certainly be
the case in other countries. In the United
a
Glusier
Kingdom, once a drug becomes available a
doctor is free to use it as he or she sees fit. If the
use accords with accepted clinical practice, legal
redress is unlikely. Thus, many doctors prescribe
oral contraceptive pills containing 50 meg
oestrogen for emergency contraception, even
though the pills are not licensed for this purpose.
Because the practice is so widespread and
clinically sound, it is acceptable medico-legally.
In this way, if RU486 were licensed for the
treatment of breast cancer in a country where it
was not licensed for abortion, a doctor could
successfully argue for the validity of its use as an
abortifacient, demonstrated in evidence from
other countries.
Even if doctors themselves refrained from
providing RU486 for the unlicensed purpose of '
abortion, once it was available for other
purposes and if it were available over the
counter, there would be potential for its use
directly by women as an abortifacient, as has
happened with the anti-ulcer drug misoprostol (a
prostaglandin) in Brazil and elsewhere, for
inducing abortion illegally.17
If contraceptives containing an anti-progestin
could only be administered in a controlled
manner, in the way that mifepristone is
administered today for early abortion, then it
would not be possible to develop anti-progestins
for contraception. Hence, either we have to
accept that anti-abortion pressure may prevent
the development or licensing of a range of
therapeutic uses for mifepristone, even where it
would be the preferred treatment, as seems to be
the case with its use for emergency contra¬
ception, or we have to find a way to overcome the
reluctance to license mifepristone for all of the
scientifically proven indications it may have,
starting with early abortion.
References
1. Urquhart D R and Templeton A
A, 1991. Psychiatric morbidity
and acceptability following
medical and surgical methods of
induced abortion. British Journal
ofObstetrics and Gynaecology.
98:396-99.
2. Thong K J, Dcwar M H and Baird
D T, 1992. What do women want
during medical abortion?
Contraception. 46:435-42.
3. Hcnshaw R C, Naji S A, Russell 1
Tet al, 1993. Comparison of
medical abortion with surgical
vacuum aspiration: women's
preferences and acceptability of
treatment. British Medical
Journal. 307:714-17.
4. Hill NC W, Ferguson J and
Mackenzie IZ, 1990. The efficacy
of oral mifepristone (RU38486)
with a prostaglandin E1 analog
vaginal pessary for the termination
ofearly pregnancy: complications
and patient acceptability.
American Journal ofObstetrics and
Gynecology. 162:414-17.
5. Holmgren K, 1992. Women's




6. Bachelot A, Cludy L and Spira A,




7. Legarlh J, Peen U B and
Michelson J W, 1991.
Mifepristone or vacuum
aspiration in termination of early
pregnancy. European Journal of
Obstetrics, Gynecology and
Reproductive Biology. 41:91-96.
8. Tang G W K, 1991. A pilot study
of acceptability of RU486 and
ONO802 in a Chinese population.
Contraception. 44:523-32.
9. Tang G W K, Lau O W K and Yip
P, 1993. Further acceptability
evaluation of RU486 and
ONO 802 as abortifacient agents
in a Chinese population.
Contraception. 48:267-77.
10. Grimes D A, Mishell D R Jr and
David H P, 1992. A randomized
clinical trial of mifepristone
(RU486) for induction ofdelayed
menses: efficacy and acceptability.
Contraception. 46:1-10.
11. UK Multicentre Trial, 1990. The
efficacy and tolerance of
150
mifepristone and prostaglandin
in first trimester termination of
pregnancy. British Journal of
Obstetrics & Gynaecology.
97:480-86.
12. Baird DT. Personal
communication.
13. Rimmer C, Horga M, Alder E M




et al, 1992. Randomised trial of





15. Webb A M C, Russel J and
Flstein M, 1992. Comparison of
the Yuzpe regime, danazol and
mifepristone in oral post-coital
contraception. British Medical
Journal. 305:927-31.
16. Klitsch M, 1989. RU4BB: The
Science and the Politics. Alan
Guttmacher Institute, New York.
17. Arilha M and Barbosa R M, 1993.
Cytotec in Brazil: 'At least it
doesn't kill'. Reproductive Health
Matters. 2(November):41-52.
392
Reproductive Health Matters, No 6, November 1995
Resume
La mise au point d'une methode medicate pour
declencher I'avortement - ['association de
mifepristone (ou RU486) et de prostaglandine -
permet desormais aux femmes de choisir la fagon
dont elles preferent mettre fin a leur grossesse,
dans les pays ou les deux produits sont autorises,
et ou on peut avoir acces a des techniques
medicates. La liberie de choisir la methode
d'interruption de grossesse peut alleger quelque
peu I'angoisse des avortees. L'article fait une
revue des etudes actuelles et se demande
pourquoi des femmes choisissent une methode
ptutot qu'une autre. It discute les potentialites de
la mifepristone a des fins contraceptives, pour la
contraception d'urgence et dans d'autres
indications eventuelles. La pression des,
adversaires de l'avortement peut empecher de
developper ou de faire homologuer diverses
utilisations therapeutiques de la mifepristone,
meme la ou ce produit semble devoir etre le
traitement de choix, par exemple pour la
contraception d'urgence. II faut ou bien
I'accepter, ou trouver des moyens de vaincre les
repugnances a son homologation pour toutes les
indications averees qu'il peut avoir, a
commencer par l'avortement precoce.
Resumen
Desde la invencion de un metodo medico para
inducir el aborto (el mifepristone, conocido
inicialmente como RU486, mas la prostaglandina)
la mujer tiene la posibilidad de elegir como
prefiere interrumpir su embarazo en aquellos
paises en que ambas sustancias estan
autorizadas, y en contextos en los que existe
acceso a tecnicas medicas. La libertad de poder
elegir el metodo de aborto puede contribuir a
aliviar en parte su ansiedad. Este ensayo hace
una revision de los estudios existentes y examina
por que las mujeres escogen uno u otro metodo.
Discute tambien el potencial del mifepristone
para uso anticonceptivo, como anticonceptivo de
emergencia y otras posibles indicaciones. La
presion en contra del aborto puede impedir el
desarrollo o autorizacion de toda una variedad
de usos terapeuticos del mifepristone, incluso en
casos en los que seria el tratamiento preferido,
como parece suceder en el caso de su utilizacion
como metodo anticonceptivo de emergencia. O
bien aceptamos esto o debemos encontrar la
forma de superar la reticencia a autorizar esta
sustancia para todas la indicaciones demostradas
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EMERGENCY postcoital contraception maybe defined as the use of a drug or device to -prevent pregnancy after intercourse. Unwant¬
ed pregnancy is common; worldwide, about 50 mil¬
lion pregnancies are terminated each year.1 It has
been calculated that each year the widespread use of
emergency contraception in the United States could
prevent over 1 million abortions and 2 million un¬
intended pregnancies that end in childbirth.2
A variety of different methods of emergency con¬
traception are available (Table I). The first to be de¬
scribed was high-dose estrogen, although currently
the most widely used is a combination of estrogen
and progestin. Recent interest in the development of
alternative regimens has led to trials of progestin
alone, the antigonadotropin danazol, and the anti-
progestogen mifepristone (RU 486) for postcoital
contraception. Highly effective, but much less con¬
venient, is the postcoital insertion of an intrauterine
contraceptive device.
PROBABILITY OF CONCEPTION
The probability of conception after a single act of
intercourse has been calculated to be about 33 per¬
cent per cycle if intercourse occurs on average every
other day12; if it occurs only once per week, the risk
of pregnancy is only 15 percent. Most women who
have unprotected intercourse on a single occasion
therefore will not conceive. Conception occurs only
around the time ofovulation. Surprisingly, the num¬
ber of days of the menstrual cycle during which a
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woman is fertile (i.e., on which conception could re¬
sult if intercourse occurred) has been difficult to
quantify. Although sperm remain in the female gen¬
ital tract and are capable of fertilization for up to five
days after ejaculation, the egg appears to be capable
of being fertilized for only about 24 hours.
In a recent study of couples actively tr ying to con¬
ceive, in which hormone measurements were used to
determine the timing of ovulation, the fertile period
lasted about six days, ending on the day of ovula¬
tion.12 There were no conceptions when intercourse
occurred after the day of ovulation; acknowledging
the small sample size in their study, however, the
authors concluded that a probability of conception
of up to 12 percent was theoretically possible if in¬
tercourse occurred on the day after ovulation. In
that study, in which pregnancy was detected on the
basis of urinary measurements of human chorionic
gonadotropin, 24 percent of the pregnancies ended
within six weeks after the last menstrual period and
only 68 percent resulted in childbirth.
mode of action of emergency
contraception
Emergency contraception could work by inhibit¬
ing or disrupting ovulation, interfering with fertiliza¬
tion or the tr ansport of the embryo to the uterus, or
inhibiting its implantation in the endometrium. Any
device or drug that acts after implantation is conven¬
tionally regarded as an abortifacient rather than a
contraceptive. In theory, the most effective method
of emergency contraception would be one that in¬
hibited implantation, because it would prevent con¬
ception at whatever time in the cycle intercourse
occurred, even after ovulation. A method that affect¬
ed ovulation or fertilization would prevent most but
not all pregnancies, because women who used the
method after they had already ovulated might still
conceive. In practice, the precise mode of action of
currently available emergency contraceptives is not
known, although there is evidence of effects at sev¬
eral critical stages of the reproductive cycle.
Effects on Ovulation
Most of the research on estrogen alone has con¬
centrated on its effects after ovulation. In theory,
large doses ofestrogen given before ovulation might
be expected to inhibit follicular development and
maturation or the release of the ovum itself; there is,
however, no evidence of any of these actions. Given
before or at the time of ovulation, both estrogen
plus progestin and danazol sometimes inhibit or
delay ovulation.1315 Mifepristone inhibits ovulation,
1(158 • October 9. 1997
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Table 1. Methods of Emergency Contraception.
Regimen
Estrogen and progestin (100 /xg
of ethinyl estradiol and
0.5 mg of levonorgestrel
given twice, with 12 hr
between doses)
Levonorgcstrel (0.75 mg
given twice, with 12 hr
between doses)
High dose estrogen (e.g.,
5 mg of ethinyl estradiol
daily for 5 days)
Mifepristone (a single
600-mg dose)
Danazol (400 to 800 mg
given twice 12 hr apart
or 400 mg given 3 times










Up to 5 days after the
earliest estimated
day of ovulation
Status of Methoo Reported EFFicACYt
Licensed in some countries since 75-80% of pregnancies
early 1980 (e.g., United King¬
dom, the Netherlands); available
unlicensed in the appropriate
combination of oral-contracep¬
tive pills
Licensed in some countries in East¬
ern Europe and Asia
Licensed in the Netherlands;
little used elsewhere
prevented
Widely used in China in a variety
of lower doses; not licensed any¬
where else for emergency contra¬
ception
Used only under research con¬
ditions








Reports vary from failure




Meta-analysis of 10 trials
involving >5000
One randomized trial in¬
volving 350 women4
Randomized trial involving
250 women; early trials
suggested failure rates
<1%*.?
Two randomized trials in¬
volving a total of 600
women*-'
Two randomized trials, one
involving >1700 women
and suggesting failure
rates of about 1%,'° and
the other involving 193
women and suggesting
little or no cflcct®
Meta-analysis of 20 pub¬
lished studies involving
>8000 women"
"The rimes given are for the first dose.
fData on efficacy arc not comparable since not all arc based on exposure during the fertile phase of the cycle (see the text).
even when given at low doses during the follicular
phase,16 and the administration of mifepristone as a
postcoital contraceptive before ovulation significant¬
ly delays the onset of menses, indicating the inhibi¬
tion of ovulation.8
Effects on Fertilization
There is no direct evidence that any of the hormo¬
nal methods ofemergency contraception prevent fer¬
tilization, although such an effect cannot be ruled
out. The intrauterine contraceptive device can com¬
promise fertilization by its toxic effects c>n sperm17; if
it is inserted after intercourse but before ovulation, it
could theoretically work by preventing fertilization.
Effects on Gamete Transport
Although high-dose estrogen impairs the trans¬
port of the ovum in some animal species,18 there is
no evidence of sucli an effect in humans. Early trials
of high-dose estrogen given after intercourse to
women at risk for conception were associated with
an increased incidence of ectopic pregnancy,19 but it
is likely that, as with the intrauterine contraceptive
device, this method is better at preventing intrauter¬
ine pregnancies than tubal pregnancies.
Effects on the Function of the Corpus Luteum
Abnormalities of luteal-phase progesterone secre¬
tion arc associated with a reduction in fertility. Since
the corpus luteum is derived from the ovarian folli¬
cle, events that affect the developing follicle may in¬
fluence the function of the corpus luteum. Although
estrogen plus progestin (given either before or after
ovulation),1318 danazol,14'15 and high-dose estrogen20
all reduce the magnitude of the midcyde surge in se¬
rum luteinizing hormone, reduce progesterone con¬
centrations in the luteal phase, or both, it is not
known whether such changes arc incompatible with
pregnancy. There is better evidence of an effect of
mifepristone on the corpus luteum; when given in
the mid-luteal or late luteal phase of the cycle, it in¬
duces regression of the corpus luteum in about 50
percent of women.21
Effects on Implantation
Mifepristone administered immediately after ovu¬
lation delays endometrial maturation without affect¬
ing ovarian hormone production or menstrual bleed¬
ing,22 and when given in this way it prevents
pregnancy.23 Insertion of an intrauterine device after
ovulation causes histologic changes in the endometri-
Volumc 337 Number 15 • 1059
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urn that would be expected to impair implantation.24
In contrast, although the postovulatory adminis¬
tration of estrogen25 or lcvonorgcstrcl" inhibits
implantation in some animals, evidence ofsimilar ef¬
fects in women has been difficult to obtain. Minor
changes in the histologic and biochemical features
of the endometrium occur when high-dose estro¬
gen,6 die estrogen-progestin combination, or dana¬
zol is administered after ovulation,27 but the effects
may not be sufficient to inhibit implantation. In a
recent morphometric study, postovulatory adminis¬
tration ofestrogen plus progestin had only minor ef¬
fects on the endometrium, and danazol had no ef¬
fect.15
Interruption of Pregnancy
It is unlikely that danazol, estrogen, or progestin,
cither alone or in combination, interrupts early preg¬
nancy in women once implantation has occurred. In
contrast, mifepristone is effective after implantation
in 80 percent ofwomen.28 Since implantation occurs
about seven days after ovulation, emergency contra¬
ception within five days after intercourse cannot be
considered to interrupt pregnancy.
Conception is much less likely if intercourse oc¬
curs after ovulation. At least one trial suggested that
both estrogen plus progestin and danazol are less
likely to be effective as postcoital contraceptives if
they are taken after ovulation.9 The balance of evi¬
dence suggests that the most widely used hormonal
emergency contraceptive, estrogen plus progestin,
works mainly by inhibiting or delaying ovulation. If
the intrauterine contraceptive device is inserted or
mifepristone is given after intercourse, the mode of




Emergency contraception is useful after unpro¬
tected intercourse or withdrawal that occurs too late
and for couples who recognize the failure of a bar¬
rier method, such as a burst condom. In a recent study
of condom breakage and slippage, 4 to 7 percent of
couples using this form of contraception in the Unit¬
ed States had a recognized condom failure during a
period of up to three months.29 Emergency contra¬
ception is not usually indicated when one or more
oral contraceptive pills have been forgotten, because
there are established and effective rules for the use
of a barrier method as secondary prevention under
these circumstances (Fig. 1).
EFFICACY OF EMERGENCY
CONTRACEPTION
The efficacy of emergency contraception is diffi¬
cult to quantify. Most studies include large numbers
of young women of unproved fertility, and for ob¬
vious reasons there can be no control group. Some
couples are not certain that there was spillage of
seminal fluid when a condom burst or that ejacula¬
tion actually occurred. Many authors simply report
failure rates in terms of the number of pregnancies
among the women treated, but most of these wom¬
en would not have conceived even if they had not
used emergency contraception. More recently, at¬
tempts have been made to estimate the number of
women genuinely at risk of pregnancy — that is,
those who had unprotected intercourse during the
fertile period —- and to relate the number of actual
pregnancies to the number of expected pregnancies.
Even this method has its shortcomings, because nei¬
ther the precise timing of intercourse nor the exact
date of the last menstrual period is always accurately
recalled, and for iirdividual women the day of ovu¬
lation may vary by as much as two or three days in
each cycle. Thus, the timing of exposure to the risk
of pregnancy in relation to the day of ovulation is,
even in these well-documented studies, an educated
guess. In a recent meta-analysis of 10 published
studies in which data on the menstrual cycle and the
timing of intercourse were reported, the efficacy of
estrogen plus progestin was estimated to be 74 per¬
cent, on average.-1 Although mathematical calcula¬
tions have their appeal, when faced with the pos¬
sibility of an unwanted pregnancy, many women
would use a method that was only 50 percent effec¬
tive or even less if there was no alternative.
COMBINED ESTROGEN AND PROGESTIN
The estrogen-progestin regimen is two doses of.a
combination of 100 jxg of ethinyl estradiol and 0.5
mg of levonorgestrel each, the first dose taken with¬
in 72 hours after intercourse and the second 12
hours later. A licensed product is available in several
countries in Western Europe and in New Zealand
(marketed under a variety of trade names, such as
Schering PC4 in the United Kingdom and Tetragy-
non in Switzerland). First described in 1977 by Yuz-
pe and Lancee,30 the combination therapy is often
referred to as the Yuzpe regimen. The same hormones
are available in some brands of combined oral-con-
traceptive pills, and these are often used in countries
where a marketed preparation is unavailable. It is not
known whether the estrogen-progestin regimen is
effective if taken later than 72 hours after inter¬
course,31 nor whether combined oral contraceptives
containing other progestins administered in a similar
manner are effective. Neither is it known whether
the two-dose regimen is strictly necessary.
Nausea (in up to 50 percent ofwomen) and vom¬
iting (in up to 20 percent) arc the main side effects
of this regimen.8 Both, in theory, may occasionally
interfere with the woman's taking the second dose,
and vomiting may reduce efficacy if it occurs within
two hours after the medication is taken, in which
DRUG THERAPY
Figure 1. Scheme for the Prevention of Pregnancy in Women Who Miss One or More
Oral-Contraceptive Pills.
case absorption may be reduced. Some clinics rou¬
tinely provide an antiemetic drug, but there arc no
data to support this practice. Moreover, in practice,
nausea and vomiting seldom prevent women either
from taking the second dose or from using the reg¬
imen on another occasion; vomiting within two
hours after swallowing the tablets is uncommon; and
failures ofemergency contraception do not appear to
be associated with vomiting. Subsequent menses
normally occur at the expected time8 but may be
heavier than usual, and some women have mastalgia
for a few days after treatment.30
Although it is widely used in Europe, there are
very few data on the safety of the estrogen-proges-
tin regimen. Long-term use of the combined oral-
contraceptive pill is associated with an increased risk
of both arterial disease (myocardial infarction and
cerebrovascular accident)32 and venous disease (deep
venous thrombosis and pulmonary embolism).33
The risk of venous thromboembolism is thought to
be dose-dependent, and it is higher with pills con¬
taining' 50 tig of ethinyl estradiol than with low-
dose pills (containing 30 to 35 /eg).34 Because the
estrogen-progestin regimen exposes women to the
same type of hormones, there has been a tendency
to extrapolate from the risks of combined oral con¬
traceptives. Although the estrogen-progestin regi¬
men exposes a woman to a total of 200 /xg ofethinyl
estradiol, the exposure is short-term. One small study
of the high-dose estrogen regimen35 demonstrated a
detrimental effect on clotting factors, but a similar
study failed to show any consistent effect of estrogen
plus progestin.36
Few adverse events associated with estrogen plus
progestin have been reported in the United King¬
dom (Committee on Safety of Medicines: personal
communication). In the 13 years since Schering
PC4 was licensed, it has been used on more than
4 million occasions. By the middle of 1996, there
had been 115 reports of 159 "reactions" (some wom¬
en had more than 1), 61 of which were pregnancies.
In the United Kingdom only three cases of venous
thrombosis (one fatal) and three cases of cerebrovas¬
cular disorder have been reported, and in none was
the relation between the administration of estrogen
and progestin and the event clear-cut. In contrast,
the risk of venous thrombosis during pregnancy is
on the order of 60 per 100,000 per year. Both the
World Health Organization,37 which in 1996 added
the estrogen-progestin regimen to its "essential
drugs list," and the International Planned Parent¬
hood Federation38 have stated that there are no
absolute contraindications to the use of the estro¬
gen-progestin regimen except known pregnancy.
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Reliable data on the outcome of pregnancies that
occurred after estrogen and progestin were taken are
lacking, but the absence of demonstrable teratoge¬
nicity of combined oral contraceptives-19'10 and the
timing of emergency contraception — long before
organogenesis starts — are reassuring. Thus, the
estrogen-progestin regimen is contraindicated in
pregnancy only because it does not work once preg¬
nancy is established, not because it is known to be
harmful.
ESTROGEN ALONE
High doses of estrogen — usually ethinyl estradiol
in a variety of regimens — given for five consecutive
days are extremely effective as postcoital contracep¬
tion, with failure rates ofonly 0.1 to 1 percent.6'7 Side
effects, particularly nausea (in 70 percent of women)
and vomiting (in 33 percent), are common, and
many clinicians stopped using estrogen alone when -
the estrogen-progestin regimen was described. The
so-called fivc-by-fivc regimen (five tablets of 1 mg
of ethinyl estradiol each, given daily for five days) is
still used in the Netherlands,11 where some clinicians
believe it is more effective than the estrogen-proges¬
tin regimen. However, a double-blind, randomized
study comparing the two regimens in the Nether¬
lands demonstrated no difference in efficacy or, in
fact, in the incidence of nausea and vomiting.5
THE INTRAUTERINE CONTRACEPTIVE
DEVICE
The copper-bearing intrauterine device is a highly
effective postcoital contraceptive, with failure rates of
less than 1 percent."'12 In the United Kingdom it is
used for up to five days after the earliest estimated day
of ovulation, which may, of course, be more than five
days after intercourse. It is particularly appropriate
for women who wish to use the intrauterine device
as a long-term method of contraception. However,
most women requesting emergency contraception are
young and nulliparous, and it can be difficult to in¬
sert a device if the uterus is small. Because of the risk
of inducing pelvic infection if the device is inserted
in the presence of a sexually transmitted disease, it is
commonplace to screen women for infection, or to
give an antibiotic, before insertion.
PROGESTIN ALONE
Progestin without estrogen has been tested as a
postcoital agent in only one randomized trial.1 Taken
within 48 hours after unprotected intercourse, two
0.75-mg doses of levonorgestrel, given 12 hours
apart, resulted in failure rates similar to those with
the estrogen-progestin regimen (2.6 percent for es¬
trogen-progestin vs. 2.4 percent for levonorgestrel).
Side effects, however, were significantly less common
with levonorgestrel. A levonorgestrel-only product
(Postinor) is available from pharmacists in parts of
•meo . n..r..i,..- o i oo7
Eastern Europe, the Far East, and many developing
countries.
DANAZOL
The antigonadotropin danazol is an effective emer¬
gency contraceptive when given within 72 hours after
intercourse. In one study the failure rates were 1.7
percent among women given two doses of 400 mg
each 12 hours apart and 0.8 percent among women
given three doses at 12-hour intervals.10 However, a
randomized study in the United Kingdom comparing
estrogen plus progestin with danazol (two doses of
600 mg each, given 12 hours apart) suggested that
danazol may be ineffective when used after inter¬
course.0
ANTIPROGESTINS
The antiprogestin mifepristone has also been test¬
ed as an emergency contraceptive. Two randomized
trials,8-9 involving a total of almost 600 women,
compared 600 mg of mifepristone with the estro¬
gen-progestin regimen. Mifepristone given within
72 hours after intercourse was 100 percent effective
in preventing pregnancy, whereas the estrogen-
progestin regimen was estimated to have prevented
between 66 percent22 and 83 percent8 of pregnan¬
cies. The difference between the two regimens is not
surprising, because mifepristone is known to inhibit
implantation as well as ovulation and so, in theory,
should almost always prevent pregnancy. All side ef¬
fects were much less common among the women
given mifepristone; however, in one of the studies 42
percent of women had a delay of more than three
days in the onset of the next menstrual period.8 This
delay was particularly likely to occur if mifepristone
was given during the follicular phase of the cycle,
when it is known to inhibit ovulation.16 This is an
obvious drawback of mifepristone, because the onset
of menses reassures the woman who has used emer¬
gency contraception that she is not pregnant. A low¬
er dose of a mifepristone compound with a shorter
half-life may not disrupt the timing of subsequent
menses. Mifepristone is now used in a variety of dos¬




Emergency contraception is not universally avail¬
able. It is not licensed, for example, in France or in
the United States, although in February 1997 the
U.S. Food and Drug Administration (FDA) pub¬
lished a formal notice in the Federal Register stating
that six brands of commonly used combined oral-
contraceptive pills were safe and effective for emer¬
gency postcoital use.13 The main reasons for the lack
of wider use of emergency contraception were dis¬
cussed at a meeting held in Italy in 1995.11 The par-
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ticipants concluded that both women and providers
are, by and large, poorly informed about the avail¬
able methods. Because currently available hormonal
regimens must be started within 72 hours after in¬
tercourse, a woman has to know about the method
before the need for it arises. A number of surveys in
some developed countries have demonstrated that
whereas knowledge of the existence of emergency
contraception is widespread among selected popula¬
tions of potential users45-46 (including teenagers47),
knowledge of the details and practicalities, particu¬
larly the time limit, is usually poor. In the United
States, a toll-free emergency-contraception hot line
operated by the Reproductive Health Technologies
Project and Bridging the Gap Foundation (1-800-
584-9911) provides callers with information about
all available methods and about local providers. In
the first year it was available, the service received
more than 40,000 calls.
Very few products are marketed for emergency,
contraception, and pharmaceutical companies ap¬
pear to be reluctant to enter the market. According
to the FDA, no U.S. drug manufacturer has sought
formal approval for the emergency use of an oral-
contraceptive regimen, despite requests from the
agency that they do so.48 In 1996 several interna¬
tional agencies formed a Consortium for Emergency
Contraception that was committed to making emer¬
gency contraception a standard part of reproductive
health care throughout the world. Working in part¬
nership with the pharmaceutical industry, the con¬
sortium aims to improve access through "model
introductions" in selected countries of specially
packaged and labeled products, including the little-
researched progestin-only regimen.
In addition, providers in many countries seem re¬
luctant to provide emergency contraception because
it is confused with abortion. It cannot be stressed
too strongly that if hormonal emergency contracep¬
tion works largely by interfering with ovulation,
then it cannot be regarded as an abortifacient. When
administered within 72 hours after a single act of in¬
tercourse, even compounds known to interrupt es¬
tablished pregnancy cannot dislodge an implanted
embryo, because implantation would not have oc¬
curred yet. For most providers and many potential
users, acceptance of emergency contraception would
improve if their knowledge improved and if the dis¬
tinction between a method that a woman can use
when she thinks that she might become pregnant
(contraception) and something to use when she
thinks she might already be pregnant (an abortifa¬
cient) were clearly understood.
Even in countries where hormonal emergency con¬
traception is licensed and free, such as the United
Kingdom, its use is limited by difficulty of access.45
In the United Kingdom, emergency contraception
must be prescribed by a doctor. Unprotected inter¬
course, particularly among young people, tends to
occur on weekends, when clinics are closed and when
calling the emergency doctor seems inappropriate.
The proposal that Schering PC4 should be sold over
the counter in pharmacies has been widely discussed
in the United Kingdom.49 Despite support for the
proposal from the Royal College ofObstetricians and
Gynaecologists, the Royal College of General Practi¬
tioners, and the Royal Pharmaceutical Society, it has
not happened yet. The Ministry of Health in New
Zealand had expected emergency contraception to
be available over the counter by July 1996.50 The
New Zealand Medical Association and the Royal
New Zealand College of General Practitioners op¬
posed the move, however, as did the pharmaceutical
industry, which is apparently concerned about mis¬
use, incorrect use, and medicolegal risks. The Minis¬
try of Health promised to allow pharmacists to cut
up packets of pills and label them appropriately if the
pharmaceutical industry did not respond to the re¬
quest to change the prescription-only status of the
marketed estrogen-progestin regimen. Despite even
this governmental pressure, emergency contraception
is not yet available over the counter in New Zealand.
Of course, in countries where oral-contraceptive pills
are available over the counter, hormonal regimens for
emergency contraception are already available with¬
out prescription.
CONCLUSIONS
Emergency contraception prevents unwanted preg¬
nancy. The most widely used method, a combina¬
tion ofethinyl estradiol and lcvonorgestrel, although
it is marketed as an emergency contraceptive in only
a few countries, is available throughout the world in
the form of combined oral-contraceptive pills. In¬
deed, countless women already have supplies in their
bathroom cupboards. When started within 72 hours
after intercourse, the estrogen-progestin regimen has
been estimated to be at least 75 percent effective
and is safe. The antiprogestin mifepristone is even
more effective and has fewer side effects.
Use of emergency contraception is limited largely
by ignorance. Although it seems likely diat the es¬
trogen-progestin regimen works mainly by inter¬
fering with ovulation, it is nevertheless regarded
by many as an abortifacient because it is taken after,
rather than before, intercourse. This confusion is
compounded when mifepristone is advocated for
emergency contraception since, when taken after preg¬
nancy is established, it can be and is used for the in¬
duction of abortion. The prevention of pregnancy
before implantation is contraception and not abor¬
tion. Intervention within 72 hours after intercourse
cannot possibly amount to abortion, because im¬
plantation is not achieved until at least seven days af¬
ter ovulation and the egg is capable of being fertil¬
ized for only about 24 hours.
Vnii.™- -xi7 N,.mh.r k . insa
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Knowledge and use of emergency contraception world-wide is extremely
limited. Recent research has demonstrated that levonorgestrel alone is at least
as effective as the Yuzpe regimen and is much better tolerated. Levonorgestrel
is likely to become the method of choice in the early 21st century. Mifepristone
is highly effective even at doses which are not abortifacient. Efficacy cannot be
calculated precisely, but all presently available methods seem to prevent at least
74% of unwanted pregnancies. The Yuzpe regimen inhibits or delays ovulation,
but there is no good evidence that it prevents implantation. There are no data
on the mechanism of action of levonorgestrel alone and the mode of action of
mifepristone depends on when in the reproductive cycle it is used. Accessibility
to emergency contraception is limited by the requirement for it to be prescribed
by a doctor. Advanced provision of emergency contraception may prevent a
significant number of unwanted pregnancies.
In the last decade of the 20th century, emergency contraception emerged
from being the 'best-kept secret' in contraception to become one of the
hottest topics in reproductive health.
Emergency contraception (EC) is defined as any drug or device which
when it is used after intercourse, will prevent pregnancy. First described in
the 1970s, the spread of emergency contraception has been slow and
patchy. A licensed product became available in the UK in 1984. It took an
invitation from the Food and Drug Administration (FDA) to manufacturers
before a dedicated product became available in the US in 1998 and France
got its first emergency contraceptive in 1999.
Research in the 1990s concentrated on: (i) developing hormonal methods
of EC that are more effective and better tolerated; (ii) determining
effectiveness and mechanism of action; and (iii) improving accessibility.
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Methods of emergency contraception
Ethinyloestradiol in combination with levonorgestrel
The first method of emergency contraception to be described was a high
dose of oestrogen taken over 5 days. It caused significant vomiting and was
British Medical Bulletin 2000; 56 (No. 3); 729-738 © The British Council 2000
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largely superseded by the so-called Yuzpe regimen of EC - 100 pg
ethinyloestradioi in combination with 0.5 mg levonorgestrel taken twice
with the two doses separated by 12 h1. This regimen, recommended for use
within 72 h of unprotected intercourse, is the method that has until very
recently been used in the industrialised world. In the UK, it is marketed as
Schering PC4®. A relatively high dose of oestrogen, the regimen is also
associated with nausea (in some studies almost 50% of women complain - •
of nausea), but has the enormous advantage of being readily available in
the form of commonly used combined oral contraceptive pills (e.g.
Ovran®) which have been used in some countries where there has been no
licensed product2.
Levonorgestrel
Although used in some Eastern European and non-industrialised
countries for many years, an EC regimen consisting of levonorgestrel
(LNG) without oestrogen was largely ignored until the mid-1990s. Two
trials3'4 comparing the Yuzpe regimen with levonorgestrel, 0.75 mg twice
with the two doses separated by 12 h, have been published. The first,3
involving 834 women, was randomised but not double-blinded, and
demonstrated that levonorgestrel was as effective (although not
significantly more effective) than the Yuzpe regimen if used up to 48 h
after intercourse. Hardly surprisingly, since it is the oestrogen which
causes the nausea and vomiting, LNG had significantly fewer side-
effects. A larger randomised double-blinded multicentre study4 involving
1998 women demonstrated that LNG was significantly more effective
than the Yuzpe regimen (85% of expected pregnancies were prevented
by LNG compared with only 58% by the Yuzpe regimen). This study
confirmed the better tolerability of LNG. It also demonstrated5 that
both LNG and the Yuzpe regimen were more effective the sooner after
intercourse they were used (Table 1). On the basis of these two studies,
licensed products became available in France (Nor-Levo®) and the US
(Plan B®) in 1999 and in the UK in 2000 (Levonette-2®) LNG is likely '
to become the method of choice of the early 21st century.
Table 1 Percentage of expected pregnancies
prevented in relation to the delay between
intercourse and time of treatment with
emergency contraception (data from WHO1)
Time of treatment LNG Yuzpe
Within 24 h 95 77
24-48 h 85 36
48-72 h 58 31




The most promising hormonal emergency contraceptive is the antiprogester-
one, mifepristone. Two randomised controlled trials6,7 compared a single dose
of 600 mg mifepristone taken within 72 h of intercourse with the standard
Yuzpe regimen. In one6, there were no pregnancies among 402 women taking
mifepristone, while in the other7 there were 3 pregnancies among 195
women, but all conceived 10-15 days after mifepristone had been given. Both
studies concluded that mifepristone was more effective than the Yuzpe
regimen and significantly better tolerated. However, it was much more
commonly associated with a delay in the onset of menses, a major concern
for women waiting for menstruation to indicate that they are not pregnant.
None of these findings should have come as a surprise, since it was already
clear from its use as an abortifacient that mifepristone is extremely well
tolerated and, from a variety of studies, that it would inhibit both ovulation
and implantation8 and, therefore, would be effective as a post-coital agent at
whatever stage of the cycle it was taken. Any delay in ovulation would
inevitably be associated with a delay in die onset of the next menstrual period.
Hypothesising that a lower dose of mifepristone would be just as effective
as an emergency contraceptive, but perhaps with less disruption of cycle
length, the World Health Organization (WHO)1' undertook a randomised
trial of diree different doses of mifepristone 600 mg (559 women), 50 mg
(560 women) and 10 mg (565 women). There was no significant difference
in effectiveness between the three doses, 84-86% of expected pregnancies
were prevented. Mifepristone was effective up to 120 h (5 days) after inter¬
course and, in contrast to LNG and the Yuzpe regimen, there appeared to be
no decrease in efficacy with time. There were no major side-effects, overall
" 17.4% of women complained of nausea, and the delay in the onset of the
next menses was significantly (P < 0.01) related to the dose of mifepristone.
A delay of more than 7 days occurred among 36% of women treated with
600 mg mifepristone, 23% treated with 50 mg and 18% with 10 mg.
A randomised double-blinded comparison of mifepristone and levo-
norgestrel is underway and the results should be available by 2001.
Although possibly the best method tested so far, mifepristone is unlikely to
become widely available as an emergency contraceptive in the foreseeable
future (except in China where it is the method of choice) because it is known
to be an abortifacient. Its development as a contraceptive has for many years
been the victim of anti-abortion politics, it is also expensive.
Other methods
Other compounds have been tested as emergency contraceptives. Interest
increased in the antigonadotrophin danazol in the late 1980s, but waned
after the publication of one trial6 (discontinued prematurely) suggesting that
it was ineffective.
British Medical Bulletin 2000; 56 (No. 3) 731
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The IUD is the most effective method (for review see Trussed and
Ellertson10). It prevents over .95% of pregnancies and can be used up to
5 days after the earliest estimated day of ovulation. Insertion requires
trained personnel and is invasive.
Efficacy of emergency contraception
There has never been a placebo-controlled trial of any method of
emergency contraception, nor, with the exception of mifepristone9, have
any dose finding studies yet been published. In recent years, it has become
accepted practice to express the effectiveness of an EC as the proportion of
expected pregnancies it prevents. The expected number of pregnancies is
estimated by multiplying the number of women who had unprotected
intercourse on each cycle day by an estimate of the probability of
conception on that day and then summing over all cycle days". In recently
published estimates of efficacy, the possibility of conception for each cycle
day has been taken from data collected by Wilcox and colleagues1'. Using
this method, the WHO reports that mifepristone and LNG both prevent
85% of pregnancies - each estimate on the basis of only one trial. Using
data from eight different trials, Trussed and colleagues'3 estimate that the
Yuzpe regimen prevents at least 74% of pregnancies and probably more.
It should be emphasised, however, that these figures are only estimates and
that there are some problems with the method used to calculate them.
Firstly, data used to calculate the probability of conception for each cycle
day come from prospective studies of women actively trying to achieve a
pregnancy and keeping written records of menstrual bleeding and coitus.
Many women seeking emergency contraception have been trying - albeit,
some of them, rather half heartedly - to avoid pregnancy. Many present
following a burst or slipped condom and are not sure whether seminal
fluid leaked into the vagina, but prefer to err on the side of caution. Most
do not keep written records of menstruation and the date of their last
menstrual period (LMP) is usually an estimate, and not infrequently a
complete guess. Although investigators undertaking clinical trials try to pin
women down to an accurate LMP date, an error of only one day makes a
significant difference to the probability pregnancy. Regular cycles too often
vary in length by 2 days in either direction and the exact day of ovulation
will vary from month to month. Thus, calculation of the cycle day when
intercourse occurred is rarely accurate. In our own trial" of mifepristone
versus the Yuzpe regimen of EC, plasma progesterone or urinary
pregnanediol was measured on the day of treatment providing the
opportunity to determine whether the cycle data were compatible with the
biochemical evidence of ovulation. Of 368 women, 51 % believed to be in
the mid-luteal phase of the cycle had a progesterone/pregnanediol value
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indicating that ovulation had not occurred, while 21% of 205 women
thought to be in the mid-follicular phase had biochemical evidence of
ovulation. Although not commented upon in the publication, other
studies7, in which progesterone have been measured, show similar
discrepancies. Estimates of efficacy also depend for their accuracy on the
assumption that, if a pregnancy does occur, it does so as the result of the
act of coitus for which EC was used. This is often not the case; women
have often had more than the one act of intercourse for which they seek
treatment and they have intercourse during the days following
treatment. In the WHO dose finding study of mifepristone9, in the group
given 600 mg mifepristone, 4 of the 7 women who conceived did so at
least 15 days after treatment. Even in trials where data are collected, it
is not possible to determine which of two (or more) acts of coitus are
responsible for conception unless they are separated by at least 7 days
and only then if accurate ultrasonography is performed in early
pregnancy. In the WHO multicentre trial of LNG versus the Yuzpe
regimen of emergency contraception4, women who had intercourse after
receiving EC (whether with or without a barrier method) had higher
pregnancy rates than women who did not. In this study, almost 10%
were already pregnant when they took emergency contraception and, in
another 10%, pregnancy status was unknown. Indeed, when women
who were, or who may have been, pregnant at the time of treatment and
those who had had further acts of intercourse were excluded from the
analysis, the proportion of pregnancies prevented increased from 85%
to 89% in the LNG group but by 19% (from 57% to 76%) in the Yuzpe
group and the difference between the two methods was no longer
statistically significant.
Mode of action
There is good evidence from a number of sources to show that mifepristone
inhibits ovulation and implantation8. Its precise mechanism of action, when
it is used as an EC, depends on when in the cycle it is taken14. In contrast to
LNG and the Yuzpe regimen, the efficacy of mifepristone does not decrease
with time since coitus9. If a method works by inhibiting implantation, then
it should be effective up to perhaps 7 days after ovulation.
There are, as yet, no published data on the mechanism of action of LNG
used as an emergency contraceptive. Several biomedical studies have
demonstrated convincingly that the Yuzpe regimen can delay or inhibit
ovulation"'"'. Some have demonstrated minor changes in the endometrium
which, the authors speculate, may be sufficient to inhibit implantation17.
However, the group with the greatest expertise and track record in research
on the endometrium were unable to demonstrate any effect which might
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be associated with the inhibition of implantation'1 Some argue that the
Yuzpe regimen could not be as effective as it appears to be, if it worked only
by preventing or delaying ovulation. A recent review used sophisticated
mathematical calculations to demonstrate that some mechanism other than
die prevention of ovulation must account for 13.38% of the estimated effic¬
acy of the Yuzpe regimen". Since LNG appears to be much more effective
(albeit in only one trial), one has to conclude that it too must do more than
simply inhibit ovulation. Of course conclusions on mechanism of action
drawn from efficacy estimated from inaccurate data may not be very robust.
There are, of course, other possible mechanisms which would reduce the
chance of conception - inhibition of fertilisation or alteration of tubal
motility for example. Although it is possible that available methods of EC
work through a number of different mechanisms, there is no good evidence
available. What can be said is that neither the Yuzpe regimen nor levonor-
gestrel alone will be effective after implantation has occurred. Mifepristone,
in contrast, will be effective after implantation in up to 60% of women if
600 mg is taken, but it is unlikely that 10 mg would act as an abortifacient.
Safety
The safety of the Yuzpe regimen of EC has long been a topic for discussion
mainly because of a tendency to extrapolate from data associated with the
combined pill (COC). The main concern has been cardiovascular disease
and particularly venous thrornbo-embolism (VTE), as the total dose of
ethinyloestradiol (200 mg) is 6 times that of a single low dose COC tablet.
There are very few data on safety and much of what can be said stems from
clinical experience and common sense.
Even with long-term use of the combined pill, the risk of MI and
stroke is extremely small18 and the risk associated with PC4 can be
disregarded. Because of concerns about the association between
migraine and cerebrovascular accident, it is sometimes suggested that
Schering PC4 should not be taken during an attack of focal migraine19.
There is no evidence for this advice, but where LNG is available for
emergency contraception this would be the method of choice.
There has only been one biochemical study of the direct effects of PC4
on clotting factors20 and no effect was identified. Schering PC4 was
licensed in 1984 and by July 1996 (when the data were last reviewed14)
it had been used more than 4 million times. Few adverse events have
been reported to the Committee on Safety of Medicines (CSM) in the
UK: 115 reports of 159 reactions (some women having more than one),
included 61 pregnancies. Only three cases of venous thrombosis had
been reported, and in none is the relationship between emergency
contraception and the event clear-cut.
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In a study using the GP research database in the UK21, the records of
over 73,000 women who had between them received over 100,000
prescriptions for Schering PC4 over an 8 year period between
1989-1996 were reviewed. No women had a venous thrombotic event
within 60 days of using PC4. During the period of study, the same
cohort of women experienced a total of 19 cases of VTE, 5 during
pregnancy or the postpartum period, 8 during COC use and 6 cases
without exposure to endogenous or exogenous oestrogens. The relative
risk of VTE (compared to the spontaneous incidence of VTE) was 1.7
for second generation COCs, 3.7 for third generation COC and 5.6 for
pregnancy/postpartum. The study concluded that PC4 use was not
associated with an increased risk of VTE.
Both the WHO (which added the Yuzpe regimen to its essential drugs
list in 1996) and the International Planned Parenthood Federation have
stated that there are no absolute contra-indications to the Yuzpe
regimen except known pregnancy. If it is inadvertently used in the
presence of an on-going pregnancy, it will almost certainly do no harm.
Reliable data on the outcome of pregnancy after failed PC4 are lacking,
but the lack of demonstrable teratogenicity of the COC and the timing
of the administration of emergency contraception (long before organo¬
genesis starts) are reassuring22-2*'. Thus, the regimen is only contra-
indicated because it does not) work once pregnancy is established, not
because it is known to be harmful.
There are few data on the safety of LNG used as an emergency contra¬
ceptive. In the two published studies3-4 there were no serious adverse events,
but follow-up ended once menstruation had occurred or if a pregnancy was
diagnosed. It seems extremely unlikely that LNG used in this manner would
have any serious side-effects. The compound has been used for many years
in a large number of contraceptive preparations and is prescribed in doses
of up to 15 mg a day for 12 days (or longer) each month and for months
on end for the management of anovulatory dysfunctional uterine bleeding
and menorrhagia. Mifepristone too has an extremely reassuring safety
profile with no serious risks associated with its use.
Accessibility of emergency contraception
It has been calculated that the wide-spread use of EC could prevent
millions of unwanted pregnancies24. Although recent interest in EC has
led to its inclusion as part oProutine family planning services in many
countries, it is still not widely'used. The barrier to lack of use is not lack
of an effective, acceptable and safe method, but rather to lack of
knowledge and difficulties with access. Although knowledge in some
countries has improved in recent years25-2", particularly among young
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women who are perhaps most likely to use EC, still very few women
have ever used EC. Data are available from nationally representative
surveys in Nigeria and the US where less than 1% of women have used
EC and in Finland where 4% have used it27. In the UK, where perhaps
the population is the most knowledgeable and where it has been
available for over 15 years, it has been estimated that around 12% of
women have ever used it2S. Access to EC is limited because of ignorance «
and confusion among both providers and potential users. EC is a
controversial therapy, which is often confused (sometimes deliberately)
with abortion. As discussed earlier there is misplaced concern about its
safety because it is confused with 'the pill'. There are also concerns
about possible abuse or misuse (including repeated use) and warnings
that its wider availability might encourage promiscuity, unsafe sex and
the abandonment of other conventional methods of contraception. In
reality what little data exist are re-assuring. In the UK, only 6% of
women who have used EC have used it more than 3 times28 and in
Finland women who had used EC were no more likely to have had an
abortion than women who had never used it29. In a pilot study30 in
which 553 women were given a supply of EC to keep at home and their
pattern of contraceptive use over 1 year of follow-up was compared
with women who had to see a doctor to get EC, easier access to EC did
not result in repeated use or in women abandoning more effective
methods of contraception.
In many countries, including the UK, accessibility is limited because
EC must be prescribed by a doctor and the 72 h rule makes that difficult.
Recognising that EC is safe and that the benefits of easier access almost
certainly outweigh the risks, the close of the 20th century is witnessing
attempts to improve, access. The most effective way to do this would be
to make EC available off prescription. In the West, only France has done
this, a levonorgestrel product was approved as a pharmacy medicine and
went on sale in 1999. In the US in 1998, pharmacists in Washington
State (and subsequently in over 20 other states) were encouraged to
arrange collaborative prescribing agreements with physicians so that
they could provide EC directly to women without the need for their
seeing a doctor. In the UK in 1999, the British Pregnancy Advisory
Service (a privately funded abortion provider) made EC available for
sale in their clinics following consultation with a nurse or doctor. It is
highly likely that Levonelle-2® will become available with prescription
in the UK in early 2001.
It remains to be seen whether improved access to EC leads to increased
use and, thereby, to a reduction in unwanted pregnancy. In the Edinburgh
study30, advanced provision of EC was associated with a non-significant
reduction in the risk of unwanted pregnancy (RR 0.67; 95% CI, 0.4-1.2).
A much larger on-going trial in which all women between the ages of 16
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and 29 years living in one health board area of Scotland (over 85,000
women) are being offered supplies of EC to keep at home31 should help to
answer this question, but results will not be available until 2002.
Key points for clinical practice
• Emergency contraception can prevent unwanted pregnancy
• Levonorgestrel 0.75 mg twice separated by 12 h may be more effective that
the Yu7.pe regimen and is better tolerated
• Levonorgestrel and the Yuzpe regimen are more effective if used within 24
h of intercourse
• Mifepristone may well be the most effective oral method
• Effectiveness of emergency contraception cannot be determined precisely
but all methods prevent at least 75% of pregnancies
• Use is limited by difficulty with access and the need to see a doctor
• Advanced provision of emergency contraception is safe, sensible and may
reduce abortion rates
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Case Studies in Emergency Contraception
From Six Countries
By Anna Glasier, Evert Kelting, V.T. I'aian, Lesley Browne, Susheel Kaur, Xiao Hilian, Josue Garza-Flores,
L. Vasquez Estrada, Grace Delano, Grace Faoye, Charlotte Ellertson and Elizabeth Armstrong
In countries where emergency contra¬ception is offered, its availability anduse vary widely, according to such fac¬
tors as regulations and policies regarding
the method, providers' and women's un¬
derstanding of and attitudes toward it,
and cost. The experiences with the meth¬
od in six countries—the United Kingdom,
the Netherlands, Malaysia, China, Mexi¬
co and Nigeria—illustrate a range of is¬
sues involved in introducing and en¬
couraging (he acceptability of emergency
contraception.
Emergency contraception first became
available in most of these countries in the
late 1960s and early 1970s. Today, in the Unit¬
ed Kingdom and the Netherlands, the meth¬
od is an accepted part of family planning
practice and is well-known among doctors
and women. This acceptance may be part¬
ly due to the method's inclusion in the health
insurance systems of these countries.
Another factor explaining the estab¬
lished role of emergency contraception, at
least in the Netherlands, is the lack of
moral debate surrounding the method.
Only its side effects and efficacy seem to
engender controversy; the need for emer¬
gency contraception is acknowledged and
accepted even for teenagers, for whom
sexual activity is socially sanctioned.
By contrast, in Malaysia, as in oilier coun¬
tries where abortion is strictly regulated.
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emergency contraceptive methods are mar¬
keted legally, but family planning organi¬
zations shy away from offering them.
In China, postcoital methods have long
been offered by the government family
planning service. However, these meth¬
ods have not been separated into those ad¬
vocated for emergency use only and those
recommended for ongoing use.
Finally, in Mexico and Nigeria, aware¬
ness of emergency contraception contin¬
ues to be low among both health care
providers and the public.
Research, both ona way to create knowl¬
edge of emergency contraception and on
a way to publicize the methods, lias been
largely concentrated in European coun¬
tries; many developing countries, and even
many developed ones, have yet to conducl
any research on this topic. For example,
Mexico's first clinical trial of an emergency
contraceptive method (a combination of
levonorgestrel and ethinyl estradiol, ad¬
ministered orally or vaginally) is under
way, fully 30 years after the original re¬
search 011 the method was conducted.
In the case studies that follow, we sum¬
marize information oil experiences with
emergency contraception in each of these
countries. We then draw on these experi¬
ences to suggest lessons for other coun¬
tries seeking to introduce or expand the
use of this method.
United Kingdom
History of Emergency Contraception
Although British doctors occasionally ad¬
ministered liigh-dosc estrogen or insert¬
ed an 1UD for the purpose of emergency
contraception in the early 1970s, it was not
until 1974 and the publication of the first
article on emergency contraception using
a combined eslrogen-progestogen regi¬
men that the method's use became wide¬
spread in the United Kingdom.1 The Na¬
tional Association of Family Planning
Doctors met in 1982 to d iscuss emergency
contraception and a year later published
a set of clinical guidelines establishing two
combined pills, Ovran and Eugynon 50,
as the preferred hormonal regimens.2
in 1982, the Department of Health stat¬
ed that treatment up to 72 hours post-
coitaily was "probably legal," but thai treat¬
ment after five days "might be considered
an abortion."3 The following year, an an-
tiabortion lobbying group filed several
complaints against clinics providing emer¬
gency contraception; the group based its
argument on the Offences Against tire Per¬
son Act of 1861, which made it illegal for a
woman or her doctor to "intend to procure
a miscarriage." In response, the attorney
general ruled that emergency contracep¬
tion administered within 72 hours after in¬
tercourse was not a criminal offense, rea¬
soning that "preventing implantation is not
procurement of a miscarriage."*1
At the request of tire Department of
Health, the Committee on Safety of Med¬
icines undertook a review of emergency
contraception in 1983 and determined that
(lie method was "acceptably safe for oc¬
casional use." The pharmaceutical com¬
pany Schering submitted an application
for a product based on Eugynon 50 to the
Medicines Division in August 1983 and re¬
ceived a license in January 1984. PC4 (50
meg of ethinyl estradiol and 0.5 mg of
norgestrel in each of four tablets) was on
tire market by October 1984.
Discussion is under way witlr regard lo
making PC4 available from pharmacists
wi thout a doctor's prescription, a step that
most professional organizations support.
Tire Royal College of Obstetricians and
Gynecologists organized meetings about
tire matter in December 1994 and July
1995. It is up to Schering to apply to
change the license, and the company thus
far seems reluctant to do so.
Availability and Prevalence
General practitioners are the major source
of emergency contraception in tire Unit¬
ed Kingdom. Everyone in the United
Kingdom is entitled to register witii a gen¬
eral practitioner. For contraceptive ser¬
vices, women may also visit a general
practitioner other than the one they are
registered with, although this option is not
widely known.
•Abortion Ls legal in the United Kingdom under the trams
of the 1967 Abortion Act, which requires agreement by
two doctors that a woman has grounds for terminating
a pregnancy. A report of the abortion, signed by the two
doctors and specifying the grounds for termination, must
be made to (lie Department of Health.
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Women in most cities and large towns
may also seek emergency contraception at
National Health Service family planning
clinics. Since 1972, these clinics have pro¬
vided contraceptives free of charge. The
clinics offer anonymity to women reluctant
to consult their general practitioner and
may be open in the evenings and on week¬
ends; however, not all towns—and few vil¬
lages—have such centers, and at leasthalf
nf these rli nirs are open only once a week.
The nonprofit Brook Advisory Centres,
which provide services to young people
in cities throughout England and in Ed¬
inburgh, Scotland, provide emergency
contraception. Some hospitals' accident
and emergency departments also provide
hormonal emergency contraception.
National data on the prevalence of emer¬
gency contraception do not exist, but re¬
ports from clinics suggest tha f use has been
rising rapidly. Knowledge of emergency
contraception is fairly high; surveys from
the late 1980s found that 65-75% of women
undergoing induced abortion had heard
of emergency contraception.5 A small, un¬
published survey conducted by Schering
in 1994 found that 90% of women had
heard of emergency contraception. How¬
ever, many women continue to be unaware
of the 72-hour time limit or of the method's
ready availability. Levels of knowledge of
postcoital 1UD insertion are low.
Schering's sales data for I'C4 indicate
that about 353,700 packets were sold in
1992, and 420,500 were sold in 1993. Scher¬
ing has sold 2.5 million packels of l'C4
since the regimen was licensed in 1984.
One clinic in Edinburgh reprorts that the
use of emergency contraception has dou¬
bled in the last five years and now ac¬
counts for about 4% of the 47,000 visits
made to the facility annually.
There is no way ofestimating the extent
to which Ovran is prescribed for emer¬
gency contraception or how many lUDs
are inserted for postcoital indications,
since these contraceptives are also used on
an ongoing basis.
Cost
All contraception in the United Kingdom,
including emergency contraception, is free
to the patient. Schering sells the PC4 com¬
bination to the National Health Service at
a cost of about U. S. $2.20 per treatment.
Many family planning clinics and some
general practitioners make up their own
supplies using Ovran, at a cost of about
25 cents for the four tablets. The actual cost
to the clinic is somewhat higher because
of packaging costs. In addition, some clin¬
ics provide six tablets, to leave a woman
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with two spares in case she vomits. Oth¬
ers add an antiemetic, at a cost of around
16 cents per tablet. An IUD costs the Na¬
tional Health Service about $11—$16, al¬
though clinics that buy in bulk may pay
considerably less.
A recent study of the cost-effectiveness
of contraception estimated considerable
savings to the National Health Service
from the use of emergency contraception
to prevent unintended pregnancy.6 Even
on the basis of failure rates as high as 25
births per 100 users of emergency contra¬
ception per year, the study estimated that
prescribing PC4 costs between $19 and
$74, depending on the provider, and saves
the government health service $727-$806.
Estimates of costs averted did not include
such costs to society as those associated
with education and social services.
Netherlands '
History of Emergency Contraception
Emergency contraception has been used
in the Netherlands since 19647 and is
widely known and accepted there, lire
Netherlands places a high priority on pre¬
venting unwanted pregnancy, and infor¬
mation on emergency contraception has
always been included in family planning
education programs and materials. The
level of contraceptive use is generally
high, and the incidence of unwanted preg¬
nancy and abortion is low. Thus, while
emergency contraception is free of moral
debate, is not considered an abortifacienl
and is considered acceptable for teenagers,
the need for it is reduced by the high lev¬
els of effective contraceptive use among
women of all ages.8
As early as 1970, emergency contra¬
ception was covered in the first family
planning handbook for Dutch doctors,'
and within a few years, the method be¬
came widely available through general
practitioners, who form the backbone of
the Dutch health care system. (Every cit¬
izen is registered with a general practi¬
tioner.) The Dutch Family Planning As¬
sociation, the Rutgers Stichting, also began
offering the method in the early 1970s.
However, overall use of emergency con¬
traception declined by 50% between 1974
and 1983 primarily because of a sharp in¬
crease in the use of ongoing methods of
contraception after their inclusion in the
national health insurance program.
The original emergency contraception
regimen used in the Netherlands consist¬
ed of five pills of ethinyl estradiol taken
for five days—a total dosage of 25 mg, or
the equivalent of three years' worth of
modern low-dose oral contraceptives.
(This regimen is commonly known as the
5x5 method.) In around 1980, the "Yuzpe
method" was introduced in the Nether¬
lands. This regimen, which came to be
known as the 2x2 method for its two doses,
of two pills taken 12 hours apart, quickly
replaced the 5x5 method; for example, by
1985,83% of prescriptions for emergency
contraception front general practitioners'"
and 97% of those from the Rutgers Stich¬
ting were for the Yuzpe method." How¬
ever, over the last 10 years, the side effects
and efficacy of both methods have been
the subject of vigorous debate among
practitioners and researchers. Several spe¬
cialists feel that the 5x5 method provides
far too heavy a hormonal dose, while oth¬
ers are of the opinion that the 2x2 meth¬
od is not sufficiently reliable.
This debate has spilled over into the
general public's consciousness and has at
times affected the willingness of physi¬
cians to prescribe certain regimens and of
women to use them. The 5x5 method,
sometimes referred to in the mass media
as a "hormonal bomb," has been subject¬
ed to par ticularly harsh criticism. After ar¬
ticles critical of the method were pub¬
lished in 1987, the number of emergency
contraception prescriptions written by
general practitioners fell by 25% from the
year before.12 Today, some doctors re¬
portedly prescribe their own emergency
contraception regimens,15 and some
women devise their own.
In response to this controversy, in 1987
the Rutgers Stichting adopted a policy of
offering women a choice of the 5x5 or the
2x2 regimen or IUD insertion. More re¬
cently, there have been calls to make
mifepristone available for emergency con¬
traception in the Netherlands.'4
Availability and Prevalence
Partial data on use of emergency contra¬
ception in the Netherlands are available
through 1991, collected as part of the na¬
tional sentinel system of general practi¬
tioners. General practitioners provide
about three-quarters of the prescriptions
for emergency contraception in the
Netherlands; in 1991, they wrote 28,000
emergency contraception prescriptions.15
This level had remained more or less sta¬
ble since 1985. The Rutgers Stichting prob¬
ably provides an additional 2,000-7,000
prescriptions annually. Data on IUD in¬
sertion for emergency contraception are
not available, although use of this meth¬
od is presumed to be rare because most
women requesting emergency contra¬
ceptive services are young and have never
been pregnant. In total, the rate of use is
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about one per 100 women per year.
In 1991, of all women receiving emer¬
gency contraception from general practi¬
tioners, about 70% were younger than 25,
and 34% were younger than 20.16 lire pro¬
portion of emergency contraception pre¬
scriptions that are for adolescents, how¬
ever, is higher (51%) at the Rutgers
Stichting clinics.
A pair of studies cond ucted in Amster¬
dam17 suggest that condom failure prompt¬
ed tire request for emergency contraception
in 19-29% of cases and that missed pills ac¬
counted for 13-25% of requests. Slightly
fewer than halfof the women in these stud¬
ies had had unprotected intercourse at mid-
cycle, suggesting that many women seek
emergency contraception even when the
risk of pregnancy is slight.
Cost
The cost to a Dutch woman of emergency
contraception is determined by the type
of health insurance that covers her. The
largest insurance carrier is the Sick Fund,
which is publicly controlled but private¬
ly administered and covers about 60% of
all citizens. The remaining 40% of citizens
are privately insured. In addition, ail
Dutch citizens are covered by the Gener¬
al Law on Exceptional Medical Cost
(AWBZ), a national form of insurance in¬
tended primarily to cover catastrophic and
long-term care, but recently expanded to
include the cost of medical drugs. Sick
Fund members may receive medication
free of charge directly from their phar¬
macy. Privately insured patients must pay
for medications out of pocket, but can be
reimbursed by the AWBZ.
At pharmacies, the price of the 2x2
method is about $7-$9. The 5x5 method,
including an antinausea medication, costs
around $41. In order to receive the pre¬
scription, however, women must consult
their general practitioner. This visit is free
for women covered by the Sick Fund; pri¬
vately insured women must pay a fee of
approximately $20.
The Rutgers Stichting provides the 2x2
regimen free, but charges a consultation
fee that varies from around $1(1 to $20, de¬
pending on whether the woman is older
than 18. Women who obtain the 5x5 meth¬
od from the Rutgers Stichting pay about
$20 for the pills and antinausea medica¬
tion, in addition to the consultation fee.
Both the Sick Fund and tire private in¬
surance system may impose obstacles for
adolescents. Young people must either re¬
quest the Sick Fund card from their par¬
ents or pay directly and then request re¬
imbursement, through their parents, from
Volume 22, Number 2. June 1996
the AWBZ. Consequently, many adoles¬
cents seek emergency contraception at the




A1 though hormonal emergency contracep¬
tion has purportedly been available in
Malaysia since 1966, the first emergency con¬
traception regimen, Posterior, was not offi¬
cially registered there until 1987 Three years
later, a second regimen, Estinor, was regis¬
tered. These are reportedly the most com¬
mon specifically registered methods used.
Both brands consist of 0.75 mg tablets
of levonorgestrel, and the recommended
dose is a single tablet to be taken within
one hour after unprotected intercourse. If
the woman has engaged in more than one
act of intercourse, the manu facturers rec¬
ommend that a second dose (two Postinor
tablets or one Estinor) be taken eight hours
later. These brands are usually sold in 10-
tablel strips, and physicians often divide
strips and provide women with only as
many pills as they need.
In Malaysia, emeigency contraception is
often erroneously viewed as an "abortion
pill." Since abortion is stringently regulat¬
ed, this misperception may have led to re¬
luctance on behalfofsome service providers
and program administrators to provide
emergency contraception or even infor¬
mation about its existence and benefits.
Availability and Prevalence
Data on emergency contraception are not
available from the national family plan¬
ning program, and the literature on the
method in Malaysia is scant. Government-
run family planning clinics do not provide
emergency contraception, and the private
practitioners who do ore reluctant to speak
about it. Although the Federation of Fam¬
ily Planning Associations, Malaysia
(FFPAM) prefers to stress regular use of
an effective method, rather than distrib¬
uting something that acts as an "abortion
pill," FFPAM members follow guidelines
for the provision of emergency contra¬
ception established in a 1992 internation¬
al Planned Parenthood Federation quali¬
ty assurance manual."1
Emergency contraception is, however,
available from both pharmacies and private
physicians in Malaysia. Although Postinor
and Estinorboth fall under the regulations
of the Poisons Act, they may be purchased
without prescription if the woman provides
her name, address and identification card
number to the pharmacist.
Very rough estimates based on sales by
pharmacies indicate that at least 20,000
women obtained emergency contracep¬
tives in 1994. The exactnumber is difficult
to determine because some women pur¬
chase just the tablets they need to cover
one act of unprotected intercourse, where¬
as others buy extra pills.
Few women receive emergency con¬
traception from FFPAM clinics; only 60
did so in 1993. These women were 20—40
years old and requested emergency con¬
traception for a variety of reasons: unex¬
pected and unprotected intercourse,
missed pills and ruptured condoms. In ad¬
dition, some pharmacies report thai Esti¬
nor is used by sex workers, as well as by
rape victims.
At pharmacies in Malaysia, the strip of
10 pills—enough to cover five episodes of
unprotected intercourse—costs the pur¬
chaser $3-$6. At private clinics, the cost
for 1-3 tablets is approximately $4, which
includes the consultation fee.
China
While postcoital contraception is a topic
of research for China's State Family Plan¬
ning Commission pmgram, and postcoital
methods are included in the government
family planning program, figures on the
prevalence of emergency contraceptive
use are not available.
Postcoital contraception was first de¬
veloped in China in the 1970s, primarily
for use by married couples living at a dis¬
tance from one another. Thus, the focus of
postcoital contraception has been on a
"visiting pill" for ongoing use by couples
who are only infrequently exposed to the
risk of pregnancy. Although the literature
on the use of visiting pills is extensive,
there are few reports of their use for emer¬
gency contraception.
Preparations packaged as visiting pills
(also known as vacation pills and quick-
action pills) often consist of high doses of
norethisterone, megestrol acetate or
norgestrel. Other compounds, such as
quingestanol, norgestrienone and norethis-
terone ncetate-3-oxime, are also used.15
The most commonly used visiting-pill
formulation is anordrin, a compound syn¬
thesized in Shanghai in 1975.20 One 75 mg
tablet is taken the morning after unpro¬
tected intercourse, and one is taken every
night for three nights. The cost of the reg¬
imen is only a few cents.
Reportedly, some women obtain lUDs
after experiencing contraceptive failure (for
example, when a condom has broken), but
it is difficult to distinguish when an IUD has
been inserted for emeigency contraception.
Researchers at the International Peace
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Maternal Hospital in Shanghai have ex¬
perimented with levonorgestrel suppos¬
itories, in the hopes that vaginal admin¬
istration would reduce the nausea and
vomiting associated with the elevated hor¬
monal dosage of emergency contracep¬
tion. The tablets, however, were not suf¬
ficiently soluble to be highly effective.
China is also testing mifepristone as an
emergency contraceptive, both alone and
in conjunction with other hormones. As
vet, mifepristone is available only in clin¬
ical trials, but family planning advocates
hope it will be introduced soon for gen¬
eral use as an emergency contraceptive.
Mexico
Emergency contraception is little known
in Mexico, among either providers or con¬
sumers. Since oral contraceptives are avail¬
able without prescription, women have
potential access at least to the Yuzpe regi¬
men (which would cost about 50 cents);
however, they may not be aware of it.
Although requests for emergency con¬
traception reportedly are frequent in Mex¬
ico, providers themselves lack adequate
information on this method. One objective
of a clinical trial currently under way in
Mexico is to increase knowledge of emer¬
gency contraception among health pro¬
fessionals, including family doctors and
general practitioners, and pharmacists.
Nigeria
Traditional fertility control methods in
Nigeria include several that are used either
immediately after unprotected intercourse
or when a pregnancy is first suspected.
Among these are potash mixed with blu¬
ing, lime taken in high concentration with
cayenne pepper seeds, and a codeine tablet
used together with illicit gin. Nigerian
women are also gradually learning that al¬
tered doses of oral contraceptives can func¬
tion as emergency contraceptives.
No data are available on the prevalence
of emergency contraception or on the costs
of hormonal regimens in Nigeria. An IUD
insertion costs $25 in a private hospital.
Codeine and gin costs about $2.25; the
other traditional emergency contracep¬
tives are very inexpensive.
Lessons Learned
The experiences with emergency contra¬
ception described in this article highlight
several issues that may be relevant in
cither countries as well.
As the case studies demonstrate, both
providers and potential users need to be
well informed about emergency contra¬
ception, how it is used and its availabili¬
ty
ty. The importance and the role of emer¬
gency contraception can easily be over¬
shadowed by family planning's tradi¬
tional mission to ensure consistent,
effective contraceptive use, particularly
in developing countries, where the focus
may be on lowering fertility.
Emergency contraception is most wide¬
ly used in countries where it is well inte¬
grated into general family planning ser¬
vices and information and education
efforts, such as the United Kingdom and
the Netherlands. It has a key place both
within family planning's traditional em¬
phasis, as a backup for method or user fail¬
ure, and as a last resort in the instance of
unexpected intercourse.
Another lesson is that a clear distinction
must be drawn between emergency con¬
traception and abortion, especially in
countries where abortion is legally re¬
stricted or carries a moral stigma. A con¬
fusion of emergency contraception with
abortion can seriously impede efforts to
prevent unintended pregnancy through
use ofemergency methods, as in Malaysia.
Emergency contraception should be cast
as an important way to reduce the need
for abortion.
Furthermore, the experiences in the
United Kingdom and the Netherlands il¬
lustrate that even in countries that have
good data on emergency contraception,
information about its use is incomplete.
Data on emergency contraception should
be collected along with other routine fam¬
ily planning statistics. To date, efforts to
examine the use of emergency contra¬
ception have been complicated by the fact
that the 1UD and combined oral contra¬
ceptives may be used for cither regular or
emergency contraception, in the future,
efforts should be made to distinguish the
different uses of these methods.
The case studies also show that emer¬
gency contraception should be available
from a variety of sources—certainly gen¬
eral practitioners or family doctors, as well
as family planning clinics, which offer
more anonymity. The British and Dutch
experiences demonstrate the importance
of both a network of highly informed,
properly motivated, easily accessible ser¬
vice providers and wide dissemination of
information among them and the lay pub¬
lic. While tire success of emergency con¬
traception in these countries probably can¬
not be separated from the overall high
quality and accessibility of their health
care and contraceptive services, it appears
that emergency contraception is most
widely used when it is well integrated into
routine care.
A further point for planners to consid¬
er is that there is more than one way to ad¬
minister emergency contraception; coun¬
tries might experiment with different
delivery mechanisms and regimens, as
China has done and as Mexico plans to do
in its current study.
The remaining lessons concern uses of
emergency contraception that have not tra¬
ditionally been the focus of most Western
countries. For example, as China has
demonstrated, emergency contraception
may have applications beyond preventing
pregnancy after a single exposure to un¬
protected intercourse. Methods like the vis¬
iting pills used in China may well be ap¬
propriate for use in other countries where
couples have intercourse infrequently. In
Malaysia, meanwhile, the reported use of
Estinor by sex workers suggests another
group for whom emergency contraception
may be particularly valuable.
Finally, the Dutch case reveals that
emergency contraception may be partic¬
ularly important for adolescents. As
young people establish their sexual iden¬
tity and contraceptive practice, they may
be likely to use contraceptives ineffectively
and subsequently experience contracep¬
tive failure. For them, emergency contra¬
ception may provide a crucial safety net
in lire event of intercourse they d id not ex¬
pect or adequately prepare for, as well as
a bridge to more regular and sustained
contraceptive use.
Conclusion
Although emergency contraception has
been available for about three decades, its
potential to reduce the incidence of unin¬
tended pregnancy and abortion is just be¬
ginning to be realized, in only one of the six
countries examined here, the Netherlands,
has the method settled into a well-accept¬
ed niche so that efforts can focus oir refin¬
ing the regimens and informing women
about them. Even in the United Kingdom,
the use of emergency contraceptives has
been growing rapidly, which suggests that
Lhe method is still regarded as "new."
Emergency contraception may well fill
an important gap among groups whose
needs have gone unmet by traditional
family planning programs. The experi¬
ences of these six countries suggest that
family planning researchers and practi¬
tioners must be both persistent and inno¬
vative as they work to make emergency
contraception available to more women
in more countries around the world.
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LETTERS
Unmet Need and Potential Demand
A digest entitled "Developing Countries
Show Sizable Crass-National Variations in
Unmet Need, Demand for Contraception,"
summarizing a Demographic and Health
Surveys comparative report [21:161-162,
1995], gave a misleading picture of the ac¬
tual situation. Instead of tire term "demand
for contraception," the phrase "potential
demand for contraception" would have
been better. Demand for contraception was
defined as a combination of current use
and unmet need, but (as the digest point¬
ed out) many women categorized as hav¬
ing an unmet need for contraception do
not intend to use any contraceptive meth¬
od. Their reasons are varied, and include
ambivalence about childbearing, a lack of
information about methods, fear of health
effects, or personal or spousal opposition
to family planning. To classify such
women as haying a demand for contra¬
ception is very misleading.
Further, the digest mentions that "some
womenclassified as having an unmetneed
for family planning were not sexually ac¬
tive in the month before the survey." Except
for tire possibility of rape, sexual abstinence
is a perfectly effective contraceptive meth¬
od, and attributing a demand for contra¬
ception to such women overstates the case.
Both a real demand for contraception
and an important level of unmet need exist
in developing countries. However, to state
that women who are not practicing con¬
traception for lack of information or mo¬
tivation are actually demanding it can mis¬
lead policymakers into ignoring the great
need for information and motivation in
addressing the reproductive health needs




South Burlington, Vt., LfM ■
The editors reply:
Our intention when we digest a published
piece of research is to report the study's find¬
ings as accurately and completely as possi¬
ble. Since tlie Demographic and Health Sur¬
veys report on which this d igest was based
used the terminology "demand for contra¬
ception" throughout, so did we. The author
of the original report agrees, however, that
"potential demand" probably represents an
improvement over "demand."
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Abstract
Levonorgestrcl (LNG) 0.75 mg administered 12 h apart within 72 h of unprotected coitus, is an established method of emergency
contraception (EC). The mechanism of action of LNG used in litis manner is unknown. We administered LNG 0.75 mg twice immediately
before ovulation, to test the hypothesis that LNG acts as an emergency contraceptive by abolishing the pre-ovulatory lutenizing hormone
(LI I ) surge and thereby delaying ovulation. Twelve women took LNG on or before the day of the first significant rise in urinary LH in 12
cycles. In four women, the LI-1 peak and the onset of next menses were significantly delayed (delay of 16.8 days (SD ± 8.7) from the day
of mean LH peak in placebo cycles). One woman did not ovulate at all, despite a normal LH peak and cycle length. In the remaining eight
women, LNG did not affect ovulation or the cycle length, but the length of the luteal phase and the total luteal phase LH concentrations
were significantly reduced. We suggest that LNG acts as an emergency contraceptive by other mechanisms as well as delaying the LH surge
and interfering with ovulation. © 2001 Elsevier Science Inc. All rights reserved.
Keywords: Emergency contraception; Levonorgcstrel; Mechanism of action
1. Introduction
Levonorgestrel (LNG) 0.75 mg administered twice with
the two doses 12 h apart lias been shown to be an effective
method of emergency contraception (EC) when used within
72 li of unprotected intercourse [1,2], Although the regimen
is now licensed in the UK., USA, and throughout much of
Europe and is widely regarded as the emergency contracep¬
tive method of choice [3], the mechanism of action remains
unknown. The mechanism of action of the Yuzpc regimen
of emergency contraception (ethinyl estradiol 100 meg and
0.5 mg LNG, two doses 12 h apart [4-6], is also incom¬
pletely understood but there is good evidence that it delays
or inhibits ovulation in at least some cycles [5]. In the WHO
study, the efficacy of both LNG and the Yuzpe regimen
decreased with time after intercourse [7] and both regimens
had a similar effect on die timing of the subsequent menses,
oThc study was supported by the Medical Researcli Conned and
Department for International Development (Grant No. G9523250).
♦Corresponding author. Tel.: +44-131-229-2875; fax: +44-131-229-
2408.
E-mail address: dtbairdfrited.ac.uk
suggesting that the mechanism of action of the two regi¬
mens may be similar. It has also been shown that large
amounts of synthetic progestogens abolish the mid-cycle
lutenizing hormone (LH) surge leading to anovulation and
delaying the onset of the subsequent menses [8-11].
To test the hypothesis that it acts as a post-coital agent by
abolishing the pre-ovulatory LH surge and by delaying
ovulation, we administered LNG 0.75 mg twice to 12
healthy female volunteers in the fertile period (immediately
before ovulation) of the menstrual cycle and investigated
the effects on die timing of ovulation and of the next
menses, bleeding patterns; ovarian activity, and LH concen¬
trations.
2. Materials and methods
This was a prospective, randomized, double-blind, cress-
over study undertaken in one center. Twelve healthy women
(mean age 33.3; range 26-41 years) with regular cycles
(mean 27.6 days; range 25-30 days) and mean BM1 25.7
(range 20-34) were recruited. They were all using a reliable
non-hormonal method of contraception or were abstinent
0010-2 824/0 l/'S - see front mailer €> 2001 Elsevier Science Inc. All rights reserved.
I'll; S0(l 10-7824(00)00 I 86-X
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during die study. All subjects gave written informed consent
for participation in the study, which was approved by the
Lothian Research Ethics Committee.
A method was sought to provide a convenient means of
identifying the fertile period prior to ovulation, and thereby
to time the administration of LNG. Unipath (Bedford, UK)
had developed a technology that can be used in the home to
monitor changes in urinary hormones [12], This monitoring
system comprises disposable test sticks and a hand-held
monitor, which together are used to detect changes in the
levels of ocstronc-3-glucuronide (E3G), a urinary metabo¬
lite of oestradiol, and LH to indicate the potentially fertile
days leading up to ovulation.
The monitor optically measures the intensity of the lines
that form on the test sticks after sampling, and the system
will delineate three levels of fertility (Low, High, and Peak
Fertility) according to the optical signal changes detected.
Low Fertility will be displayed from day 1 of the cycle until
the hormone levels rise above the baseline levels. A change '
from Low to High Fertility is triggered by detection of
elevated E3G levels, to concentrations typically between 20
and 30 ng/inL. The change front High to Peak Fertility is
triggered by the detection of an LH surge, typically with a
concentration higher than 30 IU/L. Peak fertility is dis¬
played on the day of the LH surge and on the following day.
Bach woman was studied during four cycles and was
issued a monitor at the beginning of the study. Subjects
were asked to use the monitor according to instructions, and
familiarized themselves with the monitors by using it during
a prc-shidy cycle to identify the days of high fertility and the
day of the LH surge. They also recorded days of vaginal
bleeding.
Data from the pre-study cycle was used to predict the
timing of the LH surge and of the fertile phase during the
study cycles and thereby to predict when treatment should
be administered. The three study cycles followed immedi¬
ately after the pre-study cycle. Six subjects were randomly
assigned to treatment arm A and received LNG in the first
study cycle and placebo in the third study cycle. The re¬
maining six subjects were randomized to treatment arm B
and received placebo in the first study cycle and LNG in the
third study cycle. The second study cycle was a washout
phase for all women during which time they also received
placebo tablets.
The randomization list was produced using SPSS
Rv.Bernouilli function such that each study number was
randomly assigned to either treatment arm A or treatment
arm B with the same probability, i.e. 0.5.
LNG and placebo were visually identical and were pre¬
packed. Each subject collected a sample of early morning
urine daily from the first day of the first study cycle until
and including the first day of the menstrual bleed signaling
the end of the last study cycle. Samples were frozen and
later assayed in batches (with all samples from one subject
assayed in a single batch) for measurement of urinary LH,
E3G, and pregnancdiol-3-glucuronide (P3G).
Quantitative assessment of urinary LH was performed
using an LH MAlAclone kit (BIOSTAT-DIAGNOSTICS,
Stockport, Cheshire, UK). This method incorporates two
high-affinity monoclonal antibodies into an immunoradio-
metric assay system and offers a working range of 1.5-200
mlU/mL. Urinary P3G was measured using a direct enzyme
immunoassay (working range 0.25-32 mmol/L), while di¬
rect immunoassay was used to measure E3G levels (work¬
ing range 8.36-2140 nmoI/L. Intra-assay coefficients of
variation were 6% for E3G, 10% for P3GI, and 3% for LH
[13]. Geometric means of daily replicates were divided by
the respective daily creatinine concentration to correct for
variations in the dilution of the urine specimen.
During study cycles 1 and 2, women were asked to take
the study medication on the first day of High Fertility as
identified by the monitor. However, by the third study cycle,
the variation in the number of high fertile days (range 0-8
days) meant that the monitor could not be used to administer
medication on LH-2 in every cycle. Therefore, we had to
adopt a different method of calculating the anticipated day
of the LH peak for each cycle based on the monitor infor¬
mation from the previous cycles (including the prc-study
cycle). Hence, in the third study cycle, the medication was
taken 2 days prior to the anticipated day of the LH peak. In
all cycles the first tablet was taken at 1100 h and the second
at 2300 h. A sample of venous blood was collected 5-7 days
after treatment, stored and later assayed for progesterone
using Coat-A-Cont solid-phase radioimmunoassay. The
subjects kept a daily record of all vaginal bleeding experi¬
enced during the four cycles, the fertility status information
displayed each day on the monitor LCD and the days on
which the study medications were taken.
2.1. Statistical analysis
We calculated that a total of six subjects in each of the
two treatment arms would give more than 90% power to
detect a delay of menses of >5 days in 95% of cycles.
Preliminary analysis was performed to determine
whether parametric tests were appropriate for analysis of the
data. Outlying data points were investigated while the treat¬
ment was still blinded. The period effect and interaction
between treatment and period effect were tested (two-sam¬
ple t test) before progressing to testing of a treatment effect
and was non-significant. Comparisons between LNG versus
placebo cycles was tested by paired t test.
For the purpose of the study the following definitions
based on the quantitative data were created.
A significant delay in the onset of next menses: Delay of
5 or more days from the expected onset of menses (based on
the mean cycle length for the 2 placebo cycles).
The LH peak was defined as a significant rise in urinary
LH concentration, with a minimum of 50% rise above the
average baseline level for 4 preceding days and which
remained elevated for a minimum of 3 days.
The first day of the LH peak was defined as the day of the
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Table I
Timing of Lll peak, predicted day of the LH peak and timing of LNG in treatment cycles for all subjects
Subjects Day of the Lll peak (Lll > 50%) Predicted day of the Timing of LNG in Timing of LNG in
LH peak in the relation to the day of relation to the
Pre-study Placebo Placebo I rcatnient treatment cycle LL1 peak in the predicted day of the
cycle (washout) treatment cycle Lll peak
S101 12 13 9 10 11 -1 -2
S102 M 20 19 21 19.5 -I +0.5
$103 12 27c 9 11 9 -1 + 1





14 14 13 14 -I -2
Sill 12 11 15 12 13 -I -4
SI 12 II II 12 13 11.5 -5 -3.5
S105" 14 13 15 14 14 —2
SI 06" 14 14 12 23 13 -11 -2
SI 08" 17 18 18 25 14 - 13 _2
SI 09" H 10 10 38 10 -31 -3
SI 10" 18 18 ££ 40 18 -25 -3
The woman with normal LH peak but no significant rise in prcgnanediol in the luteal phase = anovulatory cycle.
"Women who had a delay of the Ll l peak by >5 days.
Tixclltded. unusually delayed ovulation,
ft = excluded, no daily urine available.
M -- LH peak not detected by the monitor.
first significant rise (>50% above (he baseline) seen at the
beginning of the LH peak.
Retrospectively predicted first day of the LH peak for the
treatment cycles was the calculated mean of the first day of
LH peak in the two placebo cycles.
A significant delay in the first day of the LH peak: Delay
of 5 or more days from the expected first day of the LH peak
in the treatment cycle (based on the mean first day of the LH
peak during the 2 placebo cycles).
Luteal phase: time from the day after the first day of the
urinary LH peak (LH+1) until, and including, the day
before the first day of the next menses.
Follicular phase: time from the first day of the menses
until the day of the first significant rise in urinary LH
(LH+0) inclusive.
3. Results
A total of 48 menstrual cycles were studied—12 pre-
study cycles and 36 study cycles. Data from daily urine
samples were available for 34 out of the 36 study cycles. In
one woman (Si03) the first study cycle, which was a pla¬
cebo cycle, was prolonged (41 days) as a consequence of a
delay in ovulation. Her usual cycle length was 25 days, this
cycle was excluded from the analysis. In a second woman
(SI 10) there were no daily urine samples available from the
washout cycle as she was abroad on holiday. Therefore,
daily urine samples were only available for this subject from
two study cycles (the treatment cycle and one placebo
cycle).
3.1. Timing ofadministration ofLNG
Six women took LNO in the first .study cycle and six
took it during the third study cycle. During the first study
cycle, 10 women took the tablet (either placebo or LNG)
on the first day of High Fertility as indicated by the
monitor. The remaining 2 women took the tablet on the
first day of the urinary LH peak because the monitor
failed to identify any high fertile days prior to the LH
surge.
The variation in the number of High Fertile days (0-8
days) declared by the monitor meant that the system could
not be used to predict LH-2 in every cycle. Therefore, for
cycle 3 we calculated the anticipated first day of the urinary
LH peak from the information gathered front the pre-study
cycle and study cycles 1 and 2 for each woman and in¬
structed subjects to take the tablet 2 days before the antic¬
ipated day of the LH peak.
After completion of the study, we retrospectively calcu¬
lated the predicted first day of the urinary LH peak for every
treatment cycle based on the mean first day of the LIT peak
in the two placebo cycles. When vvc applied this retrospec¬
tively predicted definition to all 12 treatment cycles, the day
of taking LNG ranged from 4 days before until 1 day after
the first day of the anticipated LH peak. However, in reality,
LNG was never taken after the first significant rise in uri¬
nary LH concentrations in any treatment cycle. The timing
of the LH peak in each of the four cycles, the predicted day
of the LH peak day and the timing of LNG and placebo
treatment in relation to the start of the actual LH peak are
shown in Table 1.
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Table 2
Mean length of plaecbo and treatment cycles
Mean cycle length Treatment cycles Placebo cycles
All cycles, n = 12*
N - 4, Delay of >5 days'1





32.17 (SD i 3.36)
42.75 (SD ± 8.42)
24.88 (SD ±2.1)
26.33 (SD ± .42)
27.13 (SD ± 1.84)
26.13 (SD ± 1.69)
Treatment with LNG in the pre-ovulatory period signif¬
icantly prolonged by 5 days or more the mean cycle length
in four women (33% of (he sample, Table 2). All 4 women
reported vaginal spotting 2 to 3 days after taking LNG and
they all had a second episode of vaginal bleeding between 9
and 16 days after the delayed LH peak. In the remaining
eight women, there was no significant difference in cycle
length between treatment and placebo cycles. One of this
group of women, however, reported light vaginal bleeding
starting a week after taking LNG, the bleeding continued
until she started what she regarded as a normal menstrual
period which followed a fall in urinary pregnandiol levels.
Her hormone profile during the treatment cycle followed a
normal pattern.
3.3. The first day of the LH peak
In the four women with long cycles, LNG appeared to
abort the LH peak and a subsequent LH peak occurred 7 to
16 days later, followed by a normal rise in urinary preg-
nanediol. The urinary hormone profile of one woman
(SI 10) is illustrated in Fig. 1. In the remaining eight women.
LNG did not affect the timing of the LH peak when taken
immediately before ovulation. Fig. 2b illustrates the hor¬
mone profile in one of these women (SI 01).
3.4. Length of the. luteal phase
In all 12 volunteers the luteal phase was significantly
shortened following treatment with LNG as compared with
the placebo cycles (mean length 11.5 days [SD ± 1.8] vs.
12.9 days [SD ± 2.5] p = 0.005, Table 3).
3.5. The effect on total LH during the luteal phase
Daily urinary LH concentrations were sutnmated from the
first day of the LH peak (LH+0) up to the day before the first
day of the next menses to give a value for total LI I concen¬
trations. The 8 women in whom pre-ovulatory LNG did not
affect the cycle length, showed a significant (p = 0.01) de¬
crease in total L.H in the treatment cycles (18.7 U/mmoL,
^ Plarohn
14 21 28 35 42 49
I'.'- r Vagina! bleeding MM Menses
Day of the cycle
Fig. I. Daily levels of LH (•) oestrone-3-glucuronide (E3G) (A), and prcgnanediol (O). in urine relative to the cycle day. (a) Placebo cycle of a woman (S110)
fb) Treatment cycle of the same woman (S110) showing significantly prolonged cycle following pre-ovulatory LNG. 1, Day of taking LNG or placebo tablet;
-
, day of the LH surge
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I Menses Menses
Day of the cycle
Fig. 2. Daily levels of LH (•), oestrone-3-glucuronidc (E3G) (£), and pregnanediol (O), in urine during ihc treatment cycles, (a) Of lite woman (SI 05) with
no significant rise in pregnanediol following LNG. (b) Of a women (S101) with apparently normal cycle length. \ , Day of tuking LNG; day of the L.II
surge in the placebo cycle; . day of the LH surge.
SD ± 8.9) as compared with the placebo cycles (27.1
U/mmoL, SD ± 13.6). In contrast, among the 4 women with
significantly longer cycles after taking LNG, there was no
difference in the total LH secretion in the tnteal phase (mean
total LH = 18.8 mlU/mL, SD ± 8.3; versus mean total LH for
placebo cycles of 17.8 U/mmoL, SD ± 2.8; p = 0.81).
3.6. Effect on pregnanediol in the luteal phase
The sum of daily pregnanediol concentrations in the
luteal phase (from LH+ 1 onwards up to the day before the
first day of next menses) was compared during the treatment
and placebo cycles was employed to indirectly assess the
function of the corpus lutcum.
In one woman (SI05) after taking LNG, there was no
significant rise in urinary pregnanediol levels (>0.5 mmol/
mol creatinine as expected in the mid-luteal phase) despite
an apparently normal LH peak. The mid-luteal serum pro¬
gesterone level during this treatment cycle was consistent
with an anovulation (<5 nmol/L) (Fig. 2a). In the remaining
11 subjects, the total values of pregnanediol did not show a
significant difference between placebo or treatment cycles.
4. Discussion
Evaluation of daily hormone concentrations confirmed
that all 12 women in our study took LNG before the LH
peak, and presumably ovulation. Seven women had appar¬
ently normal ovulatory cycles after taking LNG. Five of
them took LNG on the day before the L.H surge and one on
the day of the surge. It is possible that the timing of LNG in
these women was "too late" to influence an event already
well underway. However, in the four women in whom the
LH peak and ovulation was delayed, the LNG was taken
within 3 days of the predicted LH peak. One woman did not
ovulate at all despite having an LH surge 2 days after taking
LNG.
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Table 3
Length of the luteal phase (11 = 12)













"Women who had a delay of the LH peak by >5 days
'The time from the LH surge to the next menses in the woman with an
anovulatory cycle, but a normal LH peak after LNG (Fig 2a)
It is apparent that different women respond differently to
the administration of LNG. The effects observed may be
related to administering LNG at a specific stage in follicular
development. Even though the timing of the LNG in rela¬
tionship to the onset of the LH surge did not appear to be
different between women in whom ovulation was affected
and those in whom it was not, it would be naive to accept
that our predicted day of the LH peak based on information
gathered In two cycles was always accurate. A more de¬
tailed study employing daily serum levels of gonadotro¬
pins and steroid hormones and ultrasound scans to corre¬
late follicular size and maturity to the timing of the
administration of LNG might provide an explanation.
The 7 women, who apparently ovulated normally, had a
reduced total luteal LH and a shortened luteal phase. Basal
levels of LH are essential for the normal secretory function
of the corpus lutcunt [14]. In the mid-luteal phase, LH
inhibition by the administration of GnRH antagonists con¬
sistently results in luteolysis in women as well as in non-
human primates [15-17]. There are no direct ways of mea¬
suring whether the function of the corpus luteum is
compatible with the establishment of pregnancy. Although
there was no significant difference in the urinary preg-
nanediol levels after LNG, it is possible that the shortened
luteal phase observed was a consequence of reduced total
LH and may have a contragcstive effect.
II' LNG acts as an emergency contraceptive only by
interfering with ovulation, the expected efficacy should fall
below 42% (5 of 12 women). Ho and colleagues [1] re¬
ported that LNG reduced approximately 60% of the ex¬
pected number of pregnancies (estimates were based on the
table of probabilities ofpregnancy at different cycle days by
Dixon et al. [18]). LNG fared belter in the WHO study [2]
with overall 85% reduction of expected number of pregnan¬
cies (the analysis of the prevented fraction was based on the
modified Wilcox estimates of conception probabilities
[19])-
Botli studies reported effectiveness against estimates
based on historical data. The fertile period was determined
on the assumption that ovulation occurred 14 days before
the next expected menses. The validity of using these esti¬
mates directly relies on the accuracy of reported menstrual
cycle data. Women do not regularly keep records of their
menses, and by tind large the sexual intercourse responsible
for requesting emergency contraception is unpremeditated.
Reporting errors are common and the estimates can be
inaccurate. In addition, other factors such as biologic vari¬
ability of the day of the ovulation and the length of the luteal
phase, factors affecting the probability of pregnancy unre¬
lated to the timing of intercourse, and heterogeneity among
couples in fecundability can distort the estimated number of
pregnancies. In a study comparing the efficacy of the Yuzpe
regimen of EC with a single dose of mifepristone [20], there
were frequent discrepancies among subjects between the
stage of the cycle as estimated front the date of the LMP and
that suggested by circulating concentrations of progester¬
one. There has never been a placebo-controlled trial of EC.
Thus, it is possible that the genuine effectiveness of LNG as
an emergency contraceptive is less than 42%.
One woman (SI03) in our study showed a delayed LH
peak (on day 27) during a placebo cycle and subsequently
the length of that cycle was prolonged to 41 days (Iter usual
cycle length was 25 days). In contrast to the four women
who experienced similar prolongation of the cycles after
taking LNG, this woman did not report any intermenstrual
vaginal bleeding. Although we excluded this cycle from out-
analysis, similar spontaneously occurring prolonged cycles
(with delayed ovulation), can influence the results of studies
into emergency contraception.
The discrepancy noted in the estimated effectiveness of
LNG and the prevalence of ovulation delay or inhibition in
our study may be due to mechanisms of action other than
interference with ovulation. Our study was not designed to
investigate the other possible mechanisms by which LNG
works. However, one woman in our study reported slight
vaginal bleeding after taking LNG with an apparently nor¬
mal LH peak, cycle lengtli and hormone profile. This may
suggest an additional effect of LNG on the endometrium
[21-24], Nevertheless, the question remains as to whether
similar alterations occur in the endometrium after taking the
emergency contraceptive regimen of LNG, and whether
these changes arc sufficient to prevent implantation and
account for the observed contraceptive efficacy of LNG.
The effect of progestogens on cervical ntucus and on the
cervix is well documented and this is thoughl to be the main
mechanism by which the progestogen-only pill exerts its
antifertility action [25-27], However, even if LNG has an
effect on cervical mucus, which interferes with sperm pen¬
etration, that action is unlikely to prevent pregnancy when
taken some 12-72 h after coitus.
The reason for using the monitor to time the administra¬
tion of LNG or placebo was to avoid having to subject Ihc
volunteers to regular blood samples and ultrasound scans.
However, due to the variability in the number of high
D. Hapangama ct al. / Connaception 63 (2001) J 23-129 129
fertile days declared prior to the LH surge, greater reliance
had to be placed on calendar calculations to predict the LH
surge.
in conclusion, we suggest that LNG taken immediately
before ovulation acts as an emergency contraceptive by
delaying or preventing ovulation. Other plausible actions of
LNG including the retardation of the endometrium, inter¬
fering with sperm motility and altering cervical mucus may
be important, and need to be explored further.
Acknowledgments
The authors thank Dr. Andre Ulmann, HRA Pharma, for
providing us with the study medication, Unipath Ltd. for the
provision of home use monitors and data collected from the
monitors. Dr. Rob Elton and Ms. Dawn Everington for their
assistance and advice on statistics, Mrs. Ann Mayo for
helping with the recruitment of patients, and Mrs. Martha
Urquhart for laboratory assays.
References
11] Ho PC, Kwan MSW. A prospective randomized comparison of
Icvonorgestrcl with the Yuzpc regimen in post-coital contraception.
Hum Reprcni 1993;8:389-92.
[2 j WHO Task Force on Postovul.nory Methods of Fertility Regulation.
Randomised controlled trial of LNG versus the Yuzpc regimen of
combined oral contraceptives for emergency contraception. Lancet
I99S;352:428 -33.
|3) Guillcbaud J. Time for emergency contraception with levonorgestrel
alone. Lancet 1998:352:416
[41 Yuzpc AA, Lnnccc W.I. Ethinyl estradiol and dl-norgestrel as post¬
coital contraceptive. Fertil Steril 1977:28:932.
[5] Swahn M-L, Westlund P, Johannisson E, Bygdeman M. Effect of
post-coital contraceptive methods on the endometrium and the men¬
strual cycle. Acta Obstet Gynecol Scand 1996;75:738- 44.
(6J Raymond EG, Lovey LP, Chen-Nlok M, Seppala M. Kurun R, Lessey
BA. Effect of the Yuzpc regimen of emergency contraception on
markers of endometrial receptivity. Hum Reprod 2000;15:2351-5.
17] Piaggio G, Von Hertzen H, Grimes DA, Van Look PFA. Timing of
emergency contraception with levonorgestrel or the Yuzpc regimen.
Lancet 1999:353:721.
[8] Kesseru E. Gnrmeodia F, Wcslphnl N, Parada J. The hormonal and
peripheral effects of D-norgestrel in postcoital contraception. Contra¬
ception 1974;10:411-24.
[9J Landgrcn BM, Dada O, Aedo AR, Johannisson E, Dicz.falusy E.
Pituitary, ovarian, and endometrial effects of 300 p.g LNG adminis¬
tered on cycle days 7 to 10. Contraception 1990;41:569 81.
[10] Craft I, l oss GL, Warren RJ, Fotherby K. Effect of norgestrel ad¬
ministered intermittently on pituitary ovarian function. Contraception
1975.12:589-98.
(11 ] Sopna J, Matt K. Schneider WHF. Study on the action of D-norgestrel
as a post-coital agent. Contraception 1974;! 1:31-43.
[12] Bonnar J, Flynn A. Freundl G, Kirkman R. Royston P. Snowden R.
Personal hormone monitoring for contraception. Br J Fam Plan 1999;
24:128-34.
[13] Yong EL, Glasier A, Ledger W, el al. Effect of cyclofcnil on hor¬
monal dynamics, follicular development and cervical mucus in nor¬
mal and oligomenorrhoeic women. Hum Reprod 1992;7:39 -43.
[14] Vandc Wicle RL, Bogrr.il J. Dyrenfurth 1, ct al. Mechanisms regu¬
lating the menstrua! cycle in women. Recent Progr Hormone Res
1970;26:63-94.
[15] Hall JE, Bhatta N, Adams JM. Rivicr .IE, Vale WW. Crowley WF.
Variable tolerance of the developing follicle and corpus luteum to
GnRH-releasing hormone antagonist induced gonadotropin with¬
drawal in the human. J Clin Endo Metabol 1991;72:993-1000.
[16] Hutchison JS, Zeleznik AJ. The rhesus monkey corpus luteum is
dependent on pituitary gonadotropin secretion throughout the luteal
phase of the menstrual cycle. Endocrinology 1984;115:1780-6.
[17] Ravindranath N, Little-lhrig L, Fairchild Benyo D, Zeleznik AJ. Role
of LH in the expression of cholesterol side-chain cleavage, cyto¬
chrome P450 and 3(-hydroxysteroid dehydrogenase, (5-4 isomerase
messenger ribonucleic acids in the primate corpus iutcum. Endocri¬
nology 1992;131:2065-70.
[18] Dixon GW, Schlcsselman JJ, Ory HW, Blye RP. Ethinyl cstadiol and
conjugated estrogens as postcoital contraceptives. JAMA 1980:244:
1336-9.
[19] Trussell J, Rodriguez G, Ellcrtson C. New estimates of the effective¬
ness of the Yuzpe regimen of emergency contraception. Contracep¬
tion 1998;57:363-9.
[20] Glasier AF. Thong KJ. Dewar M. Mackic M, Baird DT. Mifepristone
(RU 486) compared with high-dose estrogen, and progestogen for
emergency postcoital contraception. N Engl J Med.; 1992;327:
1041-4.
[21] Landgrcn BM, Johannisson, Aedo AR, Kumar A. Yong-cn Shi. The
effects of LNG administered in large doses at different stages of the
cycle on ovarian function and endometrial morphology. Contracep¬
tion 1989;39:275-89.
[22] Pakarincn P, Luukkainen T, Lainc II, Lahtcenmaki P. The effect of
local intrauterine LNG administration on endometrial thickness and
uterine blood circulation. Hum Reprod 1995:10:2390-4.
[23] Mandelin E, Koistinen H, Koistinen R, Aflandi B, Seppala M. LNG
releasing intrauterine device wearing women express contraceptive
glycodclin-A in endometrium during midcyclc: another contraceptive
mechanism? Hum Rcprod 1997;12:2671-5.
[24], Peek MJ, Markham R, Eraser IS. lite effects of natural and synthetic
>scx steroids on human endometrial cell proliferation. Mum Reprod
1995;10:2238-43.
[25] • Odcblad E. Biophysical techniques of assessing cervical mucus and
, microstructure of cervical epithelium. In: Elstein M, Moghissi KS,
Broth R, editors. Cervical Mucus and Human Reproduction. Copen¬
hagen: Scriptor, 1972. p. 58 74.
[26] Daunter B, Chantler EN, Elstein M. Scanning clcclrone microscopy
of cervical mucus: normal menstrual cycle and pregnancy. Br J Obstct
^Gynaecol 1976;83:738-43.
[27]' Moghissi KS, Syncr FN. McBride LC. Contraceptive mechanism of
• microdose norethindronc. Obstel Gynecol 1973;41:585- 90.
422
Contraception
ELSEVIER Contraception 66 (2002) 19-22 ===========
Original research article
Estimating the efficacy of emergency contraception—how reliable are
the data?
Alex Stirling11, Anna Glasierb'*
3Lothian Primary Care NHS Trust Family Planning and Well Woman Services. Edinburgh. Scotland, UK
^Obstetrics and Gynaecology, Reproductive and Developmental Sciences. University of Edinburgh. Edinburgh. Scotland. UK
Received 25 February 2002; accepted 5 March 2002
Abstract
Ninety-four women attending a family planning clinic for emergency contraception (EC) were asked how certain they were of the date
of their last menstrual period (LMP), of the timing of intercourse, and how many times in the cycle they had had sex. Urinary pregnandiol
concentrations were analyzed in 64 women to assess whether they had ovulated before they used EC. Forty-five women were certain of the
date of the LMP, the rest were not. Only four women could not accurately recall the timing of intercourse, and 60% had had intercourse
more than once in the cycle. Twenty-one women had urinary pregnanediol concentrations that were inconsistent with their cycle day.
Calculations of the efficacy of EC depend on knowing the timing of intercourse in relation to the estimated day of ovulation. The results
of this snidy suggest that these calculations arc likely to be inaccurate for a significant minority of women. © 2002 Elsevier Science Inc.
All rights reserved.
Keywords: Emergency contraception; Cycle; Efficacy
1. Introduction
Emergency contraception (EC) is widely regarded as a
possible solution to reducing the rate of unwanted pregnan¬
cies [1], There has never been a placebo-controlled trial of
any method of emergency contraception, and its true effi¬
cacy is unknown [2,3], in recent years it has become ac¬
cepted practice to express the efficacy of EC as the propor¬
tion of expected pregnancies that it appears to prevent [4],
This figure is arrived at by multiplying the number of
women who had intercourse on each cycle day by an esti¬
mate of the probability of conception for that day and then
summing over all cycle days. The probability of conception
for each cycle day is commonly calculated from data col¬
lected prospectively from couples actively trying to con¬
ceive [5]. In these prospective studies, the day of intercourse
(from diaries) and the day of ovulation (from biochemical
data) are known precisely. In contrast, studies used to cal¬
culate the efficacy of EC rely on the subject's recall of the
* Corresponding author. Tel.: +0131-332-7941; fax: + 0131-332-
2931.
E-mail address: a.gtasier@ed.ac.uk (A. Glasier).
0010-7824/02/$ - see front matter © 2002 Elsevier Science Inc. All rights
Pli; S00 10-7824(02)003 10-4
date of the first day of the last menstrual period, and the day
of ovulation is calculated from what she says is the usual
length of her cycle; biochemical data are not usually col¬
lected. Thus, the risk of conception on the day when inter¬
course occurred and, therefore, the efficacy of EC is esti¬
mated from data dependent usually on recall.
In a trial comparing two regimens of EC [6] in which
urinary pregnanediol or plasma progesterone were mea¬
sured on the day of treatment, discrepancies between the
time of the cycle suggested by the calendar day and that
suggested by biochemical measurement were common. In a
similar study undertaken in Spain [7], only 51% of 99
women thought (from the date of the LMP and usual cycle
length) to be in the fertile phase of the cycle had hormone
levels whiclt were compatible with the fertile phase.
In a small study designed to further explore possible
discrepancies (and therefore inaccuracies) in data used for
calculations of efficacy, we asked 94 women who had pre¬
sented for EC how certain they were of the date of their last
menstrual period and of the timing of intercourse, and cor¬
related this information with pregnanediohcreatinine ratios
in a single urine sample taken on the day of treatment.
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2. Materials and methods
Women who had presented to a large family planning
clinic for emergency contraception and who were not cur¬
rently using hormonal contraception were invited to take
part in the study but not until after they had received
hormonal EC. They completed a brief self-administered
questionnaire that asked how confident they were of the date
of their last menstrual period and of the timing of the act of
intercourse for which they had sought EC. They were also
asked how many times in that cycle intercourse had oc¬
curred. A specimen of urine was collected and stored at
-4°C until samples were later assayed in a single batch for
urinary estronexreatinine and pregnanediolxrcatinine ratios
(for detail of methodology see Yong et al. [8]). The study
was approved by the local research ethics committee and all
subjects gave written informed consent.
3. Results
Ninety-four women participated in the study and com¬
pleted the questionnaire. All had presented for EC within
72 h of intercourse. All were less than 42 years of age, and
53% were under the age of 25 years.
3.1. Dale of IMP
Asked about the certainty of the date of the last menstrual
period 45 (48%) women reported that they were "absolutely
certain," and 19 (20%) of these women kept a diary. Twen¬
ty-two (23%) women felt "fairly sure" of the date of their
LMP (to within plus or minus 1 day). Twelve women (13%)
could only estimate their LMP to within plus or minus 3
days, and 9 (10%) could only estimate it to within 1 week
cither side of the possible date. Six women said they had
"no idea" of the date.
3.2. Timing of intercourse
Fifty-two percent of women were sure of the time that
intercourse had occurred to within 30 mitt, and 85% were
sure to within 1 h. Only four women stated that they could
only be certain of the timing of intercourse to within 9-12
h.
3.3. Other episodes of intercourse
Thirty-seven (40%) women said that they had not had
any other episodes of intercourse that cycle. Forty (43%)
said they were definitely not al risk of conception despite
further acts of intercourse because they were also using
barrier or hormonal methods of contraception (29 and 11
women, respectively) in that cycle. Seven more women
regarded themselves not to be at risk, however they only
stated that they "usually used" barrier methods, not that they
had used one in that particular cycle. Six women admitted to
being at risk of pregnancy because of other episodes of
unprotected intercourse that cycle. Half of these women said
it had been on only one other occasion, and half admitted
that it had been on several occasions. One woman declined
to answer the question. In the clinical consultation before
the provision of EC, none of these 57 women admitted to
other episodes of unprotected intercourse.
3.4. Time of cycle
Twelve of the 94 women declined to provide a urine
specimen and were therefore excluded from the analysis
relating biochemical data to calendar-calculated cycle day.
Eighty-two women completed both parts of the study; how¬
ever, the laboratory was unable to locate the results of the
urinary assays of four women. A further 14 women were
excluded from the biochemical analysis: 11 were using a
hormonal method of contraception or had done so within the
last 3 months, two had irregular menstrual cycles, and one
had been unable to give the date of her LMP when asked in
the clinic (Figure 1). A total of 64 women were, therefore,
entered into an analysis comparing time of cycle according
to calendar with that estimated from urine estrone and
prcgnanedio! values.
Fifty-six women (87.5%) were recorded as having a
usual cycle length of 28 days, six had an usual cycle lasting
between 30 and 35 days in length. Twenty-three women
(36%) had had intercourse during the fertile period, defined
as 3 days before to 2 days after the estimated day of
ovulation. Two investigators independently reviewed the
results of urinary steroid concentrations. A urinary prcg-
nanedioltcreatinine ratio of S0.5 was taken to indicate ovu¬
lation. Twenty-four women (41%) presented in the follicu¬
lar phase of the cycle (between 11 days and I day before the
day of ovulation predicted on the basis of LMP and normal
cycle length). Two of these had urinary steroid concentra¬
tions that clearly indicated that they had already ovulated.
Eight women presented on the day of ovulation as estimated
by the calendar; according to the biochemical data, three of
these women had clearly already ovulated (two had preg-
nancdiol levels of 0.7 and one of 1.0). Thirty-two women
presented in the luteal phase according to the date of LMP,
and 28 of these presented on day + I after ovulation or later
but before day + 11 (after which time pregnanediohcreati-
nine values would be expected to fall to <0.5). Fourteen of
the 28 women had not ovulated according to urinary prcg-
nanediol concentrations.
We did not arrange to follow-up these women after they
had used EC; however, three of them returned to the clinic
having conceived. One kept a diary and was absolutely
certain of the date of her last menstrual period. She was also
certain of the time when intercourse occurred and adamant
that she had had intercourse only once in that cycle. Ac¬
cording to her dates, she had intercourse on day 16 and
presented for EC on day 18 of a cycle that usually lasted 28
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Fig. 1. Progress through the study of the 94 women who attended for emergency contraception.
(lays. Using Wilcox's data for calculating the risk of con¬
ception, this woman would have been estimated to have
been at no risk since she presented for treatment four days
after the usual day of ovulation. On day 18, her urinary
estrogenxreatinine ratio was 26.5 and pregnancdiokcreati-
ninc ratio 0.16, suggesting that she had not yet ovulated but
that a mature follicle was present. Case two was also sure of
her dates although she did not keep a diary. Her usual cycle
length was 28 days, she had had unprotected intercourse on
day 14 and presented for treatment on day 15. According to
Wilcox and colleagues [5], the risk of conception would
have been around 30% if intercourse occurred on the day of
ovulation and no more than 12% if it occurred on the day
after ovulation. Urinary estrogenxreatinine value was 8.9
and prcgnanediol 0.3 on day 15, values not suggestive of
imminent ovulation. This woman had had one act of inter¬
course earlier in the cycle for which a condom was used. It
is likely that she had further episodes of intercourse after
taking EC and conceived as a result of one of these episodes
but we have no way of verifying this. The third case was a
woman with a 28-day cycle with no idea of the date of her
LMP but who guessed she might have had intercourse on
day 12. She presented for EC on day 15 when urinary
estrogenxreatinine measured at 14.1 and pregnanediokcre-
atinine 0.22. She came back again on Day 22 of the cycle
(based on her earlier guess) having had intercourse 3 days
earlier on Day 19. All three women had their pregnancies
terminated.
4. Discussion
This was a small pilot study designed specifically to
determine how certain women were of the date of their last
menstrual period and whether the degree of certainty cor¬
related with the day of the cycle estimated by the calendar
and the prevailing pattern of hormone secretion. Only 20%
of women presenting for EC kept a written record of the
date of menses, but more than 30% of them had biochemical
findings that appeared to be incompatible with their cycle
day as estimated by the calendar. Among those women who
did not keep a diary, the greater the degree of uncertainty
about the date the higher percentage of inconsistent results
["very sure," 15.3% inconsistent; "fairly sure" (±1 day),
27.2% inconsistent; "quite sure" (±1-3 days), 41.6% in¬
consistent].
There are four possible reasons for these inconsistencies:
the date of the LMP was incorrectly recalled; the cycle was
an anovulatory cycle; the usual cycle length was incorrect;
or the cycle in which the woman sought EC was of atypical
length. More than half of the women participating in the
study admitted to a degree of uncertainty about the date of
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their LMP when asked directly. As in our previous study
[6], the biochemical data were more likely to be incompat¬
ible with the calendar day of the cycle among women
presenting in the luteal phase when their LMP was a more
distant memory. Eighty percent of women taking part in the
study did not record their period dates in a diary, and it is
very possible that many of those who did not record the date
were wrong by a day or two. Whatever the reason for it, diis
degree of inaccuracy could mean a difference in the esti¬
mated risk of pregnancy of between 30% on the day of
ovulation, 12% 1 day later, and no chance of conception 2
days after ovulation [5]. Discrepancies of this magnitude
will significantly alter the estimated number of pregnancies
that would be expected to occur among a cohort of women
using EC and, therefore, will also have a significant impact
on the calculated efficacy of the method.
It is possible that women are not being honest about the
date of their last menstrual period or about the number of
times they had intercourse during the cycle and whether or
not they had used a condom. They may feel that fewer
questions will be asked and EC more willingly provided if
they claim some certainty about the date of their LMP and
only one episode of intercourse. But we purposely admin¬
istered the questionnaire after they had been given EC.
Over 90% of subjects said they usually had a 28-day
cycle. That is the average cycle length and most women are
likely to regard themselves as being average. Unless they
are actively trying to conceive or using natural family plan¬
ning methods, it seems plausible that most women hazard a
guess at the usual length of their menstrual cycle. Even if
they do know, cycle length varies by a day or two from
month to month. In a study of over 650 women with regular
cycles, while the median cycle length was 28 days, only
12.4% of cycles were actually 28 days in length [9],
Could the high rate of discrepancies that we identified
among women presenting in the luteal phase be because of
frequent anovulatory cycles? In a longitudinal study of
patterns of menstruation, Mctcalf and Mackenzie [10] dem¬
onstrated ovulation occurring in 62% of women aged 20-24
years, 88% of women aged 25-29 years, and 91 % ofwomen
aged 30-39 years. In our study, we would need to hypoth¬
esize a rate of anovulatory cycles of 50% which seems
unlikely.
Calculations of the efficacy of EC assume that every user
(and her partner) is fertile; that each cycle is ovulatory; that
the calculated day of ovulation is accurate; that intercourse
occurred only once in that cycle; and that pregnancy, if it
occurs, is the result of the act of intercourse for which EC
was provided. In a recent re-analysis [11] of the data on
which the Wilcox [5] estimates of the risk of conception are
based, the authors cast serious doubt on the reliability of
using the calendar day of the cycle alone to calculate the
risk of pregnancy. It has now been demonstrated in three
studies of women using EC (the present one, and those
described by Glasier and colleagues [6] and Espinos and
coworkers [7]), that the calculated day of ovulation is often
incorrect. Moreover, our data demonstrate that despite what
women say when requesting EC, an earlier act of unpro¬
tected intercourse is not uncommon. It is also clear from
other studies [12] that women often have unprotected inter¬
course after using EC and that this accounts for some of the
pregnancies attributed to EC failure. Providers often seem
surprised, and users somehow cheated, when pregnancy
occurs after emergency contraception has been used. It is
impossible now—for obvious ethical and practical rea¬
sons—to undertake a placebo-controlled trail of the efficacy
■ qf EC. While we cannot think of a superior method of
calculating efficacy than the one which is being widely
used, we feel that authors who write papers on the efficacy
of a method of EC should acknowledge the shortcomings of
the calculations used.
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Safety of Emergency Contraception
ANNA GLASIER, MD
Emergency contraception (EC) pre¬
vents pregnane)'. Four regimens arc
available in different parts of the
world, a combination of ethinyl estra¬
diol and levonorgcstrcl, levonorgestrel
alone, mifepristone, and emergency
insertion of an intrauterine device. All
the regimens arc also used either as
long-term contraception or, in the case
of mifepristone, as an abortifacient,
and considerable data indicate their
safety when used in these ways. Data
on safety when die regimens arc used
as EC are lacking, but theoretically,
and from practical experience, all
appear to be extremely safe, particularly
when compared to the risks of preg¬
nancy. There has been a tendency to
ovcr-umedicalize" EC. Prescribing
EC is simple. Consideration should
be given to making EC available off
prescription because it is so safe.
Emergency contraception (EC) prevents
pregnancy. It has been calculated that
the use of EC after unprotected inter¬
course will prevent sonic 75% of preg¬
nancies.1 Many countries have no
licensed preparation for EC, although
probably every country has access to a
standard method of contraception that
can be used in the emergency, postcoital
situation. There are very few data on the
safety of licensed EC preparations. Much
of what can be said about the safety of
EC stems from clinical experience and
common sense.
This paper will concentrate on four
compounds or devices shown to be effec¬
tive in preventing pregnancy after inter¬
course. Two of these—the combined
estrogen-progestin (Yuzpe) regimen and
Dr. Glasicr is director of Family Planning and Well
Woman Services at the Edinburgh Healthcare
NHS Trust and senior lecturer at the University of
Edinburgh.
levonorgestrel alone—are licensed and
marketed as EC in some countries.
Mifepristone (RU 486) is licensed for
induction of abortion in four countries
(France, Sweden, United Kingdom, and
China) and used for EC in China only.
The intrauterine device (IUD), widely
available as a regular method of contra¬
ception, is used postcoi rally under cer¬
tain circumstances in a few countries.
The Combined
Estrogen-Progestin Regimen
The estrogen-progestin regimen has been
widely used in Europe since the mid-
1980s; however, very few data on its
safety are available. Because this regimen
exposes women to the same type of hor¬
mones as those in the combined oral
contraceptive pill (COC), there has been
a tendency to extrapolate from the
known risks of these preparations. Long-
term use of COCs is associated with an
increased risk of both arterial2 (myocar¬
dial infarction and cerebrovascular acci¬
dent) and venous3 (deep venous throm¬
bosis and pulmonary embolism) disease.
Most studies suggest that the risk of
venous thromboembolism (VTE) is dose
dependent and is higher with pills con¬
taining 50 meg estrogen than the low-
dose (30 to 35 meg) pills in common use
today.4 While the estrogen-progestin reg¬
imen exposes a women to a total of 200
meg ethinyl estradiol, the exposure is
acute. One small study5 of a high-dose
estrogen regimen for EC found a detri¬
mental effect on clotting factors, while a
similar study failed to show any consis¬
tent effect from the regimen/'
The combined estrogen-progestin regi¬
men was licensed in 1984 (as Schering
PC4), since then it has been used mote
than 4 million times. Few adverse events
have been reported to the Committee on
Safety of Medicines in the United King¬
dom.7 As ofJuly 1996, there were 115
reports of 159 reactions (some women
having more than one), 61 of which
were pregnancies. Only 3 cases of VTE
(one fatal) and 3 cases of cerebrovascular
disorder had been reported, and in none
was the relationship between the regimen
and the event clear cut. Haematologists
have reported further cases of VTE at
recent meetings in the United Kingdom,
bur these are anecdotal, and other risk
factors such as recent pregnane)' or pro¬
longed immobilization are commonly
involved. It should be remembered that
the reason for taking EC is to prevent
pregnancy. All the cardiovascular risks of
estrogens arc much more common in
pregnane)7 than they are during standard,
long-term COC use. The risk of VTE
during pregnancy is in the order of
60/100,000 per year and is likely to be
considerably less than the risk associated
with using EC.
Both the World Health Organization8
(which added the esrrogcn-progestin reg¬
imen to its essential drugs list in 1996)
and the International Planned Parent¬
hood Federation9 have stated recently
that there arc no absolute contraindica¬
tions to the combined estrogen-progestin
regimen, except known pregnancy. The
regimen will not work if a woman is
already pregnant when she uses it. If she
inadvertently uses it in the presence of an
ongoing pregnancy, it will almost cer¬
tainly do no harm. Reliable data on the
outcome of pregnancy after the regimen
has failed are lacking, but the lack of
demonstrable teratogenicity of COCs'0,
" and the timing of the administration
of EC (long before organogenesis starts)
are reassuring. Thus the combined estro¬
gen-progestin regimen is contraindicared
only because it docs not work once preg¬
nancy is established, not because it is
known to be harmful.
Levonorgestrel
Although there arc few data on the use
of levonorgestrel (LNG) for EC, it seems
likely to become rhe method ofchoice
in many countries. The one published
randomized controlled trial comparing
LNG with the Yuzpe regimen demon-
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strated a lower incidence of side effects,
particularly nausea and vomiting.12
Levonorgestrei has been used for many
years both alone (in low doses) in the
progestogen only pill (POP) and in com¬
bination with estrogen in COC prepara¬
tions. There have been many fewer stud¬
ies on the safety of long-term use of the
POP than of the COC, but the existing
data are largely reassuring.11 Progestins
are knowh to have an adverse effect uu
serum lipids and triglycerides, biochemi¬
cal changes that: are associated with an
increased risk of heart attack and stroke.
It is unlikely that these effects would
have any clinical relevance in the acute
use of LNG as EC. Levonorgestrei has
no known adverse effects on clotting
mechanisms. Recent data14 showing an
increased risk of breast cancer among
long-term POP users are almost certainly
not relevant to EC use.
If further studies confirm the equiva¬
lent efficacy and superior side effect pro¬
file of LNG compared with the Yuzpe
regimen, it is likely that LNG will
become the preferred compoimd as the
concerns about VTE can be forgotten.
Mifepristone (RU486)
Excluding those from China, only
two studies of the use of the antiproges-
terone mifepristone as EC have been
published.14,15 A larger trial undertaken
by the World Health Organization
(WHO) is complete but not yet pub¬
lished. Mifepristone has been available
as a medical method for pregnancy ter¬
mination for almost a decade. The dose
used for this is usually 200 nig or 600
mg. If mifepristone is to be developed
as an EC, it is likely that the dose will
be less than 50 mg. Mifepristone for
abortion induction is safe and has no
known serious side effects. (The few
serious adverse events that have been
reported have been attributed to rhc
prostaglandin part of the regimen.)
Only the antiglucocorticoid effects of
antiprogesterones might give theoretical
cause for concern, and data for both
single use (in abortion) and long-term,
usually loW-dose, use'6 (as contraception)
are very reassuring. The side effect profile
of mifepristone as an EC is considerably
better than that of the Yuzpe regimen,
with a significant reduction in all side
effects including nausea and vomiting.
It is likely that if mifepristone or
another antiprogesterone becomes widely
available for EC, it will be regarded as an
extremely safe product without the car¬
diovascular concerns associated with con¬
traceptive steroids. Indeed, in many parts
of China it is now the method of choice.
The Intrauterine Device
The 1UD is a safe and effective long*
acting method of contraception that
acquired a somewhat tarnished reputa¬
tion following reports of increased inci¬
dence of pelvic infection and subsequent
infertility. Many of the adverse reports
related to one particular device, the
Dalkon Shield. Recent large reviews of
pelvic infection and other aspects of safe¬
ty have been extremely reassuring.17,18
The IUD is a very effective emergency
contraceptive usually reserved, at least in
the United Kingdom, for women who
are beyond the 72-hour limit for oral
EC. Insertion is an invasive procedure
and can be uncomfortable. If the IUD is
inserted using aseptic techniques, the risk
of infection is very small. It has been
suggested that women in need of EC
may often, because of their sexual
lifestyles, be at increased risk ofpelvic
infection. Thus screening for sexually
transmitted infection or, if this is not
practical, antibiotic prophylaxis using a
broad spectrum antibiotic known to be
effective against chlamydia is usually rec¬
ommended before IUD insertion. The
risk of uterine perforation at the time of
insertion should be no different from
that associated with routine IUD use.
Insertion may be associated with pain
and syncope. Anecdotally, this is more
common with postcoital insertion than
with standard use. Women requesting
EC are likely to be young and nulliparous
and therefore likely to have a small uterus
and narrow cervical os. They are also
much more likely ro be anxious and upset
and have little time to be informed, in a
reassuring manner, about the IUD.
While pelvic examination is not neces¬
sary before oral EC, it is mandatory as
part of IUD insertion.
The Consultation
The management ofwomen requiring
EC is really very straightforward, hut
because in many countries it must be
prescribed by a doctor, there is a tendency
to over-"medicalize" the consultation. It
should not be forgotten that any woman
who has a packet of COC pills has the
wherewithal to make her own EC prepa¬
ration. Indeed, US doctors have recently
been advised by the US Food and Drug
Administration how to use the COC as
an emergency contraceptive.19
Physicians have all been taught that it
is essential to take a full and detailed
medical history before prescribing treat¬
ment. Because EC is so safe, this is prob¬
ably not strictly necessary. If you have
access to a choice of methods, then a .
history of VTE might sensibly indicate a
method that does not contain estrogen.
If cstrogen-progestin is the only rcginien
available, however, it should be used
since die risks of VTE in pregnancy are
much greater. The only requirement
is to ascertain that the woman is not
already pregnant. If a woman is certain
of die date of her last menstrual period
and there is no clinical suspicion ofpreg¬
nancy, it is not necessary to do a routine
pelvic examination or a pregnancy test.
Above all clinicians need to remind
themselves that they are not starting
someone on the COC pill. It is not
necessary to weigh the woman, do a
breast examination, take a cervical smear,
undertake urinalysis, or measure serum
cholesterol. It cannot be stressed enough
that you are prescribing emergency con¬
traception. Blood pressure may be elevat¬
ed because of the stressful nature of the
consultation, and it is unlikely that a sin¬
gle abnormal reading would be taken as
a contraindication to prescribing EC.
Any medical or gynecological prob¬
lems that come to light do not necessarily
need to be dealt with at the same con¬
sultation. Iris important to inform the
woman about the nature and mode of
action of EC (as best we understand it),
the possible side effects, the timing of
next menses, and what to do in the event
of vomiting or delay in the onset of next
menses. Safe sex and future contraceptive
plans should be discussed, and the
woman should be informed that it is
perfectly safe and acceptable to use EC
again if the need arises. A follow-up
appointment is not absolutely necessary,
but should be offered as an opportunity
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for review, particularly if other issues
have been raised during the consultation.
Who Should Provide
Emergency Contraception?
Emergency contraception has to be pre¬
scribed by a doctor in many Western
countries. In some countries in the Far
East and Eastern Europe, LNG EC is
available over the counter. Who can pre¬
scribe or provide EC depends of the laws
ofeach country. In some countries nurse
prescribing may be routine; given that
EC is so safe, there are no reasons (other
than legal ones) why nurses should not
prescribe it. It is arguably much safer than
many other drugs, such as paracetamol,
which can be bought in supermarkets.
Indeed, many have argued that it is safe
enough to be available off prescription.20
For a variety of reasons7 EC is still not
available over the counter in most West¬
ern countries, although it may become
available if the LNG-only regimen fulfills
its promise as an effective method.
Conclusion
There are very few data on the safety of
currently available EC regiments, but
botli the theoretical and empirical evi¬
dence is reassuring, and any risks are
substantially lower than those of preg¬
nancy. S3
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COMMENTARIES
Emergency contraception: time for de-regulation?
Abortion rates are rising. In 1991 around 200 000 preg¬
nancies were terminated in the United Kingdom. While
some of these conceptions result from contraceptive fail¬
ures, as many as half arise in couples using no contracep¬
tion at all. In a study of 733 women undergoing pregnancy
termination in Oxford (Duncan et ul. 1990), over 40%
admitted that they were using no contraception at the
time they conceived. It is argued that more open attitudes
towards sexuality and better sex education would improve
contraceptive prevalence. Even if this is true it will be
many years before such changes have any impact on abor¬
tion rates. We should look for other solutions.
In the Oxford study, 528 of the pregnancies might have
been predicted as either no contraception was used or a
recognisable contraceptive failure occurred. Eighty per
cent of these pregnancies might have been prevented by
the use of emergency contraception. In the event only 18
women admitted to using it. Emergency post coital con¬
traception (PCC) can prevent pregnancy: it is important,
therefore, to consider why it is so seldom used and how its
uptake might be increased.
Is post coital contraception effective? The true efficacy
of emergency contraception and particularly of the com¬
bined ocstrogen-progestogen oral contraceptive has
recently been questioned (Silvestre eral. 1991). Efficacy is
difficult to calculate precisely since not all women who use
PCC are genuinely at risk of conception. In a recent study
of 398 women using the standard combined oestrogen-
progestogen regime only four conceived—a failure rate of
1% of the total sample (Glasier et ill. 1992). Calculating
the chance of conception for each individual woman
based on the timing of intercourse (Dixon et til. 1980), 23
pregnancies would have been anticipated and over 80%
were prevented by PCC. It does not really matter how you
do the calculations, emergency contraception is clearly
effective. The IUCD—used in women in whom combined
oestrogen-progestogen is relatively contra-indicated or in
those who present beyond 72 h after intercourse—is even
more effective: only one pregnancy occurred in 879 post
coital insertions and that pregnancy miscarried sponta¬
neously (Fasoli et al. 1989).
Most women presenting for PCC are young and have
never given birth. IUCD insertion is invasive and the
method not usually ideal for continuing contraception.
The combined oestrogen-progestogen regimen has its
drawback's, mainly a high incidence of side effects,
particularly nausea and vomiting which may interfere
with both compliance and efficacy. Prospects for alter¬
native and better methods are promising. It has recently
been demonstrated that the antiprogesterone mifepris¬
tone (RU486) given as a single dose of 600 mg is a highly
effective post coital agent. No conceptions occurred in a
total of almost 600 women treated within 72 h of inter¬
course (GlasierefiaT 1992; Webb et al. 1992). Side effects
were significantly less frequent than among women
treated with the standard combined oestrogen-proges¬
togen regime.
If emergency contraception works why then don't
women use it? In Duncan and colleagues' study (1990),
30% of women did not know about emergency contracep¬
tion and another 10% did not know where to get it.
Similar figures were reported in two other studies (John¬
ston & Howie 1985: Burton et al. 1990). The RCOG Work¬
ing Party on Unplanned Pregnancy (1991) highlighted the
need for better information and public health education
about PCC. In a survey commissioned by Schering (1990),
over 75% of 1007 women had heard of PCC but only 10%
had an accurate knowledge of its time limits. Public adver¬
tising campaigns could rapidly increase awareness and
knowledge of emergency contraception but would this
increase its use?
Licensed in the UK since 1984, oral PCC is available
only from a doctor. Because it must be used within 72 h of
intercourse, its use constitutes an emergency. It can be dif¬
ficult to get an emergency appointment with a GP and fac¬
ing interrogation by reception staff as to the nature of the
emergency deters even the most persistent woman. Ask¬
ing for PCC involves discussing a particular act of inter¬
course, something which most people, especially the
young, find embarrassing—particularly when it is with the
doctor who looks after the rest of the family. Community
family planning clinics, while more anonymous, are not
widespread and in those places where they do exist are
often held only once each week. In our experience the
greatest need for emergency contraception is al weekends
when GP surgeries and family planning clinics are closed.
While some hospital casualty departments provide a
service (usually involving referral to the on-call gynaecol¬
ogist) many refuse to do so. In reality, emergency contra¬
ception is not easy to obtain even if you do know where
and when to get it.
If the use of emergency contraception is to have a sig¬
nificant impact on abortion rates then it must be made
more easily available. The time has come to consider the
supply in pharmacies of over-the-counter oral post coital
contraception. The arguments in favour are outlined
above; the arguments against are concerned with safely
and the lack of opportunity for follow up. Is the current
regimen of PCC dangerous? The only contra-indications
are pregnancy and a history of contra-indications to oes¬
trogen. such as thrombo-embolism. While clear warnings




is highly unlikely that any woman, whatever her history,
would suffer severe adverse effects from taking 200 jag of
ethinyl oestradiol on one occasion. There is no evidence
of any change in clotting factors (Webb et al. 1992) fol¬
lowing the use of the standard regime and pregnancy—
whether continued or terminated—for women with con-
tra-indications to oestrogen would be far more hazardous.
The vast majority of users would be healthy young
women. 11 is possible that a minority would repeatedly use
PCC as a definitive method of contraception. This hap¬
pens already, but most people motivated enough to use
PCC soon (ind it an inconvenient and disorganised way to
arrange their contraceptive needs, and PCC over the
counter would not be free. It could be argued that an
opportunity to counsel women about a more long term
method of contraception at the time of presentation for
PCC would be lost. Condoms are widely available from
pharmacies and supermarkets but no one would argue
that their availability should be limited to clinics where
users could be counselled about sexuality. A spokesman
for the Family Planning Association recently expressed
the opinion that it would be more appropriate to make
emergency family planning services more accessible at
times women need them (Anon 1992). The two solutions
are not mutually exclusive.
Emergency contraception does prevent pregnancy, and
if it were easily available and widely used might prevent
significant numbers of unwanted pregnancies. Many other
drugs potentially far more dangerous are already avail¬
able over the counter. Pharmacists are highly trained and
probably as capable of advising women about the correct
use of the drug as a harassed gynaecological houseman
who knows little about contraception. It is time for the
medical profession and the government to give serious
consideration to making oral emergency contraception
available over the counter.
Anna Glasier
Consultant Gynaecologist
Director of Family Planning tfc Well Woman Services
The Dean Terrace Centre
Edinburgh EH4 1NL
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Objective—To determine the level of knowledge
of emergency contraception among 14 and 15 year
olds.
Design—Confidential questionnaire survey.
Setting—10 secondary schools in Lothian, south
east Scotland.
Subjects—1206 pupils predominantly (98.7%)
aged 14 and 15 in the fourth year of secondary
school.
Main outcome measu res—Knowledge of the ex¬
istence of emergency contraception; of its safety,
efficacy, and time limits; and ofwhere to obtain it.
Results—1121 (93.0%) fourth year pupils aged
14-16 had heard of emergency contraception. 194
girls (32.7%) and 168 boys (27.5%) had experi¬
enced sexual intercourse. Ofgirls who had experi¬
enced sexual intercourse, 61 (31.4%) had used
emergency contraception. Knowledge of correct
time limits was poor, sexually active girls being
the most knowledgeable. Pupils attending schools
ranked lower than the national average for
academic attainment were less likely to have
heard of emergency contraception and more likely
to have been sexually active. 861 (76.8%) pupils
knew they could obtain emergency contraception
from their doctor. 925 (82.5%) pupils believed
emergency contraception to be effective but 39S
(35.5%) thought it more dangerous than the oral
contraceptive pill.
Conclusions—One third of sexually active girls
aged under 16 in Lothian have used emergency
contraception. This may help explain the fairly
constant teenage pregnancy rates despite increas¬
ing sexual activity. Scottish teenagers arc well in¬
formed about the existence of emergency contra¬
ception. However, many do not know when and
how to access it properly. Health education initia¬
tives should target teenagers from less academic
schools as they are more likely to be sexually
active at a young age and are less well informed
about emergency contraception.
Introduction
In 1989 the rate of conceptions among girls aged under
16 in England and Wales was 9.5 per 1000—the highest
in western Europe. In 1991 the government declared its
aim to reduce these conceptions by at least 50% by the
year 2000.: In 1993 the rate in England and Wales had
fallen to 8.1 per 1000. Johnson ct al have reported that
age at first intercourse has fallen in Britain over die past
four decades.5 A total of 18.7% of women aged 16-19
interviewed in 1990-1 had been sexually active before
the age ofl 6 as compared with less than 1 % of a cohort
of women aged 55-59 at the time of interview.
If teenagers have sexual intercourse before the age of
16 they are less likely to use contraception than if
first intercourse occurs at a later age.' Emergency
contraception can prevent pregnancy if unprotected
intercourse occurs but potential users must know about
it and where to obtain it. Knowledge of emergency con¬
traception has improved over the past decade but previ¬
ous studies were among adults or teenagers who were
already pregnant.Wc report a questionnaire survey of
the knowledge of emergency contraception among .
pupils in 10 secondary schools in south east Scotland.
Subjects and methods
The survey vvus done in late 1995 among fourdi year
pupils in eight state schools and two private schools in
the Lothian region ofScotland. The head teachers of 14
out of a total of 47 state secondary schools (all mixed
sex and ability) in the region were approached about the
survey. Schools were selected by the local education
department (which agreed to the srudy) on the basis
that they had participated in little research recently. Six
schools refused. All 14 private secondary schools in the
region were invited to participate. Eight refused and one
failed to reply. The first two private schools to agree to
the study (one mixed, one girls only) were enrolled.
The questionnaire was developed with the help of
teenagers attending the Edinburgh Brook Advisory
Centre and the mode of administration piloted among
fourth year pupils attending a secondary school not
included in die study.
Seven of the 10 schools sought parental consent for
the survey and five pupils were withdrawn. All fourth
year pupils at school on the day of die questionnaire
took part. Questionnaires were administered by AG and
LG under examination conditions without allowing dis¬
cussion. In order to encourage honest answers the ano¬
nymity and confidentiality of the questionnaire were
emphasised at the start of each session and pupils put
the completed questionnaire in an unmarked envelope
before placing it in a collecting box. Pupils who were
reluctant to participate were free to spoil the.
questionnaire, but only two did so. At the end of each
session the correct use of emergency contraception was
discussed.
Results
Of die 1206 pupils (612 boys, 594 girls) who
completed the questionnaire, 257 (21.3%) were 14
years of age and 933 (77.4%) were aged 15; only 16
(1.3%) were 16 years of age. All were included in the
analysis. A total of 1121 (93.0%) pupils had heard of
emergency contraception. Girls (584; 98.0%) were
more likely to have heard of it dian boys (536; 87.0%).
A history of sexual activity was not associated with a
greater likelihood ofhaving heard of emergency contra¬
ception.
Table 1 summarises the results by academic
attainment. Pupils attending schools ranked higher than
the national average for academic attainment at
standard grade (die O level equivalent in Scotland) in
the Scottish Office league tables7 were more likely to
have heard of emergency contraception than those
attending schools below average for academic attain¬
ment.
Girls were more likely than boys to have had sexual
intercourse (194 (32.7%) v 168 (27.5%)), though 101
(16.5%) boys and 61 (10.1%) girls preferred not to say
whether they had been sexually active. Of the 258 pupils
aged 14, 29 (22.0%) boys and 33 (26%) girls said they
had experienced sexual intercourse. Pupils from less
academic schools were more likely to have had sexual
BMJ volume 312 22 junk i 996
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Table 1—Survey results according to academic attainment of school
Schools Schools
above national below national
averagef average! Total
No c' questionnaires completed 613 593 1206
No of boys 308 304 612
No of girls 305 289 594
No (%) heard ol emergency contraception 583 (95.1) 538 (90.7) 1121 (93.0)
No t%) ol sexually active girls 74 (24.3) 120(41.5) 194 (32.7)
No Prsj ol sexually active boys 66 (21.4) 102(33.6) 168(27.5)
No (%) knowing correct lime limit 176(28.7) 142(23.9) 310(26.4)
t National avi
grade 1 or 2.
Table 2—Sources of knowledge about emergency
contraception (1121 pupils)
Source No (%) of pupils
School 437 (39.0)
Magazines • 425 (37.9)
Friend 253 (22.6)
Family mombor 197(17.6)
Leaflet or poster 166 (16.6)
General practitioner, family planning clinic, or
Brook Advisory Centre 103 (9.2)
TV and radio 52 (4.6)
Cannot recall 242(21.6)
inicrcoursc before the age of 16. Sixty one (31.4%) girls
who admitted to sexual intercourse said they had used
emergency contraception and 46 boys (27.4%) said
their girlfriend had used it.
Knowledge of the correct time limit for emergency
contraception (72 hours) was poor and unrelated to the
academic standard of the pupil's school. Given a choice
of time limits, only 318 (26.4%) pupils gave the correct
answer; 271 (22.4%) did not know, 173 (14.3%)
thought emergency contraception had to be used within
48 hours after intercourse, and 332 (27.3%) thought it
had ro be used within 24 hours. Girls who had been
sexually active were most likely to know the correct time
limit (108; 56.2%). Only 20 (11.9%) sexually active
boys gave die correct answer.
Asked where they had learnt about emergency
contraception, pupils gave school (437 pupils; 39.0%)
ancl magazines (425; 37.9%) as the commonest sources
(tabic 2). Most pupils (861; 76.8%) knew that
emergency contraception was available from general
practitioners. Family planning clinics (776 pupils;
69.0%), Brook Advisory Centres (345; 31.0%), and
accident and emergency departments (130; 11.6%)
were given as other sources.
Three quarters of pupils agreed widi the statement,
"If a girl under 16 is given emergency contraception by
her doctor, the doctor should not tell her parents with¬
out her permission." Most pupils (925; 82.5%) believed
that emergency contraception would prevent pregnancy
on all or nearly all occasions. However, 398 pupils
(35.5%) agreed with a statement dial using emergency
contraception twice a year is more risky to a woman's
health than taking the oral contraceptive pill. Only 151
pupils (13.5%) thought it was safer to use emergency
contraception twice in one year than to take the pill.
When asked about side effects of emergency contracep¬
tion 91 (8.0%) pupils believed infertility to be a poten¬
tial risk.
Discussion
We believe this to be the first survey of the knowledge
of emergency contraception among teenagers not seek¬
ing contraceptive advice and including both boys and
girls. The sample selected was likely to be representative
of teenagers in the area, as it included urban and
semirural schools with a range of academic attainment.
Of die schools refusing to participate, three objected on
moral grounds, one gave no reason, and 10 said they
were too busy. One other school failed to reply. Though
it is possible that schools that particularly prided their
sex education programme agreed co participate, we do
not think this was so. In seven schools over 80% of
pupils were present when die questionnaire was admin¬
istered and in two over three quarters were present. In
one school 45% of the pupils were absent. That school
had the lowest level of academic attainment and die
highest prevalence of teenage sex. Refusal of schools to
participate and absence or truancy among pupils may
have contributed to a sample bias.
The proportion of sexually active teenagers was
greater in our survey than in die sexual attitudes and
lifestyles survey covering England, Wales, and Scotland
in 1990-1a; 18.7% of girls in that survey as compared
with 32.7% in our local survey were sexually active.
Interestingly, the figures for boys in die two surveys
were similar (26.7% and 27.5%). Our figure for all
sexually active teenagers may be an underestimate
because of the large proportion (particularly boys) who
preferred not to say whether they had been sexually
active. Differences between die studies may reflect the
different methodologies used. Alternatively more
teenagers may now become sexually active at a younger
age.
The number of pupils who had heard of emergency
contraception was reassuringly higher than in previous
studies. George et al studied a general practice based
population of 1290 women aged 16-50, ofwhom 78.6%
had heard of emergency contraception/ Pearson et al
interviewed 167 pregnant teenagers, of whom 81% had
heard of it/ In our study knowlcdgc'of where ro obtain
emergency contraception was good. In rural areas gen¬
eral practitioners may be die only source.
Our study reaffirms the findings of odicrs showing
poor knowledge of the correct time limit for using
emergency contraception. Pearson et al quoted a figure
of 22%* and George et al a figure of 13.6% for pregnant
teenagers and women able to give die correct time
limit/ It is encouraging, however, diat 56% of sexually
active girls in our survey gave the correct answer and
that 31% had used emergency contraception. This may
help to explain the constant abortion rates in the face of
increasing sexual activity in the under 16s. In Scotland
during 1989-93 the rate remained steady at 8.4 per
1000 girls aged 13-15.
We were not surprised to find that only 13.5% of
pupils thought emergency contraception safer than
regular use of the oral contraceptive pill. Many health
professionals lack sufficient knowledge about emer¬
gency contraception'" and may be unsure of the correct
time limits and confused about safety, especially if it is
used more than once. It is crucial dial die under 16s
believe diat confidentiality exists between a doctor and
patient when the parien: requires contraceptive advice.
In this study most of the pupils, including most of the
girls, accepted this.
Sex education in schools is often criticised. However, in
our study, school was the most commonly cited source of
information about emergency contraception. Knowledge
of details was poor, reflecting a view that generalities rather
than specifics arc provided by schools. The crucial part
played by schools was shown recendy in a structured
school sex education programme which increased knowl¬
edge and reduced sexual activity."
Health professionals were not a prominent source of
information in this survey. Teenagers, however, attend
their gcner.il practitioners two or three times a year,"
which may be seen as a missed opportunity for promot¬
ing sexual health. An evaluation of the provision of con¬
traceptive services in the United Kingdom showed the
RMT \v>r n.vin 51 n ?? mvr 19Q6
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Key messages
• More under 16s arc sexually active than previously reported., especially those
who arc low achievers academically
• Under 1 6s have better awareness of the existence of emergency contraception
titan previously reported
• Despite good awareness of emergency contraception, teenagers have poor
knowledge of specific details—particularly time limits and safety
• One third of sexually active girls aged under 16 have used emergency contra¬
ception
• Health education initiatives should concentrate on the practicalities of
emergency contraception and target teenagers at particular risk
lowest pregnancy rates in areas where family planning
clinics were available in addition to services provided in
primary care, and this was especially noticeable in the
under 16s.'3
Health education initiatives should be directed
towards teenagers who are at high risk of becoming
sexually active at a young age and less well informed
about emergency contraception. Smith suggested that
areas of socioeconomic deprivation should be
targeted." Our study suggests that schools with lower
academic attainment should also be included in this
type of initiative.
Conclusion
Emergency contraception has the potential to prevent
unwanted pregnancies." Most teenagers in Lothian are
aware that emergency contraception exist?. Use,
however, will increase only when potential users believe
it to be safe and know where to obtain it and when to
use it. These aspects need to be tackled now. .Schools
and the media could be used more effectively "to
maximise the potential benefits of emergency" contra¬
ception in the under 16s.
The questionnaire used in the survey may be obtained by
writing direcc to AG. We thank the schools, teachers, and espe¬
cially the pupils who took parr as well as Lothian Education for
its cooperation. We also thank Fiona Sutter for help with com¬
puting, Ian Young (Health Education Board for Scotland) for
help and advice, and Peter Brocklchurst (National Perinatal
Epidemiology Unir, Oxford) for statistical advice.
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Lifetime exposure to environmental lead and children's
intelligence at 11-13 years: the Port Pirie cohort study
Shilu Tong, Peter Baghurst, Anthony McMichacl, Michael Sawyer, Jane Mudge
Abstract
Objective—To examine the association between
environmental exposure to lead and children's
intelligence at age 11-13 years, and to assess the
implications of exposure in the first seven years of
life for later childhood development.
Design—Prospective cohort study.
Subjects—375 children born in or around the
lead smelting town of Port Pirie, Australia,
between 1979 and 1982. ;
Main outcome, measure—Children's intelli¬
gence quotient (IQ) measured at 11-13 years bf
age. ,
Results—IQ was inversely associated with both
antenatal and postnatal blood lead concentrations.
Verbal, performance, and full scale IQ were
inversely related to blood lead concentration with
no apparent threshold. Multivariate analyses
indicated that after adjustment for a wide range of
confounders, the postnatal blood lead concentra¬
tions (particularly within the age range 15 months
to 7 years) exhibited inverse associations with IQ.
Strong associations with IQ were observed for
lifetime average blood lead concentrations at vari¬
ous ages. The expected mean full scale IQ declined
by 3.0 points (95% confidence interval 0.07 to 5.93)
for an increase in lifetime average blood lead con¬
centration from 0.48 to 0.96 pmol/1 (10 to 20 pg/dl).
Conclusions—Exposure to environmental lead
during the first seven years of life is associated
with cognitive deficits that seem to persist into
later childhood.
Introduction
Many studies have reported inverse associations
between low level lead exposure and neuropsychologi¬
cal development, particularly cognitive function.'"r The
accumulation of this evidence has prompted public
heaith authorities in several countries progressively to
lower the blood lead concentrations at which
environmental intervention and medical evaluation is
warranted." " Since both Australian and American data
indicate that the high childhood blood lead concentra¬
tions of 13-15 years ago are definitely decreasing," *v a
contemporary question of great interest is whether the
effects of early exposure to lead still persist into later life
when lead exposure is generally much lower.
The Port Piric cohort study started in 1979. Within
this cohort, the geometric mean blood lead concentra¬
tion in the children increased from S.3 pg/dl (0.40
mmoL'l) at birth (umbilical cord blood) to 21.2 jig dl
(1.02 mmol/1) at age 2 years, and had decreased to 11.6
22 fiJN'F. 1996 1569
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Screening for Chlamydia trachomatis infection is indicated for women
under 30 using emergency contraception
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Abstract
A total of 838 women attending a large family planning clinic in Scotland for emergency contraception were offered screening for
Chlamydia trachomatis infection. 569 were screened using ligase chain reaction test in first void urine at the time of presenting for
emergency contraception and were retcsted 1 or 2 weeks later. Women aged under 20 and over 30 years were significantly more likely to
decline to be tested than women aged 20 to 30. The prevalence of chlamydia was 7.6% in woman aged 24 or less, 5.3% in women aged
25 to 29, and 1.2% in women aged 30 or more. Only two women (< 1%) who tested negative at the time of using EC were positive I or
2 weeks later. Women under age 30 who use EC should be offered screening for chlamydia infection and testing at the time they attend
for EC is adequate to detect the great majority of infected women. © 2002 Elsevier Science Inc. All rights reserved.
I. Introduction
Women who use emergency contraception (EC) do so
because they have had unprotected sexual intercourse,
sometimes with someone they do not know well. Unpro¬
tected intercourse risks sexually transmitted infection (STI).
In the UK. the most common bacterial STI is Chlamydia
trachomatis, il is usually asymptomatic but is associated
with potentially serious sequelae including pelvic inflam¬
matory disease, ectopic pregnancy and infertility. Two UK
guidelines suggest that opportunistic testing for chlamydia
infection should be considered for all sexually active
women aged under 25 years of age [ 1,2], Targeted testing is
recommended for specific groups such as patients attending
genitourinary medicine clinics and women undergoing in¬
duced abortion [3], Women using EC may represent a group
that would be suitable for targeted chlamydia screening.
However, hormonal EC must be given within 72 h of in¬
tercourse and, because it may be more effective the sooner
il is used [4], women are encouraged to take it as early as
possible after having sex. There are no data on how long
after potential exposure it is best to test for C. trachomatis,
but testing very soon after intercourse may be too early to
* Corresponding author. Tel.: +131-332-7941; fax: +131-332-7941.
E-mail address: a.glasier@ed.ac.uk (A. Glasier).
allow detection. We undertook a study of the prevalence of
chlamydia infection, and of the value of offering delayed
testing, among a group of women requesting EC.
2. Participants and methods
Every woman presenting to a large family planning
clinic in central Edinburgh for EC and who would be avail¬
able for follow-up in the event of a positive result was
offered screening for C. Trachomatis infection. Recruitment
continued until 602 women agreed to participate in the
study. Demographic characteristics; the number of hours
elapsed since sexual intercourse; whether intercourse was
with a regular partner; the reason for requiring EC; consis¬
tency of condom use; and past history of STI were recorded.
A first void specimen of urine was collected at the clinic
visit and sent to the local laboratory for routine testing using
a ligase chain reaction (LCR) (the LCx probe system Abbot
Diagnostics, Maidenhead, UK). Women were asked to send
a second urine specimen in a prepaid envelope direct to the
laboratory either 1 week later (the first 300 women) or 2
weeks later (the second 302 women).
Women were informed of negative results by post. Pos¬
itive results were telephoned to the patient who was asked to
return to the clinic for treatment and contact tracing.
The study was approved by the local research ethics
0010-7824/02JS - see from mailer © 2002 Elsevier Science Inc. All righls reserved.
Ptl: S0010-7824(02)00387-6
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Table I
Percentage of women testing positive for C. trachomatis infection, EC
users and FP clinic attenders
Age <20 20-24 25-29 s30
Declined testing (%) 34 (28) 45(17) 52(21) 54(27)
Number tested 79 197 187 139
Percent positive: EC 7.6(6) 7.6(15) 5.3(10) 1.4 (2)
users (n)
Percent positive: 9.8 (244) 8.4 (296) l.l (363) 1.2 (251)
general FP (n)
committee and informed, written consent was obtained from
participants,
2. /. Statistical analysis
Data were analyzed with chi-squared tests using Yates
correction for 2 X 2 tables and the test for trend to inves¬
tigate association between binary and ordinal variables.
3. Results
The mean age of the 837 women requesting EC and
offered screening was 26 years (range 13 to 46 years). The
mean time since intercourse was 33 h. Forty-seven women
would have been unavailable for follow-up and 188 de¬
clined to participate. The participation rate varied signifi¬
cantly between age group (Table 1), with more women in
the youngest (under 20), and oldest age groups (30 and
over), declining to participate (y2 = 8.93, p = 0.03). The
most common reason for refusal to enter the study was a
recent test for chlamydia (42 women). There was no signif¬
icant difference between the age groups in the number who
claimed to have been recently tested. Thirty-three women
considered themselves not to be at risk of infection, 16 of
whom were aged 30 or over.
Fivc-hundrcd-ninety-six women produced a specimen of
urine when they attended the clinic, six who were unable to
pass urine when they were in the clinic said that they would
hand in a specimen later that day but none did. Thirty-three
women (5.5%) tested positive for chlamydia on their first
test. Women under 30 were significantly more likely than
older women to test positive Of2 = 4.67, p = 0.03, 95% CI
1.21-42.4) (Table I). The mean time since intercourse
among women with a positive result was 33 h.
Women who had a positive test (16 women from the first
300 subjects and 17 women from the second 302) were
informed of the result before they were due to send a second
test specimen. One hundred eighty-seven women (66%)
provided a second urine specimen 1 week later and 157
(55%) returned one 2 weeks later. Two women who tested
negative for chlamydia infection at the time of the consul¬
tation for EC had a positive result in the second test (one
after 1 week and one after 2 weeks). They had presented 28
and 70 h after intercourse. Both denied having sex with a
different partner since using EC.
In 13 of the 344 women who produced a second urine
specimen, the LCR sample/cut-off ratio increased from the
first to the second test, but was nevertheless, considered and
reported as negative. These women were asked to send a
third specimen, eight women did so, one tested positive.
Three-hundred-scventy-four of the women tested for
chlamydia infection (63%) used EC because of an accident
with a condom. Three hundred sixty-two women said that
they always used a condom, 4.7% of these tested positive
for chlamydia; 6.5% of 168 women who sometimes used a
condom tested positive, and 8.1% of women who never
used a condom tested positive. These differences were not
statistically significant. Eighty-four women had had a pre¬
vious sexually transmitted infection (14%) and 100 (17%)
had had sex with a new or 'not regular' partner. There were
no significant differences in the prevalence of chlamydia in¬
fection according to history of STI or 'regularity' of partner.
4. Discussion
We have only been able to find one other report of the
prevalence of chlamydia infection among women using EC.
None of 135 Swedish women aged under 25 presenting to a
clinic requesting EC tested positive [5], In contrast, preva¬
lence rates of C. trachomatis infection among women under
30 attending the Edinburgh clinic were similar to those
found among Scottish women [3] undergoing induced abor¬
tion (5.6%). In a study of 507 women attending a family
planning service in Aberdeen [6], the overall prevalence of
infection was 5.1%. Ten percent of women under 20, but
only 2.6% of women aged 20 to 24, and 1.4% of women
aged 25 to 29, tested positive for infection. While our study
was being undertaken we were also participating in a na¬
tional Scottish study designed to determine the prevalence
of C. trachomatis in women attending family planning (FP)
clinics for contraceptive advice. The same LCR test was
used by the same laboratory. The prevalence of chlamydia
detected in the general FP clinic is shown in Table 1.
Women under 25 and those aged 30 or more who presented
for EC in our study were not more likely to screen positive
for C. trachomatis than women attending the general FP
clinic. However, women aged 25 to 29 using EC were
significantly more likely to test positive than women in this
age group attending for general FP advice (y2 = 9.06, p =
0.003, 95% CI for odds ratios 1.71-38.7). It seems likely
that women under the age of 25 who require EC have sexual
lifestyles which are little different from those of their peers
(who do not need to use EC) since they seem to be at no
different risk of STI. For women aged 25 to 29, however,
those who present for EC are at higher risk of infection than
their peers who are perhaps more likely to be in stable
monogamous relationships.
Although inevitably some women chose not to send in a
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urine sample for a second test, 66% did so after 1 week and
55% after 2 weeks. Only two women who had a negative
test at the time of using EC tested positive for chlamydia on
repeat testing. A third woman tested positive 3 weeks later.
This detection rate does not justify the time, expense and
likely compliance involved in offering delayed testing.
Prevalence rates as low as 3% have been proposed as
cost-effective for screening [7,8]. Women under 25 would
automatically be screened if the Scottish Intercollegiate
Guidelines Network (SIGN) guidelines were followed.
Women aged 25 to 29 would not, but a prevalence rate of
5.3% does justify targeted screening of women in this age
group presenting for EC.
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THE EFFECTS OF SELF-ADMINISTERING EMERGENCY CONTRACEPTION
Anna Glasier, M.D., and David Baird, D.Sc.
Abstract
Background Emergency postcoital contraception
prevents pregnancy, but it must be prescribed by a
doctor and taken within 72 hours of intercourse. It
has been proposed that emergency contraception be
made available without a prescription. We undertook
a study to learn how women might behave if given
a supply of emergency contraceptive pills to keep
at home.
Methods We assigned 553 women to be given a
replaceable supply of hormonal emergency contra¬
ceptive pills to take home (the treatment group) and
530 women to use emergency contraception ob¬
tained by visiting a doctor (the control group). The
frequency of use of emergency contraception, the
use of other contraceptives, and the incidence of un¬
wanted pregnancy were determined in both groups
of women one year later.
Results The results for 549 women in the treat¬
ment group and 522 women in the control group
were available for analysis. Three hundred seventy-
nine of the women in the treatment group (69 per¬
cent) and 326 of the women in the control group (62
percent) contributed detailed information at follow-
up. One hundred eighty of the women in the treat¬
ment group (47 percent) used emergency contracep¬
tion at least once. Among those who returned the
study questionnaire, 98 percent used emergency con¬
traception correctly. There were no serious adverse
effects. Eighty-seven women in the control group (27
percent) used emergency contraception at least
once (P<0.001 for the comparison with the treat¬
ment group). The women in the treatment group
were not more likely to use emergency contracep¬
tion repeatedly. Their use of other methods of con¬
traception was no different from that of the women
in the control group. There were 18 unintended preg¬
nancies in the treatment group and 25 in the control
group (relative risk, 0.7; 95 percent confidence inter¬
val, 0.4 to 1.2).
Conclusions Making emergency contraception
more easily obtainable does no harm and may re¬
duce the rate of unwanted pregnancies. (N Engl J
Med 1998;339:1-4.)
©1998, Massachusetts Medical Society.
THE widespread use of emergency postco¬ital contraception could prevent 1.7 mil¬lion unintended pregnancies and 0.8 mil¬lion abortions each year in the United
States.1 Emergency contraception has been licensed
in the United Kingdom since 1984. Although many
women know that it is available,2-3 it is underused
because the method must be prescribed by a doctor
and taken within 72 hours after intercourse. Medical
consultation may be hard to arrange on short notice,
and many women are embarrassed to ask their family
doctors for emergency contraception.
Although in some countries health ministers have
considered making emergency contraception avail¬
able without a prescription and selling it in pharma¬
cies,4-5 for several reasons this has not yet happened.
Pharmaceutical companies worry about litigation.
Pharmacists are concerned about requests from girls
under 16 years of age (the legal age of consent to
sexual relations in the United Kingdom). Many doc¬
tors and the public believe that easy access to emer¬
gency contraception would encourage promiscuity
and unsafe sexual relations and discourage the use of
more reliable contraception.
However, the benefits of making hormonal emer¬
gency contraception available without a prescription
may outweigh the difficulties. With this in mind, we
investigated how women might behave if emergency
contraception were more readily available and the ef¬




We studied 1083 women, 16 to 44 years old, who were attend¬
ing a family-planning clinic and a large hospital in Edinburgh,
Scotland, from January 1994 through December 1996. Six hun-
From the Edinburgh Healthcare National Health Service Trust Family
Planning and Well Woman Services (A.G.) and the Department of Obstet¬
rics and Gynaecology, University of Edinburgh (A.G., D.B.) — both in Ed¬
inburgh, Scodand. Address reprint requests to Dr. Glasicr at the Depart¬
ment of Obstetrics and Gynaecology, University of Edinburgh, 18 Dean
Terr., Edinburgh EH4 1NL, Scotland, United Kingdom.
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drcd fifty women were recruited at their follow-up consultations
after using emergency contraception, and 433 after therapeutic
abortion. Women in whom estrogen was contraindicated (those
with a history of arterial disease, venous thromboembolism, or
severe migraine) were excluded.
After a routine consultation during which future contraception
was discussed and contraceptive agents provided, the women who
agreed to participate in the study were assigned to the treatment
or control group on the basis of their dates of birth (women
whose birthdays fell on even-numbered days were assigned to the
treatment group). The women in the treatment group were given
one packet of emergency hormonal contraceptive tablets to keep
at home (four tablets, each containing 50 /xg of ethinyl estradiol
and 0.25 mg of levonorgestrel [Schering PC4, Sobering Health
Care, Burgess Hill, West Sussex, United Kingdom!), with in¬
structions to take two tablets within 72 hours after intercourse
and two tablets 12 hours later. They were also given written in¬
structions and a telephone number to call in case they had ques¬
tions. If emergency contraception was used, the women were in¬
structed to mail a notification form to the clinic, with the time of
intercourse, the time the pills were taken, and the date of the last
menstrual period recorded. They also were instructed to come to
the clinic within one week after the date of the expected next
menstrual period, at which time the details of die emergency con¬
traceptive use were verified and a pregnancy test was performed
if indicated. If the woman was not pregnant, future contraception
was discussed; if she wished to continue taking part in the study,
she was given a replacement packet of emergency contraceptive
pills and notification forms.
The women in the control group were simply informed of or
reminded about how to use emergency contraception and where
to get it and that it was safe to use it more than once. They were
given a notification form to mail in if they used emergency con¬
traception at any time during the next year.
All the women in both groups were sent a questionnaire after
one year asking about the details of their use ofcontraception (in¬
cluding emergency contraception), about any pregnancies, wheth-
er dtey thought emergency contraception should be available
without prescription, and how much they would be willing to pay
for it. If the questionnaire was not returned, two additional ques¬
tionnaires were sent. If we did not receive a response, we contact¬
ed die woman's family doctor to obtain information about her
use of contraception and whether she had become pregnant. If
the family doctor could not provide the information, the woman
was deemed lost to follow-up and the information was sought
from the Information and Statistics Division of the Scottish
Health Department (to which all births and therapeutic abortions
are reported) to determine whcdicr she had been pregnant dur¬
ing the year.
The study was approved by the Lothian Research Ethics Com¬
mittee with die stipulation that women using emergency contra¬
ception more than four times in four months be withdrawn from
the study. All the women gave informed consent.
Statistical Analysis
Differences between the groups were tested by chi-squarc tests
with Yates' correction for binary factors or Mann-Whitney tests
for ordinal factors.
RESULTS
The results for 1071 women (549 in the treat¬
ment group and 522 in the control group) were
available for analysis. One woman was withdrawn
from the study because she used emergency contra¬
ception more than four times in four months. One
woman in the control group died in a traffic acci¬
dent, and 10 women (3 in the treatment group and
7 in tire control group) dropped out of the study for
Table 1. Characteristics of the Women
in the Treatment and Control Groups




No. enrolled in study 553 530
Recruited after use of emergency 323(58) 327(62)
contraception
Recruited after abortion 230(42) 203 (38)
Age
<20 yr 132 (24) 116 (22)
20-29 yr 314 (57) 309 (58)
>30 yr 107(19) 105 (20)
Age full-time education ended
<16 yr 93 (17) 92(17)
17-18 yr 127(23) 106 (20)
19-22 yr 116(21) 114 (22)
>23 yr 54 (10) 61 (12)
Still in school full time 154 (28) 145 (27)
Educational status unknown 9(2) 12(2)
No. with results available for 549 522
analysis
Final questionnaire returned 379 (69) 326 (62)t
Information from family doctor 136(25) 152 (29)f
Lost to follow-up 34 (6) 44<8)J
•Because of rounding, all percentages do not total 100.
fl>=0.03 for the comparison between the groups.
$P=0.12 for the comparison between the groups.
personal reasons. None of these women had used
emergency contraception before they left the study.
The characteristics of the women in the two
groups were similar (Table 1). The women in die
treatment group were more likely to return their
final questionnaires (P = 0.03). The women return¬
ing the final questionnaire were older (P<0.001)
and more likely to have been recruited after use of
emergency contraception than after an abortion
(PcO.Ol). There was no effect of education on
whether the women returned the questionnaires
(P=0.52).
The women in the treatment group were signifi¬
cantly more likely to use emergency contraception
on only one occasion than those in the control
group (36 percent vs. 14 percent, P<0.001) (Table
2) but not more likely to use it more than once (12
percent [45 of 379 women] vs. 13 percent [42 of
326 women], P = 0.77). Correct use of emergency
contraception was determined from the notification
forms, 91 of which were returned. The only woman
who used emergency contraception incorrectly had
lost the instruction sheet and did not take the sec¬
ond dose.
Twelve pregnancies were reported to have begun
during a cycle in which emergency contraception
had been used. Given that it was used on a total of
387 occasions (248 times by women in the treat-
2 • July 2, 1998
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Table 2. Use of Emergency Contraception
amonc. the women in the treatment























-P<0.001 for the comparison between the groups.
ment group and 139 times by women in the control
group), this represents a failure rate of 3 percent,
which is within the range reported in routine clinical
practice/' There was no report of any serious illness
after the use of emergency contraception.
The condom was the most common method of
contraception at the start of the study (Table 3).
During the subsequent year, many women in each
group abandoned condoms in favor of hormonal
contraception, but there was no significant differ¬
ence between the groups (P=0.07). Eighty-nine
percent of the women in the treatment group said
that their use of other methods ofcontraception was
unaffected, and 8 percent reported that the availabil¬
ity of emergency contraception gave them "peace of
mind," but 2 percent said that they took more risks.
Data on pregnancies were available from three
sources — the follow-up questionnaires, the wom¬
en's family doctors, and the Scottish Health Depart¬
ment. It was not possible to determine whether
every pregnancy was intended. There were 28 preg¬
nancies among the 549 women in the treatment
group (5 percent) and 33 pregnancies among the
522 women in the control group (6 percent) during
the year of follow-up (Table 4). Eight women in the
treatment group and four in the control group ap¬
pear to have conceived during a cycle in which emer¬
gency contraception was used; all these pregnancies
were terminated, accounting for 53 percent of the
abortions in the treatment group and 21 percent in
the control group. A total of 18 pregnancies in the
treatment group were known to have been unin¬
tended, as compared with 25 in the control group
(relative'risk, 0.7; 95 percent confidence interval, 0.4
to 1.2).
Among the women for whom detailed informa¬
tion at follow-up was available (379 in the treatment
group and 326 in the control group), more of those
in the treatment group (299 [79 percent]) thought
Table 3. Patterns or Contraceptive Use at Recruitment
and One Year Later among the Women in the Treatment
and Control Groups Who Returned
the Final Questionnaire.*
Contraception Treatment Group Control Group
at one year at one year
recruitment later recruitment later
(n=350) (n = 350) (n=336) (n = 336)
numper fpsrcamj
Oral contraception 45(13) 169 (48) 46 (14) 171 (51)
Condom 258 (74) 108 (31) 235 (70) 94 (2s)
Diaphragm 7(2) 7(2) 11 (3) 15(4)
Combination 3(1) 31 (9) 6(2) 34(10)
None 34 (10) 21 (6) 33 (10) 15(4)
Other or no answer 3(1) 12(3) 5(1) 6(2)
Pregnant 0 2(1) 0 1(<!)
*The number of women in each treatment group is the number who re¬
sponded to the question regarding the method of contraception.
Table 4. Pregnancies during the Year




Variable IN = 549) (N=522|
no. <%)"
Total no. of pregnancies 28 (5) 33 (6)
Abortions 15 (3) 19(4)
Pregnancies despite use ofemergency 8 4
contraception
Childbirths 11 11
Known planned pregnancies 8 6
Known unintended pregnancies 2 4
Miscarriages 2 3
Known unintended pregnancies 1 2
Total no. of unintended pregnancies 13(3) 25 (5)
* Percentages arc shown for key outcomes.
that emergency contraception should be available
without a prescription than was the case in the con¬
trol group (198 [61 percent], PC0.001). This was
particularly true among the women who had en¬
tered the study after having had an abortion. There
was no effect of age on the women's views. Many of
the women (42 percent in the treatment group and
52 percent in the control group) were willing to pay
£5 (about $8) for emergency contraception, and
more than 68 percent in both groups said they
would pay £3 (about $5).
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DISCUSSION
The results of this study suggest that making
emergency contraception available at home is safe
and may reduce the risk of unintended pregnancy.
However, it is important to note that we studied a
well-defined group of women who we thought were
likely to use emergency contraception because they
had used it previously or because they had terminat¬
ed a pregnancy. Furthermore, the women were well
educated (less than 20 percent had left school before
the age of 16 years, and half had gone to a university
or college) and were likely to have a responsible at¬
titude toward contraception. Nevertheless, we think
the study suggests what might happen if emergency
contraception were made available without a pre¬
scription.
Emergency contraception is not universally avail¬
able. It is not licensed, for example, in France or the
United States. However, some brands of combined
oral contraceptives contain the same hormones as
the preparation we used, and although not licensed
tor sudi use, these contraceptives can be used as a
substitute. Many clinics in the United Kingdom rou¬
tinely use these oral contraceptives tor emergency
contraception because they are considerably cheaper
than the marketed preparation we used, and many
women have supplies of oral-contraceptive pills at
home and could make up their own emergency con¬
traceptive regimen if they knew how. Indeed, in
1997 the U.S. Food and Drug Administration an¬
nounced that six brands of commonly used com¬
bined oral contraceptive pills are safe and effective
for use as emergency postcoital contraceptives.7
It has been argued that if emergency contracep¬
tion were available without a prescription, women
would not use it correctly. We found, however, that
most of the women did use it correctly, including
many who were recruited after abortions and had
never used such contraception before. It is also pos¬
sible that women might use emergency contracep¬
tion when they are already pregnant. We cannot test
this hypothesis. A small number of women in our
study conceived during the cycle in which they used
emergency contraception, and it is possible that
some of them were already pregnant when they took
the tablets. Even if it was used during pregnancy, ei¬
ther in error or intentionally in the mistaken belief
that it might cause an abortion, it would almost cer¬
tainly have done no harm. The estrogen-progestin
regimen of emergency contraception is ineffective
after implantation, and there is no evidence that it is
teratogenic.8
It has also been argued that if emergency contra¬
ception were more readily accessible, women might
use it repeatedly and abandon more reliable methods
of contraception. However, very few of the women
in the treatment group used it more than once, and
they were not more likely to do so than the women
in the control group who had to visit a doctor to ob¬
tain it. Nor did improved accessibility affect the pat¬
tern of contraceptive use. Few women said that they
took more risks, and during the study similar num¬
bers in each group switched from using barrier
methods to using more reliable oral contraception.
Aldiough the incidence of unintended pregnancy
was lower among the women who had emergency
contraception available at home than among those
who had to obtain it from a doctor, the sample was
small and the difference was not statistically signifi¬
cant. The reduction in the number of unintended
pregnancies might have been greater if we had given
more than one packet of pills to each woman. Al¬
though 135 women used emergency contraception
once, only 74 returned to the clinic for another
packet.
This study suggests that women are able to self-
administer emergency contraception correctly, at the
appropriate time, and without adverse effects. Given
the opportunity to keep the necessary tablets at
home, most of the women found emergency contra¬
ception a useful addition to their contraceptive op¬
tions. Although many of the women thought that it
should be available without a prescription, they did
not appear to abandon more reliable methods of
contraception in favor of the repeated use of emer¬
gency contraception. Making emergency contracep¬
tion more accessible may reduce the rate of unin¬
tended pregnancies.
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Abstract
A number of small studies have demonstrated increased use of emergency contraception
(EC) when women have a supply available at home. It has been suggested that
widespread use of EC could reduce abortion rates. We undertook a community
intervention study designed to determine whether offering advanced supplies of EC to
large numbers ofwomen influenced abortion rates. Women aged between 16 and 29
living in Lothian, Scotland were offered, through health services, five courses of EC to
keep at home. 17831 women took a supply of EC home and over 4500 of them gave at
least one course to a friend. 45% of women who had a supply used at least one course. In
total an estimated 8081 courses of EC were used. More than 75% of EC was used within
24 hours of intercourse. Abortion rates in Lothian were compared with those from three
other health board areas of Scotland. No effect on abortion rates was demonstrated. The
enthusiasm for distributing advanced supplies of EC through health services
may be misplaced as a strategy to reduce unintended pregnancy in the UK.
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Introduction
Unintended pregnancy is common and abortion rates are rising worldwide. Emergency
contraception (EC) may prevent up to 95% of unwanted pregnancies [1]. It is increasingly
regarded as a means to reduce abortion rates [2,3]- Considerable effort and funding are
being spent making EC available in countries where it is not yet licensed [4], promoting it
in countries where it is, [5] and relaxing restrictions on its provision[6]. But would
improving access to emergency contraception really prevent large numbers of
pregnancies ?
If EC was used whenever it was indicated, it has the theoretical potential [7]to reduce
abortions in Scotland from around 12,000 to 4,000 each year. Although most women of
reproductive age in Scotland know about EC [8,9], only 1.9% of Scottish women aged
16-44 used it during 2001 [10]. In a small study undertaken in Edinburgh [11,]advanced
provision of EC significantly increased its use. Encouraged by these findings, the Lothian
Emergency Contraception Project (LECP) was undertaken to see whether giving large
numbers of women supplies of EC to keep at home would reduce abortion rates.
Materials and Methods.
i. Participants
The project took place in the county of Lothian in South East Scotland. Everyone resident
in Scotland can register with a general practitioner (GP, family doctor) who provides
primary healthcare, including contraception, free of charge. Contraceptive supplies are
not subject to prescription charges. Emergency contraception has been licensed in the UK
since 1984.
All health providers in Lothian likely to prescribe emergency contraception were invited
to participate . This included all (124) general practices, 17 community family planning
(FP) clinics, the gynaecological and genito-urinary medicine (GUM) departments of the
main hospital (The Royal Infirmary of Edinburgh) and Brook Scotland, a non¬
governmental sexual health service for young people. Supplies of EC were also offered to
new college students at 'Fresher's Fairs' at the start of the academic year in autumn 2000.
All women aged 16-29 years who lived in Lothian were to be offered five courses of
Schering PC4 (Schering Healthcare, England) to keep at home. PC4 (ethinyl oestradiol
and levonorgestrel) was the only EC product available in 1999 and had to be prescribed
by a doctor. The five courses and a detailed information/instruction leaflet were packaged
in one box. Women who were sterilised or using an intrauterine device or contraceptive
implant were excluded from the study. The project was advertised widely with the
intention that women themselves would ask for a supply of EC when attending for routine
healthcare. Publicity materials - information leaflets and posters - were distributed to GP
surgeries, participating clinics, libraries, cinemas, hairdressers, community pharmacies,
night-clubs, pubs (bars) and discotheques, and posters were displayed in public toilets. A
press conference for the local and national media launched the study. Every invitation for
i
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media publicity was accepted. Nine months into the study every household in Lothian
was mailed a postcard inviting women to ask their doctor for supplies of emergency
contraception to keep at home.
ii. Data collection.
A record of the number of project supplies sent to each participating centre was held
centrally and centres kept a record of the number of women receiving a box of EC (five
courses). These records revealed how many women received a supply of EC to keep at
home.
A questionnaire was designed to determine, among a sample ofwomen eligible to
receive supplies, how many had been offered (and accepted) EC and whether and how
they had used it. Purposive sampling was used to select ten of the participating general
practices representing a range of socio-economic characteristics and location. The
questionnaire was mailed to all 6,486 women aged 16-29 years registered with the 10
practices after the project had been running for 18 months. One reminder was sent to
non-respondents (one practice declined to send a reminder). Using a similar
questionnaire, patterns of use of EC were also investigated among a random sample of
310 women who had received a home supply from a FP clinic.
As part of the evaluation, in depth interviews were conducted with a sample of women
who received project supplies of EC and with professional staff in case study practices.
These will be reported elsewhere. To determine the effect of the intervention, annual
abortion and birth rates [12] from 1998 to 2001 were compared between Lothian and
three other large Scottish Health Board areas (Grampian, Tayside and Greater Glasgow)
using routine data collected by the Information and Statistics Division (ISD) of the
Scottish Health Service. Abortion referral rates during 1999, 2000 and 2001 from
individual general practices in Lothian were compared using data from the centralised
Lothian Abortion Referral Service [13]. Ethical approval for the study was obtained from
the local research ethics committee.
iii. Analysis.
Total abortion rates in 1998/9 and 2000/1 between Lothian and other health boards were
compared using multiple logistic regression. Referrals for abortion in 1999, 2000 and
2001 between groups of general practices in Lothian were compared using two- sample
T-tests using a logarithmic transformation to achieve approximate normality.
Patterns of acceptance and use of EC were examined through frequencies of response
from the two questionnaires.
Characteristics of those who received advance supplies of EC were identified using
questionnaire data from women registered at case study practices. The intra- class
correlation co-efficient estimated from a variance components model based on 2,629
respondents suggested that around 10% of the total variability in the outcome occurred at
practice level. A multilevel model was therefore constructed using MlwiN software
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(Version 1.10.0006) to predict whether or not the respondent received advance supplies
of emergency contraception. The individual explanatory factors included in the model
were: age (years); highest qualification (five-way categorical scheme: still at school;
vocational qualifications; High School equivalent qualifications at age 17-19; degree /
postgraduate; and 'other'); employment status (three-way categorical scheme: full-time
paid employment; full-time student; and all others); co-residency (binary: living alone or
with unrelated others; all other states); housing tenure (three-way categorical scheme:
privately owned; rented from Public Housing Organisations; and 'other'); and past use of
emergency contraception. Due to the effects ofmultiple missingness the final model is
based on data from 2,294 (87.3%) respondents. Only associations significant at 0.01%
are reported in this paper.
Results
Ninety-seven general practices in Lothian and all the other services providing EC,
participated. Six months into the study it became clear that women were not asking for
advance supplies of EC. Since they appeared enthusiastic about taking a supply home if
actively offered, centres were asked to be more pro-active . Newsletters were sent
regularly to centres to encourage recruitment.
i. Number of women receiving advanced supply of EC
The project ran from 1st September 1999 to 31st December 2001. When it closed a supply
of emergency contraception had been distributed to 17,831 women (table 1). There was a
wide variation in the number of packets distributed by the general practices (table 2).
From the general practice survey, 943 questionnaires were returned undelivered, 2,817
women responded - a rate of 50.8%. 188 questionnaires were blank, leaving 2,629 for
analysis. 286 women (92%) completed the FPC questionnaire. 361 (13.7%) of
respondents to the GP questionnaire reported receiving project packs of EC. Only age
(odds ratio: 0.94; 99% CI 0.88 - 0.99) and receipt of EC prior to September 1999 (odds
ratio: 2.58; 99% CI 1.83 - 3.62) were significantly associated with receipt of project EC
(p = 0.01).
Of the women responding to the questionnaires, 116 (32.1%) of the GP practice sample
and 60 (21%) of the FP sample reported giving away at least one packet of EC. Assuming
that 26% (the mean of the two samples) ofwomen receiving packets from the other
project sources (table 1) also gave supplies away, we estimate that some 4772 women
received at least one course of EC from a friend. Thus a total of at least 22,603 women
had access to EC without needing to see a doctor.
ii. Use of EC
53.3% of women who received a project supply of EC from their GP were given it at the
time they presented needing emergency contraception, leaving four courses to keep at
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home. Most women receiving supplies from an FP clinic were not attending for EC,
however those who were, received the home supply in addition to the treatment required.
Fifty per cent of respondents to the GP survey who had received an advance supply of
EC, and 40% ofwomen responding to the FPC survey used at least one course of the five
supplied. Overall we estimate that at least 8081 courses of EC were used. It seems likely
that most of the 4772 women who received EC from a friend were given it because they
needed it. A total of over 12,000 courses of EC may therefore have been used in Lothian
through the project.
Of 647 women who reported receiving EC to keep at home on the questionnaires, thirty-
six (5.5%) reported unintended pregnancies. Only eight reported using EC in an attempt
to prevent the pregnancy.
294 women reported using at least one course of EC. Of these 75.7% of courses were
used within 24 hours, and 51.8% less than 12 hours, after unprotected intercourse.
Respondents completing the GP practice questionnaire who had a home supply of EC
were more likely to be using hormonal contraception (oral or injectable) at the time of
completing the questionnaire, than at the time of receiving supplies (table 3).
iii. Effect on abortion and birth rates
No significant differences were seen for any health board area in the total abortion rates
(women aged 16-44) or the rates for women aged 16-29 (table 4) when 1998 or 1999
were compared with 2000 or 2001. Using an interaction model, the multiple logistic
regression gave a 95% confidence limit of -6% to +10% for the difference between
Lothian and Grampian in the change in abortion rates between 1998-1999 and 2000-
2001. There were no significant differences in changes in birth rates between the various
health boards over the same years (data not shown).
There were no significant differences in the mean number ofwomen referred for
termination of pregnancy during 1999-2001 between the 10 practices distributing the
most packets of EC, the 10 practices distributing fewest packets and the 7 who did not
participate in the project (table 5).
Discussion
Offering advance supplies of emergency contraception appears to have had no effect on
abortion rates in Lothian. This study is the sixth, and by far the largest, to show that
advanced provision of EC increases its use [11,14,15,16,17], Moreover this study, like
one other [17], has demonstrated much earlier use of EC, thought to increase efficacy
[18]. In the present study over 75% ofwomen who had used an advance supply of EC
had used it within 24 hours, in contrast to the average 38 hours taken to access it through
a FPC [19],
If at least 18000 young women in Lothian had easy access to EC, were more likely to use
it and to use it quickly, why was there no measurable effect on abortion rates ? Abortion
rates are influenced by many factors and fluctuate from year to year. An effect of a single
event, even a major one like the third generation 'pill scare' of 1995, is hard to
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demonstrate convincingly [20]. Abortion is a relatively uncommon event in Scotland.
Fewer than 2000 of the 85000 women aged 16-29 in Lothian will have an abortion each
year. For this reason, and despite knowing that they are notoriously hard to do [21], we
chose a community intervention study in order to get supplies of EC to large numbers of
women. Almost one in four of our target group took at least four courses of EC home.
They were young, sexually active, and nearly 54% of those receiving supplies from their
GP were using condoms. A lot of EC was given away. With an abortion rate of 24/1000
(table 4) we would have expected some 530 abortions among the women who had a
supply of EC at home, but the intervention does not appear to have prevented even half of
them. Perhaps simply not enough women took a supply home. Although some general
practices issued supplies to a lot of women, many health professionals did not promote
the project to women who were not consulting for emergency contraception. Women
themselves reported finding it difficult to ask for EC proactively. Several other studies
have drawn attention to health professionals [22,23] and women's concern [24] about
deregulation and repeated use of EC. Although most women were pleased to accept a
supply of EC to keep at home when offered, very few actually asked for a supply, even in
the FPC where notices were displayed prominently.
Were advance supplies given to the right women ? The LECP made EC available almost
exclusively through health services and most often to women who had already consulted
for EC or for other contraception. In so doing, it may not have reached women most at
risk of unintended pregnancy - those using no contraception or using condoms
inconsistently who do not access contraceptive services.
Perhaps having a supply of EC so easily available encouraged women to take more risks
with unprotected intercourse. As with our pilot study however, women tended to move
from less effective methods of contraception (mainly condoms) to more effective
methods (hormonal) during the period of follow up (table 3). Moreover, we asked
women in the questionnaire surveys whether they felt that they were less careful about
contraception and the vast majority said they were not. It seems unlikely then that
pregnancies prevented by EC among women who used it were matched by pregnancies
arising from increased risky sexual behaviour.
Perhaps the most likely explanation for the failure to influence abortion rates lies in the
observation that even when women did have EC at home, it was not always used when it
might have prevented a pregnancy. 74% of the 36 women who had advance supplies and
reported an unintended pregnancy did not use EC. Many women have a Tow sense of
vulnerability towards pregnancy' [25], even when they know that they have taken risk. In
a number of studies in different countries among women having abortions [2, 26,27], the
failure to recognise a risk ofpregnancy is the commonest reason for non-use of
contraception including EC. Having a supply of EC to keep at home will not help women
who do not recognise the risk of pregnancy, and therefore do not recognise the need to
use EC.
Were we expecting too much of the intervention in this setting ? Contraceptive
prevalence is high in Scotland and abortion rates are relatively low. It has been estimated
however that in the UK some 70% of pregnancies are preventable [27] (contraception not
used or used incorrectly or inconsistently), so even although the absolute number of
unintended pregnancies is relatively small, there is plenty of opportunity for EC use. It is
1
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possible that in other settings, where contraceptive prevalence is low, abortion rates high
and women relatively naive about EC, advanced provision may reduce the public health
cost of unintended pregnancy.
Finally, it is possible that emergency contraception may be less effective than we think.
Estimates of efficacy are something of a guess, based on rather unreliable data and a great
many assumptions [28] and have been questioned both in the past [29] and more recently
[30].
Whatever the shortcomings of this study, the fact remains that multiple courses of
emergency contraception were made available to a large number ofwomen in advance of
need. More than 17,000 of them took it home and over 8000 (perhaps as many as 12000
if those who obtained EC from a friend are included) used if, yet no impact on abortion
rates was measurable. While advanced provision of EC probably prevents some
pregnancies for some women some of the time, the strategy did not produce the public
health breakthrough hoped for. The prospect of reducing abortion rates by widening
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Table 1: Number (and percentage )of project packs
distributed by participating services
Service Number (%)
Family planning clinics 6,549 (36.7)
Brook Scotland 924 (5.2)
Hospital clinics 2,025 (11.4)
General Practices 7,708 (43.2)
"Freshers' Fair" 625 (3.5)
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Table 2: Number of general practices distributing specific numbers ofproject packs







No information provided 7
NB. Two practices hold two separate branch surgeries which are counted individually in
the list of 124 Lothian Practices but functioned as a single practice during the project
thus the total number ofpractices listed here is 93.
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Table 4. Number (and rates) of abortions among women aged 16-29 in Scotland as a
whole and in the four major health board areas from 1998 - 2001.
1998 1999 2000 2001
Scotland 8882 8542 8368 8453
(18.9) (18.5) (18.5) (18.7)
Lothian 1915 1913 1769 1849
(24.2) (24.3) (22.4) (23.4)
Grampian 1009 936 857 848
(21.4) (20.3) (19.3) (19.1)
Greater Glasgow 1655 1613 1582 1643
(17.4) (17.3) (17.1) (17.8)
Tayside 882 791 829 750
(26.6) (24.6) (26.7) (24.1)
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Table 5. Total number of project supplies of EC issued and total number ofwomen
referred for abortion 1999-2001 among the 10 best performing (distributed supplies to
the most women) and 10 worst performing (distributed supplies to the fewest women)







2880 292 219 298
Worst
performance
239 70 63 66
Non
participants
0 90 93 107
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Abstract
Objectives. To explain why the Lothian Emergency Contraception Project (LECP) -
a primary care based intervention to offer advance supplies of emergency
contraception (EC) to women aged 16-29 was not associated with a reduction in
abortion rates.
Design. Case studies, utilising qualitative and quantitative methods, were used to
evaluate the intervention. In this paper findings from qualitative interviews are
presented.
Setting. 10 general practices, purposively chosen to represent a range of socio¬
economic characteristics, geographical locations and enthusiasm for the intervention,
and the central family planning clinic in Lothian.
Participants. 44 primary care professionals working at general practice case study
sites and 22 women who had received advance supplies.
Results. Professionals reported that women rarely asked for advance supplies of EC,
and they were reluctant to offer supplies to women other than when they consulted for
emergency contraception. Their reluctance was underpinned by concerns about
contradictory sexual health messages implied by the offer; a perceived association of
EC use with chaotic behaviour by women; views about the sort of women suitable for
advance supplies; and practical difficulties making the offer. Some women reported
surprise at the offer of advance supplies but most recognised benefits of having EC at
home for themselves. Nevertheless they were reluctant to ask for advance supplies
because of misgivings about the appropriateness of offering advance supplies to
everybody and concerns about being judged by health professionals as morally
inadequate.
Conclusions. As women themselves are unlikely to seek out advance supplies,
advance provision of EC may only be successful in reducing abortion rates if
professionals address their own concerns about EC and develop ways to encourage
women not already accessing or using EC or other contraception to take supplies.
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Introduction
Concerns about the high rate of unintended pregnancy in the UK have prompted the
relaxation of restrictions on the provision of emergency contraception including free
pharmacy provision in some areas of multiple deprivation (known as Health Action
Zones in England) and the removal of prescription only status to allow its supervised
sale at commercial rates through community pharmacies1. The Lothian Emergency
Contraception Project was an alternative radical initiative designed to increase use of
emergency contraception by providing multiple courses to women in advance of need.
The project, which is reported in detail elsewhere2, involved advance supplies of 5
courses of Schering PC4 being made available to all women aged 16-29 resident in
Lothian with the express aim of reducing pregnancy termination rates. Women were
encouraged to collect advance supplies from participating centres, and professionals
working in these centres were encouraged to offer supplies to eligible women.
It was clear that the success of the project was likely to be dependent upon adequate
distribution of advance supplies to the eligible women and in particular those most at
risk of unintended pregnancy, and appropriate use of supplies by women once they
had them. We have shown that sufficient numbers of packs of EC appear to have
been distributed to have had an impact on abortion rates and that women who used
their advance supplies reported doing so in a timely fashion and not forsaking more
reliable methods of contraception. Yet no impact upon abortion rates was observed2.
We have also shown that the majority of women who received advance supplies had
either previously used EC or were given the extra supplies when they consulted for
EC2. Women who have already consulted for EC are not likely to be those with the
greatest problems of access to contraception, and may not be typical of the population
most at risk of unintended pregnancy. This suggests that whilst distribution of
advance supplies of EC in the Lothian Emergency Contraception Project was
theoretically sufficient to impact upon abortion rates in Lothian, in practice it may
have been inadequately targeted at women at risk of abortion.
This paper draws upon qualitative data from a pluralistic evaluation of the Lothian
Emergency Contraception Study to describe how the project operated in practice and
to explain why enough women at risk of abortion may not have received advance
supplies.
Methods
A case study research design was used. Case study sites were ten general practices in
Lothian purposively sampled to represent a range of socio-economic characteristics,
locations and initial enthusiasm for the Lothian Emergency Contraception Project
among professionals, and the central family planning clinic in Lothian, Scotland.
Semi-structured interviews with health professionals
Staff at the case study general practices took part in interviews with one researcher
(PS) between November 2000 and June 2001. A total of 44 interviews with one or
more general practitioners and primary care nurses from each practice covered their
views, perceptions and reported response to the Lothian Emergency Contraception
Project and described the way in which the project was implemented in each practice.
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Interviews with women
Twenty two women who had responded to a postal questionnaire survey sent to
women registered with the ten case study practices, or distributed to women attending
the central family planning clinic and who had also received advance supplies of
emergency contraception were interviewed by PS between December 2001 and May
2002. Interviews covered views about emergency contraception, experience of
accessing emergency contraception, and of having it to keep at home.
Analysis
All interviews were audio-taped recorded and transcribed verbatim. In order to
develop and test an analytical framework, all authors read a sample of transcripts. A
coding scheme was developed for each set of transcripts by first identifying broad
themes within the data. These broad themes, which reflected the original research
aims, were views about emergency contraception, views about the Lothian
Emergency Contraception Project, experiences of asking for, offering or being offered
EC and use of emergency contraception. These themes were then further interrogated
to identify anticipated and emergent categories within the data3. The transcripts were
loaded into Nvivo. PS applied the coding framework to all transcripts. Further
analysis involved examining sections of interviews coded to a particular theme across
the datasets using the constant comparison method4. Commonalities within the data
between respondents and within individual respondents' accounts were identified.
Deviant cases were sought and explored. For reporting purposes, professionals were
assigned a professional identifier (General Practitioner (GP) or Practice Nurse (PN))
and their practice assigned a number whereas women were assigned a first name
pseudonym.
Results
The interview data from both health professionals and women provides insights into
the reasons that advance supplies may not have been more widely distributed to, or
targeted at women at risk of unintended pregnancy and abortion.
Professionals' views and experiences of the Lothian Emergency Contraception
Project
Professionals' working in case study general practices reported not only that women
rarely asked for advance supplies of EC but also that they were reluctant to routinely
offer women supplies. They reported that they primarily offered advance supplies to
women who were consulting for emergency contraception (confirming an analysis of
quantitative survey data reported elsewhere2). Reluctance to take a proactive approach
to distribution of the packs to more women seemed to be influenced by their concerns
about the potentially contradictory messages implied by the offer of advance supplies;
their association of EC use with "chaotic behaviour" by women; their views about the
sort of women suitable for advance supplies of EC; and the practical difficulties they
encountered in making the offer in the context of routine consultations.
Knowledge that emergency contraception is less reliable than combined oral
contraception and that its use requires no forward planning seemed to underlie a
prevailing belief that emergency contraception is not "proper contraception". The
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offer of advance supplies of EC was considered antithetical to the sort of rational and
planned approach to contraception favoured by professionals. Related fears that
women would overuse EC and abandon more reliable methods of contraception in
favour of repeated use of EC were evident. For example:
"This idea ofhaving a lot ofpackets to use for emergencies just in case is
still a little alien. I think we'd still be preferring to help people to think
more pro-actively. "GP1 practice 11
Concerns that the offer of advance supplies of EC was contradictory to the promotion
of safe sexual practices and might lead to exposure to sexually transmitted infections
also militated against pro-active distribution.
"For a number ofyears we have been advocating safer sex which involves
barrier methods, involves condoms and one would not want to dilute that
message somewhere like Edinburgh where HIV infection is still
potentially a problem "
GP3, practice 2
The possibility that the offer of advance supplies might be seen as sanctioning
promiscuous behaviour further concerned professionals and discouraged them from
pro-active distribution.
"
Obviously you 're not going to want to be encouraging them to have a
huge number - well I don 't know ifI'm talking professionally or whether I
am talking as a human being - I certainly wouldn't advocate a huge
number of sexual partners. I think also from an emotional point of view
and a feeling ofselfworth and the sort ofpsychological side ofthings "
PNpractice 11
The provision of 5 courses of EC within the project was seen to endorse repeated use
of EC. However professionals often associated repeated use of emergency
contraception with chaotic lifestyles and did not want to be seen to be encouraging
such behaviour among women.
" I mean it's just they are all...sometimes you think people who are a bit
scatty won 't be using safe sex.. In a way a lot ofpeople would be, to my
mind, a bit chaotic in their lifestyle that are relying on it too much. I mean
the occasional one whose preferred method of condoms failed, that's
maybe a different matter, if they'd maybe been a bit more sensible in
general but they \>e had a problem. But if somebody's relying on packs of
the morning after pill, I think they 're possibly a bit more chaotic in their
outlook"
GP2, practice 3
Although epidemiological risk factors for abortion are well recognised professionals
rarely acknowledged the women in their practice population as those most suitable for
emergency contraception to keep at home, either because of a perceived lack of need,
or a perceived inability to use advance supplies appropriately. Only one of the
practices, which serves a largely student population, was proactive in writing to
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women on the practice list and encouraging them to collect advance supplies. They
reported doing this because they saw their practice population as not only in need of
supplies of emergency contraception to keep at home because of perceived
promiscuous lifestyles, but also organised enough to use supplies appropriately.
Other practices justified the lack of a proactive approach by characterising their
population as either not in need of emergency contraception to keep at home because
of prevailing responsible and organised contraceptive use, for example:
"It's a very middle class practice and women here are very well aware
what they should do and shouldn't do. Which is not to say they don't have
accidents like everybody else and they would come along. But they 're not
your 15/16 year olds with the high pregnancy rate. We don V tend to get
young girls who put themselves at risk, we're not that type oj practice
really."
GP1, practice 02
or as unsuitable for supplies to keep at home because of their chaotic lifestyles, for
example:
"I think the women who is educated, maybe middle class I think these
women are more likely to take advantage ofthis initiative than some ofthe
types ofpeople we see in this practice, who perhaps aren't as aware, who
sometimes need someone to say to them this is what you should do. So I
think a lot depends on the women themselves
GP1, practice 3
Professionals also raised the difficulty of introducing contraceptive issues, and
especially the offer of packs of emergency contraception to keep at home, into routine
general practice consultations. Some considered it inappropriate to make the offer in
the context of a consultation about unrelated issues, and most found it practically
difficult to do so given the time constraints (with maximum 10 minutes appointments
and a waiting room full of people to see) of everyday general practice. For example:
"It's not the sort of thing that ifsomeone's coming into you about a cold
or a spot on their face or something, that you feel, it might not be
appropriate for them, or they might not be in a sexual relationship, it
might just be totally inappropriate. So it's not sort of thing that Ifelt was
appropriate to raise " GP3, practice 5
Despite professionals' fears that it might be inappropriate to offer advance supplies of
EC to women in routine consultations, none of the professionals interviewed reported
women'refusing an offer of advance supplies if this was made.
Women's views and experiences of the Lothian Emergency Contraception Project
Although some of the women we interviewed reported surprise at the offer of 5
courses of EC, most also recognised a number of benefits of having advance supplies
including convenience, saving the time (and embarrassment) of visiting the doctor,
and easing of anxiety. For example this 28 year old women reports her reaction to the
offer of advance supplies:
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"
I was just like yeah of course because I think it's really good to have.
Because I know previously where I thought 'oh no I need it', but you've
got to go and make phone calls and appointments and stuff and that's
more bother than it's worth really so I just thought I would take it. It's
comforting to know it's there " Queenie
Nevertheless, despite these perceived advantages women reported being reluctant to
ask for supplies to keep at home. Their reluctance seemed to be influenced by their
views that emergency contraception was not 'proper contraception' and they
expressed misgivings that the project might mean that some women would over use
emergency contraception and expose themselves to sexually transmitted infections.
For example:
"It's not going to protect you from everything. It's only going to stop you
getting pregnant. I think that's the main problem ifpeople start seeing it
as contraception then you've still got all your STD's and everything else "
Patricia
Women were also concerned about being judged if they asked for EC. For example,
this 29 year old women said:
because I think there's always an element of you feel someone is
judging you. You've made a mistake, everyone always goes along and
says it's a burst condom. I mean how many of that is people who aren't
using anything? So there's always a sort of element of guilt, anxiety...I
think anything to do with contraception things, everyone's still a bit
uptight and embarrassed about it" Sandra
Expressions of concern over being judged when they accessed EC suggests an
awareness among women that EC users may be seen in a morally ambiguous light
because use of EC is often associated with chaotic behaviour. Concern about being
judged in this context appeared to underlie their reluctance to ask for advance
supplies. If any use of emergency contraception places a woman in perceived moral
jeopardy, it is clear that many women would find it very difficult to initiate a request
for the five advance supplies included in the project pack. In consequence women
worked hard in their interviews to distance themselves from those they perceived as
irresponsible contraception users and to establish themselves and their use of
emergency contraception as responsible. Typically this distancing involved younger
women, though some women also made comparisons between their own responsible
contraceptive behaviour and that of friends or acquaintances. For example this 29
year old woman said:
"Ifyou've got it at home ...the only people who might be encouraged to
have unprotected sex are much younger people who might think 'great,
I've got it at home, I can take full advantage of it'.... It wouldn't
encourage me at all. I generally wouldn't have intercourse without
contraception anyway. It would only really be in the event of a mistake or
something like that" Ursula
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Discussion
Several studies have drawn attention to health professionals'5'6 and women's7
concerns about de-regulation and repeated use of emergency contraception. Similar
concerns are evident in the accounts in this study and are important in explaining the
lack of impact of the Lothian Emergency Contraception Project upon abortion rates.
The anomalous position 8 EC continues to hold in the contraceptive repertoire makes
it very difficult for doctors and nurses to wholeheartedly encourage its use and
promote advance supplies. Furthermore women perceive that any request for EC
represents a significant threat to their moral identity. This suggests that women
presenting for EC must be already highly motivated to prevent pregnancy. Women
who are less highly motivated to prevent pregnancy, or have a low sense of
vulnerability towards pregnancy 9, are unlikely to jeopardise their moral identity by
asking for five packets of EC to take home in advance of need. Yet paradoxically
such women may be more likely to use EC and prevent pregnancy if they have it to
hand.
Advance provision is gaining popularity as a way to increase timely and appropriate
use of emergency contraception10,11'12. Our findings demonstrate that imaginative
ways to encourage women who are not already EC users to take supplies home are
needed. Women themselves are unlikely to seek out advance supplies and need
reassurance from health professionals that having advance supplies of EC is
responsible behaviour; such reassurance comes from a pro-active offer of advance
supplies. Therefore to reach those women most in need of EC it will be necessary for
professionals to address their own concerns about emergency contraception and to be
proactive in encouraging women to take packs home and share them with friends.
Given concern over risk of sexually transmitted infections amongst young people,
health professionals may feel happier about distributing advance supplies if condoms
are included in the pack .
468
References
1. Harrison-Woolrych M, Duncan A Howe J Smith C Improving access to
emergency contraception BMJ 2001 322 186
2. Glasier A, Fairhurst K, Ziebland S, Wyke S, Seaman P, Walker, J, Lakha F.
Advanced provision of emergency contraception has not reduced abortion rates in
Lothian, Submitted BMJ
3. Backett-Milbrun K, Fraser E, Seeker J, Pavis S. Combining methods and health
education research: some considerations about appropriate use. Health Education
Journal 1994 54, 347-356.
4. Strauss A, Corbin J. Basics of qualitative research: grounded theory procedures
and techniques. Sage, London 1990.
5. Barrett G Harper R Health Professionals attitudes to the deregulation of
emergency contraception (or the problem of female sexuality) Sociology of health
& Illness 2000 22 (2) 197-216
6. Ziebland S Graham A McPherson A Concerns and cautions about prescribing and
de-regulating emergency contraception: a qualitative study of GPs using telephone
interviews. Family Practice. 1998 15:449-56.
7. Ziebland S. Maxwell K, Greenhill E. It's a mega dose of hormones isn't it? Why
women may be reluctant to use emergency contraception. Br J Fam Planning 1996,
22:84-86
8. Ziebland S Emergency Contraception: an anomalous position in the family planning
repertoirtl Social Science and Medicine. 1999 49 1409-1417
9. Free C Lee RM, Ogden J. Young women's accounts of factors influencing their
use and non-use of emergency contraception: in depth interview study. Brit Med J
2002;325:1393-7.
10. Raine T, Harper C, Leon K, Darney P. Emergency contraception; advance
provision in a young, high-risk clinic population. Obstet Gynecol 2000; 96: 1-7.
11. Ellertson C, Ambardekar S, Hedley A, Coyaji K, Trussel J, Blanchard K.
Emergency contraception: randomized comparison of advance provision and
information only. Obstet Gynecol 2001; 98: 570-5.
12. Lovoorn A, Nerquaye-Tetteh J, Glover EK, Amankwa-Poku A, Hays M,
Raymond E. Provision of emergency contraceptive pills to spermicide users in
Ghana. Contraception 2000; 61:287-293.
469
Acknowledgements
We are very grateful to the health professionals and women who consented to be
interviewed for this study, which was funded by the Wellcome Trust. We are also
grateful to Andrew Herxheimer for suggesting that health professionals may find it
easier to be proactive in their distribution of advance supplied of EC if condoms were
also included in packs.
470
